Clustering O 0 0.0001882752258097753
of O 0 3.9957353692443576e-06
missense O 0 0.0011655399575829506
mutations O 0 0.0005597101408056915
in O 0 5.180871085030958e-06
the O 0 6.203511293279007e-05
ataxia B-Disease 1 0.9999946355819702
- I-Disease 1 0.9980019927024841
telangiectasia I-Disease 1 0.9991359114646912
gene O 0 3.54144285665825e-05
in O 0 8.0437047245141e-07
a O 0 4.346720288594952e-06
sporadic B-Disease 0 0.0007535786717198789
T I-Disease 1 0.9965497255325317
- I-Disease 0 0.32036179304122925
cell I-Disease 0 0.3248162865638733
leukaemia I-Disease 1 0.9954158067703247
. O 0 2.3820381102268584e-05

Ataxia B-Disease 1 0.9999856948852539
- I-Disease 1 0.999214768409729
telangiectasia I-Disease 1 0.9998849630355835
( O 0 0.0001803697377908975
A B-Disease 1 0.9997820258140564
- I-Disease 1 0.9951266050338745
T I-Disease 1 0.9995079040527344
) O 0 3.788098581480881e-07
is O 0 2.3280404093384277e-07
a O 0 1.6718429378670407e-06
recessive B-Disease 0 0.004408654291182756
multi I-Disease 1 0.9824752807617188
- I-Disease 1 0.9986230134963989
system I-Disease 1 0.9862924814224243
disorder I-Disease 1 0.9998406171798706
caused O 0 0.00029004301177337766
by O 0 2.7637969424176845e-07
mutations O 0 9.106247489398811e-06
in O 0 1.1601775184999497e-07
the O 0 1.9205228340979374e-07
ATM O 0 3.4064913052134216e-05
gene O 0 2.1346926587284543e-05
at O 0 4.9612710427027196e-05
11q22 O 0 0.00023212908126879483
- O 0 0.00010591646423563361
q23 O 0 9.708577999845147e-05
( O 0 7.814269338268787e-07
ref O 0 0.00017272745026275516
. O 0 2.2775365948746185e-07
3 O 0 1.185313522000797e-06
) O 0 1.8291220271748898e-07
. O 0 1.415282895322889e-06

The O 0 4.519114372669719e-05
risk O 0 0.0006893700337968767
of O 0 1.6250472981482744e-05
cancer B-Disease 1 0.9996845722198486
, O 0 3.804767402471043e-06
especially O 0 1.3781545021629427e-05
lymphoid B-Disease 0 0.006769727915525436
neoplasias I-Disease 0 0.013534033671021461
, O 0 2.9875495783926453e-06
is O 0 8.625998475508823e-07
substantially O 0 1.0646144801285118e-05
elevated O 0 0.0007749300566501915
in O 0 7.418180757667869e-06
A B-Disease 1 0.9991607666015625
- I-Disease 1 0.9993723034858704
T I-Disease 1 0.9999072551727295
patients O 0 8.924501889850944e-05
and O 0 9.13418546133471e-07
has O 0 1.133945715992013e-06
long O 0 2.992964937220677e-06
been O 0 1.836464662119397e-06
associated O 0 9.644433703215327e-06
with O 0 4.805931166629307e-05
chromosomal O 1 0.9999722242355347
instability O 1 0.9997988343238831
. O 0 0.00010313397797290236

By O 0 1.1888322660524864e-05
analysing O 0 0.0013678708346560597
tumour B-Disease 1 0.9998937845230103
DNA O 0 3.418708365643397e-05
from O 0 9.236102869181195e-07
patients O 0 3.4140352909162175e-06
with O 0 3.897934277574677e-07
sporadic B-Disease 0 0.000839877175167203
T I-Disease 1 0.983363151550293
- I-Disease 0 0.005628695711493492
cell I-Disease 0 0.006481215823441744
prolymphocytic I-Disease 0 0.034605950117111206
leukaemia I-Disease 1 0.9967505931854248
( O 0 1.0195059985562693e-05
T B-Disease 0 0.06314884126186371
- I-Disease 0 0.0001755707198753953
PLL I-Disease 0 0.0002287268143845722
) O 0 2.749015663994214e-07
, O 0 1.4609970833134867e-07
a O 0 8.08013226105686e-07
rare O 0 2.9775128496112302e-05
clonal B-Disease 0 0.00022718975378666073
malignancy I-Disease 0 0.04183928295969963
with O 0 2.820620181864797e-07
similarities O 0 1.3643860938827856e-06
to O 0 1.2594772158536216e-07
a O 0 2.755884679572773e-06
mature B-Disease 0 6.613748701056466e-05
T I-Disease 0 0.3854880928993225
- I-Disease 0 0.0005442386609502137
cell I-Disease 0 0.0008690990507602692
leukaemia I-Disease 0 0.1602807343006134
seen O 0 1.639248694118578e-05
in O 0 2.354236812607269e-06
A B-Disease 1 0.8979399800300598
- I-Disease 1 0.7290002107620239
T I-Disease 1 0.9994756579399109
, O 0 5.208298148318136e-07
we O 0 5.088384824603054e-08
demonstrate O 0 8.078516344767195e-08
a O 0 1.4161453520955547e-07
high O 0 8.966163136392424e-07
frequency O 0 4.038236625092395e-07
of O 0 6.455131540406e-08
ATM O 0 9.068504732567817e-05
mutations O 0 0.0002675741561688483
in O 0 2.7090738512924872e-05
T B-Disease 1 0.9486182928085327
- I-Disease 0 0.0024679217021912336
PLL I-Disease 0 0.00424205232411623
. O 0 3.056492278119549e-05

In O 0 3.825374733423814e-06
marked O 0 1.4923301932867616e-05
contrast O 0 1.6546235883652116e-06
to O 0 3.235022205672067e-08
the O 0 2.0818032453462365e-07
ATM O 0 5.995747051201761e-05
mutation O 0 2.2457144950749353e-05
pattern O 0 1.835297189245466e-05
in O 0 5.131883426656714e-06
A B-Disease 1 0.9982622265815735
- I-Disease 1 0.9954743981361389
T I-Disease 1 0.9998432397842407
, O 0 4.4598837689591164e-07
the O 0 1.9761001723850313e-08
most O 0 4.100776607174339e-08
frequent O 0 9.041623343364336e-07
nucleotide O 0 8.436340976913925e-07
changes O 0 1.0345511327614076e-06
in O 0 3.062472160308971e-07
this O 0 4.838951213059772e-07
leukaemia B-Disease 0 0.3416469097137451
were O 0 4.852259735343978e-06
missense O 0 0.0010311651276424527
mutations O 0 0.0015843049623072147
. O 0 2.193988621002063e-05

These O 0 2.1187692311741557e-07
clustered O 0 1.6998274077195674e-05
in O 0 5.829151064062899e-07
the O 0 2.5115602397818293e-07
region O 0 1.1854355079776724e-06
corresponding O 0 2.4944449705799343e-07
to O 0 2.1613326239844355e-08
the O 0 1.0297500097067314e-07
kinase O 0 2.0554541606543353e-06
domain O 0 3.8030663063182146e-07
, O 0 1.7194078338889085e-07
which O 0 2.4572944568035382e-08
is O 0 3.3524447218269415e-08
highly O 0 2.68961230176501e-07
conserved O 0 4.5942775273033476e-07
in O 0 1.431753986480544e-07
ATM O 0 2.1075569748063572e-05
- O 0 9.497292921878397e-06
related O 0 6.63954267565714e-07
proteins O 0 1.5284317100849876e-07
in O 0 2.047769527280252e-07
mouse O 0 9.02444571693195e-06
, O 0 2.634488396324741e-07
yeast O 0 4.1428588701819535e-06
and O 0 6.805666430409474e-07
Drosophila O 0 5.824739218951436e-06
. O 0 5.936557499808259e-06

The O 0 2.4566863885411294e-06
resulting O 0 1.7270825992454775e-05
amino O 0 9.576950105838478e-06
- O 0 7.113815081538633e-05
acid O 0 1.0936150829365943e-05
substitutions O 0 1.1617379414019524e-06
are O 0 2.924265984916019e-08
predicted O 0 7.153121259761974e-07
to O 0 1.0714730436234277e-08
interfere O 0 1.0142721293959767e-06
with O 0 8.407442351199279e-07
ATP O 0 0.004299044609069824
binding O 0 1.8864244339056313e-05
or O 0 2.124174216078245e-06
substrate O 0 2.4029328415053897e-05
recognition O 0 1.840737968450412e-05
. O 0 1.704565693216864e-05

Two O 0 2.041899733740138e-07
of O 0 2.01769509544647e-07
seventeen O 0 1.9414088455960155e-05
mutated O 0 0.0004427037201821804
T B-Disease 0 0.05774964392185211
- I-Disease 0 8.549246558686718e-05
PLL I-Disease 0 0.00012498530850280076
samples O 0 1.039004359881801e-06
had O 0 3.5845300772052724e-07
a O 0 3.2633940350024204e-07
previously O 0 4.044382421852788e-06
reported O 0 5.984762537991628e-05
A B-Disease 1 0.9536918997764587
- I-Disease 1 0.6056482791900635
T I-Disease 1 0.9964817762374878
allele O 0 0.0002574024838395417
. O 0 2.3961525585036725e-05

In O 0 2.0958800632797647e-06
contrast O 0 7.236843885038979e-06
, O 0 9.241063025910989e-07
no O 0 4.6281340360110335e-07
mutations O 0 5.489321665663738e-06
were O 0 2.6672591957321856e-07
detected O 0 9.15731470740866e-06
in O 0 4.738465619880117e-08
the O 0 6.403980989944102e-08
p53 O 0 2.834663519024616e-06
gene O 0 2.830195853675832e-06
, O 0 3.9070565094334597e-07
suggesting O 0 1.2680321788138826e-06
that O 0 1.1083167095193858e-07
this O 0 1.3433922276817611e-06
tumour B-Disease 1 0.9999572038650513
suppressor O 0 0.00044333230471238494
is O 0 6.883539072077838e-07
not O 0 7.461409268216812e-08
frequently O 0 1.060224690263567e-06
altered O 0 7.5595075941237155e-06
in O 0 1.692169576017477e-06
this O 0 2.4252026378235314e-06
leukaemia B-Disease 1 0.9897583723068237
. O 0 2.3984959625522606e-05

Occasional O 0 0.00025558253400959074
missense O 0 0.0012145487125962973
mutations O 0 0.00012221247015986592
in O 0 4.6462747604891774e-07
ATM O 0 2.5047504095709883e-05
were O 0 4.1611744450165133e-07
also O 0 4.0927133682089334e-07
found O 0 1.496408344792144e-06
in O 0 3.461682126726373e-06
tumour B-Disease 1 0.9998952150344849
DNA O 0 1.3332452908798587e-05
from O 0 2.974535391331301e-07
patients O 0 1.8659396801012917e-06
with O 0 2.289649358999668e-07
B B-Disease 0 0.00019194673222955316
- I-Disease 0 0.0003250101290177554
cell I-Disease 0 0.0015408957842737436
non I-Disease 0 0.0025848790537565947
- I-Disease 1 0.9695013165473938
Hodgkins I-Disease 1 0.9995848536491394
lymphomas I-Disease 1 0.9297385811805725
( O 0 3.3729124879755545e-06
B B-Disease 0 6.628168921452016e-05
- I-Disease 0 1.8194927179138176e-05
NHL I-Disease 0 1.69047689269064e-05
) O 0 4.0748208363083904e-08
and O 0 5.7456077229289804e-08
a O 0 1.1906917052328936e-06
B B-Disease 0 3.177262988174334e-05
- I-Disease 0 4.811149483430199e-05
NHL I-Disease 0 0.00010408024536445737
cell O 0 0.00015469918434973806
line O 0 0.00024235688033513725
. O 0 1.2139687896706164e-05

The O 0 6.264701823965879e-07
evidence O 0 2.0407159695423616e-07
of O 0 2.615187710830469e-08
a O 0 2.3768498635945434e-07
significant O 0 5.216529075369181e-07
proportion O 0 1.0901765108428663e-06
of O 0 2.9764083819827647e-07
loss O 0 0.00042737755575217307
- O 0 1.7653850591159426e-05
of O 0 2.3573862506509613e-07
- O 0 1.6050125850597396e-05
function O 0 2.2968474695517216e-06
mutations O 0 8.446294486930128e-06
and O 0 1.0116893633949076e-07
a O 0 4.194350253783341e-07
complete O 0 1.9377646367502166e-06
absence O 0 2.6662773962016217e-06
of O 0 2.5860563468427245e-08
the O 0 1.2142842820139776e-07
normal O 0 2.0262696125428192e-06
copy O 0 2.3351635718427133e-06
of O 0 6.243486438961554e-08
ATM O 0 2.1570062017417513e-05
in O 0 4.2141854805777257e-07
the O 0 4.3037007912971603e-07
majority O 0 6.834277428424684e-07
of O 0 2.055273853329709e-06
mutated O 0 0.023400969803333282
tumours B-Disease 1 0.9999383687973022
establishes O 0 0.0002779167261905968
somatic O 0 0.0001436157472198829
inactivation O 0 0.003526046173647046
of O 0 7.265843748882617e-08
this O 0 2.5334751185823734e-08
gene O 0 4.4874445848108735e-07
in O 0 1.3168894952286792e-07
the O 0 2.0905289943584648e-07
pathogenesis O 0 0.00022477655147667974
of O 0 1.1117059557363973e-06
sporadic B-Disease 0 0.002803951967507601
T I-Disease 1 0.9926323294639587
- I-Disease 0 0.0006123111234046519
PLL I-Disease 0 0.0004080413782503456
and O 0 6.324895025500155e-07
suggests O 0 6.099955953686731e-07
that O 0 9.581748727782724e-09
ATM O 0 5.427185442385962e-06
acts O 0 2.2183692180988146e-06
as O 0 3.737844053830486e-06
a O 0 0.0002866465656552464
tumour B-Disease 1 0.9999731779098511
suppressor O 0 0.011848698370158672
. O 0 2.914657670771703e-05

As O 0 4.148580046603456e-06
constitutional O 0 1.0722615115810186e-05
DNA O 0 4.903373792330967e-06
was O 0 2.5385791104781674e-06
not O 0 2.0504302256085793e-08
available O 0 4.3932441684546575e-08
, O 0 1.9995127331640106e-07
a O 0 2.140403694284032e-06
putative O 0 0.00031358806882053614
hereditary O 1 0.9826765060424805
predisposition O 0 0.0072114840149879456
to O 0 1.349094782199245e-05
T B-Disease 1 0.9657022356987
- I-Disease 0 0.00019223024719394743
PLL I-Disease 0 0.00021735657355748117
will O 0 1.327986467458686e-07
require O 0 1.7084678916035045e-07
further O 0 2.3610940047547047e-07
investigation O 0 3.6051897041033953e-06
. O 0 1.1478857686597621e-06
. O 0 3.89263595934608e-06

Myotonic B-Disease 1 0.9996857643127441
dystrophy I-Disease 1 0.9998049139976501
protein O 0 9.065867925528437e-05
kinase O 0 7.062647637212649e-05
is O 0 2.398788296886778e-07
involved O 0 4.971782985307982e-08
in O 0 1.6091650678617953e-08
the O 0 1.6785666190344273e-08
modulation O 0 3.708469478169718e-07
of O 0 2.5656278879182537e-08
the O 0 3.302485254152998e-07
Ca2 O 0 3.8200028939172626e-05
+ O 0 8.94517288543284e-05
homeostasis O 0 0.018902337178587914
in O 0 1.8055263353744522e-05
skeletal O 1 0.9423667788505554
muscle O 1 0.673647403717041
cells O 0 0.0006951522664166987
. O 0 1.910576429509092e-05

Myotonic B-Disease 1 0.9999562501907349
dystrophy I-Disease 1 0.999991774559021
( O 0 0.0005700586480088532
DM B-Disease 1 0.9998548030853271
) O 0 1.420678472641157e-06
, O 0 3.688104754928645e-07
the O 0 2.0175527026822238e-07
most O 0 2.656407104950631e-06
prevalent O 0 0.005497707054018974
muscular B-Disease 1 0.9998278617858887
disorder I-Disease 1 0.9998886585235596
in O 0 8.771555258135777e-06
adults O 0 1.795764001144562e-05
, O 0 1.7846027731138747e-06
is O 0 1.6173859194168472e-06
caused O 0 1.7922260667546652e-05
by O 0 2.2802922217124433e-07
( O 0 2.525893307847582e-07
CTG O 0 3.297166767879389e-05
) O 0 1.6235102862083295e-07
n O 0 8.034045094973408e-06
- O 0 8.480622454953846e-06
repeat O 0 1.5545232372460305e-06
expansion O 0 2.5708109774313925e-07
in O 0 1.49448098341054e-08
a O 0 1.5717358081701605e-08
gene O 0 1.8788121280977066e-08
encoding O 0 2.9771001663903007e-08
a O 0 3.955076408601599e-07
protein O 0 8.50771584737231e-07
kinase O 0 1.3647293599206023e-05
( O 0 7.243344271046226e-07
DM B-Disease 1 0.8916006088256836
protein O 0 4.8358833737438545e-06
kinase O 0 2.771253821265418e-05
; O 0 4.268250961558806e-07
DMPK O 0 7.489405834348872e-05
) O 0 6.2889512264519e-08
and O 0 7.256204526129295e-08
involves O 0 6.692485499115719e-07
changes O 0 1.6359548453692696e-06
in O 0 9.997050938181928e-07
cytoarchitecture O 0 0.00014222475874703377
and O 0 5.872080691915471e-06
ion O 0 0.0036263340152800083
homeostasis O 1 0.9605944156646729
. O 0 0.00010930264397757128

To O 0 1.1947906841669464e-07
obtain O 0 2.6619710524755646e-07
clues O 0 1.9858539417327847e-06
to O 0 2.4179568569593357e-08
the O 0 1.3442569013477623e-07
normal O 0 2.9677200927835656e-06
biological O 0 2.8072449822502676e-06
role O 0 8.243287084042095e-07
of O 0 1.4254921154588374e-07
DMPK O 0 0.00014771052519790828
in O 0 7.045057373034069e-07
cellular O 0 0.0003382036229595542
ion O 0 0.0005424871342256665
homeostasis O 0 0.028868859633803368
, O 0 1.350227762486611e-06
we O 0 1.5507518469348724e-07
have O 0 4.7259018032264066e-08
compared O 0 3.046352219371329e-07
the O 0 1.3386969044404395e-07
resting O 0 3.930470847990364e-05
[ O 0 1.7073715525839361e-06
Ca2 O 0 3.182194859618903e-06
+ O 0 5.138592769071693e-06
] O 0 3.994996404799167e-06
i O 0 4.335451194492634e-06
, O 0 4.604115488859861e-08
the O 0 1.8500509568752932e-08
amplitude O 0 2.9212651497800834e-07
and O 0 2.0837337899592967e-07
shape O 0 1.7357049728161655e-05
of O 0 7.584056334053457e-07
depolarization O 0 0.00010792331886477768
- O 0 0.00019664710271172225
induced O 0 0.00013970000145491213
Ca2 O 0 1.5833380530239083e-05
+ O 0 1.35296531880158e-05
transients O 0 3.563266000128351e-05
, O 0 1.8462512230144057e-07
and O 0 2.9766857423396686e-08
the O 0 1.8572951177020514e-08
content O 0 6.399182694849515e-08
of O 0 1.1369198915645029e-07
ATP O 0 0.003368820995092392
- O 0 3.662096059997566e-05
driven O 0 6.848979410278844e-06
ion O 0 5.941504787188023e-05
pumps O 0 5.322160723153502e-05
in O 0 6.920399755472317e-07
cultured O 0 6.0202688473509625e-05
skeletal O 0 0.014757968485355377
muscle O 0 0.0012184202205389738
cells O 0 5.152779522177298e-06
of O 0 1.0912463466183908e-07
wild O 0 6.933043550816365e-06
- O 0 6.086583744036034e-05
type O 0 6.195340392878279e-05
and O 0 2.9446950975398067e-06
DMPK O 0 0.0006953494157642126
[ O 0 6.945968198124319e-05
- O 0 0.00017453351756557822
/ O 0 0.00011853870819322765
- O 0 0.0003885448968503624
] O 0 6.806701276218519e-05
knockout O 0 0.007333583664149046
mice O 0 0.00043782993452623487
. O 0 1.0398884114692919e-05

In O 0 1.1244176675972994e-05
vitro O 0 0.00010384024790255353
- O 0 0.00010098259372171015
differentiated O 0 4.7349330998258665e-05
DMPK O 0 0.0012417281977832317
[ O 0 6.937646685400978e-05
- O 0 0.00014486390864476562
/ O 0 6.448966450989246e-05
- O 0 8.05849558673799e-05
] O 0 1.0045237104350235e-05
myotubes O 0 3.189530980307609e-05
exhibit O 0 3.065226792386966e-06
a O 0 1.1505654811116983e-06
higher O 0 2.7815524390462087e-06
resting O 0 6.310312892310321e-05
[ O 0 1.6899875845410861e-06
Ca2 O 0 2.9822062970197294e-06
+ O 0 6.023686637490755e-06
] O 0 4.809791334992042e-06
i O 0 2.6356167381891282e-06
than O 0 5.322907625782136e-08
do O 0 1.8666270307221566e-07
wild O 0 1.5393751482406515e-06
- O 0 2.9566113880719058e-05
type O 0 2.4115877749864012e-05
myotubes O 0 7.81532799010165e-05
because O 0 1.8244737987060944e-07
of O 0 6.806618824128918e-09
an O 0 4.724143920498136e-08
altered O 0 2.851169483619742e-06
open O 0 2.6821303436008748e-06
probability O 0 8.003794249589191e-08
of O 0 4.6832429489995775e-08
voltage O 0 2.2176134734763764e-05
- O 0 9.933056389854755e-06
dependent O 0 1.9361077647772618e-06
l O 0 3.483482214505784e-05
- O 0 5.247722583590075e-06
type O 0 4.586289378494257e-06
Ca2 O 0 4.0326203816221096e-06
+ O 0 3.6257811188988853e-06
and O 0 3.528085699144867e-07
Na O 0 4.594362326315604e-05
+ O 0 1.2995757970202249e-05
channels O 0 1.7247486539417878e-05
. O 0 1.316429097641958e-05

The O 0 6.161402325233212e-06
mutant O 0 0.00011500441178213805
myotubes O 0 0.00026059383526444435
exhibit O 0 6.4739501794974785e-06
smaller O 0 1.8032335447060177e-06
and O 0 3.792663960666687e-07
slower O 0 3.3106759929069085e-06
Ca2 O 0 1.5490668374695815e-05
+ O 0 1.1718779205693863e-05
responses O 0 1.4784303630221984e-06
upon O 0 9.709723371997825e-07
triggering O 0 2.0689984012278728e-05
by O 0 2.5320167651443626e-07
acetylcholine O 0 0.00014994217781350017
or O 0 7.491692940675421e-06
high O 0 2.7680944185703993e-05
external O 0 3.488884249236435e-05
K O 0 0.0001304246106883511
+ O 0 0.00012611245620064437
. O 0 1.0011764061346184e-05

In O 0 1.9500762391544413e-06
addition O 0 9.7513145647099e-07
, O 0 4.734278320484009e-07
we O 0 1.5196036429188098e-07
observed O 0 2.327578840777278e-07
that O 0 5.083483411993939e-09
these O 0 1.4142067961131488e-08
Ca2 O 0 1.1733764040400274e-05
+ O 0 4.942094528814778e-05
transients O 0 0.0003858369600493461
partially O 0 9.9470533314161e-05
result O 0 1.4165913171382272e-06
from O 0 4.895225913514878e-08
an O 0 2.417846189928241e-08
influx O 0 9.710096549042646e-08
of O 0 1.1167660574074034e-08
extracellular O 0 7.993676263140514e-07
Ca2 O 0 2.6130544483748963e-06
+ O 0 1.6724264924050658e-06
through O 0 1.1672090494130316e-07
the O 0 3.7572542055386293e-07
l O 0 5.599054566118866e-05
- O 0 1.049510592565639e-05
type O 0 1.1202573659829795e-05
Ca2 O 0 8.988304216472898e-06
+ O 0 1.4436261153605301e-05
channel O 0 2.718851828831248e-05
. O 0 5.060692728875438e-06

Neither O 0 8.417026037932374e-06
the O 0 7.508420907242908e-08
content O 0 2.913066339260695e-07
nor O 0 1.1360066309862304e-06
the O 0 8.36990849961694e-08
activity O 0 1.9360619774033694e-07
of O 0 3.936771975077136e-08
Na O 0 4.466662721824832e-05
+ O 0 2.380900150456e-05
/ O 0 1.3819053492625244e-05
K O 0 1.022116975946119e-05
+ O 0 1.3676606613444164e-05
ATPase O 0 7.916445611044765e-05
and O 0 5.46826458958094e-06
sarcoplasmic O 0 0.0006555247819051147
reticulum O 0 0.00033708804403431714
Ca2 O 0 3.222926170565188e-05
+ O 0 3.4381002478767186e-05
- O 0 2.7207010134588927e-05
ATPase O 0 2.4765617126831785e-05
are O 0 1.070217265919382e-07
affected O 0 2.3577331376145594e-06
by O 0 1.0021612979471684e-06
DMPK O 0 0.003063342534005642
absence O 0 0.00010908429976552725
. O 0 9.237334779754747e-06

In O 0 2.023760998781654e-06
conclusion O 0 1.0643519772202126e-06
, O 0 2.8264904017305525e-07
our O 0 1.5423950117110508e-07
data O 0 7.749644055365934e-07
suggest O 0 6.915075800861814e-07
that O 0 4.837327338691466e-08
DMPK O 0 6.998300523264334e-05
is O 0 1.71021554251638e-07
involved O 0 2.2307112601538392e-07
in O 0 8.158556852322363e-08
modulating O 0 7.35889489078545e-06
the O 0 1.5702472921930166e-07
initial O 0 4.6449989099528466e-07
events O 0 3.4418579275552474e-07
of O 0 1.7717034950237576e-07
excitation O 0 0.00017160901916213334
- O 0 0.00044397832243703306
contraction O 0 9.514552220935002e-05
coupling O 0 3.9457860111724585e-05
in O 0 8.960932973423041e-06
skeletal O 1 0.88393634557724
muscle O 0 0.4059786796569824
. O 0 3.4277111353731016e-06
. O 0 4.933101536153117e-06

Constitutional O 0 0.0009241829393431544
RB1 O 0 0.0266106054186821
- O 0 0.0003655164618976414
gene O 0 5.2855772082693875e-05
mutations O 0 0.00016067936667241156
in O 0 3.2785151233838405e-06
patients O 0 3.2260039006359875e-05
with O 0 2.1267485408316134e-06
isolated O 0 0.001763933920301497
unilateral B-Disease 0 0.0023346738889813423
retinoblastoma I-Disease 1 0.9486989974975586
. O 0 5.474296267493628e-05

In O 0 4.0405925574305e-06
most O 0 2.6017230538855074e-06
patients O 0 1.3708285223401617e-05
with O 0 6.774099006179313e-07
isolated O 0 0.00048328141565434635
unilateral B-Disease 0 0.0004325560003053397
retinoblastoma I-Disease 1 0.9832581877708435
, O 0 4.456613169168122e-05
tumor B-Disease 0 0.03720971941947937
development O 0 3.515997377689928e-07
is O 0 1.9645784732347238e-07
initiated O 0 7.368771548499353e-07
by O 0 4.523640484421776e-08
somatic O 0 5.53921108803479e-06
inactivation O 0 0.00034628427238203585
of O 0 3.258150371721058e-08
both O 0 1.8456651673659508e-07
alleles O 0 1.1616139090619981e-06
of O 0 2.295423513487549e-07
the O 0 8.030023309402168e-06
RB1 O 0 0.010099894367158413
gene O 0 0.00014157177065499127
. O 0 1.6876803783816285e-05

However O 0 2.6059892661578488e-06
, O 0 2.4731926373533497e-07
some O 0 7.052846751065545e-09
of O 0 3.8625135090342155e-08
these O 0 1.5398934749555337e-07
patients O 0 1.1537196769495495e-05
can O 0 4.905039077129913e-07
transmit O 0 0.0003222895902581513
retinoblastoma B-Disease 0 0.040212832391262054
predisposition O 0 0.00044118621735833585
to O 0 1.734090346872108e-07
their O 0 3.4852769204007927e-07
offspring O 0 6.209518323885277e-05
. O 0 1.4691101569042075e-05

To O 0 8.694932063235683e-08
determine O 0 2.0635764030885184e-07
the O 0 8.357353920018795e-08
frequency O 0 2.6042428089567693e-06
and O 0 4.662418575662741e-07
nature O 0 2.394487637502607e-06
of O 0 5.350681817617442e-07
constitutional O 0 9.780965046957135e-05
RB1 O 0 0.027603434398770332
- O 0 0.0003770844778046012
gene O 0 5.495384903042577e-05
mutations O 0 0.00015480189176741987
in O 0 3.248187340432196e-06
patients O 0 1.3529086572816595e-05
with O 0 8.149611971930426e-07
isolated O 0 0.0003690387820824981
unilateral B-Disease 0 0.0001297859416808933
retinoblastoma I-Disease 0 0.008172652684152126
, O 0 1.2602057495314511e-06
we O 0 2.3229374335187458e-07
analyzed O 0 1.611126322131895e-06
DNA O 0 2.3071922896633623e-06
from O 0 3.645971276000637e-07
peripheral O 0 0.00018143141642212868
blood O 0 0.0005735556478612125
and O 0 1.4553912478731945e-05
from O 0 7.621351687703282e-05
tumor B-Disease 1 0.9988260865211487
tissue O 0 0.4865417778491974
. O 0 2.659716301423032e-05

The O 0 3.378601377335144e-06
analysis O 0 6.559414032381028e-06
of O 0 5.5520940804854035e-06
tumors B-Disease 1 0.9999818801879883
from O 0 2.943038680314203e-06
54 O 0 8.254810381913558e-06
( O 0 1.7552876840909448e-07
71 O 0 1.8043550653601415e-06
% O 0 1.3607299287343722e-08
) O 0 1.3196724601982623e-08
of O 0 3.099091472336113e-08
76 O 0 8.683811756782234e-06
informative O 0 2.195189881604165e-05
patients O 0 0.00023235891421791166
showed O 0 0.00012687209527939558
loss O 0 0.00015460951544810086
of O 0 8.658108185954916e-07
constitutional O 0 0.00029655336402356625
heterozygosity O 0 0.02146158181130886
( O 0 5.380329821491614e-05
LOH O 1 0.9978899359703064
) O 0 2.3797877020115266e-06
at O 0 3.846677645924501e-05
intragenic O 0 0.0009122281335294247
loci O 0 0.00021391281916294247
. O 0 1.7221978851011954e-05

Three O 0 2.8207380182720954e-06
of O 0 8.020770678740519e-07
13 O 0 5.922909622313455e-05
uninformative O 0 0.26954686641693115
patients O 0 0.0014562910655513406
had O 0 3.047565223823767e-05
constitutional O 0 0.00010170739551540464
deletions O 0 0.0005604276084341109
. O 0 3.4320099075557664e-05

For O 0 5.085513521407847e-07
39 O 0 1.198502468469087e-05
randomly O 0 4.050006282341201e-06
selected O 0 2.4093302272376604e-05
tumors B-Disease 1 0.9999895095825195
, O 0 8.145928404701408e-06
SSCP O 0 0.0015350079629570246
, O 0 4.85700093122432e-06
hetero O 0 0.0002116359828505665
- O 0 3.483276304905303e-05
duplex O 0 4.001610795967281e-05
analysis O 0 3.882552732648037e-07
, O 0 9.174731729899577e-08
sequencing O 0 3.219547579647042e-07
, O 0 2.7533317847883154e-07
and O 0 2.8855492928414606e-07
Southern O 0 2.44936882154434e-06
blot O 0 6.485656922450289e-05
analysis O 0 1.2099656032660278e-07
were O 0 2.616155470036574e-08
used O 0 6.658120810243418e-08
to O 0 5.962260019032328e-08
identify O 0 6.341374955809442e-06
mutations O 0 0.0002785751421470195
. O 0 1.073434941645246e-05

Mutations O 0 0.00017286719230469316
were O 0 1.546612224956334e-06
detected O 0 3.754592762561515e-05
in O 0 2.9017317615398497e-07
21 O 0 1.497146286055795e-06
( O 0 6.4566833657409e-08
91 O 0 1.1117398344140383e-06
% O 0 2.2970082724782515e-08
) O 0 4.981560408623409e-08
of O 0 6.598525033041369e-07
23 O 0 0.005990548990666866
tumors B-Disease 1 0.999996542930603
with O 0 0.0011038912925869226
LOH O 1 0.9998063445091248
. O 0 9.717469220049679e-05

In O 0 3.7910328956058947e-06
6 O 0 4.370971510070376e-06
( O 0 8.811498020122599e-08
38 O 0 5.62684647320566e-07
% O 0 8.649985616671074e-09
) O 0 4.245346119091664e-08
of O 0 4.2760487417581317e-07
16 O 0 0.0017329141264781356
tumors B-Disease 1 0.9999959468841553
without O 0 0.0003072464605793357
LOH O 1 0.9985882639884949
, O 0 1.778153887244116e-06
one O 0 4.787417537954752e-07
mutation O 0 7.842760169296525e-06
was O 0 4.963444098393666e-06
detected O 0 1.3745031537837349e-05
, O 0 7.867977558362327e-08
and O 0 5.682992920696961e-08
in O 0 1.7639331417740323e-07
9 O 0 2.201609959229245e-06
( O 0 7.021052539357697e-08
56 O 0 6.340295044537925e-07
% O 0 1.1278351585986002e-08
) O 0 2.8053390721538563e-08
of O 0 1.169760963648514e-07
the O 0 4.67331446998287e-05
tumors B-Disease 1 0.9999983310699463
without O 0 0.00035322015173733234
LOH O 1 0.9992445707321167
, O 0 9.528806117486965e-07
both O 0 1.797644699763623e-07
mutations O 0 9.832354407990351e-06
were O 0 4.847643708671967e-07
found O 0 2.8622796435229247e-06
. O 0 3.6458011436479865e-06

Thus O 0 4.762758635479258e-06
, O 0 2.83996797634245e-07
a O 0 1.1837258284685959e-07
total O 0 1.9564559750051558e-08
of O 0 2.7824937021136975e-08
45 O 0 5.179509230401891e-07
mutations O 0 4.164618530921871e-06
were O 0 3.898149998349254e-07
identified O 0 5.9590474847937e-06
in O 0 9.997909728554077e-06
tumors B-Disease 1 0.9999933242797852
of O 0 3.892175755026983e-06
36 O 0 0.00011407537385821342
patients O 0 0.00016909297846723348
. O 0 8.162880476447754e-06

Thirty O 0 3.106435542576946e-05
- O 0 2.3138925826060586e-05
nine O 0 5.649634431392769e-07
of O 0 4.402252784529992e-08
the O 0 5.579911999120668e-07
mutations O 0 3.0284267268143594e-05
- O 0 9.908174433803651e-06
including O 0 2.995435579578043e-07
34 O 0 1.3726919405598892e-06
small O 0 5.663795263899374e-07
mutations O 0 1.6931518985074945e-05
, O 0 4.486716989049455e-07
2 O 0 9.279920618610049e-07
large O 0 1.423564526703558e-06
structural O 0 0.001622842508368194
alterations O 0 0.0006415481329895556
, O 0 1.775066948539461e-06
and O 0 8.975873697636416e-07
hypermethylation O 0 0.002032962627708912
in O 0 1.2286041055631358e-05
3 O 0 0.0007243969012051821
tumors O 1 0.9999901056289673
- O 0 7.558226207038388e-05
were O 0 2.5784621016100573e-07
not O 0 8.981211152558899e-08
detected O 0 8.010328201635275e-06
in O 0 4.329127634150609e-08
the O 0 6.030159482861563e-08
corresponding O 0 1.9633175725175533e-06
peripheral O 0 0.0017853319877758622
blood O 0 0.001982335699722171
DNA O 0 0.00015671389701310545
. O 0 1.721183434710838e-05

In O 0 2.6107629764737794e-06
6 O 0 4.807947789231548e-06
( O 0 1.2225970635881822e-07
17 O 0 4.996443294658093e-07
% O 0 3.311155571950053e-09
) O 0 5.6209499277315444e-09
of O 0 6.4960730128404975e-09
the O 0 1.629270940384231e-07
36 O 0 7.980780537764076e-06
patients O 0 5.638816674036207e-06
, O 0 1.0660387772531976e-07
a O 0 3.723715167325281e-07
mutation O 0 4.446931598067749e-06
was O 0 2.8055505936208647e-06
detected O 0 1.0874106010305695e-05
in O 0 7.808296942357629e-08
constitutional O 0 5.469613029163156e-07
DNA O 0 9.702891929919133e-07
, O 0 1.1418987355682475e-07
and O 0 5.6569835038544625e-08
1 O 0 1.53365590449539e-07
of O 0 1.4606077236578585e-08
these O 0 3.160619499453787e-08
mutations O 0 5.289486580295488e-06
is O 0 1.3807834875478875e-07
known O 0 2.1916079617767537e-07
to O 0 1.8912666988057936e-08
be O 0 8.832497400135253e-08
associated O 0 4.689866841545154e-07
with O 0 5.960895919088216e-07
reduced O 0 4.145180355408229e-05
expressivity O 0 0.017397820949554443
. O 0 2.9905946576036513e-05

The O 0 2.411047944406164e-06
presence O 0 4.478826213016873e-06
of O 0 1.864308956101013e-07
a O 0 3.973843377025332e-06
constitutional O 0 2.3304904971155338e-05
mutation O 0 2.6858884666580707e-05
was O 0 3.6268636449676706e-06
not O 0 3.295022565907857e-08
associated O 0 1.3419462163710705e-07
with O 0 2.384004815780827e-08
an O 0 1.3389420416842768e-07
early O 0 4.713780526799383e-06
age O 0 9.201733519148547e-06
at O 0 5.535077434615232e-05
treatment O 0 0.00016583388787694275
. O 0 6.535336524393642e-06

In O 0 8.820476068649441e-06
1 O 0 1.8435592210153118e-05
patient O 0 7.574843766633421e-05
, O 0 6.591046712856041e-07
somatic O 0 3.9546837797388434e-05
mosaicism O 0 0.002134335460141301
was O 0 1.1266211913607549e-05
demonstrated O 0 8.291444828500971e-07
by O 0 1.4920599866741213e-08
molecular O 0 1.9345220607647207e-06
analysis O 0 1.232816089213884e-07
of O 0 2.594128645228011e-08
DNA O 0 1.5690258123868261e-06
and O 0 3.34554016490074e-07
RNA O 0 7.6098867793916725e-06
from O 0 9.45874660374102e-07
peripheral O 0 0.002397484378889203
blood O 0 0.006341676227748394
. O 0 3.2321968319593e-05

In O 0 7.027844276308315e-06
2 O 0 1.645945303607732e-05
patients O 0 1.145547503256239e-05
without O 0 3.9968841747395345e-07
a O 0 2.9487362098734593e-06
detectable O 0 0.000443223281763494
mutation O 0 2.7002262868336402e-05
in O 0 1.2629138836928178e-06
peripheral O 0 0.0012623232323676348
blood O 0 0.0019443747587502003
, O 0 5.940130904491525e-06
mosaicism O 0 0.0010856837034225464
was O 0 2.691339068405796e-05
suggested O 0 2.27234113481245e-06
because O 0 2.558647622663557e-07
1 O 0 3.9789594552530616e-07
of O 0 6.18757738379827e-08
the O 0 3.000046262968681e-06
patients O 0 0.0009917013812810183
showed O 0 0.007395435124635696
multifocal O 1 0.9999693632125854
tumors B-Disease 1 0.9999996423721313
and O 0 2.7206988306716084e-06
the O 0 1.0995617572007177e-07
other O 0 5.477208375737064e-08
later O 0 8.452125257463194e-07
developed O 0 6.778449460398406e-06
bilateral B-Disease 0 0.00046643122914247215
retinoblastoma I-Disease 1 0.8407070636749268
. O 0 5.647530633723363e-05

In O 0 1.471223413318512e-06
conclusion O 0 2.007163629969e-06
, O 0 5.161201102055202e-07
our O 0 2.563407974776055e-07
results O 0 1.4022001550983987e-06
emphasize O 0 1.647440399210609e-06
that O 0 6.310965261491219e-08
the O 0 2.468100888108893e-07
manifestation O 0 4.137590076425113e-05
and O 0 1.2217712992423913e-06
transmissibility O 0 0.00021933684183750302
of O 0 3.981893996751751e-07
retinoblastoma B-Disease 0 0.0005517863901332021
depend O 0 1.3160059779693256e-06
on O 0 1.7209348470714758e-06
the O 0 1.5113108986497537e-07
nature O 0 1.5374737358797574e-06
of O 0 2.1141264738844256e-08
the O 0 1.0521349480541176e-07
first O 0 5.027358156439732e-07
mutation O 0 2.8379879495332716e-06
, O 0 5.325629359731465e-08
its O 0 1.6276985093099938e-08
time O 0 1.1650849529587504e-07
in O 0 8.892777714208933e-08
development O 0 8.927225536581318e-08
, O 0 1.342551598781938e-07
and O 0 3.4758855349537043e-08
the O 0 2.737563775667695e-08
number O 0 2.5746674126025937e-08
and O 0 7.075687591395763e-08
types O 0 5.570234975493804e-07
of O 0 9.164919845261466e-08
cells O 0 2.661285634530941e-06
that O 0 4.650166829378577e-08
are O 0 4.5307295692964544e-08
affected O 0 1.3205936966187437e-06
. O 0 5.729880854232761e-07
. O 0 2.348695488763042e-06

Hereditary B-Disease 1 0.9998986721038818
deficiency I-Disease 1 0.9998927116394043
of I-Disease 0 6.901780125190271e-07
the I-Disease 0 6.56627094031137e-07
fifth I-Disease 0 2.095837589877192e-05
component I-Disease 0 4.605784852174111e-06
of I-Disease 0 5.3551787004835205e-08
complement I-Disease 0 3.1524189125775592e-06
in O 0 5.0393291530781426e-06
man O 0 0.0003346293233335018
. O 0 1.0445030966366176e-05

I O 0 0.0320417657494545
. O 0 4.926481778966263e-05

Clinical O 0 0.0006370469927787781
, O 0 1.0631240002112463e-05
immunochemical O 0 0.00041581469122320414
, O 0 2.5502752123429673e-06
and O 0 1.5838900253584143e-06
family O 0 9.753894119057804e-06
studies O 0 8.464744496450294e-06
. O 0 5.5531477300974075e-06

The O 0 2.6901200271822745e-06
first O 0 1.970687435459695e-06
recognized O 0 1.3678120012627915e-05
human O 0 4.23870405938942e-05
kindred O 0 0.03598278388381004
with O 0 0.001358845504000783
hereditary B-Disease 1 0.9999923706054688
deficiency I-Disease 1 0.9999746084213257
of I-Disease 0 7.021119472483406e-07
the I-Disease 0 9.906245850288542e-07
fifth I-Disease 0 1.9387334759812802e-05
component I-Disease 0 4.707612333731959e-06
of I-Disease 0 5.9159184218060545e-08
complement I-Disease 0 2.740265017564525e-06
( O 0 1.7030945400620112e-06
C5 O 0 0.0009287613211199641
) O 0 7.231031418086786e-07
is O 0 1.3716332887270255e-06
described O 0 1.8413595171296038e-05
. O 0 5.436364062916255e-06

The O 0 3.807086613960564e-06
proband O 0 0.00015025946777313948
, O 0 5.978510557724803e-07
a O 0 4.0706035520088335e-07
20 O 0 1.6874284938239725e-06
- O 0 1.5969497326295823e-05
year O 0 2.1342275431379676e-06
- O 0 3.5201996070099995e-05
old O 0 4.7085915866773576e-05
black O 0 3.463606844889e-05
female O 0 3.329754326841794e-05
with O 0 0.0011247365036979318
systemic B-Disease 1 0.999998927116394
lupus I-Disease 1 0.999997615814209
erythematosus I-Disease 1 0.9999959468841553
since O 0 0.002044836524873972
age O 0 4.4346819777274504e-05
11 O 0 6.845348252682015e-06
, O 0 7.173732683440903e-07
lacked O 0 6.153519643703476e-05
serum O 0 0.0005664649652317166
hemolytic O 1 0.971927285194397
complement O 0 9.120274626184255e-06
activity O 0 7.105641543603269e-06
, O 0 9.429898000234971e-07
even O 0 1.0733455155786942e-06
during O 0 3.3199878089362755e-05
remission O 0 0.000966386403888464
. O 0 5.843957296747249e-06

C5 O 0 0.05482051894068718
was O 0 0.0003634548920672387
undetectable O 0 0.0009926985949277878
in O 0 8.312061368087598e-07
her O 0 2.051496267085895e-06
serum O 0 8.526213605364319e-06
by O 0 5.3684122036656845e-08
both O 0 3.6651877621807216e-07
immunodiffusion O 0 0.0007608108571730554
and O 0 2.855293314496521e-05
hemolytic O 1 0.9991022348403931
assays O 0 0.0007606072467751801
. O 0 3.275620110798627e-05

Other O 0 5.6777487600356835e-08
complement O 0 4.5564948436549457e-07
components O 0 3.0717319532413967e-06
were O 0 3.295859301033488e-07
normal O 0 1.250781315320637e-05
during O 0 4.302303204894997e-05
remission O 0 0.0005887050065211952
of O 0 3.7017452996224165e-06
lupus O 1 0.999646782875061
, O 0 4.694982635555789e-06
but O 0 1.3799425460092607e-06
C1 O 0 0.0005389212747104466
, O 0 1.3134368828104925e-06
C4 O 0 0.0007013368303887546
, O 0 3.956173259211937e-06
C2 O 0 0.0003566043160390109
, O 0 1.049883280757058e-06
and O 0 9.383437600263278e-07
C3 O 0 0.016330566257238388
levels O 0 0.000353106705006212
fell O 0 0.2700199484825134
during O 0 7.232293137349188e-05
exacerbations O 0 0.032568227499723434
. O 0 3.8700240111211315e-05

A O 0 1.473515931138536e-05
younger O 0 7.32075386622455e-06
half O 0 3.886852937284857e-06
- O 0 6.887338531669229e-05
sister O 0 7.258555706357583e-05
, O 0 1.8980679215019336e-06
who O 0 3.268173486503656e-06
had O 0 5.4693441597919445e-06
no O 0 7.789592018525582e-06
underlying O 0 0.027164820581674576
disease O 1 0.9997267127037048
, O 0 2.2446795355790528e-06
was O 0 8.717242053535301e-06
also O 0 3.1736075811750197e-07
found O 0 2.23174311031471e-07
to O 0 8.534909312629679e-08
lack O 0 1.032411091728136e-05
immunochemically O 0 0.05542707443237305
detectable O 0 0.21106791496276855
C5 O 0 0.14370350539684296
. O 0 3.4896598663181067e-05

By O 0 3.4151828003814444e-05
hemolytic O 1 0.9943639039993286
assay O 0 0.000191221697605215
, O 0 3.158768549837987e-06
she O 0 3.939735051972093e-06
exhibited O 0 9.920011507347226e-06
1 O 0 1.3977274875287549e-06
- O 0 3.432402081671171e-06
2 O 0 2.9803902634739643e-07
% O 0 3.4307592322591063e-09
of O 0 8.017725150466504e-09
the O 0 1.3507940366253024e-07
normal O 0 7.286129857675405e-06
serum O 0 4.1476439946563914e-05
C5 O 0 0.00011531892960192636
level O 0 1.6681830175002688e-06
and O 0 1.7851989753125963e-07
normal O 0 1.8655963458513725e-06
concentrations O 0 3.291660732429591e-06
of O 0 1.1243599828958395e-08
other O 0 2.0914816545314352e-08
complement O 0 2.4429909899481572e-06
components O 0 0.0001238173572346568
. O 0 2.3076074285199866e-05

C5 O 0 0.012136577628552914
levels O 0 3.408743577892892e-05
of O 0 5.1394863476161845e-08
other O 0 8.674772544736697e-08
family O 0 6.660540634584322e-07
members O 0 2.422822475978137e-08
were O 0 7.814882252432653e-08
either O 0 1.1734974236787821e-07
normal O 0 1.2509319731179858e-06
or O 0 2.4065241177595453e-07
approximately O 0 9.779648024732523e-08
half O 0 4.2177356363026774e-07
- O 0 1.4106088201515377e-05
normal O 0 4.4076905396650545e-06
, O 0 2.2548395861576864e-07
consistent O 0 1.1033471309929155e-06
with O 0 9.230669775206479e-07
autosomal O 0 0.10237231850624084
codominant O 0 0.002507185796275735
inheritance O 0 4.848350363317877e-05
of O 0 3.805703840953356e-07
the O 0 4.4696612349071074e-06
gene O 0 0.0006250564474612474
determining O 0 0.011803860776126385
C5 B-Disease 1 0.9999855756759644
deficiency I-Disease 1 0.9999973773956299
. O 0 0.00019550927390810102

Normal O 0 0.004993508569896221
hemolytic O 1 0.9979269504547119
titers O 0 0.0029352251440286636
were O 0 9.451965752305114e-07
restored O 0 8.450629138678778e-06
to O 0 1.1041495895369735e-07
both O 0 2.5035444650711725e-06
homozygous O 0 0.0012636970495805144
C5 B-Disease 1 0.9998279809951782
- I-Disease 1 0.9989303946495056
deficient I-Disease 1 0.9998795986175537
( O 0 3.9399241359205917e-05
C5D B-Disease 1 0.9995115995407104
) O 0 2.5947601898224093e-06
sera O 0 0.00011441298556746915
by O 0 2.461201731307483e-08
addition O 0 7.530192647209333e-08
of O 0 4.653990970382438e-08
highly O 0 1.1800490028690547e-05
purified O 0 7.186019502114505e-05
human O 0 5.394282561610453e-05
C5 O 0 0.020863322541117668
. O 0 1.8753788026515394e-05

In O 0 3.1700155886937864e-06
specific O 0 2.9508319130400196e-06
C5 O 0 0.0028016981668770313
titrations O 0 0.0009350057807751
, O 0 1.3541880434786435e-06
however O 0 2.6861263791033707e-07
, O 0 1.6691124926637713e-07
it O 0 6.269859653684762e-08
was O 0 1.3893285313315573e-06
noted O 0 4.1950545437430264e-07
that O 0 1.0117777726748045e-08
when O 0 1.0539627481875868e-07
limited O 0 4.160312272460942e-08
amounts O 0 2.515378696443804e-07
of O 0 8.230014003629549e-08
C5 O 0 0.000152144260937348
were O 0 4.4821067035627493e-07
assayed O 0 7.292379450518638e-06
in O 0 1.9086418490132928e-07
the O 0 1.02220624853544e-07
presence O 0 1.1247115025980747e-06
of O 0 1.7757074033397657e-07
low O 0 8.603386959293857e-05
dilutions O 0 0.0003631752042565495
of O 0 1.5119393310669693e-06
either O 0 9.24913038033992e-05
C5D B-Disease 1 0.9998693466186523
serum O 0 0.0005243468913249671
, O 0 5.348768468138587e-07
curving O 0 1.2220403732499108e-05
rather O 0 4.050536688282591e-07
than O 0 1.397235536160224e-07
linear O 0 4.096253633179003e-06
dose O 0 4.707042535301298e-05
- O 0 8.091320523817558e-06
response O 0 3.40618072414145e-07
plots O 0 3.6513580425889813e-07
were O 0 1.9834605780033598e-07
consistently O 0 2.6412403713038657e-06
obtained O 0 4.238853534843656e-07
, O 0 2.589766268101812e-07
suggesting O 0 8.533287427781033e-07
some O 0 4.312463985911563e-08
inhibitory O 0 9.00708619155921e-06
effect O 0 1.3042542377661448e-05
. O 0 3.848725100397132e-06

Further O 0 1.937910610649851e-06
studies O 0 1.047311229740444e-06
suggested O 0 2.040545950876549e-06
that O 0 1.4795854497151595e-07
low O 0 4.8244965000776574e-05
dilutions O 0 0.0006254214094951749
of O 0 6.722115358570591e-06
C5D B-Disease 1 0.9996073842048645
serum O 0 0.0001805350766517222
contain O 0 3.1694985409558285e-06
a O 0 1.915066604851745e-06
factor O 0 5.695112577086547e-07
( O 0 8.252759897686701e-08
or O 0 2.3295085327390552e-07
factors O 0 2.779566727895144e-07
) O 0 3.42913182294069e-08
interfering O 0 1.9486783457978163e-06
at O 0 1.8331925275560934e-06
some O 0 1.7334627955278847e-08
step O 0 2.5814342734520324e-06
in O 0 2.795639488795132e-07
the O 0 1.0438072877150262e-06
hemolytic O 1 0.9932964444160461
assay O 0 3.0957387934904546e-05
of O 0 6.17464536389889e-07
C5 O 0 0.002824309514835477
, O 0 2.8995518164265377e-07
rather O 0 8.782487981306986e-08
than O 0 5.510383616069703e-08
a O 0 7.353903015427932e-07
true O 0 7.84725671110209e-06
C5 O 0 0.002368965419009328
inhibitor O 0 0.0001599250390427187
or O 0 1.7297628801316023e-05
inactivator O 0 0.0025151201989501715
. O 0 1.3326173757377546e-05

Of O 0 2.7799374038295355e-06
clinical O 0 8.820454240776598e-05
interest O 0 9.271622616324748e-07
are O 0 5.7560065158668294e-08
( O 0 8.271828022543559e-08
a O 0 3.416568574721168e-07
) O 0 5.4599773591235135e-08
the O 0 1.516408616453191e-07
documentation O 0 1.061103193933377e-05
of O 0 1.9744027667911723e-05
membranous O 1 0.9994574189186096
glomerulonephritis B-Disease 1 0.9999985694885254
, O 1 0.9816030859947205
vasculitis B-Disease 1 0.9999971389770508
, O 0 0.012757637538015842
and O 1 0.856145977973938
arthritis B-Disease 1 0.9999998807907104
in O 0 2.720872544159647e-06
an O 0 4.5622428501701506e-07
individual O 0 5.465926733450033e-07
lacking O 0 0.00011877336510224268
C5 O 0 0.004291047342121601
( O 0 2.573077608758467e-07
and O 0 7.137496993436798e-08
its O 0 7.29355846829094e-08
biologic O 0 1.2098174011043739e-05
functions O 0 4.319791173656995e-07
) O 0 1.1359649931819149e-07
, O 0 1.0198574784681114e-07
and O 0 8.009062213432117e-08
( O 0 1.0121313920308239e-07
b O 0 1.8635496417118702e-06
) O 0 2.829650647129256e-08
a O 0 2.8798694984288886e-07
remarkable O 0 5.8256055126548745e-06
propensity O 0 0.00017278823361266404
to O 0 2.1937794372206554e-05
bacterial B-Disease 1 0.999943733215332
infections I-Disease 1 0.99998939037323
in O 0 1.3691097819901188e-06
the O 0 1.0069887821373413e-06
proband O 0 0.00019002122280653566
, O 0 4.436132883256505e-07
even O 0 4.0350681729250937e-07
during O 0 9.037666472977435e-07
periods O 0 2.45787691710575e-06
of O 0 1.571916357079317e-07
low O 0 5.459687963593751e-05
- O 0 4.0665792766958475e-05
dose O 0 8.66632217366714e-06
or O 0 5.751154503741418e-07
alternate O 0 2.8480958462751005e-06
- O 0 0.00022659311071038246
day O 0 2.787232915579807e-05
corticosteroid O 0 0.007324421778321266
therapy O 0 0.0009929030202329159
. O 0 9.58523651206633e-06

Other O 0 8.404172717746405e-07
observations O 0 1.484170752519276e-05
indicate O 0 2.0715970094897784e-06
that O 0 1.832783738109356e-07
the O 0 3.2539885523874545e-06
C5D B-Disease 1 0.9986226558685303
state O 0 8.225351280088944e-07
is O 0 6.85725964899575e-08
compatible O 0 4.669471422857896e-07
with O 0 2.8943412644366617e-07
normal O 0 6.262955139391124e-06
coagulation O 0 3.595076850615442e-05
function O 0 1.0253720574837644e-06
and O 0 1.9883316326740896e-07
the O 0 1.2687613093476102e-07
capacity O 0 7.222801627904119e-07
to O 0 3.0357782065948413e-07
mount O 0 0.00010177074000239372
a O 0 8.08445765869692e-05
neutrophilic O 1 0.9525970816612244
leukocytosis O 1 0.980602502822876
during O 0 0.005142854992300272
pyogenic B-Disease 1 0.9832599759101868
infection I-Disease 1 0.9953234791755676
. O 0 5.444650469144108e-06
. O 0 8.621519555163104e-06

Susceptibility O 0 0.06904684007167816
to O 0 0.0018473309464752674
ankylosing B-Disease 1 0.9999991655349731
spondylitis I-Disease 1 1.0
in O 0 0.0023026985581964254
twins O 0 0.011412748135626316
: O 0 3.0142686568979116e-07
the O 0 2.8229013793179547e-08
role O 0 4.089420428954327e-07
of O 0 6.977079181069712e-08
genes O 0 3.073624611715786e-06
, O 0 1.8434625417285133e-06
HLA O 0 7.315661787288263e-05
, O 0 9.669350902186125e-07
and O 0 6.686092888230633e-07
the O 0 1.8982905203301925e-06
environment O 0 4.601048931363039e-05
. O 0 7.97651955508627e-06

OBJECTIVE O 0 1.1569744856387842e-05
To O 0 9.596366368214149e-08
determine O 0 3.705326605540904e-07
the O 0 3.600753188948147e-07
relative O 0 3.531731863404275e-06
effects O 0 1.666673597355839e-05
of O 0 2.794546674067533e-07
genetic O 0 4.9555681471247226e-05
and O 0 4.8251727093884256e-06
environmental O 0 2.489352846168913e-05
factors O 0 4.46155718236696e-06
in O 0 6.101205144659616e-06
susceptibility O 0 0.004038090817630291
to O 0 0.0008541425340808928
ankylosing B-Disease 1 0.9999997615814209
spondylitis I-Disease 1 1.0
( O 0 0.000609449518378824
AS B-Disease 1 0.9994977712631226
) O 0 2.531889094825601e-06
. O 0 4.349075879872544e-06

METHODS O 0 7.88000033935532e-05
Twins O 0 0.0003451251541264355
with O 0 8.195940495170362e-07
AS B-Disease 0 0.030624091625213623
were O 0 8.71281216063835e-08
identified O 0 3.1813317491469206e-07
from O 0 2.9639894094657393e-08
the O 0 2.8100765803174e-07
Royal O 0 0.0004040695203002542
National O 0 0.0010254894150421023
Hospital O 1 0.9809691905975342
for O 0 0.0002170326915802434
Rheumatic B-Disease 1 0.9999884366989136
Diseases I-Disease 1 0.9999520778656006
database O 0 0.00098845933098346
. O 0 4.947177876601927e-05

Clinical O 0 0.0013755600666627288
and O 0 8.80220795806963e-06
radiographic O 0 0.00065848499070853
examinations O 0 3.1885643693385646e-05
were O 0 3.3605311955398065e-07
performed O 0 2.8854276479250984e-06
to O 0 1.9447371357728116e-07
establish O 0 9.397243957209866e-06
diagnoses O 0 0.013217495754361153
, O 0 1.685843562881928e-05
and O 0 0.00034089258406311274
disease O 1 0.9998738765716553
severity O 0 0.03607203811407089
was O 0 2.234607563877944e-05
assessed O 0 1.0359866564613185e-06
using O 0 7.607847152257818e-08
a O 0 3.7417134990391787e-07
combination O 0 1.0063638455903856e-06
of O 0 6.775663763392004e-08
validated O 0 4.174762580078095e-06
scoring O 0 4.266457835910842e-06
systems O 0 0.0010506805265322328
. O 0 1.933716885105241e-05

HLA O 0 0.002254698658362031
typing O 0 0.00026171529316343367
for O 0 3.479814267848269e-06
HLA O 0 0.0005226170178502798
- O 0 0.00015028785855975002
B27 O 0 0.00011878876102855429
, O 0 6.101490725995973e-06
HLA O 0 0.00013330989168025553
- O 0 4.901776264887303e-05
B60 O 0 5.324881203705445e-05
, O 0 1.2265203395145363e-06
and O 0 2.214593905591755e-06
HLA O 0 0.00028136532637290657
- O 0 0.00018540206656325608
DR1 O 0 0.0020364869851619005
was O 0 6.6571574279805645e-06
performed O 0 5.750409286520153e-07
by O 0 4.245378804057509e-08
polymerase O 0 5.1264928515593056e-06
chain O 0 7.553864634246565e-06
reaction O 0 3.8766256693634205e-07
with O 0 5.960804116966756e-08
sequence O 0 6.813518211856717e-07
- O 0 3.6008395909448154e-06
specific O 0 1.4901947054113407e-07
primers O 0 9.904679245664738e-06
, O 0 8.175651942110562e-07
and O 0 8.558159834137768e-07
zygosity O 0 0.0004254668310750276
was O 0 1.4062166883377358e-05
assessed O 0 3.124994236713974e-06
using O 0 1.6406200984420138e-06
microsatellite O 0 0.0005952853243798018
markers O 0 0.0001926543191075325
. O 0 1.2982293810637202e-05

Genetic O 0 0.00029673040262423456
and O 0 1.954242634383263e-06
environmental O 0 2.7364524157746928e-06
variance O 0 7.895653908462918e-08
components O 0 2.959427774840151e-06
were O 0 4.4485037165031827e-07
assessed O 0 1.3594998335975106e-06
with O 0 9.672923084735885e-08
the O 0 2.3362898105006025e-07
program O 0 1.0976440307786106e-06
Mx O 0 3.0546128982678056e-05
, O 0 3.577593332693141e-08
using O 0 2.0479250295579732e-08
data O 0 1.2184209197130258e-07
from O 0 2.1499477753650353e-08
this O 0 7.709849647596911e-09
and O 0 4.317673685250156e-08
previous O 0 5.040430437475152e-07
studies O 0 2.9711958404732286e-07
of O 0 1.853489663972141e-07
twins O 0 0.00026913819601759315
with O 0 5.776292255177395e-06
AS B-Disease 1 0.9987360835075378
. O 0 1.8405307855573483e-05

RESULTS O 0 2.060926635749638e-05
Six O 0 1.5490019222852425e-06
of O 0 2.630448818763398e-07
8 O 0 1.7544589354656637e-05
monozygotic O 0 0.0004543223767541349
( O 0 4.805325716006337e-06
MZ O 0 0.009172218851745129
) O 0 1.9242036159994313e-06
twin O 0 0.00025177732459269464
pairs O 0 2.2968843040871434e-05
were O 0 9.722578397486359e-06
disease O 1 0.8417119383811951
concordant O 0 0.00010897097672568634
, O 0 6.923482374077139e-07
compared O 0 4.974363605469989e-07
with O 0 1.2479073063786927e-07
4 O 0 1.5015145891084103e-06
of O 0 1.1546298850362291e-07
15 O 0 2.712504056034959e-06
B27 O 0 5.761021384387277e-05
- O 0 4.260494824848138e-05
positive O 0 1.9694380171131343e-06
dizygotic O 0 0.00036855394137091935
( O 0 2.0300760752434144e-06
DZ O 0 0.0008672625990584493
) O 0 4.1138213191516115e-07
twin O 0 4.821258698939346e-05
pairs O 0 1.5948638747431687e-06
( O 0 2.0938772138379136e-07
27 O 0 1.2375603546388447e-06
% O 0 4.359551830646069e-09
) O 0 7.016364822476362e-09
and O 0 5.749993192694092e-08
4 O 0 4.1602817191233044e-07
of O 0 1.5360653549123526e-07
32 O 0 1.0252624633722007e-05
DZ O 0 0.0028985238168388605
twin O 0 0.00029821452335454524
pairs O 0 4.685039584728656e-06
overall O 0 2.529494850023184e-06
( O 0 3.4931599657284096e-07
12 O 0 6.189407599777041e-07
. O 0 5.047833795401857e-08
5 O 0 2.793805720102682e-07
% O 0 2.5270562531432006e-08
) O 0 1.9868608092110662e-07
. O 0 1.8755703194983653e-06

Nonsignificant O 0 0.003025422105565667
increases O 0 6.955208846193273e-06
in O 0 8.87906637103697e-08
similarity O 0 3.3889688211274915e-07
with O 0 1.0761513635770825e-07
regard O 0 7.136060276025091e-07
to O 0 3.890269510975486e-07
age O 0 4.514125976129435e-05
at O 0 0.002760042669251561
disease O 1 0.9988677501678467
onset O 0 0.006774956826120615
and O 0 1.1296963293716544e-06
all O 0 1.2296283102841699e-07
of O 0 5.019137461204082e-07
the O 0 8.25465758680366e-05
disease O 1 0.9994864463806152
severity O 0 0.0021041748113930225
scores O 0 1.1965918929490726e-05
assessed O 0 8.604279173596296e-06
were O 0 3.47413333656732e-07
noted O 0 7.1250628934649285e-06
in O 0 2.3287908334168606e-05
disease O 1 0.9992788434028625
- O 0 0.06407009065151215
concordant O 0 0.00970638170838356
MZ O 1 0.8762316703796387
twins O 0 0.002845442621037364
compared O 0 1.8395059669273905e-05
with O 0 4.024559984827647e-06
concordant O 0 0.013419697061181068
DZ O 1 0.9912614822387695
twins O 0 0.4949352741241455
. O 0 3.43720821547322e-05

HLA O 0 0.010031681507825851
- O 0 0.0003712756442837417
B27 O 0 0.00012640019122045487
and O 0 7.784331614857365e-07
B60 O 0 2.4349139494006522e-05
were O 0 4.1747162526917236e-07
associated O 0 7.914302386780037e-07
with O 0 5.918440706409456e-07
the O 0 2.114480230375193e-05
disease O 1 0.997468113899231
in O 0 1.327361246694636e-06
probands O 0 0.00019237364176660776
, O 0 8.189369964384241e-07
and O 0 2.551396391936578e-07
the O 0 5.508822482624964e-07
rate O 0 1.2120784958824515e-05
of O 0 1.2491450434026774e-06
disease O 1 0.6636580228805542
concordance O 0 2.249055432912428e-05
was O 0 3.971218120568665e-06
significantly O 0 1.7468039459345164e-06
increased O 0 5.040565156377852e-07
among O 0 9.68142899182567e-07
DZ O 0 0.005219243932515383
twin O 0 0.0002994027454406023
pairs O 0 3.2064133392850636e-06
in O 0 3.458751223206491e-07
which O 0 1.0792510352075624e-07
the O 0 3.7923311424492567e-07
co O 0 9.030947694554925e-05
- O 0 9.251089068129659e-05
twin O 0 0.00015408778563141823
was O 0 2.542295533203287e-06
positive O 0 2.201843329885378e-08
for O 0 1.3898140416301885e-08
both O 0 1.560178901627296e-07
B27 O 0 5.357842383091338e-05
and O 0 7.205978818092262e-06
DR1 O 0 0.059564463794231415
. O 0 4.49452199973166e-05

Additive O 0 1.502052055002423e-05
genetic O 0 3.388454933883622e-05
effects O 0 1.0124823347723577e-05
were O 0 5.83307198098737e-08
estimated O 0 2.162008883033195e-08
to O 0 6.727101098391586e-09
contribute O 0 9.002700807059227e-08
97 O 0 1.0134328931599157e-06
% O 0 1.0052701782115037e-08
of O 0 1.0115847715042037e-08
the O 0 1.1395881216458292e-07
population O 0 2.6185768220443606e-08
variance O 0 5.928998803028662e-07
. O 0 4.615335001290077e-06

CONCLUSION O 0 4.734662070404738e-05
Susceptibility O 0 7.600116077810526e-05
to O 0 4.705708818164567e-07
AS B-Disease 0 0.44563737511634827
is O 0 5.380661605158821e-07
largely O 0 7.639282557647675e-07
genetically O 0 2.1427647425298346e-06
determined O 0 3.3566982438060222e-06
, O 0 4.6273487441794714e-07
and O 0 3.6161011962576595e-07
the O 0 1.0984880418618559e-06
environmental O 0 4.8451336624566466e-05
trigger O 0 8.224030898418278e-05
for O 0 9.136650760410703e-07
the O 0 1.9728780898731202e-05
disease O 1 0.999112069606781
is O 0 3.035684812857653e-06
probably O 0 1.0790913620439824e-05
ubiquitous O 0 0.00018515897681936622
. O 0 1.1721841474354733e-05

HLA O 0 0.006794210057705641
- O 0 0.00020857797062490135
B27 O 0 4.14743808505591e-05
accounts O 0 2.430571441891516e-07
for O 0 4.676441278661514e-08
a O 0 4.2015204826384434e-07
minority O 0 2.5557773142281803e-07
of O 0 2.2834013790884455e-08
the O 0 2.7664864887810836e-07
overall O 0 5.135153514856938e-06
genetic O 0 0.00010287584882462397
susceptibility O 0 0.00014172116061672568
to O 0 1.4048597449800582e-06
AS B-Disease 1 0.9966365098953247
. O 0 1.9712741050170735e-05

Cell O 0 0.0029210818465799093
cycle O 0 0.0003978802706114948
- O 0 9.132402192335576e-05
dependent O 0 9.872663213172927e-06
colocalization O 0 0.00015326104767154902
of O 0 3.438701696723001e-07
BARD1 O 0 0.0004093200259376317
and O 0 8.028216598177096e-07
BRCA1 O 0 1.8921249647974037e-05
proteins O 0 2.6011002773884684e-07
in O 0 1.5770486072597123e-07
discrete O 0 4.012215867987834e-06
nuclear O 0 0.0006108842208050191
domains O 0 0.0001479507191106677
. O 0 2.105634121107869e-05

Germ O 0 0.021619239822030067
- O 0 0.0006947671645320952
line O 0 9.196573228109628e-05
mutations O 0 6.333287456072867e-05
of O 0 1.4460580644026777e-07
the O 0 1.7355954469167045e-06
BRCA1 O 0 0.00021900662977714092
gene O 0 1.2168305147497449e-05
predispose O 0 1.7512742488179356e-05
women O 0 5.030897796132194e-07
to O 0 2.8475477620304446e-07
early O 0 0.00033844212885014713
- O 1 0.9829164147377014
onset O 1 0.9980092644691467
breast B-Disease 1 0.9998440742492676
and I-Disease 1 0.9989823698997498
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
by O 0 1.289494093725807e-06
compromising O 0 6.27560875727795e-05
the O 0 1.2167179193056654e-06
genes O 0 1.7788863260648213e-05
presumptive O 0 0.001085689407773316
function O 0 3.7130382679606555e-06
as O 0 2.787976654872182e-06
a O 0 4.3746385927079245e-05
tumor B-Disease 1 0.8333078026771545
suppressor O 0 0.0010938236955553293
. O 0 1.7368673070450313e-05

Although O 0 2.1012597244407516e-06
the O 0 2.703437189666147e-07
biochemical O 0 2.770764876913745e-05
properties O 0 4.316860668041045e-06
of O 0 3.1976017567103554e-07
BRCA1 O 0 0.00010656240192474797
polypeptides O 0 3.6780943446501624e-06
are O 0 4.6324441171918807e-08
not O 0 5.374856471007661e-08
understood O 0 1.146793806583446e-06
, O 0 1.205446125140952e-07
their O 0 1.6580996131665415e-08
expression O 0 7.465223461622372e-07
pattern O 0 1.1529188668646384e-05
and O 0 4.85763564483932e-07
subcellular O 0 2.489547296136152e-05
localization O 0 2.5047935196198523e-05
suggest O 0 8.258584216491727e-07
a O 0 4.585413364566193e-07
role O 0 1.4331037618831033e-06
in O 0 1.6786182186478982e-06
cell O 0 0.00043832772644236684
- O 0 0.0004297640407457948
cycle O 0 8.736900781514123e-05
regulation O 0 8.06177849881351e-05
. O 0 5.872226211067755e-06

When O 0 4.2906995076918975e-05
resting O 0 0.0007916639442555606
cells O 0 1.541655365144834e-05
are O 0 2.2345778916132986e-07
induced O 0 1.746497582644224e-05
to O 0 4.6562373512415434e-08
proliferate O 0 5.058019723946927e-06
, O 0 1.1921524389890692e-07
the O 0 7.718255545796637e-08
steady O 0 5.190261163079413e-06
- O 0 1.0537779417063575e-05
state O 0 2.3066193932663737e-07
levels O 0 8.463958351967449e-07
of O 0 4.584381230188228e-08
BRCA1 O 0 1.5044965948618483e-05
increase O 0 2.661361691025377e-07
in O 0 2.981430498039117e-07
late O 0 1.0358096005802508e-05
G1 O 0 7.698633271502331e-05
and O 0 1.1083527340360888e-07
reach O 0 3.206476151262905e-07
a O 0 3.233856489259779e-07
maximum O 0 9.483585472480627e-07
during O 0 1.3526686416298617e-05
S O 0 0.0004621339903678745
phase O 0 8.016211359063163e-05
. O 0 8.473791240248829e-06

Moreover O 0 2.9318862289073877e-05
, O 0 1.5767012655487633e-06
in O 0 7.196605906756304e-07
S O 0 0.0001419824839103967
phase O 0 1.7349288100376725e-05
cells O 0 1.6658823369652964e-05
, O 0 1.0930644975815085e-06
BRCA1 O 0 5.042592601967044e-05
polypeptides O 0 7.388203812297434e-06
are O 0 2.0638735520606133e-07
hyperphosphorylated O 0 7.578390068374574e-05
and O 0 5.237226332610589e-07
accumulate O 0 9.077687536773738e-06
into O 0 5.99037548454362e-07
discrete O 0 2.8350445063551888e-05
subnuclear O 0 0.0026686391793191433
foci O 0 0.0014356954488903284
termed O 0 0.001050272723659873
" O 0 5.305584636516869e-05
BRCA1 O 0 0.0010895617306232452
nuclear O 0 0.003880843287333846
dots O 0 0.0023968073073774576
. O 0 2.8620164812309667e-05

" O 0 6.388845213223249e-05
BRCA1 O 0 0.0005536323296837509
associates O 0 0.0001872927969088778
in O 0 8.83093775883026e-07
vivo O 0 1.1796112630690914e-05
with O 0 1.5991359703093622e-07
a O 0 1.847887460826314e-06
structurally O 0 7.478216866729781e-05
related O 0 6.814038897573482e-06
protein O 0 1.4828748135187197e-05
termed O 0 0.0006007058545947075
BARD1 O 0 0.016681034117937088
. O 0 2.1017001927248202e-05

Here O 0 2.630230710565229e-06
we O 0 1.6025741444991581e-07
show O 0 8.409048746216286e-08
that O 0 7.263484924635577e-09
the O 0 5.1992852689863867e-08
steady O 0 6.110679350967985e-06
- O 0 1.3104768186167348e-05
state O 0 3.6584057738764386e-07
levels O 0 2.3102306840883102e-06
of O 0 9.551937552032541e-08
BARD1 O 0 0.00017988575564231724
, O 0 4.6591824798269954e-07
unlike O 0 9.608304480934748e-07
those O 0 9.36016704145004e-08
of O 0 1.5977184375515208e-07
BRCA1 O 0 0.00012247600534465164
, O 0 5.552346351578308e-07
remain O 0 8.513454190506309e-07
relatively O 0 8.285215926662204e-07
constant O 0 4.812673068954609e-06
during O 0 1.3572686839324888e-05
cell O 0 0.0005909850005991757
cycle O 0 0.00015911113587208092
progression O 0 0.0012335663195699453
. O 0 1.6935895473579876e-05

However O 0 7.819182428647764e-06
, O 0 3.297681132607977e-06
immunostaining O 0 0.0004785874916706234
revealed O 0 3.1657065846957266e-05
that O 0 6.025572929502232e-07
BARD1 O 0 0.0006175589514896274
resides O 0 4.703833837993443e-05
within O 0 2.756528829195304e-06
BRCA1 O 0 0.0002524778537917882
nuclear O 0 0.00023905967827886343
dots O 0 0.00014520743570756167
during O 0 2.140245123882778e-05
S O 0 8.878816879587248e-05
phase O 0 3.1462734568776796e-06
of O 0 4.4693273082430096e-08
the O 0 2.922795090398722e-07
cell O 0 4.486582474783063e-05
cycle O 0 9.755178325576708e-06
, O 0 1.7042987110471586e-07
but O 0 2.7156071169542884e-08
not O 0 1.0835490726890384e-08
during O 0 5.342018880583055e-07
the O 0 7.584381478409341e-07
G1 O 0 0.0006401073769666255
phase O 0 0.00012859923299401999
. O 0 9.540732207824476e-06

Nevertheless O 0 0.0001830173860071227
, O 0 3.878861662087729e-06
BARD1 O 0 0.00023271165264304727
polypeptides O 0 1.8844990563593456e-06
are O 0 1.7784538286491625e-08
found O 0 3.897547173892235e-08
exclusively O 0 1.6920028045319668e-08
in O 0 2.2642968389163798e-08
the O 0 3.8193416429521676e-08
nuclear O 0 2.76603009297105e-06
fractions O 0 9.900421105157875e-08
of O 0 1.904519209006139e-08
both O 0 1.536260185730498e-07
G1 O 0 0.00031682505505159497
- O 0 3.5147317248629406e-05
and O 0 1.8704400872593396e-06
S O 0 0.0004920036881230772
- O 0 4.996010102331638e-05
phase O 0 3.244945764890872e-05
cells O 0 3.758013917831704e-05
. O 0 5.263425919110887e-06

Therefore O 0 7.864083272579592e-06
, O 0 1.6287099242617842e-06
progression O 0 2.8056418159394525e-05
to O 0 5.114618488732958e-07
S O 0 0.00013688212493434548
phase O 0 1.2154549949627835e-05
is O 0 1.9727868050267716e-07
accompanied O 0 4.779803361998347e-07
by O 0 1.9962007158369488e-08
the O 0 6.016086473437099e-08
aggregation O 0 4.530942987912567e-06
of O 0 5.744434474763693e-07
nuclear O 0 0.0006136192241683602
BARD1 O 0 0.0005933379288762808
polypeptides O 0 2.0713538106065243e-05
into O 0 1.3298421436047647e-05
BRCA1 O 0 0.0015877933474257588
nuclear O 0 0.003668793011456728
dots O 0 0.001290448708459735
. O 0 3.778245081775822e-05

This O 0 3.1081478937267093e-06
cell O 0 0.00033080458524636924
cycle O 0 0.00012321937538217753
- O 0 9.684778342489153e-05
dependent O 0 9.611663699615747e-06
colocalization O 0 0.00020965067960787565
of O 0 7.698919262111303e-07
BARD1 O 0 0.001561131444759667
and O 0 4.908394203084754e-06
BRCA1 O 0 0.0001229740446433425
indicates O 0 1.3974462262922316e-06
a O 0 3.34549525859984e-07
role O 0 7.162166184571106e-07
for O 0 2.101873946003252e-07
BARD1 O 0 0.0004823621129617095
in O 0 7.1237850534089375e-06
BRCA1 O 0 0.0038377863820642233
- O 0 0.015232404693961143
mediated O 1 0.8808769583702087
tumor B-Disease 1 0.9956367611885071
suppression O 0 0.0007095608743838966
. O 0 2.899819810409099e-05

Ethnic O 0 5.407161097537028e-06
differences O 0 3.016620576090645e-05
in O 0 2.91608989755332e-06
the O 0 4.8222932491626125e-06
HFE O 0 0.0037852164823561907
codon O 0 0.00018084814655594528
282 O 0 4.7029549023136497e-05
( O 0 4.8181514102907386e-06
Cys O 0 0.010189366526901722
/ O 0 0.0003586219099815935
Tyr O 0 0.0012616856256499887
) O 0 1.9909437014575815e-06
polymorphism O 0 3.0833260098006576e-05
. O 0 7.264156920427922e-06

Recent O 0 2.149394276784733e-05
studies O 0 1.896557137115451e-06
have O 0 2.597929267267318e-07
shown O 0 7.226574780361261e-06
that O 0 3.2785330404294655e-05
hereditary B-Disease 1 0.9999973773956299
hemochromatosis I-Disease 1 0.9999998807907104
( O 0 0.00025770009960979223
HH B-Disease 1 0.9555997252464294
) O 0 8.711879218026297e-07
is O 0 5.715810971196333e-07
likely O 0 5.468058930091502e-07
to O 0 5.909140554649639e-08
be O 0 4.452463713278121e-07
caused O 0 6.135017883934779e-06
by O 0 1.2618998823654692e-07
homozygosity O 0 2.928577669081278e-05
for O 0 9.328993400004038e-08
a O 0 1.9185033579560695e-06
Cys282Tyr O 0 0.00019271088240202516
mutation O 0 1.4425485460378695e-05
in O 0 1.8976376736645761e-07
the O 0 3.1856822602094326e-07
HFE O 0 0.0005884200218133628
gene O 0 1.5991519831004553e-05
located O 0 1.560424243507441e-05
4 O 0 1.3073511581751518e-05
. O 0 5.075123681308469e-06

5 O 0 2.550954741309397e-05
Mb O 0 0.00021375707001425326
telomeric O 0 0.0008593352395109832
to O 0 5.519526439456968e-06
HLA O 0 0.0008612399105913937
- O 0 0.00020740694890264422
A O 0 2.4492392185493372e-05
. O 0 4.866802555625327e-06

Population O 0 3.332894209506776e-07
studies O 0 2.879674525502196e-07
of O 0 1.2011240002607337e-08
this O 0 1.2836944840444175e-08
polymorphism O 0 4.747539321670047e-07
are O 0 8.663987749457647e-09
facilitated O 0 3.6534268588184204e-07
by O 0 5.3433637958733016e-08
the O 0 8.863634803901732e-08
fact O 0 1.3150948063866963e-07
that O 0 3.071381016184205e-08
the O 0 2.9951641522529826e-07
Cys282Tyr O 0 0.00035618164110928774
mutation O 0 4.8881920520216227e-05
creates O 0 9.891387890093029e-06
a O 0 3.864768586936407e-06
Rsal O 0 0.0002829605946317315
restriction O 0 5.860041710548103e-06
site O 0 2.978512566187419e-05
. O 0 6.147005024104146e-06

We O 0 4.678239747590851e-06
have O 0 4.4152113787276903e-07
studied O 0 2.8307572392805014e-06
the O 0 1.0833991836989298e-06
codon O 0 3.247837594244629e-05
282 O 0 1.796048309188336e-05
( O 0 2.476407644280698e-06
Cys O 0 0.0035379482433199883
/ O 0 0.00010730432404670864
Tyr O 0 0.00016854022396728396
) O 0 6.771335137045753e-08
polymorphism O 0 4.3537090732570505e-07
in O 0 2.9376494126154284e-08
different O 0 1.3488228312041883e-08
ethnic O 0 2.174810020960649e-07
groups O 0 5.159818101674318e-07
. O 0 4.439630629349267e-06

In O 0 1.9291996977699455e-06
agreement O 0 2.9312491278687958e-06
with O 0 4.3433038854345796e-07
previous O 0 3.124910790575086e-06
observations O 0 5.471195891004754e-06
the O 0 1.1749424402296427e-06
Tyr O 0 0.00030270146089605987
allele O 0 6.2677886489836965e-06
appeared O 0 5.439143933472224e-06
to O 0 4.841637846197955e-08
be O 0 2.0044710424826917e-07
rare O 0 7.508802355005173e-06
or O 0 2.9252034892124357e-06
absent O 0 3.682062742882408e-05
in O 0 1.6964548876785557e-06
Asiatic O 0 2.0869225409114733e-05
( O 0 2.468428021984437e-07
Indian O 0 1.8050936034796905e-07
, O 0 1.4191630270943278e-07
Chinese O 0 1.2878162181095831e-07
) O 0 2.098558979923837e-07
populations O 0 2.119368446074077e-06
. O 0 3.3823023386503337e-06

The O 0 1.3271715033624787e-06
highest O 0 5.600038548436714e-06
allele O 0 1.9883991626556963e-06
frequency O 0 3.520728796502226e-06
( O 0 1.7975897037558752e-07
7 O 0 6.403394650078553e-07
. O 0 2.908524088240938e-08
5 O 0 8.63139959506043e-08
% O 0 3.5033058676248174e-09
) O 0 1.917839043130698e-08
was O 0 1.8050933476843056e-06
found O 0 4.4820171751780435e-07
in O 0 5.735828949582356e-07
Swedes O 0 7.96866079326719e-05
. O 0 1.1806240763689857e-05

Saamis O 0 0.0010762643069028854
( O 0 8.959701176536328e-07
2 O 0 7.643596973139211e-07
% O 0 2.3429695517052096e-08
) O 0 2.9056739236921203e-08
and O 0 1.1176615544172819e-07
Mordvinians O 0 1.846395571192261e-05
( O 0 9.855561700078397e-08
1 O 0 2.1576673248091538e-07
. O 0 1.7733187362978242e-08
8 O 0 1.044018915763445e-07
% O 0 3.480003618605565e-09
) O 0 8.439188015074706e-09
had O 0 8.153983799275011e-08
significantly O 0 2.651833312938834e-07
lower O 0 1.8392058791505406e-06
frequencies O 0 1.1884545756402076e-06
of O 0 9.688525892670441e-08
the O 0 2.1280002329149283e-06
Tyr O 0 0.0013918622862547636
allele O 0 0.00012756722571793944
. O 0 2.042253800027538e-05

Comparisons O 0 6.909222065587528e-07
with O 0 1.037359425026807e-07
allele O 0 1.2109483122912934e-06
frequencies O 0 2.8965139335923595e-06
based O 0 8.110658313853492e-07
on O 0 4.184340923529817e-06
prevalence O 0 4.580813765642233e-05
estimates O 0 1.2523129271357902e-06
of O 0 3.925285625427932e-07
HH B-Disease 1 0.7300074100494385
showed O 0 1.4307564015325624e-05
some O 0 4.410909681951125e-08
disagreements O 0 1.3402492186287418e-05
with O 0 3.040039757706836e-07
the O 0 3.775097638936131e-07
RFLP O 0 3.077947621932253e-05
data O 0 8.157714432854846e-07
, O 0 5.397986910793406e-07
particularly O 0 2.146896576959989e-06
in O 0 1.290422801503155e-06
Finns O 0 0.00012875556421931833
. O 0 8.145034371409565e-06

The O 0 1.014687313727336e-05
newly O 0 0.00012692631571553648
described O 0 0.00015849604096729308
HFE O 0 0.001872174208983779
marker O 0 2.3496129870181903e-05
provides O 0 2.2162623736221576e-07
a O 0 2.004947248224198e-07
new O 0 1.5756459958993219e-07
approach O 0 3.586010564049502e-07
to O 0 1.6355782506138894e-08
the O 0 5.775735800739312e-08
screening O 0 6.038591209289734e-07
of O 0 7.83552422944922e-08
HH B-Disease 0 0.0009745983988977969
as O 0 4.1009221263266227e-07
well O 0 1.5011407583642722e-07
as O 0 1.4647288537616987e-07
studies O 0 4.304968825863398e-08
of O 0 6.485957992907743e-09
the O 0 6.643494998570532e-08
relationship O 0 2.705949100345606e-06
between O 0 2.2733815967512783e-06
the O 0 5.417696229415014e-06
HFE O 0 0.007032149471342564
Tyr O 0 0.0020353710278868675
allele O 0 3.9765043766237795e-05
and O 0 4.326282123656711e-06
different O 0 1.811079346225597e-05
disorders O 1 0.9998996257781982
including O 0 0.007139834109693766
cancer B-Disease 1 0.9999189376831055

Autosomal B-Disease 1 0.9976724982261658
dominant I-Disease 1 0.9983453750610352
neurohypophyseal I-Disease 1 0.999498724937439
diabetes I-Disease 1 0.9999589920043945
insipidus I-Disease 1 0.9928850531578064
associated O 0 2.8892309273942374e-05
with O 0 6.390510520759562e-07
a O 0 4.435639311850537e-06
missense O 0 0.00011489896132843569
mutation O 0 2.5222243493772112e-05
encoding O 0 6.568778644577833e-06
Gly23 O 0 0.002076273551210761
- O 0 0.0013864077627658844
- O 0 0.00040767050813883543
> O 0 6.996191223151982e-05
Val O 0 0.0012602191418409348
in O 0 4.254155101079959e-06
neurophysin O 0 0.0014646287309005857
II O 1 0.5192598104476929
. O 0 3.07655063807033e-05

Autosomal B-Disease 1 0.995931088924408
dominant I-Disease 1 0.9982442855834961
neurohypophyseal I-Disease 1 0.9995836615562439
diabetes I-Disease 1 0.9999819993972778
insipidus I-Disease 1 0.9978333115577698
( O 0 1.8790555259329267e-05
ADNDI B-Disease 0 0.003986273892223835
) O 0 1.3252553117126809e-06
is O 0 4.213158717902843e-06
an O 0 0.0002813658502418548
inherited B-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999998807907104
caused O 1 0.9183378219604492
by O 0 2.5013441700139083e-05
progressive O 1 0.9960770010948181
degeneration O 1 0.9997013211250305
of O 0 8.346854087903921e-07
the O 0 2.7964551918557845e-06
magnocellular O 0 0.0029097492806613445
neurons O 0 0.0001220119374920614
of O 0 4.065606731273874e-07
the O 0 1.541290657769423e-06
hypothalamus O 0 0.0011548949405550957
leading O 0 2.329901690245606e-05
to O 0 1.0369993930225974e-07
decreased O 0 2.742359129115357e-06
ability O 0 3.321011945445207e-07
to O 0 3.6292011174055006e-08
produce O 0 4.1940103301385534e-07
the O 0 7.509952979489753e-07
hormone O 0 3.176551399519667e-05
arginine O 0 1.521570266049821e-05
vasopressin O 0 3.138029933325015e-05
( O 0 1.0023744607678964e-06
AVP O 0 0.00023906583373900503
) O 0 8.832899993649335e-07
. O 0 2.4915498215705156e-06

Affected O 0 2.8608237698790617e-05
individuals O 0 1.6398148261487222e-07
are O 0 7.17704509156647e-08
not O 0 5.572891836891358e-07
symptomatic O 0 0.0006543385097756982
at O 0 9.489164222031832e-05
birth O 0 3.633313826867379e-05
, O 0 1.3833578123012558e-06
but O 0 4.936127879773267e-07
usually O 0 6.389464942913037e-06
develop O 0 0.0005582423764280975
diabetes B-Disease 1 0.9989694356918335
insipidus I-Disease 0 0.11494600772857666
at O 0 0.00024289381690323353
1 O 0 3.3437099773436785e-05
- O 0 0.0002480211842339486
6 O 0 4.108063149033114e-05
yr O 0 0.0008475180366076529
of O 0 4.700326599049731e-07
age O 0 1.766803143254947e-05
. O 0 5.934180080657825e-06

The O 0 3.753304099518573e-06
genetic O 0 4.858944521402009e-05
locus O 0 5.504873115569353e-05
of O 0 7.52330038267246e-07
the O 0 3.9488619222538546e-05
disease O 1 0.9997453093528748
is O 0 1.1920301403733902e-06
the O 0 2.1104535790072987e-06
AVP O 0 0.003474441124126315
- O 0 0.0008417427306994796
neurophysin O 0 0.00151834764983505
II O 0 0.01836804486811161
( O 0 1.6083969285318744e-06
NPII O 0 0.00014592698425985873
) O 0 1.8405833657197945e-07
gene O 0 2.8192964691697853e-06
, O 0 7.121192311387858e-07
and O 0 6.834695227553311e-07
mutations O 0 4.516537592280656e-05
that O 0 3.4683762351050973e-07
cause O 0 2.724959449551534e-05
ADNDI B-Disease 0 0.0003390736528672278
have O 0 2.8247927730262745e-07
been O 0 2.090772284191189e-07
found O 0 5.1074330542633106e-08
in O 0 7.142151758898763e-09
both O 0 7.214580044490049e-09
the O 0 3.22744178049561e-08
signal O 0 1.4932904832676286e-06
peptide O 0 1.1659780057016178e-06
of O 0 3.740072074265299e-08
the O 0 1.5375250086435699e-06
prepro O 0 0.0028875181451439857
- O 0 0.0018598416354507208
AVP O 0 0.004234457854181528
- O 0 0.00034187923301942647
NPII O 0 0.00039722671499475837
precursor O 0 1.9787023120443337e-05
and O 0 1.4547906630468788e-06
within O 0 2.9841039577149786e-06
NPII O 0 0.0036604655906558037
itself O 0 8.806266851024702e-05
. O 0 9.819160368351731e-06

An O 0 4.21524509874871e-06
affected O 0 1.0002821909438353e-05
girl O 0 0.0001252304791705683
who O 0 1.567554022585682e-06
presented O 0 1.1090606903962907e-06
at O 0 5.483022050611908e-06
9 O 0 3.177082362526562e-06
months O 0 8.641074487059086e-07
of O 0 3.017258976001358e-08
age O 0 2.1497648958757054e-06
and O 0 3.3999751281044155e-07
her O 0 1.5223595255520195e-06
similarly O 0 6.32865157967899e-06
affected O 0 2.517747816455085e-06
younger O 0 2.4976543500088155e-06
brother O 0 1.1998451554973144e-05
and O 0 4.977101184522326e-07
father O 0 2.493636884537409e-06
were O 0 6.950779862791023e-08
all O 0 7.697345871804373e-09
found O 0 4.766820538293359e-08
to O 0 5.7044271528639e-09
have O 0 1.8625454956122667e-08
a O 0 4.913738393952372e-07
novel O 0 4.7821476982790045e-06
missense O 0 9.917448187479749e-05
mutation O 0 2.4018241674639285e-05
( O 0 4.872868544225639e-07
G1758 O 0 6.261195812840015e-05
- O 0 6.404193118214607e-05
- O 0 5.507451351149939e-05
> O 0 1.3932922229287215e-05
T O 0 3.835202005575411e-05
) O 0 3.819121463521924e-09
encoding O 0 9.223505514910357e-09
the O 0 3.515329183301219e-08
amino O 0 2.2603578031521465e-07
acid O 0 2.6129073376068845e-06
substitution O 0 1.0573359077170608e-06
Gly23 O 0 0.0005310359410941601
- O 0 0.000884958659298718
- O 0 0.0008032324840314686
> O 0 0.00017324155487585813
Val O 0 0.0023285187780857086
within O 0 1.70074181369273e-05
NPII O 0 0.006737920455634594
. O 0 3.794146323343739e-05

The O 0 4.1851230889733415e-06
mutation O 0 6.87881329213269e-05
was O 0 1.750484443618916e-05
confirmed O 0 1.893286025733687e-06
by O 0 6.099310212448472e-08
restriction O 0 8.37794061681052e-07
endonuclease O 0 6.264015246415511e-05
analysis O 0 2.943153731393977e-06
. O 0 4.919369075651048e-06

A O 0 5.770170537289232e-05
T1 O 0 0.004465207923203707
- O 0 4.0202619857154787e-05
weighted O 0 6.328470590233337e-06
magnetic O 0 9.343626516056247e-06
resonance O 0 4.3466683564474806e-05
imaging O 0 0.0003186277172062546
of O 0 6.837159389760927e-07
the O 0 8.631778655399103e-06
fathers O 0 0.0005130093777552247
pituitary O 1 0.9931896328926086
gland O 1 0.9034063816070557
demonstrates O 0 6.029058204148896e-05
an O 0 5.465334652399179e-06
attenuated O 0 0.008208319544792175
posterior O 1 0.6736891865730286
pituitary O 1 0.9893879890441895
bright O 0 0.008664247579872608
spot O 0 0.0021738135255873203
. O 0 2.675545147212688e-05

This O 0 3.939900125260465e-06
mutation O 0 4.425814768183045e-05
may O 0 9.201331749864039e-07
be O 0 1.3802141651808597e-08
valuable O 0 1.0641495151730851e-07
for O 0 1.644669112010888e-08
developing O 0 1.5313161156882416e-06
models O 0 1.1884003470186144e-05
of O 0 5.710995083063608e-06
dominantly B-Disease 1 0.9907647371292114
inherited I-Disease 1 0.9998711347579956
neurodegeneration I-Disease 1 0.9999983310699463
, O 0 9.96783455775585e-06
as O 0 3.9805803453418775e-07
the O 0 2.8875533075733983e-07
early O 0 3.7915353914286243e-06
age O 0 3.594848749344237e-06
of O 0 5.783131769021566e-07
onset O 0 0.48713427782058716
of O 0 1.6280160707538016e-05
symptoms O 1 0.9954270124435425
suggests O 0 5.5699820222798735e-06
that O 0 8.554319919085174e-08
this O 0 1.0834916963631258e-07
mutation O 0 8.072706805251073e-06
may O 0 1.2856886542067514e-06
be O 0 6.293570464777076e-08
particularly O 0 3.887802790814021e-07
deleterious O 0 1.3636207768286113e-05
to O 0 2.958483662496292e-07
the O 0 2.704372718653758e-06
magnocellular O 0 0.0050126672722399235
neuron O 0 0.00420174328610301
. O 0 3.2876857858354924e-06
. O 0 5.735644663218409e-06

Frequent O 0 0.0006749436142854393
inactivation O 0 0.01647098734974861
of O 0 1.146999238699209e-05
PTEN O 0 0.05414789542555809
/ O 0 0.0023528076708316803
MMAC1 O 0 0.025418564677238464
in O 0 0.00024586383369751275
primary O 1 0.9955058097839355
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 0.0001593938795849681

Sporadic B-Disease 1 0.9965325593948364
prostate I-Disease 1 0.9999979734420776
carcinoma I-Disease 1 1.0
is O 0 2.3219916329253465e-05
the O 0 5.922206582908984e-07
most O 0 6.586905669792031e-07
common O 0 1.3342680176720023e-05
male B-Disease 0 5.535895979846828e-05
cancer I-Disease 1 0.976784884929657
in O 0 1.8284644909272174e-07
the O 0 1.397138333913972e-07
Western O 0 1.4129632290860172e-06
world O 0 4.711303972726455e-06
, O 0 3.855047054912575e-07
yet O 0 1.9354546054728416e-07
many O 0 9.441946779986665e-09
of O 0 1.4054057473344983e-08
the O 0 8.223800307405327e-08
major O 0 4.644383807317354e-06
genetic O 0 4.882087523583323e-06
events O 0 1.7214030378909229e-07
involved O 0 2.0608368345165218e-07
in O 0 2.1000525407544046e-07
the O 0 4.2738798811114975e-07
progression O 0 4.424076178111136e-05
of O 0 1.091881287607066e-07
this O 0 3.315249728075287e-07
often O 0 0.00010833389387698844
fatal O 1 0.9999349117279053
cancer B-Disease 1 0.9997547268867493
remain O 0 5.00656324220472e-06
to O 0 1.5484759785522328e-07
be O 0 8.003188440852682e-07
elucidated O 0 0.00029416350298561156
. O 0 1.1995888598903548e-05

Numerous O 0 3.64687257388141e-05
cytogenetic O 0 0.017909400165081024
and O 0 1.5852629076107405e-05
allelotype O 0 0.0008569733472540975
studies O 0 2.9710190574405715e-06
have O 0 7.694735018048959e-07
reported O 0 1.3321954611456022e-05
frequent O 0 5.381545997806825e-05
loss O 0 0.0004935198230668902
of O 0 8.966385962594359e-07
heterozygosity O 0 0.0020568477921187878
on O 0 8.023928239708766e-05
chromosomal O 1 0.9717856049537659
arm O 1 0.8329036235809326
10q O 0 0.0016102775698527694
in O 0 0.00016929046250879765
sporadic B-Disease 1 0.998218834400177
prostate I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999984502792358
. O 0 0.00014537631068378687

Deletion O 0 0.0004103599931113422
mapping O 0 5.252083428786136e-05
studies O 0 2.810882733683684e-06
have O 0 4.6422178456850816e-07
unambiguously O 0 1.7599215425434522e-05
identified O 0 2.093622470056289e-06
a O 0 1.5229840073516243e-06
region O 0 4.381576673040399e-06
of O 0 2.61738392737243e-07
chromosome O 0 5.089065234642476e-05
10q23 O 0 2.6068093575304374e-05
to O 0 7.111447075658361e-08
be O 0 7.652846534256241e-08
the O 0 1.1845344261018909e-07
minimal O 0 1.0479223419679329e-05
area O 0 7.3325263656442985e-06
of O 0 1.9768519905483117e-06
loss O 0 0.007355964742600918
. O 0 1.8024727978627197e-05

A O 0 3.7022167816758156e-05
new O 0 4.802014154847711e-05
tumor B-Disease 0 0.015666671097278595
suppressor O 0 0.00016178304213099182
gene O 0 3.621441646828316e-05
, O 0 5.195951871428406e-06
PTEN O 0 0.0015708849532529712
/ O 0 0.00018522009486332536
MMAC1 O 0 0.002518262481316924
, O 0 2.7222351945965784e-06
was O 0 1.1142128641949967e-05
isolated O 0 2.062991370621603e-05
recently O 0 2.1229945559753105e-05
at O 0 5.521247658180073e-06
this O 0 4.067521786055295e-08
region O 0 1.1986360277660424e-06
of O 0 9.659132871320253e-08
chromosome O 0 4.469172563403845e-05
10q23 O 0 2.0625682736863382e-05
and O 0 2.6323209567635786e-07
found O 0 1.8921765843060712e-07
to O 0 2.6061698576995695e-08
be O 0 1.178944444291119e-07
inactivated O 0 6.546852546307491e-06
by O 0 8.68425900080183e-08
mutation O 0 5.730745215259958e-06
in O 0 2.642883146108943e-06
three O 0 0.002274504629895091
prostate B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999984502792358
cell O 0 0.08963701128959656
lines O 0 0.003125930204987526
. O 0 5.23095513926819e-05

We O 0 2.374069117649924e-05
screened O 0 0.00039547187043353915
80 O 0 0.001787927350960672
prostate B-Disease 1 0.9999785423278809
tumors I-Disease 1 0.999991774559021
by O 0 1.0834716022145585e-06
microsatellite O 0 0.00011001474194927141
analysis O 0 1.2586934872160782e-06
and O 0 3.894170674811903e-07
found O 0 8.21439186893258e-07
chromosome O 0 1.3244934052636381e-05
10q23 O 0 8.677685400471091e-06
to O 0 2.603437465609204e-08
be O 0 7.284035064003547e-08
deleted O 0 1.531094198981009e-06
in O 0 4.616047704075754e-07
23 O 0 9.612223038857337e-06
cases O 0 2.7707374101737514e-06
. O 0 5.435280399979092e-06

We O 0 1.534529474156443e-06
then O 0 2.5284384719270747e-07
proceeded O 0 2.17378357092457e-07
with O 0 1.3609843030337743e-08
sequence O 0 9.327339256515188e-08
analysis O 0 8.246968974390256e-08
of O 0 3.072470633469493e-08
the O 0 3.8394205148506444e-07
entire O 0 6.749884778400883e-05
PTEN O 0 0.006791263353079557
/ O 0 0.0005512364441528916
MMAC1 O 0 0.0014391923323273659
coding O 0 0.00035979822860099375
region O 0 5.855579729541205e-05
and O 0 2.470284471201012e-06
tested O 0 8.263426934718154e-06
for O 0 9.081274043865051e-08
homozygous O 0 3.688727474582265e-06
deletion O 0 2.670122285053367e-06
with O 0 2.040963096305859e-07
new O 0 1.5287947690012516e-06
intragenic O 0 7.44190692785196e-05
markers O 0 3.756332944249152e-06
in O 0 6.08231403020909e-08
these O 0 1.798669480024273e-08
23 O 0 2.00525801119511e-06
cases O 0 2.845178244115232e-07
with O 0 8.788651371105516e-07
10q23 O 0 0.0008374897297471762
loss O 0 0.0010464864317327738
of O 0 5.201594376558205e-06
heterozygosity O 0 0.014759923331439495
. O 0 5.000028613721952e-05

The O 0 2.69333668256877e-07
identification O 0 4.742665566936921e-07
of O 0 6.00350062995858e-08
the O 0 2.627422759360343e-07
second O 0 4.842561338591622e-06
mutational O 0 0.00010943551023956388
event O 0 9.23141669773031e-06
in O 0 5.725833034375682e-07
10 O 0 4.1260250327468384e-07
( O 0 1.1963116719471145e-07
43 O 0 2.491656687197974e-06
% O 0 3.486290722776175e-07
) O 0 1.3666124687006231e-05
tumors B-Disease 1 0.9999914169311523
establishes O 0 0.0006322446861304343
PTEN O 0 0.004021849948912859
/ O 0 0.00010154632036574185
MMAC1 O 0 0.00019824790069833398
as O 0 5.472002726492065e-07
a O 0 7.362758651652257e-07
main O 0 7.413068487949204e-06
inactivation O 0 0.0003257959324400872
target O 0 1.00192619356676e-06
of O 0 4.896757559436082e-07
10q O 0 0.00046883904724381864
loss O 0 0.0010593690676614642
in O 0 7.869922410463914e-05
sporadic B-Disease 1 0.9992063641548157
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 1.095662264560815e-05
. O 0 1.3170106285542715e-05

Risk O 0 0.0008437244687229395
reversals O 0 0.0002623003092594445
in O 0 2.563747784734005e-06
predictive O 0 6.581743218703195e-05
testing O 0 0.00028765760362148285
for O 0 0.000273078097961843
Huntington B-Disease 1 0.9999885559082031
disease I-Disease 1 0.9999979734420776
. O 0 0.00014468029257841408

The O 0 1.131628550865571e-06
first O 0 2.3659770249651046e-06
predictive O 0 3.7087967939442024e-05
testing O 0 0.00013240687258075923
for O 0 8.528986654710025e-05
Huntington B-Disease 1 0.9999781847000122
disease I-Disease 1 0.9999889135360718
( O 0 5.379296226237784e-07
HD B-Disease 0 3.158572144457139e-05
) O 0 7.280340241777594e-08
was O 0 4.934137223244761e-07
based O 0 2.4058165237761386e-08
on O 0 1.7037444877132657e-07
analysis O 0 1.7945357910775783e-07
of O 0 1.0276995254798749e-07
linked O 0 5.032619446865283e-05
polymorphic O 0 0.000115517686936073
DNA O 0 1.411583161825547e-05
markers O 0 8.177146810339764e-06
to O 0 7.404459978488376e-08
estimate O 0 2.827787284331862e-07
the O 0 1.9394991568333353e-07
likelihood O 0 1.2712965826722211e-06
of O 0 5.3526051146945974e-08
inheriting O 0 4.8911770136328414e-05
the O 0 1.2202866628285847e-06
mutation O 0 1.6842510376591235e-05
for O 0 5.824633149131841e-07
HD B-Disease 0 0.0015136768342927098
. O 0 2.1022457076469436e-05

Limits O 0 1.4701813597639557e-06
to O 0 2.964413425843304e-08
accuracy O 0 3.300539788142487e-07
included O 0 1.8532210788180237e-07
recombination O 0 8.806656524029677e-07
between O 0 2.042651487954572e-07
the O 0 1.60468772492095e-07
DNA O 0 3.5386365198064595e-06
markers O 0 1.1003293366229627e-05
and O 0 4.2449093484719924e-07
the O 0 8.529235628884635e-07
mutation O 0 4.769447332364507e-05
, O 0 9.47820581131964e-07
pedigree O 0 4.3172221921849996e-05
structure O 0 2.3506170691689476e-05
, O 0 5.418917794486333e-07
and O 0 9.32682269194629e-08
whether O 0 3.2015009310271125e-08
DNA O 0 2.537378236411314e-07
samples O 0 1.2232526103161945e-07
were O 0 3.161348871572045e-08
available O 0 7.468884177797008e-08
from O 0 2.0427955860213842e-07
family O 0 1.5980978105289978e-06
members O 0 7.706875067015062e-07
. O 0 5.306108050717739e-06

With O 0 1.5465649028101325e-07
direct O 0 3.533668859745376e-07
tests O 0 7.692225949540443e-07
for O 0 1.8360072573386788e-08
the O 0 1.337212864882531e-07
HD B-Disease 0 0.00011654043919406831
mutation O 0 1.6189032976399176e-05
, O 0 2.679673514194292e-07
we O 0 1.1803822985712031e-07
have O 0 4.688909527317264e-08
assessed O 0 7.240505510708317e-07
the O 0 4.715205292882274e-08
accuracy O 0 7.478163297491847e-07
of O 0 6.276297170870748e-08
results O 0 6.581643674508086e-07
obtained O 0 2.5814983928285073e-07
by O 0 7.907378574145696e-08
linkage O 0 8.842458555591293e-06
approaches O 0 3.7184174743742915e-06
when O 0 5.695656000170857e-07
requested O 0 1.7894771531246079e-07
to O 0 3.294205797033101e-08
do O 0 1.519493508794767e-07
so O 0 7.032230797676675e-08
by O 0 3.3108605634879495e-08
the O 0 2.1943330352769408e-07
test O 0 1.2101334050385049e-06
individuals O 0 1.0644134107451464e-07
. O 0 2.8349259082460776e-06

For O 0 2.698800471989671e-07
six O 0 3.741356806585827e-07
such O 0 3.685326532831823e-08
individuals O 0 2.3138630567132168e-08
, O 0 1.3007071686388372e-07
there O 0 8.95644021170483e-08
was O 0 2.1529244804696646e-06
significant O 0 4.3769892954514944e-07
disparity O 0 2.9088569135637954e-06
between O 0 4.6489961391671386e-07
the O 0 2.603825578262331e-06
tests O 0 2.6224231987725943e-05
. O 0 4.967611403117189e-06

Three O 0 1.2553800843306817e-06
went O 0 6.677224519080482e-06
from O 0 2.83211903706615e-07
a O 0 1.7143613604275743e-06
decreased O 0 4.238631299813278e-05
risk O 0 4.402137165016029e-06
to O 0 1.5029995026338838e-08
an O 0 1.1171201919069063e-07
increased O 0 9.789397381609888e-07
risk O 0 8.686321052664425e-06
, O 0 1.3386024022565834e-07
while O 0 8.894610203924458e-08
in O 0 3.141087745461846e-08
another O 0 1.1479368566824633e-07
three O 0 9.325559346962109e-08
the O 0 7.435970132974035e-07
risk O 0 4.165621066931635e-05
was O 0 2.7584630515775643e-05
decreased O 0 0.00010410825052531436
. O 0 7.530890798079781e-06

Knowledge O 0 2.7041176053899108e-06
of O 0 2.1514250647669542e-07
the O 0 6.670400125585729e-07
potential O 0 1.1198973197679152e-06
reasons O 0 1.7299458932029665e-07
for O 0 7.833622639452642e-09
these O 0 6.70525990287274e-09
changes O 0 4.876383172813803e-07
in O 0 4.132214996843686e-07
results O 0 1.7167565147246933e-06
and O 0 4.865155460720416e-07
impact O 0 1.8477007870387752e-06
of O 0 1.1399815491586196e-07
these O 0 4.3295864315950894e-07
risk O 0 4.522856397670694e-05
reversals O 0 3.9081052818801254e-05
on O 0 4.698883913079044e-06
both O 0 2.1364025997172575e-06
patients O 0 1.7671958630671725e-05
and O 0 2.4902786321945314e-07
the O 0 3.834627193555207e-07
counseling O 0 2.812478214764269e-06
team O 0 3.202836182936153e-07
can O 0 5.1675495882363975e-08
assist O 0 1.6136837643898616e-07
in O 0 4.685548304905751e-08
the O 0 2.6849010126284156e-08
development O 0 6.444096811719646e-08
of O 0 3.792186120676888e-08
strategies O 0 1.0676244528440293e-06
for O 0 7.008101476912998e-08
the O 0 1.3550031781051075e-06
prevention O 0 9.674318425823003e-05
and O 0 3.3903231155818503e-07
, O 0 1.1394555343713364e-07
where O 0 1.1842215741353357e-07
necessary O 0 2.4966726641650894e-07
, O 0 5.702482326341851e-07
management O 0 3.79046878151712e-06
of O 0 1.05328147981254e-07
a O 0 9.004071216622833e-06
risk O 0 5.489037721417844e-05
reversal O 0 1.059459009411512e-05
in O 0 1.2579252484101744e-07
any O 0 3.627775413406198e-08
predictive O 0 2.877930683098384e-06
testing O 0 8.114333468256518e-06
program O 0 1.3239630334282992e-06
. O 0 3.6106496281718137e-07
. O 0 3.0317617074615555e-06

A O 0 2.9435490432661027e-05
novel O 0 1.1546310815901961e-05
common O 0 1.6415640857303515e-05
missense O 0 0.00036752576124854386
mutation O 0 5.483522545546293e-05
G301C O 0 2.152272099920083e-05
in O 0 2.1445912068429607e-07
the O 0 5.913526592848939e-07
N O 0 0.00015249254647642374
- O 0 0.00016602041432633996
acetylgalactosamine O 0 0.0006470398511737585
- O 0 0.00018304235709365457
6 O 0 3.698152067954652e-05
- O 0 0.00017083711281884462
sulfate O 0 0.00047810282558202744
sulfatase O 0 0.0009330830071121454
gene O 0 3.2393247238360345e-05
in O 0 1.2179926670796704e-05
mucopolysaccharidosis B-Disease 0 0.012432236224412918
IVA I-Disease 1 0.6742866635322571
. O 0 4.119369259569794e-05

Mucopolysaccharidosis B-Disease 1 0.9538742899894714
IVA I-Disease 1 0.9936738014221191
( O 0 0.00047554844059050083
MPS B-Disease 1 0.9987761378288269
IVA I-Disease 1 0.9997445940971375
) O 0 4.09218910135678e-06
is O 0 2.890211590056424e-06
an O 0 1.0307870979886502e-05
autosomal B-Disease 1 0.9988254904747009
recessive I-Disease 1 0.9997124075889587
lysosomal I-Disease 1 0.9998937845230103
storage I-Disease 1 0.999955415725708
disorder I-Disease 1 0.999993085861206
caused O 0 0.04895947501063347
by O 0 9.962579952116357e-07
a O 0 3.8618618418695405e-05
genetic B-Disease 1 0.996557354927063
defect I-Disease 1 0.9994516968727112
in O 0 1.0638857020239811e-05
N O 0 0.0009334484930150211
- O 0 0.0004636012017726898
acetylgalactosamine O 0 0.0021556054707616568
- O 0 0.0010341524612158537
6 O 0 0.00019409466767683625
- O 0 0.0017542443238198757
sulfate O 0 0.006660581100732088
sulfatase O 0 0.006110658403486013
( O 0 4.383691248222021e-06
GALNS O 0 0.0007956881891004741
) O 0 1.8826990526576992e-06
. O 0 4.499847818806302e-06

In O 0 1.2633499864023179e-06
previous O 0 2.1156849925318966e-06
studies O 0 6.034244961483637e-07
, O 0 1.636190489762157e-07
we O 0 6.519796613702056e-08
have O 0 2.570840074156422e-08
found O 0 9.41140285704023e-08
two O 0 4.0131698852974296e-08
common O 0 1.9384094684937736e-06
mutations O 0 1.748851173033472e-05
in O 0 3.5827494571094576e-07
Caucasians O 0 3.016073605976999e-06
and O 0 6.109835908318928e-07
Japanese O 0 1.1970816558459774e-05
, O 0 2.0365255295473617e-06
respectively O 0 1.406389674230013e-05
. O 0 8.31349279906135e-06

To O 0 8.793883239377465e-07
characterize O 0 4.100599107914604e-05
the O 0 1.9040817278437316e-06
mutational O 0 0.0002456447691656649
spectrum O 0 1.7112419300246984e-05
in O 0 8.879405299921928e-08
various O 0 3.489875766149453e-08
ethnic O 0 9.062188865982534e-08
groups O 0 1.4251413915644662e-07
, O 0 5.240303835307714e-07
mutations O 0 4.928967882733559e-06
in O 0 1.331447094798932e-07
the O 0 1.832942757573619e-07
GALNS O 0 0.000249863020144403
gene O 0 1.9711258573806845e-05
in O 0 1.0210374057351146e-05
Colombian O 0 0.0007317069685086608
MPS B-Disease 1 0.996077835559845
IVA I-Disease 1 0.9997813105583191
patients O 0 0.0005021945107728243
were O 0 1.7366567135468358e-06
investigated O 0 0.00011434274347266182
, O 0 6.878866543047479e-07
and O 0 1.9165815956512233e-07
genetic O 0 2.3496208996220957e-06
backgrounds O 0 1.0447713520989055e-06
were O 0 6.56068834814505e-08
extensively O 0 1.584980964253191e-06
analyzed O 0 1.2999412319913972e-06
to O 0 3.104741708170877e-08
identify O 0 1.7767017368441884e-07
racial O 0 9.794395339213224e-08
origin O 0 9.741000894791796e-08
, O 0 1.0785843329585987e-07
based O 0 3.97340365054788e-08
on O 0 2.1548315487507352e-07
mitochondrial O 0 1.8206134200227098e-06
DNA O 0 2.4953069441835396e-06
( O 0 1.0028308139453657e-07
mtDNA O 0 8.923945529204502e-07
) O 0 2.0836206715557637e-07
lineages O 0 1.10717119241599e-05
. O 0 9.794442121346947e-06

Three O 0 3.0948763196647633e-06
novel O 0 1.6717915059416555e-05
missense O 0 0.0004427697858773172
mutations O 0 0.00022193844779394567
never O 0 1.763920772646088e-05
identified O 0 2.5714316507219337e-06
previously O 0 1.80444794750656e-06
in O 0 7.696865367279315e-08
other O 0 3.08513712354852e-08
populations O 0 2.0703041059277894e-07
and O 0 1.6209546060963476e-07
found O 0 2.767526439129142e-07
in O 0 8.187974032125567e-08
16 O 0 3.504163998968579e-07
out O 0 9.138282308640555e-08
of O 0 1.539732039645969e-07
19 O 0 2.7961992600467056e-05
Colombian O 0 0.0002996471885126084
MPS B-Disease 1 0.9920793175697327
IVA I-Disease 1 0.9988765120506287
unrelated O 0 5.901716576772742e-05
alleles O 0 4.008827090729028e-06
account O 0 7.617987876074039e-07
for O 0 6.403022325685015e-07
84 O 0 6.102211773395538e-05
. O 0 8.068634997471236e-06

2 O 0 3.56957525582402e-06
% O 0 2.5390379576606392e-08
of O 0 1.1701710711520263e-08
the O 0 4.022818700377684e-08
alleles O 0 5.092210244583839e-07
in O 0 1.9034685294627707e-07
this O 0 7.409390434531815e-08
study O 0 1.2433534948286251e-06
. O 0 2.8258373276912607e-06

The O 0 5.172202236281009e-06
G301C O 0 0.00014670268865302205
and O 0 2.9470438676071353e-06
S162F O 0 7.602246478199959e-05
mutations O 0 2.0700266759376973e-05
account O 0 5.776803391199792e-07
for O 0 5.859851057721244e-07
68 O 0 5.10201534780208e-05
. O 0 9.066093298315536e-06

4 O 0 8.139909368765075e-06
% O 0 1.0190408517019023e-07
and O 0 7.558062975476787e-07
10 O 0 3.873361947626108e-06
. O 0 2.9667889975826256e-06

5 O 0 5.7494726206641644e-06
% O 0 7.854438166532418e-08
of O 0 1.2240904823102028e-07
mutations O 0 3.0450091799139045e-05
, O 0 5.935912668064702e-07
respectively O 0 1.7491361177235376e-06
, O 0 9.602866413160882e-08
whereas O 0 2.3593204900862474e-07
the O 0 1.0595864097240337e-07
remaining O 0 5.11904886479897e-07
F69V O 0 0.00018956877465825528
is O 0 8.765702119717389e-08
limited O 0 3.401213533038572e-08
to O 0 1.4093973987883146e-08
a O 0 5.055156293565233e-07
single O 0 2.3693955881753936e-06
allele O 0 3.921859388356097e-05
. O 0 1.1513939170981757e-05

The O 0 4.320377684052801e-06
skewed O 0 7.97649918240495e-05
prevalence O 0 0.00010271155770169571
of O 0 2.472105791184731e-07
G301C O 0 1.971054371097125e-05
in O 0 2.668350589374313e-07
only O 0 1.8502173304568714e-07
Colombian O 0 1.0267654033668805e-05
patients O 0 8.2613469203352e-06
and O 0 3.950228517624055e-07
haplotype O 0 2.256815969303716e-05
analysis O 0 3.468803129180742e-07
by O 0 5.15087954511273e-08
restriction O 0 5.67608083201776e-07
fragment O 0 5.577216143137775e-06
length O 0 3.1192178084893385e-06
polymorphisms O 0 1.585864811204374e-05
in O 0 2.931168978648202e-07
the O 0 5.959986424386443e-07
GALNS O 0 0.000339624093612656
gene O 0 8.862568392942194e-06
suggest O 0 1.268709524993028e-06
that O 0 9.257561117692603e-08
G301C O 0 1.2167399290774483e-05
originated O 0 8.557311161894177e-07
from O 0 1.0636787095563704e-07
a O 0 6.835555836914864e-07
common O 0 3.440890623096493e-06
ancestor O 0 2.752726140897721e-05
. O 0 3.0206103474483825e-05

Investigation O 0 1.444136978534516e-05
of O 0 9.519053634221564e-08
the O 0 4.298651390399755e-07
genetic O 0 7.992304745130241e-06
background O 0 1.5753334992041346e-06
by O 0 1.0702907360382596e-07
means O 0 2.546461530528177e-07
of O 0 2.956908495832522e-08
mtDNA O 0 7.680461067138822e-07
lineages O 0 1.1914925153178046e-06
indicate O 0 5.305909098751727e-07
that O 0 2.162305712261059e-08
all O 0 3.8677324454283735e-08
our O 0 1.1799021422120859e-06
patients O 0 9.1150141088292e-06
are O 0 3.887746657937896e-08
probably O 0 1.8074705394610646e-06
of O 0 7.814181657295194e-08
native O 0 2.7733758543035947e-06
American O 0 1.1796708349720575e-05
descent O 0 0.0005152018275111914

Low O 0 8.020937093533576e-05
frequency O 0 1.7369136912748218e-05
of O 0 1.4348269132824498e-06
BRCA1 O 0 0.001228703884407878
germline O 0 0.0012728068977594376
mutations O 0 0.0002643429324962199
in O 0 4.8532501750742085e-06
45 O 0 4.9304766434943303e-05
German O 1 0.9992187023162842
breast B-Disease 1 0.999992847442627
/ I-Disease 1 0.9999639987945557
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
families O 0 1.975223858607933e-05
. O 0 2.295014746778179e-05

In O 0 1.411500534231891e-06
this O 0 5.744621844883113e-08
study O 0 2.7640419375529746e-07
we O 0 4.3424466866781586e-07
investigated O 0 4.6761895646341145e-05
45 O 0 2.683028651517816e-05
German O 1 0.9977806210517883
breast B-Disease 1 0.9999865293502808
/ I-Disease 1 0.9999223947525024
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999969005584717
families O 0 1.922202727655531e-06
for O 0 5.813767529616598e-07
germline O 0 0.0004813619307242334
mutations O 0 7.98094188212417e-05
in O 0 9.43478255521768e-07
the O 0 1.9327039808558766e-06
BRCA1 O 0 0.0004961951053701341
gene O 0 0.00016586677520535886
. O 0 2.018182203755714e-05

We O 0 5.310238975653192e-06
identified O 0 5.76697857468389e-06
four O 0 7.539561579505971e-07
germline O 0 0.0003097198496107012
mutations O 0 0.00020340563787613064
in O 0 5.722624337067828e-06
three O 0 4.352176620159298e-05
breast B-Disease 1 0.9993457198143005
cancer I-Disease 1 0.9948500990867615
families O 0 8.211292623627742e-08
and O 0 6.352576065182802e-07
in O 0 5.416776730271522e-06
one O 0 0.002174064749851823
breast B-Disease 1 0.9999935626983643
- I-Disease 1 0.9999964237213135
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999986886978149
family O 0 1.295874153584009e-05
. O 0 9.256147848191176e-08
among O 0 1.965050167029858e-08
these O 0 1.0149920903756993e-08
were O 0 1.0033645736484686e-07
one O 0 5.403308023232967e-07
frameshift O 0 0.0004055397876072675
mutation O 0 3.60493031621445e-05
, O 0 8.375911875191377e-07
one O 0 7.433127393596806e-07
nonsense O 0 6.464310718001798e-05
mutation O 0 2.583370587672107e-05
, O 0 3.4801419701580016e-07
one O 0 7.455035699877044e-08
novel O 0 6.704469797114143e-07
splice O 0 5.401118687586859e-05
site O 0 2.5102432118728757e-05
mutation O 0 1.6816398783703335e-05
, O 0 4.148198229358968e-07
and O 0 2.767988007690292e-07
one O 0 2.2941592305869563e-06
missense O 0 0.0005312055582180619
mutation O 0 0.0004506341938395053
. O 0 1.3941642464487813e-05

The O 0 9.147277523879893e-06
missense O 0 0.0003776209778152406
mutation O 0 4.720937795354985e-05
was O 0 1.0950250725727528e-05
also O 0 5.449052764561202e-07
found O 0 7.615329877808108e-07
in O 0 3.153899399421789e-07
2 O 0 9.757169209478889e-06
. O 0 5.237173809291562e-06

8 O 0 6.470499556598952e-06
% O 0 4.0960003389045596e-08
of O 0 2.257703002328526e-08
the O 0 1.9368302162092732e-07
general O 0 4.887379532192426e-07
population O 0 4.6842881573638806e-08
, O 0 2.288549154627617e-07
suggesting O 0 6.682676030322909e-07
that O 0 3.458334774109062e-08
it O 0 1.6215173559430696e-07
is O 0 8.313068065035623e-07
not O 0 3.2698162613087334e-06
disease O 1 0.9919852018356323
associated O 0 4.984741099178791e-05
. O 0 5.899044481338933e-06

The O 0 2.5205633846780984e-06
average O 0 1.7761640265234746e-05
age O 0 1.50609284901293e-05
of O 0 3.528042498146533e-06
disease O 1 0.999433696269989
onset O 0 0.1299791783094406
in O 0 8.454608177999035e-07
those O 0 8.536846962670097e-08
families O 0 4.300205205254315e-07
harbouring O 0 0.0005055083311162889
causative O 0 0.00045066323946230114
mutations O 0 0.00022986892145127058
was O 0 1.7356816897518e-05
between O 0 1.3861786101188045e-06
32 O 0 1.7361850041197613e-05
. O 0 4.537978838925483e-06

3 O 0 1.9398339645704255e-05
and O 0 5.34999981027795e-06
37 O 0 3.4221626265207306e-05
. O 0 8.879370398062747e-06

4 O 0 1.722877823340241e-05
years O 0 2.7321184461470693e-06
, O 0 1.4706523643326364e-07
whereas O 0 5.917091812079889e-07
the O 0 3.7132539887352323e-07
family O 0 7.1495674092147965e-06
harbouring O 0 0.00030729974969290197
the O 0 8.778289384281379e-07
missense O 0 0.000111852576083038
mutation O 0 2.0938437955919653e-05
had O 0 9.519886248199327e-07
an O 0 6.490886050869449e-08
average O 0 1.6805067843961297e-06
age O 0 2.6110242288268637e-06
of O 0 1.5773238715155458e-07
onset O 0 0.002378297969698906
of O 0 1.891800707198854e-06
51 O 0 8.288322715088725e-05
. O 0 1.3026332453591749e-05

2 O 0 5.5639462516410276e-05
years O 0 1.9864068235619925e-05
. O 0 6.609712727367878e-06

These O 0 5.88148452607129e-07
findings O 0 2.1048617782071233e-06
show O 0 1.7413566411050851e-06
that O 0 1.9238463266901817e-07
BRCA1 O 0 7.174885831773281e-05
is O 0 1.111199253500672e-06
implicated O 0 1.83754600584507e-05
in O 0 1.5183347557012894e-07
a O 0 6.59456759422028e-07
small O 0 8.555500130569271e-07
fraction O 0 1.2162527127657086e-05
of O 0 0.00010735364776337519
breast B-Disease 1 0.99997878074646
/ I-Disease 1 0.9999362230300903
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999977350234985
families O 0 1.4295164874056354e-06
suggesting O 0 2.831378196788137e-06
the O 0 2.561306473580771e-07
involvement O 0 2.377823193455697e-06
of O 0 1.3565298218054522e-07
another O 0 5.532833256438607e-06
susceptibility O 0 0.00012244646495673805
gene O 0 5.22372720297426e-05
( O 0 7.659309630980715e-06
s O 0 0.0012178069446235895
) O 0 2.0544686776702292e-05

Paternal O 0 0.014215386472642422
transmission O 1 0.996225118637085
of O 1 0.6581411361694336
congenital B-Disease 1 1.0
myotonic I-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999995231628418
. O 0 0.0027205399237573147

We O 0 7.321004886762239e-06
report O 0 1.1991905921604484e-06
a O 0 1.297869971494947e-06
rare O 0 4.055046883877367e-05
case O 0 1.6833020708872937e-05
of O 0 9.099380804400425e-06
paternally O 1 0.9984808564186096
transmitted O 1 0.9999566078186035
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999996423721313
( O 0 0.0034371267538517714
DM B-Disease 1 0.9999527931213379
) O 0 1.7374572053086013e-05
. O 0 1.2875027096015401e-05

The O 0 4.619434548658319e-06
proband O 0 0.0002864514826796949
is O 0 8.674315381540509e-07
a O 0 1.4873113514113356e-06
23 O 0 6.556248990818858e-06
year O 0 2.5988390461861854e-06
old O 0 0.00033745684777386487
, O 0 0.00016262891585938632
mentally B-Disease 1 0.9999614953994751
retarded I-Disease 1 0.998446524143219
male O 0 0.0004153860209044069
who O 0 0.011946449987590313
suffers O 1 0.9998637437820435
severe O 1 0.9999221563339233
muscular B-Disease 1 0.9999607801437378
weakness I-Disease 1 0.9994091987609863
. O 0 0.00025730926427058876

He O 0 0.00010883161303354427
presented O 0 3.858636773657054e-05
with O 0 0.00013536967162508518
respiratory O 1 0.9999591112136841
and O 0 3.186956018907949e-05
feeding O 0 0.0001353947154711932
difficulties O 0 0.0006345724686980247
at O 0 0.0003397954278625548
birth O 0 0.0001552018366055563
. O 0 9.848306945059448e-06

His O 0 0.00010101389489136636
two O 0 7.427160016959533e-05
sibs O 1 0.969685971736908
suffer O 1 0.6505364775657654
from O 0 3.304639903944917e-05
childhood O 0 0.48097535967826843
onset O 1 0.9993075132369995
DM B-Disease 1 0.9999796152114868
. O 0 0.00025774381356313825

Their O 0 1.687766484792519e-06
late O 0 0.00011749268742278218
father O 0 2.2044854631531052e-05
had O 0 1.2673648370764568e-06
the O 0 7.829697779015987e-08
adult O 0 9.92250875242462e-07
type O 0 3.0557199352188036e-05
of O 0 3.3291662475676276e-06
DM B-Disease 1 0.9999685287475586
, O 0 2.0890793166472577e-06
with O 0 7.958396963658743e-07
onset O 0 0.001420473330654204
around O 0 2.8769181881216355e-06
30 O 0 3.972691501985537e-06
years O 0 2.5464012196607655e-06
. O 0 2.550583985794219e-06

Only O 0 3.433403037433891e-07
six O 0 3.0296666864160215e-07
other O 0 4.828395105960226e-08
cases O 0 2.911699823471281e-07
of O 0 3.546808358123599e-08
paternal O 0 0.00034076281008310616
transmission O 1 0.9967613816261292
of O 0 0.0027065391186624765
congenital B-Disease 1 0.9999997615814209
DM I-Disease 1 0.999994158744812
have O 0 5.2916791901225224e-05
been O 0 2.333757402084302e-05
reported O 0 9.005940228234977e-05
recently O 0 0.00014856865163892508
. O 0 8.986153261503205e-06

We O 0 5.74623845750466e-06
review O 0 1.3729498959946795e-06
the O 0 1.9085452152012294e-07
sex O 0 1.9589861040003598e-06
related O 0 4.668252131523332e-06
effects O 0 2.8240241590538062e-05
on O 0 2.6520776373217814e-05
transmission O 0 0.3046487867832184
of O 0 0.0012666023103520274
congenital B-Disease 1 0.9999997615814209
DM I-Disease 1 0.9999936819076538
. O 0 0.0005357299814932048

Decreased O 0 0.0009013419039547443
fertility O 0 0.00018147414084523916
of O 0 1.600680121782716e-07
males O 0 5.533828471016022e-07
with O 0 9.241326779374504e-07
adult O 0 7.290381472557783e-05
onset O 1 0.9965968728065491
DM B-Disease 1 0.9999756813049316
and O 0 3.594123700167984e-05
contraction O 0 0.00012305031123105437
of O 0 7.23986417483502e-08
the O 0 5.089360115562158e-07
repeat O 0 6.0296524679870345e-06
upon O 0 2.442673405766982e-07
male O 0 1.6889691778487759e-06
transmission O 0 3.22041887557134e-05
contribute O 0 5.091453090244613e-07
to O 0 4.992403646042476e-08
the O 0 3.327419051402103e-07
almost O 0 1.7945322952073184e-06
absent O 0 3.9982776797842234e-05
occurrence O 0 5.1859602535841987e-05
of O 0 3.47958120983094e-07
paternal O 0 0.000517394277267158
transmission O 1 0.9912023544311523
of O 0 0.0042889537289738655
congenital B-Disease 1 0.9999997615814209
DM I-Disease 1 0.9999979734420776
. O 0 0.0008794942987151444

Also O 0 2.6434252049511997e-06
the O 0 3.4186217590104206e-07
fathers O 0 2.0923052943544462e-06
of O 0 1.2177541464097885e-07
the O 0 2.674406459846068e-06
reported O 0 0.0001515078474767506
congenitally O 0 0.008245798759162426
affected O 0 1.118648378906073e-05
children O 0 7.172857294790447e-07
showed O 0 3.3120024909294443e-06
, O 0 1.768199382468083e-07
on O 0 8.947831702244002e-07
average O 0 5.530955149879446e-06
, O 0 7.323284307858557e-07
shorter O 0 3.780053884838708e-05
CTG O 0 0.0004872698918916285
repeat O 0 4.8588986828690395e-05
lengths O 0 0.00012986132060177624
and O 0 1.337754156338633e-06
hence O 0 1.2253992281330284e-05
less O 0 2.59695607383037e-05
severe O 1 0.9977858066558838
clinical O 0 0.02379104122519493
symptoms O 1 0.8874093890190125
than O 0 1.719545679179646e-07
the O 0 2.731795518684521e-07
mothers O 0 2.7015141768060857e-06
of O 0 1.1191867343995909e-07
children O 0 2.5670090053608874e-06
with O 0 0.004777910653501749
congenital B-Disease 1 0.9999997615814209
DM I-Disease 1 0.9999974966049194
. O 0 0.0005627612117677927

We O 0 5.359723218134604e-06
conclude O 0 7.531889423262328e-06
that O 0 1.929196429273361e-07
paternal O 0 0.00012751563917845488
transmission O 1 0.7559238076210022
of O 0 0.0008646378410048783
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 0.999998927116394
is O 0 4.590709795593284e-05
rare O 0 3.177071994286962e-05
and O 0 6.95211781476246e-07
preferentially O 0 5.766637968918076e-06
occurs O 0 2.7446433250588598e-06
with O 0 6.556147695846448e-07
onset O 0 0.004309406038373709
of O 0 3.408241354918573e-06
DM B-Disease 1 0.9998636245727539
past O 0 8.76708872965537e-06
30 O 0 2.3858096938056406e-06
years O 0 3.4522986425145064e-07
in O 0 6.266954954980974e-08
the O 0 2.3116689362723264e-07
father O 0 1.0083553206641227e-05
. O 0 7.979600695762201e-07
. O 0 2.883975184886367e-06

The O 0 9.100960596697405e-06
RB1 O 0 0.003991910256445408
gene O 0 3.451347947702743e-05
mutation O 0 3.436201950535178e-05
in O 0 8.252466727753927e-07
a O 0 5.391775175667135e-06
child O 0 4.678469122154638e-05
with O 0 3.443447712925263e-05
ectopic B-Disease 1 0.9966380596160889
intracranial I-Disease 1 0.9998107552528381
retinoblastoma I-Disease 1 0.9979008436203003
. O 0 0.00013850440154783428

The O 0 1.9375967895030044e-05
RB1 O 0 0.007922890596091747
gene O 0 0.0001209532783832401
mutation O 0 0.00013545321417041123
was O 0 1.770194648997858e-05
investigated O 0 2.0699872038676403e-05
in O 0 5.478012212734029e-07
a O 0 5.347066689864732e-06
child O 0 5.053905624663457e-05
with O 0 1.276685725315474e-05
ectopic B-Disease 1 0.9712862372398376
intracranial I-Disease 1 0.99831223487854
retinoblastoma I-Disease 0 0.0015601596096530557
using O 0 8.896575423023023e-07
DNA O 0 1.9553986021492165e-06
obtained O 0 3.6111936196903116e-07
from O 0 1.0981469245052722e-07
both O 0 2.3247636704581964e-07
the O 0 4.13021189160645e-06
pineal B-Disease 0 0.027008913457393646
and I-Disease 0 0.0006063943728804588
retinal I-Disease 1 0.9979813694953918
tumours I-Disease 1 0.9999850988388062
of O 0 4.448959316505352e-06
the O 0 4.566019924823195e-05
patient O 0 0.01564045436680317
. O 0 2.264132308482658e-05

A O 0 8.431012247456238e-05
nonsense O 0 0.00035541909164749086
mutation O 0 7.155310595408082e-05
in O 0 2.377290229560458e-06
exon O 0 6.472131644841284e-05
17 O 0 6.516423127322923e-06
( O 0 2.1885294643197994e-07
codon O 0 3.894660039804876e-06
556 O 0 3.9594756344740745e-06
) O 0 3.524096925389131e-08
of O 0 1.6430858451599306e-08
the O 0 4.083909743712866e-07
RB1 O 0 0.0004699130658991635
gene O 0 5.146272997080814e-06
was O 0 5.002697434974834e-06
found O 0 1.283119672734756e-07
to O 0 6.886340830902782e-09
be O 0 4.762813077263672e-08
present O 0 1.4355438793245412e-07
homozygously O 0 2.000173117266968e-05
in O 0 1.0111395454259764e-07
both O 0 1.4632753675414278e-07
the O 0 1.5293313708752976e-06
retinal B-Disease 0 0.002117246389389038
and I-Disease 0 8.693514246260747e-06
the I-Disease 0 7.156429637689143e-05
pineal I-Disease 1 0.994472324848175
tumours I-Disease 1 0.999987006187439
. O 0 0.0001530697481939569

The O 0 1.9182161850039847e-06
same O 0 1.574645580149081e-06
mutation O 0 2.493320425855927e-05
was O 0 3.68486712432059e-06
present O 0 2.4570653067712556e-07
heterozygously O 0 2.6618377887643874e-05
in O 0 8.506598447866054e-08
the O 0 5.254856461078816e-08
DNA O 0 8.940173756855074e-07
from O 0 4.465816516585619e-08
the O 0 1.1789714449150779e-07
constitutional O 0 1.9316039470140822e-06
cells O 0 2.0809427496715216e-06
of O 0 6.024802701176668e-08
the O 0 1.0811646689035115e-06
patient O 0 0.00017803159425966442
, O 0 6.621659736083529e-07
proving O 0 4.809502570424229e-06
it O 0 7.732754170319822e-08
to O 0 3.538342241427017e-08
be O 0 9.995252980843361e-08
of O 0 1.4275872217694996e-07
germline O 0 0.0001312363747274503
origin O 0 7.631930202478543e-06
. O 0 1.1006042768713087e-05

The O 0 3.605396159400698e-06
initial O 0 9.882486665446777e-06
mutation O 0 3.3519470889586955e-05
was O 0 5.751622211391805e-06
shown O 0 1.412113022070116e-07
to O 0 2.517559494208399e-08
have O 0 1.3721289349177823e-07
occurred O 0 4.67079053123598e-06
in O 0 2.666325826794491e-07
the O 0 1.1305164662189782e-06
paternally O 0 0.0006116544827818871
derived O 0 2.7366158974473365e-05
RB1 O 0 0.008467057719826698
allele O 0 0.00027721229707822204
. O 0 3.16554942401126e-05

The O 0 5.794012849946739e-06
mutation O 0 6.267618300626054e-05
is O 0 4.979798404747271e-07
in O 0 6.040093580850225e-08
an O 0 5.262619851009731e-08
area O 0 4.3439254682198225e-07
of O 0 9.78408465357461e-09
the O 0 3.7669977359655604e-08
gene O 0 1.6189954976653098e-07
that O 0 2.4612898386067172e-09
encodes O 0 9.092640418373321e-09
the O 0 2.4975102874691402e-08
protein O 0 3.211896171251283e-07
- O 0 4.311795692046871e-06
binding O 0 1.229283952852711e-06
region O 0 2.375558779021958e-06
known O 0 1.2534253528428962e-06
as O 0 3.912526267413341e-07
the O 0 7.114858249224199e-07
pocket O 0 0.0002789145801216364
region O 0 7.529504728154279e-06
and O 0 7.548022153969214e-07
has O 0 9.690860451883054e-07
been O 0 5.472623456626025e-07
detected O 0 1.0146562090085354e-05
in O 0 6.126044382881446e-08
other O 0 3.047421159863006e-08
cases O 0 4.488215097353532e-07
of O 0 2.893921760005469e-07
retinoblastoma B-Disease 0 0.044270820915699005
. O 0 5.473821602208773e-06
. O 0 8.030084245547187e-06

Low O 0 0.00018940455629490316
levels O 0 1.6516816685907543e-05
of O 0 2.510092258489749e-07
beta O 0 1.1186014489794616e-05
hexosaminidase O 0 6.195671448949724e-05
A O 0 2.271409584864159e-06
in O 0 5.94641733187018e-07
healthy O 0 3.03907404486381e-06
individuals O 0 4.035136669244821e-08
with O 0 3.5232612844993128e-06
apparent O 1 0.8604697585105896
deficiency O 1 0.9996743202209473
of O 0 2.5512429147056537e-07
this O 0 5.243933287601976e-07
enzyme O 0 6.0944134020246565e-05
. O 0 7.331170763791306e-06

Appreciable O 0 0.0002498318499419838
beta O 0 0.00012019228597637266
hexosaminidase O 0 0.00014480548270512372
A O 0 5.80162077312707e-06
( O 0 2.4429553491245315e-07
hex O 0 1.2589512152771931e-05
A O 0 1.0235694389848504e-06
) O 0 5.635950017790492e-08
activity O 0 2.3073630472936202e-07
has O 0 1.8739363838449208e-07
been O 0 4.2504629504946934e-07
detected O 0 1.3935634342487901e-05
in O 0 8.198348382393306e-07
cultured O 0 0.00019542912195902318
skin O 1 0.9759737849235535
fibroblasts O 0 0.0014948458410799503
and O 0 0.0009957574075087905
melanoma B-Disease 1 0.999906063079834
tissue O 0 0.12526795268058777
from O 0 1.5942252957756864e-06
healthy O 0 5.337239144864725e-06
individuals O 0 6.40868549339757e-08
previously O 0 4.586385784932645e-06
reported O 0 1.6188230802072212e-05
as O 0 3.1965453217708273e-06
having O 0 0.0004462995857466012
deficiency B-Disease 1 0.997450053691864
of I-Disease 0 2.1262566463065014e-07
hex I-Disease 0 5.3109502914594486e-05
A I-Disease 0 1.6320606164299534e-06
activity O 0 5.876999580323172e-07
indistinguishable O 0 1.7266196437049075e-06
from O 0 9.01933816521705e-08
that O 0 1.7234965454804296e-08
of O 0 1.8932090029011306e-07
patients O 0 8.449106098851189e-05
with O 0 0.0026133921928703785
Tay B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999833106994629
Sachs I-Disease 1 0.9999706745147705
disease I-Disease 1 0.9997681975364685
( O 0 1.363269711873727e-05
TSD B-Disease 0 0.004529870115220547
) O 0 5.3784278861712664e-06
. O 0 8.365059329662472e-06

Identification O 0 5.3083908824191894e-06
and O 0 1.8992665218320326e-06
quantitation O 0 0.00044702511513605714
of O 0 1.6145623931151931e-06
hex O 0 0.00017072945774998516
A O 0 6.056202892068541e-06
, O 0 2.8218229886078916e-07
amounting O 0 9.235442348654033e-07
to O 0 1.9925514038732217e-07
3 O 0 5.391918875830015e-06
. O 0 3.5391560686548473e-06

5 O 0 2.1219742848188616e-05
% O 0 8.90812145826203e-07
- O 0 0.00014393971650861204
6 O 0 3.1833620596444234e-05
. O 0 7.795603778504301e-06

9 O 0 9.779144420463126e-06
% O 0 1.8897630127412413e-08
of O 0 1.552932715753741e-08
total O 0 7.428195658576442e-08
beta O 0 8.962385436461773e-06
hexosaminidase O 0 4.500929935602471e-05
activity O 0 1.4452448340307456e-06
, O 0 2.3178921537692077e-07
has O 0 1.370558209146111e-07
been O 0 6.980859268423956e-08
obtained O 0 1.776732290181826e-07
by O 0 3.1450508686248213e-07
cellulose O 0 0.0005595058901235461
acetate O 0 0.0002907066373154521
gel O 0 0.00089360645506531
electrophoresis O 0 0.00017611260409466922
, O 0 3.0537044040102046e-06
DEAE O 0 0.00034151828731410205
- O 0 7.914611342130229e-05
cellulose O 0 0.00017549959011375904
ion O 0 0.00020608126942534
- O 0 4.4462813093559816e-05
exchange O 0 2.5346178517793305e-05
chromatography O 0 0.0010857493616640568
, O 0 3.6330775401438586e-06
radial O 0 0.0003227200359106064
immunodiffusion O 0 0.002331777010113001
, O 0 3.2964419460768113e-06
and O 0 2.397361868133885e-06
radioimmunoassay O 0 0.002409020671620965
. O 0 1.548130421724636e-05

Previous O 0 5.173552199266851e-05
family O 0 1.224218158313306e-05
studies O 0 1.2257276011951035e-06
suggested O 0 1.0552515732342727e-06
that O 0 9.829276059747372e-09
these O 0 1.3544428689726828e-08
individuals O 0 3.3559313550313163e-08
may O 0 6.649402166658547e-07
be O 0 9.239602860589002e-08
compound O 0 1.175306579170865e-06
heterozygotes O 0 6.723532351315953e-06
for O 0 8.445052657179986e-08
the O 0 1.678208860766972e-07
common O 0 6.375824796123197e-06
mutant O 0 6.407361797755584e-05
TSD B-Disease 0 0.000602040789090097
gene O 0 9.910952940117568e-06
and O 0 1.5735497527202824e-06
a O 0 2.878861096178298e-06
rare O 0 4.1085844713961706e-05
( O 0 1.0261517218168592e-06
allelic O 0 5.615855479845777e-05
) O 0 1.0216911050520139e-06
mutant O 0 2.4680644855834544e-05
gene O 0 6.88452782924287e-05
. O 0 8.293553946714383e-06

Thus O 0 1.455455094401259e-05
, O 0 7.60620594064676e-07
the O 0 1.6848221662257856e-07
postulated O 0 5.864861122972798e-06
rate O 0 1.391033265463193e-06
mutant O 0 1.684884523456276e-06
gene O 0 1.3004234915570123e-06
appears O 0 6.740551157236041e-07
to O 0 8.295255149448622e-09
code O 0 2.6520424967202416e-08
for O 0 4.352340265967314e-09
the O 0 3.3785706676781047e-08
expression O 0 2.9754377806057164e-07
of O 0 1.214043550135102e-07
low O 0 1.3095347640046384e-05
amounts O 0 2.590203621366527e-06
of O 0 3.456502213339263e-07
hex O 0 0.00023204387980513275
A O 0 6.157850293675438e-05
. O 0 9.888388376566581e-06

Heterozygotes O 0 0.00020517213852144778
for O 0 4.119050345252617e-07
the O 0 6.610932814510306e-07
rare O 0 3.669398574857041e-05
mutant O 0 5.180419248063117e-05
may O 0 2.592477130747284e-06
be O 0 9.19145790589937e-08
indistinguishable O 0 3.117790356554906e-06
from O 0 3.2120371429300576e-07
heterozygotes O 0 6.476518592535285e-06
for O 0 6.349359438218016e-08
the O 0 4.048621065066982e-07
common O 0 2.6728977900347672e-05
TSD B-Disease 0 0.014803909696638584
mutant O 0 0.00044521078234538436
. O 0 1.9247936506872065e-05

However O 0 1.7438877648601192e-06
, O 0 1.709538679506295e-07
direct O 0 2.2199705540515424e-07
visualization O 0 3.484914486762136e-05
and O 0 3.246623691666173e-06
quantitation O 0 0.0003454774268902838
of O 0 5.202390411795932e-07
hex O 0 8.95728517207317e-05
A O 0 1.9886040263372706e-06
by O 0 5.398085889396498e-08
the O 0 1.1994784188118501e-07
methods O 0 1.449356659577461e-06
described O 0 2.063278589048423e-05
may O 0 4.326901034801267e-06
prevent O 0 7.733337042736821e-06
false O 0 1.2407224858179688e-05
- O 0 0.00013881310587748885
positive O 0 6.270646736084018e-06
prenatal O 0 0.0008098268881440163
diagnosis O 0 0.04105138033628464
of O 0 1.3665855931321857e-06
TSD B-Disease 0 0.01097562164068222
in O 0 8.186158993339632e-06
fetuses O 0 0.00011831159645225853
having O 0 1.8937447521238937e-06
the O 0 7.205478027572099e-07
incomplete O 0 0.00012244423851370811
hex B-Disease 0 0.005710827652364969
A I-Disease 0 0.0007959107169881463
deficiency I-Disease 1 0.9969592094421387
of O 0 5.841968331310454e-08
the O 0 4.60523551737424e-07
type O 0 6.907235365360975e-05
described O 0 4.874686055700295e-06
in O 0 1.714232382710179e-07
the O 0 2.5041700268957356e-07
four O 0 1.2380230600683717e-06
healthy O 0 4.247485048836097e-05
individuals O 0 1.031579540722305e-05

The O 0 2.888131893996615e-05
tumor B-Disease 0 0.3004555404186249
suppressor O 0 0.00040683773113414645
gene O 0 7.734248356427997e-05
Smad4 O 0 0.0013060655910521746
/ O 0 0.00013557933561969548
Dpc4 O 0 0.00022704359435010701
is O 0 3.1414896284331917e-07
required O 0 9.420723756647931e-08
for O 0 9.919266119595704e-08
gastrulation O 0 9.142657654592767e-05
and O 0 7.099262688825547e-07
later O 0 2.409055014140904e-06
for O 0 2.757060144631396e-07
anterior O 0 0.0035965866409242153
development O 0 7.277292297658278e-07
of O 0 1.0046495901860908e-07
the O 0 1.3949629646958783e-06
mouse O 0 0.000277260405709967
embryo O 0 0.0001713885721983388
. O 0 1.733400858938694e-05

Mutations O 0 0.0006871778750792146
in O 0 3.6931203339918284e-06
the O 0 4.796434495801805e-06
SMAD4 O 0 0.01870489865541458
/ O 0 0.0012831935891881585
DPC4 O 0 0.015346524305641651
tumor B-Disease 0 0.012144268490374088
suppressor O 0 6.759005191270262e-05
gene O 0 4.003933099738788e-06
, O 0 2.5737256237334805e-07
a O 0 3.356876447924151e-07
key O 0 5.219065315031912e-06
signal O 0 1.2344211427262053e-05
transducer O 0 3.4780179703375325e-05
in O 0 7.428039339174575e-07
most O 0 1.0284372820024146e-06
TGFbeta O 0 0.00021045980975031853
- O 0 4.4572381739271805e-05
related O 0 2.967768068629084e-06
pathways O 0 6.472949735325528e-06
, O 0 8.823506192356945e-08
are O 0 3.850396446125615e-09
involved O 0 4.358033223184066e-08
in O 0 7.684748482006398e-08
50 O 0 4.896056680081529e-07
% O 0 1.8318557692964532e-07
of O 0 1.2059113032591995e-05
pancreatic B-Disease 1 0.9999953508377075
cancers I-Disease 1 0.9999667406082153
. O 0 5.731015698984265e-05

Homozygous O 0 0.00046287503209896386
Smad4 O 0 0.0017344160005450249
mutant O 0 0.0003044451877940446
mice O 0 0.0005358765483833849
die O 0 0.0010874832514673471
before O 0 3.0025767046026886e-06
day O 0 6.3735328694747295e-06
7 O 0 1.0691521310945973e-05
. O 0 4.5614788177772425e-06

5 O 0 2.050503098871559e-05
of O 0 1.2296497970964992e-06
embryogenesis O 0 0.0009796306258067489
. O 0 5.994226012262516e-05

Mutant O 0 2.7714255338651128e-05
embryos O 0 2.705605993469362e-06
have O 0 5.814870291942498e-07
reduced O 0 2.0412603589647915e-06
size O 0 1.0213277164439205e-05
, O 0 1.7598966906007263e-06
fail O 0 1.8180651750299148e-05
to O 0 1.3243591467926308e-07
gastrulate O 0 0.00014498677046503872
or O 0 9.94413653643278e-07
express O 0 8.676458378431562e-07
a O 0 1.3176422726246528e-06
mesodermal O 0 0.00014721501793246716
marker O 0 0.0001077076158253476
, O 0 1.4701519148729858e-06
and O 0 5.90673494116345e-07
show O 0 1.2665513168030884e-05
abnormal O 0 0.0008255807915702462
visceral O 0 0.0008131267386488616
endoderm O 0 0.016406826674938202
development O 0 2.7958312784903683e-05
. O 0 3.0134227927192114e-05

Growth B-Disease 1 0.9975228905677795
retardation I-Disease 1 0.999964714050293
of O 0 2.9172665563237388e-06
the O 0 1.814857023418881e-05
Smad4 O 0 0.31083446741104126
- O 0 0.006660616025328636
deficient O 0 0.000742145988624543
embryos O 0 2.396283207417582e-06
results O 0 1.5558773611701326e-06
from O 0 1.2357105561022763e-07
reduced O 0 1.1475442533992464e-06
cell O 0 2.0649518774007447e-05
proliferation O 0 2.3613702069269493e-05
rather O 0 2.116695156928472e-07
than O 0 1.6525561363778252e-07
increased O 0 1.4078358390179346e-06
apoptosis O 0 0.00016484115622006357
. O 0 1.0055291568278335e-05

Aggregation O 0 7.208242459455505e-05
of O 0 2.216298980783904e-06
mutant O 0 0.00014538726827595383
Smad4 O 0 0.0014630109071731567
ES O 0 0.0003091433900408447
cells O 0 7.253171133925207e-06
with O 0 7.583650472042791e-07
wild O 0 2.330661482119467e-05
- O 0 0.00027238018810749054
type O 0 0.00017261960601899773
tetraploid O 0 0.002253760350868106
morulae O 0 0.02605554088950157
rescues O 0 0.0013509379932656884
the O 0 2.0350331396912225e-05
gastrulation B-Disease 1 0.5788867473602295
defect I-Disease 1 0.8787857890129089
. O 0 3.898962677340023e-05

These O 0 9.588359262124868e-07
results O 0 6.09307107879431e-06
indicate O 0 1.5722041553090094e-06
that O 0 1.5928135610465688e-07
Smad4 O 0 4.1315925045637414e-05
is O 0 1.316362130410198e-07
initially O 0 1.3273343313358055e-07
required O 0 1.5227657357286262e-08
for O 0 5.509056766328513e-09
the O 0 2.9209436647192888e-08
differentiation O 0 4.497813108628179e-07
of O 0 9.273713885704638e-08
the O 0 5.250218464425416e-07
visceral O 0 0.00014949361502658576
endoderm O 0 0.007438064552843571
and O 0 4.463348886929452e-06
that O 0 2.581606679541437e-07
the O 0 3.1081212910066824e-06
gastrulation B-Disease 0 0.011599903926253319
defect I-Disease 0 0.007779472507536411
in O 0 1.2845587207266362e-06
the O 0 8.805363336250593e-07
epiblast O 0 0.004410182125866413
is O 0 7.910800832178211e-07
secondary O 0 4.127305601286935e-06
and O 0 9.532423632663267e-07
non O 0 5.7846053096000105e-05
- O 0 0.0013697766698896885
cell O 0 0.0006100115133449435
autonomous O 0 4.9701498937793076e-05
. O 0 1.582477671036031e-05

Rescued O 0 0.0012236031470820308
embryos O 0 0.00014060823014006019
show O 0 0.0005469011375680566
severe O 1 0.9958317875862122
anterior O 1 0.991324782371521
truncations O 0 0.008478589355945587
, O 0 4.261618869350059e-06
indicating O 0 3.721503844644758e-06
a O 0 8.508218911629228e-07
second O 0 5.823822561978886e-07
important O 0 2.5916736490216863e-07
role O 0 2.7527171369001735e-06
for O 0 5.307766741680098e-07
Smad4 O 0 0.0008394390461035073
in O 0 9.612241228751373e-06
anterior O 0 0.08631181716918945
patterning O 0 0.0038240470457822084
during O 0 0.00014441813982557505
embryogenesis O 0 0.0017901447135955095
. O 0 4.5664466597372666e-05

Prevalence O 0 0.0008536498644389212
of O 0 1.2969370573046035e-06
p16 O 0 0.0001464005617890507
and O 0 1.0981603736581746e-05
CDK4 O 0 0.0038695121183991432
germline O 0 0.0016285303281620145
mutations O 0 0.0006747422739863396
in O 0 3.0700903153046966e-05
48 O 0 0.0055039916187524796
melanoma B-Disease 1 0.9999583959579468
- O 1 0.9715133905410767
prone O 0 0.04432803764939308
families O 0 1.034782940223522e-06
in O 0 4.258396984369028e-06
France O 0 0.0007603078847751021
. O 0 1.812950722523965e-05

The O 0 4.6736888180021197e-05
French O 0 0.05925443768501282
Familial B-Disease 1 0.9980897307395935
Melanoma I-Disease 1 0.999858021736145
Study O 0 3.971274782088585e-05
Group O 0 1.390462330164155e-05
. O 0 7.5512648436415475e-06

Germline O 0 0.009491879492998123
mutations O 0 0.0006636334001086652
in O 0 1.3805743037664797e-06
the O 0 6.827060019531928e-07
p16 O 0 3.331729749334045e-05
and O 0 9.952143500413513e-07
CDK4 O 0 0.00013982794189359993
genes O 0 2.110055220327922e-06
have O 0 1.3892633887735428e-07
been O 0 4.5480246058104967e-07
reported O 0 1.002431758934108e-06
in O 0 4.038817280616058e-08
a O 0 2.7538385438674595e-07
subset O 0 1.0638475487212418e-06
of O 0 3.332444521220168e-06
melanoma B-Disease 1 0.9995644688606262
pedigrees O 0 0.00014222325989976525
, O 0 1.060156932908285e-06
but O 0 1.29847009588957e-07
their O 0 6.321445766843681e-08
prevalence O 0 3.18948550557252e-05
is O 0 2.0532017686036852e-07
not O 0 4.1834521624650733e-08
well O 0 3.402242612082773e-07
known O 0 1.1334266673657112e-05
. O 0 8.445134881185368e-06

We O 0 9.701689123176038e-07
searched O 0 3.7216138935036724e-06
for O 0 3.8908549271354786e-08
such O 0 1.5993389013146952e-07
germline O 0 0.00024053436936810613
mutations O 0 9.154845611192286e-05
in O 0 3.585296781238867e-06
48 O 0 0.00011267944501014426
French O 1 0.9933640956878662
melanoma B-Disease 1 0.9999892711639404
- O 1 0.980771005153656
prone O 0 0.013001390732824802
families O 0 1.0515230997043545e-07
selected O 0 4.9295184822995e-08
according O 0 1.8412114499710697e-08
to O 0 7.2216566060490095e-09
two O 0 6.816560471634148e-08
major O 0 3.5496689179126406e-06
criteria O 0 8.539979603483516e-07
families O 0 1.5179605128423646e-08
with O 0 5.59897443963564e-08
at O 0 4.501001967582852e-06
least O 0 1.0065023303695853e-07
three O 0 4.642439321855818e-08
affected O 0 1.496512425092078e-07
members O 0 1.717589448446688e-08
( O 0 9.925985011705052e-08
n O 0 8.757956493354868e-06
= O 0 6.062536613171687e-06
20 O 0 3.656222418157995e-07
) O 0 1.6462227137026275e-08
or O 0 8.803736761819891e-08
families O 0 8.98326302234409e-09
with O 0 2.9512966293054888e-08
two O 0 1.1882340800184465e-07
affected O 0 6.069914206818794e-07
members O 0 2.7810665770289233e-08
, O 0 7.058784490254766e-08
one O 0 2.148926903089432e-08
of O 0 4.984845869415722e-09
them O 0 1.4142147897189261e-08
affected O 0 3.8194698959159723e-07
before O 0 1.846795498749998e-07
the O 0 7.407101065837196e-08
age O 0 5.879942364117596e-07
of O 0 2.525784026374822e-08
50 O 0 2.23014538391908e-07
( O 0 7.560775117099183e-08
n O 0 5.145674094819697e-06
= O 0 5.641635198117001e-06
28 O 0 1.314357973569713e-06
) O 0 2.965538925536748e-08
, O 0 5.5059921066913375e-08
and O 0 5.717097906199342e-08
one O 0 8.75754722073907e-08
additional O 0 2.472890798799199e-07
minor O 0 0.002948638517409563
criterion O 0 0.0003534350253175944
. O 0 1.9502025679685175e-05

Sixteen O 0 1.4683228982903529e-05
different O 0 7.649824738109601e-07
p16 O 0 0.00022833461116533726
germline O 0 0.0006025961483828723
mutations O 0 4.184720091870986e-05
were O 0 4.923091410091729e-07
found O 0 5.919739010096237e-07
in O 0 2.0736217720696004e-07
21 O 0 1.4965053196647204e-06
families O 0 2.001030630083278e-08
, O 0 1.437620795741168e-07
while O 0 4.286415276055777e-07
one O 0 1.0793678484333213e-06
germline O 0 0.00019529687415342778
mutation O 0 5.209718074183911e-05
, O 0 1.0465744253451703e-06
Arg24His O 0 9.879748540697619e-05
, O 0 1.1740329455278697e-06
was O 0 8.941537089413032e-06
detected O 0 2.468982529535424e-05
in O 0 2.1370698277678457e-07
the O 0 8.646985065752233e-07
CDK4 O 0 0.0007872468559071422
gene O 0 0.00010192107583861798
. O 0 1.5948418877087533e-05

The O 0 1.0725822221502312e-06
frequency O 0 4.183650617051171e-06
of O 0 1.6616509412870073e-07
p16 O 0 3.095113061135635e-05
gene O 0 1.0431293958390597e-05
mutation O 0 9.66651441558497e-06
in O 0 7.921009625988518e-08
our O 0 1.862386085349499e-07
sample O 0 9.982354498561108e-08
( O 0 3.3971481627759204e-08
44 O 0 1.825387698772829e-07
% O 0 6.548883657586657e-09
) O 0 1.2363855717012484e-08
is O 0 4.585291080161369e-08
among O 0 3.846486151815043e-08
the O 0 1.8618960950789187e-07
highest O 0 1.3975827641843352e-05
rates O 0 4.16068860431551e-06
yet O 0 1.6940459772740724e-06
reported O 0 4.163141056778841e-06
and O 0 1.92186945469075e-07
the O 0 8.806589448795421e-07
CDK4 O 0 0.0007391547551378608
mutation O 0 1.806327054509893e-05
is O 0 2.568252739365562e-07
the O 0 9.599918371350213e-08
second O 0 2.506600139895454e-06
mutation O 0 1.932061422849074e-05
detected O 0 2.676121766853612e-05
in O 0 9.948691825911737e-08
this O 0 3.14045855986933e-08
gene O 0 2.3577331376145594e-06
worldwide O 0 4.66758456241223e-06
. O 0 7.758467290841509e-06

In O 0 3.909769020538079e-06
summary O 0 7.513487616961356e-06
, O 0 3.409053306313581e-07
our O 0 2.682255626496044e-07
results O 0 5.999929157951556e-07
show O 0 8.431916853623989e-07
frequent O 0 1.3484403780239518e-06
involvement O 0 1.0597921118460363e-06
of O 0 6.16668813790966e-08
the O 0 3.774564731884311e-07
p16 O 0 4.379401070764288e-05
gene O 0 2.7030631827074103e-05
in O 0 1.0167184882448055e-05
familial B-Disease 1 0.9948049187660217
melanoma I-Disease 1 0.9999079704284668
and O 0 1.8128496321878629e-06
confirm O 0 1.7051845588866854e-06
the O 0 1.567362772902925e-07
role O 0 1.349151716567576e-06
of O 0 1.0066904820860145e-07
the O 0 6.977058433221828e-07
CDK4 O 0 0.00023258788860403
gene O 0 1.0290063073625788e-05
as O 0 4.6142567953211255e-06
a O 0 8.983176667243242e-05
melanoma B-Disease 1 0.9992127418518066
- O 0 0.00020588369807228446
predisposing O 0 8.339299529325217e-05
gene O 0 1.7577900507603772e-05
. O 0 1.6053810441007954e-06
. O 0 3.813980583800003e-06

Progression O 0 0.0014037791406735778
of O 0 2.2998503936833004e-06
somatic O 0 0.00038367987144738436
CTG O 0 0.004383035935461521
repeat O 0 7.70490660215728e-05
length O 0 6.142650818219408e-06
heterogeneity O 0 2.115640018018894e-05
in O 0 5.641186930915865e-07
the O 0 8.263587005785666e-07
blood O 0 0.0005542886210605502
cells O 0 0.00017884248518384993
of O 0 8.521565177943558e-05
myotonic B-Disease 1 0.9999948740005493
dystrophy I-Disease 1 0.9999985694885254
patients O 1 0.9572070240974426
. O 0 6.350819603540003e-05

The O 0 1.710869355520117e-06
genetic O 0 3.5515484341885895e-05
basis O 0 1.1839637409138959e-05
of O 0 0.00020256372226867825
myotonic B-Disease 1 0.9999973773956299
dystrophy I-Disease 1 0.9999990463256836
( O 0 0.0003444660978857428
DM B-Disease 1 0.9999046325683594
) O 0 7.419430403388105e-07
is O 0 1.5197890945728432e-07
the O 0 4.680706666704282e-08
expansion O 0 7.510282671319146e-07
of O 0 1.1012974709956325e-07
an O 0 2.5715273750392953e-06
unstable O 0 0.13038724660873413
CTG O 0 0.0007634355570189655
repeat O 0 1.703666930552572e-05
in O 0 1.8491871855985664e-07
the O 0 2.718152245506644e-07
34 O 0 1.7900130160342087e-06
UTR O 0 2.336153556825593e-05
of O 0 1.8981805283146969e-07
the O 0 3.0763374070374994e-06
DM B-Disease 1 0.9785398244857788
protein O 0 5.028110081184423e-06
kinase O 0 8.694186362845358e-06
gene O 0 3.0814287583780242e-06
on O 0 2.8459048735385295e-06
chromosome O 0 9.599544137017801e-05
19 O 0 1.7200969523401e-05
. O 0 2.7122146093461197e-06

One O 0 1.1402504469515407e-06
of O 0 1.0962091323563072e-07
the O 0 2.0987071991385164e-07
principal O 0 4.538290795608191e-06
features O 0 1.629548819437332e-06
of O 0 3.2463339039168204e-07
the O 0 2.5077668396988884e-05
DM B-Disease 1 0.9999481439590454
mutation O 0 0.00022235017968341708
is O 0 6.475805776062771e-07
an O 0 2.0455638605199056e-07
extraordinarily O 0 5.250786853139289e-05
high O 0 1.949298894032836e-05
level O 0 5.918670922255842e-06
of O 0 2.51179272936497e-07
somatic O 0 0.00015790050383657217
mosaicism O 0 0.0061174300499260426
, O 0 2.3012282781564863e-06
due O 0 1.937590923262178e-06
to O 0 3.7595043522742344e-08
an O 0 1.3714918623008998e-07
extremely O 0 2.162947021133732e-05
high O 0 1.7607660993235186e-05
degree O 0 2.4829416815919103e-06
of O 0 1.9391237060517597e-07
somatic O 0 8.557925320928916e-05
instability O 0 0.00010210736218141392
both O 0 3.643461639057932e-07
within O 0 5.794024104943674e-07
and O 0 4.2942997424688656e-07
between O 0 6.884661729600339e-07
different O 0 8.650531526654959e-07
tissues O 0 0.003023394849151373
. O 0 1.8355160136707127e-05

This O 0 3.4621741633600323e-06
instability O 0 8.713686838746071e-05
appears O 0 3.390156280147494e-06
to O 0 2.2861119219896864e-08
be O 0 2.6309724177053795e-08
biased O 0 2.296089149922409e-07
towards O 0 6.896438264902827e-08
further O 0 5.537841474279048e-08
expansion O 0 4.470529688660463e-07
and O 0 7.365779453039067e-08
continuous O 0 4.901602324025589e-07
throughout O 0 1.2265005580047728e-06
the O 0 1.948347687630303e-07
life O 0 7.914393336250214e-07
of O 0 1.9331610090489448e-08
an O 0 4.5312830820876115e-08
individual O 0 2.8447596278624587e-08
, O 0 9.953493673720004e-08
features O 0 3.5514904084266163e-07
that O 0 5.97733560425695e-08
could O 0 3.041330387532071e-07
be O 0 9.55288470549931e-08
associated O 0 3.5900416150980163e-07
with O 0 1.1434658375719664e-07
the O 0 1.2546679499791935e-06
progressive O 0 0.0008373468299396336
nature O 0 2.9390945201157592e-05
of O 0 2.2282838472165167e-06
the O 0 0.00030185069772414863
disease O 1 0.9997264742851257
. O 0 2.5348621420562267e-05

Although O 0 2.9153500236134278e-06
increasing O 0 1.084622226699139e-06
measured O 0 6.286466486926656e-06
allele O 0 4.34631419921061e-06
size O 0 7.826277396816295e-06
between O 0 5.629489351122174e-06
patients O 0 2.973305163322948e-05
clearly O 0 8.308162477987935e-07
correlates O 0 5.860561032022815e-07
with O 0 1.391867812117198e-07
an O 0 4.844760042033158e-07
increased O 0 7.82858387537999e-06
severity O 0 0.0006374199292622507
of O 0 1.9335207070980687e-06
symptoms O 1 0.9874489307403564
and O 0 7.814038553988212e-07
an O 0 3.83935486070186e-07
earlier O 0 6.4710425249359105e-06
age O 0 3.5506507174432045e-06
of O 0 1.658024473272235e-07
onset O 0 0.008800621144473553
, O 0 2.3609545962699485e-07
this O 0 1.3084564542964472e-08
correlation O 0 1.0097442526557643e-07
is O 0 4.5509967350199076e-08
not O 0 6.097864879706094e-09
precise O 0 4.927281338495959e-07
and O 0 1.9190746058939112e-07
measured O 0 2.2231727143662283e-06
allele O 0 1.7619622667552903e-06
length O 0 1.5936475392663851e-06
cannot O 0 3.777467156851344e-07
be O 0 1.3372187801508062e-08
used O 0 2.5177179452384735e-08
as O 0 5.6167088757774764e-08
an O 0 5.364062261037361e-08
accurate O 0 3.1793315429240465e-06
predictor O 0 5.9551406593527645e-05
of O 0 4.075435811046191e-07
age O 0 1.6338019122486003e-05
of O 0 1.3254575605969876e-06
onset O 1 0.9883692264556885
. O 0 5.8495959819993004e-05

In O 0 8.435166591880261e-07
order O 0 1.4441712892221403e-07
to O 0 1.7395503704165094e-08
further O 0 5.965342353420056e-08
characterize O 0 4.564768460113555e-06
the O 0 1.2186828826088458e-06
dynamics O 0 0.0011789279524236917
of O 0 2.6515514036873356e-05
DM B-Disease 1 0.9998979568481445
CTG O 0 0.01814751885831356
repeat O 0 0.0003456057165749371
somatic O 0 0.00032605318119749427
instability O 0 0.00037326099118217826
, O 0 5.39489406037319e-07
we O 0 1.2031983942506486e-07
have O 0 3.577101992391363e-08
studied O 0 1.4024248002897366e-06
repeat O 0 2.1249989003990777e-06
length O 0 4.50148206709855e-07
changes O 0 4.1507468040435924e-07
over O 0 1.3043654689681716e-07
time O 0 5.481608127411164e-07
in O 0 5.843483450007625e-06
111 O 0 0.0033152871765196323
myotonic B-Disease 1 0.9999779462814331
dystrophy I-Disease 1 0.9999971389770508
patients O 0 0.0007306815823540092
with O 0 1.0670146366464905e-06
varying O 0 5.850494562764652e-05
clinical O 0 0.002679920056834817
severity O 0 0.011970794759690762
and O 0 9.712218343338463e-06
CTG O 0 0.0006731879548169672
repeat O 0 2.4976588974823244e-05
size O 0 3.5982034205517266e-06
over O 0 2.2038754821096518e-07
time O 0 1.456632787721901e-07
intervals O 0 1.2025071782773011e-06
of O 0 9.455718696926851e-08
1 O 0 3.1261863568943227e-06
- O 0 3.349745747982524e-05
7 O 0 9.515035344520584e-06
years O 0 3.7226041058602277e-06
. O 0 2.4265677893708926e-06

We O 0 2.1136725081305485e-06
have O 0 1.4064669073832192e-07
found O 0 1.0365108948917623e-07
a O 0 5.057518848161635e-08
direct O 0 1.0523697824282863e-07
progression O 0 5.243916166364215e-05
of O 0 9.250588561826589e-08
the O 0 3.3991648251685547e-07
size O 0 5.220160346652847e-06
heterogeneity O 0 1.2061941561114509e-05
over O 0 5.362174988476909e-07
time O 0 3.170691229570366e-07
related O 0 1.0621758974593831e-06
to O 0 9.962914049310712e-08
initial O 0 4.194985194772016e-06
CTG O 0 0.0002003025874728337
repeat O 0 1.9069429981755093e-05
size O 0 5.409590812632814e-06
and O 0 1.7867473900423647e-07
the O 0 7.266508816883288e-08
time O 0 1.663358517589586e-07
interval O 0 4.700474391938769e-07
and O 0 9.403309775279922e-08
always O 0 3.681863063320634e-07
biased O 0 6.032967689861835e-07
towards O 0 1.459838188111462e-07
further O 0 1.7351572978441254e-07
expansion O 0 1.507015258539468e-05
. O 0 7.281816579052247e-06

Attempts O 0 3.008266048709629e-06
to O 0 1.1069224115090037e-07
mathematically O 0 1.727051085254061e-06
model O 0 7.781607109791366e-07
the O 0 2.413004551726772e-07
dynamics O 0 0.00021193547581788152
have O 0 4.5236492951516993e-07
proved O 0 6.326177754090168e-06
only O 0 1.0469921818412331e-07
partially O 0 1.96666060219286e-05
successful O 0 1.5002349300630158e-06
suggesting O 0 2.8701708743028576e-06
that O 0 1.593314102876775e-08
individual O 0 1.5066934366814166e-08
specific O 0 9.794358390990965e-08
genetic O 0 2.0708836018457077e-05
and O 0 3.536045596774784e-06
/ O 0 0.00010904383088927716
or O 0 9.550218237563968e-06
environmental O 0 8.561029062548187e-06
factors O 0 3.9082004832380335e-07
also O 0 9.308162418619759e-08
play O 0 1.9597226241785393e-07
a O 0 4.804592776963545e-07
role O 0 1.1822473879874451e-06
in O 0 1.0233605962639558e-06
somatic O 0 6.21419312665239e-05
mosaicism O 0 0.005403778050094843
. O 0 5.928167411184404e-06
. O 0 1.1711651495716069e-05

Aspartylglucosaminuria B-Disease 1 0.9967949986457825
among O 0 1.555146081955172e-05
Palestinian O 0 6.503969780169427e-05
Arabs O 0 7.12612527422607e-05
. O 0 4.0459581214236096e-05

Aspartylglucosaminuria B-Disease 1 0.9997259974479675
( O 0 0.0003996439336333424
AGU B-Disease 1 0.9988113641738892
) O 0 2.1296284558047773e-06
is O 0 1.1657800769171445e-06
a O 0 8.671224350109696e-06
rare O 0 0.008204158395528793
disorder B-Disease 1 0.9995846152305603
of I-Disease 0 2.379565330556943e-06
glycoprotein I-Disease 0 0.21679840981960297
metabolism I-Disease 1 0.9561055302619934
caused O 0 0.0019743547309190035
by O 0 1.447765157536196e-06
the O 0 4.556042404146865e-05
deficiency B-Disease 1 0.9991401433944702
of I-Disease 0 4.194006351099233e-07
the I-Disease 0 5.127783424541121e-06
lysosomal I-Disease 0 0.0869128555059433
enzyme I-Disease 0 0.0002930806949734688
aspartylglucosaminidase I-Disease 0 0.002513700630515814
( O 0 2.3523787149315467e-06
AGA O 0 0.00020622200099751353
) O 0 2.6039099338959204e-06
. O 0 5.031367436458822e-06

AGU B-Disease 1 0.9995449185371399
is O 0 0.00010177074000239372
inherited O 0 0.02648944780230522
as O 0 5.029779003962176e-06
an O 0 3.5069629120698664e-06
autosomal O 1 0.9913877844810486
recessive O 1 0.9926663041114807
trait O 0 0.010645265690982342
and O 0 4.858742613578215e-06
occurs O 0 1.948035333043663e-06
with O 0 9.405964362940722e-08
a O 0 6.828205982856161e-07
high O 0 5.162749857845483e-06
frequency O 0 2.5651197574916296e-06
in O 0 3.025252226507291e-07
Finland O 0 1.8032878870144486e-05
because O 0 2.114231847372139e-07
of O 0 5.4023189477447886e-08
a O 0 3.6097721931582782e-06
founder O 0 9.679532377049327e-05
effect O 0 2.031855001405347e-05
. O 0 5.2971595323469955e-06

While O 0 1.0564725926087704e-05
very O 0 2.7516121008375194e-06
few O 0 5.654929282172816e-06
patients O 0 3.0008335670572706e-05
with O 0 5.2018772294104565e-06
AGU B-Disease 1 0.9993717074394226
have O 0 1.2323371265665628e-06
been O 0 2.0995951217628317e-06
reported O 0 3.668758154162788e-06
from O 0 1.55018113900951e-07
non O 0 7.647397978871595e-06
- O 0 7.581852696603164e-05
Finnish O 0 0.00014784086670260876
origin O 0 1.428264113201294e-06
, O 0 7.928338163765147e-06
we O 0 4.641584382625297e-05
diagnosed O 1 0.9995239973068237
the O 0 1.9908466128981672e-05
disorder O 1 0.9994015693664551
in O 0 2.547681333453511e-06
8 O 0 9.659713214205112e-06
patients O 0 6.797326477681054e-06
originating O 0 1.2109726412745658e-06
from O 0 3.1980562198441476e-07
3 O 0 1.4843838016531663e-06
unrelated O 0 3.680280087792198e-06
families O 0 5.431030203340015e-08
, O 0 4.5200700071745814e-08
all O 0 4.779928453046978e-09
Palestinian O 0 1.1181855370523408e-06
Arabs O 0 1.1607279475356336e-06
from O 0 5.999712016091507e-07
the O 0 4.448240531473857e-07
region O 0 1.0320252840756439e-05
of O 0 3.6985798601563147e-07
Jerusalem O 0 0.00042331975419074297
. O 0 2.7952239179285243e-05

The O 0 4.8809357394929975e-05
clinical O 0 0.0064703552052378654
diagnosis O 1 0.9968752861022949
of O 0 7.074545283103362e-05
AGU B-Disease 1 0.9999661445617676
is O 0 1.036914636642905e-05
often O 0 3.892595486831851e-06
difficult O 0 6.7399473664409015e-06
, O 0 2.1850715370419493e-07
in O 0 4.292809308026335e-08
particular O 0 2.113275776594037e-08
early O 0 3.461199469256826e-07
in O 0 8.314869148762227e-08
the O 0 1.4777522494568984e-07
course O 0 6.277551619859878e-06
of O 0 2.0713429194074706e-07
the O 0 1.446670648874715e-05
disease O 1 0.9990241527557373
, O 0 3.8881142927493784e-07
and O 0 1.5189806390480953e-07
most O 0 1.4324258756914787e-07
of O 0 6.336897939718256e-08
the O 0 1.8691455352382036e-06
patients O 0 8.233988774009049e-05
are O 0 1.3548196875490248e-06
diagnosed O 1 0.9955812096595764
after O 0 1.147782882071624e-06
the O 0 1.4738255060819938e-07
age O 0 1.6588230664638104e-06
of O 0 7.826308490166412e-08
5 O 0 4.548394372250186e-06
years O 0 4.908455139229773e-06
. O 0 2.7845594559039455e-06

However O 0 4.1840376070467755e-06
, O 0 1.3642951444126084e-06
since O 0 2.3400923510052962e-06
these O 0 1.0933651140021539e-07
patients O 0 5.934621640335536e-06
excrete O 0 1.540365155960899e-05
early O 0 1.344927795798867e-06
large O 0 4.905245418740378e-07
amounts O 0 1.2360175105641247e-06
of O 0 1.9651668026199332e-07
aspartylglucosamine O 0 0.00017697278235573322
in O 0 1.130324562836904e-06
urine O 0 2.06401073228335e-05
, O 0 3.4393050896142086e-07
biochemical O 0 1.035479817801388e-05
screening O 0 2.1274606751831016e-06
is O 0 2.554402840360126e-07
easy O 0 8.718852768652141e-07
by O 0 5.288949296300416e-07
urine O 0 6.1032362282276154e-05
chromatography O 0 0.0012607475509867072
. O 0 1.6523149497515988e-06
. O 0 4.367666861071484e-06

Detection O 0 7.488649134756997e-05
of O 0 2.8056021506017714e-07
heterozygous O 0 1.2220730241097044e-06
carriers O 0 3.938773261324968e-06
of O 0 7.348210147029022e-07
the O 0 0.00019787586643360555
ataxia B-Disease 1 0.9999977350234985
- I-Disease 1 0.9997239708900452
telangiectasia I-Disease 1 0.999891996383667
( O 0 5.898155905015301e-06
ATM O 0 7.267961336765438e-05
) O 0 3.721744690210471e-07
gene O 0 2.05362016458821e-06
by O 0 7.488233109143039e-07
G2 O 0 0.0006641173968091607
phase O 0 0.00013007658708374947
chromosomal O 0 0.005625592544674873
radiosensitivity O 0 0.00104430946521461
of O 0 2.7310945824865485e-06
peripheral O 1 0.6757528185844421
blood O 1 0.7484198212623596
lymphocytes O 1 0.6849152445793152
. O 0 5.445549686555751e-05

In O 0 0.0011281472397968173
ataxia B-Disease 1 0.9999877214431763
- I-Disease 1 0.9995276927947998
telangiectasia I-Disease 1 0.9999473094940186
( O 0 0.00028438615845516324
A B-Disease 1 0.9997438788414001
- I-Disease 1 0.998508632183075
T I-Disease 1 0.999728262424469
) O 0 2.2687790988129564e-06
patients O 0 7.506504516641144e-06
, O 0 1.2433552853963192e-07
mutations O 0 1.7960526292881696e-06
in O 0 3.054415742553829e-08
a O 0 8.140246166021825e-08
single O 0 3.5539463283384976e-07
gene O 0 2.395716364844702e-06
, O 0 5.156891234037175e-07
ATM O 0 3.5050750739173964e-05
, O 0 1.4720009176016902e-06
result O 0 2.437284820189234e-06
in O 0 2.4293647129525198e-06
an O 0 0.0002517996763344854
autosomal B-Disease 1 0.999998927116394
recessive I-Disease 1 0.999998927116394
syndrome I-Disease 1 1.0
that O 0 3.532624532454065e-06
embraces O 0 2.0718001906061545e-05
a O 0 1.2519572010205593e-06
variety O 0 1.8889217017203919e-06
of O 0 3.862911626129062e-07
clinical O 0 3.6588982766261324e-05
features O 0 1.4080469554755837e-05
and O 0 4.730392902274616e-06
manifests O 0 0.00020196395053062588
extreme O 0 0.000264706090092659
radiosensitivity O 0 0.000527073338162154
and O 0 1.3275563333081664e-06
a O 0 1.9736307876883075e-06
strong O 0 7.048370207485277e-06
pre O 0 0.0008522588177584112
- O 0 0.0008807576959952712
disposition O 0 0.00030186507501639426
to O 0 7.98789278633194e-06
malignancy B-Disease 1 0.9952021837234497
. O 0 2.3748161765979603e-05

Heterozygotes O 0 0.0001261324214283377
for O 0 1.6771687683103664e-07
the O 0 2.2517731679272401e-07
ATM O 0 3.671677040983923e-05
gene O 0 6.632576514675748e-06
have O 0 3.6727277574755135e-07
no O 0 4.595798088757874e-07
clinical O 0 3.740771717275493e-06
expression O 0 1.1107246109531843e-06
of O 0 9.975290140573634e-07
A B-Disease 1 0.9998524188995361
- I-Disease 1 0.9993769526481628
T I-Disease 1 0.9999264478683472
but O 0 1.4198295502865221e-05
may O 0 3.037462374777533e-05
be O 0 1.8363090930506587e-05
cancer B-Disease 1 0.9959463477134705
prone O 0 0.00021033322263974696
with O 0 1.4171153850384144e-07
a O 0 2.7919356853089994e-06
moderate O 0 2.0139294065302238e-05
increase O 0 3.228993818993331e-07
in O 0 2.538905903293198e-07
in O 0 1.0021689149652957e-06
vitro O 0 0.0001097459826269187
radiosensitivity O 0 0.002070986432954669
. O 0 2.0846409825026058e-05

We O 0 8.227295438700821e-06
performed O 0 1.928247365867719e-05
a O 0 3.2047198601503624e-06
blind O 0 3.666841075755656e-05
chromosomal O 0 0.00023401575163006783
analysis O 0 2.3919860723253805e-06
on O 0 1.3636625226354226e-05
G2 O 0 0.000733696564566344
- O 0 0.00011697845911839977
phase O 0 3.619749622885138e-05
lymphocytes O 0 0.00010612676851451397
from O 0 1.0546801831878838e-06
7 O 0 6.021659373800503e-06
unrelated O 0 0.0002347711124457419
A B-Disease 1 0.9994866847991943
- I-Disease 1 0.9993330836296082
T I-Disease 1 0.999901533126831
patients O 0 0.00020345489610917866
, O 0 1.1378259614502895e-06
13 O 0 2.84180123344413e-06
obligate O 0 2.5797000489546917e-05
A B-Disease 1 0.9984145164489746
- I-Disease 1 0.9943654537200928
T I-Disease 1 0.9986225366592407
heterozygotes O 0 0.00010635146463755518
( O 0 6.377809995683492e-07
parents O 0 2.3388848546801455e-07
of O 0 3.755791766479888e-08
the O 0 5.397776021709433e-07
patients O 0 7.310420642170357e-06
) O 0 5.015692039478381e-08
, O 0 6.103359595499569e-08
and O 0 1.0983858089730347e-07
14 O 0 4.3869309251931554e-07
normal O 0 8.611236239630671e-07
controls O 0 1.7361550135319703e-06
following O 0 1.5419376495628967e-06
X O 0 5.125368988956325e-05
- O 0 4.510752205533208e-06
irradiation O 0 1.054277845469187e-06
with O 0 1.2808139615572145e-07
1 O 0 1.6099312460937654e-06
Gy O 0 2.0081626644241624e-05
in O 0 8.360606074120369e-08
order O 0 3.8047129891083387e-08
to O 0 2.2513688691105926e-08
evaluate O 0 9.01634280126018e-07
this O 0 1.9844362597609688e-08
cytogenetic O 0 4.4756725401384756e-05
method O 0 2.447789597681549e-07
as O 0 1.4464801267877192e-07
a O 0 1.507514895138229e-07
tool O 0 1.9657793473015772e-06
for O 0 3.360831613008486e-08
detection O 0 5.9355552366469055e-06
of O 0 1.6131329516611004e-07
ATM O 0 0.000385569641366601
carriers O 0 0.0002192184911109507
. O 0 1.563959631312173e-05

Both O 0 5.9301950386725366e-05
A B-Disease 1 0.9994125366210938
- I-Disease 1 0.998664140701294
T I-Disease 1 0.9994102716445923
homozygotes O 0 0.0011910081375390291
and O 0 2.098219965773751e-06
heterozygotes O 0 2.2302858269540593e-05
showed O 0 2.5645913410698995e-06
significantly O 0 1.5296814126486424e-06
increased O 0 5.675333909493929e-07
levels O 0 9.733097613207065e-06
of O 0 5.2037676141480915e-06
radiation O 1 0.9981751441955566
- O 1 0.7835331559181213
induced O 0 0.02295801229774952
chromatid O 1 0.7299764752388
damage O 0 0.0026776930317282677
relative O 0 1.8181008272222243e-06
to O 0 6.302159505366944e-08
that O 0 3.2583741926828225e-08
of O 0 6.758419601737842e-08
normal O 0 1.569632877362892e-05
controls O 0 0.0001171644325950183
. O 0 1.5378594980575144e-05

These O 0 3.888466437729221e-07
results O 0 1.41067027925601e-06
show O 0 1.1971874300797936e-06
that O 0 8.513090676842694e-08
the O 0 1.0020007721323054e-06
G2 O 0 0.000878858903888613
- O 0 0.00019422147306613624
phase O 0 8.418881770921871e-05
chromosomal O 0 0.001181105151772499
radiosensitivity O 0 0.00012180677003925666
assay O 0 3.2451378046971513e-06
can O 0 5.342100095617752e-08
be O 0 4.391097263578558e-09
used O 0 1.0076083079013642e-08
for O 0 4.884553650441603e-09
the O 0 5.5436963464217115e-08
detection O 0 8.330994205607567e-06
of O 0 1.1715399068634724e-06
A B-Disease 1 0.9997366070747375
- I-Disease 1 0.9990087747573853
T I-Disease 1 0.9996080994606018
heterozygotes O 0 0.001908725593239069
. O 0 3.120693872915581e-05

In O 0 2.4170728920580586e-06
combination O 0 7.23686480341712e-06
with O 0 1.3293907841216424e-06
molecular O 0 0.0001585677091497928
genetic O 0 5.1040689868386835e-05
analyses O 0 5.5862233239167836e-06
, O 0 3.619868778059754e-07
this O 0 2.0267972189458305e-08
test O 0 2.004478716344238e-07
may O 0 9.623898478139381e-08
be O 0 2.9711422211420313e-09
of O 0 1.3179134450425067e-09
value O 0 2.290236267299406e-08
in O 0 1.0362677471675852e-07
studies O 0 8.724136080218159e-08
of O 0 9.43305806799799e-08
familial B-Disease 0 0.002840795088559389
and I-Disease 0 4.34684261563234e-05
sporadic I-Disease 0 0.012916416861116886
cancers I-Disease 1 0.9986977577209473
aimed O 0 5.7551129430066794e-05
at O 0 3.948439916712232e-05
determination O 0 1.8494988580641802e-06
of O 0 6.19423730086055e-08
the O 0 2.435695023450535e-07
potential O 0 7.990140034053184e-07
involvement O 0 2.276562099723378e-06
of O 0 4.6437807554866595e-07
ATM O 0 0.0023667868226766586
mutations O 0 0.003458170685917139
in O 0 0.0001307399943470955
tumor B-Disease 1 0.9969643950462341
risk O 0 0.0001531598245492205
or O 0 2.1088601442897925e-06
development O 0 9.104355171984935e-07
. O 0 1.475223484703747e-06
. O 0 6.927062258910155e-06

Ataxia B-Disease 1 0.9999936819076538
- I-Disease 1 0.9995421171188354
telangiectasia I-Disease 1 0.9998838901519775
: O 0 7.042578090477036e-06
identification O 0 1.3281362498673843e-06
and O 0 7.504153813897574e-07
detection O 0 1.839360447775107e-05
of O 0 3.48209056255655e-07
founder O 0 0.00014751599519513547
- O 0 8.138774137478322e-05
effect O 0 3.7740317111456534e-06
mutations O 0 6.515285804198356e-06
in O 0 5.466458929959117e-08
the O 0 6.809127484075361e-08
ATM O 0 1.7156964531750418e-05
gene O 0 4.356015324447071e-06
in O 0 5.915816814194841e-07
ethnic O 0 8.243405318353325e-07
populations O 0 1.235220770468004e-05
. O 0 1.0351302080380265e-05

To O 0 1.323466563007969e-07
facilitate O 0 3.4257726611031103e-07
the O 0 6.723730052726751e-07
evaluation O 0 2.112001993737067e-06
of O 0 1.0748651391168096e-07
ATM O 0 0.00014819498755969107
heterozygotes O 0 9.449783829040825e-05
for O 0 7.942202273625298e-07
susceptibility O 0 8.057028753682971e-05
to O 0 4.143216756347101e-07
other O 0 6.797202786401613e-06
diseases O 1 0.9998373985290527
, O 0 9.814926897888654e-07
such O 0 7.86164434884995e-07
as O 0 0.00138292636256665
breast B-Disease 1 0.9999274015426636
cancer I-Disease 1 0.9996485710144043
, O 0 6.255513653741218e-07
we O 0 1.0603303479683746e-07
have O 0 2.192498094188977e-08
attempted O 0 2.656771869169461e-07
to O 0 2.137574739435877e-08
define O 0 3.870567013564141e-07
the O 0 9.646741716551333e-08
most O 0 1.1070364536180932e-07
common O 0 7.476993459931691e-07
mutations O 0 6.017182386131026e-06
and O 0 8.70414140763387e-08
their O 0 6.334602176139015e-08
frequencies O 0 1.7113445210270584e-05
in O 0 0.00010344837210141122
ataxia B-Disease 1 0.9999910593032837
- I-Disease 1 0.9994648098945618
telangiectasia I-Disease 1 0.9998818635940552
( O 0 0.00015412011998705566
A B-Disease 1 0.9996210336685181
- I-Disease 1 0.9954681396484375
T I-Disease 1 0.9993384480476379
) O 0 5.409928007793496e-07
homozygotes O 0 3.353718784637749e-05
from O 0 1.9936480555315939e-07
10 O 0 3.011332125879562e-07
ethnic O 0 2.0607858175480942e-07
populations O 0 3.982960606663255e-06
. O 0 6.399325229722308e-06

Both O 0 3.8388752727769315e-06
genomic O 0 6.456824485212564e-05
mutations O 0 6.877742998767644e-05
and O 0 3.457504362813779e-07
their O 0 6.466641622182578e-08
effects O 0 1.1961617929046042e-05
on O 0 9.321165066467074e-07
cDNA O 0 1.1479448858153773e-06
were O 0 2.1445514448714675e-06
characterized O 0 0.00016786085325293243
. O 0 1.4550068044627551e-05

Protein O 0 4.303608147893101e-05
- O 0 6.905358168296516e-05
truncation O 0 3.5053224564762786e-05
testing O 0 3.8465013858512975e-06
of O 0 2.789396269520239e-08
the O 0 5.4075353972393714e-08
entire O 0 1.6232810367000639e-06
ATM O 0 2.036539626715239e-05
cDNA O 0 4.478347818803741e-06
detected O 0 7.6598662417382e-05
92 O 0 1.0393331649538595e-05
( O 0 2.209580713952164e-07
66 O 0 2.5537237888784148e-06
% O 0 3.419550509420333e-08
) O 0 8.018722752467511e-08
truncating O 0 2.9326356525416486e-05
mutations O 0 3.1799794669495896e-05
in O 0 3.164730912885716e-07
140 O 0 8.507424240633554e-07
mutant O 0 6.779258001188282e-06
alleles O 0 9.740378118294757e-06
screened O 0 6.335039506666362e-05
. O 0 8.729720320843626e-06

The O 0 1.287742179556517e-05
haplotyping O 0 0.0013442117488011718
of O 0 1.4019514082974638e-06
patients O 0 2.450185093039181e-05
with O 0 3.305358973193506e-07
identical O 0 4.628249371307902e-05
mutations O 0 0.00014716069563291967
indicates O 0 1.518085582574713e-06
that O 0 1.1166915392379906e-08
almost O 0 9.416232416015191e-08
all O 0 8.580427923732259e-09
of O 0 5.5509410401555215e-09
these O 0 1.3346554084137097e-08
represent O 0 6.310916234042452e-08
common O 0 1.8955518044094788e-06
ancestry O 0 1.4570205166819505e-06
and O 0 7.405143946925818e-07
that O 0 5.968995964167334e-08
very O 0 8.476843049720628e-07
few O 0 1.8299034536539693e-06
spontaneously O 0 6.800888513680547e-05
recurring O 0 0.0003256211057305336
ATM O 0 0.001275761635042727
mutations O 0 0.000535461469553411
exist O 0 3.85921448469162e-05
. O 0 1.3857405065209605e-05

Assays O 0 0.00011920872930204496
requiring O 0 1.6207462977035902e-05
minimal O 0 1.1536778401932679e-05
amounts O 0 1.5686188135077828e-06
of O 0 8.338836465782151e-08
genomic O 0 6.066446076147258e-06
DNA O 0 3.093451141467085e-06
were O 0 1.1498893570660584e-07
designed O 0 2.393701379332924e-07
to O 0 8.559816855324698e-09
allow O 0 3.393450498379025e-08
rapid O 0 3.488263701001415e-06
screening O 0 1.2271193554624915e-06
for O 0 7.039396621166816e-08
common O 0 2.7893861442862544e-06
ethnic O 0 5.17633725394262e-06
mutations O 0 0.0006561295012943447
. O 0 2.1565660063060932e-05

These O 0 3.7316036127776897e-07
rapid O 0 3.352075145812705e-05
assays O 0 6.44996325718239e-05
detected O 0 0.00010821339674293995
mutations O 0 1.4205336810846347e-05
in O 0 5.754622520726116e-07
76 O 0 5.986080395814497e-06
% O 0 3.549786242729169e-08
of O 0 1.31561904481714e-07
Costa O 0 0.00014868770085740834
Rican O 0 3.0503566449624486e-05
patients O 0 9.883561688184272e-06
( O 0 4.745004389405949e-08
3 O 0 2.0621070007109665e-07
) O 0 1.1059912985444953e-08
, O 0 3.275678395198156e-08
50 O 0 6.155912046779122e-08
% O 0 5.928996404946929e-09
of O 0 4.752359217263802e-08
Norwegian O 0 0.00011331753921695054
patients O 0 1.6721982319722883e-05
( O 0 8.409417517896145e-08
1 O 0 4.342036845628172e-07
) O 0 2.3790173386828428e-08
, O 0 7.972376891984823e-08
25 O 0 1.280017869476069e-07
% O 0 9.413391843793306e-09
of O 0 7.732267448545826e-08
Polish O 0 0.0026427810080349445
patients O 0 5.8331188483862206e-05
( O 0 1.6379017608869617e-07
4 O 0 9.534551281831227e-07
) O 0 3.859832276020825e-08
, O 0 7.969655513306861e-08
and O 0 1.1683439282705876e-07
14 O 0 5.296879521665687e-07
% O 0 1.6721182660717204e-08
of O 0 1.0960858531916529e-07
Italian O 0 0.0002757290785666555
patients O 0 4.5004191633779556e-05
( O 0 1.5154905952385889e-07
1 O 0 3.2227180213340034e-07
) O 0 1.8144163504985045e-08
, O 0 1.965968543515828e-08
as O 0 5.250297974157547e-08
well O 0 1.2402371396547096e-07
as O 0 3.341515935062489e-07
in O 0 3.784787452332239e-07
patients O 0 2.492074827387114e-06
of O 0 5.4413060723845774e-08
Amish O 0 1.623866774025373e-05
/ O 0 4.3995984015055e-05
Mennonite O 0 4.16575167037081e-05
and O 0 2.1032224140071776e-06
Irish O 0 2.6169793272856623e-05
English O 0 8.979102858575061e-06
backgrounds O 0 4.325505142332986e-05
. O 0 2.6396506655146368e-05

Additional O 0 1.1695283319568262e-06
mutations O 0 2.8537639082060196e-05
were O 0 4.820150820705749e-07
observed O 0 3.31539627040911e-06
in O 0 2.8438924459806003e-07
Japanese O 0 3.6479088976193452e-06
, O 0 6.133082592896244e-07
Utah O 0 2.6844154490390792e-06
Mormon O 0 2.232232816368196e-07
, O 0 1.8104016419329128e-07
and O 0 2.431322343454667e-07
African O 0 1.7727880958773312e-06
American O 0 1.3243482499092352e-05
patients O 0 0.00019638177764136344
. O 0 7.054826255625812e-06

These O 0 1.1862334758916404e-07
assays O 0 1.794059926396585e-06
should O 0 3.579470231329651e-08
facilitate O 0 6.712082978310718e-08
screening O 0 1.5986435073500616e-06
for O 0 5.473323199112201e-07
A B-Disease 1 0.9980231523513794
- I-Disease 1 0.989590585231781
T I-Disease 1 0.9986138343811035
heterozygotes O 0 9.354434587294236e-05
in O 0 7.078872954480175e-07
the O 0 2.734605573095905e-07
populations O 0 1.3415601642918773e-06
studied O 0 9.160145054920577e-06
. O 0 7.971462423483899e-07
. O 0 2.754108663793886e-06

The O 0 0.00013334077084437013
von B-Disease 1 0.9959287047386169
Hippel I-Disease 1 0.9977503418922424
- I-Disease 1 0.9931018352508545
Lindau I-Disease 1 0.9798510670661926
tumor I-Disease 0 0.4209311008453369
suppressor O 0 0.00014689222734887153
gene O 0 5.490300736710196e-06
is O 0 1.5363906413767836e-07
required O 0 3.879894450165011e-08
for O 0 3.7071178127234816e-08
cell O 0 3.535062205628492e-05
cycle O 0 2.038284765149001e-05
exit O 0 1.8408170944894664e-05
upon O 0 5.650163984682877e-06
serum O 0 0.0003764365101233125
withdrawal O 0 0.00016665388830006123
. O 0 1.1404482393118087e-05

The O 0 1.1573872143344488e-05
inactivation O 0 0.003888168139383197
of O 0 7.85854865625879e-07
the O 0 3.403377195354551e-05
von B-Disease 1 0.9990867376327515
Hippel I-Disease 1 0.9988753199577332
- I-Disease 1 0.9939687252044678
Lindau I-Disease 1 0.9815115332603455
( I-Disease 0 4.861869820160791e-05
VHL I-Disease 0 0.25410252809524536
) I-Disease 0 2.752923137450125e-05
tumor I-Disease 0 0.050420988351106644
suppressor O 0 0.00044049558346159756
gene O 0 8.084318687906489e-05
predisposes O 0 0.00035317163565196097
affected O 0 5.664725449605612e-06
individuals O 0 5.380744383387537e-08
to O 0 1.9571992027067608e-07
the O 0 9.640663847676478e-06
human O 0 0.21268388628959656
VHL B-Disease 1 0.9998993873596191
cancer I-Disease 1 0.9999959468841553
syndrome I-Disease 1 0.9999945163726807
and O 0 4.3298232412780635e-06
is O 0 6.653062314398994e-07
associated O 0 1.910083483380731e-06
with O 0 3.6594876746676164e-06
sporadic B-Disease 1 0.65854811668396
renal I-Disease 1 0.9999939203262329
cell I-Disease 1 0.9999417066574097
carcinomas I-Disease 1 0.9999980926513672
( O 0 0.0003074017586186528
RCC B-Disease 1 0.9977108240127563
) O 0 6.82713971400517e-06
and O 0 4.473018634598702e-05
brain B-Disease 1 0.9991039633750916
hemangioblastomas I-Disease 0 0.26639848947525024
. O 0 9.836054960032925e-05

VHL O 0 0.24395239353179932
- O 0 0.001027565565891564
negative O 0 5.3658601245842874e-05
786 O 0 0.0004680337733589113
- O 0 0.0006510543753392994
0 O 0 2.5175624614348635e-05
RCC B-Disease 0 0.018577318638563156
cells O 0 1.7269030649913475e-05
are O 0 2.0300787184623914e-07
tumorigenic O 0 0.00010172795737162232
in O 0 1.769332470757945e-06
nude O 0 0.0005787447444163263
mice O 0 3.9592119719600305e-05
which O 0 2.448398959131737e-07
is O 0 1.7417956144072377e-07
suppressed O 0 1.1582135357457446e-06
by O 0 4.1025526087423714e-08
the O 0 2.374323742060369e-07
reintroduction O 0 1.948503813764546e-05
of O 0 3.153850002490799e-06
VHL B-Disease 0 0.31489959359169006
. O 0 9.289410809287801e-05

Remarkably O 0 0.0010450482368469238
, O 0 2.286750031998963e-06
this O 0 6.215729797531822e-08
occurs O 0 8.187269600057334e-07
without O 0 1.5546552845080441e-07
affecting O 0 7.337874308177561e-07
the O 0 1.9044871635287564e-07
growth O 0 8.128538411256159e-07
rate O 0 1.1955171430599876e-06
and O 0 1.9208232515666168e-07
cell O 0 1.7431264495826326e-05
cycle O 0 6.09508197157993e-06
profile O 0 2.1003500023653032e-06
of O 0 2.4365350625998872e-08
these O 0 3.921274327467472e-08
cells O 0 2.9074094527459238e-06
in O 0 4.580116694796743e-07
culture O 0 7.739075954305008e-06
. O 0 6.424917501135496e-06

The O 0 6.8263580033089966e-06
786 O 0 0.0001674878440098837
- O 0 4.3396357796154916e-05
0 O 0 2.0301013137213886e-06
cell O 0 2.189619954151567e-05
line O 0 1.99947135115508e-05
, O 0 5.412157406681217e-07
like O 0 1.5865612112975214e-06
many O 0 1.4172250075716875e-06
cancer B-Disease 1 0.9827113747596741
cells O 0 1.2112198419345077e-05
, O 0 4.1385766280654934e-07
fails O 0 2.0165305159025593e-06
to O 0 1.2017701500610656e-08
exit O 0 2.631746156112058e-06
the O 0 6.322615604403836e-07
cell O 0 0.00010816378198796883
cycle O 0 2.4397717425017618e-05
upon O 0 5.014223006583052e-06
serum O 0 0.0003836516698356718
withdrawal O 0 0.00018793981871567667
. O 0 1.3216495062806644e-05

Here O 0 7.021519650152186e-06
, O 0 2.3848332375564496e-07
it O 0 2.987327363257464e-08
is O 0 3.052039687645447e-08
shown O 0 7.690261583093161e-08
that O 0 7.848848682101561e-09
reintroduction O 0 4.48545932840716e-07
of O 0 2.412447130950568e-08
the O 0 3.640089687451109e-07
wild O 0 2.6989522666553967e-05
- O 0 0.0004146889259573072
type O 0 0.00025293827638961375
VHL B-Disease 0 0.00719424057751894
gene O 0 4.6959550672909245e-05
restores O 0 8.039928798098117e-05
the O 0 6.610517289118434e-07
ability O 0 6.001640031172428e-06
of O 0 6.762778411939507e-06
VHL O 1 0.9845526218414307
- O 1 0.754910945892334
negative O 0 0.0009588259854353964
RCC B-Disease 1 0.9991958737373352
cancer I-Disease 1 0.9929190278053284
cells O 0 2.193093450841843e-06
to O 0 4.5489656486097374e-08
exit O 0 4.346836249169428e-06
the O 0 8.056694014157983e-07
cell O 0 8.618709398433566e-05
cycle O 0 1.4474861927737948e-05
and O 0 3.9055700540302496e-07
enter O 0 8.15106432128232e-06
G0 O 0 0.0019611285533756018
/ O 0 0.00016256053640972823
quiescence O 0 0.00039549788925796747
in O 0 6.710253273922717e-06
low O 0 0.00034559634514153004
serum O 0 0.0005609775544144213
. O 0 8.689850801602006e-06

Both O 0 3.2983334676828235e-05
VHL O 0 0.07740253955125809
- O 0 0.0005645741475746036
positive O 0 3.3504936709505273e-06
and O 0 7.718872438999824e-06
VHL O 0 0.11786593496799469
- O 0 0.0010565203847363591
negative O 0 2.8531052521429956e-05
RCC B-Disease 0 0.03309960663318634
cells O 0 9.647368642617948e-06
exit O 0 5.969485300738597e-06
the O 0 4.5516046043303504e-07
cell O 0 6.168717663967982e-05
cycle O 0 1.1970827472396195e-05
by O 0 3.5957017985310813e-07
contact O 0 2.6478419385966845e-05
inhibition O 0 8.202977187465876e-05
. O 0 9.545974535285495e-06

The O 0 1.1916200492123608e-05
cyclin O 0 0.0009393963846378028
- O 0 0.00010886773088714108
dependent O 0 2.3227401470649056e-05
kinase O 0 0.00011729745892807841
inhibitor O 0 5.577072806772776e-05
, O 0 9.843704447121127e-07
p27 O 0 9.467534982832149e-05
, O 0 8.695427595739602e-07
accumulates O 0 1.1952586646657437e-05
upon O 0 8.174443451025581e-07
serum O 0 3.466395355644636e-05
withdrawal O 0 5.963629973848583e-06
, O 0 9.21619331961665e-08
only O 0 9.66655644418779e-09
in O 0 3.608879595162762e-08
the O 0 1.4922341051715193e-07
presence O 0 1.6551017552046687e-06
of O 0 3.6033674177815556e-07
VHL B-Disease 0 0.005571089219301939
, O 0 1.0676183137547923e-06
as O 0 1.555850701606687e-07
a O 0 3.186183619163785e-07
result O 0 3.4471599974494893e-07
of O 0 1.9883765745021265e-08
the O 0 1.2706648533367115e-07
stabilization O 0 3.7756553865619935e-06
of O 0 2.5009901705175253e-08
the O 0 3.624525390932831e-07
protein O 0 1.5509278455283493e-05
. O 0 4.46900094175362e-06

We O 0 3.3160131351905875e-06
propose O 0 3.7390561828942737e-06
that O 0 5.4967369322866944e-08
the O 0 4.804335844710295e-07
loss O 0 3.6104418541071936e-05
of O 0 2.7286606041343475e-07
wild O 0 3.8622558349743485e-05
- O 0 0.0007142859976738691
type O 0 0.0004642575222533196
VHL B-Disease 0 0.005204578395932913
gene O 0 2.2570506189367734e-05
results O 0 1.7636062921155826e-06
in O 0 9.623310859296907e-08
a O 0 4.1380278048563923e-07
specific O 0 1.0920537079073256e-06
cellular O 0 0.03737117722630501
defect O 0 0.14333601295948029
in O 0 4.75141223432729e-06
serum O 0 0.0001278907002415508
- O 0 4.576757055474445e-05
dependent O 0 6.855604624433909e-06
growth O 0 1.9368242192285834e-06
control O 0 4.130369234189857e-06
, O 0 8.144127150444547e-07
which O 0 4.4288242406764766e-07
may O 0 7.371959782176418e-06
initiate O 0 6.0390822909539565e-05
tumor B-Disease 1 0.9627773761749268
formation O 0 0.0009606672683730721
. O 0 1.5045812688185833e-05

This O 0 7.991390020833933e-07
is O 0 2.3512550342275063e-06
corrected O 0 5.634576882584952e-05
by O 0 6.398853003020122e-08
the O 0 9.483154883582756e-08
reintroduction O 0 3.823128281510435e-06
of O 0 1.899475279287799e-07
wild O 0 0.0001100718291127123
- O 0 0.009902563877403736
type O 0 0.01209683995693922
VHL B-Disease 1 0.9826719760894775
, O 0 4.933557647746056e-05
implicating O 0 0.005598126910626888
VHL B-Disease 0 0.01856055110692978
as O 0 2.5752085548447212e-06
the O 0 5.217584089223237e-07
first O 0 4.195085239189211e-06
tumor B-Disease 0 0.002053595148026943
suppressor O 0 1.586099278938491e-05
involved O 0 4.4461029347075964e-07
in O 0 6.663571383569433e-08
the O 0 4.1529236938231406e-08
regulation O 0 1.1055747108912328e-06
of O 0 1.1409407818518957e-07
cell O 0 0.00011663516488624737
cycle O 0 2.6348694518674165e-05
exit O 0 1.6402933397330344e-05
, O 0 5.748884746026306e-07
which O 0 7.476823782326392e-08
is O 0 7.167646742800571e-08
consistent O 0 2.820380871071393e-07
with O 0 6.205779357060237e-08
its O 0 2.7185618023395364e-07
gatekeeper O 0 6.415024108719081e-05
function O 0 3.231992877772427e-06
in O 0 1.6768967725511175e-06
the O 0 8.661545507493429e-06
kidney O 1 0.9987320303916931
. O 0 4.429907221492613e-06
. O 0 6.925437446625438e-06

Piebaldism B-Disease 1 0.999613344669342
with O 0 0.013543699868023396
deafness B-Disease 1 0.9999988079071045
: O 0 8.634636287752073e-06
molecular O 0 2.7391510229790583e-05
evidence O 0 1.0438500339660095e-06
for O 0 1.912915053026154e-07
an O 0 4.867285497311968e-06
expanded O 0 0.0056480541825294495
syndrome O 1 0.999974250793457
. O 0 4.9651378503767774e-05

In O 0 1.6179689055206836e-06
a O 0 1.7759238062353688e-06
South O 0 2.1565081169683253e-06
African O 0 2.5037115847226232e-06
girl O 0 5.0379974709358066e-05
of O 0 3.998996476184402e-07
Xhosa O 0 0.0005923999124206603
stock O 0 0.0004735016846098006
with O 0 2.7939979190705344e-05
severe O 1 0.9977194666862488
piebaldism B-Disease 1 0.9396837949752808
and O 0 0.002461889525875449
profound O 1 0.9987564086914062
congenital O 1 0.9999998807907104
sensorineural B-Disease 1 0.9999988079071045
deafness I-Disease 1 0.9999998807907104
we O 0 0.0004319424624554813
identified O 0 8.992882612801623e-06
a O 0 9.713761528473697e-07
novel O 0 1.6404120515289833e-06
missense O 0 1.2533832887129392e-05
substitution O 0 6.245594477150007e-07
at O 0 3.3938536034838762e-06
a O 0 4.89949457005423e-07
highly O 0 1.5869743492658017e-06
conserved O 0 9.778395906323567e-07
residue O 0 8.805363336250593e-07
in O 0 4.628981642440522e-08
the O 0 3.121557412555376e-08
intracellular O 0 3.7683457776438445e-06
kinase O 0 5.292726200423203e-06
domain O 0 7.462020334969566e-07
of O 0 1.0288626128840406e-07
the O 0 2.408977024970227e-06
KIT O 0 0.002274364000186324
proto O 0 0.22431160509586334
- O 0 0.005587980151176453
oncogene O 0 0.004085133317857981
, O 0 5.854321898368653e-06
R796G O 0 0.00016340796719305217
. O 0 8.747263564146124e-06

Though O 0 5.9263787989038974e-05
auditory B-Disease 0 0.0021281384397298098
anomalies I-Disease 0 0.026013875380158424
have O 0 1.1039217042707605e-06
been O 0 1.5352291029557819e-06
observed O 0 3.0047337986616185e-06
in O 0 3.357743878495967e-07
mice O 0 8.654866178403609e-06
with O 0 3.3550421107975126e-07
dominant O 0 0.00046635654871352017
white O 0 0.00025294499937444925
spotting O 0 0.003945224918425083
( O 0 7.579893463116605e-06
W O 0 0.0025082402862608433
) O 0 3.4997219700017013e-07
due O 0 2.9093118882883573e-06
to O 0 6.098484277572425e-07
KIT O 0 0.004751369822770357
mutations O 0 0.00496548181399703
, O 0 0.00045171435340307653
deafness B-Disease 1 0.9999979734420776
is O 0 6.092756848374847e-06
not O 0 2.845976041498943e-07
typical O 0 1.3858025340596214e-05
in O 0 3.1020715596241644e-06
human O 0 3.7765916204079986e-05
piebaldism B-Disease 0 0.004516772925853729
. O 0 2.4587685402366333e-05

Thus O 0 2.8602973543456756e-05
, O 0 1.8428262364977854e-06
the O 0 8.10149060725962e-07
occurrence O 0 0.0007148119620978832
of O 0 7.497108890675008e-05
sensorineural B-Disease 1 0.9999899864196777
deafness I-Disease 1 0.9999998807907104
in O 0 8.500471449224278e-05
this O 0 2.4575815587013494e-06
patient O 0 0.00013071668217889965
extends O 0 7.306796760531142e-06
considerably O 0 6.202032636792865e-06
the O 0 2.194753818685058e-07
phenotypic O 0 1.259440068679396e-05
range O 0 9.794890502234921e-06
of O 0 3.5960962918579753e-07
piebaldism B-Disease 0 0.000541956047527492
due O 0 1.4736492630618159e-05
to O 0 3.0480842383440176e-07
KIT O 0 0.00011114415974589065
gene O 0 2.5940847990568727e-05
mutation O 0 2.5434463168494403e-05
in O 0 4.7304740746767493e-07
humans O 0 3.993297468696255e-06
and O 0 1.4742051916982746e-06
tightens O 0 0.00017121365817729384
the O 0 6.129632765805582e-07
clinical O 0 1.0424959327792749e-05
similarity O 0 1.7197158967974246e-06
between O 0 1.4022389223100618e-06
piebaldism B-Disease 0 0.00032288592774420977
and O 0 3.188238508755603e-07
the O 0 8.039105381385525e-08
various O 0 5.955503183940891e-07
forms O 0 0.00010179675882682204
of O 0 0.0008661976899020374
Waardenburg B-Disease 1 0.9999862909317017
syndrome I-Disease 1 0.9999983310699463
. O 0 1.342948689853074e-05
. O 0 1.1572999937925488e-05

Cycloheximide O 0 0.0008109636255539954
facilitates O 0 9.52384107222315e-06
the O 0 5.665832532031345e-07
identification O 0 1.2067589523212519e-06
of O 0 3.9940189822118555e-07
aberrant O 0 0.00012503193283919245
transcripts O 0 3.304725032649003e-05
resulting O 0 1.3438954738376196e-05
from O 0 3.1515722298536275e-07
a O 0 4.249681069268263e-07
novel O 0 2.0105010207771556e-06
splice O 0 9.960380702978e-05
- O 0 0.00011281426850473508
site O 0 1.3306806977197994e-05
mutation O 0 1.0402058251202106e-05
in O 0 3.148279574816115e-07
COL17A1 O 0 8.574000821681693e-05
in O 0 5.209728897170862e-07
a O 0 4.156112026976189e-06
patient O 0 0.00018820934928953648
with O 0 2.0024388504680246e-05
generalized O 1 0.8652158975601196
atrophic B-Disease 1 0.9999825954437256
benign I-Disease 1 0.9998466968536377
epidermolysis I-Disease 1 0.9985170960426331
bullosa I-Disease 1 0.993515133857727
. O 0 0.0005609128857031465

Patients O 0 0.0018490594811737537
with O 0 7.935000030556694e-05
generalized O 1 0.7763733267784119
atrophic B-Disease 1 0.9999613761901855
benign I-Disease 1 0.9997991919517517
epidermolysis I-Disease 1 0.9975269436836243
bullosa I-Disease 1 0.9707246422767639
often O 0 2.6865671316045336e-05
show O 0 7.371143965428928e-06
decreased O 0 2.1424179067253135e-05
expression O 0 1.0860713928195764e-06
of O 0 3.9305749055529304e-07
type O 0 0.0034415950067341328
XVII O 1 0.9048987627029419
collagen O 0 0.006598198786377907
, O 0 1.287008672079537e-06
a O 0 1.0680001878426992e-06
transmembrane O 0 7.539830221503507e-06
hemidesmosomal O 0 1.2096270438632928e-05
protein O 0 2.633036615407036e-07
encoded O 0 2.211026810527983e-07
by O 0 9.36436947540642e-07
COL17A1 O 0 0.001393676153384149
. O 0 1.2539378985820804e-05

This O 0 7.838339683985396e-07
report O 0 5.505450531018141e-07
documents O 0 3.039376110791636e-07
a O 0 8.434651590505382e-07
novel O 0 3.934012966055889e-06
splice O 0 0.00017277966253459454
- O 0 0.00010632327030180022
site O 0 1.3256219972390682e-05
mutation O 0 8.929061550588813e-06
in O 0 4.2569092784106033e-07
COL17A1 O 0 0.00014732510317116976
in O 0 8.819027925710543e-07
a O 0 7.224341970868409e-06
patient O 0 0.0002156818809453398
with O 0 2.0475306882872246e-05
generalized O 0 0.46266141533851624
atrophic B-Disease 1 0.9999622106552124
benign I-Disease 1 0.9996764659881592
epidermolysis I-Disease 1 0.9976656436920166
bullosa I-Disease 1 0.9882553815841675
, O 0 1.7545307855471037e-05
and O 0 4.5130272496862744e-07
applies O 0 3.0236660109039804e-07
a O 0 2.1618814116663998e-07
new O 0 3.6399470104697684e-07
methodology O 0 3.8984103412076365e-07
to O 0 2.8708088350981598e-08
define O 0 1.4135858918962185e-06
and O 0 7.719608561274072e-07
characterize O 0 1.1567560250114184e-05
the O 0 3.076458767736767e-07
resulting O 0 2.3641141524421982e-06
mRNA O 0 1.6558958577661542e-06
splice O 0 0.00016921345377340913
variants O 0 8.425892883678898e-05
. O 0 3.7151257856749e-05

Mutational O 0 0.0013158151414245367
analysis O 0 4.371271643321961e-06
of O 0 6.033772592672904e-07
COL17A1 O 0 0.0020497795194387436
identified O 0 8.368059752683621e-06
a O 0 5.514254553418141e-06
maternally O 0 0.00035867077531293035
inherited O 0 0.22053109109401703
G O 0 0.0044298432767391205
- O 0 9.265337575925514e-05
to O 0 1.1643689958873438e-06
- O 0 0.00020334997680038214
T O 0 0.0004025863891001791
transversion O 0 3.957860462833196e-05
at O 0 4.373706815385958e-06
the O 0 3.0458582500614284e-07
- O 0 4.367662768345326e-06
1 O 0 5.43899091098865e-07
position O 0 1.0172431075261557e-06
of O 0 9.79293801606218e-08
exon O 0 7.041463686618954e-05
32 O 0 2.537713953643106e-05
. O 0 6.568165190401487e-06

This O 0 2.276774324627695e-07
acceptor O 0 2.9862790142942686e-06
splice O 0 0.00024920591386035085
- O 0 0.00020953494822606444
site O 0 1.70600505953189e-05
mutation O 0 7.05704633219284e-06
led O 0 5.538516916203662e-07
to O 0 2.2310807423764345e-08
the O 0 2.653510478012322e-07
formation O 0 1.0741036930994596e-05
of O 0 8.042111687700526e-08
aberrant O 0 1.88933754543541e-05
transcripts O 0 7.7523582149297e-06
present O 0 1.4532625982610625e-06
at O 0 3.481582461972721e-05
extremely O 0 8.220291056204587e-05
low O 0 0.0002015384379774332
levels O 0 7.605394057463855e-05
. O 0 6.3477586991211865e-06

Based O 0 1.7352512031720835e-06
on O 0 1.2372415767458733e-06
our O 0 5.488397505359899e-07
recent O 0 1.359398765998776e-06
finding O 0 9.29543887195905e-07
that O 0 2.898689217545325e-07
cycloheximide O 0 0.00022532499860972166
stabilized O 0 0.000862028100527823
mutant O 0 3.746749280253425e-05
COL17A1 O 0 0.00023133015201892704
transcripts O 0 6.9769780566275585e-06
in O 0 4.0654668964634766e-07
keratinocytes O 0 2.6424586394568905e-05
homozygous O 0 2.742061042226851e-06
for O 0 8.256019157215633e-08
a O 0 5.4074862418929115e-06
frameshift O 0 0.0022982857190072536
mutation O 0 0.00016219900862779468
, O 0 8.648535185784567e-07
the O 0 2.6740315206552623e-07
effects O 0 4.271042143955128e-06
of O 0 2.3281842231881456e-08
the O 0 2.2318943138088798e-07
splice O 0 0.00012020580470561981
- O 0 4.953102325089276e-05
site O 0 5.9031526689068414e-06
mutation O 0 1.4850975276203826e-06
on O 0 1.185090283684076e-07
splicing O 0 1.8526621943237842e-06
of O 0 1.498763282370419e-07
COL17A1 O 0 0.00010945241956505924
transcripts O 0 3.700792376548634e-06
were O 0 1.084041514332057e-07
determined O 0 4.5749521859761444e-07
using O 0 3.46050967436895e-07
reverse O 0 2.523882176319603e-05
transcriptase O 0 0.00011834229371743277
polymerase O 0 2.4862802092684433e-05
chain O 0 2.2527970941155218e-05
reaction O 0 5.647824536936241e-07
of O 0 1.0198785815873634e-08
total O 0 1.6108785416690807e-08
RNA O 0 1.5699687310188892e-06
from O 0 1.0766090952074592e-07
keratinocytes O 0 2.6103793970833067e-06
incubated O 0 5.659826456394512e-07
for O 0 1.4052079677639995e-07
2 O 0 4.840728252020199e-06
. O 0 3.821349309873767e-06

5 O 0 1.1227964932913892e-05
h O 0 3.3317424822598696e-05
in O 0 3.4978469898305775e-07
the O 0 8.737558232496667e-08
presence O 0 1.1760893130485783e-06
or O 0 1.3183084774937015e-06
absence O 0 6.9876323323114775e-06
of O 0 2.4752975491537654e-07
10 O 0 3.3899427762662526e-06
microg O 0 0.00016865372890606523
cycloheximide O 0 0.00024624692741781473
per O 0 3.7580957723548636e-06
ml O 0 0.0006811902276240289
. O 0 1.318710928899236e-05

Using O 0 7.00158068411838e-07
this O 0 7.574039528890353e-08
approach O 0 9.353659038424667e-07
, O 0 1.8442750615577097e-07
an O 0 1.1332176796940985e-07
abnormally O 0 6.648908311035484e-05
spliced O 0 1.7668588043306954e-05
transcript O 0 2.6570138288661838e-05
was O 0 4.977759999746922e-06
identified O 0 2.3400895088343532e-07
that O 0 2.7694198045935536e-09
contains O 0 5.142552605974515e-09
an O 0 5.600777175374105e-09
extra O 0 4.717112034313686e-08
264 O 0 2.775476843908109e-07
bases O 0 2.056650885151612e-07
upstream O 0 1.5858004189794883e-06
from O 0 3.697211639064335e-07
exon O 0 1.420880562363891e-05
32 O 0 2.290713837282965e-06
, O 0 1.8254797851113835e-07
resulting O 0 1.3607282198790926e-06
in O 0 7.150986789383751e-07
a O 0 8.589831850258633e-06
premature O 0 0.0004107796121388674
termination O 0 0.00010955170728266239
codon O 0 3.3425116271246225e-05
27 O 0 1.8342718249186873e-05
bp O 0 4.5959091949043795e-05
downstream O 0 4.636701305571478e-06
from O 0 2.2320219272842223e-07
the O 0 3.3848471048258943e-07
cryptic O 0 0.0001268926716875285
splice O 0 0.00048343715025112033
site O 0 0.00022237288067117333
. O 0 2.243143717350904e-05

Three O 0 3.032713777884055e-07
other O 0 3.2720691933718626e-08
splice O 0 2.7543333999346942e-05
variants O 0 1.1784013622673228e-05
, O 0 5.519829073818983e-07
including O 0 6.318553147366401e-08
one O 0 6.412818009948751e-08
derived O 0 1.0715591969301386e-07
from O 0 6.320722434338677e-08
the O 0 6.919456296827775e-08
skipping O 0 4.454062036529649e-06
of O 0 6.872566160609495e-08
exon O 0 2.1774299966637045e-05
32 O 0 4.385251031635562e-06
, O 0 2.9138971058273455e-07
were O 0 1.852812943070603e-07
also O 0 1.0537361276874435e-06
identified O 0 8.857751709001604e-06
. O 0 4.686433840106474e-06

These O 0 7.464639111276483e-07
results O 0 3.370292461113422e-06
indicate O 0 1.9280150809208862e-06
the O 0 4.2879813122453925e-07
usefulness O 0 7.019999884505523e-06
of O 0 6.52004587209376e-07
cycloheximide O 0 0.0017987311584874988
treatment O 0 6.915493577253073e-05
in O 0 4.7161046268229256e-07
evaluating O 0 2.0446875623747474e-06
the O 0 4.176667403044121e-07
abnormal O 0 1.4877389730827417e-05
processing O 0 6.390900466612948e-07
of O 0 2.741811933049121e-08
mRNA O 0 2.818318591835123e-07
due O 0 1.2779994449374499e-06
to O 0 5.837646810391561e-08
splice O 0 0.00010561250383034348
- O 0 0.0001044783930410631
site O 0 2.168018909287639e-05
mutations O 0 3.151555574731901e-05
, O 0 4.4550461097969674e-07
because O 0 2.503801965758612e-07
( O 0 1.3617119520858978e-07
i O 0 2.7213370685785776e-06
) O 0 3.9082742375740054e-08
aberrant O 0 2.239225068478845e-06
splicing O 0 3.613130047597224e-06
often O 0 1.1414701930334559e-06
generates O 0 9.144173418462742e-07
a O 0 3.2198470307776006e-06
premature O 0 0.00012509942462202162
termination O 0 3.602301512728445e-05
codon O 0 1.5020148566691205e-05
, O 0 1.047226305672666e-06
( O 0 1.6758083631884801e-07
ii O 0 0.0001490770955570042
) O 0 1.556865925067541e-07
transcripts O 0 2.28478370445373e-06
with O 0 1.2059720120305428e-06
premature O 0 0.00037112177233211696
termination O 0 4.0639737562742084e-05
codons O 0 1.413406880601542e-05
can O 0 1.0085736903420184e-06
occur O 0 2.3818108729756204e-06
at O 0 1.2721317943942267e-05
low O 0 3.8621121348114684e-05
or O 0 4.663313120545354e-06
undetectable O 0 0.0010736130643635988
levels O 0 1.0475466297066305e-05
due O 0 2.6329212232667487e-06
to O 0 1.1276656408654162e-07
nonsense O 0 1.662121394474525e-05
- O 0 4.17974615629646e-06
mediated O 0 7.601951438118704e-06
mRNA O 0 6.163419925542257e-07
decay O 0 9.976261026167776e-06
, O 0 3.122752048057009e-07
and O 0 2.2750509742763825e-07
( O 0 2.1268267857976753e-07
iii O 0 7.803553307894617e-05
) O 0 5.610563391655887e-08
the O 0 5.933660673917984e-08
levels O 0 3.5449357937977766e-07
of O 0 4.421613741811825e-09
these O 0 6.413146014239146e-09
transcripts O 0 5.956844120191818e-07
can O 0 6.758432391507085e-08
be O 0 4.721739088608956e-08
increased O 0 1.2000150206858962e-07
by O 0 2.6309382405997894e-07
cycloheximide O 0 0.0004376972501631826
. O 0 8.553536645194981e-06

A O 0 4.6181354264263064e-05
deletion O 0 0.0001268210617126897
mutation O 0 3.923662370652892e-05
in O 0 9.427353120372572e-07
COL17A1 O 0 0.0002824568364303559
in O 0 7.72563282680494e-07
five O 0 9.858115390670719e-07
Austrian O 0 0.0003164336085319519
families O 0 7.97366737970151e-07
with O 0 2.4838775061652996e-05
generalized O 1 0.952981173992157
atrophic B-Disease 1 0.9999819993972778
benign I-Disease 1 0.9998773336410522
epidermolysis I-Disease 1 0.9980834722518921
bullosa I-Disease 1 0.9815654754638672
represents O 0 4.0766666643321514e-05
propagation O 0 8.29988312034402e-06
of O 0 1.8127495593489584e-07
an O 0 7.512273327847652e-07
ancestral O 0 4.406992593430914e-05
allele O 0 0.00017011813179124147
. O 0 2.729151674429886e-05

Patients O 0 0.004297973122447729
with O 0 0.00012141747720306739
generalized O 1 0.9667491316795349
atrophic B-Disease 1 0.9999696016311646
benign I-Disease 1 0.9997993111610413
epidermolysis I-Disease 1 0.9977948665618896
bullosa I-Disease 1 0.9918881058692932
, O 0 2.029476672760211e-05
a O 0 3.4056745334964944e-06
usually O 0 3.333382210257696e-06
nonlethal O 0 5.267205779091455e-05
form O 0 2.2694590370520018e-05
of O 0 1.487937606725609e-05
junctional B-Disease 1 0.9789711236953735
epidermolysis I-Disease 1 0.988250732421875
bullosa I-Disease 1 0.9783471822738647
, O 0 1.7607728295843117e-05
have O 0 2.5764613837964134e-06
generalized O 0 0.00016973898163996637
blistering B-Disease 1 0.8689637780189514
, O 0 0.0004778327129315585
nail B-Disease 1 0.9999749660491943
dystrophy I-Disease 1 0.999927282333374
, O 0 0.00029005020041950047
patchy B-Disease 1 0.9959396123886108
alopecia I-Disease 1 0.9999475479125977
, O 0 0.00019289215561002493
and O 0 0.0001995050988625735
dental B-Disease 1 0.9998076558113098
abnormalities I-Disease 1 0.999976396560669
. O 0 7.584159902762622e-05

Skin B-Disease 1 0.9953352808952332
fragility I-Disease 0 0.030271129682660103
in O 0 2.443526909701177e-06
most O 0 6.319613135019608e-07
cases O 0 7.731912319286494e-07
is O 0 1.7185095657623606e-07
due O 0 9.392543347530591e-07
to O 0 5.5256027309269484e-08
mutations O 0 2.8797837785532465e-06
in O 0 4.881705706338835e-08
the O 0 3.616949229012789e-08
gene O 0 1.155815766651358e-06
encoding O 0 9.405779564986005e-06
type O 0 0.0032147280871868134
XVII O 1 0.9085838794708252
collagen O 0 0.0787373036146164
( O 0 7.134588940971298e-06
COL17A1 O 0 0.0014143337029963732
) O 0 2.0669692730734823e-06
. O 0 4.555605300993193e-06

Recently O 0 0.0003543976345099509
, O 0 2.3844152110541472e-06
we O 0 5.6777105328365e-07
reported O 0 4.313963017921196e-06
five O 0 2.435400006106647e-07
Austrian O 0 0.00012476621486712247
families O 0 5.406039349509228e-07
with O 0 2.0060990209458396e-05
generalized O 1 0.9542909860610962
atrophic B-Disease 1 0.9999781847000122
benign I-Disease 1 0.9997667670249939
epidermolysis I-Disease 1 0.997395396232605
bullosa I-Disease 1 0.9742448925971985
who O 0 3.766441295738332e-05
share O 0 1.10176563339337e-06
the O 0 1.06409413547226e-06
same O 0 6.6834045355790295e-06
COL17A1 O 0 0.010085325688123703
mutation O 0 0.000922835897654295
. O 0 1.4473881492449436e-05

Affected O 0 1.286545375478454e-05
individuals O 0 9.978680282074492e-08
in O 0 9.003696987974763e-08
three O 0 5.177434658776292e-08
families O 0 1.0954855689249143e-08
are O 0 1.1371731112319594e-08
homozygous O 0 5.023255766900547e-07
for O 0 5.727728691340417e-08
4003delTC O 0 3.1536656024400145e-05
, O 0 1.6914873413043097e-07
whereas O 0 1.1787061993118186e-07
those O 0 1.598693089022163e-08
in O 0 4.154872357275963e-08
two O 0 7.298776694142362e-08
others O 0 3.225155751351849e-07
are O 0 1.2222358236613218e-07
compound O 0 5.0178594392491505e-05
heterozygotes O 0 0.00034659411176107824
. O 0 2.6093932319781743e-05

To O 0 5.38836388841446e-07
determine O 0 1.39628866691055e-06
if O 0 4.530669457381009e-07
the O 0 2.473008748893335e-07
occurrence O 0 2.9400702260318212e-05
of O 0 2.424954459456785e-07
4003delTC O 0 0.00010917139297816902
in O 0 3.3041550295820343e-07
these O 0 9.805536649309943e-08
unrelated O 0 1.2511344721133355e-05
families O 0 1.0591862320552536e-07
signifies O 0 1.3144293689038022e-06
propagation O 0 1.1476362260509632e-06
of O 0 4.591154478816861e-08
an O 0 1.5969962419148942e-07
ancestral O 0 7.908033694548067e-06
allele O 0 2.2390402591554448e-05
or O 0 5.331022748578107e-06
a O 0 1.2679241081059445e-05
mutational O 0 0.001054868451319635
hot O 0 0.0005242404877208173
spot O 0 5.709947436116636e-05
, O 0 6.068871698516887e-07
haplotypes O 0 5.3138255680096336e-06
were O 0 1.9778165949446702e-07
determined O 0 4.880821506958455e-07
for O 0 6.535184837730412e-08
polymorphisms O 0 7.817006007826421e-06
both O 0 3.513794979426166e-07
within O 0 8.083523539426096e-07
and O 0 6.095116532378597e-06
flanking O 0 0.01477817166596651
COL17A1 O 1 0.82273930311203
. O 0 6.744750135112554e-05

Five O 0 8.565511961933225e-06
intragenic O 0 0.00020737509476020932
polymorphisms O 0 2.9510196327464655e-05
were O 0 1.828302345074917e-07
chosen O 0 2.879666283206461e-07
based O 0 1.0195132915669092e-07
on O 0 5.505508511305379e-07
their O 0 5.330304020390031e-07
informativeness O 0 0.0024530920200049877
. O 0 1.9397284631850198e-05

One O 0 1.3072711908534984e-06
of O 0 4.4556916378724054e-08
these O 0 6.196506063815832e-08
, O 0 3.982740963692777e-07
not O 0 8.340585821997593e-08
previously O 0 3.3238079595321324e-06
reported O 0 1.1560303391888738e-05
, O 0 3.3911703667399706e-07
was O 0 2.297743776580319e-06
2988 O 0 1.6338080968125723e-05
A O 0 1.4657520068794838e-06
or O 0 1.2624237797353999e-06
C O 0 7.644452125532553e-06
that O 0 1.9259918104808094e-08
introduces O 0 3.59138368821732e-07
a O 0 2.0614029949683754e-07
new O 0 2.2268640975653398e-07
restriction O 0 7.958854553180572e-08
site O 0 8.031317975110142e-07
for O 0 7.87186493766967e-08
Eco0109 O 0 5.8336256188340485e-05
I O 0 0.00031071031116880476
. O 0 7.180945885920664e-06

All O 0 5.384105747907597e-07
the O 0 1.3039615396337467e-06
4003delTC O 0 9.054852853296325e-05
alleles O 0 3.5872940316039603e-06
showed O 0 2.753657099674456e-06
the O 0 4.9275438840368224e-08
same O 0 9.969795655706548e-08
haplotype O 0 7.394928616122343e-06
for O 0 2.7306592542686303e-08
these O 0 1.941471339250711e-08
five O 0 5.737284141105192e-07
polymorphic O 0 0.00020321780175436288
markers O 0 0.000466285040602088
. O 0 2.5603012545616366e-05

Fourteen O 0 6.382707942975685e-05
microsatellite O 0 0.0002677974116522819
polymorphisms O 0 3.999330147053115e-05
were O 0 2.3726873621399136e-07
selected O 0 8.237898185825543e-08
based O 0 1.4997527841842384e-07
on O 0 5.585528697338304e-07
their O 0 1.7182506439894496e-07
high O 0 4.472076034289785e-05
heterozygosity O 0 9.409958147443831e-05
and O 0 2.6310786438443756e-07
their O 0 3.857551078567667e-08
location O 0 2.176288262489834e-06
within O 0 3.593525661926833e-06
10q23 O 0 0.0002897102676797658
- O 0 0.00037528062239289284
q25 O 0 0.0002846093848347664
near O 0 0.00032308854861184955
COL17A1 O 0 0.0035991626791656017
. O 0 1.9670244000735693e-05

Three O 0 1.5841618505874067e-06
families O 0 1.8557925329787395e-07
shared O 0 2.7893354399566306e-06
microsatellite O 0 0.0006375189987011254
polymorphisms O 0 0.0001811411784728989
covering O 0 1.7329495676676743e-05
at O 0 1.067300127033377e-05
most O 0 2.9466795581356564e-07
19 O 0 3.3687176710373024e-06
cM O 0 1.0476095667399932e-05
, O 0 2.421577960376453e-07
whereas O 0 2.674625818599452e-07
the O 0 6.011636344283033e-08
others O 0 1.6305828864915384e-07
shared O 0 1.9420792796154274e-07
smaller O 0 2.1452510736708064e-06
regions O 0 2.2477490801975364e-06
consistent O 0 2.685035042304662e-06
with O 0 4.965452831129369e-07
cross O 0 2.0797842807951383e-05
- O 0 2.2034597350284457e-05
over O 0 3.1033150094117445e-07
events O 0 1.6784233025646245e-07
during O 0 6.4268942878698e-07
passage O 0 1.6172039352113643e-07
of O 0 1.0854314780317509e-08
this O 0 3.2610103062324924e-08
mutation O 0 1.0911271601798944e-06
through O 0 8.161794795569222e-08
several O 0 2.2762964135836228e-07
generations O 0 5.8917412388836965e-06
. O 0 7.189538791863015e-06

These O 0 4.856611894865637e-07
results O 0 7.710904355917592e-06
indicate O 0 2.454749619573704e-06
that O 0 2.2287973422407958e-07
4003delTC O 0 5.1178089051973075e-05
occurs O 0 1.8973422584167565e-06
on O 0 2.0960850122264674e-07
a O 0 1.6512109368704841e-07
single O 0 4.051351822909055e-07
ancestral O 0 9.217174010700546e-06
allele O 0 3.8080619560787454e-05
. O 0 2.7526909889274975e-06
. O 0 6.620171461690916e-06

The O 0 1.57747545017628e-05
haptoglobin O 0 0.0022583070676773787
- O 0 0.00020217108249198645
gene O 0 2.1771995307062753e-05
deletion O 0 4.1800372855504975e-05
responsible O 0 1.2512406101450324e-05
for O 0 1.2155036301919608e-06
anhaptoglobinemia B-Disease 0 0.005380286835134029
. O 0 2.9697739591938443e-05

We O 0 5.875334863958415e-06
have O 0 1.9716583210538374e-07
found O 0 4.448915262855735e-07
an O 0 1.4282926485975622e-07
allelic O 0 4.5902765123173594e-05
deletion O 0 1.4188805835146923e-05
of O 0 1.6512109368704841e-07
the O 0 1.2847791595049785e-06
haptoglobin O 0 0.00027553935069590807
( O 0 3.8288098380689917e-07
Hp O 0 4.6895811465219595e-06
) O 0 2.7699229576683138e-08
gene O 0 2.431742132102954e-07
from O 0 1.5006907716497153e-08
an O 0 2.1740007127846184e-08
individual O 0 4.841010081690911e-08
with O 0 1.6995962823784794e-06
anhaptoglobinemia B-Disease 0 0.007101045921444893
. O 0 1.480930222896859e-05

The O 0 2.740761601671693e-06
Hp O 0 5.3200245019979775e-05
gene O 0 1.6548930943827145e-05
cluster O 0 3.440904038143344e-05
consists O 0 1.5817918210814241e-06
of O 0 1.6784809986347682e-07
coding O 0 8.778851042734459e-05
regions O 0 4.90442153022741e-06
of O 0 7.209094121662929e-08
the O 0 5.671876124324626e-07
alpha O 0 4.1133716877084225e-06
chain O 0 2.327931724721566e-05
and O 0 7.017785605967219e-07
beta O 0 5.717447038477985e-06
chain O 0 1.965284172911197e-05
of O 0 6.42888622337523e-08
the O 0 4.502284980389959e-07
haptoglobin O 0 8.579357381677255e-05
gene O 0 4.673566309065791e-06
( O 0 2.4031709244809463e-07
Hp O 0 2.489236521796556e-06
) O 0 4.705322353970587e-08
and O 0 8.233531190171561e-08
of O 0 1.8927751810338123e-08
the O 0 3.051076760129945e-07
alpha O 0 4.869365511694923e-06
chain O 0 1.6377018255298026e-05
and O 0 5.308839376994001e-07
beta O 0 5.762899945693789e-06
chain O 0 1.1412206731620245e-05
of O 0 5.48764447216854e-08
the O 0 9.952789241651772e-07
haptoglobin O 0 0.0006391283823177218
- O 0 0.00012055499973939732
related O 0 6.150775334390346e-06
gene O 0 7.598704542033374e-06
( O 0 6.022338538969052e-07
Hpr O 0 7.43223208701238e-05
) O 0 2.1238430747416714e-07
, O 0 1.240363616261675e-07
in O 0 1.1661632015602663e-07
tandem O 0 1.2190397683298215e-05
from O 0 2.0838849934534664e-07
the O 0 5.141486667525896e-07
5 O 0 4.884323061560281e-06
side O 0 1.8897861082223244e-05
. O 0 6.594481874344638e-06

Southern O 0 0.0002299219777341932
blot O 0 0.002882750006392598
and O 0 2.1474925233633257e-06
PCR O 0 2.8530424970085733e-05
analyses O 0 4.126475232624216e-06
have O 0 1.9831956876714685e-07
indicated O 0 1.1384859135432635e-06
that O 0 1.317185382987418e-08
the O 0 2.155256417779583e-08
individual O 0 3.463318876129051e-08
with O 0 3.737369524969836e-07
anhaptoglobinemia B-Disease 0 0.0005710570840165019
was O 0 1.2439270903996658e-05
homozygous O 0 1.0042775784313562e-06
for O 0 2.0047515647547698e-08
the O 0 6.385027262467702e-08
gene O 0 1.9223236904508667e-06
deletion O 0 5.12108817929402e-06
and O 0 1.4706131423736224e-07
that O 0 1.082276757102818e-08
the O 0 4.1090057578685446e-08
gene O 0 8.582803161516495e-07
deletion O 0 2.6154552870139014e-06
was O 0 1.6832238998176763e-06
included O 0 1.8592523076677026e-07
at O 0 2.145774715245352e-06
least O 0 4.4744957961029286e-08
from O 0 5.5735096538001017e-08
the O 0 1.9228282610583847e-07
promoter O 0 0.00019377144053578377
region O 0 5.806181889056461e-06
of O 0 2.061051134205627e-07
Hp O 0 1.1358082701917738e-05
to O 0 3.139369084692589e-07
Hpr O 0 0.00020054586639162153
alpha O 0 6.706715794280171e-06
but O 0 1.1004365774169855e-07
not O 0 2.4559168920745833e-08
to O 0 6.178390776767628e-08
Hpr O 0 0.00022554727911483496
beta O 0 2.9433049348881468e-05
( O 0 6.519305770780193e-07
Hpdel O 0 0.00014202795864548534
) O 0 1.4469177358478191e-06
. O 0 4.650504251912935e-06

In O 0 1.0684942708394374e-06
addition O 0 5.757822805207979e-07
, O 0 4.492655705234938e-07
we O 0 1.855436977393765e-07
found O 0 2.121636413221495e-07
seven O 0 1.1206157779497516e-07
individuals O 0 3.195081754725493e-09
with O 0 1.1328654636599822e-07
hypohaptoglobinemia B-Disease 0 4.593762423610315e-05
in O 0 2.2791530795984727e-07
three O 0 1.1547334111128293e-07
families O 0 2.7582876427345582e-08
, O 0 1.0774986236583572e-07
and O 0 9.895229879930412e-08
the O 0 1.248717040880365e-07
genotypes O 0 5.072191925137304e-06
of O 0 3.834297501725814e-08
six O 0 2.755879791038751e-07
of O 0 1.0291291374642242e-08
the O 0 7.530062617888689e-08
seven O 0 1.2879550581601507e-07
individuals O 0 1.013618522449633e-08
were O 0 8.875307599964799e-08
found O 0 2.312275313443024e-07
to O 0 1.2692501627498132e-07
be O 0 1.2724210591841256e-06
Hp2 O 0 0.0005404173280112445
/ O 0 0.00024004980514291674
Hpdel O 0 0.001719192136079073
. O 0 1.4485230167338159e-05

The O 0 7.361870757449651e-06
phenotypes O 0 0.00024398471578024328
and O 0 1.6833909057822893e-06
genotypes O 0 2.3920152671053074e-05
in O 0 3.000562003308005e-07
one O 0 6.400415486496058e-08
of O 0 6.255380213815442e-09
these O 0 1.2710642316449139e-08
three O 0 7.605612495353853e-08
families O 0 6.158730769811882e-08
showed O 0 1.7013705928548006e-06
the O 0 1.9162837361363927e-07
father O 0 3.8498778849316295e-06
to O 0 1.0889965551541536e-07
be O 0 7.151805334615347e-07
hypohaptoglobinemic B-Disease 0 7.977176574058831e-05
( O 0 7.038248099888733e-07
Hp2 O 0 9.440372377866879e-05
) O 0 4.0361805986321997e-07
and O 0 1.4719125829287805e-06
Hp2 O 0 0.000535744009539485
/ O 0 9.306069114245474e-05
Hpdel O 0 0.0003339052782393992
, O 0 8.478160680169822e-07
the O 0 2.1378687620199344e-07
mother O 0 3.4011532079603057e-06
to O 0 3.8467799612362796e-08
be O 0 2.0798842115254956e-07
Hp2 O 0 3.483874388621189e-05
- O 0 1.765726847224869e-05
1 O 0 1.114801648327557e-06
and O 0 5.165514949112548e-07
Hp1 O 0 0.00014606857439503074
/ O 0 1.882617834780831e-05
Hp2 O 0 8.72076052473858e-05
, O 0 2.518535211493145e-07
one O 0 4.588370217106785e-08
of O 0 5.596601404533885e-09
the O 0 3.8137944358140885e-08
two O 0 4.8639911653935997e-08
children O 0 8.251390681834891e-08
to O 0 4.0156969305371604e-08
be O 0 2.9280565172484785e-07
hypohaptoglobinemic B-Disease 0 3.663904863060452e-05
( O 0 2.8308389232734044e-07
Hp2 O 0 3.653974272310734e-05
) O 0 1.6507731004367088e-07
and O 0 5.677401873072085e-07
Hp2 O 0 0.00025868203374557197
/ O 0 6.182563083712012e-05
Hpdel O 0 0.000174382483237423
, O 0 6.304047133198765e-07
and O 0 1.0232127323206441e-07
the O 0 6.112761496979147e-08
other O 0 4.44745573702221e-08
child O 0 1.0334269973100163e-06
to O 0 6.636871319187776e-08
be O 0 5.623493279927061e-07
Hp1 O 0 0.00013629642489831895
and O 0 5.751211119786603e-06
Hp1 O 0 0.000826705654617399
/ O 0 0.0001448706752853468
Hpdel O 0 0.0007037711911834776
, O 0 1.572742576172459e-06
showing O 0 3.769222757910029e-06
an O 0 5.583590336755151e-07
anomalous O 0 0.00013991596642881632
inheritance O 0 4.4002696085954085e-05
of O 0 1.5705302303103963e-06
Hp O 0 0.00011117511166958138
phenotypes O 0 0.00011631329107331112
in O 0 1.4558579550794093e-06
the O 0 1.8624019730850705e-06
child O 0 4.384695421322249e-05
with O 0 7.449829354300164e-06
Hp1 O 0 0.013563030399382114
. O 0 4.3554322473937646e-05

The O 0 2.417597352177836e-05
Hp2 O 0 0.0022521675564348698
/ O 0 0.00017298308375757188
Hpdel O 0 0.00022855329734738916
individuals O 0 2.325249255363815e-07
had O 0 1.2230442507643602e-06
an O 0 8.989042754592447e-08
extremely O 0 8.553764928365126e-06
low O 0 1.347042871202575e-05
level O 0 2.7972153020527912e-06
of O 0 8.265740092383567e-08
Hp O 0 8.508571227139328e-06
( O 0 1.682952870396548e-07
mean O 0 1.7429483705200255e-06
+ O 0 5.473529199662153e-06
/ O 0 9.210144526150543e-06
- O 0 1.716385486361105e-05
SD O 0 5.317772229318507e-05
= O 0 7.369056675088359e-06
0 O 0 3.442855813773349e-07
. O 0 1.056528944332058e-07
049 O 0 3.761176049010828e-05
+ O 0 5.937746664130827e-06
/ O 0 8.081017767835874e-06
- O 0 1.170501946035074e-05
0 O 0 7.159366646192211e-07
. O 0 1.1052389226051673e-07
043 O 0 3.126464071101509e-05
mg O 0 3.1363368179881945e-05
/ O 0 7.409979389194632e-06
ml O 0 1.747054011502769e-05
; O 0 2.3379814706459e-07
n O 0 4.3970180740871e-06
= O 0 2.4915568701544544e-06
6 O 0 7.600347089464776e-07
) O 0 1.8119333589083908e-08
, O 0 2.746580207713123e-08
compared O 0 9.92087407780673e-08
with O 0 1.7058720658269522e-08
the O 0 7.262961787546374e-08
level O 0 7.775406061227841e-07
( O 0 4.675460019143429e-08
1 O 0 1.1592340598554074e-07
. O 0 9.79581127324991e-09
64 O 0 1.5110745721358398e-07
+ O 0 9.969887742045103e-07
/ O 0 2.4579846922279103e-06
- O 0 2.7598036922427127e-06
1 O 0 3.37283438511804e-07
. O 0 7.067406215810479e-08
07 O 0 7.737910891592037e-06
mg O 0 1.7805479728849605e-05
/ O 0 5.652055733662564e-06
ml O 0 6.774488156224834e-06
) O 0 1.7545520591966124e-08
obtained O 0 1.1228259211293334e-07
from O 0 1.303651657735827e-07
52 O 0 4.191234438621905e-06
healthy O 0 7.445731171173975e-06
volunteers O 0 4.150804215896642e-06
having O 0 7.916259164630901e-06
phenotype O 0 8.896157669369131e-05
Hp2 O 0 0.0004279717104509473
, O 0 1.1082740911660949e-06
whereas O 0 1.5311584320443217e-06
the O 0 7.002809638834151e-07
serum O 0 2.050915645668283e-05
Hp O 0 5.786326255474705e-06
level O 0 8.415657362093043e-07
of O 0 2.0433132519315222e-08
an O 0 3.452475993981352e-08
individual O 0 2.770615203928628e-08
with O 0 9.027458531818411e-07
Hp1 O 0 0.0012032699305564165
/ O 0 0.0001203962237923406
Hpdel O 0 0.0004781114694196731
was O 0 7.338439900195226e-05
0 O 0 7.034093414404197e-06
. O 0 4.467181042855373e-06

50 O 0 3.3341642847517505e-05
mg O 0 0.0002018278610194102
/ O 0 3.460648804320954e-05
ml O 0 7.538330100942403e-05
, O 0 3.933012351353682e-07
which O 0 5.724933060946569e-08
was O 0 6.716712164234195e-07
approximately O 0 8.516594540708411e-09
half O 0 2.3239163482458025e-08
the O 0 2.7661059220918105e-08
level O 0 6.770863478777756e-07
of O 0 1.080256097907295e-07
Hp O 0 1.0994324838975444e-05
in O 0 1.0139568757949746e-06
control O 0 7.404432108160108e-05
sera O 0 0.002227429300546646
from O 0 3.198468050413794e-07
the O 0 4.5568032192022656e-07
Hp1 O 0 0.00015712162712588906
phenotype O 0 2.5383771571796387e-05
( O 0 1.0924624405106442e-07
1 O 0 2.4947544829956314e-07
. O 0 3.264731773811036e-08
26 O 0 5.216668910179578e-07
+ O 0 7.335103191508097e-07
/ O 0 1.7610936993150972e-06
- O 0 2.650976057338994e-06
0 O 0 2.150885478613418e-07
. O 0 3.337044418572077e-08
33 O 0 1.0100887948283344e-06
mg O 0 6.88033651385922e-06
/ O 0 3.7526847336266655e-06
ml O 0 1.498393885412952e-05
; O 0 3.951690530357155e-07
n O 0 6.6779252847481985e-06
= O 0 4.4020953282597475e-06
9 O 0 1.2078112376912031e-06
) O 0 1.8079356678413205e-08
, O 0 2.6352012127972557e-08
showing O 0 3.138994770779391e-07
a O 0 1.3756917951468495e-06
gene O 0 1.829997927416116e-05
- O 0 0.00021673450828529894
dosage O 0 0.00027237579342909157
effect O 0 2.7868103643413633e-05
. O 0 5.612929726339644e-06

The O 0 1.0780933052956243e-06
other O 0 3.0896455882611917e-07
allele O 0 1.2006337783532217e-05
( O 0 9.824282187764766e-07
Hp2 O 0 8.854221232468262e-05
) O 0 9.514243259900468e-08
of O 0 2.6776033834607915e-08
individuals O 0 3.185487074119919e-08
with O 0 9.089025638786552e-07
Hp2 O 0 0.0018141978653147817
/ O 0 0.00012439035344868898
Hpdel O 0 0.000396164832636714
was O 0 1.2333091945038177e-05
found O 0 8.135977935808114e-08
to O 0 6.549820241730231e-09
have O 0 3.8086554354777036e-08
, O 0 6.474688518665062e-08
in O 0 1.5704442191122325e-08
all O 0 1.276350580781127e-08
exons O 0 5.74712612433359e-06
, O 0 5.239039637672249e-07
no O 0 4.417957484292856e-07
mutation O 0 4.290568540454842e-06
, O 0 9.373566456361004e-08
by O 0 2.9110214683214508e-08
DNA O 0 1.7587086631465354e-06
sequencing O 0 3.56702298631717e-06
. O 0 5.591627996182069e-06

On O 0 3.605712208809564e-06
the O 0 2.0557214952532377e-07
basis O 0 1.3990502623073553e-07
of O 0 2.7391617862804196e-08
the O 0 1.5469409220258967e-07
present O 0 3.3074653060793935e-07
study O 0 6.453826699726051e-07
, O 0 1.0068978895105829e-07
the O 0 5.739113007052765e-08
mechanism O 0 2.4785199457255658e-06
of O 0 1.197517036644058e-07
anhaptoglobinemia B-Disease 0 0.00015763394185341895
and O 0 6.021792842147988e-07
the O 0 1.5681834497627278e-07
mechanism O 0 1.1820864528999664e-05
of O 0 5.486848522195942e-07
anomalous O 0 0.0003092878614552319
inheritance O 0 8.706902008270845e-05
of O 0 1.4592176285077585e-06
Hp O 0 0.00016203468840103596
phenotypes O 0 0.00012209982378408313
were O 0 1.3679273251909763e-06
well O 0 3.1052563826960977e-06
explained O 0 6.844681774964556e-05
. O 0 1.228955625265371e-05

However O 0 8.084240107564256e-06
, O 0 6.773298082407564e-07
the O 0 3.9079023395061085e-07
mechanism O 0 1.9320743376738392e-05
of O 0 1.5277206557584577e-06
hypohaptoglobinemia B-Disease 0 0.026877261698246002
remains O 0 0.0008431764435954392
unknown O 0 0.0006362966960296035

ATM O 0 0.0026258020661771297
mutations O 0 0.001634008251130581
and O 0 2.2742686269339174e-05
phenotypes O 0 0.0037269422318786383
in O 0 0.0005497427191585302
ataxia B-Disease 1 0.9999986886978149
- I-Disease 1 0.9998307228088379
telangiectasia I-Disease 1 0.9999475479125977
families O 0 6.227113772183657e-06
in O 0 1.552034746055142e-06
the O 0 7.94539914750203e-07
British O 0 1.206440447276691e-05
Isles O 0 2.153475179511588e-05
: O 0 1.920579535408251e-07
expression O 0 2.1138930605957285e-07
of O 0 3.3677874711202094e-08
mutant O 0 5.4381066547648516e-06
ATM O 0 3.2283733162330464e-05
and O 0 8.29492478260363e-07
the O 0 2.8742276754201157e-06
risk O 0 0.00022706242452841252
of O 0 2.451180807838682e-05
leukemia B-Disease 1 0.9999943971633911
, O 1 0.9689335227012634
lymphoma B-Disease 1 1.0
, O 0 0.0028685659635812044
and O 0 0.027436627075076103
breast B-Disease 1 0.999974250793457
cancer I-Disease 1 0.9999219179153442
. O 0 3.3163840271299705e-05

We O 0 6.6726538534567226e-06
report O 0 3.858633306208503e-07
the O 0 7.854497852122222e-08
spectrum O 0 3.731731794687221e-06
of O 0 2.043804983031805e-07
59 O 0 1.6166770365089178e-05
ATM O 0 0.00016631226753816009
mutations O 0 0.00028967991238459945
observed O 0 0.0001037122929119505
in O 0 5.33160382474307e-05
ataxia B-Disease 1 0.9999926090240479
- I-Disease 1 0.9996217489242554
telangiectasia I-Disease 1 0.999936580657959
( O 0 0.00016345737094525248
A B-Disease 1 0.99977046251297
- I-Disease 1 0.9985343217849731
T I-Disease 1 0.9996581077575684
) O 0 1.991243607335491e-06
patients O 0 3.939449470635736e-06
in O 0 8.409497809225286e-08
the O 0 2.1768350677575654e-07
British O 0 2.1425343220471404e-05
Isles O 0 0.0002585891052149236
. O 0 1.4152493349683937e-05

Of O 0 1.433848751730693e-06
51 O 0 2.541118738008663e-05
ATM O 0 0.00024252955336123705
mutations O 0 0.00011604186875047162
identified O 0 5.2213549679436255e-06
in O 0 2.95593395094329e-07
families O 0 3.898186662354419e-08
native O 0 1.9326361666571756e-07
to O 0 2.628544848448655e-08
the O 0 1.966453027080206e-07
British O 0 5.986183168715797e-06
Isles O 0 2.0325891455286182e-05
, O 0 5.044383328822732e-07
11 O 0 4.303799414628884e-07
were O 0 6.941108665614593e-08
founder O 0 3.049167617064086e-06
mutations O 0 5.267247161100386e-06
, O 0 1.325103369254066e-07
and O 0 9.306528880870246e-08
2 O 0 2.999809396442288e-07
of O 0 1.635840440883385e-08
these O 0 7.483615149794787e-08
11 O 0 2.623952241265215e-06
conferred O 0 1.591549334989395e-05
a O 0 5.464443347591441e-06
milder O 0 0.00023117622185964137
clinical O 0 4.689162233262323e-05
phenotype O 0 8.385363798879553e-06
with O 0 1.3871067494619638e-07
respect O 0 5.073644615549711e-07
to O 0 5.46834542092256e-07
both O 0 2.211996979895048e-05
cerebellar B-Disease 1 0.9996721744537354
degeneration I-Disease 1 0.9996564388275146
and O 0 1.1526133675943129e-05
cellular O 0 0.009269200265407562
features O 0 0.00026593601796776056
. O 0 4.2989642679458484e-05

We O 0 5.33085494680563e-06
report O 0 7.566904969280586e-07
, O 0 5.438576877736523e-08
in O 0 3.5208721271828836e-08
two O 0 5.737114747716987e-07
A B-Disease 1 0.9958946704864502
- I-Disease 1 0.8410316109657288
T I-Disease 1 0.9991169571876526
families O 0 2.4484714344907843e-07
, O 0 1.442515440430725e-07
an O 0 9.389742672283319e-08
ATM O 0 4.393711424199864e-05
mutation O 0 2.1938296413281932e-05
( O 0 3.6630490285460837e-07
7271T O 0 2.609077637316659e-05
- O 0 4.0261551475850865e-05
- O 0 3.7264344427967444e-05
> O 0 1.1709329555742443e-05
G O 0 1.15180137072457e-05
) O 0 3.117904157079465e-08
that O 0 1.179042996568569e-08
may O 0 9.56977217470012e-08
be O 0 9.095034059214413e-09
associated O 0 5.01481238757151e-08
with O 0 2.2217722772666093e-08
an O 0 2.0116812038395437e-07
increased O 0 3.2851660307642305e-06
risk O 0 0.00010697433754103258
of O 0 7.937969712656923e-06
breast B-Disease 1 0.9998511075973511
cancer I-Disease 1 0.9994124174118042
in O 0 8.57681413890532e-07
both O 0 9.294907385992701e-07
homozygotes O 0 0.00030787603463977575
and O 0 2.0863813006144483e-06
heterozygotes O 0 5.600132863037288e-05
( O 0 7.815193612259463e-07
relative O 0 7.384892796835629e-06
risk O 0 2.3559085093438625e-05
12 O 0 1.2837149370170664e-06
. O 0 1.3941820498075685e-07
7 O 0 1.6360500012524426e-06
; O 0 7.08618131284311e-07
P O 0 9.191313438350335e-05
= O 0 6.159551048767753e-06
. O 0 1.5826321941858623e-07
0025 O 0 8.415189950028434e-05
) O 0 4.1185938215448914e-08
, O 0 3.293998318554259e-08
although O 0 2.982761415637469e-08
there O 0 1.3477246874060711e-08
is O 0 4.8021369991602114e-08
a O 0 4.796150392394338e-07
less O 0 4.706095296569401e-06
severe O 1 0.9820629358291626
A B-Disease 1 0.9996131062507629
- I-Disease 1 0.9952646493911743
T I-Disease 1 0.9981005787849426
phenotype O 0 2.6429350327816792e-05
in O 0 2.7749368314289313e-07
terms O 0 2.6540521957940655e-07
of O 0 4.2457838134168924e-08
the O 0 8.602634693488653e-07
degree O 0 4.61023228126578e-05
of O 0 2.7984404368908145e-05
cerebellar B-Disease 1 0.999843955039978
degeneration I-Disease 1 0.9999523162841797
. O 0 0.00026300002355128527

This O 0 2.3677964691160014e-06
mutation O 0 2.4238956029876135e-05
( O 0 6.363308102663723e-07
7271T O 0 3.718238076544367e-05
- O 0 4.154797352384776e-05
- O 0 2.9191640351200476e-05
> O 0 9.860355021373834e-06
G O 0 6.1960854509379715e-06
) O 0 1.5362463301471507e-08
also O 0 1.2181462061278125e-08
allows O 0 2.801776144423229e-09
expression O 0 2.7037717842404163e-08
of O 0 8.783706206827446e-09
full O 0 3.268988280069607e-07
- O 0 1.8744473209153512e-06
length O 0 2.2083672490680328e-07
ATM O 0 2.5602028017601697e-06
protein O 0 3.888622472913994e-07
at O 0 1.0842032907021348e-06
a O 0 1.8455330064170994e-07
level O 0 3.9827941122894117e-07
comparable O 0 1.3872339650333743e-06
with O 0 1.79217053641878e-07
that O 0 1.0078066736696201e-07
in O 0 7.408485203086457e-07
unaffected O 0 5.8946683566318825e-05
individuals O 0 4.938232223139494e-07
. O 0 6.214726454345509e-06

In O 0 1.0992279158017482e-06
addition O 0 4.977713956577645e-07
, O 0 1.9580076582315087e-07
we O 0 6.44307718289383e-08
have O 0 4.0921115385117446e-08
studied O 0 2.9537122827605344e-06
18 O 0 6.897884759382578e-06
A B-Disease 1 0.9734704494476318
- I-Disease 1 0.9944461584091187
T I-Disease 1 0.9996726512908936
patients O 0 5.3309024224290624e-05
, O 0 3.2163313790078973e-07
in O 0 8.801906403732573e-08
15 O 0 4.290185984245909e-07
families O 0 6.440250643890977e-08
, O 0 1.1130870234410395e-06
who O 0 1.2467107808333822e-05
developed O 0 0.013240128755569458
leukemia B-Disease 1 0.9999940395355225
, O 1 0.7176117897033691
lymphoma B-Disease 1 1.0
, O 0 0.00011675756104523316
preleukemic O 0 0.01371306087821722
T O 1 0.6352578401565552
- O 0 0.0006880009896121919
cell O 0 0.0011485448339954019
proliferation O 0 0.05882416293025017
, O 0 9.601657802704722e-05
or O 1 0.7989100217819214
Hodgkin B-Disease 1 0.9999996423721313
lymphoma I-Disease 1 1.0
, O 0 2.7134045012644492e-05
mostly O 0 3.3171515951835318e-06
in O 0 8.680979590280913e-06
childhood O 0 0.0029782219789922237
. O 0 2.6846078981179744e-05

A O 0 9.001753824122716e-06
wide O 0 4.01738498112536e-06
variety O 0 1.967994421647745e-06
of O 0 3.3151579259538266e-07
ATM O 0 0.0002233886916656047
mutation O 0 4.131994501221925e-05
types O 0 5.3993030633137096e-06
, O 0 8.106939048957429e-07
including O 0 8.293152973237738e-07
missense O 0 0.00010772835230454803
mutations O 0 5.3207138989819214e-05
and O 0 1.1231434200453805e-06
in O 0 1.2778641576005612e-06
- O 0 3.9660932088736445e-05
frame O 0 3.844056118396111e-05
deletions O 0 2.730870255618356e-05
, O 0 6.478912837337703e-07
were O 0 1.1116406284372715e-07
seen O 0 1.9812139271380147e-06
in O 0 2.5566964723111596e-07
these O 0 3.7742518088634824e-07
patients O 0 7.5278636359144e-05
. O 0 6.944908363948343e-06

We O 0 2.302945176779758e-06
also O 0 1.913785325768913e-07
show O 0 2.41082858565278e-07
that O 0 8.747242041806658e-09
25 O 0 5.30957393607423e-08
% O 0 2.0281303303448794e-09
of O 0 6.7409215986913296e-09
all O 0 3.6710119388772e-07
A B-Disease 1 0.9997087121009827
- I-Disease 1 0.9983184337615967
T I-Disease 1 0.999824583530426
patients O 0 3.4376964322291315e-05
carried O 0 7.225048079817498e-07
in O 0 4.1109112203230325e-07
- O 0 1.1263280612183735e-05
frame O 0 1.6653801139909774e-05
deletions O 0 1.0165052117372397e-05
or O 0 3.09339202431147e-06
missense O 0 0.00016117315681185573
mutations O 0 4.950207949150354e-05
, O 0 1.7937675522716745e-07
many O 0 7.11970971067899e-09
of O 0 9.752783469707538e-09
which O 0 3.1487537910379615e-08
were O 0 7.748329977630419e-08
also O 0 1.323931115848609e-07
associated O 0 9.021058389180325e-08
with O 0 2.2983316583236046e-08
expression O 0 3.06739764255326e-07
of O 0 2.4920334240619013e-08
mutant O 0 7.5351435953052714e-06
ATM O 0 9.401670104125515e-05
protein O 0 3.2085063139675185e-05
. O 0 6.858259894215735e-06

The O 0 1.4458085388469044e-05
DMPK O 0 0.0019379727309569716
gene O 0 0.00016130291623994708
of O 0 1.8411594282952137e-05
severely O 1 0.9979197382926941
affected O 1 0.9303411245346069
myotonic B-Disease 1 0.9999978542327881
dystrophy I-Disease 1 0.9999995231628418
patients O 1 0.865473210811615
is O 0 1.1458709195721895e-05
hypermethylated O 0 0.000989834195934236
proximal O 0 0.0004853181599173695
to O 0 3.247910456138925e-07
the O 0 6.908286422913079e-07
largely O 0 4.394544703245629e-06
expanded O 0 2.1747573555330746e-05
CTG O 0 0.0028834242839366198
repeat O 0 0.0005220757448114455
. O 0 2.0170355128357187e-05

Using O 0 3.2720031413191464e-06
methylation O 0 2.2358948626788333e-05
- O 0 3.62755345122423e-05
sensitive O 0 3.2463634852319956e-05
restriction O 0 1.6361140069420799e-06
enzymes O 0 5.4419920161308255e-06
, O 0 6.807957788623753e-07
we O 0 1.6129882851600996e-07
characterized O 0 2.951014721475076e-06
the O 0 1.0316353638017972e-07
methylation O 0 2.0351938019302906e-06
pattern O 0 5.730028988182312e-06
on O 0 7.142644449231739e-07
the O 0 3.7040510392216675e-07
5 O 0 1.6070108586063725e-06
side O 0 1.617577140677895e-06
of O 0 9.691945734857654e-08
the O 0 9.181924269796582e-07
CTG O 0 0.0002639168524183333
repeat O 0 1.436291859135963e-05
in O 0 2.9046884719718946e-07
the O 0 1.2935656457102596e-07
DMPK O 0 4.7277993871830404e-05
gene O 0 1.0137461003978387e-06
of O 0 5.4895600953841495e-08
normal O 0 2.1737409952038433e-06
individuals O 0 3.103960111161541e-08
and O 0 8.927478347686701e-07
of O 0 1.8407887409921386e-06
patients O 0 0.0006058201543055475
affected O 0 0.00013472427963279188
with O 0 0.004458608105778694
myotonic B-Disease 1 0.9999957084655762
dystrophy I-Disease 1 0.9999988079071045
, O 0 1.3105443031236064e-05
showing O 0 6.961990948184393e-06
expansions O 0 1.7199428839376196e-05
of O 0 2.785122887871694e-07
the O 0 2.2084839201852446e-06
repetitive O 0 0.009919506497681141
sequence O 0 3.7127250834601e-05
. O 0 1.6410460375482216e-05

The O 0 1.1548814882189617e-06
gene O 0 4.633717708202312e-06
segment O 0 7.645136975042988e-06
analyzed O 0 2.5663211999926716e-06
corresponds O 0 1.4635865852596908e-07
to O 0 2.47055176316735e-08
the O 0 2.465875468260492e-07
genomic O 0 1.8286340491613373e-05
SacI O 0 0.000500019290484488
- O 0 5.611883170786314e-05
HindIII O 0 5.806324406876229e-05
fragment O 0 6.408590252249269e-06
carrying O 0 8.809462315184646e-07
exons O 0 1.545237682876177e-05
11 O 0 1.2914304534206167e-05
- O 0 6.38966157566756e-05
15 O 0 7.1474605647381395e-06
. O 0 3.2182690574700246e-06

There O 0 1.7980937627726234e-06
is O 0 5.193338665776537e-07
constitutive O 0 1.1904785424121656e-05
methylation O 0 6.098314315750031e-06
in O 0 6.638883860432543e-07
intron O 0 0.00010633005877025425
12 O 0 3.5405200833338313e-06
at O 0 1.7468572650614078e-06
restriction O 0 1.5030546762773156e-07
sites O 0 2.9475313567672856e-07
of O 0 8.85020483565313e-08
SacII O 0 0.00013262798893265426
and O 0 3.2453419862576993e-06
HhaI O 0 0.00023864430841058493
, O 0 1.1979184364463435e-06
localized O 0 2.3586715542478487e-05
1 O 0 1.6473005644002114e-06
, O 0 2.0622051977170486e-07
159 O 0 1.5737898593215505e-06
- O 0 7.083288437570445e-06
1 O 0 9.765144568518735e-07
, O 0 1.2953928774095402e-07
232 O 0 6.358873179124203e-07
bp O 0 1.6605181372142397e-05
upstream O 0 1.1768847798521165e-06
of O 0 5.110239698069563e-08
the O 0 8.690685717738234e-07
CTG O 0 0.000428149476647377
repeat O 0 2.2210824681678787e-05
, O 0 2.736943258696556e-07
whereas O 0 3.439338058797148e-07
most O 0 1.743941311360686e-07
, O 0 1.1267454880226069e-07
if O 0 3.210538679354613e-08
not O 0 8.637785597898073e-09
all O 0 6.194648793922397e-09
, O 0 5.7106134931927954e-08
of O 0 6.28858920492803e-09
the O 0 2.615681538031822e-08
other O 0 1.652965231357939e-08
sites O 0 3.889304878157418e-07
of O 0 9.282243240704702e-08
SacII O 0 0.0001920360664371401
, O 0 1.3117944490659283e-06
HhaI O 0 0.00011852366878883913
, O 0 8.226567160818377e-07
and O 0 5.919123395869974e-07
HpaII O 0 8.992056245915592e-05
in O 0 4.25111579716031e-07
this O 0 1.0210779066710529e-07
region O 0 2.356000095460331e-06
are O 0 9.198561912171499e-08
unmethylated O 0 5.3231804486131296e-05
, O 0 4.17140569197727e-07
in O 0 8.365839221369242e-08
normal O 0 9.342185194327612e-07
individuals O 0 2.323420034144874e-08
and O 0 1.1864179327858437e-07
most O 0 1.1614262263037745e-07
of O 0 1.4439758899698063e-07
the O 0 6.324633432086557e-06
patients O 0 0.0003186231479048729
. O 0 1.034387150866678e-05

In O 0 6.586359404536779e-07
a O 0 3.556123147063772e-07
number O 0 4.853824719930344e-08
of O 0 1.1748343808903883e-07
young O 0 1.1149750207550824e-05
and O 0 2.6483368856133893e-05
severely O 1 0.9901757836341858
affected O 0 0.00011725004151230678
patients O 0 7.892288704169914e-05
, O 0 3.0074949108893634e-07
however O 0 1.0487629253930209e-07
, O 0 4.357766769658156e-08
complete O 0 1.3463969139593246e-07
methylation O 0 4.894077392236795e-07
of O 0 6.8898486915713875e-09
these O 0 5.4177533570509695e-09
restriction O 0 2.900314122200598e-08
sites O 0 2.4945282461885654e-07
was O 0 1.4621248283219757e-06
found O 0 8.136785112355938e-08
in O 0 3.70831294560503e-08
the O 0 1.5128192387692252e-07
mutated O 0 4.087216075276956e-05
allele O 0 7.288782944669947e-05
. O 0 1.8609018297865987e-05

In O 0 9.927742894433322e-07
most O 0 1.326018548297725e-07
of O 0 6.142845876411229e-08
these O 0 1.9433724673945107e-07
patients O 0 2.098685763485264e-05
, O 0 4.983518238077522e-07
the O 0 6.55203450605768e-07
onset O 0 0.005193253979086876
of O 0 1.4581381719835917e-06
the O 0 0.0004670165362767875
disease O 1 0.9999701976776123
was O 1 0.9969508647918701
congenital O 1 0.9999977350234985
. O 0 0.00017025541455950588

Preliminary O 0 6.281637615757063e-05
in O 0 1.2323005648795515e-05
vivo O 0 0.0005577346892096102
footprinting O 0 0.0022711169440299273
data O 0 1.734165948619193e-06
gave O 0 7.591763164782606e-07
evidence O 0 6.726436652115808e-08
for O 0 1.920152392642649e-08
protein O 0 5.383227517086198e-07
- O 0 3.994771304860478e-06
DNA O 0 8.43145073758933e-07
contact O 0 1.2424821989043267e-06
in O 0 8.845530174994565e-08
normal O 0 9.334036690233916e-07
genes O 0 9.381308245792752e-07
at O 0 3.2468342396896333e-06
an O 0 2.560656753303192e-07
Sp1 O 0 4.272155638318509e-05
consensus O 0 5.235328330854827e-07
binding O 0 2.2920621631783433e-06
site O 0 2.9118323254806455e-06
upstream O 0 1.4291512115960359e-06
of O 0 3.1416988122145995e-08
the O 0 2.884954994897271e-07
CTG O 0 0.00015507267380598933
repeat O 0 1.0521211152081378e-05
and O 0 2.347420888781926e-07
for O 0 1.587284081949747e-08
a O 0 2.5781426415960595e-07
significant O 0 2.9285257596711745e-07
reduction O 0 1.0526202913752059e-06
of O 0 8.177186039404205e-09
this O 0 5.537521996501482e-09
interaction O 0 1.0661058524874534e-07
in O 0 2.2278453570834245e-07
cells O 0 1.0218917623205925e-06
with O 0 1.8868192341869872e-07
a O 0 4.277751486370107e-06
hypermethylated O 0 0.0004356887366157025
DMPK O 0 0.0008856875938363373
gene O 0 2.0754547222168185e-05
. O 0 1.8710894664764055e-06
. O 0 4.912397798761958e-06

The O 0 7.68805475672707e-05
hemochromatosis B-Disease 1 0.9992235898971558
gene O 0 3.8348360249074176e-05
product O 0 2.1026628473919118e-06
complexes O 0 3.6559681575454306e-06
with O 0 7.844091953757015e-08
the O 0 2.7636809818432084e-07
transferrin O 0 6.272682367125526e-05
receptor O 0 4.392701157485135e-06
and O 0 7.799379204698198e-07
lowers O 0 1.3675250556843821e-05
its O 0 2.7257884838149948e-08
affinity O 0 5.001644467483857e-07
for O 0 7.588079142806237e-08
ligand O 0 1.4013061445439234e-05
binding O 0 5.556930773309432e-05
. O 0 7.734354767308105e-06

We O 0 7.77928016759688e-06
recently O 0 7.602826372021809e-05
reported O 0 2.750885414570803e-06
the O 0 4.6325766334121e-08
positional O 0 7.655965418962296e-06
cloning O 0 4.887342129222816e-06
of O 0 6.462695978370903e-08
a O 0 1.673019824011135e-06
candidate O 0 5.757834969699616e-06
gene O 0 4.435667869984172e-05
for O 0 9.313083137385547e-05
hereditary B-Disease 1 0.9999985694885254
hemochromatosis I-Disease 1 0.9999998807907104
called O 1 0.937169075012207
HFE O 1 0.9769954681396484
. O 0 0.00018056866247206926

The O 0 5.440661539068969e-07
gene O 0 2.0994407350372057e-06
product O 0 7.517132303291874e-07
, O 0 1.4601319264784252e-07
a O 0 1.5351500337601465e-07
member O 0 2.8697147058664996e-07
of O 0 2.08569748139098e-08
the O 0 6.284868163675128e-07
major O 0 0.00011044191342080012
histocompatibility O 0 0.33707326650619507
complex O 0 0.0004926982801407576
class O 0 5.595670154434629e-05
I O 0 0.001968014519661665
- O 0 3.846131221507676e-05
like O 0 2.481750925653614e-06
family O 0 2.9343623282329645e-06
, O 0 3.7740031189059664e-07
was O 0 1.0113457165061845e-06
found O 0 4.468082792641326e-08
to O 0 6.378002126439242e-09
have O 0 4.012940379993779e-08
a O 0 6.018944986863062e-07
mutation O 0 9.83814061328303e-06
, O 0 2.303731434949441e-06
Cys O 0 0.000935073068831116
- O 0 0.00012244423851370811
282 O 0 3.3559776056790724e-05
- O 0 0.00016704032896086574
- O 0 0.0001453084114473313
> O 0 2.9874649044359103e-05
Tyr O 0 0.0001495714532211423
( O 0 2.646782775173051e-07
C282Y O 0 6.4345258579123765e-06
) O 0 3.906783518914381e-08
, O 0 7.808207413972923e-08
in O 0 6.238891359089394e-08
85 O 0 5.30643035290268e-07
% O 0 2.3786816072401962e-08
of O 0 1.698693949947483e-07
patient O 0 0.00011439825902925804
chromosomes O 0 8.384871034650132e-05
. O 0 9.460160072194412e-06

This O 0 1.4859984958093264e-06
mutation O 0 5.0089292926713824e-05
eliminates O 0 1.947158671100624e-05
the O 0 1.7870557655896846e-07
ability O 0 1.2719660844595637e-06
of O 0 2.4326470793312183e-07
HFE O 0 0.0004867265233770013
to O 0 4.2597923766152235e-07
associate O 0 9.731408681545872e-06
with O 0 3.74373030354036e-06
beta2 O 0 0.0119074247777462
- O 0 0.0013184122508391738
microglobulin O 0 0.0004872204444836825
( O 0 8.568792964069871e-07
beta2m O 0 4.322288805269636e-05
) O 0 1.0000287176126221e-07
and O 0 3.8134098190312216e-07
prevents O 0 6.992878752498655e-06
cell O 0 0.0004313867539167404
- O 0 0.0002236269210698083
surface O 0 0.00014548294711858034
expression O 0 4.3317966628819704e-05
. O 0 9.571655027684756e-06

A O 0 1.5514100596192293e-05
second O 0 4.512542545853648e-06
mutation O 0 8.554417945561e-06
that O 0 8.54836628150224e-08
has O 0 3.782463693369209e-07
no O 0 1.979114756522904e-07
effect O 0 1.2805834330720245e-06
on O 0 4.815413831238402e-06
beta2m O 0 0.0006588358664885163
association O 0 7.09798814568785e-06
, O 0 1.011056383504183e-06
H63D O 0 0.0002052576601272449
, O 0 4.3379597514103807e-07
was O 0 2.453122988299583e-06
found O 0 1.7440960675685346e-07
in O 0 3.8582133043973954e-08
eight O 0 1.4033035711236153e-07
out O 0 7.700800352949955e-08
of O 0 6.94305484216784e-08
nine O 0 2.7438372853794135e-06
patients O 0 5.609253548755078e-06
heterozygous O 0 3.11069015879184e-07
for O 0 3.840650819597613e-08
the O 0 8.555475119464973e-07
C282Y O 0 0.0002413291804259643
mutant O 0 0.0002480401308275759
. O 0 1.817319935071282e-05

In O 0 2.1823050246894127e-06
this O 0 2.0152835134013003e-07
report O 0 4.4248727704143676e-07
, O 0 1.344480011766791e-07
we O 0 5.151547810555712e-08
demonstrate O 0 1.4455589791850798e-07
in O 0 3.000338608671882e-07
cultured O 0 3.153725992888212e-05
293 O 0 2.0986117306165397e-05
cells O 0 4.28694074798841e-05
overexpressing O 0 0.00045758215128444135
wild O 0 2.6940380848827772e-05
- O 0 0.00010564684635028243
type O 0 4.14993119193241e-05
or O 0 1.977549800358247e-06
mutant O 0 1.045218414219562e-05
HFE O 0 0.0001174419594462961
proteins O 0 2.859448215986049e-07
that O 0 2.888268468836941e-08
both O 0 9.257543354124209e-08
the O 0 4.526329178133892e-07
wild O 0 1.2498870091803838e-05
- O 0 0.0001382691116305068
type O 0 6.794069486204535e-05
and O 0 4.074443495483138e-06
H63D O 0 0.001274377340450883
HFE O 0 0.0009606269304640591
proteins O 0 2.3726336166873807e-06
form O 0 2.0563129510264844e-06
stable O 0 1.7837617633631453e-05
complexes O 0 4.5581305130326655e-06
with O 0 2.1108350267695641e-07
the O 0 1.045706312652328e-06
transferrin O 0 0.00014148189802654088
receptor O 0 2.3339867766480893e-05
( O 0 1.0165448429688695e-06
TfR O 0 0.0001440628693671897
) O 0 6.067836011425243e-07
. O 0 2.1666689917765325e-06

The O 0 2.6746009098133072e-05
C282Y O 0 0.001283376244828105
mutation O 0 0.00013177304936107248
nearly O 0 5.111378413857892e-06
completely O 0 1.2316002539591864e-05
prevents O 0 4.944721240462968e-06
the O 0 4.292948574402544e-07
association O 0 1.1376750990166329e-06
of O 0 4.783926144114048e-08
the O 0 3.8273347513495537e-07
mutant O 0 2.0347732061054558e-05
HFE O 0 0.0005070443148724735
protein O 0 2.87023112832685e-06
with O 0 9.247277148460853e-07
the O 0 4.731854915007716e-06
TfR O 0 0.0026423491071909666
. O 0 2.1650064809364267e-05

Studies O 0 5.846042313351063e-06
on O 0 4.979312507202849e-06
cell O 0 0.00015286594862118363
- O 0 6.72531605232507e-05
associated O 0 4.360650109447306e-06
transferrin O 0 6.187087274156511e-05
at O 0 8.530173545295838e-06
37 O 0 1.8058767636830453e-06
degrees O 0 3.36989387506037e-06
C O 0 1.2257567505002953e-05
suggest O 0 3.993904442722851e-07
that O 0 2.6897346572241077e-08
the O 0 2.507898386738816e-07
overexpressed O 0 7.243038999149576e-05
wild O 0 1.3213545571488794e-05
- O 0 4.805239223060198e-05
type O 0 2.6475690901861526e-05
HFE O 0 0.00034518653410486877
protein O 0 2.180397359552444e-06
decreases O 0 1.739599042593909e-06
the O 0 3.6884767240508154e-08
affinity O 0 8.403306424042967e-07
of O 0 6.920328132764553e-08
the O 0 1.0373510122008156e-06
TfR O 0 0.00026290121604688466
for O 0 6.570912773895543e-07
transferrin O 0 0.0008900061948224902
. O 0 1.3601816135633271e-05

The O 0 6.540269168908708e-06
overexpressed O 0 0.0008450662717223167
H63D O 0 0.0003465544432401657
protein O 0 2.4644559744047e-06
does O 0 2.776183691821643e-07
not O 0 2.21655778176455e-08
have O 0 9.221325036889993e-09
this O 0 7.836641557901203e-09
effect O 0 2.403677399342996e-07
, O 0 2.2450953096608828e-08
providing O 0 1.765677737353144e-08
the O 0 1.457863429976669e-08
first O 0 1.4795255687261033e-08
direct O 0 6.485488146523721e-09
evidence O 0 2.8585587230622878e-08
for O 0 9.283513513480557e-09
a O 0 3.376586903414136e-07
functional O 0 2.728548452068935e-06
consequence O 0 9.695809239929076e-06
of O 0 1.948494485759511e-07
the O 0 7.915752576082014e-06
H63D O 0 0.02296239696443081
mutation O 0 0.0008872720645740628
. O 0 1.8110740711563267e-05

Addition O 0 1.8305719322597724e-06
of O 0 4.571903673422639e-07
soluble O 0 0.0011346893152222037
wild O 0 0.00019226268341299146
- O 0 0.0015148374950513244
type O 0 0.001072823302820325
HFE O 0 0.028966644778847694
/ O 0 0.0004249699122738093
beta2m O 0 0.0005628606304526329
heterodimers O 0 0.00034634373150765896
to O 0 2.738326827511628e-07
cultured O 0 9.988570127461571e-06
cells O 0 8.825137228996027e-06
also O 0 6.982270406297175e-07
decreased O 0 3.0671360491396626e-06
the O 0 7.258834955337079e-08
apparent O 0 5.465350113809109e-06
affinity O 0 1.2616101230378263e-06
of O 0 1.0484308887726002e-07
the O 0 4.809919573744992e-07
TfR O 0 5.0513135647634044e-05
for O 0 1.2645473113082062e-08
its O 0 2.9838652437774726e-08
ligand O 0 1.389882413604937e-06
under O 0 6.76866875437554e-07
steady O 0 1.981956302188337e-05
- O 0 5.984356903354637e-05
state O 0 9.669986411608988e-07
conditions O 0 6.171364020701731e-06
, O 0 1.0945836947939824e-07
both O 0 5.0875890167390025e-08
in O 0 1.6203672714709683e-07
293 O 0 3.2611151254968718e-06
cells O 0 4.24157678935444e-06
and O 0 1.46497927744349e-06
in O 0 4.4217613321961835e-06
HeLa O 0 0.0011519229738041759
cells O 0 0.00010823930642800406
. O 0 1.2100192179786973e-05

Furthermore O 0 2.534081431804225e-05
, O 0 1.1500334267111612e-06
at O 0 2.9918689961050404e-06
4 O 0 7.133808139769826e-07
degrees O 0 3.499673084661481e-06
C O 0 1.394893024553312e-05
, O 0 1.7948883623830625e-07
the O 0 2.2212388728348742e-07
added O 0 3.0731353035662323e-06
soluble O 0 3.244110484956764e-05
complex O 0 2.19718804146396e-05
of O 0 2.1901214495301247e-06
HFE O 0 0.00824547465890646
/ O 0 0.0002923060383182019
beta2m O 0 0.0002513511572033167
inhibited O 0 1.0351578566769604e-05
binding O 0 4.192393589619314e-06
of O 0 1.2222194811783993e-07
transferrin O 0 0.00010924574598902836
to O 0 7.597977287332469e-07
HeLa O 0 0.0003975883300881833
cell O 0 0.00012430877541191876
TfR O 0 0.0001353278785245493
in O 0 5.692886588803958e-07
a O 0 2.3813383904780494e-06
concentration O 0 0.00020842191588599235
- O 0 0.00011065907165175304
dependent O 0 1.2149821486673318e-05
manner O 0 8.577123662689701e-05
. O 0 1.822703779907897e-05

Scatchard O 0 0.0003464649198576808
plots O 0 4.299276497476967e-06
of O 0 1.224274939204406e-07
these O 0 3.706015050397582e-08
data O 0 3.6020858829033386e-07
indicate O 0 5.878798106095928e-07
that O 0 3.510725932187597e-08
the O 0 1.2486073330819636e-07
added O 0 2.8389840736053884e-06
heterodimer O 0 8.717369200894609e-05
substantially O 0 1.1577559234865475e-05
reduced O 0 1.0843781410585507e-06
the O 0 1.0892125601458247e-07
affinity O 0 1.71054637121415e-06
of O 0 4.825348014492192e-07
TfR O 0 0.00036793239996768534
for O 0 7.739799343653431e-07
transferrin O 0 0.001039318391121924
. O 0 1.4870339327899273e-05

These O 0 4.1937141759262886e-07
results O 0 1.5822730574654997e-06
establish O 0 4.799001089850208e-07
a O 0 5.820691058033844e-07
molecular O 0 1.810937828850001e-05
link O 0 1.4533689864038024e-05
between O 0 1.5589296253892826e-06
HFE O 0 0.0006657942431047559
and O 0 4.5167777784627106e-07
a O 0 3.474829100014176e-07
key O 0 1.660073280618235e-06
protein O 0 4.401266835429851e-07
involved O 0 3.130877814783162e-07
in O 0 2.702555548239616e-07
iron O 0 0.0018819511169567704
transport O 0 3.2710937375668436e-05
, O 0 9.044694024851196e-07
the O 0 3.8231542021094356e-07
TfR O 0 0.00014635814295616
, O 0 4.4652588826465944e-07
and O 0 2.538917840411159e-07
raise O 0 4.217675382278685e-07
the O 0 1.1407210820379987e-07
possibility O 0 1.2039713510603178e-06
that O 0 3.42221895266448e-08
alterations O 0 5.06058631799533e-06
in O 0 1.204758888206925e-07
this O 0 3.4679917604307775e-08
regulatory O 0 4.0256154534290545e-06
mechanism O 0 7.38400558475405e-06
may O 0 1.0035194009105908e-06
play O 0 1.7659142770298786e-07
a O 0 2.339518232474802e-07
role O 0 5.611162237073586e-07
in O 0 3.0523719374286884e-07
the O 0 2.843408992703189e-06
pathogenesis O 0 0.06568500399589539
of O 0 0.00025604816619306803
hereditary B-Disease 1 0.9999996423721313
hemochromatosis I-Disease 1 1.0
. O 0 0.0007284386083483696
. O 0 4.204240030958317e-05

Genomic O 0 0.00016544945538043976
organization O 0 8.145718311425298e-06
of O 0 2.2070199179324845e-07
the O 0 1.6695324802640243e-06
UBE3A O 0 0.0032437348272651434
/ O 0 0.0002804357500281185
E6 O 0 0.0023916352074593306
- O 0 0.000378463591914624
AP O 0 8.083871944108978e-05
gene O 0 4.590826847561402e-06
and O 0 1.6458999425594811e-06
related O 0 8.637607606942765e-06
pseudogenes O 0 0.00034181377850472927
. O 0 2.2426154828281142e-05

The O 0 3.1745503292768262e-06
UBE3A O 0 0.0007294844835996628
gene O 0 5.665698154189158e-06
encodes O 0 8.885188549356826e-07
the O 0 6.705159876219113e-07
E6 O 0 0.0005209699738770723
- O 0 0.00010751479567261413
AP O 0 4.984503539162688e-05
ubiquitin O 0 6.090241640777094e-06
- O 0 4.357735633675475e-06
protein O 0 4.663761501433328e-07
ligase O 0 2.1392322651081486e-06
and O 0 2.7627638132798893e-07
has O 0 3.20070768111691e-07
recently O 0 2.2498420548799913e-06
been O 0 1.0003167716376993e-07
shown O 0 5.0922391636731845e-08
to O 0 2.2273050959142893e-08
be O 0 5.614876386061951e-07
mutated O 0 0.00034406044869683683
in O 0 0.0010025922674685717
Angelman B-Disease 1 0.999996542930603
syndrome I-Disease 1 1.0
patients O 1 0.7156573534011841
who O 0 3.513146657496691e-05
lack O 0 2.659647725522518e-05
15q11 O 0 0.0015955223934724927
- O 0 0.0009129538666456938
q13 O 0 0.00020298463641665876
deletions O 0 7.160504173953086e-05
or O 0 1.5047634406073485e-05
chromosome O 0 0.000908364076167345
15 O 0 3.4256077924510464e-05
paternal O 0 0.0011424691183492541
uniparental B-Disease 1 0.9449761509895325
disomy I-Disease 1 0.6987075805664062
. O 0 0.0001178710808744654

Previous O 0 1.2838831025874242e-05
UBE3A O 0 0.0003723986737895757
cDNA O 0 1.7619840946281329e-06
analysis O 0 9.907058711178252e-07
has O 0 3.2227731594502984e-07
shown O 0 1.8367224186022213e-07
a O 0 5.311554218678793e-07
coding O 0 2.6386212994111702e-05
region O 0 6.055902758816956e-06
of O 0 1.203492274726159e-07
approximately O 0 7.519613518525148e-07
2 O 0 9.891463378153276e-06
. O 0 6.582700734725222e-06

6 O 0 1.946534939634148e-05
kb O 0 1.787269502528943e-05
and O 0 6.074477028050751e-07
a O 0 4.1062703530769795e-06
3 O 0 2.380998012085911e-05
- O 0 0.00020125920127611607
untranslated O 0 0.0007532522431574762
region O 0 2.5275481675635092e-05
( O 0 4.6868575509506627e-07
UTR O 0 2.8199630833114497e-05
) O 0 8.266844275794938e-08
of O 0 6.946737585167284e-08
< O 0 1.0342776477045845e-05
50 O 0 1.6520928056706907e-06
bp O 0 3.711666431627236e-05
, O 0 1.8213290786661673e-07
whereas O 0 2.6176687129009224e-07
Northern O 0 3.2526310178582207e-07
analysis O 0 3.0020160579624644e-07
has O 0 2.219614856358021e-07
indicated O 0 1.2239667057656334e-07
mRNA O 0 4.1488224411523333e-08
sizes O 0 1.1588256256800378e-06
of O 0 1.6247308565198182e-07
5 O 0 4.801642717211507e-06
- O 0 4.5029646571492776e-05
8 O 0 9.760891771293245e-06
kb O 0 8.353673911187798e-05
. O 0 8.680905011715367e-06

We O 0 2.2316951344691915e-06
have O 0 5.214907972117544e-08
analyzed O 0 2.3388446379613015e-07
additional O 0 9.271445833292091e-09
cDNA O 0 1.5301088751584757e-07
clones O 0 1.7558194258526783e-06
and O 0 4.301324807443052e-08
provide O 0 1.5675922782065754e-08
evidence O 0 3.307042106825975e-08
for O 0 5.8704485716987165e-09
an O 0 1.8530737833089006e-08
additional O 0 1.1593126458819825e-07
0 O 0 4.577161689667264e-06
. O 0 2.897447757277405e-06

5 O 0 9.780534128367435e-06
kb O 0 1.5377025192719884e-05
of O 0 3.548145457443752e-07
5 O 0 5.587619398284005e-06
- O 0 1.9247972886660136e-05
UTR O 0 4.0554448787588626e-05
and O 0 6.885620678076521e-07
> O 0 2.668114120751852e-06
2 O 0 8.557319688407006e-07
kb O 0 6.5033295868488494e-06
of O 0 5.50739912341669e-07
3 O 0 3.070781531278044e-05
- O 0 0.00046895278501324356
UTR O 0 0.0017377380281686783
. O 0 2.60603610513499e-05

We O 0 2.1459632080222946e-06
have O 0 6.179156741836778e-08
established O 0 2.0864003147380572e-07
the O 0 1.3275914056976035e-07
genomic O 0 2.762484200502513e-06
organization O 0 1.3734802450926509e-06
of O 0 7.634709930925965e-08
UBE3A O 0 0.0002789594582282007
and O 0 4.6397124719987914e-07
the O 0 1.6525309831649793e-07
sequence O 0 1.215843326463073e-06
of O 0 1.575270403009199e-06
intron O 0 0.002664626808837056
- O 0 0.0019581601954996586
exon O 0 0.0009737538639456034
borders O 0 0.0001634787186048925
. O 0 2.0122379282838665e-05

We O 0 5.831097041664179e-06
have O 0 4.096442864920391e-07
also O 0 1.8667606127564795e-07
mapped O 0 1.6767176020948682e-06
two O 0 8.003717510973729e-08
highly O 0 1.7619016716707847e-06
homologous O 0 1.0282274160999805e-05
processed O 0 1.2125258763262536e-05
pseudogenes O 0 0.00013492611469700933
, O 0 4.221472408971749e-06
UBE3AP1 O 0 0.0004647487949114293
and O 0 2.120848421327537e-06
UBE3AP2 O 0 0.0002685862418729812
, O 0 1.9720343402696017e-07
to O 0 2.0876875339581602e-08
chromosomes O 0 5.90373304021341e-07
2 O 0 4.823958192901046e-07
and O 0 1.8367433085586526e-07
21 O 0 1.2529771993285976e-06
, O 0 1.6583786077717377e-07
respectively O 0 1.2482388456191984e-06
, O 0 1.876796176247808e-07
and O 0 1.1506330821475785e-07
determined O 0 4.5284403427103825e-07
their O 0 9.728968564104434e-08
genomic O 0 1.833458554756362e-05
organization O 0 1.0515453141124453e-05
. O 0 3.998388365289429e-06

These O 0 6.367004630192241e-07
results O 0 2.661722191987792e-06
will O 0 5.175341755148111e-08
form O 0 7.214114106091074e-08
the O 0 2.4043394830641773e-08
basis O 0 2.3507000790345955e-08
for O 0 1.2597062060137887e-08
studies O 0 1.4684296445466316e-07
of O 0 2.9775090837347307e-08
mutation O 0 8.620121661806479e-06
and O 0 1.2123800843255594e-06
imprinting O 0 0.0003688808355946094
of O 0 5.808568857901264e-06
UBE3A O 0 0.05751599743962288
. O 0 8.661188621772453e-05

Mutation O 0 0.0007175311329774559
spectrum O 0 0.0003121158224530518
and O 0 1.5055155017762445e-05
genotype O 0 0.0011907224543392658
- O 0 0.0037821487057954073
phenotype O 0 0.0007079066708683968
analyses O 0 8.823852112982422e-05
in O 0 6.208772538229823e-05
Cowden B-Disease 1 0.9940656423568726
disease I-Disease 1 0.9996801614761353
and O 0 0.0007585782441310585
Bannayan B-Disease 1 0.9987658262252808
- I-Disease 1 0.9998533725738525
Zonana I-Disease 1 0.9994480013847351
syndrome I-Disease 1 0.9999953508377075
, O 0 2.9527058359235525e-05
two O 0 3.826759348157793e-05
hamartoma B-Disease 1 0.9921984076499939
syndromes I-Disease 1 0.9878312945365906
with O 0 5.995655374135822e-05
germline O 0 0.08602266013622284
PTEN O 0 0.43821248412132263
mutation O 0 0.006021006964147091
. O 0 4.64943477709312e-05

The O 0 0.0003652848245110363
tumour B-Disease 1 0.9997175335884094
suppressor O 0 0.0015239357016980648
gene O 0 0.00016878756287042052
PTEN O 0 0.0026376431342214346
, O 0 5.403771297096682e-07
which O 0 3.938544423931489e-08
maps O 0 7.550757459284796e-07
to O 0 3.2479846368005383e-07
10q23 O 0 0.0002133404923370108
. O 0 1.2115815479774028e-05

3 O 0 3.18216757477785e-06
and O 0 7.286647729642937e-08
encodes O 0 8.242880511488693e-08
a O 0 3.0413823992603284e-07
403 O 0 3.760114566375705e-07
amino O 0 3.068082037316344e-07
acid O 0 2.8062411274731858e-06
dual O 0 2.5327681214548647e-06
specificity O 0 4.9496702558826655e-06
phosphatase O 0 0.0007554664625786245
( O 0 7.900276273176132e-07
protein O 0 3.4688832784013357e-06
tyrosine O 0 2.7463313017506152e-05
phosphatase O 0 0.0007856864831410348
; O 0 3.8033925875424757e-07
PTPase O 0 3.168328112224117e-05
) O 0 1.0534903793768535e-07
, O 0 1.2970245677479397e-07
was O 0 1.2342836726020323e-06
shown O 0 2.3498175494296447e-07
recently O 0 1.4096065115154488e-06
to O 0 9.56268841889596e-09
play O 0 1.7786564399102645e-07
a O 0 3.686757850118738e-07
broad O 0 1.8787710587275797e-06
role O 0 4.754516794491792e-06
in O 0 4.069170245202258e-06
human O 0 0.0001701517030596733
malignancy B-Disease 1 0.9952002763748169
. O 0 3.181475040037185e-05

Somatic O 0 0.0018306142883375287
PTEN O 0 0.010901741683483124
deletions O 0 0.0001792069524526596
and O 0 2.127971811205498e-06
mutations O 0 1.9967483240179718e-05
were O 0 2.7808815161733946e-07
observed O 0 2.3609957224834943e-06
in O 0 1.1363034673195216e-06
sporadic B-Disease 0 0.0021281526423990726
breast I-Disease 1 0.9992226362228394
, I-Disease 0 0.0003569835389498621
brain I-Disease 1 0.9998530149459839
, I-Disease 0 0.0012368112802505493
prostate I-Disease 1 0.9999556541442871
and I-Disease 0 0.003842109814286232
kidney I-Disease 1 0.9999736547470093
cancer I-Disease 1 0.9996107220649719
cell O 0 0.0004172155458945781
lines O 0 8.605766925029457e-05
and O 0 6.177578484312107e-07
in O 0 2.2578564085051767e-07
several O 0 6.77733055454155e-07
primary O 0 0.0003612262080423534
tumours B-Disease 1 0.9999802112579346
such O 0 5.319040428730659e-05
as O 0 0.43595945835113525
endometrial B-Disease 1 0.9999555349349976
carcinomas I-Disease 1 0.9999997615814209
, O 1 0.999866247177124
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9997828602790833
thyroid B-Disease 1 0.9999998807907104
tumours I-Disease 1 0.9999992847442627
. O 0 0.000689677253831178

In O 0 1.7172166053569526e-06
addition O 0 1.7445348703404306e-06
, O 0 1.5940079265419627e-06
PTEN O 0 0.00030321843223646283
was O 0 7.71164741308894e-06
identified O 0 4.2033761360471544e-07
as O 0 1.3968890755222674e-07
the O 0 3.6153357996226987e-07
susceptibility O 0 1.1294687283225358e-05
gene O 0 3.962051778216846e-06
for O 0 9.870740313999704e-07
two O 0 7.783703040331602e-05
hamartoma B-Disease 1 0.9989390969276428
syndromes I-Disease 1 0.9997537732124329
Cowden B-Disease 1 0.9997108578681946
disease I-Disease 1 0.9999397993087769
( O 0 3.789298034462263e-06
CD B-Disease 0 0.00018227707187179476
; O 0 5.248954039416276e-06
MIM O 0 0.0005270928959362209
158350 O 0 0.00013873544230591506
) O 0 3.833157222743466e-07
and O 0 2.09250470106781e-06
Bannayan B-Disease 0 0.028197031468153
- I-Disease 0 0.0842379629611969
Zonana I-Disease 0 0.12206731736660004
( I-Disease 0 5.586713541561039e-06
BZS I-Disease 0 0.0008876217762008309
) I-Disease 0 8.331132335115399e-07
or I-Disease 0 1.3957326700619888e-05
Ruvalcaba I-Disease 0 0.007966335862874985
- I-Disease 0 0.0172213613986969
Riley I-Disease 0 0.008656092919409275
- I-Disease 1 0.9923646450042725
Smith I-Disease 1 0.6915057897567749
syndrome I-Disease 1 0.9999605417251587
( O 0 6.006747753417585e-06
MIM O 0 0.0014009904116392136
153480 O 0 0.0005495122168213129
) O 0 2.50832431447634e-06
. O 0 4.371225713839522e-06

Constitutive O 0 7.9591445683036e-05
DNA O 0 1.0809669220179785e-05
from O 0 4.915847284792108e-07
37 O 0 1.4710072946400032e-06
CD B-Disease 0 3.64914762940316e-06
families O 0 1.3410966914761957e-07
and O 0 6.92615685693454e-07
seven O 0 2.96266671284684e-06
BZS B-Disease 0 0.0004991100286133587
families O 0 6.363247280205542e-07
was O 0 7.15170835974277e-06
screened O 0 5.463755769596901e-06
for O 0 1.0026908512372756e-06
germline O 0 0.0029328118544071913
PTEN O 0 0.02532399632036686
mutations O 0 0.0034626007545739412
. O 0 3.727674993569963e-05

PTEN O 0 0.0061411382630467415
mutations O 0 4.280669963918626e-05
were O 0 2.2733938465080428e-07
identified O 0 5.05179230003705e-07
in O 0 6.169700128566546e-08
30 O 0 2.4818049837449507e-07
of O 0 2.050152581034581e-08
37 O 0 1.149917125076172e-06
( O 0 9.982068860381332e-08
81 O 0 1.4602547935282928e-06
% O 0 9.427550295981746e-09
) O 0 1.2730610343680837e-08
CD B-Disease 0 9.979124797609984e-07
families O 0 2.3164197671121656e-08
, O 0 1.0009046036429936e-07
including O 0 1.5604987879669352e-07
missense O 0 8.461280231131241e-05
and O 0 2.9233847271825653e-06
nonsense O 0 0.00032103474950417876
point O 0 7.68107856856659e-05
mutations O 0 0.00017558578110765666
, O 0 2.059894995909417e-06
deletions O 0 1.392362446495099e-05
, O 0 8.799747774901334e-07
insertions O 0 1.8765629647532478e-05
, O 0 1.2242181810506736e-06
a O 0 2.118907787007629e-06
deletion O 0 3.237563942093402e-05
/ O 0 1.3884112377127167e-05
insertion O 0 3.7665492982341675e-06
and O 0 8.273846106021665e-07
splice O 0 0.00033896035165525973
site O 0 0.00016726681496948004
mutations O 0 0.0007201346452347934
. O 0 1.1981802344962489e-05

These O 0 9.215523277816828e-07
mutations O 0 3.681283487821929e-05
were O 0 3.658998934952251e-07
scattered O 0 1.0051179515357944e-06
over O 0 1.8625887321377377e-07
the O 0 1.486578184994869e-07
entire O 0 2.370100673942943e-06
length O 0 2.965425665024668e-06
of O 0 3.4379149838059675e-07
PTEN O 0 0.00041984798735938966
, O 0 3.854602255159989e-07
with O 0 4.593580626988114e-08
the O 0 9.616264406986375e-08
exception O 0 2.684469109226484e-07
of O 0 1.4084434951655567e-08
the O 0 1.1277839462309203e-07
first O 0 8.278202585643157e-07
, O 0 6.105357215346885e-07
fourth O 0 2.8191673209221335e-06
and O 0 7.613818979734788e-07
last O 0 7.98850305727683e-06
exons O 0 7.477003964595497e-05
. O 0 1.3477304491971154e-05

A O 0 5.59302388865035e-05
hot O 0 0.00021063085296191275
spot O 0 2.7104122636956163e-05
for O 0 4.785970304510556e-07
PTEN O 0 0.0003427332849241793
mutation O 0 9.78477874014061e-06
in O 0 1.5282364529412007e-07
CD B-Disease 0 7.436016403516987e-06
was O 0 5.4421843742602505e-06
identified O 0 1.024608536681626e-06
in O 0 1.3577334811998298e-07
exon O 0 8.838934263621923e-06
5 O 0 6.674408723483793e-07
that O 0 1.1061072946461081e-08
contains O 0 6.299202937043447e-08
the O 0 2.3482785138639883e-07
PTPase O 0 7.105937402229756e-05
core O 0 9.840702659857925e-06
motif O 0 1.5337629520217888e-05
, O 0 1.6893464760414645e-07
with O 0 5.029938066059003e-08
13 O 0 4.663708352836693e-07
of O 0 1.5351625748394326e-08
30 O 0 4.044368608902005e-07
( O 0 3.5189920311040623e-08
43 O 0 2.2516098852065625e-07
% O 0 6.467946622734644e-09
) O 0 2.2078486594523383e-08
CD B-Disease 0 3.5231805668445304e-06
mutations O 0 9.621587196306791e-06
identified O 0 1.1577044460864272e-06
in O 0 1.3385003683197283e-07
this O 0 1.9832468467484432e-07
exon O 0 0.00015431069186888635
. O 0 9.805460649658926e-06

Seven O 0 1.6081147578006494e-06
of O 0 1.8341843599500862e-07
30 O 0 1.3693030496142455e-06
( O 0 1.1789872189638118e-07
23 O 0 6.954465447961411e-07
% O 0 5.762484267535228e-09
) O 0 8.67156035866401e-09
were O 0 1.974359697953787e-08
within O 0 4.289207922170135e-08
the O 0 9.403292011711528e-08
core O 0 1.2473422430048231e-05
motif O 0 3.638441921793856e-05
, O 0 6.956813649594551e-07
the O 0 6.876433644720237e-08
majority O 0 1.1288287993238555e-07
( O 0 7.152787873110356e-08
five O 0 7.10531864456243e-08
of O 0 1.878959210444009e-08
seven O 0 1.6346014319879032e-07
) O 0 2.952783084708699e-08
of O 0 2.5318808383190117e-08
which O 0 1.394736699467103e-07
were O 0 3.493646261176764e-07
missense O 0 0.00014072962221689522
mutations O 0 0.0001299772848142311
, O 0 1.2063666190442746e-06
possibly O 0 6.261557246034499e-06
pointing O 0 5.200929535931209e-06
to O 0 2.477814575740922e-08
the O 0 6.706951438673059e-08
functional O 0 1.2509558473539073e-06
significance O 0 8.950272558649885e-07
of O 0 1.0855954002408907e-07
this O 0 5.099451527712517e-07
region O 0 4.2384330299682915e-05
. O 0 1.152290224126773e-05

Germline O 0 0.024194583296775818
PTEN O 0 0.01506288442760706
mutations O 0 0.00017144742014352232
were O 0 6.384333346431958e-07
identified O 0 5.523210120372823e-07
in O 0 6.759850634807663e-08
four O 0 6.318625622725449e-08
of O 0 3.6613929665918477e-08
seven O 0 5.980837158858776e-07
( O 0 1.8632673004503886e-07
57 O 0 2.745067604337237e-06
% O 0 7.068282315003671e-08
) O 0 2.0963946667507116e-07
BZS B-Disease 0 0.00024665132514201105
families O 0 1.059047349372122e-06
studied O 0 3.953699706471525e-05
. O 0 8.633878678665496e-06

Interestingly O 0 8.438927034148946e-05
, O 0 1.258850829799485e-06
none O 0 6.837321961938869e-07
of O 0 3.480516141962653e-08
these O 0 6.60813483932543e-08
mutations O 0 2.04388088604901e-05
was O 0 8.993792107503396e-06
observed O 0 1.9959472865593852e-06
in O 0 1.4729234010246728e-07
the O 0 9.603166972738109e-07
PTPase O 0 0.0004454089794307947
core O 0 0.00017299942555837333
motif O 0 0.0006854985258542001
. O 0 2.4684386517037638e-05

It O 0 1.6343050219802535e-06
is O 0 3.6805397485295543e-07
also O 0 1.1969073909767758e-07
worthy O 0 7.592045108140155e-07
of O 0 6.13366708535068e-08
note O 0 1.985246171898325e-06
that O 0 2.0836615988173435e-08
a O 0 4.2262394117642543e-07
single O 0 3.0368489660759224e-06
nonsense O 0 8.053280180320144e-05
point O 0 1.3311161637830082e-05
mutation O 0 2.551047145971097e-05
, O 0 9.145185231318465e-07
R233X O 0 1.4681549146189354e-05
, O 0 5.415978421297041e-07
was O 0 1.951292915691738e-06
observed O 0 7.524053557972366e-07
in O 0 4.1323954036442956e-08
the O 0 8.097737946854977e-08
germline O 0 1.7476755601819605e-05
DNA O 0 1.28016949929588e-06
from O 0 5.0049507649418956e-08
two O 0 4.461865898974793e-08
unrelated O 0 3.83581209462136e-06
CD B-Disease 0 1.6558135030209087e-05
families O 0 2.3494165191095817e-07
and O 0 1.1272328492850647e-06
one O 0 2.8911074423376704e-06
BZS B-Disease 0 0.0023562281858175993
family O 0 6.491954991361126e-05
. O 0 1.8844715668819845e-05

Genotype O 0 0.0013393519911915064
- O 0 0.00036251056008040905
phenotype O 0 2.9192533474997617e-05
studies O 0 1.364942789905399e-07
were O 0 1.6762758292543367e-08
not O 0 1.141848215979735e-08
performed O 0 5.760145427302632e-07
on O 0 2.0185495941404952e-07
this O 0 2.656158137881448e-08
small O 0 4.070514307841222e-07
group O 0 7.214973720692797e-07
of O 0 3.041959928395954e-07
BZS B-Disease 0 0.001873304252512753
families O 0 2.244874167445232e-06
. O 0 8.530247214366682e-06

However O 0 6.682410003122641e-06
, O 0 3.647707217169227e-06
genotype O 0 6.349603063426912e-05
- O 0 0.00011624921171460301
phenotype O 0 4.433781941770576e-05
analysis O 0 1.2482900046961731e-06
inthe O 0 4.5972854422871023e-05
group O 0 4.902878458779014e-07
of O 0 2.3412496830133023e-08
CD B-Disease 0 7.965512850205414e-06
families O 0 1.211411131407658e-07
revealed O 0 4.3283534978399985e-06
two O 0 4.896308780644176e-08
possible O 0 1.394618180938778e-07
associations O 0 1.5670369180043053e-07
worthy O 0 1.0023600225395057e-06
of O 0 5.913515011002346e-08
follow O 0 1.0428501582282479e-06
- O 0 1.842082929215394e-05
up O 0 1.5058049029903486e-06
in O 0 3.182912848842534e-07
independent O 0 9.057900456355128e-07
analyses O 0 1.370029895042535e-05
. O 0 5.832098395330831e-06

The O 0 5.147810497874161e-07
first O 0 7.530686616519233e-07
was O 0 5.957678240520181e-06
an O 0 1.8169416193813959e-07
association O 0 1.3919834600528702e-06
noted O 0 8.035102041503706e-07
in O 0 9.33191230956254e-08
the O 0 1.3905913931466785e-07
group O 0 2.125699154476024e-07
of O 0 4.56828601613779e-08
CD B-Disease 0 3.880833537550643e-05
families O 0 2.2727529085386777e-06
with O 0 0.0004632038762792945
breast B-Disease 1 0.9999167919158936
disease I-Disease 1 0.9997780919075012
. O 0 4.622805863618851e-05

A O 0 5.46538149137632e-06
correlation O 0 1.5354384004240273e-06
was O 0 3.41926147484628e-06
observed O 0 7.189951247710269e-07
between O 0 1.1718444170583098e-07
the O 0 1.9210575885608705e-07
presence O 0 6.791086889279541e-06
/ O 0 3.527091394062154e-05
absence O 0 5.836738637299277e-06
of O 0 1.9525830907696218e-07
a O 0 5.150716333446326e-06
PTEN O 0 0.0012700610095635056
mutation O 0 3.156806997139938e-05
and O 0 2.958215361559269e-07
the O 0 5.294404559208488e-07
type O 0 0.00019412390247453004
of O 0 4.42390364696621e-06
breast O 1 0.998375654220581
involvement O 0 0.00016953179147094488
( O 0 1.1235537385800853e-05
unaffected O 0 0.004664239473640919
versus O 0 0.040179986506700516
benign O 1 0.9975554347038269
versus O 1 0.9456391334533691
malignant O 1 0.999672532081604
) O 0 1.022391916194465e-05
. O 0 1.1510228432598524e-05

Specifically O 0 3.1372462672152324e-06
and O 0 2.737441775479965e-07
more O 0 1.1316016568230225e-08
directly O 0 1.8730305839653738e-07
, O 0 1.773109943314921e-07
an O 0 1.1336155125718506e-07
association O 0 2.0278394003980793e-06
was O 0 2.0805421172553906e-06
also O 0 1.6783785383722716e-07
observed O 0 3.203046787803032e-07
between O 0 7.825323677934648e-08
the O 0 5.447308026873543e-08
presence O 0 4.3058969367848476e-07
of O 0 9.57072074925236e-08
a O 0 2.22282214963343e-05
PTEN O 0 0.05590067431330681
mutation O 0 0.009423417039215565
and O 0 0.014983453787863255
malignant B-Disease 1 0.999996542930603
breast I-Disease 1 0.9999924898147583
disease I-Disease 1 0.9999340772628784
. O 0 5.306070306687616e-05

Secondly O 0 0.00021433299116324633
, O 0 2.0086840777366888e-06
there O 0 9.591261829200448e-08
appeared O 0 1.9254152903158683e-06
to O 0 2.743156457540863e-08
be O 0 4.8889177151068e-08
an O 0 9.428885050510871e-08
interdependent O 0 0.0002011774922721088
association O 0 6.011950972606428e-06
between O 0 7.819055554136867e-07
mutations O 0 1.7824897440732457e-05
upstream O 0 3.345199957038858e-06
and O 0 2.2090772233696043e-07
within O 0 1.925648831502258e-07
the O 0 3.2050024856289383e-07
PTPase O 0 0.00018415943486616015
core O 0 3.3895503293024376e-05
motif O 0 7.148612348828465e-05
, O 0 4.7603336383872374e-07
the O 0 1.2199207333196682e-07
core O 0 6.731391295033973e-06
motif O 0 1.6808653526823036e-05
containing O 0 6.833157044638938e-07
the O 0 3.575435130187543e-07
majority O 0 2.7802053637060453e-07
of O 0 3.2520262038815417e-07
missense O 0 0.0003512777911964804
mutations O 0 0.00013217248488217592
, O 0 7.609180556755746e-07
and O 0 1.0396769312137621e-07
the O 0 1.0168390929266025e-07
involvement O 0 1.7378562233716366e-06
of O 0 7.975570781582064e-08
all O 0 2.34057168313484e-07
major O 0 7.986835407791659e-05
organ O 1 0.9963418841362
systems O 1 0.8757126927375793
( O 0 5.552824859478278e-06
central O 0 1.252820402442012e-05
nervous O 0 0.2172611504793167
system O 0 0.25463399291038513
, O 0 0.005061023402959108
thyroid O 1 0.9999948740005493
, O 0 0.002055658958852291
breast O 1 0.9998082518577576
, O 0 0.0007156516658142209
skin O 1 0.9998925924301147
and O 1 0.7857872247695923
gastrointestinal O 1 0.9999905824661255
tract O 1 0.9994509816169739
) O 0 1.4588708836527076e-05
. O 0 1.3425363249552902e-05

However O 0 1.2642466344914283e-06
, O 0 1.6400775848524063e-07
these O 0 3.827762995456396e-09
observations O 0 4.3779243696917547e-07
would O 0 4.370660988683994e-08
need O 0 4.9499824683607585e-08
to O 0 2.406280152911222e-08
be O 0 8.09756812714113e-08
confirmed O 0 1.6661972779274947e-07
by O 0 4.331686120906397e-09
studying O 0 3.604607456964004e-08
a O 0 3.266725201456211e-08
larger O 0 6.981099431868643e-08
number O 0 2.33583037356766e-08
of O 0 4.435849376704937e-08
CD B-Disease 0 2.0793200746993534e-05
families O 0 8.685830152899143e-07
. O 0 6.734930138918571e-06

Molecular O 1 0.9019451141357422
defects O 1 0.9995846152305603
leading O 0 0.00024324955302290618
to O 0 5.983398523312644e-07
human O 0 1.5679914213251323e-05
complement B-Disease 0 0.00019968037668149918
component I-Disease 1 0.9960055947303772
C6 I-Disease 1 0.9999958276748657
deficiency I-Disease 1 0.9999978542327881
in O 0 2.150121645172476e-06
an O 0 4.027744466839067e-07
African O 0 1.605477564226021e-06
- O 0 2.9009594072704203e-05
American O 0 2.2331300897349138e-06
family O 0 1.4560395356966183e-05
. O 0 6.681396826024866e-06

Complement B-Disease 0 0.0017460610251873732
component I-Disease 1 0.9960229396820068
C6 I-Disease 1 0.999996542930603
deficiency I-Disease 1 0.9999986886978149
( O 0 1.1744130461011082e-05
C6D B-Disease 0 0.0013687986647710204
) O 0 2.0018703708046814e-06
was O 0 0.0001106323761632666
diagnosed O 1 0.5871698260307312
in O 0 1.270626057703339e-07
a O 0 8.08789593520487e-07
16 O 0 2.7249675440543797e-06
- O 0 1.493623130954802e-05
year O 0 2.334430973860435e-06
- O 0 9.218905688612722e-06
old O 0 1.18504822239629e-05
African O 0 8.430349680565996e-07
- O 0 7.714067578490358e-06
American O 0 9.547972013024264e-07
male O 0 8.325998351210728e-06
with O 0 0.00018578750314190984
meningococcal B-Disease 1 0.9999723434448242
meningitis I-Disease 1 0.9999858140945435
. O 0 5.596870687440969e-05

The O 0 1.5452968000317924e-05
patients O 0 0.00011023609840776771
father O 0 2.6636254915501922e-05
and O 0 5.030672127759317e-07
two O 0 4.342682586866431e-07
brothers O 0 2.1272344383760355e-05
also O 0 1.4270307246988523e-06
had O 0 3.051614157811855e-06
C6D B-Disease 0 0.0002519639383535832
, O 0 4.846959882343072e-07
but O 0 1.3020451206102734e-07
gave O 0 6.005104182804644e-07
no O 0 5.880077083020296e-07
history O 0 6.65058360027615e-06
of O 0 7.205332622106653e-06
meningitis B-Disease 1 0.9999179840087891
or O 0 1.9159333533025347e-05
other O 0 1.098042048397474e-05
neisserial B-Disease 1 0.9878288507461548
infection I-Disease 1 0.99819415807724
. O 0 2.8483014830271713e-05

By O 0 2.9040930371593277e-07
using O 0 1.7217935237567872e-06
exon O 0 6.384995504049584e-05
- O 0 1.1649448424577713e-05
specific O 0 3.979820917265897e-07
polymerase O 0 3.3407239243388176e-05
chain O 0 5.073249485576525e-05
reaction O 0 2.141479853889905e-06
( O 0 1.4230253952973726e-07
PCR O 0 2.623501814014162e-06
) O 0 4.421202604021346e-08
/ O 0 6.863081694064022e-07
single O 0 5.444756538963702e-07
- O 0 4.928991529595805e-06
strand O 0 2.0216641587467166e-06
conformation O 0 1.9414919734117575e-06
polymorphism O 0 9.722288041302818e-07
as O 0 1.028105387490541e-07
a O 0 1.2349930500477058e-07
screening O 0 4.5884144128649496e-07
step O 0 6.857023322481837e-07
and O 0 2.5960490646070866e-08
nucleotide O 0 1.1414022793587719e-07
sequencing O 0 8.373788773496926e-08
of O 0 2.154504308293781e-08
target O 0 5.004965260013705e-07
exons O 0 5.949632850388298e-06
, O 0 3.643037871370325e-07
we O 0 1.2386756509386032e-07
determined O 0 6.179475349199492e-07
that O 0 1.9058273181826735e-08
the O 0 2.0954492185865092e-07
proband O 0 3.7554487789748237e-05
was O 0 1.840704499045387e-06
a O 0 2.604344615519949e-07
compound O 0 1.4952556739444844e-06
heterozygote O 0 3.994756298197899e-06
for O 0 5.876063369214535e-08
two O 0 6.483715537797252e-07
C6 O 0 0.011282338760793209
gene O 0 0.00023530112230218947
mutations O 0 0.0011889887973666191
. O 0 1.8793170966091566e-05

The O 0 1.0789871112137916e-06
first O 0 2.513120307412464e-06
, O 0 8.291737572108104e-07
1195delC O 0 2.5177738280035555e-05
located O 0 2.402534391876543e-06
in O 0 5.301538976709708e-07
exon O 0 2.0675925043178722e-05
7 O 0 4.397089469421189e-06
, O 0 1.9743339407796157e-07
is O 0 5.924477619601021e-08
a O 0 3.5680400856108463e-07
novel O 0 1.2727170997095527e-06
mutation O 0 2.9045879728073487e-06
, O 0 1.7325511691979045e-07
while O 0 1.2312557373661548e-07
the O 0 1.3016440902902104e-07
second O 0 1.76409741925454e-06
, O 0 3.2192684784604353e-07
1936delG O 0 1.6045076336013153e-05
in O 0 5.320887908055738e-07
exon O 0 1.6465499356854707e-05
12 O 0 2.283775074829464e-06
, O 0 2.0303497194618103e-07
has O 0 3.5432660183687403e-07
been O 0 2.4157029088200943e-07
described O 0 1.019469095808745e-06
before O 0 5.886417397960031e-07
to O 0 1.5147406884352677e-07
cause O 0 1.5067996173456777e-05
C6D B-Disease 0 0.000225476294872351
in O 0 3.0066030376474373e-07
an O 0 1.869320556124876e-07
unrelated O 0 1.704749411146622e-05
African O 0 2.5755107344593853e-06
- O 0 3.502141771605238e-05
American O 0 1.057092845258012e-06
individual O 0 9.206457889376907e-07
. O 0 5.179497748031281e-06

Both O 0 1.2691121810348704e-05
mutations O 0 0.0006459908909164369
result O 0 2.236543150502257e-05
in O 0 4.162418917985633e-06
premature O 0 0.000355581782059744
termination O 0 7.53147469367832e-05
codons O 0 3.3145028282888234e-05
and O 0 7.357238700933522e-06
C6 O 0 0.055431488901376724
null O 0 0.0006007424672134221
alleles O 0 0.00019654231437016279
. O 0 2.9307009754120372e-05

Allele O 0 0.00019105621322523803
- O 0 4.579110463964753e-05
specific O 0 7.360006861745205e-07
PCR O 0 3.3297637855866924e-05
indicated O 0 3.545317895259359e-06
that O 0 9.59822976653868e-09
the O 0 6.660839346750436e-08
probands O 0 4.566633651847951e-05
two O 0 6.075091505408636e-07
brothers O 0 6.373115320457146e-05
also O 0 6.222020601853728e-06
inherited O 0 0.0027795210480690002
the O 0 3.186057710991008e-06
1195delC O 0 0.0002482246491126716
mutation O 0 8.107201210805215e-06
from O 0 1.3751800054251362e-07
their O 0 6.869944968457276e-08
heterozygous O 0 1.6720724715924007e-06
mother O 0 1.608902312000282e-05
and O 0 2.0875407358289522e-07
the O 0 5.883515541427187e-07
1936delG O 0 0.00013054754526820034
mutation O 0 7.836591976229101e-06
from O 0 1.3324455494512222e-07
their O 0 1.2552169437185512e-07
homozygous O 0 1.3466551536112092e-05
father O 0 2.8628242944250815e-05
. O 0 1.6129972664202796e-06
. O 0 4.49542994829244e-06

PAX6 O 0 0.07649797201156616
mutations O 0 0.005843267310410738
reviewed O 0 0.0005664558266289532
. O 0 4.364225242170505e-05

Mutations O 0 0.0005808236310258508
in O 0 4.635432560462505e-06
PAX6 O 0 0.0007328709471039474
are O 0 1.2328303000685992e-07
responsible O 0 2.016132384596858e-06
for O 0 2.887828713937779e-07
human O 0 3.810680937021971e-05
aniridia B-Disease 1 0.9999021291732788
and O 0 1.619864860913367e-06
have O 0 1.714520152518162e-07
also O 0 2.0035096781612083e-07
been O 0 2.7047781259170733e-07
found O 0 7.084802291501546e-07
in O 0 1.0921141893049935e-06
patients O 0 2.8583064704434946e-05
with O 0 2.0782257706741802e-05
Peters B-Disease 1 0.9997757077217102
anomaly I-Disease 1 0.9998736381530762
, O 0 0.00044241955038160086
with O 1 0.6166995167732239
congenital B-Disease 1 0.9999998807907104
cataracts I-Disease 1 0.9999958276748657
, O 0 4.368947702459991e-05
with O 0 2.0763653083122335e-05
autosomal B-Disease 1 0.9978146553039551
dominant I-Disease 1 0.9920672178268433
keratitis I-Disease 1 0.99868243932724
, O 0 3.954925341531634e-05
and O 0 8.551000064471737e-06
with O 0 0.00013286748435348272
isolated B-Disease 1 0.9954665899276733
foveal I-Disease 1 0.9999251365661621
hypoplasia I-Disease 1 0.9999693632125854
. O 0 0.000502787996083498

No O 0 3.681719363157754e-06
locus O 0 1.0790881788125262e-05
other O 0 1.490203374032717e-07
than O 0 4.070743386819231e-07
chromosome O 0 5.3626827138941735e-05
11p13 O 0 6.122057675383985e-05
has O 0 2.626480863909819e-06
been O 0 2.489625785528915e-06
implicated O 0 0.00014117249520495534
in O 0 9.801814485399518e-06
aniridia B-Disease 1 0.9996738433837891
, O 0 6.819097052357392e-06
and O 0 2.5616586754040327e-06
PAX6 O 0 0.0019914554432034492
is O 0 2.572847051851568e-06
clearly O 0 1.634641762393585e-06
the O 0 2.9026392667219625e-07
major O 0 9.700943337520584e-06
, O 0 2.9313059712876566e-07
if O 0 5.2369664160778484e-08
not O 0 1.7172062882764294e-08
only O 0 3.19351762811948e-08
, O 0 1.6927040746850253e-07
gene O 0 2.96518805953383e-06
responsible O 0 1.7025882698362693e-05
. O 0 1.0682379070203751e-05

Twenty O 0 3.463881148491055e-05
- O 0 3.810652196989395e-05
eight O 0 1.33605078644905e-06
percent O 0 1.0175642728427192e-06
of O 0 8.163662812421535e-08
identified O 0 4.429666205396643e-06
PAX6 O 0 0.0008526251767762005
mutations O 0 7.859077595639974e-05
are O 0 7.095472938090097e-07
C O 0 0.000638590136077255
- O 0 0.0010364338522776961
T O 0 0.0017215663101524115
changes O 0 6.526666766148992e-06
at O 0 1.9563220121199265e-05
CpG O 0 4.003947469755076e-05
dinucleotides O 0 5.213350959820673e-05
, O 0 2.6798676344697014e-07
20 O 0 8.940244100585915e-08
% O 0 2.752835737140913e-09
are O 0 7.11289560584305e-09
splicing O 0 4.161886863585096e-06
errors O 0 9.833823423832655e-05
, O 0 8.790196659447247e-08
and O 0 1.5575572831494355e-08
more O 0 2.276954846891499e-09
than O 0 1.2037982166646088e-08
30 O 0 2.1218953349944059e-07
% O 0 6.7974332829123796e-09
are O 0 1.1409165168174695e-08
deletion O 0 2.8609533728740644e-06
or O 0 5.770449433839531e-07
insertion O 0 1.0659707186277956e-05
events O 0 6.77604566590162e-06
. O 0 9.22383969736984e-06

There O 0 2.669997684279224e-06
is O 0 4.3655415993271163e-07
a O 0 1.6350828673239448e-06
noticeably O 0 9.080082963919267e-05
elevated O 0 0.0004602789122145623
level O 0 9.112224688578863e-06
of O 0 2.2042054581561388e-07
mutation O 0 1.165103731182171e-05
in O 0 1.0516072990185421e-07
the O 0 9.613715690193203e-08
paired O 0 2.0666107047873084e-06
domain O 0 5.948016905676923e-07
compared O 0 1.1704187272698618e-06
with O 0 1.0217559065495152e-07
the O 0 1.879703432905444e-07
rest O 0 5.379106937652978e-07
of O 0 4.053843838391913e-08
the O 0 8.960675472735602e-07
gene O 0 2.9710487069678493e-05
. O 0 8.69911218615016e-06

Increased O 0 7.375834229605971e-06
mutation O 0 2.5778161216294393e-05
in O 0 2.998087609284994e-07
the O 0 3.462833717549074e-07
homeodomain O 0 6.159101758385077e-05
is O 0 3.8335556951096805e-07
accounted O 0 4.025939119856048e-07
for O 0 2.064443727078924e-08
by O 0 8.758950542642197e-08
the O 0 9.210199323206325e-07
hypermutable O 0 0.00035279509029351175
CpG O 0 0.00010845068754861131
dinucleotide O 0 0.00012276235793251544
in O 0 1.1503800578793744e-06
codon O 0 2.458906965330243e-05
240 O 0 9.209284144162666e-06
. O 0 6.474209385487484e-06

Very O 0 3.3967064609896624e-06
nearly O 0 2.4711091555218445e-06
all O 0 1.7202410163008608e-07
mutations O 0 2.1179754185141064e-05
appear O 0 5.721134129998973e-06
to O 0 9.591532261765678e-07
cause O 0 0.0006369980983436108
loss O 0 6.722481339238584e-05
of O 0 8.944677176714322e-08
function O 0 8.077975053311093e-07
of O 0 4.24092760908934e-08
the O 0 1.5505212047628447e-07
mutant O 0 4.389175501273712e-06
allele O 0 1.8451053165335907e-06
, O 0 1.1914454489669879e-07
and O 0 1.7676253349918625e-08
more O 0 2.2291910539706805e-09
than O 0 2.503725049507466e-08
80 O 0 1.2073144262103597e-07
% O 0 8.952389052296894e-09
of O 0 3.950559346321825e-08
exonic O 0 0.00012677424820140004
substitutions O 0 1.0636523256835062e-05
result O 0 6.7629462137119845e-06
in O 0 3.7137215258553624e-06
nonsense O 0 0.00021511322120204568
codons O 0 0.000290033029159531
. O 0 2.3108976165531203e-05

In O 0 6.697464982607926e-07
a O 0 2.410447166312224e-07
gene O 0 5.758552674706152e-07
with O 0 9.785488686020472e-08
such O 0 2.7466282404020603e-07
extraordinarily O 0 0.00014658509462606162
high O 0 1.043973406922305e-05
sequence O 0 5.256671897768683e-07
conservation O 0 4.222323468638933e-07
throughout O 0 1.2831857532091817e-07
evolution O 0 1.9940284801123198e-07
, O 0 1.184285878252922e-07
there O 0 3.669866543987155e-08
are O 0 4.162153999232032e-08
presumed O 0 2.942684841400478e-05
undiscovered O 0 0.0005634371191263199
missense O 0 0.0004282208683434874
mutations O 0 0.00013730015780311078
, O 0 4.767784673731512e-07
these O 0 1.4736084352762191e-08
are O 0 1.9372876636225556e-08
hypothesized O 0 6.474576821347e-07
to O 0 1.1333513683098317e-08
exist O 0 1.2537046245597594e-07
in O 0 1.892804561975936e-07
as O 0 2.759061544566066e-06
- O 0 8.272095874417573e-05
yet O 0 4.010257271147566e-06
unidentified O 0 9.94663787423633e-05
phenotypes O 0 7.420434849336743e-05
. O 0 1.5311774177462212e-06
. O 0 2.1669025045412127e-06

Genetic O 0 0.0007510593859478831
heterogeneity O 0 0.00017775650485418737
and O 0 5.678361503669294e-06
penetrance O 0 0.0007654625806026161
analysis O 0 1.3313637055034633e-06
of O 0 1.3063086612419283e-07
the O 0 1.1202732821402606e-06
BRCA1 O 0 0.0003240565420128405
and O 0 6.425149877031799e-06
BRCA2 O 0 0.0010031096171587706
genes O 0 0.0002677256998140365
in O 0 0.0003060057933907956
breast B-Disease 1 0.9997392296791077
cancer I-Disease 1 0.9994685053825378
families O 0 3.899473085766658e-06
. O 0 1.4421798368857708e-05

The O 0 0.018110673874616623
Breast B-Disease 1 0.9999970197677612
Cancer I-Disease 1 0.9999874830245972
Linkage O 0 0.0032328811939805746
Consortium O 0 0.0009594076545909047
. O 0 4.2575706174829975e-05

The O 0 1.3810839618599857e-06
contribution O 0 3.6467542940954445e-06
of O 0 1.165946855508082e-06
BRCA1 O 0 0.0007939859642647207
and O 0 2.205614873673767e-05
BRCA2 O 0 0.005788684356957674
to O 0 0.00030577133293263614
inherited B-Disease 1 0.9999992847442627
breast I-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999997615814209
was O 0 0.0003039744624402374
assessed O 0 6.426626896427479e-06
by O 0 5.266455715968732e-08
linkage O 0 9.714543921290897e-06
and O 0 6.465778028541536e-07
mutation O 0 5.586489805864403e-06
analysis O 0 2.882276248783455e-07
in O 0 1.8158624470743234e-07
237 O 0 6.596329171770776e-07
families O 0 1.2228765555732934e-08
, O 0 1.6355658161160136e-08
each O 0 3.620411970217674e-09
with O 0 4.5081279154146614e-08
at O 0 2.8054382710251957e-06
least O 0 1.0719720933138888e-07
four O 0 1.7656481077210628e-07
cases O 0 1.7139215060524293e-06
of O 0 4.714054739451967e-06
breast B-Disease 1 0.9998511075973511
cancer I-Disease 1 0.9996826648712158
, O 0 7.709043643444602e-07
collected O 0 3.416803053823969e-07
by O 0 8.096546935121296e-07
the O 0 0.0002505115990061313
Breast B-Disease 1 0.999996542930603
Cancer I-Disease 1 0.9999829530715942
Linkage O 0 0.001126918476074934
Consortium O 0 0.000376012030756101
. O 0 1.537846401333809e-05

Families O 0 3.007302780133614e-07
were O 0 1.0929397120662543e-07
included O 0 1.5527496088907355e-07
without O 0 1.0660266269724161e-07
regard O 0 9.904671571803192e-08
to O 0 5.669708258437822e-08
the O 0 9.399666396348039e-07
occurrence O 0 0.0003382490831427276
of O 0 1.184964639833197e-05
ovarian B-Disease 1 0.9998384714126587
or I-Disease 0 0.00010118145291926339
other I-Disease 0 2.7309299184707925e-05
cancers I-Disease 1 0.999834418296814
. O 0 4.5873879571445286e-05

Overall O 0 0.000429350882768631
, O 0 0.00034125891397707164
disease O 1 0.9994078874588013
was O 0 4.536099368124269e-05
linked O 0 1.4575677596440073e-05
to O 0 7.731397744237256e-08
BRCA1 O 0 1.4684769666928332e-05
in O 0 7.373581212277713e-08
an O 0 3.6453311480499906e-08
estimated O 0 8.581397992202255e-08
52 O 0 2.944909738289425e-07
% O 0 2.656197262140836e-09
of O 0 5.247262180319012e-09
families O 0 2.18398348295068e-08
, O 0 7.93206140770053e-08
to O 0 3.495798495123381e-08
BRCA2 O 0 9.946299542207271e-06
in O 0 1.4699148209729174e-07
32 O 0 4.3939607508036715e-07
% O 0 9.070537210220664e-09
of O 0 8.808688001238352e-09
families O 0 2.6901297189851903e-08
, O 0 1.126386663941048e-07
and O 0 3.087320976646879e-08
to O 0 1.3861050973673628e-08
neither O 0 2.6515675699556596e-07
gene O 0 5.19579600677389e-07
in O 0 1.5551268006674945e-07
16 O 0 3.323023918255785e-07
% O 0 9.101229103691821e-09
( O 0 2.6220403626098232e-08
95 O 0 3.2573433372817817e-07
% O 0 4.117572771633604e-08
confidence O 0 5.307135324983392e-06
interval O 0 1.1459047527750954e-05
[ O 0 1.8626737073645927e-05
CI O 0 0.0006608626572415233
] O 0 7.458686468453379e-06
6 O 0 1.6608935311523965e-06
% O 0 4.995661484485936e-08
- O 0 4.410482688399497e-06
28 O 0 1.5308693264159956e-06
% O 0 1.4166689155103995e-08
) O 0 2.896223350035143e-08
, O 0 1.0703458741545546e-07
suggesting O 0 1.2133551763326977e-06
other O 0 3.092313534125424e-07
predisposition O 0 0.0002643610932864249
genes O 0 6.726636638632044e-05
. O 0 1.1330851521051954e-05

The O 0 2.8415952328941785e-06
majority O 0 1.4805722230448737e-06
( O 0 4.920303808830795e-07
81 O 0 3.1556191970594227e-06
% O 0 1.534451143925253e-08
) O 0 3.157992267688314e-08
of O 0 2.3173481622507097e-07
the O 0 0.0007963583921082318
breast B-Disease 1 0.9999961853027344
- I-Disease 1 0.9999967813491821
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999961853027344
families O 0 4.202045431611623e-07
were O 0 1.5937312980440765e-07
due O 0 1.2977957339899149e-06
to O 0 7.874342600189266e-08
BRCA1 O 0 2.5923935027094558e-05
, O 0 1.6906325583931903e-07
with O 0 5.5927415587575524e-08
most O 0 1.2728746412449254e-07
others O 0 2.1955993645406124e-07
( O 0 6.32723597959739e-08
14 O 0 4.140664771057345e-07
% O 0 1.073465405454499e-08
) O 0 3.5583070712164044e-08
due O 0 1.9006218963113497e-06
to O 0 8.280239853775129e-07
BRCA2 O 0 0.0007818126468919218
. O 0 2.0852396119153127e-05

Conversely O 0 9.634171146899462e-05
, O 0 4.971181510882161e-07
the O 0 9.409786372316375e-08
majority O 0 1.6173042638456536e-07
of O 0 3.1625852159322676e-08
families O 0 2.979474622577527e-08
with O 0 3.4185859476565383e-07
male B-Disease 0 5.110842266731197e-06
and I-Disease 0 9.437532753509004e-06
female I-Disease 0 0.0005583107122220099
breast I-Disease 1 0.9998637437820435
cancer I-Disease 1 0.9988516569137573
were O 0 4.81548227071471e-07
due O 0 3.4647571283130674e-06
to O 0 3.3879862826324825e-07
BRCA2 O 0 7.403090421576053e-05
( O 0 6.712927529406443e-07
76 O 0 8.703992534719873e-06
% O 0 8.948141783093888e-08
) O 0 2.4027355038924725e-07
. O 0 3.07831533064018e-06

The O 0 4.4375942707119975e-06
largest O 0 2.9028133212705143e-05
proportion O 0 2.026261881837854e-06
( O 0 3.718934635799087e-07
67 O 0 1.9822325612040004e-06
% O 0 1.5883015791473554e-08
) O 0 1.3065860393624007e-08
of O 0 9.206843287756783e-09
families O 0 1.3398586240498389e-08
due O 0 6.749286285412381e-07
to O 0 9.627218133800852e-09
other O 0 2.304319046686487e-08
genes O 0 3.895459599334572e-07
was O 0 1.9311030428070808e-06
found O 0 8.573479703954945e-08
in O 0 2.1733953303737508e-08
families O 0 4.7650545731414695e-09
with O 0 3.009362359307488e-08
four O 0 1.8004446644681593e-07
or O 0 4.878122581430944e-07
five O 0 6.088442887630663e-07
cases O 0 1.6408861256422824e-06
of O 0 8.879504207470745e-07
female O 0 0.0017515735235065222
breast B-Disease 1 0.9999276399612427
cancer I-Disease 1 0.9997755885124207
only O 0 1.6037620298448019e-06
. O 0 6.387448593159206e-06

These O 0 2.505736915736634e-07
estimates O 0 1.049061552294006e-06
were O 0 1.1890050188867463e-07
not O 0 4.298020073179032e-08
substantially O 0 2.9666844056919217e-06
affected O 0 3.2462412491440773e-07
either O 0 1.932173745444743e-07
by O 0 8.272601093040066e-08
changing O 0 3.5817149637296097e-06
the O 0 4.803089836968866e-07
assumed O 0 1.6933392544160597e-05
penetrance O 0 0.00011904945858987048
model O 0 2.3333025183092104e-06
for O 0 1.8162884884986852e-07
BRCA1 O 0 3.968158853240311e-05
or O 0 5.838782044520485e-07
by O 0 7.049285244420389e-08
including O 0 3.202585503458977e-07
or O 0 2.1937000838079257e-06
excluding O 0 2.6665964469430037e-05
BRCA1 O 0 0.001188251655548811
mutation O 0 0.00014017356443218887
data O 0 1.660271118453238e-05
. O 0 1.3663504432770424e-05

Among O 0 1.972851805476239e-06
those O 0 3.0868977773934603e-07
families O 0 2.9444549909385387e-07
with O 0 2.6155275918426923e-05
disease O 1 0.9997474551200867
due O 0 1.5355366485891864e-05
to O 0 2.5589528718228394e-07
BRCA1 O 0 2.416521056147758e-05
that O 0 4.460470037770392e-08
were O 0 1.7674035746040317e-07
tested O 0 1.0567380286374828e-06
by O 0 1.231419677338863e-08
one O 0 3.15770307679486e-08
of O 0 7.305166693782894e-09
the O 0 3.460815989342336e-08
standard O 0 2.8353179004625417e-06
screening O 0 1.1448596524132881e-06
methods O 0 1.0033451189883635e-06
, O 0 3.878430163695157e-07
mutations O 0 1.9668202639877563e-06
were O 0 1.1008879852170139e-07
detected O 0 8.600800356362015e-06
in O 0 4.485536209131169e-08
the O 0 4.258793140365924e-08
coding O 0 4.467420239961939e-06
sequence O 0 3.7797448726450966e-07
or O 0 2.0139962941811973e-07
splice O 0 9.170878001896199e-06
sites O 0 6.177496061354759e-07
in O 0 5.879729769731057e-08
an O 0 2.1519621640209152e-08
estimated O 0 1.2891077005861007e-07
63 O 0 6.43729151761363e-07
% O 0 1.1070086181064198e-08
( O 0 2.8472566526716037e-08
95 O 0 5.618144314212259e-07
% O 0 1.1053653992121326e-07
CI O 0 0.00024323028628714383
51 O 0 4.249759513186291e-06
% O 0 1.2736614962705062e-07
- O 0 1.4245277270674706e-05
77 O 0 3.240020078010275e-06
% O 0 8.242141547043502e-08
) O 0 2.056574430753244e-07
. O 0 2.1912433112447616e-06

The O 0 2.903281028920901e-06
estimated O 0 6.294147283369966e-07
sensitivity O 0 1.7606386109036976e-06
was O 0 1.584855567671184e-06
identical O 0 3.156294496875489e-07
for O 0 3.4968306028559937e-09
direct O 0 1.5022887822624398e-08
sequencing O 0 4.1920509374904213e-07
and O 0 1.5494302374463587e-07
other O 0 4.2831175051105674e-08
techniques O 0 8.722040547581855e-06
. O 0 8.983419320429675e-06

The O 0 1.2485681509133428e-05
penetrance O 0 0.0022147842682898045
of O 0 2.4446851512038847e-06
BRCA2 O 0 0.00042581011075526476
was O 0 1.8036145775113255e-05
estimated O 0 2.3029180340472521e-07
by O 0 4.303761969026709e-08
maximizing O 0 8.113552212307695e-07
the O 0 4.295577866741951e-07
LOD O 0 0.00027884458540938795
score O 0 2.7351686640031403e-06
in O 0 2.376882321186713e-06
BRCA2 O 0 0.00040513984276913106
- O 0 0.0001225718151545152
mutation O 0 1.2950068594363984e-05
families O 0 7.76735902263681e-08
, O 0 1.1283228928959943e-07
over O 0 4.3081151090973435e-08
all O 0 4.6826269084476735e-08
possible O 0 1.6415623349530506e-06
penetrance O 0 0.0008070550975389779
functions O 0 3.3879216061905026e-05
. O 0 2.4337789000128396e-05

The O 0 2.829056938935537e-06
estimated O 0 4.469337454793276e-06
cumulative O 0 3.050734994758386e-05
risk O 0 0.00018757799989543855
of O 0 8.578346751164645e-06
breast B-Disease 1 0.9996514320373535
cancer I-Disease 1 0.9984216690063477
reached O 0 2.005898204515688e-05
28 O 0 3.1862462037679506e-06
% O 0 1.6589853046866665e-08
( O 0 3.1451762083634094e-08
95 O 0 2.6008126496890327e-07
% O 0 4.737507453000944e-08
CI O 0 0.0001770656235748902
9 O 0 2.508525312805432e-06
% O 0 2.1746350498119682e-08
- O 0 1.229391841661709e-06
44 O 0 1.9253641880823125e-07
% O 0 4.599461256304949e-09
) O 0 3.1413196488472295e-09
by O 0 1.046053554887294e-08
age O 0 4.330284184561606e-07
50 O 0 1.3372574869663367e-07
years O 0 1.4352481514379178e-07
and O 0 9.039487736117735e-08
84 O 0 8.696654845152807e-07
% O 0 1.5292096477992345e-08
( O 0 3.5188108427064435e-08
95 O 0 4.098654358131171e-07
% O 0 1.0113208759321424e-07
CI O 0 0.00023078953381627798
43 O 0 3.2174098123505246e-06
% O 0 4.4897817019773356e-08
- O 0 1.9534563762135804e-06
95 O 0 3.574538425255014e-07
% O 0 8.053651079364954e-09
) O 0 8.759847958117462e-09
by O 0 2.0359761876420635e-08
age O 0 1.5017494661151432e-06
70 O 0 1.1967046020799899e-06
years O 0 2.3016300474409945e-06
. O 0 2.5563065264577745e-06

The O 0 0.00033598410664126277
corresponding O 1 0.9910470843315125
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999986886978149
risks O 0 0.014591413550078869
were O 0 3.0657909064757405e-06
0 O 0 1.067424273060169e-05
. O 0 5.567597327171825e-06

4 O 0 7.4724844125739764e-06
% O 0 6.116411555012746e-08
( O 0 6.840981825462222e-08
95 O 0 6.26207963705383e-07
% O 0 7.718180938809382e-08
CI O 0 0.00014978210674598813
0 O 0 7.578344138892135e-07
% O 0 4.524425989416159e-08
- O 0 1.5633455632269033e-06
1 O 0 2.446958831114898e-07
% O 0 6.686639242303727e-09
) O 0 4.508495354826891e-09
by O 0 1.1414650558094763e-08
age O 0 2.2380541508937313e-07
50 O 0 9.133822231888189e-08
years O 0 1.0493012325696327e-07
and O 0 4.4697959111772434e-08
27 O 0 8.426048907494987e-07
% O 0 6.86013423845111e-09
( O 0 1.817554640126673e-08
95 O 0 2.610966873817233e-07
% O 0 3.940760961995693e-08
CI O 0 6.770306936232373e-05
0 O 0 3.9118845052144025e-07
% O 0 1.511964597966653e-08
- O 0 1.4934541923139477e-06
47 O 0 4.2567629066070367e-07
% O 0 5.206377551303376e-09
) O 0 5.456830542982516e-09
by O 0 1.666577986725315e-08
age O 0 5.092992410027364e-07
70 O 0 1.295829292757844e-06
years O 0 2.8613951599254506e-06
. O 0 3.2214654765994055e-06

The O 0 2.9509661544580013e-05
lifetime O 0 0.0008125384920276701
risk O 0 0.0021779420785605907
of O 0 5.6202545238193125e-05
breast B-Disease 1 0.9999539852142334
cancer I-Disease 1 0.9997250437736511
appears O 0 1.1492470548546407e-05
similar O 0 4.514624549756263e-07
to O 0 6.320843226603756e-08
the O 0 7.387417895188264e-07
risk O 0 1.610286744835321e-05
in O 0 4.3765257373706845e-07
BRCA1 O 0 3.1421979656443e-05
carriers O 0 4.644955424737418e-06
, O 0 2.709652733301482e-07
but O 0 5.7578400713964584e-08
there O 0 4.294864908160889e-08
was O 0 6.707801389893575e-07
some O 0 8.921025695940443e-09
suggestion O 0 1.1046610097764642e-06
of O 0 6.255692142076441e-08
a O 0 6.074574230297003e-06
lower O 0 0.00021866780298296362
risk O 0 3.7280766264302656e-05
in O 0 7.350845976361597e-07
BRCA2 O 0 3.7171390431467444e-05
carriers O 0 6.003219823469408e-06
< O 0 1.0600199857435655e-05
50 O 0 5.582131734627183e-07
years O 0 2.6729378532763803e-07
of O 0 1.0692704677239817e-07
age O 0 1.2303336006880272e-05
. O 0 4.3177910811209586e-06

Eye B-Disease 1 0.9852867126464844
movement I-Disease 0 0.001342168659903109
abnormalities I-Disease 1 0.8858214616775513
correlate O 0 3.055151682929136e-05
with O 0 5.165094080439303e-06
genotype O 0 0.00031863866024650633
in O 0 2.563061934779398e-05
autosomal O 1 0.9979203343391418
dominant O 1 0.9977454543113708
cerebellar B-Disease 1 0.9995393753051758
ataxia I-Disease 1 0.9998149275779724
type I-Disease 1 0.999744713306427
I I-Disease 1 0.9994303584098816
. O 0 7.481810462195426e-05

We O 0 8.201952368835919e-06
compared O 0 1.6052483260864392e-05
horizontal O 0 0.0003658919595181942
eye O 1 0.6409192681312561
movements O 0 8.375999459531158e-05
( O 0 1.5436178273375845e-06
visually O 0 2.522729482734576e-05
guided O 0 5.1559538405854255e-05
saccades O 0 0.004176518879830837
, O 0 4.451573659025598e-06
antisaccades O 0 0.00011141994764329866
, O 0 7.490147027056082e-07
and O 0 1.617730021052921e-07
smooth O 0 7.077738700900227e-06
pursuit O 0 6.111600669100881e-06
) O 0 1.0787879745066675e-07
in O 0 1.3428294209916203e-07
control O 0 3.156636694257031e-06
subjects O 0 4.353440544946352e-06
( O 0 3.55116839045877e-07
n O 0 1.3343214959604666e-05
= O 0 9.736792890180368e-06
14 O 0 1.0810646244863165e-06
) O 0 3.245633806159276e-08
and O 0 2.0553430601921718e-07
patients O 0 8.301224170281785e-07
with O 0 2.8776996785495612e-08
three O 0 1.8252588063205621e-07
forms O 0 4.3565469241002575e-06
of O 0 4.340241957834223e-06
autosomal O 1 0.9977431297302246
dominant O 1 0.9960119724273682
cerebellar B-Disease 1 0.9987329840660095
ataxias I-Disease 1 0.974582314491272
type I-Disease 1 0.9680555462837219
I I-Disease 1 0.522548258304596
spinocerebellar B-Disease 1 0.9714893102645874
ataxias I-Disease 0 0.002440471202135086
1 I-Disease 0 6.235802629817044e-06
and I-Disease 0 4.5181650421000086e-07
2 I-Disease 0 1.6133710687427083e-06
( O 0 2.7286009185445437e-07
SCA1 B-Disease 0 7.976773486007005e-05
, O 0 9.205351716445875e-07
n O 0 9.541468898532912e-06
= O 0 8.97220252227271e-06
11 O 0 1.3254866644274443e-06
; O 0 1.4619712374042138e-07
SCA2 B-Disease 0 4.522235394688323e-05
, O 0 5.520682293536083e-07
n O 0 6.439443041017512e-06
= O 0 4.598455234372523e-06
10 O 0 3.0867829536873614e-07
) O 0 7.478135444216605e-08
and O 0 3.4021395549643785e-06
SCA3 B-Disease 1 0.9991413354873657
/ O 0 0.0028684132266789675
Machado B-Disease 0 0.02612193301320076
- I-Disease 0 0.20331795513629913
Joseph I-Disease 0 0.01117466390132904
disease I-Disease 1 0.9986521601676941
( O 0 4.109791916562244e-06
MJD B-Disease 1 0.9915404915809631
) O 0 4.4835988433078455e-07
( O 0 3.119581890587142e-07
n O 0 1.6339219655492343e-05
= O 0 1.5169311154750176e-05
16 O 0 4.087271008756943e-06
) O 0 3.9405247775903263e-07
. O 0 2.125732635249733e-06

In O 0 1.5038510355225299e-05
SCA1 B-Disease 0 0.0011120925191789865
, O 0 1.391659679939039e-06
saccade O 0 2.571243567217607e-05
amplitude O 0 2.672971049832995e-06
was O 0 3.996901796199381e-06
significantly O 0 1.9072112991125323e-06
increased O 0 7.336313956329832e-07
, O 0 2.880122167425725e-07
resulting O 0 2.6343980152887525e-06
in O 0 3.3716457892296603e-06
hypermetria B-Disease 0 0.0015695273177698255
. O 0 2.3807320758351125e-05

The O 0 1.1821447287729825e-06
smooth O 0 2.7592997867031954e-05
pursuit O 0 2.552797013777308e-05
gain O 0 1.9916858946089633e-05
was O 0 0.00012369603791739792
decreased O 0 0.00020797309116460383
. O 0 1.3857471458322834e-05

In O 0 2.496951856301166e-05
SCA2 B-Disease 0 0.0016676567029207945
, O 0 3.0026139938854612e-06
saccade O 0 0.00013228344323579222
velocity O 0 5.184971450944431e-05
was O 0 3.4394339309073985e-05
markedly O 0 0.00016864261124283075
decreased O 0 0.00017128647596109658
. O 0 9.623430742067285e-06

The O 0 7.245731922012055e-06
percentage O 0 2.6079953386215493e-05
of O 0 4.815362899535103e-07
errors O 0 0.00046348143951036036
in O 0 1.9381066067580832e-06
antisaccades O 0 0.00026396263274364173
was O 0 8.048093150136992e-06
greatly O 0 1.9672943381010555e-06
increased O 0 1.9700193831795332e-07
and O 0 2.653356148130115e-07
was O 0 1.5305744227589457e-06
significantly O 0 8.399924809054937e-07
correlated O 0 2.7978555863228394e-06
with O 0 9.23095115012984e-07
age O 0 9.144602518063039e-05
at O 0 0.006165271159261465
disease O 1 0.9987391829490662
onset O 1 0.966779351234436
. O 0 6.335008947644383e-05

In O 0 9.72625684880768e-07
addition O 0 2.7834977345264633e-07
, O 0 7.309671445909771e-08
a O 0 5.102788236399647e-08
correlation O 0 3.949617521925575e-08
between O 0 8.547257834834454e-08
smooth O 0 3.787820105571882e-06
pursuit O 0 3.5443918022792786e-06
gain O 0 1.0290799536960549e-06
and O 0 1.5229230143631867e-07
the O 0 1.0228809799173177e-07
number O 0 1.0484090040563387e-07
of O 0 2.5485095989097317e-07
trinucleotide O 0 0.0021198217291384935
repeats O 0 0.00029812296270392835
was O 0 6.300980021478608e-05
found O 0 9.228238923242316e-06
. O 0 3.6658166209235787e-06

In O 0 0.00010789717634906992
SCA3 B-Disease 1 0.999082088470459
, O 0 5.988147677271627e-05
gaze B-Disease 0 0.02915334142744541
- I-Disease 0 0.012106439098715782
evoked I-Disease 0 0.001372270635329187
nystagmus I-Disease 0 0.018930800259113312
was O 0 1.9844492271658964e-05
often O 0 6.126284120000491e-07
present O 0 2.2225654561225383e-07
as O 0 5.794156550109619e-07
was O 0 5.883459380129352e-06
saccade O 0 3.347315578139387e-05
hypometria O 0 5.648532533086836e-05
and O 0 3.329599849166698e-07
smooth O 0 1.1191285921086092e-05
pursuit O 0 1.2239018360560294e-05
gain O 0 6.815046162955696e-06
was O 0 3.943036062992178e-05
markedly O 0 0.0001163206179626286
decreased O 0 0.0001967376738321036
. O 0 1.1445100426499266e-05

Three O 0 3.3245087251998484e-06
major O 0 1.9396822608541697e-05
criteria O 0 5.168853931536432e-06
, O 0 9.623262258173781e-07
saccade O 0 2.4152999685611576e-05
amplitude O 0 3.4689560379774775e-06
, O 0 3.4924804026559286e-07
saccade O 0 1.0788270628836472e-05
velocity O 0 5.568659162236145e-06
, O 0 2.989847303069837e-07
and O 0 1.3832111278588854e-07
presence O 0 1.4954381413190276e-06
of O 0 1.2327896001806948e-06
gaze B-Disease 0 0.06009378656744957
- I-Disease 0 0.006627319846302271
evoked I-Disease 0 0.0006946026114746928
nystagmus I-Disease 0 0.0023636019323021173
, O 0 3.4810048532563087e-07
permitted O 0 8.603358736536393e-08
the O 0 1.459015663840546e-07
correct O 0 7.4700687946460675e-06
assignment O 0 5.284132384986151e-06
of O 0 3.375697588126059e-08
90 O 0 2.4698647393961437e-07
% O 0 1.2692230377808755e-08
of O 0 1.6043809836219225e-08
the O 0 2.934295935119735e-07
SCA1 B-Disease 0 0.00016862250049598515
, O 0 2.3382602876154124e-07
90 O 0 9.346643992103054e-08
% O 0 5.178221851309672e-09
of O 0 8.245078397806083e-09
the O 0 2.306964717035953e-07
SCA2 B-Disease 0 0.00023291657271329314
, O 0 3.300766309166647e-07
and O 0 1.3808229937239958e-07
93 O 0 1.1131741075587342e-06
% O 0 1.0374143322167129e-08
of O 0 2.3473889498859535e-08
the O 0 8.095697694443516e-07
patients O 0 1.9413329937378876e-05
with O 0 1.3766209576715482e-06
SCA3 B-Disease 1 0.999478280544281
to O 0 9.227344577311669e-08
their O 0 4.294438937790801e-08
genetically O 0 6.113664312579203e-06
confirmed O 0 1.0059032319986727e-05
patient O 0 1.109733602788765e-05
group O 0 4.554557051505981e-07
and O 0 3.524904172991228e-07
, O 0 4.687452133111947e-07
therefore O 0 5.963488547422457e-07
, O 0 7.972907383191341e-07
may O 0 1.478988792769087e-06
help O 0 8.992315088107716e-07
orient O 0 0.0008441302343271673
diagnoses O 0 0.0015908714849501848
of O 0 1.2482566944527207e-06
SCA1 B-Disease 0 0.008589101955294609
, O 0 6.5902445385290775e-06
SCA2 B-Disease 0 0.0008595326798968017
, O 0 1.9701969904417638e-06
and O 0 3.394180794202839e-06
SCA3 B-Disease 1 0.9991951584815979
at O 0 3.883614408550784e-05
early O 0 7.008969532762421e-06
clinical O 0 2.20267193071777e-05
stages O 0 3.573481444618665e-05
of O 0 5.428430540632689e-07
the O 0 6.525608478114009e-05
diseases O 1 0.9999487400054932
. O 0 2.5067004116863245e-06
. O 0 4.335401627031388e-06

Genetic O 0 5.360555951483548e-05
basis O 0 1.3946304306955426e-06
and O 0 7.343208494603459e-07
molecular O 0 0.00018476111290510744
mechanism O 0 0.0021591687109321356
for O 0 0.0007312649395316839
idiopathic B-Disease 1 0.9999991655349731
ventricular I-Disease 1 0.999994158744812
fibrillation I-Disease 1 0.9999967813491821
. O 0 0.0009442370501346886

Ventricular B-Disease 1 0.9972274899482727
fibrillation I-Disease 1 0.9962739944458008
causes O 0 0.000645639025606215
more O 0 6.782025252505264e-08
than O 0 1.0031828168166612e-07
300 O 0 4.1203546174983785e-07
, O 0 2.605335680527787e-07
000 O 0 1.107194293581415e-06
sudden O 0 3.494152406346984e-05
deaths O 0 2.470070057825069e-06
each O 0 6.441995736850004e-08
year O 0 5.25668156114989e-07
in O 0 1.1144302192178657e-07
the O 0 5.984294944028079e-07
USA O 0 8.188527135644108e-05
alone O 0 1.8143586203223094e-05
. O 0 5.210342351347208e-06

In O 0 1.108695869334042e-06
approximately O 0 2.1583670672953303e-07
5 O 0 1.3101366675982717e-06
- O 0 4.636086487153079e-06
12 O 0 3.0884348234394565e-07
% O 0 4.543639242626796e-09
of O 0 4.60766225174325e-09
these O 0 1.4429525130310594e-08
cases O 0 2.198822102172926e-07
, O 0 9.106806686531854e-08
there O 0 2.1454130916254144e-08
are O 0 4.049160651220518e-08
no O 0 1.8712501059781061e-06
demonstrable O 0 0.01075644139200449
cardiac O 1 0.9983186721801758
or O 0 0.00011211931996513158
non O 0 0.44107288122177124
- O 1 0.999158501625061
cardiac O 1 0.9993945360183716
causes O 0 0.00013807820505462587
to O 0 3.023134809154726e-08
account O 0 2.62598920386381e-08
for O 0 6.731863066988808e-09
the O 0 3.5485474114693716e-08
episode O 0 1.2917489584651776e-06
, O 0 1.449165694111798e-07
which O 0 4.614330961771884e-08
is O 0 1.4678639104204194e-07
therefore O 0 4.993942184228217e-07
classified O 0 9.27291257539764e-05
as O 0 0.0014873318141326308
idiopathic B-Disease 1 0.9999980926513672
ventricular I-Disease 1 0.99998939037323
fibrillation I-Disease 1 0.9999970197677612
( O 0 0.00037149025592952967
IVF B-Disease 1 0.9985957741737366
) O 0 6.210016636032378e-06
. O 0 6.91105424266425e-06

A O 0 1.017452814267017e-05
distinct O 0 7.085633114911616e-06
group O 0 9.680685252533294e-06
of O 0 3.105137921011192e-06
IVF B-Disease 1 0.9993683695793152
patients O 0 0.0003263573453295976
has O 0 6.879949410176778e-07
been O 0 1.0689299756450055e-07
found O 0 3.777113732894577e-08
to O 0 3.435677076168986e-09
present O 0 4.842312151254191e-08
with O 0 1.442463144485373e-07
a O 0 3.8230332393141e-06
characteristic O 0 0.0001907631231006235
electrocardiographic O 0 0.009235018864274025
pattern O 0 0.002094169380143285
. O 0 4.152100518695079e-05

Because O 0 2.0785823835467454e-06
of O 0 3.99837034592565e-08
the O 0 1.506033413534169e-07
small O 0 2.930090090558224e-07
size O 0 2.434580892440863e-06
of O 0 5.8709552774871554e-08
most O 0 1.067558699219262e-07
pedigrees O 0 7.486479262297507e-06
and O 0 3.889338415774546e-07
the O 0 1.0282481071044458e-06
high O 0 0.0005399659858085215
incidence O 0 0.005730857606977224
of O 0 1.605641386959178e-06
sudden B-Disease 0 0.0032695885747671127
death I-Disease 0 6.034367470419966e-05
, O 0 4.278284109204833e-07
however O 0 1.5420744148286758e-07
, O 0 1.6464024099605012e-07
molecular O 0 1.3199465684010647e-05
genetic O 0 2.0437346393009648e-05
studies O 0 1.1968461421929533e-06
of O 0 2.9605158147205657e-07
IVF B-Disease 1 0.9598071575164795
have O 0 2.7616468400992744e-07
not O 0 9.990525740022349e-08
yet O 0 9.420522815162258e-07
been O 0 1.6561864413233707e-06
done O 0 2.65542666966212e-06
. O 0 3.1839495022722986e-06

Because O 0 0.0010751934023573995
IVF B-Disease 1 0.9967464208602905
causes O 1 0.7766828536987305
cardiac O 1 0.9993865489959717
rhythm O 1 0.9962806105613708
disturbance O 1 0.849838137626648
, O 0 3.2118550734594464e-06
we O 0 7.052263413243054e-07
investigated O 0 2.2290460037766024e-05
whether O 0 1.71623923961306e-06
malfunction O 0 0.022467344999313354
of O 0 1.8513098609673762e-07
ion O 0 5.689391400665045e-05
channels O 0 2.385498009971343e-05
could O 0 5.7561723224353045e-05
cause O 0 0.0001404025824740529
the O 0 7.154306786105735e-06
disorder O 1 0.9395142793655396
by O 0 1.7626987869334698e-07
studying O 0 2.2517310753755737e-06
mutations O 0 8.943038665165659e-06
in O 0 1.7951143149730342e-07
the O 0 7.887267656769836e-07
cardiac O 0 0.012606333009898663
sodium O 0 5.220893581281416e-05
channel O 0 0.00011600957805057988
gene O 0 0.00019774853717535734
SCN5A O 0 0.005546828266233206
. O 0 2.6493877157918178e-05

We O 0 3.3812671063060407e-06
have O 0 2.4454260483253165e-07
now O 0 6.305195370259753e-07
identified O 0 1.0235382887913147e-06
a O 0 8.405823450630123e-07
missense O 0 8.063793211476877e-05
mutation O 0 1.3861435945727862e-05
, O 0 1.7954276643195044e-07
a O 0 6.999444508437591e-07
splice O 0 0.0001417769817635417
- O 0 0.00014442033716477454
donor O 0 2.214158303104341e-05
mutation O 0 3.420384382479824e-05
, O 0 3.968753787830792e-07
and O 0 1.5416244991683925e-07
a O 0 2.5425235889997566e-06
frameshift O 0 0.0005156985716894269
mutation O 0 1.1691910003719386e-05
in O 0 1.7104029836900736e-07
the O 0 1.9263045203388174e-07
coding O 0 5.785576286143623e-05
region O 0 1.5149982573348098e-05
of O 0 4.4325597059469146e-07
SCN5A O 0 0.0007494506426155567
in O 0 2.2782433006796055e-06
three O 0 4.5552706069429405e-06
IVF B-Disease 1 0.9174196124076843
families O 0 2.579691908977111e-06
. O 0 5.827894710819237e-06

We O 0 7.096968488440325e-07
show O 0 2.0912590059651848e-07
that O 0 5.471338049289898e-09
sodium O 0 1.1698022461814617e-07
channels O 0 1.374808817899975e-07
with O 0 1.1140922850927382e-07
the O 0 1.0946542943202076e-06
missense O 0 0.00022059983166400343
mutation O 0 7.780912710586563e-05
recover O 0 4.7647507017245516e-05
from O 0 2.3249853597917536e-07
inactivation O 0 7.94752559158951e-05
more O 0 2.1277633877048174e-08
rapidly O 0 2.9303994324436644e-06
than O 0 6.812374664377785e-08
normal O 0 1.9890173916792264e-06
and O 0 2.1156112950393435e-07
that O 0 5.4234632784755377e-08
the O 0 1.4547990758728702e-06
frameshift O 0 0.003368640085682273
mutation O 0 0.00013302659499458969
causes O 0 1.4789698980166577e-05
the O 0 9.451013482930648e-08
sodium O 0 1.3021473250773852e-06
channel O 0 1.3706226127396803e-06
to O 0 5.313403050877241e-08
be O 0 2.4657225594637566e-07
non O 0 6.097924597270321e-06
- O 0 7.567233114968985e-05
functional O 0 4.01169054384809e-05
. O 0 9.513419172435533e-06

Our O 0 1.2519281881395727e-05
results O 0 1.364260879199719e-05
indicate O 0 3.066399131057551e-06
that O 0 1.8741026508450886e-07
mutations O 0 3.058290894841775e-05
in O 0 2.516837867005961e-06
cardiac O 0 0.00867826584726572
ion O 0 0.0001909476559376344
- O 0 2.394738476141356e-05
channel O 0 5.8377854657010175e-06
genes O 0 9.491946570960863e-07
contribute O 0 2.0734893269036547e-07
to O 0 3.761060796136917e-08
the O 0 6.87193619341997e-07
risk O 0 2.8275841032154858e-05
of O 0 4.5968809558871726e-07
developing O 0 0.00022503346554003656
IVF B-Disease 1 0.9971355199813843
. O 0 6.686866527161328e-06
. O 0 8.580711437389255e-06

Molecular O 0 0.0007169299642555416
heterogeneity O 0 0.0002300417108926922
in O 0 1.177015383291291e-05
mucopolysaccharidosis B-Disease 0 0.0056522926315665245
IVA I-Disease 0 0.007099277805536985
in O 0 1.1700370805556304e-06
Australia O 0 3.050814996186091e-07
and O 0 1.398712612399322e-07
Northern O 0 2.707149405978271e-06
Ireland O 0 3.81917061531567e-06
: O 0 5.245588567959203e-07
nine O 0 8.818582841740863e-07
novel O 0 3.5355903946765466e-06
mutations O 0 2.147974373656325e-05
including O 0 1.0266626304655802e-06
T312S O 0 5.729425174649805e-05
, O 0 4.993727884539112e-07
a O 0 4.211758835026558e-07
common O 0 2.160054691557889e-06
allele O 0 9.583446626493242e-06
that O 0 3.7271473729560967e-07
confers O 0 4.204560900689103e-05
a O 0 5.8185247326036915e-05
mild O 0 0.1852331906557083
phenotype O 0 0.001617439673282206
. O 0 2.4506265617674217e-05

Mucopolysaccharidosis B-Disease 1 0.906965970993042
IVA I-Disease 1 0.9856640100479126
( O 0 0.0003554906288627535
MPS B-Disease 1 0.9986698627471924
IVA I-Disease 1 0.9997805953025818
) O 0 4.514169177127769e-06
is O 0 2.8592785383807495e-06
an O 0 1.1170194738951977e-05
autosomal B-Disease 1 0.9990266561508179
recessive I-Disease 1 0.9997715353965759
lysosomal I-Disease 1 0.9999072551727295
storage I-Disease 1 0.9999557733535767
disorder I-Disease 1 0.9999949932098389
caused O 0 0.010232850909233093
by O 0 1.0320362662241678e-06
a O 0 4.219108814140782e-05
genetic B-Disease 1 0.9956973791122437
defect I-Disease 1 0.9993706345558167
in O 0 5.786668680229923e-06
N O 0 0.0005209902883507311
- O 0 0.0003322648408357054
acetylgalactosamine O 0 0.0014256204012781382
- O 0 0.0004369287344161421
6 O 0 7.115966582205147e-05
- O 0 0.0006293757469393313
sulfate O 0 0.0048645841889083385
sulfatase O 0 0.010206895880401134
( O 0 4.317560524214059e-06
GALNS O 0 0.0007424356881529093
) O 0 2.746858626778703e-06
. O 0 5.051791049481835e-06

Previous O 0 1.4242260476748925e-05
studies O 0 2.0533088900265284e-06
of O 0 2.469527657922299e-07
patients O 0 8.119411177176517e-06
from O 0 1.81900119855527e-07
a O 0 8.979392873698089e-07
British O 0 2.5850366000668146e-05
- O 0 8.884169801604003e-05
Irish O 0 1.0508055311220232e-05
population O 0 6.17310149664263e-08
showed O 0 1.1042039886888233e-06
that O 0 2.392276776674862e-08
the O 0 2.231458040569123e-07
I113F O 0 3.3006239391397685e-05
mutation O 0 9.930718078976497e-06
is O 0 1.0418645501886203e-07
the O 0 3.923683067341699e-08
most O 0 1.4791029911975784e-07
common O 0 1.94646418094635e-06
single O 0 1.2132418305554893e-05
mutation O 0 0.0002121653378708288
among O 0 4.4359680032357574e-05
MPS B-Disease 1 0.9987000226974487
IVA I-Disease 1 0.9999419450759888
patients O 0 0.003855733433738351
and O 0 2.990100483657443e-06
produces O 0 6.192009459482506e-05
a O 0 0.00017395235772710294
severe O 1 0.9912307262420654
clinical O 0 0.006975848227739334
phenotype O 0 0.004609602503478527
. O 0 2.800979564199224e-05

We O 0 1.4349391676660161e-05
studied O 0 4.494899258133955e-05
mutations O 0 4.8239071475109085e-05
in O 0 3.3193589388247347e-07
the O 0 5.099388431517582e-07
GALNS O 0 0.00011471964535303414
gene O 0 4.108843768335646e-06
from O 0 8.994039149001765e-07
23 O 0 1.0104152352141682e-05
additional O 0 6.381950242939638e-06
MPS B-Disease 1 0.9959158301353455
IVA I-Disease 1 0.9998102784156799
patients O 0 0.00048132610390894115
( O 0 2.53454373932982e-07
15 O 0 5.016601107854513e-07
from O 0 7.675753721514411e-08
Australia O 0 9.588097071855373e-08
, O 0 8.470589563103204e-08
8 O 0 3.542269269019016e-07
from O 0 8.175364740736768e-08
Northern O 0 5.479235483107914e-07
Ireland O 0 1.3116531363266404e-06
) O 0 6.138371588804148e-08
, O 0 4.006844278592325e-08
with O 0 3.8143692648873184e-08
various O 0 1.0952745697068167e-06
clinical O 0 0.0003985387156717479
phenotypes O 0 0.001400807755999267
( O 0 1.6738094927859493e-05
severe O 1 0.9680284261703491
, O 0 1.5040884591144277e-06
16 O 0 2.129697577402112e-06
cases O 0 4.17756012893733e-07
; O 0 1.1321363757588188e-07
intermediate O 0 2.990285793202929e-06
, O 0 6.733014288329287e-07
4 O 0 2.543794380471809e-06
cases O 0 1.0797323284350568e-06
; O 0 1.1606781527007115e-06
mild O 0 0.0010659933323040605
, O 0 8.742790669202805e-07
3 O 0 2.1201285562710837e-06
cases O 0 1.181447032649885e-06
) O 0 4.243848934493144e-07
. O 0 3.808506562563707e-06

We O 0 3.4361619327683e-06
found O 0 8.315391823998652e-07
two O 0 7.691978254342757e-08
common O 0 1.5160615021159174e-06
mutations O 0 7.217608072096482e-06
that O 0 1.3877161642028568e-08
together O 0 3.354465860638811e-08
accounted O 0 3.6150390769762453e-07
for O 0 2.394294362773053e-08
32 O 0 3.376316612957453e-07
% O 0 8.585454125409342e-09
of O 0 1.5451474766337014e-08
the O 0 2.390731026480353e-07
44 O 0 1.4123799019216676e-06
unrelated O 0 5.213125405134633e-06
alleles O 0 2.046333975158632e-06
in O 0 5.193942911319027e-07
these O 0 5.215216560827685e-07
patients O 0 0.00012157468154327944
. O 0 1.0643667337717488e-05

One O 0 4.6180298340914305e-06
is O 0 7.560680046481139e-07
the O 0 6.557222604897106e-07
T312S O 0 8.84369874256663e-05
mutation O 0 2.495749322406482e-05
, O 0 3.8438244587268855e-07
a O 0 3.9443560240215447e-07
novel O 0 1.3375398566495278e-06
mutation O 0 8.37792958918726e-06
found O 0 3.8729228890588274e-07
exclusively O 0 8.763927326072007e-07
in O 0 2.6865923246077728e-06
milder O 0 0.001181442872621119
patients O 0 0.00042027601739391685
. O 0 9.604012120689731e-06

The O 0 9.153169457931654e-07
other O 0 2.3751505295876996e-07
is O 0 4.50571690180368e-07
the O 0 2.660001712229132e-07
previously O 0 4.721509412775049e-06
described O 0 4.006324161309749e-06
I113F O 0 3.028493119927589e-05
that O 0 2.99341934351105e-07
produces O 0 2.5141505830106325e-05
a O 0 0.00010023666982306167
severe O 1 0.990090012550354
phenotype O 0 0.00296493386849761
. O 0 3.568700049072504e-05

The O 0 6.879542524984572e-06
I113F O 0 0.00013355824921745807
and O 0 2.277185330967768e-06
T312S O 0 6.8819681473542e-05
mutations O 0 2.3652512027183548e-05
accounted O 0 2.968039780171239e-06
for O 0 7.562779558156763e-08
8 O 0 9.606206958778785e-07
( O 0 5.3781178621647996e-08
18 O 0 2.0795927468952868e-07
% O 0 3.0834121922396207e-09
) O 0 8.609132962078547e-09
and O 0 7.742671925825562e-08
6 O 0 9.796681297302712e-07
( O 0 4.956728361094065e-08
14 O 0 2.0514755760814296e-07
% O 0 4.656634633448675e-09
) O 0 7.775893706707393e-09
of O 0 1.6026834970261916e-08
44 O 0 7.924785450086347e-07
unrelated O 0 3.8032471820770297e-06
alleles O 0 2.6207760583929485e-06
, O 0 1.8313664895686088e-06
respectively O 0 2.0958177628926933e-05
. O 0 7.778359758958686e-06

The O 0 2.4416538053628756e-06
relatively O 0 1.5419818737427704e-05
high O 0 8.368973794858903e-05
residual O 0 0.000134033864014782
GALNS O 0 0.0007536748889833689
activity O 0 2.7211374344915384e-06
seen O 0 3.359362608534866e-06
when O 0 3.9028779497130017e-07
the O 0 1.465740524508874e-07
T312S O 0 6.302877864072798e-06
mutant O 0 1.404061436005577e-06
cDNA O 0 7.936213251014124e-07
is O 0 7.446529934895807e-07
overexpressed O 0 3.68632136087399e-05
in O 0 3.1738130701342016e-07
mutant O 0 5.895804861211218e-06
cells O 0 1.7730739045873634e-06
provides O 0 6.310808942089352e-08
an O 0 4.1526067917629916e-08
explanation O 0 3.042148364329478e-07
for O 0 4.8569546606813674e-08
the O 0 1.7894188886202755e-06
mild O 0 0.003943214658647776
phenotype O 0 0.0001309944491367787
in O 0 1.938372633958352e-06
patients O 0 6.79611366649624e-06
with O 0 2.421409419639531e-07
this O 0 6.434848955905181e-07
mutation O 0 0.00010331892553949729
. O 0 7.1874815148476046e-06

The O 0 2.0547531676129438e-07
distribution O 0 2.1354236423576367e-07
and O 0 7.660893430738724e-08
relative O 0 2.0261310851310554e-07
frequencies O 0 1.282323751183867e-06
of O 0 5.4696087659067416e-08
the O 0 3.900600802353438e-07
I113F O 0 4.858903048443608e-05
and O 0 1.4086509736443986e-06
T312S O 0 8.180496661225334e-05
mutations O 0 3.3020438422681764e-05
in O 0 4.182722364021174e-07
Australia O 0 1.1643318487131182e-07
corresponded O 0 3.825816747848876e-07
to O 0 2.4830470124470594e-08
those O 0 5.0174143950698635e-08
observed O 0 1.6364635939680738e-06
in O 0 1.4862973785056965e-07
Northern O 0 2.036234263869119e-06
Ireland O 0 4.40118856204208e-06
and O 0 2.3964332740433747e-07
are O 0 6.456926993081424e-09
unique O 0 4.99080421434428e-08
to O 0 1.1938790400733978e-08
these O 0 7.174633331885616e-09
two O 0 9.535736467114475e-08
populations O 0 4.1137110429190216e-07
, O 0 1.6165702731996134e-07
suggesting O 0 3.7335470892685407e-07
that O 0 4.909810336073406e-09
both O 0 4.585334778539618e-08
mutations O 0 3.113675120403059e-06
were O 0 9.891437002806924e-08
probably O 0 4.1614165979808604e-07
introduced O 0 1.273153742431532e-07
to O 0 2.0859362237501955e-08
Australia O 0 1.3163243295366556e-07
by O 0 4.964694966247407e-08
Irish O 0 4.3013965296268e-06
migrants O 0 3.0266835437942063e-07
during O 0 1.0404074828329613e-06
the O 0 1.8216555019989755e-07
19th O 0 1.297344351769425e-05
century O 0 2.7701624276232906e-05
. O 0 1.1267276022408623e-05

Haplotype O 0 0.00025752082001417875
analysis O 0 8.091066661108925e-07
using O 0 5.586072688856802e-07
6 O 0 4.198010174150113e-06
RFLPs O 0 3.393295264686458e-05
provides O 0 8.571632292841969e-08
additional O 0 1.7745707125982335e-08
data O 0 3.506263226427109e-07
that O 0 2.3187006092939555e-08
the O 0 3.5975472201243974e-07
I113F O 0 5.197852442506701e-05
mutation O 0 7.572241884190589e-06
originated O 0 9.466336337027315e-07
from O 0 6.97416524531036e-08
a O 0 2.643286336478923e-07
common O 0 1.9598230664996663e-06
ancestor O 0 2.8913726055179723e-05
. O 0 1.723952664178796e-05

The O 0 1.934819238158525e-06
other O 0 2.76612240668328e-07
9 O 0 4.489329057832947e-06
novel O 0 1.6488708070028224e-06
mutations O 0 1.124413302022731e-05
identified O 0 5.029410772294796e-07
in O 0 8.931925776778371e-08
these O 0 4.77353552241766e-08
23 O 0 4.2612164179445244e-06
patients O 0 1.039382937051414e-06
were O 0 1.4683002369508813e-08
each O 0 3.246090285458081e-09
limited O 0 2.5147375737333277e-08
to O 0 1.2843876184831515e-08
a O 0 5.682255164174421e-07
single O 0 4.102117600268684e-06
family O 0 2.2912008716957644e-05
. O 0 9.262342246074695e-06

These O 0 9.368508102625128e-08
data O 0 2.9475171459125704e-07
provide O 0 1.9222483160774573e-08
further O 0 1.8725978989664327e-08
evidence O 0 3.6048756868467535e-08
for O 0 2.1232997582387725e-08
extensive O 0 1.2405685993144289e-05
allelic O 0 0.00036539140273816884
heterogeneity O 0 0.000455159432021901
in O 0 8.644052286399528e-05
MPS B-Disease 1 0.9968131184577942
IVA I-Disease 1 0.9995083808898926
in O 0 9.980857612390537e-06
British O 0 0.0004297640407457948
- O 0 0.008164962753653526
Irish O 0 0.00039455341175198555
patients O 0 2.442518962197937e-05
and O 0 4.498868122482236e-08
provide O 0 1.6684161607827264e-08
evidence O 0 3.349766686255862e-08
for O 0 6.790889184316029e-09
their O 0 1.3698651102345138e-08
transmission O 0 9.501704880676698e-06
to O 0 5.812736247889916e-08
Australia O 0 1.328809844380885e-07
by O 0 5.011541759358806e-08
British O 0 7.553065188403707e-06
- O 0 5.599919313681312e-05
Irish O 0 1.3466744348988868e-05
migrants O 0 9.398573297403345e-07
. O 0 7.3773367148533e-07
. O 0 2.6800566956808325e-06

Identification O 0 1.3695113921130542e-05
of O 0 2.3900206542748492e-06
constitutional O 0 0.0002910521870944649
WT1 O 0 0.02801673859357834
mutations O 0 0.001070649130269885
, O 0 3.0380335829249816e-06
in O 0 1.5570188907076954e-06
patients O 0 3.38669415214099e-05
with O 0 7.5315588219382335e-06
isolated O 1 0.945965588092804
diffuse B-Disease 1 0.9992783665657043
mesangial I-Disease 1 0.9999862909317017
sclerosis I-Disease 1 0.9999997615814209
, O 0 1.066758886736352e-05
and O 0 3.528516288042738e-07
analysis O 0 5.648993237628019e-07
of O 0 2.351148964407912e-07
genotype O 0 6.838529225206003e-05
/ O 0 5.5120752222137526e-05
phenotype O 0 2.145871621905826e-05
correlations O 0 1.4045757552594296e-06
by O 0 2.256316733451058e-08
use O 0 4.561146482728873e-08
of O 0 3.1619340035149435e-08
a O 0 2.054550577668124e-06
computerized O 0 0.0012155146105214953
mutation O 0 0.00020050458260811865
database O 0 3.207753616152331e-05
. O 0 1.2778294149029534e-05

Constitutional O 0 0.00026481717941351235
mutations O 0 9.426860196981579e-05
of O 0 1.644469023176498e-07
the O 0 6.700653329971828e-07
WT1 O 0 0.0004450011474546045
gene O 0 5.161657099961303e-06
, O 0 1.423017295110185e-07
encoding O 0 3.54862606855022e-07
a O 0 1.258718293684069e-05
zinc O 0 0.004108339548110962
- O 0 0.00010213502537226304
finger O 0 0.00013226477312855422
transcription O 0 9.032772140926681e-06
factor O 0 1.5375206885437365e-06
involved O 0 1.410418690284132e-06
in O 0 4.5238448365125805e-06
renal O 1 0.9998769760131836
and O 0 1.433958277630154e-05
gonadal O 0 0.005311673507094383
development O 0 2.7408323148847558e-06
, O 0 4.44815157152334e-07
are O 0 1.8024953973849733e-08
found O 0 2.1885335854676669e-07
in O 0 1.270429805799722e-07
most O 0 9.09899085854704e-07
patients O 0 1.8535443814471364e-05
with O 0 1.0190997272729874e-05
Denys B-Disease 1 0.9990057349205017
- I-Disease 1 0.9998112320899963
Drash I-Disease 1 0.998933732509613
syndrome I-Disease 1 0.9999923706054688
( O 0 3.949569509131834e-05
DDS B-Disease 1 0.9998313188552856
) O 0 5.008693278796272e-06
, O 0 7.260341135406634e-06
or O 0 0.0002331565337954089
diffuse B-Disease 1 0.9994195699691772
mesangial I-Disease 1 0.9999886751174927
sclerosis I-Disease 1 0.9999997615814209
( O 0 0.00015521027671638876
DMS B-Disease 0 0.468432754278183
) O 0 1.095844936571666e-06
associated O 0 4.584102953231195e-06
with O 0 5.043328656029189e-06
pseudohermaphroditism B-Disease 1 0.9999121427536011
and O 0 0.00011093926150351763
/ O 0 0.0021681098733097315
or O 0 0.0012522657634690404
Wilms B-Disease 1 0.999484658241272
tumor I-Disease 1 0.9993786811828613
( O 0 3.400999048608355e-05
WT B-Disease 1 0.9944809675216675
) O 0 3.276590177847538e-06
. O 0 4.288511263439432e-06

Most O 0 3.7820231227669865e-05
mutations O 0 0.001953045022673905
in O 0 9.95187510852702e-05
DDS B-Disease 1 0.999943733215332
patients O 0 0.006054367404431105
lie O 0 0.00011744822404580191
in O 0 1.888100428004691e-06
exon O 0 5.288833563099615e-05
8 O 0 4.322372205933789e-06
or O 0 1.6468261492263991e-06
exon O 0 2.7672338546835817e-05
9 O 0 4.733366495202063e-06
, O 0 1.3375304774854158e-07
encoding O 0 1.3693108940060483e-06
zinc O 0 0.003443623660132289
finger O 0 0.002835979452356696
2 O 0 7.137025477277348e-06
or O 0 5.454842266772175e-06
zinc O 0 0.0022952482104301453
finger O 0 0.0010711622890084982
3 O 0 1.7005886547849514e-06
, O 0 1.3641606244618742e-07
respectively O 0 4.178021981715574e-07
, O 0 4.99866388281589e-08
with O 0 5.0791150840723276e-08
a O 0 2.5210467811120907e-06
hot O 0 0.00014170115173328668
spot O 0 2.37744261539774e-05
( O 0 2.091097428547073e-07
R394W O 0 6.53108781989431e-06
) O 0 8.891166203284229e-08
in O 0 2.684988942291966e-07
exon O 0 6.844818562967703e-05
9 O 0 2.8009555535390973e-05
. O 0 5.331577085598838e-06

We O 0 3.723271674971329e-06
analyzed O 0 3.105291852989467e-06
a O 0 2.7913239364352194e-07
series O 0 3.2106129310705e-07
of O 0 1.1521770204581117e-07
24 O 0 7.661793461011257e-06
patients O 0 7.673610525671393e-06
, O 0 1.990467950463426e-07
10 O 0 3.5191135339118773e-07
with O 0 9.647152410252602e-07
isolated B-Disease 0 0.0020272068213671446
DMS I-Disease 0 0.2574559152126312
( O 0 3.7631957638950553e-06
IDMS B-Disease 0 0.002989055123180151
) O 0 3.784733451084321e-07
, O 0 3.364039002917707e-07
10 O 0 3.4535960935500043e-07
with O 0 1.4920932471795822e-06
DDS B-Disease 1 0.9999123811721802
, O 0 4.753220309794415e-06
and O 0 1.032900740938203e-06
4 O 0 8.425176929449663e-06
with O 0 1.573183180880733e-05
urogenital B-Disease 1 0.9986175298690796
abnormalities I-Disease 1 0.9999120235443115
and O 0 8.553887164453045e-05
/ O 0 0.0021219581831246614
or O 0 0.0006389091140590608
WT B-Disease 1 0.9990504384040833
. O 0 5.291199704515748e-05

We O 0 1.7576056052348576e-05
report O 0 6.790879524487536e-06
WT1 O 0 0.0006737951189279556
heterozygous O 0 5.1898850870202295e-06
mutations O 0 2.7730591682484373e-05
in O 0 6.485873882411397e-07
16 O 0 4.883750079898164e-06
patients O 0 6.888155894557713e-06
, O 0 3.1057902560860384e-07
4 O 0 7.011590810179769e-07
of O 0 6.486579451348007e-08
whom O 0 2.5893687052302994e-06
presented O 0 8.67642756929854e-06
with O 0 1.4917754015186802e-05
IDMS B-Disease 1 0.9903942942619324
. O 0 0.00011125687888124958

One O 0 3.5701680189959006e-06
male O 0 2.7705737011274323e-06
and O 0 8.188191031877068e-07
two O 0 1.037895231092989e-06
female O 0 5.853926995769143e-05
IDMS B-Disease 1 0.9888807535171509
patients O 0 0.0005914002540521324
with O 0 1.4825001926510595e-05
WT1 O 0 0.33774325251579285
mutations O 0 0.03565627709031105
underwent O 1 0.9664363861083984
normal O 0 0.0008990852511487901
puberty O 0 0.01426180824637413
. O 0 2.21096179302549e-05

Two O 0 1.167111076938454e-05
mutations O 0 0.0004768164362758398
associated O 0 1.8237262338516302e-05
with O 0 1.850460307650792e-06
IDMS B-Disease 0 0.04261256381869316
are O 0 5.160881144661289e-08
different O 0 2.0139957257470087e-08
from O 0 2.151109015358088e-07
those O 0 1.53101680666623e-07
described O 0 2.7303180104354396e-05
in O 0 3.1628820579499006e-05
DDS B-Disease 1 0.9999486207962036
patients O 0 0.013103809207677841
. O 0 2.2127165721030906e-05

No O 0 3.8094167393865064e-05
WT1 O 0 0.004849435295909643
mutations O 0 0.00022127307602204382
were O 0 1.376438490297005e-06
detected O 0 4.655534939956851e-05
in O 0 1.27762120882835e-07
the O 0 8.875544210695807e-08
six O 0 1.2236591828695964e-06
other O 0 1.2522855286078993e-06
IDMS B-Disease 1 0.991902768611908
patients O 0 0.0005166615010239184
, O 0 2.1371197362896055e-06
suggesting O 0 1.6089819837361574e-05
genetic O 0 4.4035106839146465e-05
heterogeneity O 0 8.060102845774963e-05
of O 0 1.9219148725824198e-06
this O 0 2.674274583114311e-05
disease O 1 0.9994028806686401
. O 0 3.296817885711789e-05

We O 0 8.104527296382003e-06
analyzed O 0 2.519676309020724e-05
genotype O 0 3.994645521743223e-05
/ O 0 4.4928376155439764e-05
phenotype O 0 1.8357943190494552e-05
correlations O 0 3.0351463919942034e-06
, O 0 2.2942241173495859e-07
on O 0 1.4501030420888128e-07
the O 0 1.7595992218844003e-08
basis O 0 3.699341633023323e-08
of O 0 2.81900582876915e-08
the O 0 3.5121232144774694e-07
constitution O 0 8.034366487663647e-07
of O 0 6.614868652832229e-08
a O 0 3.887868842866737e-06
WT1 O 0 0.0011442825198173523
mutation O 0 2.568988384155091e-05
database O 0 1.998057541641174e-06
of O 0 2.867673742912302e-07
84 O 0 4.253251972841099e-05
germ O 0 0.0023400476202368736
- O 0 0.00026903196703642607
line O 0 4.981228994438425e-05
mutations O 0 3.2179381378227845e-05
, O 0 1.0088971436061911e-07
to O 0 6.399289986802614e-09
compare O 0 3.3423700074308726e-07
the O 0 2.4916531060625857e-08
distribution O 0 8.28240587225082e-08
and O 0 2.707741089125193e-07
type O 0 1.363118917652173e-05
of O 0 2.5372040113325056e-07
mutations O 0 3.2644002203596756e-05
, O 0 2.672162793260213e-07
according O 0 4.560207145232198e-08
to O 0 2.5136873915698743e-08
the O 0 1.879703432905444e-07
different O 0 1.7822251265897648e-06
symptoms O 1 0.8622971773147583
. O 0 1.901201540022157e-05

This O 0 5.459273779706564e-07
demonstrated O 0 2.6035002065327717e-06
( O 0 1.623909895442921e-07
1 O 0 3.3423575018787233e-07
) O 0 1.733912391443937e-08
the O 0 5.2077211876166984e-08
association O 0 3.306759026600048e-07
between O 0 1.6575690153786127e-07
mutations O 0 8.23729806143092e-06
in O 0 1.960386128985192e-07
exons O 0 3.7098809571034508e-06
8 O 0 2.0162767668807646e-06
and O 0 6.254392133087094e-07
9 O 0 4.808786798093934e-06
and O 0 1.8218047443951946e-06
DMS B-Disease 0 0.002333746524527669
; O 0 6.330978408186638e-07
( O 0 1.213911531294798e-07
2 O 0 4.7041922357493604e-07
) O 0 5.9119702910948035e-08
among O 0 2.3443425334335188e-07
patients O 0 4.272834303264972e-06
with O 0 4.605854542205634e-07
DMS B-Disease 0 0.00321782985702157
, O 0 1.5361487726295309e-07
a O 0 1.2473779520405515e-07
higher O 0 2.0118615395858797e-07
frequency O 0 6.398792038453394e-07
of O 0 1.3797067310861166e-07
exon O 0 7.116733468137681e-05
8 O 0 7.412085324176587e-06
mutations O 0 3.4945485822390765e-05
among O 0 1.2063412668794626e-06
46 O 0 1.4866666788293514e-05
, O 0 3.5801440390059724e-06
XY O 0 0.0010013821301981807
patients O 0 9.732801117934287e-06
with O 0 1.2153594752817298e-07
female O 0 1.0541552910581231e-06
phenotype O 0 5.687769771611784e-06
than O 0 1.7354452097606554e-07
among O 0 6.63241621623456e-07
46 O 0 1.068397887138417e-05
, O 0 5.879263881070074e-06
XY O 0 0.004625167232006788
patients O 0 3.660838774521835e-05
with O 0 5.132120008966012e-07
sexual O 0 2.453263505231007e-06
ambiguity O 0 3.3130763767985627e-06
or O 0 3.838593329419382e-06
male O 0 5.154362497705733e-06
phenotype O 0 3.960526373703033e-05
; O 0 4.339863153290935e-07
and O 0 3.666834231808025e-07
( O 0 1.2322847453560826e-07
3 O 0 4.0264040990223293e-07
) O 0 2.122862419184912e-08
statistically O 0 2.780210763830837e-07
significant O 0 5.3613515405004364e-08
evidence O 0 7.821010683528584e-08
that O 0 2.5716442308976184e-08
mutations O 0 2.790703319988097e-06
in O 0 1.1629080631792021e-07
exons O 0 6.6123420765507035e-06
8 O 0 3.102000619037426e-06
and O 0 2.5803120706768823e-07
9 O 0 1.520447312941542e-06
preferentially O 0 1.3151553730494925e-06
affect O 0 4.895860570286459e-07
amino O 0 1.4094463551828085e-07
acids O 0 1.0581906906281802e-07
with O 0 7.696216108854514e-09
different O 0 9.447386872807328e-09
functions O 0 4.708312246748392e-07
. O 0 9.365860478283139e-07
. O 0 4.048577011417365e-06

The O 0 3.419699351070449e-05
185delAG O 0 0.0027420097030699253
BRCA1 O 0 0.0010972113814204931
mutation O 0 5.538050027098507e-05
originated O 0 2.134146143362159e-06
before O 0 4.743602062262653e-07
the O 0 9.766693409574145e-08
dispersion O 0 2.040300842054421e-06
of O 0 4.2922689402757896e-08
Jews O 0 3.3281963851550245e-07
in O 0 1.7627408510634268e-07
the O 0 7.010039837496151e-08
diaspora O 0 4.6768738570790447e-07
and O 0 4.3618211975626764e-07
is O 0 1.1106381236913876e-07
not O 0 2.7606242625211053e-08
limited O 0 1.0307541487009075e-07
to O 0 3.461262281234667e-07
Ashkenazim O 0 0.0015603809151798487
. O 0 3.0865270673530176e-05

The O 0 7.829024070815649e-06
185delAG O 0 0.0007413320709019899
mutation O 0 8.153199451044202e-05
in O 0 2.4350567855435656e-06
BRCA1 O 0 0.0002551452780608088
is O 0 3.3874027849378763e-06
detected O 0 8.679933671373874e-05
in O 0 7.194958584477718e-07
Ashkenazi O 0 4.617276499629952e-05
Jews O 0 7.643473054486094e-07
both O 0 1.2378058045214857e-06
in O 0 2.1429083062685095e-05
familial B-Disease 1 0.9984763264656067
breast I-Disease 1 0.9999750852584839
and I-Disease 1 0.9997523427009583
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
and O 0 4.421879111760063e-06
in O 0 4.794815140485298e-07
the O 0 2.624960586672387e-07
general O 0 9.712251767268754e-07
population O 0 2.1711377939936938e-07
. O 0 3.68000655726064e-06

All O 0 5.52762776351301e-06
tested O 0 0.0002689632528927177
Ashkenazi O 0 0.0005372115992940962
mutation O 0 3.9582075260113925e-05
carriers O 0 5.099265308672329e-06
share O 0 4.544395721950423e-07
the O 0 1.8902989040725515e-07
same O 0 4.1103112380369566e-07
allelic O 0 5.0650221965042874e-05
pattern O 0 6.152762216515839e-05
at O 0 2.2605940102948807e-05
the O 0 2.7874475563294254e-06
BRCA1 O 0 0.000872638076543808
locus O 0 0.0003320029645692557
. O 0 3.2243278837995604e-05

Our O 0 1.7853636791187455e-06
previous O 0 4.245336185704218e-06
study O 0 1.0388854434495443e-06
showed O 0 1.9196929770259885e-06
that O 0 3.0262558681215523e-08
this O 0 1.0329387833962755e-07
Ashkenazi O 0 0.0001741427113302052
mutation O 0 4.763583274325356e-05
also O 0 1.0295806305293809e-06
occurs O 0 6.450509886235523e-07
in O 0 4.3316056519415724e-08
Iraqi O 0 3.9033059806570236e-07
Jews O 0 1.6796947477359936e-07
with O 0 1.260632132016326e-07
a O 0 1.0241963082080474e-06
similar O 0 3.7939623780403053e-06
allelic O 0 0.00043359072878956795
pattern O 0 0.0007654391811229289
. O 0 3.614679371821694e-05

We O 0 1.0001896271205624e-06
extended O 0 2.3733073817311379e-07
our O 0 8.468521883742142e-08
analysis O 0 6.442929390004792e-08
to O 0 2.2430109325455305e-08
other O 0 1.0157032193092164e-07
non O 0 1.0833075975824613e-05
- O 0 5.756166865467094e-05
Ashkenazi O 0 0.00011965743760811165
subsets O 0 1.1560998245840892e-05
354 O 0 8.229830200434662e-06
of O 0 9.492654839959869e-08
Moroccan O 0 6.965291504457127e-06
origin O 0 3.7762859506074165e-07
, O 0 3.256579077515198e-07
200 O 0 2.6257043828081805e-07
Yemenites O 0 3.528931847540662e-05
and O 0 4.782936002811766e-07
150 O 0 6.946114012862381e-07
Iranian O 0 3.455906380622764e-06
Jews O 0 7.544490927102743e-06
. O 0 1.1939702744712122e-05

Heteroduplex O 0 0.00043881204328499734
analysis O 0 4.787275997841789e-07
complemented O 0 9.363922686134174e-07
by O 0 1.575223151917271e-08
direct O 0 2.244140517859705e-08
DNA O 0 1.4029960766492877e-06
sequencing O 0 1.799840219973703e-06
of O 0 2.417770303964062e-07
abnormally O 0 0.00024370431492570788
migrating O 0 3.4318063626415096e-06
bands O 0 1.225226151291281e-05
were O 0 6.404940222637379e-07
employed O 0 6.598174877581187e-06
. O 0 6.4717833083705045e-06

Four O 0 1.494227944931481e-06
of O 0 1.509490203943642e-07
Moroccan O 0 5.77438095206162e-06
origin O 0 2.1579204201316315e-07
( O 0 1.0727003285637693e-07
1 O 0 3.021590373464278e-07
. O 0 1.6983692674443773e-08
1 O 0 1.2856797582116997e-07
% O 0 5.385947687841508e-09
) O 0 1.6635768318451483e-08
and O 0 8.523228700596519e-08
none O 0 3.7527991025854135e-07
of O 0 1.9355702818302234e-08
the O 0 1.6011641434943158e-07
Yemenites O 0 7.027061656117439e-05
or O 0 8.642071520625905e-07
Iranians O 0 8.445630896858347e-07
was O 0 2.8337094590824563e-06
a O 0 8.800427053756721e-07
carrier O 0 1.1084241123171523e-05
of O 0 9.35408053237552e-08
the O 0 2.467920239723753e-06
185delAG O 0 0.0009343356941826642
mutation O 0 0.0003360782575327903
. O 0 1.3838533050147817e-05

BRCA1 O 0 0.0048361243680119514
allelic O 0 0.000783740368206054
patterns O 0 3.133469363092445e-05
were O 0 2.3873158738751954e-07
determined O 0 2.6136174824387126e-07
for O 0 9.444612203424185e-09
four O 0 2.6453486512423297e-08
of O 0 4.148235088763386e-09
these O 0 1.0148914597607472e-08
individuals O 0 5.712865736029471e-09
and O 0 7.115028921589328e-08
for O 0 2.724114978036596e-08
12 O 0 3.8647024780402717e-07
additional O 0 1.6669156366333482e-07
non O 0 2.5868417651508935e-05
- O 0 0.0003274924820289016
Ashkenazi O 0 0.0006463787867687643
185delAG O 0 0.0004367981746327132
mutation O 0 7.382751209661365e-05
carriers O 0 0.0001143391418736428
who O 0 0.0001591833570273593
had O 0 0.012022587470710278
breast B-Disease 1 0.9999666213989258
/ I-Disease 1 0.9999336004257202
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 0.00010032416321337223

Six O 0 2.915372169809416e-05
non O 0 9.771493205334991e-05
- O 0 0.00032964005367830396
Ashkenazi O 0 0.0001436120510334149
individuals O 0 5.924997381612229e-08
shared O 0 4.4030088020008407e-07
the O 0 2.895023101245897e-07
common O 0 6.528833182528615e-06
Ashkenazi O 0 0.00032206595642492175
haplotype O 0 0.00016339503054041415
, O 0 1.0506054195502657e-06
four O 0 2.0731768302084674e-07
had O 0 5.011699499846145e-07
a O 0 3.935255961096118e-07
closely O 0 1.7795890698835137e-06
related O 0 3.3471530969109153e-06
pattern O 0 3.5046607081312686e-05
, O 0 9.052563427758287e-07
and O 0 1.4592467323382152e-07
the O 0 1.549853010374136e-07
rest O 0 2.1698742784792557e-06
( O 0 3.675814923553844e-07
n O 0 1.1957762581005227e-05
= O 0 9.07068624655949e-06
6 O 0 1.6431082485723891e-06
) O 0 2.6281137266437327e-08
displayed O 0 8.909149755709223e-07
a O 0 1.1861287703140988e-06
distinct O 0 5.198092821956379e-06
BRCA1 O 0 0.0009533986449241638
allelic O 0 0.0010438001481816173
pattern O 0 0.0018007889157161117
. O 0 6.692687748000026e-05

We O 0 5.002955276722787e-06
conclude O 0 8.591618097852916e-06
that O 0 8.255388905809014e-08
the O 0 1.0891403690038715e-06
185delAG O 0 0.0007155154016800225
BRCA1 O 0 0.0019900817424058914
mutation O 0 0.00016119176871143281
occurs O 0 5.8825612541113514e-06
in O 0 1.7272257935019297e-07
some O 0 1.0946651229915005e-07
non O 0 2.3960474209161475e-05
- O 0 0.00021456282411236316
Ashkenazi O 0 0.00014907793956808746
populations O 0 2.111567027895944e-06
at O 0 5.272534053801792e-06
rates O 0 1.0739240678958595e-06
comparable O 0 1.0935909813269973e-06
with O 0 1.0790822813078194e-07
that O 0 9.142885204482809e-08
of O 0 2.815189077409741e-07
Ashkenazim O 0 0.004319045227020979
. O 0 5.148515265318565e-05

The O 0 4.466836344363401e-06
majority O 0 1.7399540865881136e-06
of O 0 3.635922496414423e-07
Jewish O 0 2.2211204850464128e-05
185delAG O 0 0.000951332098338753
mutation O 0 9.984420466935262e-05
carriers O 0 1.0864124305953737e-05
have O 0 2.956917910523771e-07
a O 0 1.2185527111796546e-06
common O 0 1.2125837201892864e-05
allelic O 0 0.0005740438355132937
pattern O 0 0.0004667174653150141
, O 0 2.4330256565008312e-06
supporting O 0 2.023162778641563e-06
the O 0 1.2492272389863501e-06
founder O 0 5.0290211220271885e-05
effect O 0 3.5430061871011276e-06
notion O 0 2.6900688681052998e-06
, O 0 5.044955742050661e-07
but O 0 7.73024737554806e-08
dating O 0 2.1556611500272993e-06
the O 0 9.025911396065567e-08
mutations O 0 1.2991541780138505e-06
origin O 0 1.7977297872562303e-08
to O 0 1.0060374755482826e-08
an O 0 3.4663980130744676e-08
earlier O 0 7.91427225976804e-07
date O 0 5.442934707389213e-07
than O 0 9.056970640131112e-08
currently O 0 4.78252616176178e-07
estimated O 0 1.072356099030003e-06
. O 0 2.3288630472961813e-06

However O 0 4.573169007926481e-06
, O 0 3.4155880257458193e-07
the O 0 7.368786469896804e-08
different O 0 1.0973932518254514e-07
allelic O 0 5.409613731899299e-05
pattern O 0 7.61009578127414e-05
at O 0 2.098507684422657e-05
the O 0 7.990094559318095e-07
BRCA1 O 0 8.650739619042724e-05
locus O 0 1.409562537446618e-05
even O 0 6.890106760693016e-07
in O 0 1.1602327987247918e-07
some O 0 2.8006342134290207e-08
Jewish O 0 1.822955368879775e-06
mutation O 0 2.2958245608606376e-05
carriers O 0 1.4240495147532783e-05
, O 0 8.722827828933077e-07
might O 0 1.1155226502523874e-06
suggest O 0 5.986429414406302e-07
that O 0 5.4867548726633686e-08
the O 0 3.862646451580076e-07
mutation O 0 8.459967830276582e-06
arose O 0 2.2711885776516283e-06
independently O 0 1.327751306234859e-06
. O 0 1.034979391079105e-06
. O 0 3.254453986301087e-06

Crystal O 0 0.0028215472120791674
structure O 0 0.00010475992894498631
of O 0 1.4293706271928386e-06
the O 0 2.8451493562897667e-05
hemochromatosis B-Disease 1 0.9999223947525024
protein O 0 0.0001080562433344312
HFE O 0 0.0041665248572826385
and O 0 1.1689295433825464e-06
characterization O 0 4.5895922085037455e-06
of O 0 3.692109018516021e-08
its O 0 3.3614341532484104e-08
interaction O 0 2.770615878944227e-07
with O 0 3.785884814533347e-07
transferrin O 0 0.000384119019145146
receptor O 0 0.00012405643064994365
. O 0 8.22578113002237e-06

HFE O 0 0.012318137101829052
is O 0 3.6285830447013723e-06
an O 0 8.947848755269661e-07
MHC O 0 0.00017843405657913536
- O 0 1.876083479146473e-05
related O 0 1.1189075621587108e-06
protein O 0 6.454355911955645e-07
that O 0 2.586357084055635e-08
is O 0 5.788175627685632e-08
mutated O 0 1.8851299046218628e-06
in O 0 3.657331149042875e-07
the O 0 6.897043022036087e-06
iron B-Disease 1 0.9997989535331726
- I-Disease 1 0.9999047517776489
overload I-Disease 1 0.9997968077659607
disease I-Disease 1 0.9999912977218628
hereditary B-Disease 1 0.9999994039535522
hemochromatosis I-Disease 1 0.9999998807907104
. O 0 0.004585637710988522

HFE O 0 0.0020117652602493763
binds O 0 7.89923797128722e-06
to O 0 6.439612434405717e-07
transferrin O 0 7.128830475267023e-05
receptor O 0 1.3188103366701398e-05
( O 0 4.3656623915921955e-07
TfR O 0 4.602962508215569e-05
) O 0 7.688575465181202e-08
and O 0 6.8671020869715e-08
reduces O 0 6.889114843033894e-07
its O 0 3.242855584062454e-08
affinity O 0 1.7339210671707406e-06
for O 0 3.373760932845471e-07
iron O 0 0.0642620176076889
- O 0 0.0001179846512968652
loaded O 0 2.55705581366783e-05
transferrin O 0 0.00025243283016607165
, O 0 5.093141226097941e-06
implicating O 0 0.00099816988222301
HFE O 0 0.0037399211432784796
in O 0 1.4274240129452664e-05
iron O 1 0.916841983795166
metabolism O 0 0.12904053926467896
. O 0 3.477308200672269e-05

The O 0 6.76759145790129e-06
2 O 0 5.041847180109471e-05
. O 0 1.172082465927815e-05

6 O 0 5.61673405172769e-05
A O 0 2.364252031838987e-05
crystal O 0 0.003291306784376502
structure O 0 0.00011217514838790521
of O 0 2.2410345081880223e-06
HFE O 0 0.008090040646493435
reveals O 0 5.3477706387639046e-05
the O 0 5.019846298637276e-07
locations O 0 4.979379355063429e-06
of O 0 7.704171366640367e-06
hemochromatosis B-Disease 1 0.9999854564666748
mutations O 0 0.04000061750411987
and O 0 1.199151938635623e-05
a O 0 1.6141073501785286e-05
patch O 1 0.8758362531661987
of O 0 5.217664238443831e-07
histidines O 0 0.00025239429669454694
that O 0 7.818012903726412e-08
could O 0 1.8898933262789797e-07
be O 0 6.433142374362433e-08
involved O 0 2.138288976993863e-07
in O 0 7.687796710342809e-07
pH O 0 0.00020046366262249649
- O 0 3.166769602103159e-05
dependent O 0 2.9166683361836476e-06
interactions O 0 1.2666188922594301e-05
. O 0 7.788997208990622e-06

We O 0 3.3363367037964053e-06
also O 0 6.207105229805165e-07
demonstrate O 0 1.953357696038438e-06
that O 0 4.6334071157616563e-07
soluble O 0 0.00041111145401373506
TfR O 0 0.0009295539930462837
and O 0 2.788471192616271e-06
HFE O 0 0.000989314867183566
bind O 0 2.0613706510630436e-05
tightly O 0 2.4230726921814494e-05
at O 0 8.53585333970841e-06
the O 0 1.2918546588025492e-07
basic O 0 1.7676946981737274e-06
pH O 0 5.3964231483405456e-05
of O 0 5.704158567709783e-08
the O 0 4.358561227491009e-07
cell O 0 6.954545096959919e-05
surface O 0 0.00023081239487510175
, O 0 7.784888680362201e-07
but O 0 9.524357125201277e-08
not O 0 4.8061501445317845e-08
at O 0 2.703932068470749e-06
the O 0 8.556576744922495e-07
acidic O 0 0.00031599460635334253
pH O 0 0.00019544590031728148
of O 0 4.011789087599027e-07
intracellular O 0 0.0002408997534075752
vesicles O 0 0.0021466847974807024
. O 0 3.0378185329027474e-05

TfR O 0 0.01834113523364067
HFE O 0 0.008830769918859005
stoichiometry O 0 0.0001367002842016518
( O 0 1.4067487654756405e-06
2 O 0 1.6092376426968258e-06
1 O 0 5.337476522981888e-07
) O 0 5.302054617573049e-08
differs O 0 1.0825109484358109e-06
from O 0 5.947143222329032e-07
TfR O 0 0.0001332544779870659
transferrin O 0 4.0442606405122206e-05
stoichiometry O 0 8.422237442573532e-06
( O 0 1.4728193775681575e-07
2 O 0 4.3446544850667124e-07
2 O 0 3.5605890502665716e-07
) O 0 1.803355154095243e-08
, O 0 2.2868752225235767e-08
implying O 0 7.484513986355523e-08
a O 0 1.7385486827947716e-08
different O 0 3.1981242099021756e-09
mode O 0 7.638525403308449e-07
of O 0 2.4317948543739476e-08
binding O 0 3.073158723054803e-06
for O 0 2.899405160405877e-07
HFE O 0 0.0007613316411152482
and O 0 1.1441665037636994e-06
transferrin O 0 5.6168144510593265e-05
to O 0 3.28786654790747e-07
TfR O 0 0.00019820765010081232
, O 0 5.787672989754356e-07
consistent O 0 1.5460075246664928e-06
with O 0 2.1345969969388534e-07
our O 0 1.7758966350811534e-06
demonstration O 0 1.1449991689005401e-05
that O 0 5.088627972327231e-07
HFE O 0 0.0009378622053191066
, O 0 2.8786967050109524e-06
transferrin O 0 9.308502194471657e-05
, O 0 1.0943014103759197e-06
and O 0 4.2698425772869086e-07
TfR O 0 7.034216105239466e-05
form O 0 1.219603745994391e-06
a O 0 2.6364439236203907e-06
ternary O 0 0.00014745103544555604
complex O 0 0.0009723443072289228
. O 0 2.663798295543529e-05

Identification O 0 3.3853420973173343e-06
of O 0 1.7465261237248342e-07
three O 0 2.057467156646453e-07
novel O 0 1.9596923266362865e-06
mutations O 0 1.0180875506193843e-05
and O 0 3.021826842086739e-07
a O 0 7.225888793982449e-07
high O 0 5.139729637448909e-06
frequency O 0 2.6280795282218605e-06
of O 0 7.828667492049135e-08
the O 0 1.0597636901366059e-06
Arg778Leu O 0 0.000664922408759594
mutation O 0 6.951501563889906e-05
in O 0 3.4071690606651828e-06
Korean O 0 0.00012544190394692123
patients O 0 9.221583604812622e-05
with O 0 2.7432633942225948e-05
Wilson B-Disease 1 0.8468517065048218
disease I-Disease 1 0.9994885921478271
. O 0 2.835349914676044e-05

Four O 0 1.2893875464214943e-05
mutations O 0 0.0003749528550542891
- O 0 0.00045558466808870435
- O 0 0.00017367160762660205
R778L O 0 8.66336195031181e-05
, O 0 1.1686776133501553e-06
A874V O 0 1.8606087905936874e-05
, O 0 5.511155336535012e-07
L1083F O 0 6.984574156376766e-06
, O 0 3.360527784934675e-07
and O 0 4.3747897393586754e-07
2304delC O 0 7.347683276748285e-05
- O 0 3.317348819109611e-05
- O 0 1.0528287930355873e-05
in O 0 2.4792808517304366e-07
the O 0 5.116315833220142e-07
copper O 0 0.0001741525047691539
- O 0 5.265645086183213e-06
transporting O 0 2.163282943001832e-06
enzyme O 0 4.915059435006697e-06
, O 0 1.4319178944788291e-06
P O 0 7.42192059988156e-05
- O 0 1.779782360245008e-05
type O 0 3.41895611200016e-05
ATPase O 0 6.735995702911168e-05
( O 0 5.133603053764091e-07
ATP7B O 0 6.246913108043373e-05
) O 0 4.1303465536657313e-08
, O 0 4.0190911931858864e-08
were O 0 4.605309911198674e-08
identified O 0 5.804675993204e-07
in O 0 5.04357558384072e-07
Korean O 0 4.793989137397148e-05
Patients O 0 8.072564378380775e-05
with O 0 1.4859197108307853e-05
Wilson B-Disease 1 0.6195359230041504
disease I-Disease 1 0.9992740750312805
. O 0 3.7286634324118495e-05

Arg778Leu O 0 0.0025679180398583412
, O 0 2.4528656012989813e-06
the O 0 2.6050921064779686e-07
most O 0 2.7659115175993065e-07
frequently O 0 4.917141268379055e-06
reported O 0 5.662948296958348e-06
mutation O 0 2.1756884507340146e-06
of O 0 1.5424914678874302e-08
this O 0 3.3076918981578274e-08
enzyme O 0 1.661627152316214e-06
, O 0 3.6254522228773567e-07
was O 0 1.3836744301443105e-06
found O 0 1.0284368556767731e-07
in O 0 3.567916806446192e-08
six O 0 6.296248500348156e-08
of O 0 3.9653635042213864e-08
eight O 0 2.056050107057672e-06
unrelated O 0 3.6290130083216354e-05
patients O 0 1.0429901522002183e-05
studied O 0 3.7716715723945526e-06
, O 0 5.752472276299159e-08
an O 0 2.234828677671885e-08
allele O 0 5.088331818114966e-07
frequency O 0 3.775745426537469e-06
of O 0 4.829592512578529e-07
37 O 0 2.1187957827351056e-05
. O 0 6.595136255782563e-06

5 O 0 9.290544767281972e-06
% O 0 1.1288577894674745e-07
, O 0 1.551479726913385e-07
which O 0 5.041964001861743e-08
is O 0 5.374467093588464e-08
considerably O 0 7.929162393338629e-07
higher O 0 2.015514155573328e-07
than O 0 2.2349993855641515e-08
those O 0 2.7942100189193297e-08
in O 0 7.59421894258594e-08
other O 0 7.676852220583896e-08
Asian O 0 2.4417890926997643e-06
populations O 0 8.549051926820539e-06
. O 0 5.610312655335292e-06

The O 0 1.080799734154425e-06
novel O 0 2.193388354498893e-06
single O 0 1.948758153957897e-06
nucleotide O 0 5.249154128250666e-06
deletion O 0 4.2292638681828976e-05
, O 0 7.820248697498755e-07
2304delC O 0 3.693978942465037e-05
, O 0 5.552298603106465e-07
was O 0 3.0431922368734377e-06
found O 0 4.2919577936118003e-07
in O 0 2.448202849336667e-07
one O 0 1.2070318007317837e-06
patient O 0 0.00014968987670727074
. O 0 8.375349352718331e-06

Since O 0 2.0413270249264315e-05
a O 0 2.7059827516495716e-06
mutation O 0 1.5456800610991195e-05
at O 0 5.420394245447824e-06
cDNA O 0 7.257848665176425e-06
nucleotide O 0 5.817686906084418e-05
2302 O 0 0.0023453293833881617
( O 0 9.840775874181418e-07
2302insC O 0 5.6643861171323806e-05
) O 0 2.2630885609942197e-07
had O 0 1.1190635405000648e-06
been O 0 2.867053012778342e-07
previously O 0 1.605996658327058e-06
described O 0 3.396508645892027e-06
, O 0 1.4623783783918043e-07
this O 0 3.358518441132219e-08
region O 0 1.7683101987131522e-06
of O 0 8.961959707676215e-08
the O 0 1.167379878097563e-06
ATP7B O 0 0.0007195305661298335
gene O 0 1.9661390979308635e-05
may O 0 4.830872967431787e-06
be O 0 3.2369607083637675e-07
susceptible O 0 4.02419718739111e-05
to O 0 7.679142299821251e-07
gene O 0 0.00029051542514935136
rearrangements O 1 0.6429316997528076
causing O 1 0.9952078461647034
Wilson B-Disease 1 0.9835941195487976
disease I-Disease 1 0.9995949864387512
. O 0 3.287744038971141e-05

Disruption O 0 0.00033962682937271893
of O 0 1.7313949740582757e-07
splicing O 0 1.0414733878860716e-05
regulated O 0 6.119591034803307e-06
by O 0 2.3998683218451333e-07
a O 0 2.0443558241822757e-06
CUG O 0 0.00020428669813554734
- O 0 1.591332329553552e-05
binding O 0 8.696458280610386e-06
protein O 0 3.404821836738847e-05
in O 0 6.394952652044594e-05
myotonic B-Disease 1 0.999962329864502
dystrophy I-Disease 1 0.9999949932098389
. O 0 0.0002235503779957071

Myotonic B-Disease 1 0.9999581575393677
dystrophy I-Disease 1 0.9999949932098389
( O 0 0.0009162674541585147
DM B-Disease 1 0.9999197721481323
) O 0 4.653042196878232e-06
is O 0 2.6600296223477926e-06
caused O 0 1.459086524846498e-05
by O 0 1.0731832134069919e-07
a O 0 1.50330993164971e-06
CTG O 0 0.00011606301268329844
expansion O 0 3.0808969313511625e-06
in O 0 3.9024720877023356e-07
the O 0 3.1072775641405315e-07
3 O 0 2.322728050785372e-06
untranslated O 0 0.0001980332745006308
region O 0 1.215631164086517e-05
of O 0 5.150982929080783e-07
the O 0 1.783370680641383e-05
DM B-Disease 1 0.9996908903121948
gene O 0 0.0004224802542012185
. O 0 2.7046929972129874e-05

One O 0 2.453001343383221e-06
model O 0 1.2607402823050506e-05
of O 0 1.022559627017472e-05
DM B-Disease 1 0.9999202489852905
pathogenesis O 1 0.6467404365539551
suggests O 0 1.6258813047898002e-05
that O 0 1.4370286294251855e-07
RNAs O 0 2.426416176604107e-05
from O 0 7.664138479412941e-08
the O 0 1.3785644625841087e-08
expanded O 0 8.626922465282405e-08
allele O 0 2.025244469905374e-07
create O 0 6.754900994110358e-08
a O 0 3.8928894241507805e-07
gain O 0 2.1615405785269104e-06
- O 0 7.359371466009179e-06
of O 0 1.6319611972903658e-07
- O 0 1.114113001676742e-05
function O 0 1.6410583612014307e-06
mutation O 0 3.930098046112107e-06
by O 0 3.579319951541038e-08
the O 0 5.066034347578352e-08
inappropriate O 0 9.310414839092118e-07
binding O 0 5.01162787713838e-07
of O 0 9.719153482024012e-09
proteins O 0 1.0576641074067084e-07
to O 0 1.3950146637853322e-07
the O 0 1.1757988431781996e-06
CUG O 0 0.0034008892253041267
repeats O 0 0.0004744785255752504
. O 0 1.546448220324237e-05

Data O 0 6.353130629577208e-06
presented O 0 5.7782426665653475e-06
here O 0 6.029516725902795e-07
indicate O 0 2.629714117574622e-07
that O 0 8.419750230359568e-09
the O 0 4.573638889837639e-08
conserved O 0 2.3938891899888404e-06
heterogeneous O 0 7.333640678552911e-05
nuclear O 0 0.003863312304019928
ribonucleoprotein O 0 0.001514418632723391
, O 0 1.993765408769832e-06
CUG O 0 0.0002406527491984889
- O 0 1.3944168131274637e-05
binding O 0 3.5887449030269636e-06
protein O 0 2.8978342925256584e-06
( O 0 8.230467187786417e-07
CUG O 0 0.0004631054471246898
- O 0 0.00015169547987170517
BP O 0 0.00022934441221877933
) O 0 1.8630595377544523e-07
, O 0 2.2406103994399018e-07
may O 0 4.138165934364224e-07
mediate O 0 7.97637585492339e-06
the O 0 6.420761451408907e-07
trans O 0 7.770917000016198e-05
- O 0 0.00011501417611725628
dominant O 0 5.6134944315999746e-05
effect O 0 4.088237801624928e-06
of O 0 8.167587139951138e-08
the O 0 7.022860586403112e-07
RNA O 0 4.309760333853774e-05
. O 0 6.5495064518472645e-06

CUG O 0 0.026700207963585854
- O 0 0.0022554672323167324
BP O 0 0.0014873446198180318
was O 0 6.451300578191876e-06
found O 0 1.0843186259990034e-07
to O 0 5.472068131950891e-09
bind O 0 1.1686927336995723e-07
to O 0 2.6068757819075472e-08
the O 0 4.2847190684369707e-07
human O 0 5.9561061789281666e-05
cardiac O 1 0.9963526725769043
troponin O 1 0.9902535080909729
T O 0 0.33892005681991577
( O 0 9.259093189939449e-07
cTNT O 0 2.128526830347255e-05
) O 0 1.4446686691371724e-07
pre O 0 1.111633719119709e-05
- O 0 8.329182492161635e-06
messenger O 0 5.1098431868012995e-06
RNA O 0 1.0723214245444979e-06
and O 0 4.1207233181239644e-08
regulate O 0 4.3483356648721383e-07
its O 0 1.0228790614519312e-07
alternative O 0 2.623006366775371e-06
splicing O 0 7.95694359112531e-05
. O 0 1.4330710655485746e-05

Splicing O 0 5.196638812776655e-05
of O 0 2.4921628209995106e-06
cTNT O 0 0.000930560810957104
was O 0 0.0002953316434286535
disrupted O 0 0.01140934880822897
in O 0 0.00021264937822706997
DM B-Disease 1 0.9998385906219482
striated O 1 0.989874005317688
muscle O 0 0.056377120316028595
and O 0 9.643703151596128e-07
in O 0 4.921805043522909e-07
normal O 0 1.2062379937560763e-05
cells O 0 6.466163085860899e-06
expressing O 0 1.4477997183348634e-06
transcripts O 0 7.54770098865265e-06
that O 0 3.106726467194676e-07
contain O 0 8.446463652944658e-06
CUG O 0 0.005711396224796772
repeats O 0 0.0006636960315518081
. O 0 1.8701242879615165e-05

Altered O 0 0.0001570205349707976
expression O 0 6.680542810499901e-06
of O 0 1.7175642597067053e-07
genes O 0 6.7391501943347976e-06
regulated O 0 8.356820762855932e-05
posttranscriptionally O 0 0.0003587258397601545
by O 0 2.617591235321015e-06
CUG O 0 0.00326072727330029
- O 0 0.0005952977808192372
BP O 0 0.0003439869615249336
therefore O 0 7.740766250208253e-07
may O 0 9.850109563558362e-07
contribute O 0 7.808176292201097e-07
to O 0 3.6728613395098364e-06
DM B-Disease 1 0.9998569488525391
pathogenesis O 0 0.3473140597343445
. O 0 5.817255896545248e-06
. O 0 5.575408067670651e-06

Identification O 0 6.460689746745629e-06
of O 0 5.129252258484485e-07
a O 0 7.520412509620655e-06
novel O 0 2.196467357862275e-05
nonsense O 0 0.00021750169980805367
mutation O 0 5.231149771134369e-05
and O 0 1.7675975527708943e-07
a O 0 5.808713012811495e-07
missense O 0 1.1813032870122697e-05
substitution O 0 2.527799267681985e-07
in O 0 2.1304623487594654e-07
the O 0 3.9529345485789236e-07
vasopressin O 0 6.03221014898736e-05
- O 0 7.862997881602496e-05
neurophysin O 0 0.00022856549185235053
II O 0 0.0004558952641673386
gene O 0 3.3565188459760975e-06
in O 0 2.899338937822904e-07
two O 0 3.5526926467355224e-07
Spanish O 0 1.5957515643094666e-05
kindreds O 0 0.00030825164867565036
with O 0 4.70894665340893e-05
familial B-Disease 1 0.9991825222969055
neurohypophyseal I-Disease 1 0.9997476935386658
diabetes I-Disease 1 0.9999921321868896
insipidus I-Disease 1 0.9988573789596558
. O 0 0.00018753779295366257

Familial B-Disease 1 0.9970293045043945
neurohypophyseal I-Disease 1 0.9988802075386047
diabetes I-Disease 1 0.9999756813049316
insipidus I-Disease 1 0.9980858564376831
( O 0 9.778988896869123e-05
FNDI B-Disease 1 0.9997455477714539
) O 0 1.009366542348289e-06
is O 0 9.993382263928652e-07
an O 0 2.584244839454186e-06
autosomal B-Disease 1 0.9995997548103333
dominant I-Disease 1 0.9998636245727539
disease I-Disease 1 0.999995231628418
caused O 1 0.9784345626831055
by O 0 0.00013186105934437364
deficiency O 1 0.9997944235801697
in O 0 3.4942002002935624e-06
the O 0 7.045379334158497e-06
antidiuretic O 0 0.006702939048409462
hormone O 0 0.00037931205588392913
arginine O 0 4.0898987208493054e-05
vasopressin O 0 2.0501080143731087e-05
( O 0 2.418107101220812e-07
AVP O 0 1.365977823297726e-05
) O 0 6.347637526715744e-09
encoded O 0 8.609378987500804e-09
by O 0 3.373033052866958e-08
the O 0 8.696911777406058e-07
AVP O 0 0.001385588082484901
- O 0 0.0005246898508630693
neurophysin O 0 0.0014143518637865782
II O 0 0.018683122470974922
( O 0 5.625882749882294e-06
AVP O 0 0.0006278785294853151
- O 0 0.00010734341049101204
NPII O 0 0.0001400630862917751
) O 0 1.4378566959294403e-07
gene O 0 2.0260358724044636e-06
on O 0 3.3375458770024125e-06
chromosome O 0 0.0002463047276251018
20p13 O 0 0.00034145062090829015
. O 0 9.637574294174556e-06

In O 0 8.785132195043843e-07
this O 0 3.410047710872277e-08
study O 0 1.3857329861366452e-07
, O 0 5.51147678606867e-08
we O 0 2.1209926259757594e-08
analyzed O 0 2.2637360075350443e-07
two O 0 2.419700706468575e-08
families O 0 2.5548796855900946e-08
with O 0 1.79781949327662e-07
FNDI B-Disease 0 0.1598733365535736
using O 0 9.402359779642211e-08
direct O 0 1.6040084460655635e-07
automated O 0 2.722590579651296e-05
fluorescent O 0 6.690109148621559e-05
, O 0 5.135385663379566e-07
solid O 0 6.721692443534266e-06
phase O 0 7.2474736043659505e-06
, O 0 3.319302379622968e-07
single O 0 1.0246242254652316e-06
- O 0 7.485993592126761e-06
stranded O 0 1.8156231362809194e-06
DNA O 0 1.7198686919073225e-07
sequencing O 0 1.525341701835714e-07
of O 0 1.5023181276774267e-07
PCR O 0 6.101146573200822e-05
- O 0 0.00020103712449781597
amplified O 0 0.00041377521120011806
AVP O 0 0.004207149147987366
- O 0 0.000692498404532671
NPII O 0 0.0014872928149998188
DNA O 0 7.309833017643541e-05
. O 0 1.0478593139851e-05

In O 0 1.0357555311202304e-06
one O 0 1.7850730671398196e-07
of O 0 1.785874204074389e-08
the O 0 1.6322600515650265e-07
families O 0 1.597852445911485e-07
, O 0 6.777562475690502e-07
affected O 0 7.894687428233738e-07
individuals O 0 2.5344318643760744e-08
presented O 0 5.856058464814851e-07
a O 0 1.2104726465622662e-06
novel O 0 4.004731181339594e-06
nonsense O 0 3.901358286384493e-05
mutation O 0 1.2219623386044987e-05
in O 0 2.649788086728222e-07
exon O 0 8.508482096658554e-06
3 O 0 4.574389151912328e-07
of O 0 7.969926052453502e-09
the O 0 5.487142118454358e-08
gene O 0 5.600426220553345e-07
, O 0 7.537894219922237e-08
consisting O 0 5.466802832643225e-08
in O 0 6.635693949874621e-08
a O 0 8.68327902026067e-07
G O 0 1.631049599382095e-05
to O 0 2.1129093852323422e-07
T O 0 0.0002624904445838183
transition O 0 5.915042493143119e-06
at O 0 7.908705811132677e-06
nucleotide O 0 4.146270384808304e-06
2101 O 0 0.00024674448650330305
, O 0 2.3444275143447157e-07
which O 0 2.1207902989317517e-08
produces O 0 2.1065415012344602e-07
a O 0 1.7776746119579911e-07
stop O 0 7.527922321060032e-07
signal O 0 1.8313368173039635e-06
in O 0 5.65879020086868e-07
codon O 0 1.0032725185737945e-05
82 O 0 1.274271107831737e-05
( O 0 7.802057666594919e-07
Glu O 0 0.0007918242481537163
) O 0 5.201993644732283e-07
of O 0 8.472591730424028e-07
NPII O 0 0.005068880971521139
. O 0 2.3304217393160798e-05

The O 0 6.45576001261361e-05
premature O 0 0.0023571092169731855
termination O 0 0.0003000402357429266
eliminates O 0 3.370740887476131e-05
part O 0 1.03356103409169e-06
of O 0 1.5879297166065953e-07
the O 0 1.6586221818215563e-06
C O 0 0.00011104689474450424
- O 0 1.719595275062602e-05
terminal O 0 2.3524602511315607e-05
domain O 0 1.067096150109137e-06
of O 0 1.3338416238184436e-07
NPII O 0 0.00029413826996460557
, O 0 2.2348038442032703e-07
including O 0 3.250143976174513e-08
a O 0 2.4936244358286785e-07
cysteine O 0 1.0556138931860914e-06
residue O 0 2.1433572783280397e-06
in O 0 1.1519968268203229e-07
position O 0 1.1721422197297215e-06
85 O 0 9.028087220031011e-07
, O 0 1.0978453701682156e-07
which O 0 3.1941024047910105e-08
could O 0 5.880582065742601e-08
be O 0 3.063564335548108e-08
involved O 0 8.908107673732957e-08
in O 0 1.1297366597773362e-07
the O 0 2.222934369910945e-07
correct O 0 2.153779314539861e-05
folding O 0 0.0005312571884132922
of O 0 6.185926508806006e-07
the O 0 1.0135518095921725e-05
prohormone O 0 0.05369129031896591
. O 0 4.621839980245568e-05

In O 0 1.962583837666898e-06
the O 0 5.289862770041509e-07
second O 0 1.9850267563015223e-06
family O 0 2.4547846351197222e-06
, O 0 1.804706215580154e-07
a O 0 3.045951189051266e-07
G279A O 0 2.9198411084507825e-06
substitution O 0 1.572147141359892e-07
at O 0 3.9702217691228725e-06
position O 0 3.3097762752731796e-06
- O 0 5.059486284153536e-06
1 O 0 1.6398178104282124e-07
of O 0 6.393092721879157e-09
the O 0 3.401784098855387e-08
signal O 0 2.224886429758044e-06
peptide O 0 2.716576318562147e-06
was O 0 1.922210003613145e-06
observed O 0 6.243307666409237e-07
in O 0 5.4532332427470465e-08
all O 0 4.475323933661457e-08
affected O 0 1.8208182837042841e-06
individuals O 0 4.3862195298061124e-07
. O 0 5.743225301557686e-06

This O 0 4.243737294018501e-06
missense O 0 0.000716259004548192
mutation O 0 0.00021273392485454679
, O 0 1.8318746697332244e-06
which O 0 7.438956117766793e-07
replaces O 0 0.0007326118648052216
Ala O 0 0.0004196154768578708
with O 0 3.5393925372773083e-06
Thr O 0 0.0038110078312456608
, O 0 4.016940692963544e-06
is O 0 9.040407462634903e-07
frequent O 0 2.563841553637758e-05
among O 0 1.4028665646037553e-05
FNDI B-Disease 1 0.999901294708252
patients O 0 0.0003209116985090077
and O 0 1.1343307733113761e-06
is O 0 5.210926019572071e-07
thought O 0 4.041457657422143e-07
to O 0 2.0671192757504286e-08
reduce O 0 3.949057258978428e-07
the O 0 1.0756424018154576e-07
efficiency O 0 1.9135807178827235e-06
of O 0 5.317336615462409e-08
cleavage O 0 2.931478047685232e-05
by O 0 3.093646796514804e-07
signal O 0 2.483285243215505e-05
peptidases O 0 0.00018912788073066622
. O 0 1.8190305581811117e-06
. O 0 3.878122242895188e-06

Genetic O 0 0.0008782176882959902
heterogeneity O 0 0.000367200089385733
of O 0 3.4399916330585256e-05
Saethre B-Disease 1 0.998101532459259
- I-Disease 1 0.9996849298477173
Chotzen I-Disease 1 0.9991251826286316
syndrome I-Disease 1 0.9999954700469971
, O 0 2.756465846687206e-06
due O 0 3.12254542222945e-06
to O 0 2.672078665000299e-07
TWIST O 0 9.337546362075955e-05
and O 0 1.049143338605063e-05
FGFR O 0 0.012951957061886787
mutations O 0 0.0008507991442456841
. O 0 1.5228217307594605e-05

Thirty O 0 9.072346438188106e-05
- O 0 0.00010827078949660063
two O 0 8.368565431737807e-07
unrelated O 0 4.685460953623988e-05
patients O 0 7.246824225148885e-06
with O 0 9.635395770146715e-08
features O 0 5.916701411479153e-06
of O 0 7.765781447233167e-06
Saethre B-Disease 1 0.9938890933990479
- I-Disease 1 0.9992687106132507
Chotzen I-Disease 1 0.9988579750061035
syndrome I-Disease 1 0.9999836683273315
, O 0 3.2440980248793494e-06
a O 0 3.4978743315150496e-06
common O 0 8.327743853442371e-05
autosomal B-Disease 1 0.9988163709640503
dominant I-Disease 1 0.9981960654258728
condition I-Disease 1 0.9994008541107178
of O 0 5.1281462219776586e-05
craniosynostosis B-Disease 1 0.9996722936630249
and O 0 0.007376096677035093
limb B-Disease 1 0.9997158646583557
anomalies I-Disease 1 0.9886953234672546
, O 0 1.564855097058171e-06
were O 0 1.7209910652127292e-07
screened O 0 1.670905589890026e-06
for O 0 9.997692984597961e-08
mutations O 0 1.008060007734457e-05
in O 0 6.980985745030921e-07
TWIST O 0 7.363717304542661e-05
, O 0 4.7033672672114335e-06
FGFR2 O 0 0.0007655526278540492
, O 0 2.900333811339806e-06
and O 0 4.496171641221736e-06
FGFR3 O 0 0.008457022719085217
. O 0 2.3726206563878804e-05

Nine O 0 8.172874004230835e-06
novel O 0 2.773841288217227e-06
and O 0 1.1425549928389955e-06
three O 0 2.162303189834347e-06
recurrent O 0 0.0034283555578440428
TWIST O 0 0.00020334783766884357
mutations O 0 5.9576461353572085e-05
were O 0 6.044272140570683e-07
found O 0 1.046368765855732e-06
in O 0 3.970146735809976e-07
12 O 0 1.8217752995042247e-06
families O 0 4.190104334611533e-07
. O 0 5.771127234766027e-06

Seven O 0 1.1122997420898173e-06
families O 0 9.983097015719977e-08
were O 0 8.889826830227321e-08
found O 0 1.2616423816780298e-07
to O 0 1.6507661015907615e-08
have O 0 9.208971363250384e-08
the O 0 5.173200747776718e-07
FGFR3 O 0 0.0006145691149868071
P250R O 0 0.00010123752144863829
mutation O 0 1.979583794309292e-05
, O 0 2.495015962722391e-07
and O 0 1.1633196095317544e-07
one O 0 5.6895107292120883e-08
individual O 0 4.221219995770298e-08
was O 0 1.0278637091687415e-05
found O 0 2.6424950760883803e-07
to O 0 2.5557179483826076e-08
have O 0 1.1603080452005088e-07
an O 0 6.978236228860624e-07
FGFR2 O 0 0.0009770282777026296
VV269 O 0 0.00024084463075269014
- O 0 0.00018355304200667888
270 O 0 1.546694511489477e-05
deletion O 0 0.0001188659225590527
. O 0 9.806713933357969e-06

To O 0 4.851566473007551e-07
date O 0 3.410299541428685e-06
, O 0 3.994917676664045e-07
our O 0 2.5881936949190276e-07
detection O 0 2.081581624224782e-05
rate O 0 3.1917202250042465e-06
for O 0 5.038454631289824e-08
TWIST O 0 2.7877911634277552e-05
or O 0 3.7268880532792537e-06
FGFR O 0 0.0006799821276217699
mutations O 0 5.517555109690875e-05
is O 0 1.0129460861207917e-06
68 O 0 1.8563799812909565e-06
% O 0 2.6833651745050702e-08
in O 0 2.3471747567782586e-07
our O 0 9.23197058000369e-06
Saethre B-Disease 1 0.8965708017349243
- I-Disease 1 0.9984679818153381
Chotzen I-Disease 1 0.9959740042686462
syndrome I-Disease 1 0.9999822378158569
patients O 0 0.0003692900645546615
, O 0 3.636803569406766e-07
including O 0 1.0043218878763582e-07
our O 0 9.865883612292237e-07
five O 0 3.248190523663652e-06
patients O 0 1.7024114640662447e-05
elsewhere O 0 4.578029802360106e-06
reported O 0 6.744731308572227e-06
with O 0 8.85531790117966e-07
TWIST O 0 0.0005097137182019651
mutations O 0 0.000865910027641803
. O 0 2.204887096013408e-05

More O 0 4.171945988673542e-08
than O 0 4.511035101018024e-08
35 O 0 2.2572450575353287e-07
different O 0 2.8883016867098377e-08
TWIST O 0 2.8557808036566712e-05
mutations O 0 1.5859011909924448e-05
are O 0 4.56675266491402e-08
now O 0 4.919538696412928e-07
known O 0 6.943511152712745e-07
in O 0 1.536419915737497e-07
the O 0 2.3173349461558246e-07
literature O 0 2.220649093942484e-06
. O 0 7.036233910184819e-06

The O 0 1.3946570334155695e-06
most O 0 4.1786199744819896e-07
common O 0 7.622689963682205e-07
phenotypic O 0 6.386467703123344e-06
features O 0 3.18004390464921e-06
, O 0 3.074235621625121e-07
present O 0 5.279087389453707e-08
in O 0 2.9129765266588947e-08
more O 0 3.2094658042325364e-09
than O 0 1.5394876484720044e-08
a O 0 1.3958769784494507e-07
third O 0 5.281046355776198e-07
of O 0 6.836182109282163e-08
our O 0 1.3234378002380254e-06
patients O 0 1.3642529665958136e-05
with O 0 8.304993457386445e-07
TWIST O 0 0.0003461261803749949
mutations O 0 0.0001723222667351365
, O 0 1.3378269159147749e-06
are O 0 2.6230915750602435e-07
coronal B-Disease 0 0.0015661080833524466
synostosis I-Disease 0 0.004176218993961811
, O 0 1.2553390661196318e-05
brachycephaly B-Disease 0 0.0033623736817389727
, O 0 3.2093019399326295e-05
low B-Disease 0 0.012189130298793316
frontal I-Disease 1 0.9996181726455688
hairline I-Disease 1 0.9999605417251587
, O 0 0.0005194568657316267
facial B-Disease 1 0.9994434714317322
asymmetry I-Disease 1 0.9319587349891663
, O 0 0.00029206313774921
ptosis B-Disease 1 0.9974488615989685
, O 0 9.888965723803267e-05
hypertelorism B-Disease 1 0.5513982772827148
, O 0 1.0549323633313179e-05
broad B-Disease 0 4.172426997683942e-05
great I-Disease 0 0.0005887576844543219
toes I-Disease 1 0.9879036545753479
, O 0 8.782846634858288e-06
and O 0 5.442630936158821e-06
clinodactyly B-Disease 0 0.00285774446092546
. O 0 1.5989644452929497e-05

Significant O 0 1.4244244084693491e-05
intra O 0 0.0014552570646628737
- O 0 0.0006924951449036598
and O 0 3.2950811146292835e-06
interfamilial O 0 0.0003051283420063555
phenotypic O 0 0.00019516062457114458
variability O 0 0.0004507826524786651
is O 0 6.279009312493145e-07
present O 0 1.6185107654109743e-07
for O 0 8.51939248036615e-08
either O 0 2.800228912747116e-06
TWIST O 0 0.00035812618443742394
mutations O 0 0.00042760022915899754
or O 0 4.171086038695648e-05
FGFR O 0 0.021647751331329346
mutations O 0 0.0017876464407891035
. O 0 2.2853871996630915e-05

The O 0 1.9497376797517063e-06
overlap O 0 1.1512489436427131e-05
in O 0 1.4699191979161697e-06
clinical O 0 1.2719036931230221e-05
features O 0 2.726043931033928e-06
and O 0 5.656853545588092e-07
the O 0 1.6253693502221722e-07
presence O 0 1.008734329843719e-06
, O 0 2.3346326827322628e-07
in O 0 3.3928031939467473e-08
the O 0 3.054834962767927e-08
same O 0 5.881905806859322e-08
genes O 0 4.882236908088089e-07
, O 0 9.820659130355125e-08
of O 0 1.6364333887963767e-08
mutations O 0 1.8161011894335388e-06
for O 0 1.567427787563247e-08
more O 0 5.701403349434031e-09
than O 0 5.890910159678242e-08
one O 0 4.918689455735148e-07
craniosynostotic B-Disease 0 0.0003339918330311775
condition I-Disease 0 0.001665318151935935
- O 0 1.0637416380632203e-05
such O 0 1.3999270720432833e-07
as O 0 3.5677921914611943e-06
Saethre B-Disease 0 0.00039159844163805246
- I-Disease 0 0.0003622031072154641
Chotzen I-Disease 0 0.00043829515925608575
, I-Disease 0 3.654089368865243e-06
Crouzon I-Disease 0 0.0002998031850438565
, I-Disease 0 5.314980626280885e-06
and I-Disease 0 1.2932767276652157e-05
Pfeiffer I-Disease 1 0.9949995279312134
syndromes I-Disease 1 0.9951314926147461
- O 0 6.442844460252672e-05
support O 0 3.0912400461602374e-07
the O 0 3.167463376030355e-07
hypothesis O 0 9.246818990504835e-07
that O 0 1.7530936702314648e-08
TWIST O 0 8.668726877658628e-06
and O 0 4.854408075516403e-07
FGFRs O 0 2.821310772560537e-05
are O 0 2.648054397980104e-08
components O 0 5.184016345083364e-07
of O 0 1.7836752519428956e-08
the O 0 3.82265774589996e-08
same O 0 5.961600635373543e-08
molecular O 0 4.490930223255418e-06
pathway O 0 1.107192247218336e-06
involved O 0 4.1614961787672655e-07
in O 0 9.752452712064041e-08
the O 0 1.9221754143927683e-07
modulation O 0 4.29666179115884e-05
of O 0 8.140670615830459e-06
craniofacial O 1 0.9997223019599915
and O 0 0.00032985510188154876
limb O 1 0.9898582100868225
development O 0 3.2570310395385604e-06
in O 0 1.2276028655833215e-06
humans O 0 1.0609757737256587e-05
. O 0 9.688226327853044e-07
. O 0 3.473149945421028e-06

Mutation O 0 0.00034267574665136635
analysis O 0 1.2106632311770227e-05
of O 0 8.347193215740845e-06
UBE3A O 1 0.9693900346755981
in O 1 0.610123336315155
Angelman B-Disease 1 0.9999994039535522
syndrome I-Disease 1 1.0
patients O 1 0.9923956394195557
. O 0 8.514197543263435e-05

Angelman B-Disease 1 0.9999954700469971
syndrome I-Disease 1 1.0
( O 0 0.00010371507232775912
AS B-Disease 1 0.9979904890060425
) O 0 1.0485595112186274e-06
is O 0 1.2018548432024545e-06
caused O 0 1.4525847291224636e-05
by O 0 3.7983070910740935e-07
chromosome O 0 0.00012988806702196598
15q11 O 0 0.00030508500640280545
- O 0 0.00020549695182126015
q13 O 0 0.00013813140685670078
deletions O 0 3.1202802347252145e-05
of O 0 4.029745923617156e-07
maternal O 0 4.42029740952421e-05
origin O 0 1.2825842077290872e-06
, O 0 1.1785954256993136e-06
by O 0 5.748303806285548e-07
paternal O 0 0.0004368525405880064
uniparental B-Disease 1 0.9401450753211975
disomy I-Disease 1 0.7475808262825012
( O 0 4.301736771594733e-05
UPD B-Disease 1 0.9954441785812378
) O 0 9.901948487822665e-07
15 O 0 1.5189995110631571e-06
, O 0 1.8049283312393527e-07
by O 0 4.3920630332650035e-07
imprinting O 0 0.007262691389769316
defects O 1 0.9993124008178711
, O 0 8.40340305785503e-07
and O 0 1.6685697801221977e-07
by O 0 1.9663441719330876e-07
mutations O 0 1.2889819117845036e-05
in O 0 4.358661271908204e-07
the O 0 2.1973853563395096e-06
UBE3A O 0 0.002405148232355714
gene O 0 0.00020110653713345528
. O 0 3.0252107535488904e-05

UBE3A O 0 0.0010244161821901798
encodes O 0 6.4066506411109e-07
a O 0 1.0859324675038806e-06
ubiquitin O 0 5.123085884406464e-06
- O 0 5.737614173995098e-06
protein O 0 3.852239274237945e-07
ligase O 0 3.0786177376285195e-06
and O 0 4.351944653535611e-07
shows O 0 1.0120275874214713e-05
brain O 1 0.9480452537536621
- O 0 6.737338117090985e-05
specific O 0 1.9014649978998932e-06
imprinting O 0 0.0007232401985675097
. O 0 1.227300708706025e-05

Here O 0 1.0052099241875112e-05
we O 0 2.8673612177954055e-06
describe O 0 2.3198026610771194e-05
UBE3A O 0 0.003535639261826873
coding O 0 0.002672781003639102
- O 0 0.0013026988599449396
region O 0 5.153407619218342e-05
mutations O 0 8.466566941933706e-05
detected O 0 4.3912568798987195e-05
by O 0 1.1728842963520947e-07
SSCP O 0 5.262712875264697e-05
analysis O 0 4.942312443745323e-07
in O 0 3.8569518778786005e-07
13 O 0 3.067516445298679e-06
AS B-Disease 0 0.0013867762172594666
individuals O 0 3.416140970102788e-08
or O 0 1.1447460792624042e-06
families O 0 3.431494519645639e-07
. O 0 5.422363756224513e-06

Two O 0 1.6840941725604353e-06
identical O 0 3.874555113725364e-05
de O 0 0.0004247590550221503
novo O 0 6.505844066850841e-05
5 O 0 8.726881787879393e-06
- O 0 5.325938036548905e-05
bp O 0 6.974529242143035e-05
duplications O 0 2.7590049285208806e-05
in O 0 9.67852088251675e-07
exon O 0 3.139772161375731e-05
16 O 0 2.45954151978367e-06
were O 0 2.4696242917343625e-07
found O 0 2.609378725537681e-06
. O 0 3.981513600592734e-06

Among O 0 1.4392604725799174e-06
the O 0 1.644459644012386e-07
other O 0 5.814033698925414e-08
11 O 0 5.343165412341477e-07
unique O 0 5.37603511929774e-07
mutations O 0 2.6812638679984957e-05
, O 0 7.762647555864532e-07
8 O 0 8.184661624e-07
were O 0 9.606402073814024e-08
small O 0 5.955872666163486e-07
deletions O 0 1.9442604752839543e-05
or O 0 1.8384203031018842e-06
insertions O 0 7.12416076567024e-05
predicted O 0 2.2660700778942555e-05
to O 0 3.0758280900045065e-07
cause O 0 2.347505505895242e-05
frameshifts O 0 0.0001500796206528321
, O 0 5.424973323897575e-07
1 O 0 5.722175728806178e-07
was O 0 1.0547465763011132e-06
a O 0 2.0969585534658108e-07
mutation O 0 5.937452556281642e-07
to O 0 1.5757370519509095e-08
a O 0 2.5807551651269023e-07
stop O 0 1.8938748098662472e-06
codon O 0 2.8377253329381347e-06
, O 0 1.9879107071574253e-07
1 O 0 2.741493858593458e-07
was O 0 1.1754333399949246e-06
a O 0 8.106413247332966e-07
missense O 0 3.955807915190235e-05
mutation O 0 9.24703726923326e-06
, O 0 2.614445122617326e-07
and O 0 1.8887725161675917e-07
1 O 0 2.414248456261703e-06
was O 0 3.0350416636792943e-05
predicted O 0 3.7659494864783483e-06
to O 0 8.339806356616464e-08
cause O 0 3.874739377351943e-06
insertion O 0 1.5026563460196485e-06
of O 0 6.213549141875774e-08
an O 0 6.97091934398486e-07
isoleucine O 0 0.000526523042935878
in O 0 8.510231168656901e-07
the O 0 4.190708011719835e-07
hect O 0 4.189623359707184e-05
domain O 0 6.660636131528008e-07
of O 0 2.7015703452093476e-08
the O 0 2.885373078242992e-07
UBE3A O 0 0.00016045308439061046
protein O 0 1.2041332411172334e-06
, O 0 7.820295166993674e-08
which O 0 6.120984163970888e-09
functions O 0 4.320598279150545e-08
in O 0 1.1599274785112357e-07
E2 O 0 8.83123266248731e-06
binding O 0 1.2138748388679232e-06
and O 0 2.1770780733731954e-07
ubiquitin O 0 3.5194061638321728e-06
transfer O 0 3.306170583528001e-06
. O 0 8.803140190138947e-06

Eight O 0 3.143622507195687e-06
of O 0 6.405178254453858e-08
the O 0 3.118306040050811e-07
cases O 0 7.953450449349475e-07
were O 0 2.8745625968440436e-07
familial O 0 0.0005910342442803085
, O 0 1.3046407048022957e-06
and O 0 2.8355674430713407e-07
five O 0 2.714799904879328e-07
were O 0 5.291749403113499e-07
sporadic O 0 8.035644714254886e-05
. O 0 1.3804999070998747e-05

In O 0 2.409721446383628e-06
two O 0 8.638091344437271e-07
familial O 0 0.0025155269540846348
cases O 0 7.627092145412462e-06
and O 0 8.953132919486961e-07
one O 0 6.701120014440676e-07
sporadic O 0 6.632197619182989e-05
case O 0 1.0966009540425148e-05
, O 0 1.2462940048862947e-06
mosaicism O 0 0.0002673976414371282
for O 0 9.7285112587997e-07
UBE3A O 0 0.0021738074719905853
mutations O 0 0.0002078184625133872
was O 0 2.0551897250697948e-05
detected O 0 3.1230072636390105e-05
in O 0 1.4700017914037744e-07
the O 0 2.0552725743527844e-07
mother O 0 5.518836587725673e-06
of O 0 4.929941610498645e-08
three O 0 8.654599810142827e-07
AS B-Disease 1 0.9569641351699829
sons O 0 9.483048052061349e-05
, O 0 3.428557135976007e-07
in O 0 7.197594698027387e-08
the O 0 1.311030075612507e-07
maternal O 0 1.025323126668809e-05
grandfather O 0 2.7197360395803116e-05
of O 0 4.331456793238431e-08
two O 0 2.641174887685338e-07
AS B-Disease 0 0.06186245009303093
first O 0 6.78094465911272e-07
cousins O 0 1.0844301868928596e-05
, O 0 2.178891236326308e-07
and O 0 7.370867649569846e-08
in O 0 5.545303949361369e-08
the O 0 2.3773147006522777e-07
mother O 0 1.2656444596359506e-05
of O 0 7.698451298665532e-08
an O 0 2.1919311166129773e-06
AS B-Disease 1 0.9997653365135193
daughter O 0 0.012377208098769188
. O 0 2.070409755106084e-05

The O 0 3.703736695115367e-07
frequencies O 0 2.72119973487861e-06
with O 0 2.4053630909293133e-07
which O 0 2.0242693210548168e-07
we O 0 2.4464571879434516e-07
detected O 0 1.0427454981254414e-05
mutations O 0 1.961197312994045e-06
were O 0 1.0494032665064879e-07
5 O 0 2.851093938716076e-07
( O 0 3.5644205809148843e-08
14 O 0 1.5202125780433562e-07
% O 0 2.3214519195846606e-09
) O 0 3.047907704001318e-09
of O 0 4.401830899780634e-09
35 O 0 3.4985808383680705e-07
in O 0 9.905615883099017e-08
sporadic O 0 1.0984987056872342e-05
cases O 0 7.650102133993641e-07
and O 0 3.6308151152297796e-07
8 O 0 1.3955736903881188e-06
( O 0 5.688056958774723e-08
80 O 0 1.6512328215867456e-07
% O 0 6.642048688831892e-09
) O 0 6.0082179231812916e-09
of O 0 1.156269124891196e-08
10 O 0 4.1155243479806813e-07
in O 0 3.625880822255567e-07
familial O 0 0.0014189252397045493
cases O 0 1.75272307387786e-05
. O 0 2.858406105588074e-06
. O 0 9.004209459817503e-06

The O 0 0.00015046219050418586
hemochromatosis B-Disease 1 0.9995236396789551
845 O 0 0.0027800786774605513
G O 0 0.0013213835190981627
- O 0 7.748067582724616e-05
- O 0 1.6747739209677093e-05
> O 0 2.108906528519583e-06
A O 0 8.37127970498841e-07
and O 0 2.7833175408886746e-07
187 O 0 1.7837622863225988e-06
C O 0 1.882384458440356e-05
- O 0 2.0252618924132548e-05
- O 0 3.3135420380858704e-05
> O 0 1.9943945517297834e-05
G O 0 5.027242150390521e-05
mutations O 0 3.547963569872081e-05
: O 0 1.2728992260235827e-06
prevalence O 0 1.8557886505732313e-05
in O 0 6.081020842430007e-07
non O 0 4.279290806152858e-05
- O 0 0.0013999883085489273
Caucasian O 0 0.0003899126313626766
populations O 0 2.397338903392665e-05
. O 0 8.230395906139165e-06

Hemochromatosis B-Disease 1 0.9931578040122986
, O 0 0.0002574510872364044
the O 0 0.001124225091189146
inherited B-Disease 1 0.9999983310699463
disorder I-Disease 1 0.9999992847442627
of I-Disease 0 4.5961194700794294e-05
iron I-Disease 1 0.9986477494239807
metabolism I-Disease 1 0.9758255481719971
, O 0 1.8574903151602484e-05
leads O 0 4.568637450574897e-05
, O 0 6.120728812675225e-06
if O 0 7.852039743738715e-06
untreated O 0 0.21730563044548035
, O 0 1.4151560208119918e-06
to O 0 9.110712539950327e-07
progressive O 1 0.5588345527648926
iron B-Disease 1 0.9997586607933044
overload I-Disease 1 0.9979798197746277
and O 0 5.892358967685141e-05
premature B-Disease 0 0.009590500965714455
death I-Disease 0 0.00022107486438471824
. O 0 8.18343414721312e-06

The O 0 0.00017304725770372897
hemochromatosis B-Disease 1 0.9997772574424744
gene O 0 0.0004250484926160425
, O 0 9.977716217690613e-06
HFE O 0 0.0014475787756964564
, O 0 3.831106823781738e-06
recently O 0 3.381123678991571e-05
has O 0 1.0385447239968926e-06
been O 0 6.305448323473684e-07
identified O 0 7.07169988345413e-07
, O 0 1.241267710838656e-07
and O 0 1.0242378323255252e-07
characterization O 0 3.1667191251472104e-06
of O 0 2.7786169809473904e-08
this O 0 3.537066817216328e-08
gene O 0 8.805884021967358e-07
has O 0 3.065622138365143e-07
shown O 0 6.077929981529451e-08
that O 0 5.6768039158328065e-09
it O 0 6.563764642919523e-09
contains O 0 1.4043687990294984e-08
two O 0 4.378679818728415e-08
mutations O 0 3.4135894111386733e-06
that O 0 1.701595486736096e-08
result O 0 3.3164292290166486e-07
in O 0 1.602587929028232e-07
amino O 0 4.771487169819011e-07
acid O 0 4.542334409052273e-06
substitutions O 0 1.96254632101045e-06
- O 0 2.0233924260537606e-06
cDNA O 0 5.379465619625989e-07
nucleotides O 0 1.9078079276368953e-06
845 O 0 2.7570586098590866e-05
G O 0 4.6049208322074264e-05
- O 0 2.1323729015421122e-05
- O 0 1.570329004607629e-05
> O 0 3.135056658720714e-06
A O 0 1.1228318044231855e-06
( O 0 5.1489642771684885e-08
C282Y O 0 2.204563770646928e-06
) O 0 1.6897580223940167e-08
and O 0 1.4248479374145973e-07
187 O 0 1.3015562672080705e-06
C O 0 2.4684693926246837e-05
- O 0 3.236925113014877e-05
- O 0 5.7603618188295513e-05
> O 0 3.308830855530687e-05
G O 0 7.213751086965203e-05
( O 0 7.515799325119588e-07
H63D O 0 0.00021969451336190104
) O 0 7.317622134905832e-07
. O 0 2.3570969460706692e-06

Although O 0 0.0005782573134638369
hemochromatosis B-Disease 1 0.99994957447052
is O 0 7.70840506447712e-06
common O 0 8.336891369253863e-06
in O 0 1.7200915181092569e-06
Caucasians O 0 1.732523196551483e-05
, O 0 1.6925390582400723e-06
affecting O 0 2.2573025489691645e-05
> O 0 3.3174248528666794e-05
= O 0 1.3414331078820396e-05
1 O 0 1.763825025591359e-06
/ O 0 3.5210846363042947e-06
300 O 0 2.480818181993527e-07
individuals O 0 1.5059264057981636e-08
of O 0 2.4265268905310222e-08
northern O 0 1.929670816025464e-06
European O 0 2.16408989217598e-06
origin O 0 3.56931280975914e-07
, O 0 5.148552304490295e-07
it O 0 1.1745588324174605e-07
has O 0 9.731139982704917e-08
not O 0 1.455390741256224e-08
been O 0 6.98149875688614e-08
recognized O 0 1.3154308931007108e-07
in O 0 7.051975359217977e-08
other O 0 1.3661696129929624e-07
populations O 0 3.478865210126969e-06
. O 0 5.529035206564004e-06

The O 0 7.524427019234281e-07
present O 0 1.8711790517045301e-07
study O 0 8.511791804721724e-08
used O 0 1.1143621492237799e-07
PCR O 0 3.506009988996084e-06
and O 0 1.657455328540891e-07
restriction O 0 3.029608990345878e-07
- O 0 2.715866685321089e-06
enzyme O 0 7.109290436346782e-07
digestion O 0 3.031518872376182e-06
to O 0 1.6463513219378e-08
analyze O 0 3.653789235613658e-07
the O 0 4.425573152389006e-08
frequency O 0 7.414860760945885e-07
of O 0 4.662672026256587e-08
the O 0 4.78260346881143e-07
845 O 0 3.634141830843873e-05
G O 0 6.59157958580181e-05
- O 0 1.2974026503798086e-05
- O 0 6.7711807787418365e-06
> O 0 1.0914279755525058e-06
A O 0 3.6810979509027675e-07
and O 0 1.5959473387283651e-07
187 O 0 8.153896260409965e-07
C O 0 7.9421643022215e-06
- O 0 8.616357263235841e-06
- O 0 1.1898066077264957e-05
> O 0 7.598356660309946e-06
G O 0 3.0180506655597128e-05
mutations O 0 1.0673754331946839e-05
in O 0 8.538618772035989e-07
HLA O 0 5.3160278184805065e-05
- O 0 1.2107221664336976e-05
typed O 0 9.325226528744679e-06
samples O 0 8.367321129298944e-07
from O 0 4.5243785962156835e-07
non O 0 1.78359496203484e-05
- O 0 0.00025957715115509927
Caucasian O 0 0.00011533244833117351
populations O 0 2.495490207365947e-06
, O 0 2.967041723422881e-07
comprising O 0 4.330445335654076e-07
Australian O 0 1.2183412536614924e-06
Aboriginal O 0 6.701605457237747e-07
, O 0 2.924250281921559e-07
Chinese O 0 2.0641886067096493e-07
, O 0 1.4473455394181656e-06
and O 0 5.411489382822765e-06
Pacific O 0 0.0003951121761929244
Islanders O 0 0.0003826100146397948
. O 0 8.507638085575309e-06

Results O 0 6.0382066294550896e-05
showed O 0 1.6817666619317606e-05
that O 0 1.2128930393373594e-07
the O 0 6.086225425860903e-07
845 O 0 9.263898391509429e-05
G O 0 0.0002032090851571411
- O 0 4.1051145672099665e-05
- O 0 1.946000338648446e-05
> O 0 3.1593135645380244e-06
A O 0 8.658017236484739e-07
mutation O 0 4.854296093981247e-06
was O 0 9.58593659561302e-07
present O 0 8.350709634896702e-08
in O 0 5.9129511953415204e-08
these O 0 9.988787574854996e-09
populations O 0 7.154902448291978e-08
( O 0 1.736702692767267e-08
allele O 0 1.9117460681172815e-07
frequency O 0 1.5372772850241745e-06
0 O 0 3.0302359732559125e-07
. O 0 2.3715102770438534e-08
32 O 0 1.6775624089859775e-07
% O 0 4.848557111358787e-09
) O 0 1.4605018527902303e-08
, O 0 7.738390195299871e-08
and O 0 1.9212444613003754e-07
, O 0 1.7180114753045928e-07
furthermore O 0 2.2150281608901423e-07
, O 0 1.2370654189908237e-07
it O 0 8.198694700922715e-08
was O 0 3.2866137189557776e-06
always O 0 5.106692810841196e-07
seen O 0 9.572241879141075e-07
in O 0 9.177724535902598e-08
conjunction O 0 9.007017638396064e-07
with O 0 1.107871412386885e-06
HLA O 0 0.00015164197247941047
haplotypes O 0 2.5984129024436697e-05
common O 0 4.5554270400316454e-06
in O 0 9.138890391113819e-07
Caucasians O 0 1.3575404409493785e-05
, O 0 5.251585548649018e-07
suggesting O 0 2.381883405178087e-06
that O 0 2.40934610928889e-07
845 O 0 3.7102188798598945e-05
G O 0 0.00010615023347781971
- O 0 4.013477882836014e-05
- O 0 2.819124529196415e-05
> O 0 4.808387984667206e-06
A O 0 1.95028837879363e-06
may O 0 5.636965738631261e-07
have O 0 1.7641964333847682e-08
been O 0 5.8910448075266686e-08
introduced O 0 7.14455197226016e-08
into O 0 3.9792894312995486e-08
these O 0 1.6077137843240052e-08
populations O 0 4.308595862312359e-07
by O 0 2.7776721367445134e-07
Caucasian O 0 0.00010799743176903576
admixture O 0 0.0005414601182565093
. O 0 5.018185038352385e-05

187 O 0 5.686473014065996e-05
C O 0 7.809919043211266e-05
- O 0 3.479092993075028e-05
- O 0 2.2665608412353322e-05
> O 0 9.242990927305073e-06
G O 0 1.2782963494828437e-05
was O 0 7.442887408615206e-07
present O 0 4.461048774828669e-08
at O 0 3.8146464476085384e-07
an O 0 2.107210050894537e-08
allele O 0 2.864300938654196e-07
frequency O 0 1.1971806088695303e-06
of O 0 1.8566690584975731e-07
2 O 0 1.332370811724104e-05
. O 0 5.4487691159010865e-06

68 O 0 3.6587305658031255e-05
% O 0 6.019576659355153e-08
in O 0 1.1528803867122406e-07
the O 0 1.593412122247173e-07
two O 0 2.2221797735255677e-07
populations O 0 6.719178600178566e-07
analyzed O 0 3.070197180932155e-06
( O 0 1.311615278609679e-07
Australian O 0 5.003242335988034e-07
Aboriginal O 0 1.8546373325989407e-07
and O 0 2.2979293134994805e-07
Chinese O 0 5.054018856753828e-07
) O 0 1.2588219533427036e-06
. O 0 4.7960502342903055e-06

In O 0 1.3469687019096455e-06
the O 0 3.045027767711872e-07
Australian O 0 1.6021646160879754e-06
Aboriginal O 0 6.055666972315521e-07
samples O 0 7.998824003152549e-07
, O 0 4.145568368585373e-07
187 O 0 1.6997259990603197e-06
C O 0 2.241035326733254e-05
- O 0 2.070516347885132e-05
- O 0 2.1493226086022332e-05
> O 0 8.821822120808065e-06
G O 0 1.6612055333098397e-05
was O 0 2.0145525922998786e-06
found O 0 9.467828476772411e-08
to O 0 1.2757543466079824e-08
be O 0 6.449987210999097e-08
associated O 0 4.69968995275849e-07
with O 0 6.176788929224131e-07
HLA O 0 0.00014265884237829596
haplotypes O 0 3.289741653134115e-05
common O 0 5.5522264119645115e-06
in O 0 1.4606641798309283e-06
Caucasians O 0 1.4060852663533296e-05
, O 0 5.799756763735786e-07
suggesting O 0 6.155748337732803e-07
that O 0 2.1127799954001603e-08
it O 0 3.7029980859415446e-08
was O 0 7.545704647782259e-07
introduced O 0 1.9162088449320436e-07
by O 0 6.87632919493808e-08
recent O 0 2.135396243829746e-06
admixture O 0 0.00014975099475122988
. O 0 2.1790108803543262e-05

In O 0 7.565916462226596e-07
the O 0 1.0344312784127396e-07
Chinese O 0 9.008110879449305e-08
samples O 0 5.902787165723566e-07
analyzed O 0 2.9381142212514533e-06
, O 0 2.1480975931353896e-07
187 O 0 9.198366797136259e-07
C O 0 1.8831853594747372e-05
- O 0 1.705809700069949e-05
- O 0 1.6692250937921926e-05
> O 0 6.96691904522595e-06
G O 0 1.4914965504431166e-05
was O 0 1.2073933248757385e-06
present O 0 9.407956724771793e-08
in O 0 9.10758828354119e-08
association O 0 1.71734797049794e-07
with O 0 2.246294528163162e-08
a O 0 4.188015054751304e-07
wide O 0 2.7010144094674615e-06
variety O 0 3.457528464423376e-06
of O 0 1.1198310403415235e-06
HLA O 0 0.0002557922271080315
haplotypes O 0 4.3599655327852815e-05
, O 0 7.90764829616819e-07
showing O 0 1.7819564845922287e-06
this O 0 6.173949884669128e-08
mutation O 0 1.1315001984257833e-06
to O 0 2.0750553275661332e-08
be O 0 7.15794712391471e-08
widespread O 0 4.808828180102864e-07
and O 0 6.869335038572899e-07
likely O 0 8.672495823702775e-07
to O 0 4.840188339017004e-08
predate O 0 4.552881819108734e-06
the O 0 7.313478533887974e-08
more O 0 1.9986694965723473e-08
genetically O 0 6.103372243160265e-07
restricted O 0 1.0645945849319105e-06
845 O 0 8.032855112105608e-05
G O 0 0.00027418555691838264
- O 0 8.12993966974318e-05
- O 0 4.357874786364846e-05
> O 0 1.5768722732900642e-05
A O 0 9.988703823182732e-06
mutation O 0 6.571483390871435e-05
. O 0 3.7172933389229e-06

Genotype O 0 0.0038672080263495445
- O 0 0.002100000623613596
phenotype O 0 0.0008750639972276986
correlations O 0 0.0004096740740351379
in O 0 0.00016878788301255554
attenuated B-Disease 1 0.9831889867782593
adenomatous I-Disease 1 0.9999598264694214
polyposis I-Disease 1 0.9998156428337097
coli I-Disease 1 0.9997652173042297
. O 0 0.0003304613346699625

Germ O 0 0.02141634002327919
- O 0 0.0007498013437725604
line O 0 0.00012733945914078504
mutations O 0 6.020440923748538e-05
of O 0 3.5039735735153954e-07
the O 0 6.476024736912223e-06
tumor B-Disease 0 0.42752254009246826
suppressor O 0 0.00034140338539145887
APC O 0 0.00024823457351885736
are O 0 1.3199843351685558e-06
implicated O 0 0.0029613557271659374
in O 0 0.00016060385678429157
attenuated B-Disease 1 0.9917750358581543
adenomatous I-Disease 1 0.9999843835830688
polyposis I-Disease 1 0.9999397993087769
coli I-Disease 1 0.999927282333374
( O 0 0.00022527389228343964
AAPC B-Disease 1 0.998149037361145
) O 0 1.1734587133105379e-06
, O 0 4.5385746716419817e-07
a O 0 3.11290614263271e-06
variant O 0 0.001694417791441083
of O 0 0.0001759417646098882
familial B-Disease 1 0.9999910593032837
adenomatous I-Disease 1 0.9999363422393799
polyposis I-Disease 1 0.9999872446060181
( O 0 0.0006962044280953705
FAP B-Disease 0 0.005176907405257225
) O 0 4.842542693950236e-06
. O 0 1.1229732081119437e-05

AAPC B-Disease 1 0.9973533153533936
is O 0 7.749179530947004e-06
recognized O 0 2.726220373006072e-06
by O 0 1.5179234935658314e-07
the O 0 5.098867745800817e-07
occurrence O 0 6.216550536919385e-05
of O 0 8.291761446344026e-07
< O 0 0.0001657559332670644
100 O 0 8.570153113396373e-06
colonic B-Disease 0 0.01706232689321041
adenomas I-Disease 0 0.008676600642502308
and O 0 1.4379871799974353e-06
a O 0 3.8076859709690325e-06
later O 0 6.020038927090354e-05
onset O 1 0.991975724697113
of O 1 0.5604197382926941
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
( O 0 2.5994786483352073e-06
age O 0 7.547484528913628e-06
> O 0 9.056277121999301e-06
40 O 0 2.192744432250038e-06
years O 0 1.0667206424841424e-06
) O 0 2.849278359917662e-07
. O 0 1.717626105346426e-06

The O 0 5.774765554633632e-07
aim O 0 4.44090937889996e-06
of O 0 8.706980736405967e-08
this O 0 6.938275731727117e-08
study O 0 2.667055696292664e-07
was O 0 1.2172076822025701e-06
to O 0 1.1410344313844689e-07
assess O 0 1.3662110177392606e-05
genotype O 0 0.00014363958325702697
- O 0 0.0006854638922959566
phenotype O 0 0.0003263094404246658
correlations O 0 0.00017703050980344415
in O 0 4.889665433438495e-05
AAPC B-Disease 1 0.9968558549880981
families O 0 8.86474117578473e-06
. O 0 1.6429044990218244e-05

By O 0 3.971430828642042e-07
protein O 0 4.361718765721889e-06
- O 0 2.2357457055477425e-05
truncation O 0 2.3309416064876132e-05
test O 0 2.567014007581747e-06
( O 0 1.4998886399553157e-07
PTT O 0 1.9708211766555905e-05
) O 0 8.528676431751592e-08
assay O 0 1.224066522809153e-06
, O 0 7.136462443213532e-08
the O 0 5.7720356494428415e-08
entire O 0 1.2077445035174605e-06
coding O 0 4.891951539320871e-05
region O 0 5.5702580539218616e-06
of O 0 7.272998203688985e-08
the O 0 5.02047782902082e-07
APC B-Disease 0 2.698931893974077e-05
gene O 0 5.098307156004012e-06
was O 0 6.2689960032003e-06
screened O 0 2.232231508969562e-06
in O 0 2.0469806827350112e-07
affected O 0 6.117339808042743e-07
individuals O 0 4.338617287658053e-08
from O 0 1.8806067600962706e-06
11 O 0 0.00012553200940601528
AAPC B-Disease 1 0.9988515377044678
kindreds O 0 0.0018713597673922777
, O 0 1.1756094409065554e-06
and O 0 5.655451573716164e-08
their O 0 4.2063675209647045e-08
phenotypic O 0 1.735387195367366e-05
differences O 0 2.677785960258916e-05
were O 0 5.481829703057883e-06
examined O 0 0.0003613569133449346
. O 0 1.4091096090851352e-05

Five O 0 8.6015625129221e-06
novel O 0 2.3415559553541243e-05
germ O 0 0.0018252963200211525
- O 0 0.00025465580984018743
line O 0 9.378801041748375e-05
APC B-Disease 0 0.00011147085024276748
mutations O 0 2.1098310753586702e-05
were O 0 2.95468851163605e-07
identified O 0 1.420337071067479e-06
in O 0 4.901766033071908e-07
seven O 0 5.273368969938019e-06
kindreds O 0 0.001269752625375986
. O 0 3.075095446547493e-05

Mutations O 0 0.00010679494880605489
were O 0 4.171493230842316e-07
located O 0 8.337991630469332e-07
in O 0 3.356315403379995e-08
three O 0 1.3114521912882537e-08
different O 0 6.860382928408626e-09
regions O 0 6.381119987963757e-07
of O 0 3.719384622513644e-08
the O 0 3.6052679774911667e-07
APC B-Disease 0 1.5542802429990843e-05
gene O 0 1.334879129899491e-06
( O 0 9.964359293235248e-08
1 O 0 2.259472040577748e-07
) O 0 1.5492966909391725e-08
at O 0 4.6097744643702754e-07
the O 0 4.98477277233178e-08
5 O 0 2.2129211174615193e-07
end O 0 6.190912813508476e-07
spanning O 0 7.63727439334616e-06
exons O 0 8.80720472196117e-06
4 O 0 1.5416200085383025e-06
and O 0 1.9332502176894195e-07
5 O 0 7.552529268650687e-07
, O 0 1.322558063066026e-07
( O 0 3.8110751887643346e-08
2 O 0 2.055100054576542e-07
) O 0 1.613744693429453e-08
within O 0 1.2305514474064694e-07
exon O 0 8.660760613565799e-06
9 O 0 3.370292461113422e-06
, O 0 2.564209751199087e-07
and O 0 8.364083470269179e-08
( O 0 4.340794390600422e-08
3 O 0 1.8273141222380218e-07
) O 0 1.2308561281315633e-08
at O 0 3.9890701941658335e-07
the O 0 7.662457335300132e-08
3 O 0 5.050279696661164e-07
distal O 0 4.760541196446866e-05
end O 0 2.0873367247986607e-06
of O 0 5.3885500506112294e-08
the O 0 4.1767953007365577e-07
gene O 0 2.548341035435442e-05
. O 0 1.0099787687067874e-05

Variability O 0 0.00035947177093476057
in O 0 1.0917788131337147e-06
the O 0 8.548379923922766e-07
number O 0 3.2350519632018404e-06
of O 0 0.000572078803088516
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999948740005493
was O 0 0.004046443849802017
most O 0 9.368254723085556e-07
apparent O 0 1.545161103422288e-05
in O 0 2.1046962217496912e-07
individuals O 0 1.1653511045039977e-08
with O 0 1.3932755393852858e-07
mutations O 0 1.3673294233740307e-05
in O 0 4.473617423172982e-07
region O 0 6.4717155510152224e-06
1 O 0 5.319971023709513e-06
, O 0 1.3822078699377016e-06
and O 0 1.618815258552786e-05
upper O 1 0.9985723495483398
- O 1 0.9995768666267395
gastrointestinal O 1 0.9996191263198853
manifestations O 0 0.0007755362312309444
were O 0 1.7323327483609319e-06
more O 0 4.4232777440811333e-07
severe O 1 0.5901281833648682
in O 0 6.918386930010456e-07
them O 0 3.2285626616612717e-07
. O 0 6.3620859691582154e-06

In O 0 6.166559956000128e-07
individuals O 0 2.9731733519611225e-08
with O 0 2.8017089448439947e-07
mutations O 0 1.4876183740852866e-05
in O 0 4.784195652973722e-07
either O 0 8.234848678512208e-07
region O 0 3.942982402804773e-06
2 O 0 1.6990193216770422e-06
or O 0 5.149033199813857e-07
region O 0 2.1700107026845217e-06
3 O 0 6.764041131646081e-07
, O 0 5.315319029364218e-08
the O 0 2.2435328261849463e-08
average O 0 5.72891337924375e-07
number O 0 7.35685006247877e-08
of O 0 1.9204385637294763e-07
adenomas B-Disease 0 0.0022267173044383526
tended O 0 5.402728220360586e-06
to O 0 5.267942881914678e-08
be O 0 1.5361064242824796e-07
lower O 0 1.4065180948819034e-06
than O 0 2.2680746170067323e-08
those O 0 1.610952260477916e-08
in O 0 2.2372086405653135e-08
individuals O 0 5.130198932334906e-09
with O 0 1.3091046469071443e-07
mutations O 0 1.2768670785590075e-05
in O 0 3.884167369960778e-07
region O 0 2.8311405912972987e-06
1 O 0 1.1591096154006664e-06
, O 0 2.0953353896402405e-07
although O 0 4.1614561041569686e-07
age O 0 4.7607832129870076e-06
at O 0 3.945165371987969e-05
diagnosis O 0 0.007592582143843174
was O 0 2.198097536165733e-05
similar O 0 7.819018719601445e-06
. O 0 5.844080078531988e-06

In O 0 1.2640570275834762e-05
all O 0 1.1084199286415242e-05
AAPC B-Disease 1 0.9967085123062134
kindreds O 0 0.0026468464639037848
, O 0 2.0989184577047126e-06
a O 0 1.6724918623367557e-06
predominance O 0 5.675361899193376e-05
of O 0 1.0243302313028835e-05
right O 1 0.9994495511054993
- O 1 0.9999438524246216
sided O 1 0.9999517202377319
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999960660934448
and O 1 0.9322839379310608
rectal B-Disease 1 0.9999533891677856
polyp I-Disease 1 0.9991638660430908
sparing O 0 0.00031616821070201695
was O 0 0.00022441570763476193
observed O 0 7.74888030719012e-05
. O 0 1.3643440070154611e-05

No O 0 0.0005123501759953797
desmoid B-Disease 1 0.9915319085121155
tumors I-Disease 1 0.9999942779541016
were O 0 3.1670695079810685e-06
found O 0 1.5367495507234707e-06
in O 0 2.67064706349629e-07
these O 0 3.019608527665696e-07
kindreds O 0 0.0009946707868948579
. O 0 2.831766687449999e-05

Our O 0 3.983025635534432e-06
data O 0 1.892107434287027e-06
suggest O 0 2.1703067432099488e-06
that O 0 1.7512296324184717e-07
, O 0 1.0578229421298602e-06
in O 0 2.7269070415059105e-06
AAPC B-Disease 1 0.9962849617004395
families O 0 2.889498205149721e-07
, O 0 1.5573620260056487e-07
the O 0 3.293508399337952e-08
location O 0 4.978326160198776e-07
of O 0 1.1903301100346653e-07
the O 0 3.3065614388760878e-06
APC B-Disease 0 0.0013512854930013418
mutation O 0 0.0002934559597633779
may O 0 1.0907238902291283e-05
partially O 0 7.794294651830569e-05
predict O 0 4.4059001993446145e-06
specific O 0 2.3614994404397294e-07
phenotypic O 0 7.523650856455788e-05
expression O 0 7.188254676293582e-05
. O 0 2.75585989584215e-05

This O 0 5.746987881138921e-07
should O 0 2.2706376512360293e-07
help O 0 7.711898319939792e-08
in O 0 4.5648107516171876e-08
the O 0 3.961145011999179e-08
design O 0 1.950972773556714e-06
of O 0 1.497191988164559e-07
tailored O 0 3.1698422390036285e-05
clinical O 0 0.0003639933711383492
- O 0 0.00017401573131792247
management O 0 7.589246251882287e-06
protocols O 0 1.4791010471526533e-05
in O 0 3.1772839292898425e-07
this O 0 3.282777427671135e-08
subset O 0 7.333341045523412e-07
of O 0 6.098001676946296e-07
FAP B-Disease 0 0.0019999630749225616
patients O 0 0.00014142523286864161
. O 0 1.5909779449430062e-06
. O 0 3.7618071928591235e-06

Wilms B-Disease 1 0.9723305702209473
' I-Disease 0 0.002255902858451009
tumor I-Disease 0 0.01757579669356346
1 O 0 3.9811684473534115e-06
and O 0 1.4599554560845718e-06
Dax O 1 0.9528385996818542
- O 0 5.7131011999445036e-05
1 O 0 1.5127859569474822e-06
modulate O 0 5.812841664010193e-06
the O 0 7.823441023901978e-07
orphan O 0 5.9495105233509094e-05
nuclear O 0 9.060856245923787e-05
receptor O 0 2.510762533347588e-05
SF O 0 0.0028412165120244026
- O 0 1.2995571523788385e-05
1 O 0 4.566552433971083e-07
in O 0 8.520351713059426e-08
sex O 0 3.9627255432606034e-07
- O 0 2.1094735984661384e-06
specific O 0 1.0519001136799488e-07
gene O 0 3.1153297186392592e-06
expression O 0 9.845837666944135e-06
. O 0 6.271824986470165e-06

Products O 0 1.141440498031443e-05
of O 0 1.1836722251246101e-06
steroidogenic O 0 0.0011323197977617383
factor O 0 9.487435818300582e-06
1 O 0 7.584145350847393e-06
( O 0 1.3061346635367954e-06
SF O 0 0.0020387102849781513
- O 0 3.5354903957340866e-05
1 O 0 2.3576228613819694e-06
) O 0 1.61709138524202e-07
and O 0 4.450181222637184e-06
Wilms B-Disease 1 0.9929600358009338
tumor I-Disease 1 0.9184613823890686
1 O 0 4.84591510030441e-06
( O 0 2.341417655316036e-07
WT1 O 0 8.36114923004061e-05
) O 0 4.4937142007484e-08
genes O 0 1.438750985016668e-07
are O 0 5.47121281613272e-09
essential O 0 9.638245046517113e-08
for O 0 3.504523959918515e-08
mammalian O 0 1.020757008518558e-05
gonadogenesis O 0 0.00010421392653370276
prior O 0 6.956555012038734e-07
to O 0 8.166060894154725e-08
sexual O 0 1.2719053756882204e-06
differentiation O 0 2.664671956154052e-05
. O 0 1.5769473975524306e-05

In O 0 4.273645572538953e-06
males O 0 1.9341475763212657e-06
, O 0 2.622291276566102e-06
SF O 0 0.00679126987233758
- O 0 3.392842336324975e-05
1 O 0 9.457312444283161e-07
participates O 0 1.0937693559753825e-06
in O 0 1.0949219131362042e-07
sexual O 0 1.1492424789594224e-07
development O 0 3.3419361500364175e-08
by O 0 2.5866876640634473e-08
regulating O 0 4.5324081838771235e-06
expression O 0 5.027046654504375e-07
of O 0 7.226564946449798e-08
the O 0 1.092117258849612e-06
polypeptide O 0 0.0002625317429192364
hormone O 0 0.000379899051040411
Mullerian O 0 0.003611199092119932
inhibiting O 0 0.00026574137154966593
substance O 0 0.00034368608612567186
( O 0 3.0123169381113257e-06
MIS O 0 0.005746204871684313
) O 0 1.889363147711265e-06
. O 0 4.51029654868762e-06

Here O 0 2.9231005100882612e-06
, O 0 4.135025903906353e-07
we O 0 1.0823226403999797e-07
show O 0 5.884957658963685e-07
that O 0 2.950152122593863e-07
WT1 O 0 0.0015459646238014102
- O 0 0.0002471027837600559
KTS O 0 0.0013813625555485487
isoforms O 0 2.8500548978627194e-06
associate O 0 6.058958206267562e-06
and O 0 3.9952109887053666e-07
synergize O 0 0.00022850690584164113
with O 0 1.0261497664032504e-05
SF O 0 0.12096700072288513
- O 0 4.9348422180628404e-05
1 O 0 7.745396715108654e-07
to O 0 3.850090024570818e-08
promote O 0 2.1463315533765126e-06
MIS O 0 0.004218304995447397
expression O 0 5.838533616042696e-05
. O 0 1.2610120393219404e-05

In O 0 1.1582208571780939e-05
contrast O 0 4.429589171195403e-05
, O 0 1.694103229965549e-05
WT1 O 0 0.010602118447422981
missense O 0 0.0021827309392392635
mutations O 0 0.0005718855536542833
, O 0 2.4365156150452094e-06
associated O 0 1.4739113112227642e-06
with O 0 1.0335551223761286e-06
male B-Disease 0 7.093654858181253e-05
pseudohermaphroditism I-Disease 1 0.9997401833534241
in O 0 0.00019280902051832527
Denys B-Disease 1 0.9988977909088135
- I-Disease 1 0.9998098015785217
Drash I-Disease 1 0.9992879033088684
syndrome I-Disease 1 0.9999947547912598
, O 0 9.090455932891928e-06
fail O 0 6.351364572765306e-05
to O 0 5.923494086346182e-07
synergize O 0 0.0004417779273353517
with O 0 3.1763756851432845e-05
SF O 1 0.981810450553894
- O 0 0.0015141945332288742
1 O 0 3.2531035685678944e-05
. O 0 6.053488505131099e-06

Additionally O 0 1.8321772586205043e-05
, O 0 1.1384512390577584e-06
the O 0 8.408861731368233e-07
X O 0 0.00848508719354868
- O 0 0.0008346089161932468
linked O 0 0.0002663328486960381
, O 0 1.5599141534039518e-06
candidate O 0 4.331789568823297e-06
dosage O 0 8.167845226125792e-05
- O 0 1.6313964806613512e-05
sensitive O 0 3.813844159594737e-05
sex O 0 7.625877060490893e-06
- O 0 2.164616307709366e-05
reversal O 0 1.4255181667977013e-05
gene O 0 4.4183889258420095e-06
, O 0 1.8587606973596849e-06
Dax O 0 0.42529621720314026
- O 0 0.00011548937618499622
1 O 0 4.66382425656775e-06
, O 0 6.181833782648027e-07
antagonizes O 0 2.09254831133876e-05
synergy O 0 6.932190444786102e-06
between O 0 7.0598402999166865e-06
SF O 0 0.0181130263954401
- O 0 7.330172957153991e-05
1 O 0 2.1932316940365126e-06
and O 0 5.613163125417486e-07
WT1 O 0 0.0003418114793021232
, O 0 4.982111931894906e-07
most O 0 7.418157110805623e-08
likely O 0 6.960596721228285e-08
through O 0 1.8004062241061547e-08
a O 0 5.575869721496929e-08
direct O 0 3.204855048011268e-08
interaction O 0 7.199749916253495e-07
with O 0 4.53492020824342e-06
SF O 1 0.9526821970939636
- O 0 0.0008212825050577521
1 O 0 1.6376488929381594e-05
. O 0 4.967417225998361e-06

We O 0 5.90700437896885e-06
propose O 0 1.1992422514595091e-05
that O 0 1.6553637749439076e-07
WT1 O 0 0.0002791515726130456
and O 0 4.687757154897554e-06
Dax O 1 0.99574214220047
- O 0 0.00015176550368778408
1 O 0 1.7552301869727671e-06
functionally O 0 6.164105798234232e-06
oppose O 0 2.5491900146334956e-07
each O 0 1.2509024038820371e-08
other O 0 4.3149569250999775e-08
in O 0 4.1281188600805763e-07
testis O 0 0.00018859883130062371
development O 0 9.616555871616583e-07
by O 0 1.1181407444382785e-06
modulating O 0 0.0008139120182022452
SF O 1 0.5971072316169739
- O 0 0.00020447200222406536
1 O 0 9.674962711869739e-06
- O 0 3.3629039535298944e-05
mediated O 0 0.00018242624355480075
transactivation O 0 0.0006076448480598629
. O 0 4.339881797932321e-06
. O 0 4.241204806021415e-06

A O 0 2.4536269847885706e-05
mouse O 0 9.632628643885255e-05
model O 0 3.192714211763814e-05
for O 0 5.902436896576546e-05
Prader B-Disease 1 0.9999957084655762
- I-Disease 1 0.9999878406524658
Willi I-Disease 1 0.999996542930603
syndrome I-Disease 1 0.9999945163726807
imprinting O 1 0.9289785027503967
- O 0 0.10675236582756042
centre O 0 0.0009400245035067201
mutations O 0 0.0008112565847113729
. O 0 1.2981550753465854e-05

Imprinting O 0 0.000678860058542341
in O 0 2.7947382932325127e-06
the O 0 1.5637764363418682e-06
15q11 O 0 0.0003409672062844038
- O 0 0.00019856911967508495
q13 O 0 6.904140172991902e-05
region O 0 8.648025868751574e-06
involves O 0 2.016495955103892e-06
an O 0 6.544228199345525e-07
imprinting O 0 0.00014169805217534304
centre O 0 2.597805723780766e-05
( O 0 3.476038727967534e-07
IC O 0 2.0675806808867492e-05
) O 0 1.2686766126535076e-07
, O 0 6.833105459236322e-08
mapping O 0 6.995640546847426e-07
in O 0 5.3161503643650576e-08
part O 0 7.554518788310816e-08
to O 0 2.7998758866942808e-08
the O 0 1.2787927516910713e-07
promoter O 0 9.464727918384597e-05
and O 0 5.60300122742774e-07
first O 0 2.8546846806420945e-06
exon O 0 0.00010213375935563818
of O 0 3.0146386507112766e-06
SNRPN O 0 0.023814134299755096
. O 0 5.1446280849631876e-05

Deletion O 0 6.975100404815748e-05
of O 0 3.7581966694233415e-07
this O 0 4.6759060978729394e-07
IC O 0 0.0005001811659894884
abolishes O 0 0.0003756920632440597
local O 0 8.826626185509667e-07
paternally O 0 0.00012100289313821122
derived O 0 6.406485795196204e-07
gene O 0 2.7632431738311425e-06
expression O 0 1.3138077292751404e-06
and O 0 1.622295144443342e-06
results O 0 5.9806141507579014e-05
in O 0 0.0006536061991937459
Prader B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999978542327881
Willi I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999994039535522
( O 0 0.0007880034972913563
PWS B-Disease 1 0.999685525894165
) O 0 1.4771529095014557e-05
. O 0 1.5644249288016e-05

We O 0 3.864834980049636e-06
have O 0 2.3918667579891917e-07
created O 0 5.285787665343378e-07
two O 0 2.6607577296999807e-07
deletion O 0 4.060967330588028e-05
mutations O 0 4.0877970604924485e-05
in O 0 1.050468085850298e-06
mice O 0 1.8411295968689956e-05
to O 0 3.2246484238385165e-07
understand O 0 1.751027230056934e-05
PWS B-Disease 1 0.9995841383934021
and O 0 2.958798404506524e-06
the O 0 3.2229144153461675e-07
mechanism O 0 7.429721790686017e-06
of O 0 1.8767890708204504e-07
this O 0 6.481039349637285e-07
IC O 0 0.0010921681532636285
. O 0 3.3008127502398565e-05

Mice O 0 0.007627891842275858
harbouring O 0 0.004428190644830465
an O 0 4.6998789002827834e-06
intragenic O 0 0.0010867553064599633
deletion O 0 8.465275459457189e-05
in O 0 1.4835729871265357e-06
Snrpn O 0 0.00013679495896212757
are O 0 1.6094050181436614e-07
phenotypically O 0 0.00017990428023040295
normal O 0 3.581055352697149e-05
, O 0 8.074740094343724e-07
suggesting O 0 3.031533196917735e-06
that O 0 1.128519855342347e-07
mutations O 0 1.0578558431006968e-05
of O 0 3.049462691251392e-07
SNRPN O 0 0.0005976323736831546
are O 0 8.00423691771357e-08
not O 0 4.2531759447683726e-08
sufficient O 0 1.6195916430206125e-07
to O 0 6.804842200835992e-07
induce O 0 0.0003031267842743546
PWS B-Disease 1 0.9994041919708252
. O 0 9.433677041670308e-05

Mice O 0 0.00015209898992907256
with O 0 5.886518579245603e-07
a O 0 1.0764351827674545e-06
larger O 0 2.416517418168951e-06
deletion O 0 1.9983332094852813e-05
involving O 0 2.869336412913981e-06
both O 0 8.064258167905791e-07
Snrpn O 0 0.0003340785042382777
and O 0 1.6181264754777658e-06
the O 0 5.191335731069557e-06
putative O 0 0.003594596404582262
PWS O 1 0.9994531273841858
- O 0 0.004152202047407627
IC O 0 0.0003522852493915707
lack O 0 4.933426680509001e-06
expression O 0 1.5685665175624308e-06
of O 0 2.0278032764053933e-07
the O 0 1.6093741805889294e-06
imprinted O 0 0.00028987054247409105
genes O 0 3.6185418139211833e-05
Zfp127 O 0 0.0007216882659122348
( O 0 9.901306157189538e-07
mouse O 0 5.5726228310959414e-05
homologue O 0 5.757759208790958e-05
of O 0 1.287590635001834e-06
ZNF127 O 0 0.0010897844331339002
) O 0 1.2961235142938676e-06
, O 0 2.1166174519748893e-06
Ndn O 0 0.0015786145813763142
and O 0 2.209590093116276e-06
Ipw O 0 0.0006808977923355997
, O 0 1.8439724271956948e-06
and O 0 2.143832489309716e-07
manifest O 0 4.452439497981686e-06
several O 0 1.063333343154227e-06
phenotypes O 0 0.00017225394549313933
common O 0 4.902618093183264e-05
to O 0 4.1520332160871476e-05
PWS B-Disease 1 0.9999176263809204
infants O 1 0.8720550537109375
. O 0 7.29006205801852e-05

These O 0 1.563660134706879e-07
data O 0 3.4181459795945557e-07
demonstrate O 0 2.1919424852967495e-07
that O 0 1.469373245299721e-08
both O 0 3.6551618620705995e-08
the O 0 1.2357871526091913e-07
position O 0 1.3556701787820202e-06
of O 0 2.444826208147788e-08
the O 0 2.2744434602373076e-07
IC O 0 3.9707978430669755e-05
and O 0 1.7259235107758286e-07
its O 0 4.752830307097611e-08
role O 0 3.9789256334188394e-07
in O 0 8.78309052154691e-08
the O 0 3.411869187175398e-08
coordinate O 0 7.012246214799234e-07
expression O 0 6.009951221130905e-07
of O 0 9.985230065012729e-08
genes O 0 1.0253055506836972e-06
is O 0 1.2618831135569053e-07
conserved O 0 4.5367093548520643e-07
between O 0 5.168200232219533e-07
mouse O 0 2.8339900381979533e-05
and O 0 4.088352056896838e-07
human O 0 1.697021161817247e-06
, O 0 4.95237202358112e-07
and O 0 2.4390467956436623e-07
indicate O 0 4.703734646227531e-07
that O 0 2.609308502599106e-08
the O 0 1.8417281921756512e-07
mouse O 0 1.7018272046698257e-05
is O 0 6.533913676776137e-08
a O 0 5.247825285437102e-08
suitable O 0 1.4941794290734833e-07
model O 0 8.44955422962812e-07
system O 0 2.9296197681105696e-06
in O 0 1.3564729783865914e-07
which O 0 3.378312740665024e-08
to O 0 1.1797538945756969e-08
investigate O 0 5.307599622028647e-07
the O 0 1.128248712234381e-07
molecular O 0 1.2745190360874403e-05
mechanisms O 0 1.0172568181587849e-05
of O 0 2.735813211529603e-07
imprinting O 0 9.252448217011988e-05
in O 0 6.275614623518777e-07
this O 0 7.069186125363558e-08
region O 0 1.3321575806912733e-06
of O 0 3.595447495285953e-08
the O 0 3.5752475469053024e-07
genome O 0 1.090875593945384e-05
. O 0 1.059462647390319e-06
. O 0 3.0984585919213714e-06

Mutations O 0 0.0001903307274915278
of O 0 2.518069095458486e-07
the O 0 6.824443516961765e-07
ATM O 0 0.00017501045658718795
gene O 0 7.640388503205031e-05
detected O 0 0.0006185388774611056
in O 0 9.731074896990322e-06
Japanese O 0 0.012057697400450706
ataxia B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999563694000244
telangiectasia I-Disease 1 0.999987006187439
patients O 0 0.4677380621433258
: O 0 1.8426979977448354e-06
possible O 0 1.918982661663904e-06
preponderance O 0 2.9686358175240457e-05
of O 0 4.88483529181849e-08
the O 0 2.470097797413473e-07
two O 0 9.847225328485365e-07
founder O 0 0.00013130571460351348
mutations O 0 0.00017276007565669715
4612del165 O 0 0.00019537958723958582
and O 0 9.85812675935449e-06
7883del5 O 0 0.0007187430746853352
. O 0 1.81409213837469e-05

The O 0 2.311129946974688e-06
ATM O 0 0.00035281426971778274
( O 0 1.0302838745701592e-05
A O 1 0.998116135597229
- O 1 0.9911860823631287
T O 1 0.9995132684707642
, O 0 1.3248421737444005e-06
mutated O 0 5.349683306121733e-06
) O 0 6.00487481960954e-08
gene O 0 7.249079772009281e-07
on O 0 1.1963691122218734e-06
human O 0 4.7471771722484846e-06
chromosome O 0 0.00025806474150158465
11q22 O 0 0.0005147787160240114
. O 0 1.6013891581678763e-05

3 O 0 1.6322552255587652e-05
has O 0 1.7456965224482701e-06
recently O 0 6.03275884714094e-06
been O 0 3.8724650153199036e-07
identified O 0 1.5323328739214048e-07
as O 0 2.309440461090162e-08
the O 0 2.145159427868748e-08
gene O 0 4.758427110118646e-07
responsible O 0 9.075037610273284e-07
for O 0 8.746162194483986e-08
the O 0 3.4004820008703973e-06
human O 0 0.0016467667883262038
recessive B-Disease 1 0.9997879862785339
disease I-Disease 1 0.9999945163726807
ataxia B-Disease 1 0.9999990463256836
- I-Disease 1 0.9998644590377808
telangiectasia I-Disease 1 0.999962568283081
( O 0 0.00041919448995031416
A B-Disease 1 0.9998039603233337
- I-Disease 1 0.9985973238945007
T I-Disease 1 0.9998231530189514
) O 0 2.695512876016437e-06
. O 0 4.36482287113904e-06

In O 0 1.4533262628901866e-06
order O 0 1.3059013781457907e-07
to O 0 2.1009736173027704e-08
define O 0 4.851751214118849e-07
the O 0 2.943373829111806e-07
types O 0 1.7671047316980548e-05
of O 0 1.316027464781655e-05
disease O 1 0.9998437166213989
- O 0 0.005673982668668032
causing O 0 0.00030425918521359563
ATM O 0 0.00018167308007832617
mutations O 0 5.527207758859731e-05
in O 0 5.855399081156065e-07
Japanese O 0 6.651000876445323e-05
A B-Disease 1 0.9997871518135071
- I-Disease 1 0.9996843338012695
T I-Disease 1 0.9999089241027832
patients O 0 2.5928038667188957e-05
as O 0 1.4318003138669155e-07
well O 0 6.18833340126912e-08
as O 0 3.7155771792640735e-08
to O 0 9.69484403867682e-09
look O 0 4.528811814452638e-07
for O 0 3.1738373706957645e-08
possible O 0 1.6537053397769341e-06
mutational O 0 0.0003010870423167944
hotspots O 0 0.00013013799616601318
, O 0 1.4009597180120181e-06
reverse O 0 2.0190120267216116e-05
- O 0 1.356119719275739e-05
transcribed O 0 4.265949428372551e-06
RNA O 0 1.6670984450684045e-06
derived O 0 9.208216766865007e-08
from O 0 7.410802993490506e-08
ten O 0 3.913414445833041e-07
patients O 0 2.000874019358889e-06
belonging O 0 7.148654503907892e-07
to O 0 5.9058280044155254e-08
eight O 0 1.0621333785820752e-06
unrelated O 0 2.207845500379335e-05
Japanese O 0 0.0002045215223915875
A B-Disease 1 0.9996542930603027
- I-Disease 1 0.9966316819190979
T I-Disease 1 0.9995571970939636
families O 0 4.2179570414191403e-07
was O 0 3.036029511349625e-06
analyzed O 0 1.0429665735500748e-06
for O 0 1.6090851318040222e-08
mutations O 0 2.192434749304084e-06
by O 0 5.4990231035390025e-08
the O 0 1.2524284898063343e-07
restriction O 0 4.434504603523237e-07
endonuclease O 0 4.529987199930474e-05
fingerprinting O 0 2.4911150831030682e-05
method O 0 8.820038601697888e-06
. O 0 6.83225925968145e-06

As O 0 7.495087174902437e-06
has O 0 2.3157122086558957e-06
been O 0 4.329598937147239e-07
reported O 0 7.149581620069512e-07
by O 0 1.7800555696112497e-08
others O 0 3.143530591387389e-07
, O 0 2.5658488311819383e-07
mutations O 0 4.619386345439125e-06
that O 0 5.5539622678679734e-08
lead O 0 1.4621485888710595e-06
to O 0 2.2956446343869175e-07
exon O 0 9.445901378057897e-05
skipping O 0 6.487988866865635e-05
or O 0 2.24347013499937e-06
premature O 0 3.240643854951486e-05
protein O 0 7.023905368441774e-07
truncation O 0 6.0630163716268726e-06
were O 0 2.2486615591787995e-07
also O 0 1.6865003260591038e-07
predominant O 0 2.2825361156719737e-06
in O 0 3.59519788162288e-07
our O 0 1.9913234154955717e-06
mutants O 0 0.00015498694847337902
. O 0 1.8241889847558923e-05

Six O 0 1.067955395228637e-06
different O 0 4.215909399363227e-08
mutations O 0 3.82680900656851e-06
were O 0 6.010352393559515e-08
identified O 0 2.219832850869352e-07
on O 0 2.82762272263426e-07
12 O 0 2.7603408625509473e-07
of O 0 1.5913277806589576e-08
the O 0 5.394641675593448e-07
16 O 0 5.548304216063116e-06
alleles O 0 1.3684969417226966e-05
examined O 0 0.0002789435093291104
. O 0 1.4448864021687768e-05

Four O 0 1.3483413567882963e-06
were O 0 3.104016741417581e-07
deletions O 0 8.748247637413442e-06
involving O 0 7.262376584549202e-06
a O 0 1.44064042615355e-05
loss O 0 0.00011293115676380694
of O 0 4.287801402824698e-08
a O 0 1.3220098935562419e-06
single O 0 5.348520517145516e-06
exon O 0 9.378827962791547e-05
exon O 0 6.781259435229003e-05
7 O 0 5.725823029933963e-06
, O 0 3.008260875958513e-07
exon O 0 1.224691095558228e-05
16 O 0 1.8873695353249786e-06
, O 0 2.725753063259617e-07
exon O 0 1.4235212802304886e-05
33 O 0 5.935017725278158e-06
or O 0 2.4160565317288274e-06
exon O 0 0.0001646862510824576
35 O 0 3.247955464757979e-05
. O 0 7.862808161007706e-06

The O 0 1.5213553297144244e-06
others O 0 8.149199857143685e-07
were O 0 3.532967696173728e-07
minute O 0 2.1484695480467053e-06
deletions O 0 1.3537679478758946e-05
, O 0 7.836127338123333e-07
4649delA O 0 4.521205119090155e-05
in O 0 8.255056513917225e-07
exon O 0 5.012350084143691e-05
33 O 0 8.328197509399615e-06
and O 0 8.379523137591605e-07
7883del5 O 0 2.0595354726538062e-05
in O 0 1.6003962173272157e-06
exon O 0 0.00010379777086200193
55 O 0 3.364276926731691e-05
. O 0 7.715936590102501e-06

The O 0 1.0774965630844235e-05
mutations O 0 0.00020939156820531934
4612del165 O 0 4.720528158941306e-05
and O 0 5.803934186587867e-07
7883del5 O 0 8.1249427239527e-06
were O 0 1.3345005811515875e-07
found O 0 1.250287482434942e-07
in O 0 1.5714869405769605e-08
more O 0 2.250689412619522e-09
than O 0 1.3902382356434373e-08
two O 0 3.867216236130844e-08
unrelated O 0 1.0271484143231646e-06
families O 0 3.9050629396797376e-08
; O 0 6.789441187038392e-08
44 O 0 1.217742493508922e-07
% O 0 7.45898720566629e-09
( O 0 2.707549207059401e-08
7 O 0 2.8248331318536657e-07
of O 0 1.6050206497197905e-08
16 O 0 4.73141710699565e-07
) O 0 1.1503561658798844e-08
of O 0 3.76818887204422e-09
the O 0 6.460797408180952e-08
mutant O 0 1.9552046524040634e-06
alleles O 0 6.825029004176031e-07
had O 0 6.634959390794393e-07
one O 0 5.604584174534466e-08
of O 0 1.0703046449123121e-08
the O 0 1.602931973820887e-07
two O 0 2.0005361420771806e-06
mutations O 0 0.00022007209190633148
. O 0 1.4837731214356609e-05

The O 0 6.745580321876332e-06
4612del165 O 0 0.00011464352428447455
mutations O 0 3.0101371521595865e-05
in O 0 1.3530284093121736e-07
three O 0 1.4625200606133149e-08
different O 0 2.8692197506785533e-09
families O 0 9.203366957422077e-09
were O 0 2.9667324596971412e-08
all O 0 6.180663536525799e-09
ascribed O 0 2.682127728803607e-07
to O 0 1.4822116867208024e-08
the O 0 1.1039642799914873e-07
same O 0 1.1644866617643856e-06
T O 0 0.0007940986542962492
- O 0 1.8325827113585547e-05
- O 0 8.173622518370394e-06
> O 0 8.772088904152042e-07
A O 0 1.5653833429496444e-07
substitution O 0 5.4513407121703494e-08
at O 0 4.853305881624692e-07
the O 0 3.791463143443252e-08
splice O 0 2.6632469598553143e-05
donor O 0 6.1961090978002176e-06
site O 0 7.385089702438563e-06
in O 0 1.6850050315042608e-06
intron O 0 0.0005032477783970535
33 O 0 7.608455780427903e-05
. O 0 7.121136150090024e-06

Microsatellite O 0 0.0019850044045597315
genotyping O 0 0.00020176955149509013
around O 0 1.477817136219528e-06
the O 0 3.5310949897393584e-07
ATM O 0 9.6703261078801e-05
locus O 0 5.894045170862228e-05
also O 0 1.4837186199656571e-06
indicated O 0 1.8338272411710932e-06
that O 0 1.2765916324042337e-08
a O 0 2.761557595931663e-07
common O 0 2.327331003471045e-06
haplotype O 0 7.724239549133927e-05
was O 0 5.45503962712246e-06
shared O 0 2.578678675035917e-07
by O 0 5.481493303705065e-08
the O 0 1.4060925934700208e-07
mutant O 0 3.6995995742472587e-06
alleles O 0 1.6496555872436147e-06
in O 0 5.721940965486283e-07
both O 0 2.1421599285531556e-06
mutations O 0 0.0005247011431492865
. O 0 1.7898279111250304e-05

This O 0 6.774118901375914e-07
suggests O 0 1.1937011095142225e-06
that O 0 7.675194702017052e-09
these O 0 1.1230096852443694e-08
two O 0 2.0810509226976137e-07
founder O 0 5.475757643580437e-05
mutations O 0 6.619351916015148e-05
may O 0 3.0505811992043164e-06
be O 0 1.140383858455607e-07
predominant O 0 2.1215971628407715e-06
among O 0 1.7375681693465594e-07
Japanese O 0 4.219347374601057e-06
ATM O 0 0.0001227924512932077
mutant O 0 9.52702685026452e-05
alleles O 0 6.324125570245087e-05
. O 0 1.780001366569195e-05

W474C O 0 0.0003159566840622574
amino O 0 8.391299161303323e-06
acid O 0 1.0465330888109747e-05
substitution O 0 3.984218892583158e-07
affects O 0 1.971225174202118e-06
early O 0 2.332358519652189e-07
processing O 0 1.6417831716353248e-07
of O 0 1.9036113130255217e-08
the O 0 1.0168100317287099e-07
alpha O 0 7.416041967189813e-07
- O 0 5.44590477602469e-07
subunit O 0 1.4780651724777272e-07
of O 0 9.724163163582489e-08
beta O 0 8.479612006340176e-06
- O 0 1.530850749986712e-05
hexosaminidase O 0 3.761867992579937e-05
A O 0 1.3800701026411843e-06
and O 0 2.5907024792104494e-07
is O 0 3.763436495773931e-07
associated O 0 1.7815845012592035e-06
with O 0 3.271862397014047e-06
subacute O 1 0.9928663969039917
G B-Disease 0 0.01812957413494587
( I-Disease 0 2.849000566129689e-06
M2 I-Disease 0 0.0004658418183680624
) I-Disease 0 3.0976875677879434e-06
gangliosidosis I-Disease 0 0.0006528597441501915
. O 0 1.703579255263321e-05

Mutations O 0 0.00023220434377435595
in O 0 1.8652599464985542e-06
the O 0 7.098992682585958e-07
HEXA O 0 0.0005523641593754292
gene O 0 2.129685299223638e-06
, O 0 4.634308936601883e-08
encoding O 0 4.813177412188452e-08
the O 0 1.352754850358906e-07
alpha O 0 8.384702709918201e-07
- O 0 5.506001912181091e-07
subunit O 0 3.3132835142168915e-07
of O 0 1.2495722501171258e-07
beta O 0 1.204397722176509e-05
- O 0 1.9172384781995788e-05
hexosaminidase O 0 4.117794378544204e-05
A O 0 3.589799234759994e-06
( O 0 1.1852949199919749e-07
Hex O 0 6.685163953079609e-06
A O 0 1.3631128013003035e-06
) O 0 5.673970449038279e-08
, O 0 4.5772868162430314e-08
that O 0 7.931710399589065e-09
abolish O 0 2.3078171125234803e-06
Hex O 0 2.3118720491765998e-05
A O 0 5.302451427269261e-06
enzyme O 0 4.743225872516632e-05
activity O 0 9.014704846777022e-05
cause O 1 0.7404588460922241
Tay B-Disease 1 0.9999966621398926
- I-Disease 1 0.9999597072601318
Sachs I-Disease 1 0.9999895095825195
disease I-Disease 1 0.9998469352722168
( O 0 4.8687988964957185e-06
TSD B-Disease 0 0.001419933745637536
) O 0 7.31206910131732e-07
, O 0 1.0082178505399497e-06
the O 0 3.296986051282147e-06
fatal O 1 0.9965215921401978
infantile B-Disease 0 0.4504094421863556
form I-Disease 0 1.5111656466615386e-05
of I-Disease 0 1.8114585600415012e-06
G I-Disease 0 0.0006309583550319076
( I-Disease 0 1.1692450243572239e-06
M2 I-Disease 0 0.0001256759715033695
) I-Disease 0 5.139652898833447e-07
gangliosidosis I-Disease 0 6.625135574722663e-05
, I-Disease 0 1.1820748113677837e-06
Type I-Disease 0 3.016867776750587e-05
1 I-Disease 0 1.3570265764428768e-05
. O 0 6.820059297751868e-06

Less O 0 0.0007142924005165696
severe O 1 0.9984130859375
, O 0 8.471274486510083e-05
subacute O 1 0.9952800273895264
( O 0 4.787971556652337e-05
juvenile O 1 0.9413800835609436
- O 0 0.19789980351924896
onset O 1 0.799329936504364
) O 0 5.689136742148548e-06
and O 0 5.1944778533652425e-05
chronic O 1 0.999882698059082
( O 0 1.894452793749224e-06
adult O 0 3.7426460039569065e-05
- O 0 0.0020176635589450598
onset O 0 0.00167859869543463
) O 0 9.427014191487615e-08
variants O 0 1.6629476249363506e-06
are O 0 1.385656247521183e-07
characterized O 0 7.91957245382946e-06
by O 0 1.1184398829300335e-07
a O 0 9.462012258154573e-07
broad O 0 9.35453954298282e-06
spectrum O 0 5.18348315381445e-05
of O 0 7.90936780958873e-07
clinical O 0 0.00015873319352976978
manifestations O 0 0.00023321899061556906
and O 0 1.3964364597995882e-06
are O 0 1.1311877301523054e-07
associated O 0 1.072967847903783e-06
with O 0 2.691429017431801e-07
residual O 0 2.831993333529681e-05
levels O 0 5.57728026251425e-06
of O 0 8.573087484364805e-08
Hex O 0 2.9043168979114853e-05
A O 0 3.042942580577801e-06
enzyme O 0 1.0213238056167029e-05
activity O 0 5.427645646705059e-06
. O 0 2.5636916234361706e-06

We O 0 5.352398147806525e-06
identified O 0 5.347326805349439e-06
a O 0 4.596026428771438e-06
1422 O 0 0.0013231092598289251
G O 0 0.00035971656325273216
- O 0 4.236461245454848e-05
- O 0 3.352302155690268e-05
> O 0 6.548488727275981e-06
C O 0 5.2996911108493805e-06
( O 0 2.7183640227690375e-08
amino O 0 1.4456223595971096e-07
acid O 0 1.7818614423958934e-06
W474C O 0 1.4110321444604779e-06
) O 0 2.7093043364345704e-09
substitution O 0 7.822902325926862e-09
in O 0 2.0270176648296e-08
the O 0 3.054275765634884e-08
first O 0 9.153424684882339e-08
position O 0 7.035617386463855e-07
of O 0 7.879886965156402e-08
exon O 0 2.7885196686838754e-05
13 O 0 2.050522198260296e-06
of O 0 2.6548570986051345e-07
HEXA O 0 0.0014886268181726336
of O 0 5.35472963747452e-07
a O 0 6.845165444246959e-06
non O 0 3.497349098324776e-05
- O 0 0.00017136437236331403
Jewish O 0 1.490032173023792e-05
proband O 0 0.0014358096523210406
who O 0 9.911614142765757e-06
manifested O 0 4.3514381104614586e-05
a O 0 1.3292842595546972e-05
subacute O 0 0.04557540640234947
variant O 0 0.0011887317523360252
of O 0 4.885338057647459e-06
G B-Disease 0 0.0029651059303432703
( I-Disease 0 2.3266741209226893e-06
M2 I-Disease 0 0.0006043973844498396
) I-Disease 0 5.394202162278816e-06
gangliosidosis I-Disease 0 0.0013173529878258705
. O 0 2.0868888896075077e-05

On O 0 1.1629103028099053e-05
the O 0 1.950550540641416e-06
second O 0 1.2102938853786327e-05
maternally O 0 0.00038733435212634504
inherited O 0 0.003843157086521387
allele O 0 5.157625855645165e-05
, O 0 1.2221255474287318e-06
we O 0 5.442830683932698e-07
identified O 0 3.288786501798313e-06
the O 0 1.8383519773124135e-06
common O 0 0.001405335613526404
infantile O 1 0.9997497200965881
disease O 1 0.999963641166687
- O 0 0.08965537697076797
causing O 0 0.0026505521964281797
4 O 0 3.000790638907347e-05
- O 0 5.800900544272736e-05
bp O 0 5.751218122895807e-05
insertion O 0 5.35887465957785e-06
, O 0 1.4068278915146948e-06
+ O 0 1.6735955796320923e-05
TATC O 0 0.0003880050790030509
1278 O 0 0.0004853704303968698
, O 0 9.062756021194218e-07
in O 0 7.244256039484753e-07
exon O 0 5.422252070275135e-05
11 O 0 1.3462262359098531e-05
. O 0 3.476341362329549e-06

Pulse O 0 0.00201238295994699
- O 0 0.00017668885993771255
chase O 0 3.2701707823434845e-05
analysis O 0 4.7624857302253076e-07
using O 0 1.1133821544717648e-06
proband O 0 0.00024350550665985793
fibroblasts O 0 1.6093688827822916e-05
revealed O 0 1.058872203429928e-05
that O 0 2.6791205698373233e-08
the O 0 1.6814738046377897e-07
W474C O 0 1.0351924174756277e-05
- O 0 2.2245681066124234e-06
containing O 0 2.9502282927751367e-07
alpha O 0 1.9517190139595186e-06
- O 0 1.0891975534832454e-06
subunit O 0 4.241101692059601e-07
precursor O 0 3.5366090287425322e-06
was O 0 1.691085344646126e-06
normally O 0 2.9018008262937656e-07
synthesized O 0 2.0728975869133137e-06
, O 0 1.8489014053102437e-07
but O 0 4.907565553935456e-08
not O 0 1.3862876180326111e-08
phosphorylated O 0 8.253553005488357e-07
or O 0 4.332382843585947e-07
secreted O 0 1.204453610625933e-06
, O 0 1.8114569400040637e-07
and O 0 1.5393503360883187e-07
the O 0 1.7522921780255274e-07
mature O 0 6.790335191908525e-06
lysosomal O 0 0.0001325278717558831
alpha O 0 3.87818499802961e-06
- O 0 2.7574649266171036e-06
subunit O 0 6.477980605268385e-07
was O 0 3.860911419906188e-06
not O 0 2.7979788796983485e-07
detected O 0 6.991416012169793e-05
. O 0 3.1186289106699405e-06

When O 0 3.618002438088297e-06
the O 0 2.3488921385705908e-07
W474C O 0 1.0495656169950962e-05
- O 0 1.4926141602700227e-06
containing O 0 2.2501116347939387e-07
alpha O 0 9.758393844094826e-07
- O 0 1.1764437886085943e-06
subunit O 0 1.135118623096787e-06
was O 0 4.107409949938301e-06
transiently O 0 1.273413363378495e-05
co O 0 1.1756881576729938e-05
- O 0 2.5881390683935024e-06
expressed O 0 3.4877267296451464e-08
with O 0 3.067446741056301e-08
the O 0 1.1079448114514889e-07
beta O 0 1.1019504881915054e-06
- O 0 3.063453561935603e-07
subunit O 0 5.5159148359962273e-08
to O 0 4.766418371104919e-09
produce O 0 1.281996873103708e-07
Hex O 0 1.9449094907031395e-05
A O 0 3.665526492113713e-06
( O 0 2.4111113816616125e-07
alphabeta O 0 3.196113902959041e-05
) O 0 1.3752821814705385e-07
in O 0 6.271013717196183e-07
COS O 0 0.00035021748044528067
- O 0 1.4333690160128754e-05
7 O 0 1.7417271465092199e-06
cells O 0 7.194368549789942e-07
, O 0 3.970926343299652e-08
the O 0 1.794591675263746e-08
mature O 0 5.897475716665213e-07
alpha O 0 9.923143124979106e-07
- O 0 1.1532206372066867e-06
subunit O 0 3.0833908226668427e-07
was O 0 1.4849191529719974e-06
present O 0 5.818215953468098e-08
, O 0 7.362478982031462e-08
but O 0 1.9018402852566396e-08
its O 0 2.791679776237288e-08
level O 0 1.313577172368241e-06
was O 0 1.292493266191741e-06
much O 0 7.26135525042082e-08
lower O 0 1.568979314470198e-06
than O 0 2.023170431186827e-08
that O 0 4.503562411883877e-09
from O 0 3.417111926751204e-08
normal O 0 1.2677262475335738e-06
alpha O 0 1.4314632608147804e-06
- O 0 1.8783177893055836e-06
subunit O 0 7.817117193553713e-07
transfections O 0 3.006955375894904e-05
, O 0 7.181961336755194e-08
although O 0 3.4668808268634166e-08
higher O 0 1.0567566732788691e-07
than O 0 2.4013742105921665e-08
in O 0 3.696083084037127e-08
those O 0 2.1189061172322e-08
cells O 0 5.981818276268314e-07
transfected O 0 1.2944758964295033e-05
with O 0 7.491669862247363e-08
an O 0 1.8277513902376086e-07
alpha O 0 2.962451844723546e-06
- O 0 7.366393674601568e-06
subunit O 0 3.7978215914336033e-06
associated O 0 6.1922401073388755e-06
with O 0 1.1551740499271546e-05
infantile O 1 0.9832425117492676
TSD B-Disease 0 0.4042137861251831
. O 0 8.579480345360935e-05

Furthermore O 0 1.1564504347916227e-05
, O 0 6.46963940198475e-07
the O 0 8.400199646985129e-08
precursor O 0 3.0033841085241875e-06
level O 0 1.31679314563371e-06
of O 0 1.9328659561779205e-08
the O 0 1.6751803855186154e-07
W474C O 0 9.782968845684081e-06
alpha O 0 1.7621554206925794e-06
- O 0 1.2003473557342659e-06
subunit O 0 3.247250504045951e-07
was O 0 1.695123842182511e-06
found O 0 5.463268948346922e-08
to O 0 7.509048494114268e-09
accumulate O 0 9.96533572106273e-07
in O 0 1.4707751461173757e-08
comparison O 0 6.26373974910166e-08
to O 0 8.228817627298213e-09
the O 0 5.3039357794659736e-08
normal O 0 2.0381264675961575e-06
alpha O 0 2.3718009742879076e-06
- O 0 4.2336155274824705e-06
subunit O 0 1.7302804735663813e-06
precursor O 0 3.232733070035465e-05
levels O 0 2.4341061362065375e-05
. O 0 3.863681286020437e-06

We O 0 5.014677299186587e-06
conclude O 0 5.838943707203725e-06
that O 0 6.803052343684612e-08
the O 0 5.624619916488882e-07
1422 O 0 0.001249617664143443
G O 0 0.0004404941282700747
- O 0 8.390973380301148e-05
- O 0 6.045351619832218e-05
> O 0 2.2265558072831482e-05
C O 0 3.027387174370233e-05
mutation O 0 1.129664815380238e-05
is O 0 2.042513074229646e-07
the O 0 2.06160734705918e-07
cause O 0 7.54149868953391e-06
of O 0 3.737694100891531e-07
Hex B-Disease 0 0.0008501998381689191
A I-Disease 0 0.002964143408462405
enzyme I-Disease 1 0.9997476935386658
deficiency I-Disease 1 0.9999957084655762
in O 0 4.089618414582219e-06
the O 0 5.938137292105239e-06
proband O 0 0.005590693559497595
. O 0 2.0772764401044697e-05

The O 0 5.315589078236371e-06
resulting O 0 2.823439717758447e-05
W474C O 0 4.646801244234666e-05
substitution O 0 8.64371941133868e-07
clearly O 0 1.4518218449666165e-06
interferes O 0 3.905811354343314e-06
with O 0 1.0216876944468822e-07
alpha O 0 1.192856757370464e-06
- O 0 9.523918151899124e-07
subunit O 0 1.9211273638575221e-07
processing O 0 1.7082672911783447e-06
, O 0 2.1779212033834483e-07
but O 0 5.758246501841313e-08
because O 0 3.9941170371093904e-08
the O 0 4.372153483700458e-08
base O 0 8.954643817560282e-07
substitution O 0 6.093804358897614e-07
falls O 0 0.00011683219054248184
at O 0 2.2135213839646894e-06
the O 0 5.186794993505828e-08
first O 0 2.3850492425481207e-07
position O 0 1.0926048616966e-06
of O 0 9.950153412319196e-08
exon O 0 3.096822547377087e-05
13 O 0 2.2869637632538797e-06
, O 0 1.5757737514832115e-07
aberrant O 0 2.6594766495691147e-06
splicing O 0 9.967178812075872e-06
may O 0 2.3729187432763865e-06
also O 0 1.1283993472943621e-07
contribute O 0 1.7680527264474222e-07
to O 0 2.9370818310781033e-07
Hex B-Disease 0 0.0005575016839429736
A I-Disease 0 0.0005395569605752826
deficiency I-Disease 1 0.9942613840103149
in O 0 6.254887239265372e-07
this O 0 2.641326091179508e-07
proband O 0 0.00013206287985667586
. O 0 1.1673487279040273e-06
. O 0 3.4375450468360214e-06

Two O 0 7.032557277852902e-06
frequent O 0 0.00022982730297371745
missense O 0 0.004880049265921116
mutations O 0 0.020133696496486664
in O 0 0.0029510001186281443
Pendred B-Disease 1 0.9999827146530151
syndrome I-Disease 1 1.0
. O 0 0.00025087420362979174

Pendred B-Disease 1 0.9999732971191406
syndrome I-Disease 1 0.9999998807907104
is O 0 0.0023689293302595615
an O 0 0.004899564664810896
autosomal B-Disease 1 0.9999996423721313
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9887747764587402
by O 0 2.759262679319363e-05
early O 0 0.08645249903202057
childhood O 1 0.9995805621147156
deafness B-Disease 1 0.9999998807907104
and O 1 0.9993545413017273
goiter B-Disease 1 0.9999996423721313
. O 0 0.0007847602246329188

A O 0 6.967776243982371e-06
century O 0 2.018423856497975e-06
after O 0 6.98735277637752e-07
its O 0 2.112816410715368e-08
recognition O 0 4.616972262283525e-07
as O 0 5.210873951000394e-06
a O 0 0.0002594977559056133
syndrome O 1 0.9999067783355713
by O 0 1.2623070233530598e-06
Vaughan O 0 0.00015979501768015325
Pendred O 0 0.00040669189183972776
, O 0 2.044539087364683e-06
the O 0 4.8033602979558054e-06
disease O 1 0.9785895943641663
gene O 0 1.6405687347287312e-05
( O 0 1.3589321952167666e-06
PDS O 0 0.0006432648515328765
) O 0 2.43172138425507e-07
was O 0 4.454644113138784e-06
mapped O 0 7.438073225785047e-06
to O 0 3.743876675343927e-07
chromosome O 0 0.00017919090169016272
7q22 O 0 0.00047808626550249755
- O 0 0.00048320405767299235
q31 O 0 0.00045754198799841106
. O 0 1.3636871699418407e-05

1 O 0 1.475049793953076e-05
and O 0 2.1627529349643737e-06
, O 0 8.681076337779814e-07
recently O 0 1.0548397767706774e-05
, O 0 1.6875591768439335e-07
found O 0 3.6742861198035826e-08
to O 0 4.095014105587325e-09
encode O 0 8.842999221769787e-08
a O 0 2.0780155409738654e-06
putative O 0 0.0001247994223376736
sulfate O 0 0.0023011784069240093
transporter O 0 0.008846653625369072
. O 0 2.218986628577113e-05

We O 0 3.942779130738927e-06
performed O 0 8.353062185051385e-06
mutation O 0 4.187127160548698e-06
analysis O 0 1.716169180099314e-07
of O 0 4.7460634533535995e-08
the O 0 5.664206241817737e-07
PDS B-Disease 0 0.0016306473407894373
gene O 0 2.0768920876435004e-05
in O 0 3.426456032684655e-06
patients O 0 2.4107690478558652e-05
from O 0 3.3386905329280125e-07
14 O 0 2.0409606804605573e-06
Pendred B-Disease 0 2.3426524421665817e-05
families O 0 2.9191726369504067e-08
originating O 0 6.106574232944695e-07
from O 0 1.150288611029282e-07
seven O 0 9.071233364466025e-08
countries O 0 8.604635226561186e-09
and O 0 1.052066664897211e-07
identified O 0 8.590074571657169e-07
all O 0 1.5751757587167958e-07
mutations O 0 7.2414506576024e-05
. O 0 7.25617383068311e-06

The O 0 1.724837261463108e-06
mutations O 0 2.75259226327762e-05
include O 0 2.941300181191764e-07
three O 0 1.8463147455349826e-07
single O 0 8.554757755518949e-07
base O 0 6.994833256612765e-06
deletions O 0 1.3539191058953293e-05
, O 0 2.0348547025150765e-07
one O 0 1.3316503100213595e-07
splice O 0 6.0974707594141364e-05
site O 0 2.2198964870767668e-05
mutation O 0 1.578030423843302e-05
and O 0 7.472374363715062e-07
10 O 0 4.717904175777221e-06
missense O 0 0.0005363129312172532
mutations O 0 0.0011966308811679482
. O 0 2.8147349439677782e-05

One O 0 3.381191345397383e-05
missense O 0 0.0010754455579444766
mutation O 0 0.00015196243475656956
( O 0 6.194037496243254e-07
L236P O 0 1.737670936563518e-05
) O 0 1.1607684768932813e-07
was O 0 2.1216658296907553e-06
found O 0 1.0588792775934053e-07
in O 0 3.1854327176006336e-08
a O 0 2.005572525831667e-07
homozygous O 0 1.4599762607758748e-06
state O 0 9.815209267571845e-08
in O 0 6.1114789673411e-08
two O 0 1.2043855690535565e-07
consanguineous O 0 0.00011290897964499891
families O 0 1.7294280496571446e-07
and O 0 2.018830826955309e-07
in O 0 8.116681016190341e-08
a O 0 1.595881684579581e-07
heterozygous O 0 1.1119353615640648e-07
state O 0 2.610996041596536e-08
in O 0 2.727712988814801e-08
five O 0 2.0560893432275407e-08
additional O 0 1.252160899412047e-07
non O 0 2.2335081666824408e-05
- O 0 0.00043733668280765414
consanguineous O 0 0.0013991218293085694
families O 0 4.70124177809339e-06
. O 0 1.7507098164060153e-05

Another O 0 5.117491673445329e-05
missense O 0 0.0010006417287513614
mutation O 0 0.00015048299974296242
( O 0 5.247345029602002e-07
T416P O 0 1.825924300646875e-05
) O 0 1.3665774645232887e-07
was O 0 1.5701409665780375e-06
found O 0 1.2689355344264186e-07
in O 0 2.5521670110606465e-08
a O 0 1.0451146437162606e-07
homozygous O 0 5.166928644939617e-07
state O 0 4.80791051415963e-08
in O 0 3.994330555201486e-08
one O 0 8.507701920734689e-08
family O 0 5.099723807688861e-07
and O 0 2.0429241942565568e-07
in O 0 9.181663784829652e-08
a O 0 2.4481445848323347e-07
heterozygous O 0 1.3388411446157988e-07
state O 0 9.563184732996888e-08
in O 0 1.3657852093729161e-07
four O 0 2.0766279362760542e-07
families O 0 4.0080718122226244e-07
. O 0 7.396388809866039e-06

Pendred B-Disease 0 0.01718122325837612
patients O 0 0.00020234925614204258
in O 0 5.026116696171812e-07
three O 0 2.9333503448469855e-07
non O 0 1.70108560269e-05
- O 0 8.185958722606301e-05
consanguineous O 0 0.00010542052768869326
families O 0 9.633907183115298e-08
were O 0 4.837105649357909e-08
shown O 0 1.152354940359146e-07
to O 0 2.1348325773828947e-08
be O 0 9.065214356951401e-08
compound O 0 3.0115729714452755e-06
heterozygotes O 0 1.2783682905137539e-05
for O 0 3.176435541263345e-07
L236P O 0 5.184566180105321e-05
and O 0 4.117355729249539e-06
T416P O 0 0.00044876307947561145
. O 0 1.4356769497680943e-05

In O 0 9.176864637083781e-07
total O 0 1.2513324065821507e-07
, O 0 1.7769151838820108e-07
one O 0 6.966308063738325e-08
or O 0 1.343271378573263e-07
both O 0 2.9535152989978997e-08
of O 0 8.833858977652653e-09
these O 0 2.0248073440143344e-08
mutations O 0 1.9441563381406013e-06
were O 0 8.157047659551608e-08
found O 0 1.218637066813244e-07
in O 0 2.2201668059551594e-08
nine O 0 8.623993608125602e-08
of O 0 8.940017615088891e-09
the O 0 2.2537582822224067e-07
14 O 0 1.1836010571641964e-06
families O 0 4.9367727683602425e-08
analyzed O 0 1.064796197169926e-05
. O 0 6.0461502471298445e-06

The O 0 8.635348649477237e-07
identification O 0 1.364591753372224e-06
of O 0 2.777852046165208e-07
two O 0 1.4052268397790613e-06
frequent O 0 0.00016284057346638292
PDS B-Disease 0 0.028989050537347794
mutations O 0 4.76060486107599e-05
will O 0 9.825830460385987e-08
facilitate O 0 5.357779286896402e-07
the O 0 2.603430630188086e-06
molecular O 0 0.007849319837987423
diagnosis O 1 0.9974039196968079
of O 0 0.0016061394708231091
Pendred B-Disease 1 0.9999966621398926
syndrome I-Disease 1 1.0
. O 0 0.0005161258741281927

Insertional O 0 0.006062573753297329
mutation O 0 0.0001592206972418353
by O 0 6.963344958421658e-07
transposable O 0 0.00024644119548611343
element O 0 2.072689494525548e-05
, O 0 3.548751465132227e-06
L1 O 0 0.0001591338950674981
, O 0 1.7044707192326314e-06
in O 0 3.722589667631837e-07
the O 0 1.4385029771801783e-06
DMD B-Disease 1 0.9874008297920227
gene O 0 1.7849326468422078e-05
results O 0 5.31479327037232e-06
in O 0 6.0518495956785046e-06
X B-Disease 1 0.9977906942367554
- I-Disease 1 0.9958682060241699
linked I-Disease 1 0.989686906337738
dilated I-Disease 1 0.9984644651412964
cardiomyopathy I-Disease 1 0.9999969005584717
. O 0 0.00014181711594574153

X B-Disease 1 0.9979091286659241
- I-Disease 1 0.997450053691864
linked I-Disease 1 0.9920024871826172
dilated I-Disease 1 0.997218132019043
cardiomyopathy I-Disease 1 0.9999877214431763
( O 0 7.947634912852664e-06
XLDCM B-Disease 0 0.0007933877059258521
) O 0 3.5943099874202744e-07
is O 0 2.1264109761887084e-07
a O 0 1.162562625722785e-06
clinical O 0 4.45281075371895e-05
phenotype O 0 3.404769813641906e-05
of O 0 3.5053673741458624e-07
dystrophinopathy B-Disease 0 0.0029947487637400627
which O 0 1.9329270344314864e-06
is O 0 1.304411853197962e-06
characterized O 0 1.9179971786797978e-05
by O 0 1.0644351959854248e-06
preferential O 0 0.0001490847789682448
myocardial B-Disease 1 0.9991908669471741
involvement I-Disease 0 2.8735519663314335e-05
without O 0 5.669464258062362e-07
any O 0 3.6032813000019814e-07
overt O 0 3.30266120727174e-05
clinical O 0 0.0019207150908187032
signs O 0 0.009423894807696342
of O 0 0.0003533491399139166
skeletal B-Disease 1 0.9999992847442627
myopathy I-Disease 1 1.0
. O 0 0.005387257318943739

To O 0 2.6683275677896745e-07
date O 0 2.681104888324626e-06
, O 0 1.5693130706040392e-07
several O 0 2.0187209770483605e-07
mutations O 0 3.0516486731357872e-05
in O 0 2.0884456262137974e-06
the O 0 7.131054007913917e-05
Duchenne B-Disease 1 0.9999295473098755
muscular I-Disease 1 0.9998534917831421
dystrophy I-Disease 1 0.9995759129524231
gene O 0 0.0019166331039741635
, O 0 0.00011529308540048078
DMD O 1 0.9993452429771423
, O 0 2.6202762910543242e-06
have O 0 2.1525127635868557e-07
been O 0 6.61016372305312e-07
identified O 0 1.3507532230505603e-06
in O 0 3.683703653223347e-07
patients O 0 3.938190729968483e-06
with O 0 4.81904748994566e-07
XLDCM B-Disease 0 0.002003276254981756
, O 0 8.940565976445214e-07
but O 0 6.7040353712855e-08
a O 0 2.6578260303722345e-07
pathogenic O 0 6.9011616687930655e-06
correlation O 0 3.4123058867407963e-07
of O 0 4.4993488046429775e-08
these O 0 2.1695193197501794e-07
cardiospecific O 0 0.0007320332806557417
mutations O 0 0.000353945535607636
in O 0 1.03479860626976e-05
DMD O 1 0.9993031024932861
with O 0 4.718588570540305e-06
the O 0 5.21927449881332e-06
XLDCM B-Disease 0 0.005214990116655827
phenotype O 0 0.00010393038974143565
has O 0 1.5934531347738812e-06
remained O 0 4.276417712389957e-06
to O 0 6.674740404832846e-08
be O 0 6.471527740359306e-07
elucidated O 0 0.00024073374515864998
. O 0 1.2557066838780884e-05

We O 0 9.014382158056833e-06
report O 0 4.7254823698494874e-07
here O 0 6.625779036539825e-08
the O 0 1.0503420355689741e-08
identification O 0 9.582173277067341e-08
of O 0 3.864171205236744e-08
a O 0 1.4699642179039074e-06
unique O 0 8.121502105495892e-06
de O 0 0.00044133744086138904
novo O 0 0.00011140060087200254
L1 O 0 0.00012943703040946275
insertion O 0 1.3475826563080773e-05
in O 0 6.853028935438488e-07
the O 0 1.3388313391260453e-06
muscle O 0 0.0003868085041176528
exon O 0 8.51074728416279e-05
1 O 0 6.949884209461743e-06
in O 0 3.333929043947137e-06
DMD O 1 0.9988204836845398
in O 0 2.1759519768238533e-06
three O 0 3.2402024316979805e-06
XLDCM B-Disease 0 0.0049599590711295605
patients O 0 3.4066277294186875e-05
from O 0 2.08970192261404e-07
two O 0 2.9531756240430695e-07
unrelated O 0 1.7870255760499276e-05
Japanese O 0 1.90769242180977e-05
families O 0 1.7151495512734982e-06
. O 0 7.00373129802756e-06

The O 0 8.379011546821857e-07
insertion O 0 5.566334039031062e-06
was O 0 7.155398634495214e-06
a O 0 7.408725650748238e-07
5 O 0 1.2500340744736604e-06
- O 0 3.3465466913185082e-06
truncated O 0 3.818151071754983e-06
form O 0 5.893618322261318e-07
of O 0 9.201738038200347e-08
human O 0 1.9574022189772222e-06
L1 O 0 3.825621024589054e-05
inversely O 0 7.667773388675414e-06
integrated O 0 1.4237249160942156e-05
in O 0 7.519197424699087e-07
the O 0 7.662134748898097e-07
5 O 0 7.48405909689609e-06
- O 0 6.863053567940369e-05
untranslated O 0 0.0003129880060441792
region O 0 1.1007848115696106e-05
in O 0 5.622801495519525e-07
the O 0 6.461401085289253e-07
muscle O 0 0.0001626227021915838
exon O 0 3.238598583266139e-05
1 O 0 1.7010913779813563e-06
, O 0 1.329315608700199e-07
which O 0 3.216459631971702e-08
affected O 0 7.862456641305471e-08
the O 0 3.646318447181329e-08
transcription O 0 1.9523574792401632e-06
or O 0 5.985515940665209e-07
the O 0 2.796346336708666e-07
stability O 0 5.268975655781105e-06
of O 0 2.137143013669629e-07
the O 0 2.342975221836241e-06
muscle O 0 0.0005517879617400467
form O 0 1.6865194538695505e-06
of O 0 1.4658496638730867e-07
dystrophin O 0 0.00012198263721074909
transcripts O 0 1.5090256965777371e-05
but O 0 4.169560270383954e-07
not O 0 3.3657197917591475e-08
that O 0 1.683048367340234e-08
of O 0 5.3332939842221094e-08
the O 0 2.7221572054259013e-06
brain O 1 0.9986920952796936
or O 0 1.9450244508334436e-05
Purkinje O 0 0.0065384223125875
cell O 0 0.0004484619421418756
form O 0 1.192714898934355e-05
, O 0 2.409941998848808e-06
probably O 0 4.535443622444291e-06
due O 0 5.605999717772647e-07
to O 0 1.2345993560813895e-08
its O 0 3.080703692148745e-08
unique O 0 3.185919297266082e-07
site O 0 4.1365028664586134e-06
of O 0 1.3052265046553657e-07
integration O 0 1.4544115401804447e-05
. O 0 1.7020138329826295e-05

We O 0 4.889905994787114e-06
speculate O 0 2.8745732834067894e-06
that O 0 1.9417935703813782e-08
this O 0 1.2862507503541565e-08
insertion O 0 2.7514050771060283e-07
of O 0 1.743872424242454e-08
an O 0 1.0277191364593818e-07
L1 O 0 4.1505249100737274e-05
sequence O 0 3.8625389606750105e-06
in O 0 6.832591225247597e-06
DMD O 1 0.9990383386611938
is O 0 9.650253787185648e-07
responsible O 0 9.545814236844308e-07
for O 0 2.1626645363426178e-08
some O 0 1.487558876078765e-08
of O 0 1.5975865963469005e-08
the O 0 1.2069598653852154e-07
population O 0 1.3645192531441808e-08
of O 0 4.355299410008229e-08
Japanese O 0 1.5261495718732476e-05
patients O 0 2.2564910977962427e-05
with O 0 2.185583298341953e-06
XLDCM B-Disease 0 0.012173020280897617
. O 0 3.8864227462909184e-06
. O 0 6.641906566073885e-06

Severe O 1 0.9940569400787354
early O 0 0.24755658209323883
- O 1 0.9991483688354492
onset O 1 0.9996733665466309
obesity B-Disease 1 0.9999960660934448
, O 0 0.2827775180339813
adrenal B-Disease 1 0.9999938011169434
insufficiency I-Disease 1 0.9999961853027344
and O 0 0.020911525934934616
red O 1 0.9976946711540222
hair O 1 0.9995988011360168
pigmentation O 1 0.998053789138794
caused O 0 0.009354719892144203
by O 0 4.596017788571771e-06
POMC O 0 0.023131581023335457
mutations O 0 0.0003612650907598436
in O 0 3.760949766729027e-06
humans O 0 1.7654556359048e-05
. O 0 7.796139470883645e-06

Sequential O 0 1.7692851542960852e-05
cleavage O 0 0.00019150431035086513
of O 0 9.432194758574042e-08
the O 0 1.3952674748907157e-07
precursor O 0 4.044170509587275e-06
protein O 0 4.224448730383301e-06
pre O 0 0.00016560129006393254
- O 0 0.00041051264270208776
pro O 0 0.0012468488421291113
- O 0 0.0005515202647075057
opiomelanocortin O 0 0.00044689836795441806
( O 0 1.0198142490480677e-06
POMC O 0 0.0003239484503865242
) O 0 1.1796912957606764e-07
generates O 0 5.410758490143053e-07
the O 0 1.2672342108999146e-06
melanocortin O 0 0.0024289791472256184
peptides O 0 9.003536979435012e-05
adrenocorticotrophin O 0 0.0004181167169008404
( O 0 2.2818353500042576e-06
ACTH O 0 0.00022260665718931705
) O 0 4.861686306867341e-07
, O 0 1.3184192084736424e-06
melanocyte O 0 0.001380212721414864
- O 0 0.0005119825364090502
stimulating O 0 0.00012864462041761726
hormones O 0 7.287692278623581e-05
( O 0 3.8832340010230837e-07
MSH O 0 0.00020741327898576856
) O 0 5.116823231787748e-08
alpha O 0 2.211547638353295e-07
, O 0 5.0611959068191936e-08
beta O 0 3.3036511126738333e-07
and O 0 3.2615076861475245e-08
gamma O 0 5.570723828896007e-07
as O 0 5.5309165247763303e-08
well O 0 4.223805660785729e-08
as O 0 9.498596398316295e-08
the O 0 9.194509686949459e-08
opioid O 0 1.3824655979988165e-05
- O 0 3.5682514862855896e-06
receptor O 0 2.4990313249872997e-06
ligand O 0 1.909778620756697e-05
beta O 0 0.0001698954147286713
- O 0 0.0004170280008111149
endorphin O 0 0.002831805031746626
. O 0 1.4421413652598858e-05

While O 0 2.841289187927032e-06
a O 0 1.0910210903603001e-06
few O 0 1.5318945543185691e-06
cases O 0 2.8422755349311046e-06
of O 0 1.7017566733557032e-06
isolated O 1 0.8504902124404907
ACTH B-Disease 1 0.9940431714057922
deficiency I-Disease 1 0.9993583559989929
have O 0 1.927015091496287e-06
been O 0 5.452616278489586e-06
reported O 0 1.880066338344477e-05
( O 0 1.3708214510188554e-06
OMIM O 0 0.0036055741365998983
201400 O 0 0.00028742101858370006
) O 0 8.231566539507185e-07
, O 0 1.4132029946267721e-06
an O 0 8.182513738574926e-06
inherited O 1 0.9987201690673828
POMC O 1 0.9960511326789856
defect O 1 0.9623249769210815
has O 0 4.35181345892488e-06
not O 0 1.8447060767812218e-07
been O 0 5.783793426417105e-07
described O 0 2.1775608729512896e-06
so O 0 7.364669158960169e-07
far O 0 5.291626166581409e-06
. O 0 6.152300557005219e-06

Recent O 0 2.0758308892254718e-05
studies O 0 8.751466111789341e-07
in O 0 2.6328481794735126e-07
animal O 0 1.045622639139765e-06
models O 0 1.8518655906518688e-06
elucidated O 0 1.6326072000083514e-05
a O 0 5.586477413999091e-07
central O 0 4.348534616838151e-07
role O 0 1.6955749515545904e-06
of O 0 4.672674265293608e-07
alpha O 0 3.625834142439999e-05
- O 0 0.00027904435410164297
MSH O 0 0.002077487763017416
in O 0 4.0091077835313627e-07
the O 0 1.6036199212976499e-07
regulation O 0 1.391185946886253e-06
of O 0 6.450479617114979e-08
food O 0 8.866929306350357e-07
intake O 0 3.373694426045404e-06
by O 0 6.181549849770818e-08
activation O 0 2.271526454933337e-06
of O 0 1.9144407303883781e-07
the O 0 4.122364771319553e-06
brain O 1 0.627021312713623
melanocortin O 0 0.0035158407408744097
- O 0 0.00010551828017923981
4 O 0 6.201287305884762e-06
- O 0 1.4085560906096362e-05
receptor O 0 7.04984904587036e-06
( O 0 7.547359928139485e-07
MC4 O 0 0.0010364979971200228
- O 0 5.240306563791819e-05
R O 0 6.030461736372672e-05
; O 0 1.8883565644500777e-07
refs O 0 1.7839931388152763e-05
3 O 0 1.81220309514174e-06
- O 0 4.071250714332564e-06
5 O 0 2.9903179665780044e-07
) O 0 1.1570876701227917e-08
and O 0 2.2558262813276997e-08
the O 0 4.360618888199497e-08
linkage O 0 1.0696682693378534e-05
of O 0 9.286746944781044e-07
human O 0 0.00034510839032009244
obesity B-Disease 1 0.9997703433036804
to O 0 2.00158851271226e-07
chromosome O 0 1.4009266124048736e-05
2 O 0 6.716058464917296e-07
in O 0 6.389401363549041e-08
close O 0 3.86082348313721e-07
proximity O 0 6.327260280158953e-07
to O 0 1.0600371069813264e-07
the O 0 6.455205721067614e-07
POMC O 0 0.0007340881857089698
locus O 0 2.594317265902646e-05
, O 0 6.855421474938339e-07
led O 0 5.114803229844256e-07
to O 0 2.8169365506869326e-08
the O 0 1.01286907749909e-07
proposal O 0 9.010909138851275e-07
of O 0 5.6124253688949466e-08
an O 0 5.065919026492338e-07
association O 0 3.2766492950031534e-06
of O 0 5.475682769429113e-07
POMC O 0 0.017429545521736145
with O 0 3.688396463985555e-05
human O 0 0.0542089007794857
obesity B-Disease 1 0.9999600648880005
. O 0 7.644294237252325e-05

The O 0 6.350049943648628e-07
dual O 0 8.274782885564491e-06
role O 0 1.5311179595300928e-05
of O 0 1.6723755607017665e-06
alpha O 0 9.584606596035883e-05
- O 0 0.0005285855149850249
MSH O 0 0.0027999812737107277
in O 0 7.885823265496583e-07
regulating O 0 3.70829802704975e-05
food O 0 6.439037406380521e-06
intake O 0 2.4382505216635764e-05
and O 0 1.2056684681738261e-06
influencing O 0 0.00013469009718392044
hair O 1 0.9926369190216064
pigmentation O 1 0.843437910079956
predicts O 0 9.080809832084924e-05
that O 0 8.157638831107761e-08
the O 0 4.173585637090582e-07
phenotype O 0 2.5454748538322747e-05
associated O 0 1.695232072052022e-06
with O 0 3.564325936622481e-07
a O 0 2.1217720131971873e-05
defect O 0 0.04766002297401428
in O 0 2.0785428205272183e-06
POMC O 0 0.0012249688152223825
function O 0 7.90423382568406e-06
would O 0 3.0266598969319602e-06
include O 0 6.438766286009923e-05
obesity B-Disease 1 0.9999788999557495
, O 0 1.2435511052899528e-05
alteration O 0 0.0012117443839088082
in O 0 2.8920094337081537e-05
pigmentation O 1 0.9903417825698853
and O 0 0.013813215307891369
ACTH B-Disease 1 0.9958531856536865
deficiency I-Disease 1 0.9997377991676331
. O 0 3.111799742328003e-05

The O 0 3.619317340053385e-06
observation O 0 7.530706352554262e-05
of O 0 5.436988885776373e-07
these O 0 1.568548441355233e-06
symptoms O 0 0.2843087613582611
in O 0 6.394485581040499e-07
two O 0 6.1019983377264e-07
probands O 0 0.00017498125089332461
prompted O 0 3.937473593396135e-06
us O 0 1.7806880237003497e-07
to O 0 1.1057086801713467e-08
search O 0 2.3354655809271208e-07
for O 0 9.555709112873956e-08
mutations O 0 1.0744633073045406e-05
within O 0 4.659178216570581e-07
their O 0 6.515992936328985e-07
POMC O 0 0.004973266739398241
genes O 0 0.00011414533946663141
. O 0 1.6974639947875403e-05

Patient O 0 0.00047241064021363854
1 O 0 6.450248292821925e-06
was O 0 9.369646249979269e-06
found O 0 1.9748198099023284e-07
to O 0 1.1173072245185267e-08
be O 0 2.7732058427432094e-08
a O 0 1.6995787177620514e-07
compound O 0 1.2913153568661073e-06
heterozygote O 0 2.2962256025493843e-06
for O 0 2.529761822245291e-08
two O 0 1.1606267946717708e-07
mutations O 0 5.29771568835713e-06
in O 0 6.50775803023862e-07
exon O 0 4.490113497013226e-05
3 O 0 5.428096301329788e-06
( O 0 4.613349631199526e-07
G7013T O 0 4.1724542825249955e-05
, O 0 1.4272756061473046e-06
C7133delta O 0 4.7043184167705476e-05
) O 0 6.00206959688876e-08
which O 0 2.2020156364987997e-08
interfere O 0 1.5926008245514822e-07
with O 0 3.7417059672861797e-08
appropriate O 0 1.214620084510898e-07
synthesis O 0 2.713225967454491e-06
of O 0 6.271671963986591e-07
ACTH O 0 0.0004547988064587116
and O 0 9.512603355688043e-06
alpha O 0 0.00028639251831918955
- O 0 0.004553921055048704
MSH O 0 0.04943017661571503
. O 0 2.7282358132652007e-05

Patient O 0 0.00031787887564860284
2 O 0 4.551067377178697e-06
was O 0 3.455299975030357e-06
homozygous O 0 4.7263432634281344e-07
for O 0 1.8100266174769786e-08
a O 0 3.3590504244784825e-07
mutation O 0 3.0157111723383423e-06
in O 0 3.1845399917074246e-07
exon O 0 3.352599742356688e-05
2 O 0 4.683011411543703e-06
( O 0 4.466442646844371e-07
C3804A O 0 2.241621223220136e-05
) O 0 1.8489454589598608e-07
which O 0 7.851499503885861e-07
abolishes O 0 0.0006205988465808332
POMC O 0 0.003551471047103405
translation O 0 4.684982923208736e-05
. O 0 3.0119059374555945e-05

These O 0 3.4967328588209057e-07
findings O 0 5.883554763386201e-07
represent O 0 1.6291831883563646e-08
the O 0 5.979547523793372e-08
first O 0 1.965796627700911e-07
examples O 0 7.497786782550975e-07
of O 0 3.589000812098675e-07
a O 0 0.00023504415003117174
genetic B-Disease 1 0.9997119307518005
defect I-Disease 1 0.9999150037765503
within O 0 3.1406316338689066e-06
the O 0 1.9720487216545735e-06
POMC O 0 0.0009585032239556313
gene O 0 6.0594961723836605e-06
and O 0 6.640948413405567e-07
define O 0 6.083815605961718e-06
a O 0 1.4401142834685743e-05
new O 0 0.00017601926811039448
monogenic B-Disease 1 0.9983049631118774
endocrine I-Disease 1 0.9999494552612305
disorder I-Disease 1 0.9998503923416138
resulting O 0 0.00012684670218732208
in O 0 1.1335715498717036e-05
early O 0 0.004937502555549145
- O 1 0.9990992546081543
onset O 1 0.9997257590293884
obesity B-Disease 1 0.9999957084655762
, O 0 0.07690468430519104
adrenal B-Disease 1 0.9999916553497314
insufficiency I-Disease 1 0.9999940395355225
and O 0 0.0017677373252809048
red O 1 0.9069214463233948
hair O 1 0.9958600401878357
pigmentation O 1 0.67805016040802
. O 0 1.2022953342238907e-05
. O 0 1.5819827240193263e-05

A O 0 3.839410419459455e-05
European O 0 6.65648331050761e-05
multicenter O 0 0.012736053206026554
study O 0 2.07432694878662e-05
of O 0 3.962853588745929e-05
phenylalanine B-Disease 1 0.9999653100967407
hydroxylase I-Disease 1 0.9999266862869263
deficiency I-Disease 1 0.9999992847442627
: O 0 8.777169568929821e-06
classification O 0 4.253852239344269e-05
of O 0 1.610158903986303e-07
105 O 0 3.080538590438664e-06
mutations O 0 1.5169413018156774e-05
and O 0 2.0706754355614976e-07
a O 0 4.7544219228257134e-07
general O 0 3.704895732425939e-07
system O 0 1.7104385960919899e-06
for O 0 1.052578468829779e-07
genotype O 0 1.3307327208167408e-05
- O 0 3.044585173483938e-05
based O 0 1.0798455605254276e-06
prediction O 0 2.4286986445076764e-05
of O 0 1.3638475593324983e-06
metabolic O 1 0.8643189072608948
phenotype O 0 0.003987037111073732
. O 0 2.564233000157401e-05

Phenylketonuria B-Disease 1 0.9807327389717102
( O 0 9.35172283789143e-05
PKU B-Disease 0 0.011707575991749763
) O 0 5.115572548675118e-06
and O 0 5.255119685898535e-05
mild B-Disease 1 0.9987002611160278
hyperphenylalaninemia I-Disease 1 0.999992847442627
( O 0 0.0017313911812379956
MHP B-Disease 1 0.9999760389328003
) O 0 3.9415235733031295e-06
are O 0 3.338099759275792e-06
allelic B-Disease 0 0.48712876439094543
disorders I-Disease 1 0.999968409538269
caused O 0 0.0006475580157712102
by O 0 2.7648673039948335e-07
mutations O 0 9.776421393326018e-06
in O 0 8.99190624181756e-08
the O 0 7.525066081370824e-08
gene O 0 4.164527126704343e-06
encoding O 0 1.5583140339003876e-05
phenylalanine O 0 0.00889683235436678
hydroxylase O 0 0.047819580882787704
( O 0 3.676060077850707e-05
PAH O 1 0.998802661895752
) O 0 3.781348823395092e-06
. O 0 7.293012458831072e-06

Previous O 0 9.092848813452292e-06
studies O 0 1.3353653685044264e-06
have O 0 9.82496857204751e-08
suggested O 0 5.246964747129823e-07
that O 0 1.535221194615133e-08
the O 0 1.7178983569010597e-07
highly O 0 2.2290183551376686e-05
variable O 0 0.0005533666117116809
metabolic O 1 0.9944998025894165
phenotypes O 0 0.3351672887802124
of O 0 0.002569979289546609
PAH B-Disease 1 0.9999953508377075
deficiency I-Disease 1 0.9997958540916443
correlate O 0 0.00036730911233462393
with O 0 0.0005220389575697482
PAH O 1 0.9998190999031067
genotypes O 0 0.009572871960699558
. O 0 4.891633943771012e-05

We O 0 5.851938112755306e-06
identified O 0 3.757984586627572e-06
both O 0 1.1141703453176888e-06
causative O 0 0.00041466657421551645
mutations O 0 0.00025682247360236943
in O 0 3.0178000542946393e-06
686 O 0 0.00017656390264164656
patients O 0 1.6004929420887493e-05
from O 0 2.3760588874210953e-07
seven O 0 5.774688247583981e-07
European O 0 5.979325123917079e-06
centers O 0 2.8550972274388187e-05
. O 0 1.2357510058791377e-05

On O 0 1.3247624792711576e-06
the O 0 6.883782788236203e-08
basis O 0 7.850319150293217e-08
of O 0 2.9351236108254852e-08
the O 0 1.6631111066089943e-07
phenotypic O 0 2.1520791051443666e-05
characteristics O 0 7.497782462451141e-06
of O 0 9.682315749159898e-07
297 O 0 9.994451829697937e-05
functionally O 0 0.001633509760722518
hemizygous O 0 0.01057133637368679
patients O 0 0.00012247005361132324
, O 0 2.9029217785137007e-07
105 O 0 3.9425208342436235e-07
of O 0 1.77703309844901e-08
the O 0 2.3345792499185336e-07
mutations O 0 4.279796030459693e-06
were O 0 1.3841031432093587e-07
assigned O 0 3.3233754948014393e-07
to O 0 1.131176574631354e-08
one O 0 4.15642631423907e-08
of O 0 1.750060008021137e-08
four O 0 2.62438760501027e-07
arbitrary O 0 1.2547504866233794e-06
phenotype O 0 0.00011198064021300524
categories O 0 5.0237009418196976e-05
. O 0 1.5742816685815342e-05

We O 0 5.954344032943482e-06
proposed O 0 2.7511580356076593e-06
and O 0 6.456904770857363e-07
tested O 0 2.6323209567635786e-06
a O 0 6.792277673639546e-08
simple O 0 8.24190564685523e-08
model O 0 1.5982395495939272e-07
for O 0 9.720321436645918e-09
correlation O 0 6.881787584234189e-08
between O 0 1.9809500884093723e-07
genotype O 0 5.86177429795498e-06
and O 0 4.6817737597848463e-07
phenotypic O 0 7.489520794479176e-05
outcome O 0 8.88755894266069e-05
. O 0 2.1306206690496765e-05

The O 0 8.609712494944688e-06
observed O 0 4.6364173613255844e-05
phenotype O 0 9.643151861382648e-05
matched O 0 1.682462971075438e-05
the O 0 1.3371980003284989e-06
predicted O 0 1.2600467016454786e-05
phenotype O 0 6.866865987831261e-06
in O 0 3.0153063335092156e-07
79 O 0 1.9903932297893334e-06
% O 0 8.65559623974832e-09
of O 0 6.0350018316057685e-09
the O 0 1.053637106451788e-07
cases O 0 3.523277598560526e-07
, O 0 1.0176909626125052e-07
and O 0 5.1206697548877855e-08
in O 0 4.6369436290660815e-08
only O 0 2.8826219633515393e-08
5 O 0 2.0742923823036108e-07
of O 0 4.062234282287136e-08
184 O 0 4.534392701316392e-06
patients O 0 7.902975085016806e-06
was O 0 2.420795908619766e-06
the O 0 1.158092715058956e-07
observed O 0 1.504820147602004e-06
phenotype O 0 8.304914445034228e-07
more O 0 2.744850791103204e-09
than O 0 1.3390462072493392e-08
one O 0 4.894348037964846e-08
category O 0 5.176526656214264e-07
away O 0 2.9875388918298995e-07
from O 0 6.921489159594785e-08
that O 0 6.617190706492693e-08
expected O 0 2.367259185120929e-06
. O 0 2.685780373212765e-06

Among O 0 9.636082722863648e-07
the O 0 4.503444301917625e-07
seven O 0 6.610289915442991e-07
contributing O 0 2.0294394289521733e-06
centers O 0 1.3857979865861125e-06
, O 0 2.1752933321295131e-07
the O 0 8.668322237781467e-08
proportion O 0 8.100184913928388e-07
of O 0 2.3068217558375181e-07
patients O 0 8.011917998373974e-06
for O 0 6.180358980145684e-08
whom O 0 9.682130439614411e-07
the O 0 3.5526591091183946e-07
observed O 0 6.658161055383971e-06
phenotype O 0 1.060279828379862e-05
did O 0 3.623067073021957e-07
not O 0 4.065955039322944e-08
match O 0 1.1850106602651067e-06
the O 0 5.362543333831127e-07
predicted O 0 8.332908691954799e-06
phenotype O 0 6.343117092910688e-06
was O 0 2.360369762754999e-06
4 O 0 4.2798185972969804e-07
% O 0 4.2618808038241696e-08
- O 0 4.4374501158017665e-06
23 O 0 1.5159835129452404e-06
% O 0 2.711601077010073e-08
( O 0 1.4743723397714348e-07
P O 0 3.3018011890817434e-05
< O 0 6.577040494448738e-06
. O 0 2.422968634618883e-07
0001 O 0 0.00012779927055817097
) O 0 9.180000404285238e-08
, O 0 7.545806113284925e-08
suggesting O 0 4.4370258933668083e-07
that O 0 1.6871432251264196e-08
differences O 0 4.218298954583588e-07
in O 0 3.916998281283668e-08
methods O 0 7.311135874488173e-08
used O 0 2.357624424575988e-07
for O 0 1.4541842574544717e-07
mutation O 0 2.0446741473278962e-05
detection O 0 6.483040488092229e-05
or O 0 1.052207426255336e-05
phenotype O 0 0.0003297321673016995
classification O 0 0.0002580448053777218
may O 0 1.5733216969238129e-06
account O 0 5.330954877535987e-08
for O 0 5.464850794112408e-09
a O 0 1.2031169660531305e-07
considerable O 0 2.2574926106244675e-07
proportion O 0 1.048656486091204e-06
of O 0 6.126243192738912e-07
genotype O 0 0.0007398417801596224
- O 0 0.01860225573182106
phenotype O 0 0.0008709592511877418
inconsistencies O 0 0.0007391019025817513
. O 0 2.83694316749461e-05

Our O 0 3.7515360418183263e-06
data O 0 3.921143161278451e-06
indicate O 0 3.1504773687629495e-06
that O 0 3.407255917409202e-07
the O 0 1.4416711564990692e-05
PAH O 1 0.9984790682792664
- O 0 0.00032743907650001347
mutation O 0 2.0335761291789822e-05
genotype O 0 1.1106018064310774e-05
is O 0 1.4397612346783717e-07
the O 0 5.3702041924452715e-08
main O 0 2.402495510978042e-06
determinant O 0 3.22163441524026e-06
of O 0 8.104117910079367e-07
metabolic O 0 0.12996089458465576
phenotype O 0 0.0002005513961194083
in O 0 1.7994267409449094e-06
most O 0 6.965776719880523e-06
patients O 0 0.002607363276183605
with O 1 0.6099902391433716
PAH B-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.9999603033065796
. O 0 8.238992450060323e-05

In O 0 8.287428840958455e-07
the O 0 1.0083508072966652e-07
present O 0 2.314298228611733e-07
study O 0 3.1170958436632645e-07
, O 0 6.18212752101499e-08
the O 0 5.073586351045378e-08
classification O 0 2.9119240934960544e-05
of O 0 1.109179038394359e-06
105 O 0 0.0001877888134913519
PAH O 1 0.9994189739227295
mutations O 0 0.0004558387154247612
may O 0 1.2317226492086775e-06
allow O 0 3.125960290617513e-08
the O 0 1.5756596383198485e-07
prediction O 0 5.315923772286624e-06
of O 0 1.8593048878301488e-08
the O 0 2.705330359731306e-07
biochemical O 0 6.685479456791654e-05
phenotype O 0 3.1963027140591294e-05
in O 0 6.192418595674098e-07
> O 0 4.91471246277797e-06
10 O 0 5.390543265093584e-07
, O 0 1.7132322227553232e-07
000 O 0 5.91197022004053e-07
genotypes O 0 8.010145393200219e-06
, O 0 2.586170353424677e-07
which O 0 6.587634970856016e-08
may O 0 1.9154816754962667e-07
be O 0 9.803886591441824e-09
useful O 0 3.405283166557638e-08
for O 0 2.400297915983174e-08
the O 0 1.7647693084654748e-07
management O 0 1.648800025577657e-05
of O 0 1.2851639894506661e-06
hyperphenylalaninemia B-Disease 1 0.9997506737709045
in O 0 5.558261545957066e-05
newborns O 0 0.0017880421364679933
. O 0 1.2897639862785581e-05

Somatic O 0 0.0010881464695557952
instability O 0 0.0008472281624563038
of O 0 7.282471301550686e-07
the O 0 3.2450077469547978e-06
CTG O 0 0.0018811424961313605
repeat O 0 9.067155770026147e-05
in O 0 2.451004320391803e-06
mice O 0 2.498347203072626e-05
transgenic O 0 6.572808160854038e-06
for O 0 8.707277743269515e-07
the O 0 0.00011785556853283197
myotonic B-Disease 1 0.9999918937683105
dystrophy I-Disease 1 0.9999977350234985
region O 0 0.0014966140734031796
is O 0 4.3753880163421854e-06
age O 0 2.615445282572182e-06
dependent O 0 7.800956609571585e-07
but O 0 1.1107229624940373e-07
not O 0 1.643872593604101e-08
correlated O 0 3.6429963756745565e-07
to O 0 1.5693123245341667e-08
the O 0 9.897362929223164e-08
relative O 0 4.1417256397835445e-06
intertissue O 0 0.00010226375889033079
transcription O 0 4.9289541493635625e-05
levels O 0 5.7510973419994116e-05
and O 0 6.247731562325498e-06
proliferative O 1 0.6681622862815857
capacities O 0 0.006926580332219601
. O 0 8.516586240148172e-05

A O 0 8.534365042578429e-05
( O 0 2.263057012896752e-06
CTG O 0 0.00018902026931755245
) O 0 2.956199125492276e-07
nexpansion O 0 3.6037272366229445e-05
in O 0 2.574265636212658e-07
the O 0 6.692096121696522e-07
3 O 0 1.742469976306893e-05
- O 0 0.00011287129746051505
untranslated O 0 0.0008775823516771197
region O 0 2.569615753600374e-05
( O 0 4.583931456636492e-07
UTR O 0 2.4573784685344435e-05
) O 0 5.619077114715765e-08
of O 0 2.1082714241060785e-08
the O 0 2.2336582787829684e-06
DM O 1 0.9932344555854797
protein O 0 1.1818159691756591e-05
kinase O 0 2.073464565910399e-05
gene O 0 6.179732736200094e-06
( O 0 5.482454525918001e-07
DMPK O 0 8.359562343684956e-05
) O 0 1.212490730040372e-07
is O 0 3.503656103021058e-07
responsible O 0 6.744898655597353e-06
for O 0 1.4780293895455543e-05
causing O 1 0.9984276294708252
myotonic B-Disease 1 0.9999971389770508
dystrophy I-Disease 1 0.9999992847442627
( O 0 0.0014974630903452635
DM B-Disease 1 0.9999350309371948
) O 0 1.220065496454481e-05
. O 0 1.3131177183822729e-05

Major O 0 0.0018044216558337212
instability O 0 0.000882069522049278
, O 0 7.03922125921963e-07
with O 0 1.3738964810272591e-07
very O 0 4.0215303442892036e-07
large O 0 4.419559047619259e-07
expansions O 0 4.0613349483464845e-06
between O 0 2.8016609121550573e-07
generations O 0 1.7070426565624075e-06
and O 0 7.401860671052418e-07
high O 0 1.3488529475580435e-05
levels O 0 3.319477627883316e-06
of O 0 1.0667873340253209e-07
somatic O 0 2.820154077198822e-05
mosaicism O 0 0.0023570016492158175
, O 0 1.9824178707494866e-06
is O 0 5.282240067572275e-07
observed O 0 3.0530347885360243e-06
in O 0 2.3377301658911165e-06
patients O 0 6.130366091383621e-05
. O 0 6.2675080698681995e-06

There O 0 6.568569688170101e-07
is O 0 2.3257659620412596e-07
a O 0 1.9849157695261965e-07
good O 0 4.166006988270965e-07
correlation O 0 1.3950278798802174e-07
between O 0 3.2945331440714654e-07
repeat O 0 8.286533557111397e-06
size O 0 5.4091365200292785e-06
( O 0 2.400733762897289e-07
at O 0 3.226972694392316e-06
least O 0 2.3875159627095854e-07
in O 0 3.034776625554514e-07
leucocytes O 0 9.306336141889915e-05
) O 0 4.827649036087678e-07
, O 0 9.589776936991257e-07
clinical O 0 4.142844773014076e-05
severity O 0 0.0003200345381628722
and O 0 2.473726226526196e-06
age O 0 3.0769730074098334e-05
of O 0 3.923832537111593e-06
onset O 1 0.9861940741539001
. O 0 3.5362521884962916e-05

The O 0 8.465331484330818e-05
trinucleotide O 0 0.07947304099798203
repeat O 0 0.0010227574966847897
instability O 0 0.00016626628348603845
mechanisms O 0 3.826879765256308e-05
involved O 0 1.5521811292273924e-05
in O 0 1.9310151401441544e-05
DM B-Disease 1 0.9999592304229736
and O 0 4.3336362978152465e-06
other O 0 3.1006225071905646e-06
human O 0 0.0034969819243997335
genetic B-Disease 1 0.9998970031738281
diseases I-Disease 1 0.999998927116394
are O 0 3.050892473765998e-06
unknown O 0 8.252036786871031e-05
. O 0 1.0168688277190086e-05

We O 0 4.734698450192809e-06
studied O 0 1.970629637071397e-05
somatic O 0 7.503031520172954e-05
instability O 0 8.21794819785282e-05
by O 0 3.6182848361931974e-07
measuring O 0 0.00033224804792553186
the O 0 3.417260131755029e-06
CTG O 0 0.0008328139083459973
repeat O 0 2.7954472898272797e-05
length O 0 3.8085538562881993e-06
at O 0 2.8806600766984047e-06
several O 0 1.1045961656463987e-07
ages O 0 1.367363893223228e-06
in O 0 7.627505027585357e-08
various O 0 1.7937675522716745e-07
tissues O 0 7.812869444023818e-05
of O 0 2.545621384797414e-07
transgenic O 0 2.0335315639385954e-05
mice O 0 3.044849290745333e-05
carrying O 0 4.04378852181253e-06
a O 0 3.7251822959660785e-06
( O 0 8.711970735930663e-07
CTG O 0 0.00014084951544646174
) O 0 2.330030781649839e-07
55expansion O 0 3.570170883904211e-05
surrounded O 0 4.7278358579205815e-06
by O 0 7.90436303077513e-08
45 O 0 3.3319886938443233e-07
kb O 0 3.7656300264643505e-06
of O 0 1.291055298224819e-07
the O 0 3.084313220824697e-06
human O 0 0.0003204305248800665
DM B-Disease 1 0.9999451637268066
region O 0 3.7278314266586676e-05
, O 0 3.17873258381951e-07
using O 0 1.7029290688697074e-07
small O 0 2.9549378268711735e-06
- O 0 0.00014396908227354288
pool O 0 7.656186062376946e-05
PCR O 0 9.660500654717907e-05
. O 0 7.119873771443963e-06

These O 0 9.561084652887075e-07
mice O 0 2.306274473085068e-05
have O 0 8.81257378182454e-08
been O 0 1.0566035513193128e-07
shown O 0 6.822804010653272e-08
to O 0 1.4138884729675283e-08
reproduce O 0 7.251105671457481e-07
the O 0 8.222263403467878e-08
intergenerational O 0 3.454350917309057e-06
and O 0 1.0222418040939374e-06
somatic O 0 4.909939525532536e-05
instability O 0 7.88444303907454e-05
of O 0 1.5065477043663122e-07
the O 0 2.198970150857349e-06
55 O 0 2.455270259815734e-05
CTG O 0 0.0008022518013603985
repeat O 0 2.928795584011823e-05
suggesting O 0 4.941294264426688e-06
that O 0 2.6019581156333516e-08
surrounding O 0 4.892453375759942e-07
sequences O 0 2.3058255749219825e-07
and O 0 1.055284286621827e-07
the O 0 1.1450993753214789e-07
chromatin O 0 1.5016839824966155e-05
environment O 0 7.731839104963001e-06
are O 0 9.734165473673784e-08
involved O 0 1.4596073469874682e-06
in O 0 1.939593175848131e-06
instability O 0 0.0002637940924614668
mechanisms O 0 0.0004978800425305963
. O 0 3.26830631820485e-05

As O 0 2.120573526553926e-06
observed O 0 4.178753897576826e-06
in O 0 6.320289003269863e-08
some O 0 6.2608709328060286e-09
of O 0 3.593397579493285e-08
the O 0 1.2877477502115653e-06
tissues O 0 0.0036557645071297884
of O 0 4.870361590292305e-05
DM B-Disease 1 0.9999904632568359
patients O 0 0.002200300572440028
, O 0 6.882626735205122e-07
there O 0 8.002847096122423e-08
is O 0 8.752586921900729e-08
a O 0 4.3673486516127014e-07
tendency O 0 2.076003283946193e-06
for O 0 1.0441264208793655e-07
repeat O 0 7.223935426736716e-06
length O 0 1.8996850030816859e-06
and O 0 2.220247807827036e-07
somatic O 0 9.552376468491275e-06
mosaicism O 0 0.00012927544594276696
to O 0 4.327501201828454e-08
increase O 0 3.4212270350053586e-08
with O 0 6.240342997898551e-08
the O 0 4.013308227968082e-07
age O 0 2.6248508220305666e-06
of O 0 6.123988072204156e-08
the O 0 2.0912220861646347e-06
mouse O 0 0.0004102559760212898
. O 0 1.6273563232971355e-05

Furthermore O 0 2.5513756554573774e-05
, O 0 1.887041889858665e-06
we O 0 2.0180145554604678e-07
observed O 0 4.0211889995589445e-07
no O 0 3.9783479621746665e-08
correlation O 0 3.786772495573132e-08
between O 0 4.6494221805915004e-08
the O 0 1.5772832284710603e-07
somatic O 0 2.428448715363629e-05
mutation O 0 6.15276803728193e-05
rate O 0 9.633587069401983e-06
and O 0 1.4264469427871518e-06
tissue O 0 0.005848119501024485
proliferation O 0 0.008048747666180134
capacity O 0 5.095251981401816e-05
. O 0 1.0321945410396438e-05

The O 0 2.511929551474168e-06
somatic O 0 0.00011472838377812877
mutation O 0 0.0001219169280375354
rates O 0 4.379082383820787e-06
in O 0 5.008006453977032e-08
different O 0 3.021826344706824e-08
tissues O 0 2.3276164938579313e-05
were O 0 1.6706651706499542e-07
also O 0 1.0723320542638248e-07
not O 0 1.2222003853423757e-08
correlated O 0 2.508878935714165e-07
to O 0 1.2844464158945357e-08
the O 0 1.0655529081304849e-07
relative O 0 6.94955951985321e-06
inter O 0 0.0004955855547450483
- O 0 0.0004163007251918316
tissue O 0 0.00015540068852715194
difference O 0 1.3289813978190068e-06
in O 0 5.593904361944624e-08
transcriptional O 0 1.0982397498082719e-06
levels O 0 2.33243031289021e-06
of O 0 2.8929992623716316e-08
the O 0 1.2417484640536713e-07
three O 0 2.0729713412492856e-07
genes O 0 2.100798838000628e-06
( O 0 6.750309466951876e-07
DMAHP O 0 0.00016921298811212182
, O 0 1.366623450849147e-06
DMPK O 0 0.0001884537487057969
and O 0 1.7087984360841801e-06
59 O 0 9.53578364715213e-06
) O 0 1.0003873285313603e-07
surrounding O 0 6.201076416800788e-07
the O 0 6.97140535521612e-07
repeat O 0 4.013554644188844e-05
. O 0 1.5237437764881179e-06
. O 0 3.9145556911535095e-06

A O 0 3.782037310884334e-05
novel O 0 5.2185838285367936e-05
missense O 0 0.0012767189182341099
mutation O 0 0.00035481431405059993
in O 0 5.161165063327644e-06
patients O 0 2.824430885084439e-05
from O 0 4.0201496176450746e-07
a O 0 3.268338559792028e-06
retinoblastoma B-Disease 0 0.0042130667716264725
pedigree O 0 0.0001783163461368531
showing O 0 2.082264472846873e-05
only O 0 6.254762183743878e-07
mild O 0 0.0002028772432822734
expression O 0 1.8811590507539222e-06
of O 0 5.135831315783435e-07
the O 0 5.850918751093559e-05
tumor B-Disease 1 0.9971535205841064
phenotype O 0 0.0021328635048121214
. O 0 2.4424771254416555e-05

We O 0 8.744850106268132e-07
have O 0 3.8055038231732397e-08
used O 0 6.842809341378597e-08
single O 0 3.1686960255683516e-07
strand O 0 2.691855115699582e-06
conformation O 0 3.3256692404393107e-06
polymorphism O 0 6.672538006569084e-07
analysis O 0 3.289045125143275e-08
to O 0 7.605623686401941e-09
study O 0 4.521509922028599e-08
the O 0 4.0123204314568284e-08
27 O 0 1.2331800007814309e-06
exons O 0 2.5655454010120593e-06
of O 0 6.626158466360721e-08
the O 0 1.5933861732264631e-06
RB1 O 0 0.0009207617840729654
gene O 0 7.570516572741326e-06
in O 0 2.956258242647891e-07
individuals O 0 1.1683914280524732e-08
from O 0 9.118277688457965e-08
a O 0 9.920455568135367e-07
family O 0 7.531968549301382e-06
showing O 0 3.938177542295307e-05
mild O 0 0.0015387256862595677
expression O 0 2.578496605565306e-06
of O 0 3.0640262593806256e-07
the O 0 6.066168225515867e-06
retinoblastoma B-Disease 1 0.6970150470733643
phenotype O 0 0.004088442772626877
. O 0 3.7497084122151136e-05

In O 0 2.168320634154952e-06
this O 0 1.7281799102875084e-07
family O 0 2.0065226635779254e-06
affected O 0 2.4927096546889516e-06
individuals O 0 1.5645969142497052e-07
developed O 0 0.0002099529083352536
unilateral B-Disease 1 0.9719946980476379
tumors I-Disease 1 0.9999995231628418
and O 0 1.2679339306487236e-05
, O 0 3.9891082792564703e-07
as O 0 2.483727428170823e-07
a O 0 4.236174220295652e-07
result O 0 4.74351139700957e-07
of O 0 6.539823260709454e-08
linkage O 0 2.9159116820665076e-05
analysis O 0 2.8635326998482924e-06
, O 0 7.039624279059353e-07
unaffected O 0 4.316094418754801e-05
mutation O 0 7.847361302992795e-06
carriers O 0 2.1765040401078295e-06
were O 0 1.7640896032844466e-07
also O 0 3.8610772890024236e-07
identified O 0 6.599154289688158e-07
within O 0 2.0147761858879676e-07
the O 0 1.1853157957375515e-06
pedigree O 0 0.00035957564250566065
. O 0 1.188191890832968e-05

A O 0 1.0995341654052027e-05
single O 0 1.582639697517152e-06
band O 0 1.1803100278484635e-05
shift O 0 3.854929218505276e-06
using O 0 1.2769821751135169e-06
SSCP O 0 0.0002750390849541873
was O 0 9.861145372269675e-06
identified O 0 1.2822600865547429e-06
in O 0 2.948731889773626e-07
exon O 0 1.700284337857738e-05
21 O 0 2.348832140341983e-06
which O 0 4.745655957094641e-08
resulted O 0 3.402109598482639e-07
in O 0 1.729338805489533e-07
a O 0 1.1191808653165936e-06
missense O 0 7.185005233623087e-05
mutation O 0 6.471431333920918e-06
converting O 0 1.0837113677553134e-06
a O 0 1.309213894273853e-05
cys O 0 0.005456135608255863
- O 0 0.00029586540767923
- O 0 8.417420031037182e-05
> O 0 1.0894367733271793e-05
arg O 0 1.4384108908416238e-05
at O 0 8.83457630607154e-07
nucleotide O 0 5.510793243956869e-07
position O 0 1.1484103197290096e-06
28 O 0 1.1604125802477938e-06
in O 0 9.077844964622273e-08
the O 0 6.726795618305914e-07
exon O 0 0.00017693433619569987
. O 0 8.72418695507804e-06

The O 0 5.51126322534401e-06
mutation O 0 5.710263576474972e-05
destroyed O 0 3.1479688914259896e-05
an O 0 1.687711687736737e-06
NdeI O 0 0.000388989137718454
restriction O 0 4.390326921566157e-06
enzyme O 0 1.8766937500913627e-05
site O 0 5.916784721193835e-05
. O 0 6.730576842528535e-06

Analysis O 0 1.2455501519070822e-06
of O 0 7.27981301906766e-08
all O 0 1.4327400776892318e-07
family O 0 1.6072453945525922e-06
members O 0 7.926419698378595e-08
demonstrated O 0 7.7391422337314e-07
that O 0 4.166983202935626e-08
the O 0 9.327407610726368e-07
missense O 0 0.00029594413354061544
mutation O 0 0.0002542516740504652
co O 0 0.0002285114605911076
- O 0 9.686503472039476e-05
segregated O 0 1.907099249365274e-05
with O 0 4.0026311580732e-06
patients O 0 0.00017859131912700832
with O 0 8.66026384755969e-05
tumors B-Disease 1 0.999998927116394
or O 0 2.731703716563061e-05
who O 0 6.299152573774336e-06
, O 0 1.2469854482333176e-07
as O 0 1.1521330378627681e-07
a O 0 2.681181570096669e-07
result O 0 4.867843017564155e-07
of O 0 2.949732191837029e-08
linkage O 0 9.149659490503836e-06
analysis O 0 1.5128279073906015e-06
had O 0 3.293048848718172e-06
been O 0 4.653117287034547e-07
predicted O 0 5.650286425407103e-07
to O 0 1.2245851443992706e-08
carry O 0 2.1819272433276637e-07
the O 0 1.4215796682037762e-06
predisposing O 0 0.0005433636833913624
mutation O 0 0.000516466679982841
. O 0 1.858617179095745e-05

These O 0 1.304362911014323e-07
observations O 0 2.1237349301372888e-06
point O 0 1.5108655588846887e-06
to O 0 2.7766143162466506e-08
another O 0 3.981407985520491e-07
region O 0 1.8139304529540823e-06
of O 0 4.9040476568507074e-08
the O 0 8.467252428090433e-07
RB1 O 0 0.0010185082210227847
gene O 0 8.452192560071126e-06
where O 0 1.238372533407528e-06
mutations O 0 2.661511416590656e-06
only O 0 2.0926867350112843e-08
modify O 0 7.710278850936447e-07
the O 0 7.281882119514194e-08
function O 0 3.287223648840154e-07
of O 0 2.4759769345905625e-08
the O 0 2.5227780042769155e-07
gene O 0 4.654986241803272e-06
and O 0 1.1890451787621714e-06
raise O 0 1.2915518254885683e-06
important O 0 6.607857017115748e-07
questions O 0 1.8897287645813776e-06
for O 0 2.524164131045836e-07
genetic O 0 1.885158235381823e-05
counseling O 0 5.030484317103401e-06
in O 0 1.6644042943880777e-07
families O 0 4.001299913625189e-08
with O 0 6.236250271740573e-08
these O 0 1.0398514405096648e-07
distinctive O 0 8.429775334661826e-05
phenotypes O 0 0.0008637649589218199
. O 0 4.593327503243927e-06
. O 0 8.083306966000237e-06

Maternal B-Disease 0 0.012834020890295506
disomy I-Disease 1 0.7566366195678711
and O 0 0.24169623851776123
Prader B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999970197677612
Willi I-Disease 1 0.9999990463256836
syndrome I-Disease 1 0.9999969005584717
consistent O 0 6.601720087928697e-05
with O 0 1.5855009678489296e-06
gamete O 0 0.00012815241643693298
complementation O 0 0.0002251452679047361
in O 0 7.138456226130074e-07
a O 0 1.3180797395762056e-06
case O 0 2.202536052209325e-06
of O 0 1.406068577125552e-07
familial O 0 0.001072534010745585
translocation O 0 0.0003027787897735834
( O 0 1.1874744814122096e-06
3 O 0 1.507849901827285e-06
; O 0 2.5848365226011083e-07
15 O 0 7.254349725371867e-07
) O 0 4.166808409422629e-08
( O 0 6.971824717538766e-08
p25 O 0 7.648258360859472e-06
; O 0 3.075922165862721e-07
q11 O 0 9.803768080018926e-06
. O 0 2.5149350335595955e-07
2 O 0 1.8118835214409046e-06
) O 0 3.1808400535737746e-07
. O 0 1.930215603351826e-06

Maternal B-Disease 0 0.05737394094467163
uniparental I-Disease 1 0.9371560215950012
disomy I-Disease 1 0.7419629096984863
( I-Disease 0 4.4731081288773566e-05
UPD I-Disease 1 0.9918400049209595
) I-Disease 0 2.375286527467324e-07
for I-Disease 0 6.554871845310117e-08
chromosome I-Disease 0 9.801319720281754e-06
15 I-Disease 0 6.842664674877597e-07
is O 0 3.990370700535095e-08
responsible O 0 1.1683762579650647e-07
for O 0 6.236866578746003e-09
an O 0 2.3738952137364322e-08
estimated O 0 3.5514858609531075e-08
30 O 0 8.346012236870592e-08
% O 0 2.847548419282475e-09
of O 0 2.3890347478072727e-08
cases O 0 7.103948064468568e-06
of O 0 0.00019599139341153204
Prader B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999991655349731
Willi I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999995231628418
( O 0 0.0005140278371982276
PWS B-Disease 1 0.9994845390319824
) O 0 1.6324780517606996e-05
. O 0 1.4059994100534823e-05

We O 0 9.240012332156766e-06
report O 0 8.020816153475607e-07
on O 0 2.6066155101034383e-07
an O 0 8.347938518227238e-08
unusual O 0 2.0060538190591615e-06
case O 0 1.3899831401431584e-06
of O 0 9.320243776755888e-08
maternal B-Disease 0 9.966119250748307e-05
disomy I-Disease 0 0.0020284438505768776
15 I-Disease 0 1.1929742868233006e-05
in O 0 3.5857069633493666e-06
PWS B-Disease 1 0.9993922710418701
that O 0 2.3259035231149028e-07
is O 0 6.835725940845805e-08
most O 0 2.687908917664572e-08
consistent O 0 1.712477626369946e-07
with O 0 4.615809601205001e-08
adjacent O 0 1.3890163245378062e-05
- O 0 4.8490990593563765e-05
1 O 0 1.388695295645448e-06
segregation O 0 2.1705261588067515e-06
of O 0 3.666249526190768e-08
a O 0 1.2633354344870895e-06
paternal O 0 5.3917374316370115e-05
t O 0 0.0005069419275969267
( O 0 2.217898753542613e-07
3 O 0 5.113213887852908e-07
; O 0 9.969110692509275e-08
15 O 0 2.7605409513853374e-07
) O 0 2.809344401555336e-08
( O 0 5.4205880672952844e-08
p25 O 0 6.674754331470467e-06
; O 0 1.73458474250765e-07
q11 O 0 4.020896085421555e-06
. O 0 6.09632095915913e-08
2 O 0 1.2090704615275172e-07
) O 0 4.829516342397255e-09
with O 0 1.4152321092808506e-08
simultaneous O 0 1.922870069392957e-06
maternal O 0 0.00014235934941098094
meiotic O 0 0.0006706054555252194
nondisjunction O 0 0.0004912492004223168
for O 0 1.0374023986514658e-06
chromosome O 0 0.0002916346420533955
15 O 0 1.7805648894864134e-05
. O 0 4.438660653249826e-06

The O 0 3.3628399251028895e-05
patient O 0 0.00021582610497716814
( O 0 6.19976901816699e-07
J O 0 0.00010189464956056327
. O 0 2.1933560390152707e-07
B O 0 2.255238541692961e-06
. O 0 2.1413903539269086e-08
) O 0 9.309082393826884e-09
, O 0 3.8539180735597256e-08
a O 0 3.827605041806237e-07
17 O 0 4.135863946430618e-06
- O 0 2.3387639885186218e-05
year O 0 5.327190592652187e-06
- O 0 3.5202971048420295e-05
old O 0 3.439545616856776e-05
white O 0 9.51792117120931e-06
male O 0 3.3570631785551086e-06
with O 0 4.994827122573042e-06
PWS B-Disease 1 0.9993835687637329
, O 0 3.1528577437711647e-06
was O 0 3.2565124001848744e-06
found O 0 8.878591728489482e-08
to O 0 5.2006510209423595e-09
have O 0 2.314141056558583e-08
47 O 0 2.5508194312351407e-07
chromosomes O 0 2.4085352379188407e-07
with O 0 1.1901836671768251e-07
a O 0 1.7615487877264968e-06
supernumerary O 0 0.0002616925921756774
, O 0 1.31306876482995e-06
paternal O 0 7.798688602633774e-05
der O 0 0.006948545109480619
( O 0 4.50551482344963e-07
15 O 0 3.2165522156901716e-07
) O 0 1.1385143494635486e-08
consisting O 0 1.310800001874668e-07
of O 0 4.540877895919948e-08
the O 0 9.626979817767278e-07
short O 0 2.2922808057046495e-05
arm O 0 0.03954031318426132
and O 0 8.765607617533533e-07
the O 0 1.1821435919046053e-06
proximal O 0 0.00522101204842329
long O 0 0.00021937738347332925
arm O 0 0.0015956303104758263
of O 0 3.4972666185240087e-07
chromosome O 0 7.13350236765109e-05
15 O 0 3.873314199154265e-06
, O 0 4.1083319501922233e-07
and O 0 9.965107210518909e-07
distal O 0 0.07780520617961884
chromosome O 1 0.7770780324935913
arm O 1 0.9921002984046936
3p O 1 0.9328213930130005
. O 0 7.769508374622092e-05

The O 0 1.186359986604657e-05
t O 0 0.0005499396938830614
( O 0 2.7936835067521315e-07
3 O 0 5.39489406037319e-07
; O 0 4.971223788174939e-08
15 O 0 1.2673427818299388e-07
) O 0 1.4934750325323876e-08
was O 0 4.7542314973725297e-07
present O 0 2.518270214579843e-08
in O 0 3.2958084261736076e-08
the O 0 5.12731546109535e-08
balanced O 0 8.49353682497167e-07
state O 0 1.422503146386589e-07
in O 0 1.4860167141250713e-07
the O 0 7.178755367931444e-07
patients O 0 1.7315882359980606e-05
father O 0 7.937689588288777e-06
and O 0 1.0832515044967295e-06
a O 0 9.794011930353008e-06
sister O 0 0.0012261606752872467
. O 0 1.9404371414566413e-05

Fluorescent O 0 0.0002519379777368158
in O 0 1.7852837572718272e-06
situ O 0 3.6897079553455114e-05
hybridization O 0 1.4144085298539721e-06
analysis O 0 5.06131186739367e-07
demonstrated O 0 3.0131586754578166e-06
that O 0 1.195125776121131e-07
the O 0 4.55737381344079e-06
PWS B-Disease 1 0.9989469647407532
critical O 0 0.00011447573342593387
region O 0 2.822688657033723e-05
resided O 0 1.818389500840567e-05
on O 0 6.78648234497814e-07
the O 0 9.627808594814269e-08
derivative O 0 2.9266402634675615e-06
chromosome O 0 1.1115066627098713e-05
3 O 0 4.798154122909182e-07
and O 0 1.0098983693751507e-07
that O 0 1.599001286933799e-08
there O 0 5.686451487463273e-08
was O 0 2.913635171353235e-06
no O 0 2.6038776468340075e-07
deletion O 0 5.7083379942923784e-06
of O 0 2.614036418435717e-07
the O 0 8.328785952471662e-06
PWS B-Disease 1 0.999224066734314
region O 0 4.6411241783061996e-05
on O 0 2.3141469682741445e-06
the O 0 4.2885289985861164e-07
normal O 0 4.831886599276913e-06
pair O 0 3.31623755300825e-06
of O 0 9.316902094269608e-08
15s O 0 3.691179153975099e-05
present O 0 1.2921198049298255e-06
in O 0 4.19192974732141e-06
J O 0 0.009543579071760178
. O 0 1.3249230505607557e-05

B O 0 0.003344255732372403
. O 0 2.9610415367642418e-05

Methylation O 0 1.6764421161497012e-05
analysis O 0 1.788537019820069e-06
at O 0 6.0386641962395515e-06
exon O 0 1.4377621482708491e-05
alpha O 0 1.4736358480149647e-06
of O 0 2.7294511539821542e-08
the O 0 2.0479491524838522e-07
small O 0 4.528372755885357e-06
nuclear O 0 0.000982712721452117
ribonucleoprotein O 0 0.001621731324121356
- O 0 7.600057870149612e-05
associated O 0 5.0845856094383635e-06
polypeptide O 0 3.0853265343466774e-05
N O 0 4.0282753616338596e-05
( O 0 4.98291456096922e-07
SNRPN O 0 7.487307448172942e-05
) O 0 1.130521312120436e-07
gene O 0 2.206848193964106e-06
showed O 0 2.3213794975163182e-06
a O 0 4.76630731327532e-07
pattern O 0 1.352258459519362e-05
characteristic O 0 1.491280272603035e-05
of O 0 8.885130853286682e-08
only O 0 9.763378017169089e-08
the O 0 5.805949285786483e-07
maternal O 0 5.9828329540323466e-05
chromosome O 0 0.00017303356435149908
15 O 0 6.298810149019118e-06
in O 0 1.639584752410883e-06
J O 0 0.004347254056483507
. O 0 1.3856677469448186e-05

B O 0 0.005764997098594904
. O 0 3.7930611142655835e-05

Maternal B-Disease 0 0.0017158914124593139
disomy I-Disease 0 0.006399341393262148
was O 0 7.655638182768598e-05
confirmed O 0 1.5860197208894533e-06
by O 0 6.343331904190563e-08
polymerase O 0 1.1289475878584199e-05
chain O 0 3.552394991857e-05
reaction O 0 2.111117964886944e-06
analysis O 0 2.9285257596711745e-07
of O 0 1.2789904246801598e-07
microsatellite O 0 0.00015738628280814737
repeats O 0 5.77422724745702e-05
at O 0 1.6098752894322388e-05
the O 0 1.4645656847278588e-06
gamma O 0 6.979751196922734e-05
- O 0 6.18865160504356e-05
aminobutyric O 0 0.00017598201520740986
acid O 0 2.0188386770314537e-05
receptor O 0 3.6295141399023123e-06
beta3 O 0 5.2957133448217064e-05
subunit O 0 5.763477020082064e-06
( O 0 1.3819613968735212e-06
GABRB3 O 0 0.0004253062652423978
) O 0 9.224157793141785e-07
locus O 0 0.00011887159053003415
. O 0 1.3048327673459426e-05

A O 0 8.055261423578486e-05
niece O 0 0.0006815334199927747
( O 0 1.0667725973689812e-06
B O 0 8.117259312712122e-06
. O 0 9.467088801784485e-08
B O 0 1.1115150755358627e-06
. O 0 9.768086783878971e-09
) O 0 1.886254485938821e-09
with O 0 1.0274816553135224e-08
45 O 0 6.20794580186157e-08
chromosomes O 0 1.752175080582674e-07
and O 0 4.648499540849116e-08
the O 0 3.214913846250056e-08
derivative O 0 8.232366894844745e-07
3 O 0 7.277146778505994e-07
but O 0 1.1818375611483134e-07
without O 0 1.5315424661821453e-07
the O 0 4.063048208990949e-07
der O 0 0.0008074089419096708
( O 0 1.7170499688745622e-07
15 O 0 2.9091771125422383e-07
) O 0 1.8859317663100228e-08
demonstrated O 0 3.1730718319522566e-07
a O 0 5.059757768322015e-07
phenotype O 0 9.293034963775426e-06
consistent O 0 1.3527823057302157e-06
with O 0 1.7580032363184728e-07
that O 0 2.459203471971705e-07
reported O 0 3.0150038128340384e-06
for O 0 7.526889334030784e-08
haploinsufficiency O 0 6.895704427734017e-05
of O 0 5.528980864255573e-07
distal O 0 0.004090673755854368
3 O 0 0.0001669544872129336
p O 0 0.001142724882811308
. O 0 1.46821366797667e-05

Uniparental B-Disease 1 0.9967654943466187
disomy I-Disease 1 0.9980071187019348
associated O 0 5.6810582464095205e-05
with O 0 2.6857314878725447e-06
unbalanced O 0 0.001975876512005925
segregation O 0 0.000146110774949193
of O 0 1.1893968121512444e-06
non O 0 0.0002973843365907669
- O 0 0.0015025524189695716
Robertsonian O 0 0.0006720453384332359
translocations O 0 0.0004062316147610545
has O 0 4.522425570030464e-06
been O 0 1.0421899787615985e-06
reported O 0 2.6302407150069484e-06
previously O 0 9.226515658156131e-07
but O 0 1.0950973461376634e-07
has O 0 1.5175587009252922e-07
not O 0 1.8452368522048346e-08
, O 0 2.9741149987216886e-08
to O 0 3.4819356287130176e-09
our O 0 5.691062909818356e-08
knowledge O 0 3.319270547308406e-07
, O 0 3.1497333452534804e-07
been O 0 2.8284588893257023e-07
observed O 0 8.446347692370182e-07
in O 0 1.022024918029274e-07
a O 0 1.5715866084065055e-06
case O 0 9.831594979914371e-06
of O 0 5.538239292945946e-06
PWS B-Disease 1 0.9995263814926147
. O 0 0.00012956594582647085

Furthermore O 0 2.0597397451638244e-05
, O 0 1.1675113000819692e-06
our O 0 3.9068143564691127e-07
findings O 0 4.818959951080615e-07
are O 0 6.206688496490642e-09
best O 0 1.4152340099826688e-07
interpreted O 0 1.4755751465145295e-07
as O 0 9.925246047259861e-08
true O 0 8.372637125830806e-07
gamete O 0 6.970977847231552e-05
complementation O 0 0.0005302736535668373
resulting O 0 4.644488581106998e-05
in O 0 9.353791028843261e-06
maternal B-Disease 0 0.0032080698292702436
UPD I-Disease 1 0.9996309280395508
15 I-Disease 0 0.0004401310288812965
and O 0 0.00018855313828680664
PWS B-Disease 1 0.9991658926010132

Schwartz B-Disease 1 0.8869805335998535
- I-Disease 1 0.9927010536193848
Jampel I-Disease 1 0.9774489998817444
syndrome I-Disease 1 0.9998183846473694
type I-Disease 0 0.002232939237728715
2 I-Disease 0 5.358393900678493e-05
and O 0 3.6796231142943725e-05
Stuve B-Disease 1 0.9864489436149597
- I-Disease 1 0.9992521405220032
Wiedemann I-Disease 1 0.9983515739440918
syndrome I-Disease 1 0.9999754428863525
: O 0 9.795196547202067e-07
a O 0 8.375145057470945e-07
case O 0 8.957308637036476e-07
for O 0 7.022204329132364e-08
" O 0 9.269138558920531e-07
lumping O 0 3.121869667666033e-05
" O 0 1.4680204913020134e-05
. O 0 6.908595878485357e-06

Recent O 0 2.758084337983746e-05
studies O 0 1.7638518556850613e-06
demonstrated O 0 2.193785803683568e-06
the O 0 1.1182692816191775e-07
existence O 0 6.290571263889433e-07
of O 0 9.074348383819597e-08
a O 0 1.429767394256487e-06
genetically O 0 5.42824636795558e-06
distinct O 0 2.085647565763793e-06
, O 0 7.163566806411836e-07
usually O 0 7.969022703946393e-07
lethal O 0 6.976971690164646e-06
form O 0 7.943474997773592e-07
of O 0 2.601117898848315e-07
the O 0 2.3410244466504082e-05
Schwartz B-Disease 1 0.9803378582000732
- I-Disease 1 0.9989112615585327
Jampel I-Disease 1 0.9974966645240784
syndrome I-Disease 1 0.9999780654907227
( O 0 1.5265615729731508e-05
SJS B-Disease 0 0.03973506763577461
) O 0 1.6775990161477239e-06
of O 0 2.7028181648347527e-06
myotonia B-Disease 1 0.9973167777061462
and O 0 0.0008604921749792993
skeletal B-Disease 1 0.9993273019790649
dysplasia I-Disease 1 0.9999377727508545
, O 0 4.731954049930209e-06
which O 0 1.7559439413616929e-07
we O 0 5.315121143212309e-07
called O 0 1.1896681826328859e-05
SJS B-Disease 0 0.007445232011377811
type I-Disease 0 0.00041762334876693785
2 I-Disease 0 2.7294432584312744e-05
. O 0 9.07897629076615e-06

This O 0 6.729067536070943e-05
disorder O 1 0.999056875705719
is O 0 3.4513413993408903e-06
reminiscent O 0 0.00010607980948407203
of O 0 3.3548118949511263e-07
another O 0 5.497740403370699e-06
rare O 0 0.0006654161843471229
condition O 0 0.13499300181865692
, O 0 5.983317805657862e-06
the O 0 1.7386655599693768e-05
Stuve B-Disease 1 0.9968792200088501
- I-Disease 1 0.9997846484184265
Wiedemann I-Disease 1 0.9996778964996338
syndrome I-Disease 1 0.9999932050704956
( O 0 1.5294892364181578e-05
SWS B-Disease 0 0.010605810210108757
) O 0 4.5680508264922537e-07
, O 0 2.526606408537191e-07
which O 0 7.18308470482043e-08
comprises O 0 7.221548230518238e-07
campomelia B-Disease 0 0.0002960030979011208
at O 0 5.86282076255884e-05
birth O 0 3.388186451047659e-05
with O 0 3.539356475812383e-05
skeletal B-Disease 1 0.9995436072349548
dysplasia I-Disease 1 0.999903678894043
, O 0 0.00013729833881370723
contractures B-Disease 1 0.9882793426513672
, O 0 6.462396868300857e-06
and O 0 2.142609446309507e-06
early B-Disease 0 3.522660699672997e-05
death I-Disease 0 0.00011079844261985272
. O 0 5.30761144545977e-06

To O 0 2.8773493454536947e-07
test O 0 9.190421792482084e-07
for O 0 2.9021567371501078e-08
possible O 0 7.919519475763082e-07
nosologic O 0 0.0001299245050176978
identity O 0 2.1242492493911413e-06
between O 0 3.433204028624459e-06
these O 0 4.378096946311416e-06
disorders O 1 0.9998090863227844
, O 0 1.1951717624469893e-06
we O 0 1.8642307964000793e-07
reviewed O 0 8.005600875549135e-07
the O 0 5.897183541492268e-08
literature O 0 5.664238500457941e-08
and O 0 3.033803608332164e-08
obtained O 0 1.0795104543603884e-07
a O 0 1.521201511422987e-07
follow O 0 2.2672143984436843e-07
- O 0 3.3708902265061624e-06
up O 0 3.9618336700186774e-07
of O 0 7.674316293559968e-09
the O 0 2.052312275679924e-08
only O 0 2.37406734271417e-08
two O 0 9.294875269461045e-08
surviving O 0 2.25107251026202e-05
patients O 0 1.530897498014383e-05
, O 0 1.0889280588344263e-07
one O 0 5.2158330987595036e-08
with O 0 3.892288020779233e-07
SJS B-Disease 0 0.0018450480420142412
type I-Disease 0 4.796924986294471e-05
2 I-Disease 0 3.6670721783593763e-06
at O 0 6.849527835584013e-06
age O 0 1.067029984369583e-06
10 O 0 1.2911698377138237e-07
years O 0 9.631904873685926e-08
and O 0 4.096195382885526e-08
another O 0 1.1456369009010814e-07
with O 0 7.061927931317769e-07
SWS B-Disease 0 0.005483826156705618
at O 0 5.044757199357264e-05
age O 0 1.0905188901233487e-05
7 O 0 6.633847988268826e-06
years O 0 4.9024670261133e-06
. O 0 3.097787839578814e-06

Patients O 0 0.0012300476664677262
reported O 0 2.6058225557790138e-05
as O 0 1.211177163895627e-06
having O 0 8.177677045750897e-06
either O 0 5.386952398112044e-05
neonatal O 1 0.999137282371521
SJS B-Disease 1 0.992966890335083
or O 0 0.00013471322017721832
SWS B-Disease 0 0.02701125666499138
presented O 0 2.151645730918972e-06
a O 0 1.4736443745277938e-06
combination O 0 7.064164037728915e-06
of O 0 1.410390495948377e-06
a O 0 0.00014226516941562295
severe O 1 0.9976266026496887
, O 0 9.390721243107691e-05
prenatal O 1 0.9795815944671631
- O 1 0.9989884495735168
onset O 1 0.9993971586227417
neuromuscular B-Disease 1 0.9999897480010986
disorder I-Disease 1 0.9999892711639404
( O 0 5.219081504037604e-05
with O 0 0.0014009164879098535
congenital B-Disease 1 0.9999996423721313
joint I-Disease 1 0.9996892213821411
contractures I-Disease 1 0.9999740123748779
, O 1 0.9236506223678589
respiratory O 1 0.9999921321868896
and O 0 7.565999840153381e-05
feeding O 0 0.00036139495205134153
difficulties O 0 0.0013004407519474626
, O 0 2.730081632762449e-06
tendency O 0 1.6039353795349598e-05
to O 0 1.6617032088106498e-06
hyperthermia B-Disease 1 0.9077551364898682
, O 0 7.545251605733938e-07
and O 0 3.302501170310279e-07
frequent O 0 9.270189366361592e-06
death O 0 1.1169533536303788e-05
in O 0 5.804726015412598e-07
infancy O 0 2.7023621441912837e-05
) O 0 3.505045143015195e-08
with O 0 4.964600108792183e-08
a O 0 1.5660763210689765e-06
distinct O 0 1.1600327525229659e-05
campomelic B-Disease 1 0.609595537185669
- I-Disease 1 0.9556570053100586
metaphyseal I-Disease 1 0.9497928023338318
skeletal I-Disease 1 0.9992642998695374
dysplasia I-Disease 1 0.9998726844787598
. O 0 0.00016089706332422793

The O 0 1.7636165239309776e-06
similarity O 0 4.451408130989876e-06
of O 0 3.963972972087504e-07
the O 0 2.9277987323439447e-06
clinical O 0 0.000190456717973575
and O 0 4.162807726970641e-06
radiographic O 0 0.0034487969242036343
findings O 0 1.764038643159438e-05
is O 0 4.030806621813099e-07
so O 0 2.3614836663909955e-07
extensive O 0 4.6897557695047e-06
that O 0 4.493967082908057e-07
these O 0 1.5919371207928634e-06
disorders O 1 0.9995785355567932
appear O 0 1.9703436464624247e-06
to O 0 3.5960372457566336e-08
be O 0 8.906697246402473e-08
a O 0 5.787755412711704e-07
single O 0 2.460970563333831e-06
entity O 0 0.00010856967855943367
. O 0 1.647420140216127e-05

The O 0 1.7904175138028222e-06
follow O 0 1.7724061081025866e-06
- O 0 1.6713724107830785e-05
up O 0 1.16395153781923e-06
observation O 0 4.970815098204184e-06
of O 0 1.562484719386248e-08
an O 0 7.007660229874091e-08
identical O 0 1.6786678997959825e-06
and O 0 2.247919752562666e-07
unique O 0 1.2403806977090426e-06
pattern O 0 0.00023730470275040716
of O 0 1.0442870006954763e-05
progressive O 1 0.9992243051528931
bone B-Disease 1 0.999971866607666
dysplasia I-Disease 1 0.9999402761459351
in O 0 2.1620971892843954e-06
the O 0 4.6165408207343717e-07
two O 0 1.5709931631135987e-06
patients O 0 1.8992333934875205e-05
( O 0 7.30535134607635e-08
one O 0 8.029512343910028e-08
with O 0 5.529280997507158e-07
SJS B-Disease 0 0.0029250583611428738
type I-Disease 0 0.000125556078273803
2 I-Disease 0 6.586066319869133e-06
, O 0 4.4126014131506963e-07
one O 0 1.9833697706417297e-07
with O 0 1.6758688161644386e-06
SWS B-Disease 0 0.02463391423225403
) O 0 6.18395631590829e-07
surviving O 0 7.327871117013274e-06
beyond O 0 8.994597919809166e-06
infancy O 0 0.00011005010310327634
adds O 0 1.7649928167884354e-06
to O 0 1.5327721314406517e-08
the O 0 4.8261576068853174e-08
evidence O 0 2.0835709335642605e-07
in O 0 1.4565881656380952e-07
favor O 0 4.5822616812074557e-07
of O 0 1.4257368263770331e-07
identity O 0 7.369232662313152e-06
. O 0 1.606945625098888e-05

The O 0 4.347499725554371e-06
hypothesis O 0 1.8089440345647745e-05
that O 0 5.457966949506954e-07
SWS B-Disease 0 0.0021307170391082764
and O 0 2.7760270313592628e-06
SJS B-Disease 0 0.005054065026342869
type I-Disease 0 0.00016393796249758452
2 I-Disease 0 3.262437303419574e-06
are O 0 5.6495867539752e-08
the O 0 5.652302093039907e-07
same O 0 1.1636869203357492e-05
disorder O 1 0.9984839558601379
should O 0 4.610574535490741e-07
be O 0 4.5154081362852594e-08
testable O 0 2.85553767298552e-07
by O 0 2.5867567643445e-08
molecular O 0 6.992865564825479e-06
methods O 0 3.96006862501963e-06
. O 0 1.785709400792257e-06
. O 0 3.5378875509195495e-06

A O 0 2.2114085368230008e-05
mouse O 0 0.000136426548124291
model O 0 3.777697202167474e-05
of O 0 4.3214851757511497e-05
severe O 1 0.9998499155044556
von B-Disease 1 0.9999992847442627
Willebrand I-Disease 1 0.9999983310699463
disease I-Disease 1 1.0
: O 0 0.2434055358171463
defects O 1 0.9997522234916687
in O 0 0.00011819793871836737
hemostasis O 1 0.9972931742668152
and O 0 0.007947470061480999
thrombosis B-Disease 1 0.9996088147163391
. O 0 0.00011829265713458881

von B-Disease 1 0.99131178855896
Willebrand I-Disease 1 0.9961000680923462
factor I-Disease 0 0.0017061909893527627
( I-Disease 0 7.767412171233445e-05
vWf I-Disease 0 0.04949060454964638
) I-Disease 0 0.0016096446197479963
deficiency I-Disease 1 0.9998407363891602
causes O 1 0.9988117218017578
severe O 1 0.999963641166687
von B-Disease 1 0.9999995231628418
Willebrand I-Disease 1 0.9999972581863403
disease I-Disease 1 0.9999997615814209
in O 0 4.759610601468012e-05
humans O 0 0.00014394739991985261
. O 0 2.664621024450753e-05

We O 0 1.512325752628385e-06
generated O 0 1.3685442468158726e-07
a O 0 3.45032049153815e-07
mouse O 0 4.51371306553483e-06
model O 0 4.898906240669021e-07
for O 0 6.281710085431769e-08
this O 0 3.751489714431955e-07
disease O 0 0.0010592788457870483
by O 0 7.178000416274699e-09
using O 0 2.0464770500439045e-07
gene O 0 4.7231937969627324e-06
targeting O 0 7.299817752937088e-06
. O 0 6.898555511725135e-06

vWf B-Disease 0 0.050118569284677505
- I-Disease 0 0.07517458498477936
deficient I-Disease 0 0.01233369018882513
mice O 0 0.00011010268644895405
appeared O 0 8.196806447813287e-06
normal O 0 6.990651399974013e-06
at O 0 8.136060387187172e-06
birth O 0 1.9499143490975257e-06
; O 0 4.189928404230159e-08
they O 0 1.3156487455034949e-08
were O 0 2.9590639272214503e-08
viable O 0 3.4238755688420497e-06
and O 0 1.835011630646477e-06
fertile O 0 0.00013241318811196834
. O 0 2.960027995868586e-05

Neither O 0 0.0004111941088922322
vWf O 0 0.007058747112751007
nor O 0 0.000703862402588129
vWf O 0 0.007057370152324438
propolypeptide O 0 0.011310494504868984
( O 0 1.8549586457083933e-05
von B-Disease 1 0.8377970457077026
Willebrand I-Disease 1 0.9510813355445862
antigen O 0 0.002032136544585228
II O 0 0.10120749473571777
) O 0 3.2567251651016704e-07
were O 0 2.1640225611463393e-07
detectable O 0 2.300620144524146e-05
in O 0 3.369902117356105e-07
plasma O 0 3.0197577871149406e-05
, O 0 1.2000451761196018e-06
platelets O 0 0.00011245060159126297
, O 0 9.774256568562123e-07
or O 0 1.552831122353382e-06
endothelial O 0 3.2509480661246926e-05
cells O 0 4.243765943101607e-06
of O 0 6.776620153914337e-08
the O 0 7.990086601239454e-07
homozygous O 0 3.2120427931658924e-05
mutant O 0 0.00010552663297858089
mice O 0 0.0002673326525837183
. O 0 8.398865247727372e-06

The O 0 1.3648880667460617e-05
mutant O 0 0.0006312511977739632
mice O 0 0.0022580407094210386
exhibited O 0 0.004998403135687113
defects O 1 0.9986112117767334
in O 0 7.844959327485412e-06
hemostasis O 0 0.007706753443926573
with O 0 2.3346938178292476e-06
a O 0 2.6339650503359735e-05
highly O 0 0.0007191048352979124
prolonged O 1 0.9386206865310669
bleeding O 1 0.9995494484901428
time O 0 5.1818146857840475e-06
and O 0 4.431758043210721e-06
spontaneous O 0 0.00019257974054198712
bleeding O 1 0.9974479675292969
events O 0 4.592556024363148e-07
in O 0 8.40431866322433e-08
approximately O 0 5.836755789800918e-08
10 O 0 1.3541554721996363e-07
% O 0 1.7813055919191356e-08
of O 0 1.39575575985873e-07
neonates O 0 0.0004683323495555669
. O 0 1.3013283023610711e-05

As O 0 4.913902102998691e-06
in O 0 9.126853797170043e-07
the O 0 1.8824656535798567e-06
human O 0 0.00012390699703246355
disease O 1 0.9966667294502258
, O 0 3.2062374089036894e-07
the O 0 1.270409200060385e-07
factor O 0 1.6885167042346438e-06
VIII O 0 0.00022257777163758874
level O 0 4.418473508849274e-06
in O 0 2.535092562538921e-07
these O 0 8.60217781450956e-08
mice O 0 1.6797115677036345e-05
was O 0 3.776775429287227e-06
reduced O 0 1.0856136896109092e-06
strongly O 0 3.7946537645439093e-07
as O 0 1.1482850226229857e-07
a O 0 2.9384432309598196e-07
result O 0 3.6622282095777337e-07
of O 0 3.0326233968480665e-08
the O 0 2.143141557553463e-07
lack O 0 1.6927264141486376e-06
of O 0 2.9486531616385037e-07
protection O 0 1.2617963875527494e-05
provided O 0 9.084649832402647e-07
by O 0 1.5463466525034164e-06
vWf O 0 0.000936736527364701
. O 0 1.5078864635142963e-05

Defective O 1 0.9939171671867371
thrombosis B-Disease 1 0.9981529116630554
in O 0 7.129739515221445e-06
mutant O 0 8.911108307074755e-05
mice O 0 9.063241304829717e-05
was O 0 6.823579042247729e-06
also O 0 2.571277093466051e-07
evident O 0 9.916747103488888e-07
in O 0 4.624481064752217e-08
an O 0 5.865616259370654e-08
in O 0 2.963473093586799e-07
vivo O 0 1.5016710676718503e-05
model O 0 7.754177204333246e-06
of O 0 1.799489291443024e-05
vascular B-Disease 1 0.9999938011169434
injury I-Disease 1 0.9999085664749146
. O 0 6.50941874482669e-05

In O 0 5.413427288658568e-07
this O 0 4.027056377253757e-08
model O 0 1.0821054274856579e-06
, O 0 2.952637601083552e-07
the O 0 5.594383765128441e-07
exteriorized O 0 0.0008971631759777665
mesentery O 0 0.002192583866417408
was O 0 7.452083082171157e-05
superfused O 0 0.0001705693284748122
with O 0 2.2257522687141318e-06
ferric O 0 0.008586227893829346
chloride O 0 0.00020324163779150695
and O 0 1.641865992496605e-06
the O 0 1.625866843824042e-06
accumulation O 0 0.0001408766402164474
of O 0 1.108042511077656e-06
fluorescently O 0 0.0041144066490232944
labeled O 0 0.0006813898216933012
platelets O 0 0.001868451596237719
was O 0 3.964871939388104e-05
observed O 0 4.842381258640671e-06
by O 0 2.0401245137691149e-07
intravital O 0 0.00019505381351336837
microscopy O 0 0.00021013036894146353
. O 0 3.346779340063222e-05

We O 0 5.562264050240628e-06
conclude O 0 4.980428457201924e-06
that O 0 5.951399018044867e-08
these O 0 4.9855810146937074e-08
mice O 0 1.2780195902450942e-05
very O 0 1.4474669569608523e-06
closely O 0 5.5449676438001916e-05
mimic O 0 0.09675361961126328
severe O 1 0.9981473684310913
human O 1 0.9218249320983887
von B-Disease 1 0.9999983310699463
Willebrand I-Disease 1 0.9999967813491821
disease I-Disease 1 0.9999997615814209
and O 0 4.523563984548673e-05
will O 0 5.664227842316905e-07
be O 0 8.657548988821873e-08
very O 0 1.207474582543e-07
useful O 0 2.267984342552154e-07
for O 0 4.1516802440355605e-08
investigating O 0 1.495646301918896e-06
the O 0 9.578025128575973e-08
role O 0 1.060141812558868e-06
of O 0 2.924947750670981e-07
vWf O 0 9.323470294475555e-05
in O 0 1.4684172811030294e-06
normal O 0 2.9146438464522362e-05
physiology O 0 0.000550499593373388
and O 0 2.247914153485908e-06
in O 0 7.190820724645164e-06
disease O 1 0.9713087677955627
models O 0 1.7015789126162417e-05
. O 0 1.7110291992139537e-06
. O 0 4.818059096578509e-06

Oral O 0 0.0014313154388219118
contraceptives O 0 0.0017866402631625533
and O 0 7.462906069122255e-06
the O 0 1.3821952961734496e-05
risk O 0 0.006172869820147753
of O 0 0.0005129409837536514
hereditary B-Disease 1 0.9999980926513672
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.0002936246746685356

Hereditary B-Disease 1 0.9999032020568848
Ovarian I-Disease 1 0.999991774559021
Cancer I-Disease 1 0.9997338652610779
Clinical O 0 0.0008767920080572367
Study O 0 8.495987458445597e-06
Group O 0 1.0080072570417542e-05
. O 0 7.125728643586626e-06

BACKGROUND O 0 8.232136315200478e-05
Women O 0 7.951477982715005e-07
with O 0 5.226204962127667e-07
mutations O 0 2.3947042791405693e-05
in O 0 2.6878277026298747e-07
either O 0 2.2195089854903927e-07
the O 0 5.043127657700097e-07
BRCA1 O 0 7.118898793123662e-05
or O 0 6.499570872620097e-07
the O 0 3.209789269931207e-07
BRCA2 O 0 2.0537732780212536e-05
gene O 0 2.141253162335488e-06
have O 0 2.0345986229131086e-07
a O 0 2.442837057969882e-06
high O 0 8.327664545504376e-05
lifetime O 0 0.0005109086050651968
risk O 0 0.008036011829972267
of O 0 0.0036199961323291063
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999992847442627
. O 0 0.00010753080277936533

Oral O 0 0.009470483288168907
contraceptives O 1 0.7013905048370361
protect O 0 0.25274893641471863
against O 1 0.9990600943565369
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999980926513672
in O 0 2.7732276066672057e-06
general O 0 1.6783574210421648e-06
, O 0 2.607756641737069e-07
but O 0 5.8401521840778514e-08
it O 0 2.56715519952877e-08
is O 0 4.209858772696862e-08
not O 0 1.145390626788867e-08
known O 0 2.0059415817286208e-07
whether O 0 9.999391181736428e-08
they O 0 1.871834172106901e-07
also O 0 9.920001957652858e-07
protect O 0 7.882291356509086e-06
against O 0 1.1496789738885127e-05
hereditary B-Disease 1 0.9934225678443909
forms I-Disease 0 0.010911225341260433
of I-Disease 1 0.9708850383758545
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 0.00030737361521460116

METHODS O 0 4.315719706937671e-05
We O 0 6.629054496443132e-06
enrolled O 0 1.17315712486743e-05
207 O 0 2.8134709282312542e-05
women O 0 4.666293534683064e-06
with O 0 0.0005340169882401824
hereditary B-Disease 1 0.9999940395355225
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
and O 0 6.15917497270857e-06
161 O 0 2.183104470532271e-06
of O 0 4.9182109052026135e-08
their O 0 1.0619961443580905e-07
sisters O 0 7.358031325566117e-06
as O 0 4.211995303649019e-07
controls O 0 2.6276784410583787e-06
in O 0 3.793597329604381e-07
a O 0 2.293748138981755e-06
case O 0 1.3256421880214475e-05
- O 0 6.451968511100858e-05
control O 0 2.2167676434037276e-05
study O 0 6.779407158319373e-06
. O 0 3.5761893286689883e-06

All O 0 5.784985432910617e-07
the O 0 1.4058850865694694e-06
patients O 0 1.1247994734731037e-05
carried O 0 1.2581150485857506e-06
a O 0 9.272118290937215e-07
pathogenic O 0 4.715219256468117e-05
mutation O 0 1.608733509783633e-05
in O 0 3.032161259852728e-07
either O 0 1.0528470966164605e-06
BRCA1 O 0 9.871969814412296e-05
( O 0 5.798772235721117e-07
179 O 0 2.9890229598095175e-06
women O 0 2.3643073632229061e-07
) O 0 1.3100975593260955e-07
or O 0 2.0083316485397518e-06
BRCA2 O 0 0.00010966281843138859
( O 0 1.211318021887564e-06
28 O 0 1.074766623787582e-05
women O 0 6.374477834469872e-07
) O 0 5.396926781031652e-07
. O 0 2.62074854617822e-06

The O 0 2.9657819595740875e-06
control O 0 1.5592995623592287e-05
women O 0 3.734027984592103e-07
were O 0 2.593451426946558e-07
enrolled O 0 1.1215624908800237e-06
regardless O 0 5.497255415320978e-07
of O 0 4.439370471231996e-08
whether O 0 2.476416796071135e-07
or O 0 5.400443114922382e-07
not O 0 8.105217119691588e-08
they O 0 2.0690704616299627e-07
had O 0 1.5948213558658608e-06
either O 0 2.5791309781197924e-06
mutation O 0 0.00011040084064006805
. O 0 7.654183718841523e-06

Lifetime O 0 0.0003357120440341532
histories O 0 0.00011509886098792776
of O 0 2.5349067982460838e-06
oral O 0 0.00038369299727492034
- O 0 5.2620001952163875e-05
contraceptive O 0 7.308378826564876e-06
use O 0 6.903295002302912e-08
were O 0 6.336306057619367e-08
obtained O 0 1.1319431791889656e-07
by O 0 5.487372334300744e-08
interview O 0 7.629375431861263e-06
or O 0 1.7287896980633377e-07
by O 0 3.000524628760104e-08
written O 0 9.250059207488448e-08
questionnaire O 0 2.0303750147832034e-07
and O 0 3.768974465856445e-08
were O 0 7.141391478171499e-08
compared O 0 7.054113098092785e-07
between O 0 9.911774441206944e-07
patients O 0 1.3473782928485889e-05
and O 0 4.567249050069222e-07
control O 0 9.039278666023165e-06
women O 0 6.23846290181973e-07
, O 0 2.6215658976980194e-07
after O 0 1.0936869330180343e-06
adjustment O 0 1.2875023003289243e-06
for O 0 3.1753511819943014e-08
year O 0 3.553079181983776e-07
of O 0 9.263142430881999e-08
birth O 0 1.3672263776243199e-05
and O 0 2.634950760693755e-06
parity O 0 0.00019131087174173445
. O 0 1.8361515685683116e-05

RESULTS O 0 6.790104816900566e-05
The O 0 3.0431747291004285e-06
adjusted O 0 0.0001912949956022203
odds O 0 0.0010552799794822931
ratio O 0 0.00014358000771608204
for O 0 0.013086558319628239
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
associated O 0 3.884584657498635e-06
with O 0 1.1864450755183498e-07
any O 0 4.1146364537780755e-08
past O 0 2.471975903972634e-07
use O 0 1.0523216076308017e-07
of O 0 1.4463657294072618e-07
oral O 0 5.3129770094528794e-05
contraceptives O 0 0.0013566677225753665
was O 0 0.00018781334802042693
0 O 0 1.1788319170591421e-05
. O 0 3.7591462387354113e-06

5 O 0 4.889509909844492e-06
( O 0 1.1376834407883507e-07
95 O 0 9.74808017417672e-07
percent O 0 1.2831910680688452e-06
confidence O 0 1.512615767751413e-06
interval O 0 5.076146862847963e-07
, O 0 1.1007011835317826e-07
0 O 0 4.92572098664823e-08
. O 0 6.0119322853324775e-09
3 O 0 2.7898593657482706e-08
to O 0 4.700350775266315e-09
0 O 0 1.557136215524224e-07
. O 0 5.868749397563988e-08
8 O 0 8.109204827633221e-07
) O 0 1.4070853637804248e-07
. O 0 1.2190153029223438e-06

The O 0 1.5171003724390175e-05
risk O 0 0.00011212059325771406
decreased O 0 1.540547418699134e-05
with O 0 1.6699898708338878e-07
increasing O 0 7.757963089716213e-07
duration O 0 1.0150056368729565e-06
of O 0 1.3099446860564967e-08
use O 0 1.6537101998892467e-07
( O 0 2.271974182121994e-07
P O 0 9.468292773817666e-06
for O 0 3.2862860877003186e-08
trend O 0 1.3335582025320036e-06
, O 0 1.8473996021839412e-07
< O 0 1.4742684015800478e-06
0 O 0 1.2636172641578014e-07
. O 0 1.14625819946923e-08
001 O 0 1.3153096460882807e-06
) O 0 7.52322648622794e-09
; O 0 4.053238633616729e-09
use O 0 5.327983831904248e-09
for O 0 5.980789197224112e-09
six O 0 2.1526270543859027e-08
or O 0 2.4466363157671367e-08
more O 0 7.526685052994253e-09
years O 0 2.457681773648801e-07
was O 0 1.0055483699034085e-06
associated O 0 9.580492843497268e-08
with O 0 2.7632793830889568e-08
a O 0 4.6291717126223375e-07
60 O 0 1.275722297577886e-06
percent O 0 3.2007612844608957e-06
reduction O 0 6.589044460270088e-06
in O 0 2.716861445151153e-06
risk O 0 0.00012084514310117811
. O 0 4.899765372101683e-06

Oral O 0 0.0024120088201016188
- O 0 0.0004724667523987591
contraceptive O 0 8.680555038154125e-05
use O 0 5.535883701668354e-06
protected O 0 0.07915584743022919
against O 1 0.9898120760917664
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999923706054688
both O 0 4.542658018635848e-07
for O 0 7.806421109535222e-08
carriers O 0 2.300069809280103e-06
of O 0 1.1432891966478564e-07
the O 0 1.190756506730395e-06
BRCA1 O 0 0.00044452291331253946
mutation O 0 4.462324795895256e-05
( O 0 3.0149499252729584e-07
odds O 0 1.3398542250797618e-05
ratio O 0 9.986503073378117e-07
, O 0 1.705656416106649e-07
0 O 0 1.3626055306303897e-07
. O 0 1.674888849834133e-08
5 O 0 6.241855032840249e-08
; O 0 2.965397527532332e-08
95 O 0 3.0119755933810666e-07
percent O 0 6.252460025280016e-07
confidence O 0 9.70491896623571e-07
interval O 0 7.56388942591002e-07
, O 0 7.088155484780145e-08
0 O 0 4.4160447743024633e-08
. O 0 3.568772610762494e-09
3 O 0 2.1374809477947565e-08
to O 0 2.6456246082773305e-09
0 O 0 5.844977479796398e-08
. O 0 1.6960612470029446e-08
9 O 0 2.047148655037745e-07
) O 0 4.517818119609274e-09
and O 0 1.3749485106018255e-08
for O 0 1.6725202556244767e-08
carriers O 0 7.092407940945122e-07
of O 0 5.3403578448296685e-08
the O 0 2.4941459741967265e-06
BRCA2 O 0 0.0007944188546389341
mutation O 0 0.000112998801341746
( O 0 6.288471467996715e-07
odds O 0 2.699670585570857e-05
ratio O 0 1.6112322782646515e-06
, O 0 2.1228001401141228e-07
0 O 0 1.6280718284633622e-07
. O 0 1.8269004087301255e-08
4 O 0 1.62063912512167e-07
; O 0 3.690834660119435e-08
95 O 0 3.045512926291849e-07
percent O 0 4.403214575177117e-07
confidence O 0 7.567944066977361e-07
interval O 0 3.7032245359114313e-07
, O 0 7.644647581628305e-08
0 O 0 3.519831182074995e-08
. O 0 4.914504359021521e-09
2 O 0 2.2194090121274712e-08
to O 0 8.563016962170877e-09
1 O 0 1.4934371961317083e-07
. O 0 3.0348804358482084e-08
1 O 0 5.701296572624415e-07
) O 0 1.5787595941674226e-07
. O 0 1.3330343335837824e-06

CONCLUSIONS O 0 0.0002864416455850005
Oral O 0 0.0006162530626170337
- O 0 0.0001456806348869577
contraceptive O 0 3.513173578539863e-05
use O 0 1.0038094160336186e-06
may O 0 7.014954462647438e-06
reduce O 0 5.133576905791415e-06
the O 0 4.3631835069390945e-06
risk O 0 0.0011092995991930366
of O 0 0.0007131441961973906
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
in O 0 2.2797669316787506e-06
women O 0 2.0644365861244296e-07
with O 0 3.455698163179477e-07
pathogenic O 0 8.26325049274601e-05
mutations O 0 4.784434349858202e-05
in O 0 5.517976546798309e-07
the O 0 1.3447175888359197e-06
BRCA1 O 0 0.0005822836537845433
or O 0 4.954028190695681e-05
BRCA2 O 0 0.004621787928044796
gene O 0 0.002487463178113103

A O 0 2.9105583962518722e-05
Japanese O 0 2.7293104722048156e-05
family O 0 1.3318626770342235e-05
with O 0 9.684175893198699e-06
adrenoleukodystrophy B-Disease 1 0.9999850988388062
with O 0 1.8952208620248712e-06
a O 0 4.411466761666816e-06
codon O 0 2.1370349713834003e-05
291 O 0 6.1649757299164776e-06
deletion O 0 1.5740355593152344e-05
: O 0 3.485047272988595e-07
a O 0 1.3513511021301383e-06
clinical O 0 2.792389022943098e-05
, O 0 8.049774464780057e-07
biochemical O 0 0.00010770247899927199
, O 0 2.4584910534031224e-06
pathological O 0 0.0017234981060028076
, O 0 3.01650516121299e-06
and O 0 2.917235860877554e-06
genetic O 0 0.0002165477635571733
report O 0 1.913125379360281e-05
. O 0 5.91260140936356e-06

We O 0 5.504214186657919e-06
report O 0 5.065763843958848e-07
a O 0 3.4201545418000023e-07
Japanese O 0 5.4803508646728005e-06
family O 0 1.6620328096905723e-05
with O 0 0.0005006715073250234
adrenoleukodystrophy B-Disease 1 0.9999970197677612
( O 0 0.0001625650329515338
ALD B-Disease 1 0.9999011754989624
) O 0 1.816976293866901e-07
with O 0 7.36448697580272e-08
a O 0 3.958604395393195e-07
three O 0 1.8821411629232898e-07
base O 0 3.187668426107848e-06
pair O 0 5.749554929934675e-06
deletion O 0 1.903721204143949e-05
( O 0 3.875213678838918e-07
delGAG O 0 3.457198181422427e-05
291 O 0 4.687882210419048e-06
) O 0 2.3266845516900503e-07
in O 0 4.522630945302808e-07
the O 0 1.012537359201815e-05
ALD B-Disease 1 0.999789297580719
gene O 0 0.0003895453701261431
. O 0 2.8502036002464592e-05

A O 0 1.4474033378064632e-05
variety O 0 2.7251419396634446e-06
of O 0 2.4707432544346375e-07
phenotypes O 0 5.6166481954278424e-05
were O 0 9.212992608809145e-07
observed O 0 3.646302047854988e-06
within O 0 4.059845366555237e-07
this O 0 1.2191451048693125e-07
family O 0 8.35112587083131e-06
. O 0 9.696124834590591e-06

While O 0 7.835747055651154e-06
the O 0 2.0958559616701677e-06
proband O 0 0.0005125465686433017
( O 0 2.0151271655777236e-06
patient O 0 2.954971023427788e-05
1 O 0 8.913696660783899e-07
) O 0 6.464446755671815e-08
was O 0 1.3784141401629313e-06
classified O 0 1.171090843854472e-06
as O 0 1.8761215869744774e-07
having O 0 3.417999323573895e-07
a O 0 3.667264252271707e-07
rare O 0 5.6569251682958566e-06
intermediate O 0 1.1154556887049694e-05
type O 0 4.0402515878668055e-05
of O 0 5.89745241086348e-07
adult O 0 8.213795808842406e-05
cerebral O 1 0.9992973804473877
and O 0 6.723866681568325e-05
cerebello O 1 0.994417667388916
- O 1 0.9967623949050903
brain O 1 0.9977261424064636
stem O 0 5.3141826356295496e-05
forms O 0 6.0987563301750924e-06
, O 0 1.1144784366479144e-06
his O 0 3.032154836546397e-06
younger O 0 2.4685399694135413e-05
brother O 0 8.624332258477807e-05
( O 0 9.721212563817971e-07
patient O 0 2.361271072004456e-05
2 O 0 1.0461970987307723e-06
) O 0 9.758834806916639e-08
and O 0 5.716388500331959e-07
nephew O 0 0.00025367658236064017
( O 0 1.1268094795013894e-06
patient O 0 4.118434662814252e-05
3 O 0 1.6046952850956586e-06
) O 0 1.6115613732381462e-07
had O 0 1.5911055015749298e-06
a O 0 1.2809089639631566e-05
childhood O 0 0.09714257717132568
ALD B-Disease 1 0.9999192953109741
type O 1 0.5382463932037354
. O 0 5.3924417443340644e-05

Another O 0 5.106664320919663e-05
nephew O 0 0.0017047736328095198
( O 0 3.4819024676835397e-06
patient O 0 4.7246670874301344e-05
4 O 0 2.721326609389507e-06
) O 0 8.496884618125478e-08
of O 0 1.7316790490440326e-07
patient O 0 5.452679397421889e-05
1 O 0 2.9376967631833395e-06
was O 0 6.475154350482626e-06
classified O 0 2.8830838800786296e-06
as O 0 3.118781819466676e-07
having O 0 1.4067393294681096e-06
an O 0 7.775776680318813e-07
adolescent O 0 0.00022368320787791163
form O 0 2.139239222742617e-05
. O 0 2.094315095746424e-05

The O 0 3.928910246031592e-06
tau O 0 3.437565464992076e-05
level O 0 7.000138339208206e-06
in O 0 2.5531612664053682e-06
the O 0 1.4143560292723123e-05
cerebrospinal O 1 0.7511900663375854
fluid O 0 0.04976225271821022
( O 0 1.0683449545467738e-05
CSF O 0 0.04093722254037857
) O 0 2.673006633813202e-07
in O 0 2.9526603384510963e-07
patient O 0 1.1087085113103967e-05
1 O 0 9.195787811222544e-07
was O 0 2.037390004261397e-06
as O 0 2.004778849595823e-07
high O 0 2.5459155494900187e-06
as O 0 1.3143900901013694e-07
that O 0 4.137506337542618e-08
of O 0 2.2263330379246327e-07
patients O 0 0.00013762287562713027
with O 0 0.00032148341415449977
Alzheimers B-Disease 1 0.9999810457229614
disease I-Disease 1 0.9998741149902344
( O 0 2.002586370508652e-06
AD B-Disease 0 1.556074494146742e-05
) O 0 8.01116073034791e-07
. O 0 3.035117515537422e-06

His O 0 0.0002022771368501708
brain O 1 0.5257308483123779
magnetic O 0 0.00010050370474345982
resonance O 0 0.00025398319121450186
image O 0 0.00020622082229238003
( O 0 4.51825280833873e-06
MRI O 0 0.0026172888465225697
) O 0 1.0374291150583304e-06
showed O 0 3.427852789172903e-05
abnormalities B-Disease 0 0.25684162974357605
in I-Disease 0 4.068391490363865e-07
the I-Disease 0 1.0000160273193615e-06
bilateral I-Disease 0 0.0029395781457424164
cerebellar I-Disease 1 0.9970591068267822
hemispheres I-Disease 1 0.5150436162948608
and O 0 0.00022395381529349834
brain O 1 0.9990531802177429
stem O 0 0.00024364973069168627
, O 0 2.127164407283999e-06
but O 0 2.448765599183389e-07
not O 0 6.767294280507485e-08
in O 0 3.4648354585442576e-07
the O 0 4.55951294497936e-06
cerebral O 1 0.995148241519928
white O 0 7.543399988207966e-05
matter O 0 1.1543645996425766e-05
, O 0 1.3097045439280919e-06
where O 0 7.299304911612126e-07
marked O 0 8.1384350778535e-06
reductions O 0 3.0027889806660824e-05
of O 0 1.242589462435717e-07
the O 0 4.93593961437e-06
cerebral O 1 0.9923639297485352
blood O 0 0.00024404426221735775
flow O 0 1.2336349755059928e-05
and O 0 2.0023915112687973e-06
oxygen O 0 2.928236972365994e-05
metabolism O 0 5.990511635900475e-05
were O 0 2.8377667149470653e-07
clearly O 0 9.966827292373637e-07
demonstrated O 0 7.474612289115612e-07
by O 0 1.3034652113219636e-07
positron O 0 0.0001082941162167117
emission O 0 7.621220720466226e-05
tomography O 0 0.00015368413005489856
( O 0 1.4511933841276914e-06
PET O 0 0.000111266432213597
) O 0 7.552903298346791e-07
. O 0 2.3002473881206242e-06

In O 0 8.141780199366622e-06
patients O 0 1.408690422977088e-05
2 O 0 9.739400184116676e-07
and O 0 3.1722305493531167e-07
3 O 0 1.983041784114903e-06
, O 0 3.3250938713536016e-07
the O 0 8.527283625880955e-07
autopsy O 0 0.0009552021510899067
findings O 0 2.02482333406806e-05
showed O 0 0.00014027826546225697
massive O 0 0.021155061200261116
demyelination B-Disease 1 0.9999748468399048
of I-Disease 0 6.073183612897992e-06
the I-Disease 0 7.714890671195462e-05
cerebral I-Disease 1 0.9994766116142273
white I-Disease 0 6.710914021823555e-05
matter I-Disease 0 2.168424089177279e-06
with O 0 2.955874833787675e-07
sparing O 0 2.1477587779372698e-06
of O 0 7.92168961538664e-08
the O 0 1.5728414837212767e-06
U O 0 0.0004788312071468681
- O 0 0.00026898167561739683
fibers O 0 6.08982918492984e-05
, O 0 1.0598450472798504e-07
compatible O 0 2.6690275944929454e-07
with O 0 1.2774616209298983e-07
the O 0 8.196769840651541e-07
findings O 0 6.594953902094858e-06
of O 0 4.494032054935815e-06
childhood O 1 0.9889771342277527
ALD B-Disease 1 0.9999856948852539
. O 0 0.00022516031458508223

Oleic O 0 0.013027145527303219
and O 0 6.610192212974653e-05
erucic O 0 0.020368942990899086
acids O 0 8.824450196698308e-05
( O 0 1.1762015219574096e-06
Lorenzos O 0 6.210673745954409e-05
Oil O 0 3.551849431460141e-06
) O 0 4.410733112081289e-08
were O 0 2.567733048408627e-08
administered O 0 2.526131765989703e-07
to O 0 3.5127957431768664e-08
patients O 0 1.9671349491545698e-06
1 O 0 3.135084511995956e-07
and O 0 1.7901854221236135e-07
4 O 0 1.0778290970847593e-06
, O 0 1.0337408440364015e-07
but O 0 3.660191794097045e-08
sufficient O 0 6.439120880941118e-08
effectiveness O 0 1.574399334458576e-06
was O 0 4.5386282181425486e-06
not O 0 8.658837202801806e-08
obtained O 0 1.2678773373409058e-06
. O 0 2.813392939060577e-06

The O 0 5.0988564908038825e-06
findings O 0 7.645662662980612e-06
in O 0 2.7044839612244687e-07
this O 0 3.8715707972869495e-08
family O 0 1.0026851668953896e-06
suggest O 0 5.30422937572439e-07
that O 0 8.343609181338252e-08
delGAG291 O 0 2.191914063587319e-05
is O 0 1.294723404043907e-07
part O 0 2.17983071593153e-07
of O 0 1.0747339018735147e-07
the O 0 1.7978330788537278e-06
cause O 0 0.00011678072769427672
of O 0 1.023790105136868e-06
Japanese O 0 0.0017168679041787982
ALD B-Disease 1 0.9999291896820068
with O 0 7.1338204179483e-06
phenotypic O 0 0.0004553579492494464
variations O 0 0.000882491935044527
. O 0 2.865514761651866e-05

Moreover O 0 5.358337512006983e-05
, O 0 1.4512307870973018e-06
although O 0 1.786377481494128e-07
the O 0 1.1829809665186986e-07
scale O 0 5.865923867531819e-06
of O 0 6.669624497135374e-08
the O 0 3.263907615291828e-07
study O 0 3.3952639455492317e-07
is O 0 1.073598809853138e-07
limited O 0 1.5299279709779512e-07
, O 0 1.657246713193672e-07
there O 0 3.908609969016652e-08
is O 0 5.625586396718063e-08
a O 0 2.1817213280428405e-07
possibility O 0 6.942590857761388e-07
that O 0 5.384810108921556e-08
PET O 0 2.777153167698998e-05
can O 0 1.4242082215787377e-06
detect O 0 0.0004585338174365461
an O 0 4.876866569247795e-06
insidious B-Disease 0 0.37013936042785645
lesion I-Disease 1 0.9988756775856018
which O 0 2.22516655412619e-06
is O 0 8.272205036519154e-07
undetectable O 0 8.881705434760079e-05
by O 0 1.1230700636133406e-07
computed O 0 7.96066797192907e-06
tomogram O 0 7.552504393970594e-05
( O 0 1.053785354088177e-06
CT O 0 0.0006522670155391097
) O 0 1.6568263561111962e-07
or O 0 1.0523732498768368e-06
MRI O 0 8.845444972394034e-05
analysis O 0 3.259332004290627e-07
, O 0 1.1289869661368357e-07
and O 0 3.7872705860309e-08
that O 0 4.089971472609477e-09
the O 0 4.90423488486158e-08
higher O 0 4.1917311932593293e-07
level O 0 1.0776851695482037e-06
of O 0 5.1423590718968626e-08
tau O 0 6.237753041204996e-06
reflects O 0 4.281492351765337e-07
the O 0 4.05693789673478e-08
process O 0 1.7186636114274734e-07
of O 0 4.5627129452441295e-07
neuronal B-Disease 0 0.0010258860420435667
degeneration I-Disease 1 0.9997164607048035
in O 0 0.0013285138411447406
ALD B-Disease 1 0.99997878074646
. O 0 0.00020795484306290746

Lorenzos O 0 0.0014830592554062605
Oil O 0 2.262830821564421e-05
should O 0 2.1832489949247247e-07
be O 0 2.516484087777826e-08
given O 0 8.586927613407624e-09
in O 0 1.807570271239456e-08
the O 0 5.62822641825278e-08
early O 0 1.7687250419839984e-06
stage O 0 3.642559386207722e-05
. O 0 1.3595155223811162e-06
. O 0 4.604115929396357e-06

Nonsense O 0 0.0008970212657004595
mutation O 0 0.00011676112626446411
in O 0 1.0349439207857358e-06
exon O 0 3.063907934119925e-05
4 O 0 1.5117907423700672e-06
of O 0 5.507000722104749e-08
human O 0 9.998358336815727e-07
complement O 0 3.5851189750246704e-06
C9 O 0 0.0012731386814266443
gene O 0 1.2101230822736397e-05
is O 0 1.097808421945956e-06
the O 0 4.5724050323769916e-07
major O 0 4.695485040429048e-05
cause O 0 6.487896462203935e-05
of O 0 6.337194236039068e-07
Japanese O 0 0.00033215651637874544
complement B-Disease 0 0.005812305491417646
C9 I-Disease 1 0.998595654964447
deficiency I-Disease 1 0.9998143315315247
. O 0 5.180088191991672e-05

Deficiency B-Disease 1 0.9992420673370361
of I-Disease 0 7.881417900534871e-07
the I-Disease 0 1.9560961845854763e-06
ninth I-Disease 0 0.0001584705023560673
component I-Disease 0 7.878781616454944e-06
of I-Disease 0 1.5166212108397303e-07
human I-Disease 0 1.6337611441485933e-06
complement I-Disease 0 4.8750434871180914e-06
( O 0 1.4704435216117417e-06
C9 O 0 0.0009355619549751282
) O 0 2.507312331090361e-07
is O 0 9.115008481330733e-08
the O 0 1.0202466427244872e-07
most O 0 5.857666565134423e-07
common O 0 0.00021470279898494482
complement B-Disease 1 0.9997653365135193
deficiency I-Disease 1 0.9999983310699463
in O 0 3.859733624267392e-06
Japan O 0 2.1869260308449157e-05
but O 0 6.634187457166263e-07
is O 0 1.5321970181503275e-07
rare O 0 1.3918029253545683e-06
in O 0 8.10347060564709e-08
other O 0 5.416640291855401e-08
countries O 0 4.4586761305254186e-07
. O 0 8.391147275688127e-06

We O 0 2.61091213360487e-06
studied O 0 1.368655603073421e-06
the O 0 1.1001134225807618e-07
molecular O 0 1.7578538972884417e-05
basis O 0 1.963999238796532e-06
of O 0 1.0574564839771483e-05
C9 B-Disease 1 0.9973483085632324
deficiency I-Disease 1 0.9997519850730896
in O 0 1.2938374993609614e-06
four O 0 8.830600108922226e-07
Japanese O 0 6.066701826057397e-05
C9 B-Disease 1 0.9863729476928711
- I-Disease 1 0.986657440662384
deficient I-Disease 1 0.5127343535423279
patients O 0 0.0003097154258284718
who O 0 2.3840515495976433e-05
had O 0 0.00018422002904117107
suffered O 1 0.9998410940170288
from O 0 0.0029387425165623426
meningococcal B-Disease 1 0.9999918937683105
meningitis I-Disease 1 0.9999898672103882
. O 0 9.374205546919256e-05

Direct O 0 5.081421932118246e-07
sequencing O 0 2.1577261577476747e-06
of O 0 2.2281342637597845e-07
amplified O 0 7.459896733053029e-05
C9 O 0 0.0002918780082836747
cDNA O 0 1.2892026006738888e-06
and O 0 8.117592642520322e-07
DNA O 0 5.194812274567084e-06
revealed O 0 8.778450137469918e-06
a O 0 2.1552334601437906e-06
nonsense O 0 2.0187328118481673e-05
substitution O 0 2.1970543002680643e-06
( O 0 1.4140605344437063e-06
CGA O 0 0.00014717037265654653
- O 0 0.0001061976290657185
- O 0 4.188081220490858e-05
> O 0 1.0999158803315368e-05
TGA O 0 2.7159776436747052e-05
) O 0 8.645882587643428e-08
at O 0 5.438985795080953e-07
codon O 0 6.660724807261431e-07
95 O 0 3.227768274882692e-07
in O 0 9.665343725373532e-08
exon O 0 3.843868398689665e-06
4 O 0 5.892797503292968e-07
in O 0 6.616471637244103e-08
the O 0 2.7304827199259307e-07
four O 0 3.4401787161186803e-06
C9 B-Disease 0 0.06658685207366943
- I-Disease 0 0.03673073276877403
deficient I-Disease 0 0.004502597730606794
individuals O 0 1.7697660723570152e-06
. O 0 8.360577339772135e-06

An O 0 1.0341210554543068e-06
allele O 0 1.6107565897982568e-05
- O 0 1.7254149497603066e-05
specific O 0 4.935901642966201e-07
polymerase O 0 4.968832217855379e-05
chain O 0 9.486937779001892e-05
reaction O 0 7.166264367697295e-06
system O 0 4.545198862615507e-06
designed O 0 1.0115965096701984e-06
to O 0 3.412571913941065e-08
detect O 0 4.248191544320434e-06
exclusively O 0 5.716061934890604e-08
only O 0 1.66791362943286e-08
one O 0 1.8501779663893103e-08
of O 0 6.051738665746598e-09
the O 0 9.558334568282589e-08
normal O 0 1.9752296793740243e-06
and O 0 3.2380009429289203e-07
mutant O 0 3.848794676741818e-06
alleles O 0 1.4251810398491216e-06
indicated O 0 2.151891976609477e-06
that O 0 9.260629596496983e-09
all O 0 7.523914824503208e-09
the O 0 8.77287789080583e-08
four O 0 4.0598374084765965e-07
patients O 0 1.8977511899720412e-06
were O 0 3.42111619033858e-08
homozygous O 0 4.5907430035185826e-07
for O 0 1.6793352486388358e-08
the O 0 1.8516841748805746e-07
mutation O 0 3.0120438623271184e-06
in O 0 1.3610198834612675e-07
exon O 0 7.534403721365379e-06
4 O 0 5.868033099432068e-07
and O 0 7.502594456809675e-08
that O 0 1.2758906819954063e-08
the O 0 7.409036584249407e-08
parents O 0 7.685701319815053e-08
of O 0 8.800362394367767e-08
patient O 0 2.678125565580558e-05
2 O 0 1.1940882131966646e-06
were O 0 2.9676220947294496e-07
heterozygous O 0 2.7669166229316033e-06
. O 0 2.8062011097063078e-06

The O 0 3.2778216336737387e-06
common O 0 1.5749545127619058e-05
mutation O 0 4.174348941887729e-05
at O 0 9.826373570831493e-06
codon O 0 5.029016392654739e-06
95 O 0 1.0775978580568335e-06
in O 0 3.055980926092161e-07
exon O 0 1.4823134733887855e-05
4 O 0 1.9839799278997816e-06
might O 0 6.425968877010746e-07
be O 0 5.3087937601503654e-08
responsible O 0 5.065754180577642e-07
for O 0 6.177271671958806e-08
most O 0 1.9385427094675833e-06
Japanese O 0 0.0009196093888022006
C9 B-Disease 1 0.9982715845108032
deficiency I-Disease 1 0.9998307228088379
. O 0 6.514714641525643e-06
. O 0 8.674640412209556e-06

BRCA1 O 0 0.0003745691501535475
required O 0 9.736688753037015e-07
for O 0 2.3886002509243554e-07
transcription O 0 0.0002000498934648931
- O 0 0.0014808702981099486
coupled O 0 0.00031675503123551607
repair O 1 0.5844364166259766
of O 0 5.897840765101137e-06
oxidative O 0 0.056080933660268784
DNA O 0 0.003026713849976659
damage O 1 0.8442520499229431
. O 0 3.064456905121915e-05

The O 0 0.0004803331394214183
breast B-Disease 1 0.9996308088302612
and I-Disease 1 0.9978837370872498
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999945163726807
susceptibility O 0 0.002731590298935771
gene O 0 6.333728379104286e-05
BRCA1 O 0 0.0001569857995491475
encodes O 0 4.334111963544274e-06
a O 0 9.767493793333415e-06
zinc O 0 0.001696207677014172
finger O 0 0.00027122159372083843
protein O 0 1.3069096667095437e-06
of O 0 1.1908979047348112e-07
unknown O 0 1.2137267731304746e-05
function O 0 1.860578777268529e-05
. O 0 6.855003448436037e-06

Association O 0 1.1406808880565222e-05
of O 0 5.371413180910167e-08
the O 0 3.427138324241241e-07
BRCA1 O 0 2.330123788851779e-05
protein O 0 4.1336025446980784e-07
with O 0 4.296372324574804e-08
the O 0 1.4178968399392033e-07
DNA O 0 6.570257028215565e-06
repair O 0 0.0005015833303332329
protein O 0 3.4111517379642464e-06
Rad51 O 0 0.00020286756625864655
and O 0 2.2041633940261818e-07
changes O 0 3.016620837570372e-07
in O 0 2.9311067351045494e-08
the O 0 1.2948908612031573e-08
phosphorylation O 0 5.699677529946712e-08
and O 0 1.2170215768492199e-07
cellular O 0 2.1238127374090254e-05
localization O 0 5.272182079352206e-06
of O 0 4.5710752516470166e-08
the O 0 1.0339459777242155e-07
protein O 0 1.3781616416963516e-06
after O 0 3.816898697550641e-06
exposure O 0 1.2102107575628906e-05
to O 0 1.2428218099103105e-07
DNA O 0 2.1074543838039972e-05
- O 0 9.614769805921242e-05
damaging O 0 9.390390187036246e-05
agents O 0 7.087884341672179e-07
are O 0 1.618430012229055e-08
consistent O 0 1.6161848748197372e-07
with O 0 3.765783773701514e-08
a O 0 3.8509281807819207e-07
role O 0 1.2913953923998633e-06
for O 0 1.7734599566665565e-07
BRCA1 O 0 9.100680472329259e-05
in O 0 2.129713948306744e-06
DNA O 0 8.081798296188936e-05
repair O 0 0.4083216190338135
. O 0 2.4242444851552136e-05

Here O 0 1.1138687113998458e-05
, O 0 3.857959995912097e-07
it O 0 6.593706558533086e-08
is O 0 5.70847937808594e-08
shown O 0 8.243603843993697e-08
that O 0 4.775538897661136e-08
mouse O 0 5.81906242587138e-05
embryonic O 0 0.00018100201850757003
stem O 0 0.00012649159180000424
cells O 0 0.00011973835353273898
deficient B-Disease 0 0.000957961252424866
in I-Disease 0 1.0484104677743744e-06
BRCA1 I-Disease 0 5.349699131329544e-05
are O 0 8.406819773654206e-08
defective O 0 0.0001541210076538846
in O 0 2.373286918100348e-07
the O 0 6.037122091129277e-08
ability O 0 2.3746522970213846e-07
to O 0 1.934599502817491e-08
carry O 0 1.344600519814776e-07
out O 0 2.2174165792421263e-07
transcription O 0 3.200228456989862e-05
- O 0 0.00027342853718437254
coupled O 0 0.00010219406976830214
repair O 0 0.017652515321969986
of O 0 1.9290910131530836e-06
oxidative O 0 0.006082507316023111
DNA O 0 0.0009102619951590896
damage O 1 0.7656576037406921
, O 0 1.7700192529446213e-06
and O 0 2.796074056732323e-07
are O 0 1.5198007474737096e-07
hypersensitive O 0 0.0012811401393264532
to O 0 3.906615802407032e-06
ionizing O 0 0.01824231818318367
radiation O 0 0.08680811524391174
and O 0 1.8913209487436689e-06
hydrogen O 0 4.159875970799476e-05
peroxide O 0 0.002838629065081477
. O 0 1.7012253010761924e-05

These O 0 1.343551161880896e-06
results O 0 5.2967911869927775e-06
suggest O 0 2.0800659967790125e-06
that O 0 1.9311826804369048e-07
BRCA1 O 0 6.15488679613918e-05
participates O 0 6.708737146254862e-06
, O 0 4.28729833856778e-07
directly O 0 2.945887445093831e-07
or O 0 8.504551942678518e-07
indirectly O 0 5.144417627889197e-06
, O 0 4.4252905695429945e-07
in O 0 2.981527416068275e-07
transcription O 0 5.4779295169282705e-05
- O 0 0.0005322298384271562
coupled O 0 0.00011636566341621801
repair O 0 0.05872366204857826
of O 0 2.1769565137219615e-06
oxidative O 0 0.0063088382594287395
DNA O 0 0.0006984592764638364
damage O 0 0.20138518512248993
. O 0 1.8695163817028515e-06
. O 0 5.969149242446292e-06

Truncation O 0 0.0019321927102282643
mutations O 0 0.0007461562636308372
in O 0 2.05024457500258e-06
the O 0 1.4182904806148144e-06
transactivation O 0 0.0006318679079413414
region O 0 3.9673715946264565e-05
of O 0 9.296361440647161e-07
PAX6 O 0 0.0022701965644955635
result O 0 1.9193164916941896e-05
in O 0 2.4725777620915323e-06
dominant O 0 0.0013581111561506987
- O 0 0.00077299919212237
negative O 0 2.5038954845513217e-05
mutants O 0 0.00020349914848338813
. O 0 9.319136552221607e-06

PAX6 O 0 0.004759873729199171
is O 0 1.032601403494482e-06
a O 0 2.673521635188081e-07
transcription O 0 3.1248987397702876e-06
factor O 0 3.244087167786347e-07
with O 0 3.65864245566172e-08
two O 0 8.621313440926315e-08
DNA O 0 3.5100947570754215e-06
- O 0 1.0411307812319137e-05
binding O 0 4.169653493590886e-06
domains O 0 4.030197942483937e-06
( O 0 2.5607664611015934e-07
paired O 0 4.598981377057498e-06
box O 0 1.2840264389524236e-05
and O 0 6.819797704338271e-07
homeobox O 0 1.5485424228245392e-05
) O 0 6.419536902058098e-08
and O 0 9.382670640434299e-08
a O 0 1.6238631133091985e-06
proline O 0 6.759469397366047e-05
- O 0 4.814086787519045e-05
serine O 0 2.462739030306693e-05
- O 0 5.335209425538778e-05
threonine O 0 7.680294947931543e-05
( O 0 1.2398095350363292e-06
PST O 0 0.0001909217971842736
) O 0 6.110331582931394e-07
- O 0 2.039184619206935e-05
rich O 0 6.319170552160358e-06
transactivation O 0 0.0002910155162680894
domain O 0 4.0018938307184726e-05
. O 0 1.306068770645652e-05

PAX6 O 0 0.0874638706445694
regulates O 0 0.007715912070125341
eye O 0 0.0566040463745594
development O 0 2.143382062058663e-06
in O 0 1.3624500070363865e-06
animals O 0 2.0946251879649935e-06
ranging O 0 1.0352210665587336e-05
from O 0 1.8000618240421318e-07
jellyfish O 0 8.569733154217829e-07
to O 0 1.0926392235433013e-08
Drosophila O 0 8.198303902418047e-08
to O 0 4.2248526455068713e-08
humans O 0 4.27838403993519e-06
. O 0 5.181533197173849e-06

Heterozygous O 0 5.4587868362432346e-05
mutations O 0 9.973515261663124e-05
in O 0 4.9027943305191e-07
the O 0 2.6628242721926654e-07
human O 0 3.872778506774921e-06
PAX6 O 0 0.0007759904256090522
gene O 0 1.2923100257467013e-05
result O 0 1.6246066252278979e-06
in O 0 1.5676437215006445e-07
various O 0 3.324142596738966e-07
phenotypes O 0 0.0001243283477379009
, O 0 2.8099341307097347e-06
including O 0 1.1386529877199791e-05
aniridia B-Disease 1 0.9999635219573975
, O 0 0.0009497020510025322
Peters B-Disease 1 0.9996591806411743
anomaly I-Disease 1 0.9998195767402649
, O 0 5.9721627621911466e-05
autosomal B-Disease 1 0.9842206239700317
dominant I-Disease 1 0.9752026200294495
keratitis I-Disease 1 0.9979473948478699
, O 0 0.00013873928401153535
and O 0 9.370433690492064e-05
familial B-Disease 1 0.9985063672065735
foveal I-Disease 1 0.99866783618927
dysplasia I-Disease 1 0.9999141693115234
. O 0 0.0005060015246272087

It O 0 1.9959397832280956e-06
is O 0 4.375953892576945e-07
believed O 0 3.340579155519663e-07
that O 0 1.4908394518897694e-08
the O 0 7.933604706522601e-08
mutated O 0 1.0284068594046403e-05
allele O 0 6.778313945687842e-06
of O 0 5.431153908830311e-07
PAX6 O 0 0.0007403454510495067
produces O 0 8.756052011449356e-06
an O 0 3.516899482747249e-07
inactive O 0 1.2798917850886937e-05
protein O 0 1.4413619737752015e-06
and O 0 4.048627488373313e-06
aniridia B-Disease 1 0.9998346567153931
is O 0 1.539765980851371e-05
caused O 0 8.638531289761886e-05
due O 0 9.786403097677976e-06
to O 0 6.696565151287359e-07
genetic O 0 0.0002057839883491397
haploinsufficiency O 0 0.006348876282572746
. O 0 2.2117059415904805e-05

However O 0 1.952288585016504e-06
, O 0 2.0598366745616659e-07
several O 0 1.3156969203009794e-07
truncation O 0 4.970424561179243e-05
mutations O 0 4.339536462794058e-05
have O 0 1.41467808134621e-07
been O 0 2.0141192180744838e-07
found O 0 4.6357850891354246e-08
to O 0 7.312498606637519e-09
occur O 0 1.8574057492060092e-07
in O 0 4.111914009286011e-08
the O 0 2.47428488364676e-07
C O 0 4.491235813475214e-05
- O 0 1.8693628589971922e-05
terminal O 0 4.499565329751931e-05
half O 0 7.558206789326505e-07
of O 0 1.4744975374014757e-07
PAX6 O 0 0.0005349168786779046
in O 0 3.484659373498289e-06
patients O 0 2.0857567506027408e-05
with O 0 2.200856442868826e-06
Aniridia B-Disease 1 0.9991003274917603
resulting O 0 1.0169736015086528e-05
in O 0 5.022274081056821e-07
mutant O 0 3.342055833854829e-06
proteins O 0 3.035847839782946e-07
that O 0 1.9633867864854437e-08
retain O 0 3.521383007409895e-07
the O 0 1.5728041091733758e-07
DNA O 0 2.7968605991191e-06
- O 0 3.7770419112348463e-06
binding O 0 7.337664555961965e-07
domains O 0 1.713120809654356e-06
but O 0 2.0142441314874304e-07
have O 0 8.24983246161537e-08
lost O 0 5.249874902801821e-06
most O 0 7.676558766434027e-08
of O 0 2.884343430764602e-08
the O 0 5.789030410596752e-07
transactivation O 0 0.00021895069221500307
domain O 0 3.23405911331065e-05
. O 0 1.3928777661931235e-05

It O 0 2.0366071566968458e-06
is O 0 2.3419045191985788e-07
not O 0 3.041654750290945e-08
clear O 0 1.7157992715510773e-07
whether O 0 5.458113605527615e-08
such O 0 7.248790012681638e-08
mutants O 0 9.329221029474866e-06
really O 0 2.075120619338122e-06
behave O 0 5.769195922766812e-06
as O 0 2.6929333216685336e-06
loss O 0 6.807708268752322e-05
- O 0 8.357188562513329e-06
of O 0 2.3718908437331265e-07
- O 0 8.473080015392043e-06
function O 0 1.5727815707577975e-06
mutants O 0 1.158170107373735e-05
as O 0 1.2207766530991648e-06
predicted O 0 7.123458999558352e-06
by O 0 4.625292717719276e-07
haploinsufficiency O 0 0.0003132348647341132
. O 0 1.0249652405036613e-05

Contrary O 0 3.9742189983371645e-06
to O 0 8.702647136260566e-08
this O 0 2.291302436674414e-08
theory O 0 2.068863267368215e-07
, O 0 7.015724889924968e-08
our O 0 3.039642137991905e-08
data O 0 4.2148965917476744e-07
showed O 0 3.406901782909699e-07
that O 0 2.6183757384501405e-09
these O 0 2.166217871746312e-09
mutants O 0 1.3212070371082518e-06
are O 0 2.6680192277694914e-08
dominant O 0 4.650574192055501e-05
- O 0 7.123312389012426e-05
negative O 0 1.656704512242868e-06
in O 0 2.975088762013911e-07
transient O 0 7.621958047820954e-06
transfection O 0 5.6122848036466166e-05
assays O 0 5.75973535887897e-06
when O 0 7.319464430111111e-07
they O 0 2.440921598179102e-08
are O 0 2.1518717474577898e-08
coexpressed O 0 2.0316496375016868e-05
with O 0 9.60312945608166e-07
wild O 0 5.8629942941479385e-05
- O 0 0.002290967386215925
type O 0 0.0012860291171818972
PAX6 O 0 0.0197792686522007
. O 0 4.163853373029269e-05

We O 0 6.107871286076261e-06
found O 0 9.283540975957294e-07
that O 0 3.419420124828321e-08
the O 0 2.8162094167782925e-07
dominant O 0 0.0004975043702870607
- O 0 0.0005886848084628582
negative O 0 6.679855232505361e-06
effects O 0 1.2358865205897018e-05
result O 0 4.658738248508598e-07
from O 0 2.1347023704265666e-08
the O 0 1.847740982441337e-08
enhanced O 0 1.7347498442177312e-06
DNA O 0 2.439133595544263e-06
binding O 0 9.613786460249685e-07
ability O 0 6.725788921357889e-07
of O 0 8.365615400407478e-08
these O 0 2.0121763100178214e-07
mutants O 0 8.256917499238625e-05
. O 0 8.44215537654236e-06

Kinetic O 0 4.390076355775818e-05
studies O 0 1.3966082406113856e-06
of O 0 7.429541426517972e-08
binding O 0 1.0071636097563896e-05
and O 0 1.3934763956058305e-06
dissociation O 0 3.867943451041356e-05
revealed O 0 3.1438983114639996e-06
that O 0 6.0887650477070565e-09
various O 0 2.1682776463194386e-08
truncation O 0 8.413013347308151e-06
mutants O 0 7.998488399607595e-06
have O 0 2.8154764208920824e-07
3 O 0 1.361379872832913e-06
- O 0 1.0172083420911804e-05
5 O 0 2.2490055471280357e-06
- O 0 4.0552467908128165e-06
fold O 0 9.741676194607862e-07
higher O 0 1.4079645893616544e-07
affinity O 0 8.920706306980719e-08
to O 0 8.148880681346782e-09
various O 0 4.7916518752799675e-08
DNA O 0 1.9548579075490125e-06
- O 0 2.2136439383757534e-06
binding O 0 5.462767944663938e-07
sites O 0 5.548915851250058e-07
when O 0 4.494854408676474e-07
compared O 0 4.038683414364641e-07
with O 0 6.79457130559058e-08
the O 0 4.474287038647162e-07
wild O 0 2.311993193870876e-05
- O 0 0.0005224311607889831
type O 0 0.0005812811432406306
PAX6 O 0 0.013058408163487911
. O 0 3.5934597690356895e-05

These O 0 2.7745107900045696e-07
results O 0 4.155340889155923e-07
provide O 0 2.1686126672193495e-08
a O 0 1.9337073808856076e-07
new O 0 2.1618154733005213e-07
insight O 0 5.176980835130962e-07
into O 0 8.134581719332346e-08
the O 0 1.1111806230701404e-07
role O 0 1.1194872513442533e-06
of O 0 2.9375942744991335e-07
mutant O 0 0.00014613766688853502
PAX6 O 0 0.007825609296560287
in O 0 5.076235538581386e-05
causing O 0 0.03464193642139435
aniridia B-Disease 1 0.9996042847633362
. O 0 8.517501555616036e-06
. O 0 8.571199032303412e-06

Reversal O 0 0.012657969258725643
of O 0 0.0007893832516856492
severe O 1 0.999945878982544
hypertrophic B-Disease 1 0.9999908208847046
cardiomyopathy I-Disease 1 0.9999994039535522
and O 0 8.754331065574661e-05
excellent O 0 0.00014323240611702204
neuropsychologic O 0 0.0008943317807279527
outcome O 0 1.0029042641690467e-05
in O 0 1.056424707712722e-06
very B-Disease 0 3.1033321192808216e-06
- I-Disease 0 0.00024407358432654291
long I-Disease 0 4.116883792448789e-05
- I-Disease 0 9.252165182260796e-05
chain I-Disease 0 6.979997124290094e-05
acyl I-Disease 0 3.483655018499121e-05
- I-Disease 0 6.627271795878187e-05
coenzyme I-Disease 0 2.5858107619569637e-05
A I-Disease 0 0.0001385651557939127
dehydrogenase I-Disease 0 0.25233978033065796
deficiency I-Disease 1 0.9990949630737305
. O 0 4.34425710409414e-05

Very B-Disease 0 0.00011348602856742218
- I-Disease 0 0.0008579263812862337
long I-Disease 0 0.00014050088066142052
- I-Disease 0 0.0001341696479357779
chain I-Disease 0 0.00012961601896677166
acyl I-Disease 0 1.597522532392759e-05
- I-Disease 0 1.3792918252875097e-05
coenzyme I-Disease 0 2.532417965994682e-06
A I-Disease 0 4.99751922689029e-06
dehydrogenase I-Disease 0 0.00011201887537026778
( I-Disease 0 5.532353043236071e-06
VLCAD I-Disease 0 0.017552684992551804
) I-Disease 0 3.5733792174141854e-05
deficiency I-Disease 1 0.9982485771179199
is O 0 3.903792730852729e-06
a O 0 5.36159350303933e-05
disorder O 1 0.9987026453018188
of O 0 9.731509180710418e-07
fatty O 0 0.00014957130770199
acid O 0 4.2679894249886274e-05
beta O 0 3.731393917405512e-06
oxidation O 0 3.835171810351312e-06
that O 0 1.277737027294279e-07
reportedly O 0 1.965246701729484e-05
has O 0 1.9866381535393884e-06
high O 0 3.0610364774474874e-05
rates O 0 1.0017972272180486e-05
of O 0 1.3147101753929746e-06
morbidity O 0 0.03583206608891487
and O 0 2.004110319830943e-05
mortality O 0 0.0019122123485431075
. O 0 1.530992449261248e-05

We O 0 2.9265484045026824e-06
describe O 0 1.905131512103253e-06
the O 0 2.4481212790306017e-07
outcome O 0 6.336076125990076e-07
of O 0 3.432875317344042e-08
a O 0 1.3611889926323784e-06
5 O 0 2.738347575359512e-06
- O 0 2.682550075405743e-05
year O 0 2.850079226845992e-06
- O 0 4.6916531573515385e-05
old O 0 0.00017448158178012818
girl O 0 0.0003877059498336166
with O 0 0.0001399529428454116
VLCAD B-Disease 1 0.999950647354126
deficiency I-Disease 1 0.9999966621398926
who O 0 1.799954588932451e-05
was O 0 4.712715053756256e-06
first O 0 3.1542842293674767e-07
seen O 0 2.414791879346012e-06
at O 0 3.456921604083618e-06
5 O 0 4.835694085159048e-07
months O 0 5.617650913336547e-07
of O 0 5.151488835508644e-08
age O 0 1.958675784408115e-05
with O 0 0.00044752800022251904
severe O 1 0.9999217987060547
hypertrophic B-Disease 1 0.999993085861206
cardiomyopathy I-Disease 1 0.9999998807907104
, O 1 0.9987058639526367
hepatomegaly B-Disease 1 0.9999997615814209
, O 1 0.9981811046600342
encephalopathy B-Disease 1 0.9999918937683105
, O 0 7.034181908238679e-05
and O 0 4.960183287039399e-05
hypotonia B-Disease 1 0.9890245795249939
. O 0 5.084582880954258e-05

Biochemical O 0 0.017131518572568893
studies O 0 0.0009569378453306854
indicated O 1 0.8843972682952881
VLCAD B-Disease 1 0.999992847442627
deficiency I-Disease 1 0.9999996423721313
caused O 0 0.009866262786090374
by O 0 4.1790264049268444e-07
a O 0 2.5665267457952723e-06
stable O 0 7.438997272402048e-05
yet O 0 1.1220096894248854e-05
inactive O 0 5.102029535919428e-05
enzyme O 0 2.290283373440616e-05
. O 0 6.840858532086713e-06

Molecular O 0 0.0004874375881627202
genetic O 0 9.991879051085562e-05
analysis O 0 1.9371418602531776e-06
of O 0 2.7433509330876404e-07
her O 0 2.7334235710441135e-05
VLCAD O 0 0.004852754529565573
gene O 0 4.7369383537443355e-05
revealed O 0 3.579938493203372e-05
a O 0 4.995632025384111e-06
T1372C O 0 8.365080429939553e-05
( O 0 8.845848356031638e-07
F458L O 0 3.3653104765107855e-05
) O 0 6.285065978772764e-07
missense O 0 9.166988456854597e-05
mutation O 0 5.98508158873301e-05
and O 0 2.175649115088163e-06
a O 0 5.1662951591424644e-05
1668 O 0 0.03203507885336876
ACAG O 0 0.00919350702315569
1669 O 0 0.002423765603452921
splice O 0 0.0011501028202474117
site O 0 0.0003845730097964406
mutation O 0 0.0006369429174810648
. O 0 1.4807621482759714e-05

After O 0 2.7481777578941546e-05
initial O 0 5.564439106819918e-06
treatment O 0 2.3490661988034844e-05
with O 0 5.302560452946636e-07
intravenous O 0 0.0001340171293122694
glucose O 0 0.00063920090906322
and O 0 4.546872332866769e-06
carnitine O 0 0.0010972765740007162
, O 0 1.6001717995095532e-06
the O 0 6.250802471186034e-07
patient O 0 5.413432518253103e-05
has O 0 1.0622123909342918e-06
thrived O 0 9.367269740323536e-06
on O 0 1.124411255659652e-06
a O 0 3.318844619570882e-06
low O 0 0.00011052260379074141
- O 0 7.925373938633129e-05
fat O 0 2.0948025849065743e-05
diet O 0 2.2971194084675517e-06
supplemented O 0 1.0831775654196463e-07
with O 0 6.56111396324377e-08
medium O 0 4.33252489528968e-06
- O 0 3.148296309518628e-05
chain O 0 3.899379225913435e-05
triglyceride O 0 3.309837120468728e-05
oil O 0 1.4474433555733413e-05
and O 0 9.789648629521253e-07
carnitine O 0 0.00020959631365258247
and O 0 1.2937350675201742e-06
avoidance O 0 0.0003686788841150701
of O 0 2.042247615463566e-06
fasting O 0 0.00011840856313938275
. O 0 8.638217877887655e-06

Her O 0 0.0018483485328033566
ventricular O 1 0.9929124712944031
hypertrophy O 0 0.47000429034233093
resolved O 0 3.7712292396463454e-05
significantly O 0 3.546352672856301e-06
over O 0 2.7288689352644724e-07
1 O 0 1.0278912441208377e-06
year O 0 6.474799647548934e-07
, O 0 1.9923670890875655e-07
and O 0 5.26346866536187e-07
cognitively O 0 0.000522474991157651
, O 0 1.2150504744568025e-06
she O 0 3.916799869330134e-06
is O 0 1.1824598544762921e-07
in O 0 8.175489796258262e-08
the O 0 1.8001786372678907e-07
superior O 0 3.063212352572009e-05
range O 0 5.1123583943990525e-06
for O 0 3.068187481858331e-07
age O 0 2.6859037461690605e-05
. O 0 5.213528311287519e-06

Clinical O 0 0.0005592898814938962
recognition O 0 0.00011158517736475915
of O 0 0.000981072778813541
VLCAD B-Disease 1 0.9999982118606567
deficiency I-Disease 1 0.9999997615814209
is O 0 4.309094947529957e-06
important O 0 3.776278845180059e-07
because O 0 2.5084148091991665e-07
it O 0 7.082128661295428e-08
is O 0 3.3138551458478105e-08
one O 0 3.0008163065531335e-08
of O 0 1.2407417315785096e-08
the O 0 2.3236819401972753e-07
few O 0 3.868360181513708e-06
directly O 0 0.0002104441518895328
treatable O 1 0.9999693632125854
causes O 0 0.3796471357345581
of O 0 5.4499603720614687e-05
cardiomyopathy B-Disease 1 0.9999988079071045
in O 0 2.8385424229782075e-05
children O 0 3.699684384628199e-06
. O 0 1.2589612197189126e-06
. O 0 4.146815626882017e-06

Cloning O 0 3.237076452933252e-05
of O 0 3.1257462751455023e-07
a O 0 8.902601393856457e-07
novel O 0 1.4527553275911487e-06
member O 0 3.633963956417574e-07
of O 0 2.247023012103e-08
the O 0 4.6598134417763504e-07
low O 0 6.772451160941273e-05
- O 0 2.3836833861423656e-05
density O 0 9.010711892187828e-07
lipoprotein O 0 0.0011300035985186696
receptor O 0 3.314097921247594e-05
family O 0 2.6145873562199995e-05
. O 0 5.993815193505725e-06

A O 0 2.7126259283249965e-06
gene O 0 9.328919645668066e-07
encoding O 0 3.801042964823864e-07
a O 0 1.045771227836667e-06
novel O 0 1.5797987771293265e-06
transmembrane O 0 1.181419338536216e-05
protein O 0 1.3433435697152163e-06
was O 0 1.5087921383383218e-06
identified O 0 1.1219310636079172e-07
by O 0 4.530589237106142e-09
DNA O 0 1.6686557557932247e-07
sequence O 0 9.521087918074045e-08
analysis O 0 7.432064563772656e-08
within O 0 1.1280894796072971e-07
the O 0 1.9924195839848835e-06
insulin B-Disease 0 0.021020429208874702
- I-Disease 1 0.6933151483535767
dependent I-Disease 0 0.036770984530448914
diabetes I-Disease 1 0.999996542930603
mellitus I-Disease 1 0.99998939037323
( O 0 3.277614086982794e-05
IDDM B-Disease 0 0.0032963051926344633
) O 0 1.3154526641301345e-06
locus O 0 4.8338355554733425e-05
IDDM4 O 0 0.0009110780665650964
on O 0 2.0344237782410346e-05
chromosome O 0 0.0007640680414624512
11q13 O 0 0.0010949695715680718
. O 0 1.75509321707068e-05

Based O 0 1.6560978792767855e-06
on O 0 6.894096600262856e-07
its O 0 4.622091296369035e-07
chromosomal O 0 0.0005932477652095258
position O 0 1.7206810298375785e-05
, O 0 3.7232109661999857e-07
this O 0 1.9849965227081157e-08
gene O 0 7.082965112203965e-07
is O 0 1.2740780164222087e-07
a O 0 2.547294570831582e-07
candidate O 0 7.292485975085583e-07
for O 0 7.757276421216375e-08
conferring O 0 7.358460425166413e-05
susceptibility O 0 0.0008349649142473936
to O 0 3.345349614392035e-05
diabetes B-Disease 1 0.9999089241027832
. O 0 4.398079545353539e-05

The O 0 1.369962774333544e-06
gene O 0 1.0852951163542457e-05
, O 0 2.1224389001872623e-06
termed O 0 5.497680831467733e-05
low O 0 5.9879705077037215e-05
- O 0 1.5019361853774171e-05
density O 0 4.997753535462834e-07
lipoprotein O 0 0.00014856284542474896
receptor O 0 3.068411615458899e-06
related O 0 9.655740313974093e-07
protein O 0 1.4030937336428906e-06
5 O 0 7.892037388046447e-07
( O 0 1.387715400369416e-07
LRP5 O 0 2.692437919904478e-05
) O 0 1.6997173446497982e-08
, O 0 8.583456612143436e-09
encodes O 0 7.841471472147532e-09
a O 0 5.780970724345025e-08
protein O 0 1.1397402488455555e-07
of O 0 4.114981777547655e-08
1615 O 0 1.6191750546568073e-05
amino O 0 1.8132683976546105e-07
acids O 0 2.0457628124859184e-07
that O 0 2.280879929372759e-09
contains O 0 1.1545236766608014e-08
conserved O 0 2.1153572049570357e-07
modules O 0 2.997384456193686e-07
which O 0 2.359279349661847e-08
are O 0 5.694893001617629e-09
characteristic O 0 6.048994691809639e-07
of O 0 5.861019758413022e-08
the O 0 1.4466969560089638e-06
low O 0 0.00026512713520787656
- O 0 0.00010435692092869431
density O 0 3.3942258141905768e-06
lipoprotein O 0 0.0033115351106971502
( O 0 3.208670705134864e-06
LDL O 0 0.0006868122727610171
) O 0 3.45255244837972e-07
receptor O 0 5.564667389990063e-06
family O 0 8.26003906695405e-06
. O 0 5.321762728272006e-06

These O 0 2.0960889912657876e-07
modules O 0 9.929617590387352e-07
include O 0 3.0306753728837066e-07
a O 0 5.331870056579646e-07
putative O 0 5.30723173142178e-06
signal O 0 3.4797944863385055e-06
peptide O 0 6.406124839486438e-07
for O 0 4.4166070800599755e-09
protein O 0 2.978082846993857e-08
export O 0 1.2653802627937694e-07
, O 0 1.4679871185308002e-07
four O 0 1.6013305526030308e-07
epidermal O 0 3.2114636269398034e-05
growth O 0 3.2074560749606462e-06
factor O 0 2.872561708500143e-06
( O 0 3.8882367903170234e-07
EGF O 0 4.996405550627969e-05
) O 0 9.314893389955614e-08
repeats O 0 4.687774890044238e-06
with O 0 1.392584891846127e-07
associated O 0 2.372072458456387e-06
spacer O 0 4.295047256164253e-05
domains O 0 1.2203401638544165e-05
, O 0 7.60991383685905e-07
three O 0 1.067214157046692e-06
LDL O 0 0.0027033286169171333
- O 0 7.401494804071262e-05
receptor O 0 1.261572560906643e-05
( O 0 5.786844781141554e-07
LDLR O 0 4.8392783355666324e-05
) O 0 7.64095986482971e-08
repeats O 0 2.0760703591804486e-06
, O 0 9.205213302720949e-08
a O 0 1.8978457205776067e-07
single O 0 1.6200256141019054e-06
transmembrane O 0 1.6850432075443678e-05
spanning O 0 2.477260750310961e-05
domain O 0 2.428857442282606e-06
, O 0 4.82080793062778e-07
and O 0 9.553504298764892e-08
a O 0 4.0430109038425144e-07
cytoplasmic O 0 8.423346116614994e-06
domain O 0 1.2036157386319246e-05
. O 0 4.65535458715749e-06

The O 0 1.825083018047735e-07
encoded O 0 1.5440345180195436e-07
protein O 0 9.341962368125678e-07
has O 0 2.4899674144762685e-07
a O 0 1.211787719057611e-07
unique O 0 4.25437661988326e-07
organization O 0 2.4642231437610462e-06
of O 0 2.5514762569400773e-07
EGF O 0 0.0004427628009580076
and O 0 8.863624316290952e-06
LDLR O 0 0.0034719689283519983
repeats O 0 0.00018544663907960057
; O 0 8.847661661093298e-07
therefore O 0 9.151597737400152e-07
, O 0 7.837913926778128e-07
LRP5 O 0 0.0002466581354383379
likely O 0 1.1159526138726505e-06
represents O 0 1.5693071020450589e-07
a O 0 2.935440761575592e-07
new O 0 5.093089043839427e-07
category O 0 1.5025459561002208e-06
of O 0 5.389084378748521e-08
the O 0 1.0264052434649784e-06
LDLR O 0 0.004608544055372477
family O 0 4.098511271877214e-05
. O 0 1.5818710380699486e-05

Both O 0 5.206517471378902e-06
human O 0 1.9562436136766337e-05
and O 0 6.297609161265427e-06
mouse O 0 0.0006792768253944814
LRP5 O 0 0.0025326646864414215
cDNAs O 0 0.00013169895100872964
have O 0 4.960890009897412e-07
been O 0 5.08094672113657e-07
isolated O 0 3.763698259717785e-06
and O 0 4.44787140452263e-08
the O 0 1.4719875984781083e-08
encoded O 0 3.705534723508208e-08
mature O 0 4.645774254186108e-07
proteins O 0 4.0571389803290003e-08
are O 0 6.599466306766999e-09
95 O 0 1.0378145987033349e-07
% O 0 7.164473014853456e-09
identical O 0 1.8804183810061659e-06
, O 0 2.760088193554111e-07
indicating O 0 1.303018052567495e-06
a O 0 1.2020370832033223e-06
high O 0 1.5589084796374664e-05
degree O 0 3.142860805382952e-06
of O 0 1.3141720955900382e-07
evolutionary O 0 9.476259947405197e-06
conservation O 0 6.2177141444408335e-06
. O 0 7.557558205917303e-07
. O 0 3.6444662327994592e-06

The O 0 5.407986463978887e-06
APC B-Disease 0 0.00013401061005424708
variants O 0 2.3668892026762478e-05
I1307K O 0 9.042848978424445e-05
and O 0 1.6994521274682484e-06
E1317Q O 0 6.614940502913669e-05
are O 0 1.3389934565566364e-06
associated O 0 0.0008061897242441773
with O 1 0.9995392560958862
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 7.481382635887712e-05
but O 0 7.258197456394555e-07
not O 0 6.23859364168311e-08
always O 0 1.7273509911319707e-07
with O 0 8.380244054251307e-08
a O 0 1.622041509108385e-06
family O 0 3.8389594010368455e-06
history O 0 6.844754352641758e-06
. O 0 4.898713996226434e-06

Classical O 0 0.33157089352607727
familial B-Disease 1 0.9999595880508423
adenomatous I-Disease 1 0.9998422861099243
polyposis I-Disease 1 0.9999785423278809
( O 0 0.0001796192373149097
FAP B-Disease 0 0.0008505453588441014
) O 0 5.078931621937954e-07
is O 0 6.314926395134535e-07
a O 0 1.0283304618496913e-05
high O 0 0.008799921721220016
- O 1 0.9837294220924377
penetrance O 1 0.9360135793685913
autosomal B-Disease 1 0.9988744854927063
dominant I-Disease 1 0.9995372295379639
disease I-Disease 1 0.9999315738677979
that O 0 1.2164939562353538e-06
predisposes O 0 4.156541035627015e-05
to O 0 1.3382539520989667e-07
hundreds O 0 9.207213338413567e-07
or O 0 3.5636771826830227e-06
thousands O 0 1.7497817680123262e-05
of O 0 0.0024122002068907022
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.999998927116394
and I-Disease 1 0.9996721744537354
carcinoma I-Disease 1 1.0
and O 0 0.00012000022252323106
that O 0 3.555126397714048e-07
results O 0 1.6708258954167832e-06
from O 0 7.257934839799418e-07
truncating O 0 9.575572039466351e-05
mutations O 0 4.160614116699435e-05
in O 0 9.519168884253304e-07
the O 0 1.8023910115516628e-06
APC B-Disease 0 0.00023072570911608636
gene O 0 9.315569332102314e-05
. O 0 1.632453131605871e-05

A O 0 3.847129119094461e-05
variant O 0 0.0008767068502493203
of O 0 7.17350530976546e-06
FAP B-Disease 0 0.02483384869992733
is O 0 0.00024034339003264904
attenuated B-Disease 1 0.9697009921073914
adenomatous I-Disease 1 0.9999605417251587
polyposis I-Disease 1 0.9997931122779846
coli I-Disease 1 0.9997722506523132
, O 0 4.870104021392763e-06
which O 0 2.1738932787229714e-07
results O 0 8.884256317287509e-07
from O 0 3.5257210129202576e-07
germ O 0 0.0002884925343096256
- O 0 4.5776210754411295e-05
line O 0 1.1851793715322856e-05
mutations O 0 7.76181241235463e-06
in O 0 8.600176215622923e-08
the O 0 4.9307125493669446e-08
5 O 0 3.1015753165775095e-07
and O 0 1.6707480199329439e-07
3 O 0 5.350640890355862e-07
regions O 0 4.4389048525772523e-07
of O 0 6.509719696623506e-08
the O 0 9.534841751701606e-07
APC B-Disease 0 0.00018946919590234756
gene O 0 5.4380921937990934e-05
. O 0 1.2676062397076748e-05

Attenuated B-Disease 1 0.9875548481941223
adenomatous I-Disease 1 0.9999558925628662
polyposis I-Disease 1 0.9998656511306763
coli I-Disease 1 0.9997691512107849
patients O 0 0.0032713308464735746
have O 0 3.395420662855031e-06
" O 0 1.4220857337932102e-05
multiple O 0 0.0024751857854425907
" O 1 0.9984651803970337
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999669790267944
( O 0 2.5491128781141015e-06
typically O 0 5.402452529779112e-07
fewer O 0 1.5205604597667843e-07
than O 0 4.0983607618727547e-08
100 O 0 1.3686799604784028e-07
) O 0 3.2624349444176914e-08
without O 0 1.9293491959615494e-07
the O 0 8.473601837977185e-07
florid O 0 0.0023117871023714542
phenotype O 0 0.0001461049250792712
of O 0 8.97216807516088e-07
classical O 0 0.0004024284426122904
FAP B-Disease 0 0.006671881303191185
. O 0 3.586810635169968e-05

Another O 0 7.047590315778507e-06
group O 0 2.5129788809863385e-06
of O 0 2.0196242189740587e-07
patients O 0 1.4020053640706465e-05
with O 0 7.047926828818163e-07
multiple O 0 0.00044058586354367435
adenomas B-Disease 1 0.9947688579559326
has O 0 7.880659723014105e-06
no O 0 9.177722404274391e-07
mutations O 0 6.006638614053372e-06
in O 0 1.7882045710848615e-07
the O 0 1.9438768106283533e-07
APC B-Disease 0 3.0268703994806856e-05
gene O 0 3.2160446608031634e-06
, O 0 4.362141510227957e-07
and O 0 1.1572358715739028e-07
their O 0 1.0717901943735342e-07
phenotype O 0 6.263716932153329e-05
probably O 0 7.887727406341583e-06
results O 0 1.1034965154976817e-06
from O 0 7.08515486280703e-08
variation O 0 1.3572509942605393e-06
at O 0 4.391118181956699e-06
a O 0 9.772988960321527e-07
locus O 0 1.2745190360874403e-05
, O 0 3.6332536978989083e-07
or O 0 4.467073040359537e-07
loci O 0 2.8615181690838654e-06
, O 0 3.7935902241770236e-07
elsewhere O 0 1.1547239182618796e-06
in O 0 1.2496580836796056e-07
the O 0 5.846560497957398e-07
genome O 0 2.9733675546594895e-05
. O 0 8.792903827270493e-06

Recently O 0 0.0003704792761709541
, O 0 1.467574520574999e-06
however O 0 2.173953532746964e-07
, O 0 2.3497145207329595e-07
a O 0 1.007975583888765e-06
missense O 0 6.0814902099082246e-05
variant O 0 0.00020497971854638308
of O 0 2.4237945126515115e-06
APC B-Disease 0 0.0003089992969762534
( O 0 1.348602381767705e-06
I1307K O 0 4.0589151467429474e-05
) O 0 2.622331010115886e-07
was O 0 3.6663552691607038e-06
described O 0 7.6525242320713e-07
that O 0 1.847166686275159e-08
confers O 0 1.6754340776969912e-06
an O 0 4.0633739217810216e-07
increased O 0 1.034232263918966e-05
risk O 0 0.003601218806579709
of O 0 0.12096993625164032
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 4.498561247601174e-05
including O 0 1.1015092695743078e-06
multiple O 0 0.00022887758677825332
adenomas B-Disease 1 0.9925850033760071
, O 0 1.207196601171745e-05
in O 0 4.198506758257281e-06
Ashkenazim O 0 0.005019277799874544
. O 0 5.79266416025348e-05

We O 0 1.0486384098840063e-06
have O 0 4.9757293396623936e-08
studied O 0 5.521355888049584e-07
a O 0 1.5647638917926088e-07
set O 0 2.4746225335547933e-07
of O 0 1.2615195998932904e-07
164 O 0 3.0106568374321796e-05
patients O 0 5.332061482477002e-05
with O 0 1.5246700968418736e-05
multiple O 1 0.9991866946220398
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999885559082031
and I-Disease 0 0.029639936983585358
/ I-Disease 1 0.7510326504707336
or I-Disease 1 0.7578918933868408
carcinoma I-Disease 1 0.9999998807907104
and O 0 2.912262971221935e-05
analyzed O 0 0.0001250126224476844
codons O 0 0.00029079365776851773
1263 O 0 0.0027442793361842632
- O 0 0.0004873226280324161
1377 O 0 0.000704410660546273
( O 0 1.4766886806683033e-06
exon O 0 6.230112194316462e-05
15G O 0 0.000139238138217479
) O 0 7.793328649086106e-08
of O 0 2.6408567777025382e-08
the O 0 3.1206323569676897e-07
APC B-Disease 0 2.1033163648098707e-05
gene O 0 2.7017458705813624e-06
for O 0 4.857640192312829e-07
germ O 0 0.0012349466560408473
- O 0 0.0001951773592736572
line O 0 9.034721733769402e-05
variants O 0 7.366878708126023e-05
. O 0 2.111072899424471e-05

Three O 0 4.5285109990800265e-06
patients O 0 1.1949622603424359e-05
with O 0 9.656259436496839e-08
the O 0 2.3810356708509062e-07
I1307K O 0 1.0385435416537803e-05
allele O 0 1.720711793495866e-06
were O 0 4.1754489643608395e-07
detected O 0 2.9129296308383346e-05
, O 0 1.1916635855868662e-07
each O 0 2.4105981211164362e-08
of O 0 3.8543925029443926e-07
Ashkenazi O 0 0.0006812801002524793
descent O 0 0.00048139659338630736
. O 0 2.7759961085394025e-05

Four O 0 2.0854226022493094e-05
patients O 0 4.3528078094823286e-05
had O 0 2.71893236458709e-06
a O 0 5.141053406987339e-06
germ O 0 0.005303441546857357
- O 0 0.00035071230377070606
line O 0 9.159656474366784e-05
E1317Q O 0 0.00016326530021615326
missense O 0 0.0001125216149375774
variant O 0 0.00010143861436517909
of O 0 4.000850140073453e-07
APC O 0 5.043419878347777e-05
that O 0 1.1556411294577629e-07
was O 0 1.393415345773974e-06
not O 0 1.2483758915493581e-08
present O 0 2.8557629150327557e-08
in O 0 7.266675083883456e-08
controls O 0 1.887151711343904e-06
; O 0 1.1320187098817769e-07
one O 0 3.365347467365609e-08
of O 0 4.532214159524983e-09
these O 0 7.621190789564025e-09
individuals O 0 9.986502291781107e-09
had O 0 2.4350376293114095e-07
an O 0 5.62846267371242e-08
unusually O 0 4.76868945042952e-06
large O 0 3.3737737226147146e-07
number O 0 3.034785152067343e-07
of O 0 1.6694275473128073e-06
metaplastic B-Disease 0 0.40037801861763
polyps I-Disease 1 0.5780174136161804
of I-Disease 0 4.0813011992213433e-07
the I-Disease 0 2.714336460485356e-06
colorectum I-Disease 0 0.007997110486030579
. O 0 3.244723120587878e-05

There O 0 6.796657316954224e-07
is O 0 1.6390580981351377e-07
increasing O 0 1.140101133501048e-07
evidence O 0 1.2860058973274135e-07
that O 0 1.7072098401627045e-08
there O 0 4.252218488431936e-08
exist O 0 5.972219128125289e-07
germ O 0 0.00013683905126526952
- O 0 1.1782452020270284e-05
line O 0 2.5316885512438603e-06
variants O 0 1.0742046470113564e-06
of O 0 4.97702039581327e-08
the O 0 3.8510748368025816e-07
APC B-Disease 0 2.4859980840119533e-05
gene O 0 2.2413444185076514e-06
that O 0 2.313743863169293e-08
predispose O 0 3.9806448626222846e-07
to O 0 1.771243240966669e-08
the O 0 1.0644581038832257e-07
development O 0 9.099355224861938e-07
of O 0 1.0043628208222799e-05
multiple O 1 0.9996838569641113
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999992847442627
and I-Disease 1 0.9998140931129456
carcinoma I-Disease 1 1.0
, O 0 7.149110024329275e-05
but O 0 8.715984449736425e-07
without O 0 4.981379788659979e-07
the O 0 8.000860702850332e-07
florid O 0 0.001957396976649761
phenotype O 0 6.662872328888625e-05
of O 0 4.791386913893803e-07
classical O 0 9.667715494288132e-05
FAP B-Disease 0 0.0008010093006305397
, O 0 1.4189398598318803e-06
and O 0 4.282635472918628e-07
possibly O 0 2.3237405457621207e-06
with O 0 5.443386044134968e-07
importance O 0 0.00012692365271504968
for O 1 0.9861867427825928
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
risk O 0 0.0013901805505156517
in O 0 4.519220908605348e-07
the O 0 2.1703635866288096e-07
general O 0 4.465063057068619e-07
population O 0 7.115096423149225e-08
. O 0 4.507096207362338e-07
. O 0 2.134581791324308e-06

Genomic O 0 0.00012396254169289023
structure O 0 3.6290890420787036e-05
of O 0 1.2731455854009255e-06
the O 0 5.0569138693390414e-05
human O 1 0.9842793345451355
congenital B-Disease 1 0.9999997615814209
chloride I-Disease 1 0.9999831914901733
diarrhea I-Disease 1 0.9999998807907104
( O 0 8.108207111945376e-05
CLD B-Disease 0 0.2494654506444931
) O 0 2.742722699622391e-06
gene O 0 6.0636768466793e-05
. O 0 1.2418327969498932e-05

Congenital B-Disease 1 0.9999984502792358
chloride I-Disease 1 0.9999563694000244
diarrhea I-Disease 1 0.9999998807907104
( O 0 0.0001370511163258925
CLD B-Disease 1 0.871971845626831
) O 0 2.811188551277155e-06
is O 0 1.286501856156974e-06
caused O 0 9.461234185437206e-06
by O 0 9.957253865877647e-08
mutations O 0 3.5663158541865414e-06
in O 0 6.164054155988197e-08
a O 0 1.837419603134549e-07
gene O 0 6.48697550786892e-07
which O 0 9.79452678961934e-08
encodes O 0 2.106102556354017e-06
an O 0 9.264117579732556e-06
intestinal O 1 0.9985598921775818
anion O 0 0.0019719433039426804
transporter O 0 0.07064764946699142
. O 0 3.6276571336202323e-05

We O 0 1.5118806004466023e-05
report O 0 1.2771465662808623e-06
here O 0 1.162287190936695e-07
the O 0 4.860281421770196e-08
complete O 0 6.761204076610738e-07
genomic O 0 8.426020940532908e-06
organization O 0 1.1186760957571096e-06
of O 0 8.852433097672474e-08
the O 0 9.349636798106076e-07
human O 0 2.0896708520012908e-05
CLD B-Disease 0 0.0053300512954592705
gene O 0 9.600074008631054e-06
which O 0 4.89628064315184e-07
spans O 0 1.9211256585549563e-05
approximately O 0 6.20738944689947e-07
39kb O 0 0.00016461090126540512
, O 0 8.390261996282788e-07
and O 0 4.219928371185233e-07
comprises O 0 2.5805334189499263e-06
21 O 0 1.3677832612302154e-05
exons O 0 9.38322045840323e-05
. O 0 1.2750198948197067e-05

All O 0 1.527966787762125e-06
exon O 0 0.0004474068700801581
/ O 0 8.907412848202512e-05
intron O 0 0.0002039394894381985
boundaries O 0 1.5019958254924859e-06
conform O 0 4.030763193441089e-06
to O 0 1.2810203031676792e-07
the O 0 1.4351759318742552e-06
GT O 0 0.00041119998786598444
/ O 0 0.0006428717751987278
AG O 1 0.9982613921165466
rule O 0 0.00012898954446427524
. O 0 1.456785321352072e-05

An O 0 3.3076167937906575e-07
analysis O 0 4.4125172848907823e-07
of O 0 5.667913427487292e-08
the O 0 5.909489573241444e-07
putative O 0 9.85070873866789e-05
promoter O 0 0.0005384221440181136
region O 0 5.891061391594121e-06
sequence O 0 9.718468163555372e-07
shows O 0 1.42555086313223e-06
a O 0 2.07147468245239e-06
putative O 0 5.056056033936329e-05
TATA O 0 0.003533190581947565
box O 0 3.670574369607493e-05
and O 0 9.13116309675388e-07
predicts O 0 2.972447418869706e-06
multiple O 0 5.904695399294724e-07
transcription O 0 8.407590939896181e-06
factor O 0 1.7294819372182246e-06
binding O 0 7.032993835309753e-06
sites O 0 1.3842111002304591e-05
. O 0 5.840124231326627e-06

The O 0 2.1583907710009953e-06
genomic O 0 2.1500505681615323e-05
structure O 0 1.8710090444074012e-05
was O 0 2.5756185095815454e-06
determined O 0 6.843696809255562e-08
using O 0 3.889882904672959e-08
DNA O 0 4.011425573935412e-07
from O 0 1.7745774627542232e-08
several O 0 8.894453173979855e-09
sources O 0 3.850905372360103e-08
including O 0 6.381277728451096e-08
multiple O 0 3.1368660984298913e-06
large O 0 2.5181050659739412e-05
- O 0 0.0019526733085513115
insert O 0 0.00029165635351091623
libaries O 0 0.0002247821248602122
and O 0 1.2173250070190988e-06
genomic O 0 1.09236634671106e-05
DNA O 0 2.5851966711343266e-05
from O 0 5.232391231402289e-06
Finnish O 0 0.054114606231451035
CLD B-Disease 1 0.9756850004196167
patients O 0 0.0008976522949524224
and O 0 8.122532562993001e-06
controls O 0 0.00036965071922168136
. O 0 3.09186834783759e-05

Exon O 0 0.00052357476670295
- O 0 2.3111047994461842e-05
specific O 0 1.4907264755947836e-07
primers O 0 3.2362338515667943e-06
developed O 0 1.411826360708801e-06
in O 0 7.448214489613747e-08
this O 0 1.6002276836957208e-08
study O 0 5.369425792878246e-08
will O 0 8.289783082204849e-09
facilitate O 0 9.1162775106568e-08
mutation O 0 6.4146192926273216e-06
screening O 0 2.506760210962966e-06
studies O 0 3.669275940865191e-07
of O 0 1.0284583851216667e-07
patients O 0 1.677651198406238e-05
with O 0 2.4795413082756568e-06
the O 0 0.00015044915198814124
disease O 1 0.9997031092643738
. O 0 1.9499459085636772e-05

Genomic O 0 1.9174578483216465e-05
sequencing O 0 4.630528110283194e-06
of O 0 7.179460794759507e-07
a O 0 1.831779081840068e-05
BAC O 0 0.0024747434072196484
clone O 0 0.003389996010810137
H O 1 0.9994125366210938
_ O 0 6.258349458221346e-05
RG364P16 O 0 6.858017150079831e-05
revealed O 0 9.919425792759284e-06
the O 0 1.6890209053599392e-07
presence O 0 3.339665113344381e-07
of O 0 2.8005809227238387e-08
another O 0 3.2863741239452793e-07
, O 0 4.7876323350237726e-08
highly O 0 3.9543144225717697e-07
homologous O 0 2.319637815162423e-06
gene O 0 2.5408121473446954e-06
3 O 0 8.817766570246022e-07
of O 0 7.803681256746131e-08
the O 0 7.974305731295317e-07
CLD B-Disease 0 0.0016523068770766258
gene O 0 7.164282578742132e-06
, O 0 3.988293997281289e-07
with O 0 4.1403481532142905e-08
a O 0 4.4884160388392047e-07
similar O 0 6.696890295643243e-07
genomic O 0 7.276631095010089e-06
structure O 0 1.6037702152971178e-05
, O 0 1.3241221950011095e-06
recently O 0 1.4367588846653234e-05
identified O 0 1.7478137124271598e-06
as O 0 1.6130881022036192e-06
the O 0 9.567721281200647e-05
Pendred B-Disease 1 0.9999743700027466
syndrome I-Disease 1 0.9999996423721313
gene O 0 0.0006712390459142625
( O 0 1.0751172339951154e-05
PDS B-Disease 0 0.0021150836255401373
) O 0 9.770062661118573e-07
. O 0 9.677108891992248e-07
. O 0 4.573120804707287e-06

The O 0 1.0493994523130823e-05
APCI1307K O 0 0.0031295055523514748
allele O 0 0.00028560205828398466
and O 0 0.0003238573553971946
cancer B-Disease 1 0.9995344877243042
risk O 0 6.562984344782308e-05
in O 0 4.172805745383812e-07
a O 0 1.0228180826743483e-06
community O 0 6.152685045890394e-07
- O 0 2.077444878523238e-05
based O 0 5.422427875600988e-07
study O 0 3.8273020663837087e-07
of O 0 8.250194838410607e-08
Ashkenazi O 0 0.00012901118316221982
Jews O 0 2.172017229895573e-05
. O 0 1.8060050933854654e-05

Mutations O 0 0.0012423479929566383
in O 0 8.58929161040578e-06
APC O 0 0.00020989528275094926
are O 0 1.1903817949132645e-06
classically O 0 0.011609737761318684
associated O 0 0.0001370384416077286
with O 0 0.0007102153613232076
familial B-Disease 1 0.9999972581863403
adenomatous I-Disease 1 0.9999843835830688
polyposis I-Disease 1 0.9999922513961792
( O 0 0.00025341863511130214
FAP B-Disease 0 0.0012445533648133278
) O 0 1.102097712646355e-06
, O 0 1.1390636700525647e-06
a O 0 7.800638741173316e-06
highly O 0 0.0022941147908568382
penetrant O 1 0.9929366707801819
autosomal B-Disease 1 0.9999955892562866
dominant I-Disease 1 0.9999698400497437
disorder I-Disease 1 0.9999998807907104
characterized O 1 0.9776673913002014
by O 0 3.6395631468622014e-05
multiple O 1 0.985535740852356
intestinal O 1 0.9999972581863403
polyps B-Disease 1 0.999401330947876
and O 0 8.872665603121277e-06
, O 0 1.1833380995085463e-06
without O 0 3.5912237308366457e-06
surgical O 0 0.028706438839435577
intervention O 0 2.905466317315586e-05
, O 0 1.0740612879089895e-06
the O 0 1.0679207207431318e-06
development O 0 1.67906291608233e-05
of O 0 0.22052477300167084
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
( O 0 4.8028570745373145e-05
CRC B-Disease 0 0.0012403278378769755
) O 0 1.6069679986685514e-06
. O 0 5.094768766866764e-06

APC B-Disease 0 0.0011062592966482043
is O 0 1.1544383596628904e-05
a O 0 9.186983515974134e-05
tumour O 1 0.9999299049377441
- O 0 0.00022328838531393558
suppressor O 0 0.00011318374163238332
gene O 0 1.0987270798068494e-05
, O 0 1.006431034511479e-06
and O 0 1.6985204638331197e-06
somatic O 0 0.00028822917374782264
loss O 0 0.006895748432725668
occurs O 0 0.00019159035582561046
in O 0 8.025229180930182e-05
tumours B-Disease 1 0.9999836683273315
. O 0 7.263541192514822e-05

The O 0 1.5605492080794647e-05
germline O 0 0.0017808870179578662
T O 0 0.019612830132246017
- O 0 2.9695416742470115e-05
to O 0 3.730952471414639e-07
- O 0 1.2513588444562629e-05
A O 0 2.451918362567085e-06
transversion O 0 4.03564226871822e-05
responsible O 0 1.5869169374127523e-06
for O 0 3.7705131461507335e-08
the O 0 3.83146499416398e-07
APC O 0 2.7663763830787502e-05
I1307K O 0 8.067896487773396e-06
allele O 0 8.41124403905269e-07
converts O 0 4.663205572796869e-07
the O 0 2.6490454274608055e-07
wild O 0 4.490339506446617e-06
- O 0 1.457506550650578e-05
type O 0 6.039378604327794e-06
sequence O 0 7.758991955597594e-07
to O 0 2.5752819965418894e-07
a O 0 1.4499411008728202e-05
homopolymer O 0 0.03759824484586716
tract O 1 0.6535870432853699
( O 0 2.1004620975872967e-06
A8 O 0 0.0017138882540166378
) O 0 3.1401927458318823e-07
that O 0 8.533444173508542e-08
is O 0 9.96858602775319e-07
genetically O 0 3.491783718345687e-05
unstable O 1 0.6585513949394226
and O 0 2.4077568014035933e-05
prone O 0 0.010434550233185291
to O 0 1.1628220590864657e-06
somatic O 0 0.0005108801415190101
mutation O 0 0.0010442686034366488
. O 0 2.021489490289241e-05

The O 0 2.668315119080944e-06
I1307K O 0 6.434875103877857e-05
allele O 0 9.264877007808536e-06
was O 0 7.62024274081341e-06
found O 0 1.1153268815178308e-06
in O 0 6.041966571501689e-07
6 O 0 1.9814913684967905e-05
. O 0 4.028572675451869e-06

1 O 0 1.1770939636335243e-05
% O 0 1.3805069443151297e-07
of O 0 3.5321122027198726e-07
unselected O 0 0.00379680166952312
Ashkenazi O 0 0.0008507979800924659
Jews O 0 7.917693437775597e-06
and O 0 4.6219952309911605e-06
higher O 0 1.4679701052955352e-05
proportions O 0 0.0001806878426577896
of O 0 3.126199601410917e-07
Ashkenazim O 0 0.0005028375890105963
with O 0 3.6262583762436407e-06
family O 0 2.2600466763833538e-05
or O 0 2.86577574115654e-06
personal O 0 2.0536794181680307e-05
histories O 0 8.169527427526191e-05
of O 0 4.524979885900393e-06
CRC B-Disease 0 0.001216613920405507
( O 0 1.8500562646295293e-06
ref O 0 0.0006237835623323917
. O 0 6.39858512840874e-07
2 O 0 2.2933324999030447e-06
) O 0 4.950233005729388e-07
. O 0 1.4909211358826724e-06

To O 0 6.348112719933852e-07
evaluate O 0 4.8779270400700625e-06
the O 0 2.2808380606420542e-07
role O 0 2.771760136965895e-06
of O 0 3.9274274854506075e-07
I1307K O 0 0.0002867882139980793
in O 0 2.9288903533597477e-05
cancer B-Disease 1 0.9913888573646545
, O 0 9.109218694902665e-07
we O 0 8.109869895633892e-07
genotyped O 0 0.00014462265244219452
5 O 0 5.642323685606243e-06
, O 0 1.1424971262385952e-06
081 O 0 0.00038835962186567485
Ashkenazi O 0 0.00010074204328702763
volunteers O 0 3.096024784099427e-06
in O 0 2.193044252862819e-07
a O 0 9.533023330732249e-07
community O 0 1.0062439059765893e-06
survey O 0 1.0747963642643299e-05
. O 0 4.574084869091166e-06

Risk O 0 0.0010688758920878172
of O 0 8.75677778822137e-06
developing O 1 0.9922986626625061
colorectal B-Disease 1 0.9999998807907104
, I-Disease 0 0.001944252522662282
breast I-Disease 1 0.9923270344734192
and I-Disease 0 2.324669139852631e-06
other I-Disease 0 1.1337618843754171e-06
cancers I-Disease 1 0.9981896281242371
were O 0 2.562684358053957e-07
compared O 0 1.302842861150566e-06
between O 0 1.2430155038600788e-06
genotyped O 0 0.0002754912420641631
I1307K O 0 5.981281356071122e-05
carriers O 0 5.6975636653078254e-06
and O 0 5.27069687450421e-07
non O 0 5.8748305491462816e-06
- O 0 2.0162720829830505e-05
carriers O 0 2.2772092052036896e-06
and O 0 6.787395534502139e-08
their O 0 3.636643342019852e-08
first O 0 1.3851902167516528e-06
- O 0 4.3602733057923615e-05
degree O 0 8.757046089158393e-06
relatives O 0 1.5131225154618733e-05
. O 0 1.1301292943244334e-05

Sperm O 0 3.231835944461636e-05
DNA O 0 1.6831285392981954e-05
analysis O 0 2.2245574200496776e-06
in O 0 2.133637281076517e-06
a O 0 6.954312993912026e-05
Friedreich B-Disease 1 0.9898616075515747
ataxia I-Disease 1 0.9992701411247253
premutation O 1 0.940456748008728
carrier O 0 0.002841516397893429
suggests O 0 1.325676294072764e-05
both O 0 4.3616549305625085e-07
meiotic O 0 7.874020229792222e-05
and O 0 9.9026851785311e-07
mitotic O 0 2.0656452761613764e-05
expansion O 0 3.2201446629187558e-06
in O 0 5.055450742474932e-07
the O 0 1.172085262624023e-06
FRDA B-Disease 0 0.0015244886744767427
gene O 0 0.00011757136962842196
. O 0 1.8786613509291783e-05

Friedreich B-Disease 1 0.995051920413971
ataxia I-Disease 1 0.9996579885482788
is O 0 0.00022030262334737927
usually O 0 2.5832892788457684e-05
caused O 0 2.6055689886561595e-05
by O 0 4.3791224868527934e-08
an O 0 5.0411561147711836e-08
expansion O 0 1.2678325447268435e-06
of O 0 1.351139502503429e-07
a O 0 1.0975164514093194e-05
GAA O 0 0.00038298184517771006
trinucleotide O 0 0.000735310313757509
repeat O 0 2.3208005586639047e-05
in O 0 5.730361749556323e-07
intron O 0 4.994004484615289e-05
1 O 0 1.206892420668737e-06
of O 0 7.040618754672323e-08
the O 0 1.4692507193103665e-06
FRDA B-Disease 0 0.0011899842647835612
gene O 0 0.0001348517689621076
. O 0 2.1236040993244387e-05

Occasionally O 0 7.299760181922466e-05
, O 0 6.135293801889929e-07
a O 0 4.529857164925488e-07
fully O 0 1.513662027718965e-06
expanded O 0 4.576483831897349e-07
allele O 0 3.184626848451444e-06
has O 0 5.110557026455353e-07
been O 0 3.4567199236335e-07
found O 0 1.7447099764922314e-07
to O 0 2.3549183936211193e-08
arise O 0 1.1390060308258398e-06
from O 0 8.701867670879437e-08
a O 0 7.753620820949436e-07
premutation O 0 4.014882870251313e-05
of O 0 1.076586499948462e-07
100 O 0 4.4914690988662187e-07
or O 0 9.982427400245797e-07
less O 0 2.9871619062760146e-06
triplet O 0 0.0030822749249637127
repeats O 0 0.0011169746285304427
. O 0 2.1484169337782077e-05

We O 0 5.161760327609954e-06
have O 0 3.465641782440798e-07
examined O 0 2.8264601041882997e-06
the O 0 5.666000291171258e-08
sperm O 0 7.056010531414358e-07
DNA O 0 8.95352570751129e-07
of O 0 5.428420379871568e-08
a O 0 4.01905208491371e-06
premutation O 0 0.0023024026304483414
carrier O 0 0.0012149115791544318
. O 0 1.7084374121623114e-05

This O 0 6.915610128999106e-07
mans O 0 2.5743695005076006e-05
leucocyte O 0 0.0001194049691548571
DNA O 0 6.3677371144876815e-06
showed O 0 1.5702802329542465e-06
one O 0 7.083816910835594e-08
normal O 0 6.843004030088196e-07
allele O 0 9.358592478747596e-07
and O 0 1.1816256773045097e-07
one O 0 4.807727549405172e-08
allele O 0 3.980162830430345e-07
of O 0 5.894844434806146e-08
approximately O 0 3.3353299500049616e-07
100 O 0 1.0046454690382234e-06
repeats O 0 5.461875116452575e-05
. O 0 6.1030500546621624e-06

His O 0 6.170022061269265e-06
sperm O 0 8.948515642259736e-06
showed O 0 2.335457338631386e-06
an O 0 3.813118354401013e-08
expanded O 0 4.3323331055944436e-07
allele O 0 2.3636971491214354e-06
in O 0 2.750014687080693e-07
a O 0 1.0374855037298403e-06
tight O 0 3.262541940785013e-05
range O 0 2.9544560220529092e-06
centering O 0 2.145337020920124e-06
on O 0 6.599469202228647e-07
a O 0 4.227150327551499e-07
size O 0 2.2153651570988586e-06
of O 0 1.4732773934156285e-07
approximately O 0 1.3749809113505762e-06
320 O 0 2.832687459886074e-05
trinucleotide O 0 0.003506507957354188
repeats O 0 0.000634817173704505
. O 0 2.3154641894507222e-05

His O 0 0.00011348093539709225
affected O 0 0.00011681079922709614
son O 0 0.001487746718339622
has O 0 8.963940672401804e-06
repeat O 0 1.5969148080330342e-05
sizes O 0 1.675110797805246e-05
of O 0 7.88756835845561e-07
1040 O 0 0.000497899018228054
and O 0 5.505379704118241e-06
540 O 0 5.203655382501893e-05
. O 0 1.1472136066004168e-05

These O 0 1.2530615833838965e-07
data O 0 1.0016012765845517e-06
suggest O 0 6.425233323170687e-07
that O 0 2.4249031227441264e-08
expansion O 0 9.486878980169422e-07
occurs O 0 6.002442205499392e-07
in O 0 3.786093571989113e-08
two O 0 3.657958558278551e-08
stages O 0 4.137544692639494e-06
, O 0 1.9285269559077278e-07
the O 0 3.6385721102760726e-08
first O 0 1.7428058640689414e-07
during O 0 5.905534976591298e-07
meiosis O 0 3.343777507325285e-06
followed O 0 3.2901499480431085e-07
by O 0 3.826312067189974e-08
a O 0 2.65474056959647e-07
second O 0 1.524325284663064e-06
mitotic O 0 8.497699309373274e-05
expansion O 0 4.550527228275314e-05
. O 0 1.425446225766791e-05

We O 0 2.7451119422039483e-06
also O 0 3.093496161454823e-07
show O 0 2.1183025467053085e-07
that O 0 1.2587431541533078e-08
in O 0 2.7693367599113117e-08
all O 0 6.8700072297644965e-09
informative O 0 1.296697178077011e-06
carrier O 0 1.7157521142507903e-05
father O 0 4.080890903424006e-06
to O 0 1.6179274098249152e-07
affected O 0 3.3379660635546315e-06
child O 0 3.3042570066754706e-06
transmissions O 0 4.2333194869570434e-05
, O 0 3.3798312415456166e-07
with O 0 3.5512488949507315e-08
the O 0 1.320763232115496e-07
notable O 0 1.0250815876133856e-06
exception O 0 7.83033783591236e-07
of O 0 7.732356266387796e-08
the O 0 7.627627951478644e-07
premutation O 0 0.0003816108510363847
carrier O 0 5.287905878503807e-05
, O 0 2.1351691259496874e-07
the O 0 5.739036268437303e-08
expansion O 0 1.2491437928474625e-06
size O 0 1.1983093827439006e-05
decreases O 0 3.377263419679366e-05
. O 0 1.0219093837804394e-06
. O 0 2.8142462724645156e-06

The O 0 1.2851289284299128e-05
R496H O 0 0.0004586807335726917
mutation O 0 7.037437171675265e-05
of O 0 5.60793012027716e-07
arylsulfatase O 0 0.0010218964889645576
A O 0 4.876640741713345e-05
does O 0 1.2326284377195407e-05
not O 0 5.971506197965937e-06
cause O 0 0.015897303819656372
metachromatic B-Disease 1 0.9998342990875244
leukodystrophy I-Disease 1 0.9999486207962036
. O 0 0.00024766341084614396

Deficiency B-Disease 1 0.9989659786224365
of I-Disease 0 3.596755504986504e-06
arylsulfatase I-Disease 0 0.006243299692869186
A I-Disease 0 6.360650877468288e-05
( O 0 5.137950665812241e-06
ARSA O 0 0.0047768522053956985
) O 0 2.2737372091796715e-06
enzyme O 0 6.523742194985971e-05
activity O 0 7.808913505868986e-05
causes O 0 0.2102668732404709
metachromatic B-Disease 1 0.9998262524604797
leukodystrophy I-Disease 1 0.9999707937240601
( O 0 0.0007783318869769573
MLD B-Disease 1 0.9993457198143005
) O 0 1.4212410860636737e-05
. O 0 1.071913902706001e-05

A O 0 6.7909122662968e-06
number O 0 3.702532467286801e-07
of O 0 8.796886277195881e-07
ARSA O 0 0.013796131126582623
gene O 0 0.00018673801969271153
mutations O 0 0.0003479103615973145
responsible O 0 3.605301753850654e-05
for O 0 2.4210085030063055e-06
MLD B-Disease 1 0.999625563621521
have O 0 1.4975903468439355e-06
been O 0 3.931803803425282e-06
identified O 0 1.0155235941056162e-05
. O 0 4.034027824673103e-06

Recently O 0 0.0004955186741426587
, O 0 1.8718124010774773e-06
the O 0 1.3614330782729667e-06
R496H O 0 0.00012969761155545712
mutation O 0 4.690553396358155e-05
of O 0 9.056536214302469e-07
ARSA O 0 0.009562965482473373
was O 0 1.9302271539345384e-05
proposed O 0 3.740664737961197e-07
to O 0 3.0548992668855135e-08
be O 0 1.804329343713107e-07
a O 0 3.33925549966807e-06
cause O 0 9.100610623136163e-05
of O 0 7.115841071936302e-06
MLD B-Disease 1 0.9991844296455383
( O 0 1.0447799468238372e-05
Draghia O 0 0.0006936464342288673
et O 0 0.0008271110709756613
al O 0 7.389921665890142e-05
. O 0 1.2197664318591706e-06
, O 0 1.4187531860443414e-06
1997 O 0 1.025478559313342e-05
) O 0 4.836422817788844e-07
. O 0 2.3406346372212283e-06

We O 0 7.672381798329297e-06
have O 0 5.146200692252023e-07
investigated O 0 1.1583678315219004e-05
the O 0 6.026567120898108e-07
R496H O 0 8.127156615955755e-05
mutation O 0 1.9324152162880637e-05
and O 0 6.061034127924358e-07
found O 0 4.6595201297350286e-07
this O 0 3.3196247528621825e-08
mutation O 0 1.3359577906157938e-06
at O 0 1.0500834832782857e-06
a O 0 2.002608141538076e-07
relatively O 0 6.545626547449501e-07
high O 0 1.8188848116551526e-06
frequency O 0 5.8789441936824e-07
in O 0 7.130638834951242e-08
an O 0 2.026476408900635e-08
African O 0 3.3825166667611484e-08
American O 0 8.10994933431175e-08
population O 0 6.810813690805162e-09
( O 0 6.216204440079309e-08
f O 0 1.1120982890133746e-05
= O 0 2.3695652089372743e-06
0 O 0 3.3832077406259486e-07
. O 0 6.750058645366153e-08
09 O 0 4.326917405705899e-06
, O 0 2.449520195568766e-07
n O 0 7.887758329161443e-06
= O 0 8.650945346744265e-06
61 O 0 4.64852701043128e-06
subjects O 0 7.971926606842317e-06
) O 0 1.4728827864018967e-06
. O 0 4.347545655036811e-06

The O 0 8.944436558522284e-06
ARSA O 0 0.003079865360632539
enzyme O 0 1.3896643395128194e-05
activity O 0 1.2572035075208987e-06
in O 0 1.2399307536270499e-07
subjects O 0 1.7858934597825282e-06
with O 0 1.8719823913215805e-07
and O 0 3.6234263234291575e-07
without O 0 1.7483360181813623e-07
the O 0 3.9292632436627173e-07
R496H O 0 5.588886415353045e-05
mutation O 0 1.419964883098146e-05
was O 0 3.5832970297633437e-06
determined O 0 4.3958135620414396e-07
and O 0 1.0475374523366554e-07
found O 0 1.7563709775458847e-07
to O 0 3.9302594956325265e-08
be O 0 3.8144790437399934e-07
normal O 0 1.6118799976538867e-05
. O 0 8.223067197832279e-06

It O 0 2.6412833449285245e-06
is O 0 7.075039434312203e-07
therefore O 0 7.725897717136831e-07
concluded O 0 2.5698136596474797e-06
that O 0 2.838115165104682e-08
the O 0 2.5022720251399733e-07
R496H O 0 7.171541074058041e-05
mutation O 0 2.98931154247839e-05
of O 0 7.485077162527887e-07
ARSA O 0 0.005117031279951334
does O 0 6.802013672313478e-07
not O 0 5.7681173615264925e-08
negatively O 0 5.155603162165789e-07
influence O 0 2.5830055960796017e-07
the O 0 2.896053103995655e-07
activity O 0 7.466675810974266e-07
of O 0 1.792591035609803e-07
ARSA O 0 0.005699196830391884
and O 0 3.6084713883610675e-06
is O 0 7.431865469698096e-07
not O 0 2.476681402185932e-07
a O 0 7.76640354160918e-06
cause O 0 0.0003775011282414198
of O 0 4.2776176996994764e-05
MLD B-Disease 1 0.999576985836029

Down O 0 0.006499116308987141
- O 0 0.00023488573788199574
regulation O 0 2.3558141037938185e-05
of O 0 1.4693279126731795e-06
transmembrane O 0 0.0016153804026544094
carbonic O 0 0.04194236174225807
anhydrases O 0 0.019823433831334114
in O 0 0.00025585075491108
renal B-Disease 1 0.9999756813049316
cell I-Disease 1 0.9998921155929565
carcinoma I-Disease 1 0.9999998807907104
cell O 0 0.4477127194404602
lines O 0 0.00045725988456979394
by O 0 2.194524540755083e-06
wild O 0 9.603159560356289e-05
- O 0 0.0027189364191144705
type O 0 0.008944356814026833
von B-Disease 1 0.9985601305961609
Hippel I-Disease 1 0.9966838955879211
- I-Disease 1 0.8640794157981873
Lindau I-Disease 1 0.7766226530075073
transgenes O 0 0.008878141641616821
. O 0 4.907374022877775e-05

To O 0 6.587163170479471e-07
discover O 0 1.0086476322612725e-05
genes O 0 2.6780026018968783e-06
involved O 0 3.096656655543484e-06
in O 0 9.382485586684197e-06
von B-Disease 1 0.9977900981903076
Hippel I-Disease 1 0.9978228807449341
- I-Disease 1 0.9903203845024109
Lindau I-Disease 1 0.9373219609260559
( O 0 1.7430018488084897e-05
VHL B-Disease 0 0.012229184620082378
) O 0 3.2413520330010215e-06
- O 0 0.0001116684143198654
mediated O 0 0.0006660014623776078
carcinogenesis O 0 0.024391818791627884
, O 0 2.440836851747008e-06
we O 0 1.1235665624553803e-06
used O 0 6.976311124162748e-05
renal B-Disease 1 0.9999878406524658
cell I-Disease 1 0.9999566078186035
carcinoma I-Disease 1 1.0
cell O 1 0.9630804657936096
lines O 0 0.0016163390828296542
stably O 0 0.002021022839471698
transfected O 0 0.0006730824243277311
with O 0 3.558501703082584e-06
wild O 0 0.0001597130612935871
- O 0 0.0032189940102398396
type O 0 0.0037761954590678215
VHL O 1 0.9301897287368774
- O 0 0.002937975572422147
expressing O 0 5.411114761955105e-05
transgenes O 0 0.0016207154840230942
. O 0 2.793369276332669e-05

Large O 0 9.364223842567299e-06
- O 0 3.9009300962788984e-05
scale O 0 1.3769131328444928e-05
RNA O 0 4.301794433558825e-06
differential O 0 4.16077591580688e-06
display O 0 1.215310021507321e-06
technology O 0 3.1326119369623484e-06
applied O 0 4.4948970412406197e-07
to O 0 1.4335540754473186e-08
these O 0 2.77575136209407e-08
cell O 0 1.5560952306259423e-05
lines O 0 9.294631126977038e-06
identified O 0 7.692607368880999e-07
several O 0 2.599190196406198e-08
differentially O 0 6.549106728925835e-06
expressed O 0 2.2240242003590538e-07
genes O 0 6.801247991461423e-07
, O 0 1.9226614256240282e-07
including O 0 7.141963465073786e-08
an O 0 4.746380568576569e-07
alpha O 0 3.2172414648812264e-05
carbonic O 0 0.001238725963048637
anhydrase O 0 0.0019088481785729527
gene O 0 3.295416172477417e-05
, O 0 5.781384516012622e-06
termed O 0 0.0005595135735347867
CA12 O 0 0.02222786657512188
. O 0 3.027687307621818e-05

The O 0 6.947133783796744e-07
deduced O 0 1.2688691413131892e-06
protein O 0 4.563905235954735e-07
sequence O 0 4.805847879651992e-07
was O 0 1.3933702120993985e-06
classified O 0 7.124425565052661e-07
as O 0 9.755168406400117e-08
a O 0 4.7165997330012033e-07
one O 0 7.522905320911377e-07
- O 0 6.864566239528358e-05
pass O 0 1.8588016246212646e-05
transmembrane O 0 0.00040514025022275746
CA O 0 0.00014093899517320096
possessing O 0 3.612272394093452e-06
an O 0 2.8525926154543413e-07
apparently O 0 4.840520432480844e-06
intact O 0 6.7451942413754296e-06
catalytic O 0 9.015722753247246e-06
domain O 0 1.128069470723858e-06
in O 0 2.779534611363488e-07
the O 0 3.7438874755935103e-07
extracellular O 0 7.356993592111394e-05
CA O 0 0.011475566774606705
module O 0 0.000585084140766412
. O 0 7.059617928462103e-06

Reintroduced O 0 0.0002208797523053363
wild O 0 0.00016324630996678025
- O 0 0.0011708004167303443
type O 0 0.0007917872862890363
VHL B-Disease 0 0.03427455946803093
strongly O 0 2.01227048819419e-05
inhibited O 0 1.3255751582619268e-05
the O 0 3.4329710274505487e-07
overexpression O 0 4.163895482633961e-06
of O 0 6.163454457919215e-08
the O 0 4.2927396748382307e-07
CA12 O 0 0.0002182528842240572
gene O 0 5.923521712247748e-06
in O 0 7.988311381268431e-07
the O 0 2.390802364971023e-06
parental O 0 0.000820302520878613
renal B-Disease 1 0.9999923706054688
cell I-Disease 1 0.9999769926071167
carcinoma I-Disease 1 1.0
cell O 1 0.9988892674446106
lines O 0 0.05324740707874298
. O 0 5.314040754456073e-05

Similar O 0 8.02298109192634e-06
results O 0 5.431628324004123e-06
were O 0 1.6980152395262849e-07
obtained O 0 3.533284598233877e-07
with O 0 7.923742373350251e-07
CA9 O 0 0.0018783932318910956
, O 0 1.9720587829397118e-07
encoding O 0 7.436346436406893e-07
another O 0 4.025477210234385e-06
transmembrane O 0 0.0005567757179960608
CA O 0 0.00013661726552527398
with O 0 2.2736604421425e-07
an O 0 4.1789067495301424e-07
intact O 0 4.1003371734404936e-05
catalytic O 0 6.117885641288012e-05
domain O 0 2.3258082364918664e-05
. O 0 8.554589840059634e-06

Although O 0 2.285457185280393e-06
both O 0 4.5956227268106886e-07
domains O 0 5.744780537497718e-06
of O 0 1.8976267313064454e-07
the O 0 8.486792353323835e-07
VHL B-Disease 0 0.0011923823039978743
protein O 0 2.184160166507354e-06
contribute O 0 4.852954589296132e-07
to O 0 7.619100728106787e-08
regulation O 0 2.7297901397105306e-06
of O 0 1.4562186834155e-07
CA12 O 0 0.0005505589069798589
expression O 0 6.723705610056641e-06
, O 0 6.017854161655123e-07
the O 0 3.554722809440136e-07
elongin O 0 6.790817133150995e-05
binding O 0 7.653015927644446e-06
domain O 0 5.010370387026342e-06
alone O 0 5.797661287942901e-06
could O 0 8.778608275861188e-07
effectively O 0 2.007955663430039e-05
regulate O 0 8.651795360492542e-05
CA9 O 0 0.01422473881393671
expression O 0 7.986804121173918e-05
. O 0 2.480740840837825e-05

We O 0 3.0440016416832805e-05
mapped O 0 0.00027119519654661417
CA12 O 0 0.0022292910143733025
and O 0 9.680112270871177e-06
CA9 O 0 0.005988454446196556
loci O 0 2.225377829745412e-05
to O 0 9.598011274647433e-07
chromosome O 0 8.348028495674953e-05
bands O 0 8.279679605038837e-05
15q22 O 0 0.00022932668798603117
and O 0 6.186355221871054e-06
17q21 O 0 0.0005560502177104354
. O 0 1.8347704099141993e-05

2 O 0 2.913251955760643e-05
respectively O 0 3.048292091989424e-05
, O 0 4.556748081085971e-06
regions O 0 1.5179861293290742e-05
prone O 0 0.0012671363074332476
to O 0 1.4035204287665692e-07
amplification O 0 8.426848580711521e-06
in O 0 3.029958577371872e-07
some O 0 2.849881468591775e-07
human O 0 0.0001781827595550567
cancers B-Disease 1 0.9991974234580994
. O 0 2.965528801723849e-05

Additional O 0 9.75717512119445e-07
experiments O 0 7.845221261959523e-06
are O 0 2.009839761285548e-08
needed O 0 1.1640831587556022e-07
to O 0 1.482811118336258e-08
define O 0 6.543791641888674e-07
the O 0 2.3109967628442973e-07
role O 0 3.973877483076649e-06
of O 0 1.216290911543183e-06
CA O 0 0.0010584157425910234
IX O 0 0.0014120814157649875
and O 0 1.0444314284541178e-05
CA O 0 0.0003998815664090216
XII O 0 0.0008109768386930227
enzymes O 0 6.702259270241484e-06
in O 0 1.8720341188327438e-07
the O 0 8.430552611571329e-08
regulation O 0 2.938209490821464e-06
of O 0 1.715441015903707e-07
pH O 0 0.0001269852655241266
in O 0 1.9037172194202867e-07
the O 0 1.6583628337230039e-07
extracellular O 0 1.3191662219469436e-05
microenvironment O 0 0.00011369485582690686
and O 0 3.4883959187936853e-07
its O 0 1.6261476787349238e-07
potential O 0 1.5157609141169814e-06
impact O 0 1.4086272130953148e-05
on O 0 9.476937702856958e-05
cancer B-Disease 1 0.994648277759552
cell O 0 0.0008410162990912795
growth O 0 3.5189612390240654e-05
. O 0 7.0059086283436045e-06

A O 0 1.7704480796965072e-06
gene O 0 4.2751111095640226e-07
encoding O 0 2.669022478585248e-07
a O 0 7.587904633510334e-07
transmembrane O 0 1.3894933545088861e-05
protein O 0 1.502815393905621e-06
is O 0 4.2766646402014885e-07
mutated O 0 1.2979247912880965e-05
in O 0 2.2217780042410595e-06
patients O 0 0.00014624514733441174
with O 0 0.0008837520144879818
diabetes B-Disease 1 0.9999996423721313
mellitus I-Disease 1 0.9999990463256836
and O 1 0.9984831213951111
optic B-Disease 1 0.9999991655349731
atrophy I-Disease 1 0.9999681711196899
( O 0 0.06428384780883789
Wolfram B-Disease 1 0.9999427795410156
syndrome I-Disease 1 0.9999998807907104
) O 0 3.224499960197136e-05
. O 0 2.5010052922880277e-05

Wolfram B-Disease 1 0.9999485015869141
syndrome I-Disease 1 0.9999998807907104
( O 0 0.0003623989468906075
WFS B-Disease 1 0.7988051772117615
; O 0 7.048074621707201e-05
OMIM O 0 0.03348956257104874
222300 O 0 0.0009026362095028162
) O 0 9.537787946101162e-07
is O 0 1.1269147535131196e-06
an O 0 6.176298029458849e-06
autosomal B-Disease 1 0.9995508790016174
recessive I-Disease 1 0.9999761581420898
neurodegenerative I-Disease 1 0.9999991655349731
disorder I-Disease 1 0.9999676942825317
defined O 0 4.7445151722058654e-05
by O 0 3.311515911263996e-06
young O 0 4.8045156290754676e-05
- O 0 0.0039027149323374033
onset O 0 0.13735783100128174
non O 0 0.0014764650259166956
- O 0 0.11381246894598007
immune O 1 0.7226660847663879
insulin B-Disease 0 0.4082346558570862
- I-Disease 0 0.3767590820789337
dependent I-Disease 0 0.01420765183866024
diabetes I-Disease 1 0.9999972581863403
mellitus I-Disease 1 0.999990701675415
and O 0 0.1046462431550026
progressive O 1 0.9996711015701294
optic B-Disease 1 0.9999974966049194
atrophy I-Disease 1 0.9998193383216858
. O 0 0.00022334116511046886

Linkage O 0 0.00011138998524984345
to O 0 5.127457711751049e-07
markers O 0 3.689103323267773e-05
on O 0 9.294763913203496e-06
chromosome O 0 0.0004850859986618161
4p O 0 0.020431168377399445
was O 0 3.4962486097356305e-05
confirmed O 0 1.7988844547289773e-06
in O 0 1.8645098975866858e-07
five O 0 4.079332143192005e-07
families O 0 5.471501935971901e-07
. O 0 5.333606168278493e-06

On O 0 2.633895519466023e-06
the O 0 1.942920277997473e-07
basis O 0 6.251911486288009e-07
of O 0 1.1231509233766701e-06
meiotic O 0 0.004936762619763613
recombinants O 1 0.6875039339065552
and O 0 0.003054598579183221
disease O 1 0.9998291730880737
- O 0 0.0019504331285133958
associated O 0 1.6989455616567284e-05
haplotypes O 0 6.817770918132737e-05
, O 0 1.9017443264601752e-06
the O 0 1.1018433951903717e-06
WFS B-Disease 0 0.0014429764123633504
gene O 0 2.2057958631194197e-05
was O 0 9.904612852551509e-06
localized O 0 2.0832716472796164e-05
to O 0 1.7061184109934402e-07
a O 0 6.859861969132908e-06
BAC O 0 0.0004723728634417057
/ O 0 3.818022014456801e-05
P1 O 0 0.0002307433169335127
contig O 0 7.245187589433044e-05
of O 0 7.838139737259553e-08
less O 0 4.0336294659937266e-07
than O 0 2.018572757833681e-07
250 O 0 1.415297674611793e-06
kb O 0 8.694340067449957e-05
. O 0 1.022352898871759e-05

Mutations O 0 0.0002468553138896823
in O 0 7.043384471216996e-07
a O 0 1.1104513077953015e-06
novel O 0 1.958046368599753e-06
gene O 0 5.441115263238316e-06
( O 0 3.905510368440446e-07
WFS1 O 0 4.525168697000481e-05
) O 0 1.2523682535459102e-08
encoding O 0 4.606592440836721e-08
a O 0 3.3506745467093424e-07
putative O 0 3.7705674458266003e-06
transmembrane O 0 5.28646069142269e-06
protein O 0 3.674710740142473e-07
were O 0 3.0193604061423684e-08
found O 0 6.428714272033176e-08
in O 0 2.0375804155037258e-08
all O 0 1.1525216336849553e-08
affected O 0 4.763912500038714e-07
individuals O 0 2.3068167820383678e-08
in O 0 3.628651370490843e-07
six O 0 3.0931826131563867e-06
WFS B-Disease 0 0.001244480605237186
families O 0 2.6833225774680614e-07
, O 0 2.1757290369350812e-07
and O 0 1.2452467501589126e-07
these O 0 3.274841375855431e-08
mutations O 0 7.610380180267384e-06
were O 0 2.8673289875769115e-07
associated O 0 1.162928583653411e-06
with O 0 1.5278983482858166e-06
the O 0 0.00010317813575966284
disease O 1 0.9995587468147278
phenotype O 0 0.002175448229536414
. O 0 2.1829897377756424e-05

WFS1 O 0 0.003910118248313665
appears O 0 1.1380396244931035e-05
to O 0 7.724602113512447e-08
function O 0 1.1674255802063271e-06
in O 0 7.798791443747177e-07
survival O 0 2.4213910364778712e-05
of O 0 3.907961740878818e-07
islet O 0 0.0008400203078053892
beta O 0 8.244266064139083e-05
- O 0 7.512611045967788e-05
cells O 0 5.538777713809395e-06
and O 0 1.5064326817082474e-06
neurons O 0 3.5555236536310986e-05
. O 0 1.3019609923503594e-06
. O 0 4.637404344975948e-06

Stable O 0 4.703932791016996e-05
interaction O 0 7.323109230128466e-07
between O 0 7.16271983947081e-07
the O 0 1.3196930126468942e-07
products O 0 7.915177775430493e-07
of O 0 4.159915789614388e-08
the O 0 9.43464783631498e-07
BRCA1 O 0 0.00035778252640739083
and O 0 1.149489344243193e-05
BRCA2 O 0 0.003819575998932123
tumor B-Disease 0 0.03213673084974289
suppressor O 0 0.00012335210340097547
genes O 0 9.809726179810241e-06
in O 0 1.0173799864787725e-06
mitotic O 0 7.876483869040385e-05
and O 0 4.663108484237455e-06
meiotic O 0 0.003235821845009923
cells O 0 0.0006338396342471242
. O 0 2.4268303604912944e-05

BRCA1 O 0 0.005081405863165855
and O 0 1.2750794667226728e-05
BRCA2 O 0 0.00014893685874994844
account O 0 3.5991635627397045e-07
for O 0 8.06087712135195e-08
most O 0 1.7521033157663624e-07
cases O 0 5.555222628572665e-07
of O 0 2.5084315780077304e-07
familial O 0 0.011540811508893967
, O 0 1.0517279406485613e-05
early O 0 0.0001069804493454285
onset O 1 0.9929297566413879
breast B-Disease 1 0.9982724189758301
and I-Disease 0 0.00022775451361667365
/ I-Disease 1 0.929410994052887
or I-Disease 1 0.9991556406021118
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999997615814209
and O 0 4.73544787382707e-07
encode O 0 1.0964182450834414e-07
products O 0 7.1846255877972e-07
that O 0 1.643439873078023e-08
each O 0 1.834865948069364e-08
interact O 0 2.727864512053202e-07
with O 0 1.4129632290860172e-06
hRAD51 O 0 0.0006873527891002595
. O 0 1.2803251593140885e-05

Results O 0 2.3302172849071212e-05
presented O 0 6.301501798589015e-06
here O 0 9.336146717942029e-07
show O 0 2.257235109937028e-06
that O 0 3.0061815436965844e-07
BRCA1 O 0 0.0001034499509842135
and O 0 2.4770927211648086e-06
BRCA2 O 0 0.00012913807586301118
coexist O 0 1.2247390259290114e-05
in O 0 3.9302076970670896e-07
a O 0 1.2853172393079149e-06
biochemical O 0 5.015850183553994e-05
complex O 0 8.078724204096943e-05
and O 0 5.623447123070946e-06
colocalize O 0 0.0006114771822467446
in O 0 2.817055019477266e-06
subnuclear O 0 0.000252565456321463
foci O 0 6.315104110399261e-05
in O 0 3.268719979132584e-07
somatic O 0 6.884097274451051e-06
cells O 0 8.014791092136875e-06
and O 0 3.766639338209643e-07
on O 0 4.875982995145023e-07
the O 0 1.7640458338519238e-07
axial O 0 7.087667199812131e-06
elements O 0 1.3057111800662824e-06
of O 0 4.042216801281029e-07
developing O 0 5.864174090675078e-05
synaptonemal O 0 0.007105700206011534
complexes O 0 0.0010834488784894347
. O 0 4.5691998820984736e-05

Like O 0 9.627099643694237e-05
BRCA1 O 0 0.0022158147767186165
and O 0 2.985463106597308e-05
RAD51 O 0 0.025313304737210274
, O 0 1.11183944682125e-05
BRCA2 O 0 0.00028959845076315105
relocates O 0 7.726250623818487e-05
to O 0 1.0285540383847547e-06
PCNA O 0 0.0009747559088282287
+ O 0 1.3797483916277997e-05
replication O 0 6.117671091487864e-06
sites O 0 1.510524043624173e-06
following O 0 1.4334250408865046e-06
exposure O 0 4.074544631293975e-05
of O 0 4.3469671595630643e-07
S O 0 0.0004889087867923081
phase O 0 2.9777058443869464e-05
cells O 0 1.1554880074982066e-05
to O 0 1.1608851764322026e-06
hydroxyurea O 0 0.0006176373572088778
or O 0 2.5005856514326297e-05
UV O 0 0.00937403179705143
irradiation O 0 0.00022460773470811546
. O 0 1.1000113772752229e-05

Thus O 0 2.411477362329606e-05
, O 0 5.676780347130261e-06
BRCA1 O 0 0.00014656803978141397
and O 0 2.8169959023216506e-06
BRCA2 O 0 5.365972174331546e-05
participate O 0 1.091560193344776e-06
, O 0 3.2251159609586466e-07
together O 0 1.619031166910645e-07
, O 0 2.3569725726702018e-07
in O 0 8.205562807006572e-08
a O 0 5.825222046951239e-07
pathway O 0 4.18334730056813e-06
( O 0 3.374990171778336e-07
s O 0 1.8585569705464877e-05
) O 0 4.436509470906458e-08
associated O 0 1.4152057303817855e-07
with O 0 1.9523183070191408e-08
the O 0 8.863702305461629e-08
activation O 0 2.0332536223577335e-06
of O 0 1.1614196182563319e-07
double O 0 2.8916396331624128e-05
- O 0 7.783353794366121e-05
strand O 0 2.239949935756158e-05
break O 0 5.156332554179244e-05
repair O 0 0.0421438105404377
and O 0 3.7912066090939334e-06
/ O 0 2.821550333464984e-05
or O 0 2.701354333112249e-06
homologous O 0 5.8663943491410464e-05
recombination O 0 9.617455361876637e-05
. O 0 1.3929030501458328e-05

Dysfunction O 0 0.3735921382904053
of O 0 9.681475603429135e-07
this O 0 4.0171448745240923e-07
pathway O 0 1.4866227502352558e-05
may O 0 1.951207195816096e-06
be O 0 7.027765036582423e-08
a O 0 3.3874340488182497e-07
general O 0 3.1892997753857344e-07
phenomenon O 0 5.0400981308484916e-06
in O 0 1.1508570452178901e-07
the O 0 1.1337343863715432e-07
majority O 0 1.9012641416793485e-07
of O 0 1.4693654293296277e-07
cases O 0 4.959327725373441e-06
of O 0 3.844744696834823e-06
hereditary B-Disease 1 0.9998117089271545
breast I-Disease 1 0.999900221824646
and I-Disease 0 0.08422060310840607
/ I-Disease 1 0.998024582862854
or I-Disease 1 0.9996145963668823
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 1.6294543456751853e-05
. O 0 1.198957488668384e-05

A O 0 2.4471797587466426e-05
novel O 0 1.94128297152929e-05
Arg362Ser O 0 0.00025563276722095907
mutation O 0 1.80031329364283e-05
in O 0 2.5073839537981257e-07
the O 0 6.038706032995833e-07
sterol O 0 0.00038133154157549143
27 O 0 0.000120684620924294
- O 0 9.447296906728297e-05
hydroxylase O 0 0.00011947148595936596
gene O 0 6.395609489118215e-06
( O 0 3.1149204460234614e-07
CYP27 O 0 9.59764001891017e-05
) O 0 6.796165763489626e-08
: O 0 3.913533319632734e-08
its O 0 3.2199832133983364e-08
effects O 0 1.425873051630333e-06
on O 0 3.755978639219393e-07
pre O 0 4.601969521900173e-06
- O 0 6.251756303754519e-07
mRNA O 0 6.066961333317522e-08
splicing O 0 1.1316080872347811e-06
and O 0 3.049148347145092e-07
enzyme O 0 5.0776120588125195e-06
activity O 0 7.893882866483182e-06
. O 0 3.320180439914111e-06

A O 0 1.5109566447790712e-05
novel O 0 4.328840532252798e-06
C O 0 8.109483133011963e-06
to O 0 2.8172214783239724e-08
A O 0 6.311169613582024e-07
mutation O 0 2.3261038677446777e-06
in O 0 1.1410408973233643e-07
the O 0 3.4520024883022415e-07
sterol O 0 0.000389392051147297
27 O 0 8.34454913274385e-05
- O 0 0.00011137109686387703
hydroxylase O 0 0.0001763545733410865
gene O 0 4.634212473320076e-06
( O 0 4.857121780332818e-07
CYP27 O 0 0.00011100170377176255
) O 0 1.3828220346567832e-07
was O 0 8.659181389703008e-07
identified O 0 1.86523720913101e-07
by O 0 2.2499479612747564e-08
sequencing O 0 1.0404759223092697e-06
amplified O 0 3.559719698387198e-05
CYP27 O 0 0.00013093961752019823
gene O 0 2.6721270387497498e-06
products O 0 2.792628038150724e-06
from O 0 4.779607820637466e-07
a O 0 4.545086085272487e-06
patient O 0 0.00018541303870733827
with O 0 3.291031316621229e-05
cerebrotendinous B-Disease 1 0.9997075200080872
xanthomatosis I-Disease 1 0.9994333386421204
( O 0 3.785598892136477e-05
CTX B-Disease 0 0.04211129993200302
) O 0 6.908615887368796e-06
. O 0 8.981929568108171e-06

The O 0 7.30459487385815e-06
mutation O 0 7.523364183725789e-05
changed O 0 7.922201803012285e-06
the O 0 9.762965191839612e-07
adrenodoxin O 0 0.00012800075637642294
cofactor O 0 9.41565212997375e-06
binding O 0 2.112553374900017e-05
residue O 0 4.677835386246443e-05
362Arg O 0 0.00012173606228316203
to O 0 9.884898872769554e-07
362Ser O 0 0.0008188140927813947
( O 0 5.707091531803599e-06
CGT O 0 0.02180550992488861
362Arg O 0 0.0007847452070564032
to O 0 4.272451405995525e-06
AGT O 0 0.01832062192261219
362Ser O 0 0.0004661252605728805
) O 0 4.3632317670017073e-07
, O 0 3.456637500676152e-07
and O 0 2.701241328395554e-07
was O 0 1.085072653950192e-05
responsible O 0 8.877167601895053e-06
for O 0 4.356746558187297e-06
deficiency O 1 0.9953765869140625
in O 0 2.4994312752824044e-07
the O 0 2.9586217920041236e-07
sterol O 0 0.00029186272877268493
27 O 0 3.074013511650264e-05
- O 0 1.7618007404962555e-05
hydroxylase O 0 2.6066576538141817e-05
activity O 0 2.1759800006293517e-07
, O 0 3.340992904554696e-08
as O 0 4.815179011075088e-08
confirmed O 0 2.1706119923692313e-07
by O 0 7.760247555665956e-09
expression O 0 8.38611242670595e-08
of O 0 2.228469497822516e-08
mutant O 0 1.515213057246001e-06
cDNA O 0 5.561158786804299e-07
into O 0 2.389537257840857e-06
COS O 0 0.0016817597206681967
- O 0 0.00010319831199012697
1 O 0 6.763268629583763e-06
cells O 0 1.752116259012837e-05
. O 0 4.034439825773006e-06

Quantitative O 0 1.1680454008455854e-05
analysis O 0 2.635755208757473e-06
showed O 0 3.0594499094149796e-06
that O 0 9.533168920938806e-09
the O 0 3.215582466964406e-08
expression O 0 1.910894837919841e-07
of O 0 4.632638450630111e-08
CYP27 O 0 5.0109258154407144e-05
gene O 0 5.707858008463518e-07
mRNA O 0 2.723874104049173e-07
in O 0 1.6590207962963177e-07
the O 0 3.1774231956660515e-07
patient O 0 1.3804656191496179e-05
represented O 0 1.766009859238693e-06
52 O 0 3.0705821700394154e-05
. O 0 5.4837073548696935e-06

5 O 0 7.506038400606485e-06
% O 0 4.175313250698309e-08
of O 0 2.3666800075261563e-08
the O 0 5.407952698988083e-07
normal O 0 3.785147418966517e-05
level O 0 8.048735617194325e-05
. O 0 2.1299521904438734e-05

As O 0 2.352028559471364e-06
the O 0 9.708899142424343e-07
mutation O 0 2.1763546101283282e-05
occurred O 0 1.1962108146690298e-05
at O 0 1.8186957504440215e-06
the O 0 1.4996670927303057e-07
penultimate O 0 1.3498926819011103e-05
nucleotide O 0 1.0091971489600837e-06
of O 0 1.3192223491387267e-07
exon O 0 2.4842611310305074e-05
6 O 0 5.52179517399054e-06
( O 0 2.2917794240129297e-07
- O 0 4.091022674401756e-06
2 O 0 8.226959380408516e-07
position O 0 1.336537593488174e-06
of O 0 1.3949588151263015e-07
exon O 0 5.423135735327378e-05
6 O 0 1.5393077774206176e-05
- O 0 2.071014023385942e-05
intron O 0 6.729908636771142e-05
6 O 0 2.033152895819512e-06
splice O 0 2.224274430773221e-05
site O 0 3.285961838628282e-06
) O 0 2.0096249997436644e-08
of O 0 3.5878693349644664e-09
the O 0 5.017357196379635e-08
gene O 0 1.4503494867312838e-06
, O 0 3.5247495588919264e-07
we O 0 2.068577202862798e-07
hypothesized O 0 1.963411250471836e-06
that O 0 3.133446213610114e-08
the O 0 2.735873181336501e-07
mutation O 0 3.235836265957914e-05
may O 0 2.346575456613209e-06
partially O 0 1.2059434993716422e-05
affect O 0 3.2095169899548637e-07
the O 0 3.1815829970582854e-08
normal O 0 5.504248292709235e-07
splicing O 0 2.0101501831959467e-06
efficiency O 0 5.208345100982115e-06
in O 0 7.421284067277156e-07
exon O 0 3.409848432056606e-05
6 O 0 5.2783348110096995e-06
and O 0 1.7757379566774034e-07
cause O 0 2.6855395844904706e-06
alternative O 0 6.494935860246187e-07
splicing O 0 9.483953363087494e-06
elsewhere O 0 6.063247383281123e-06
, O 0 1.5598055824739276e-07
which O 0 1.5459050928257057e-08
resulted O 0 4.792268555320334e-07
in O 0 1.8148045910493238e-07
decreased O 0 5.825194421049673e-06
transcript O 0 8.478576091874857e-06
in O 0 4.966476012668863e-07
the O 0 2.652467856023577e-06
patient O 0 0.0004887974355369806
. O 0 1.464482738811057e-05

Transfection O 0 0.0014393512392416596
of O 0 1.6338640307367314e-06
constructed O 0 0.00018799341341946274
minigenes O 0 0.002248043194413185
, O 0 1.0576334261713782e-06
with O 0 1.4962812144858617e-07
or O 0 5.856672373738547e-07
without O 0 3.523533109728305e-07
the O 0 3.3980043667725113e-07
mutation O 0 4.963311312167207e-06
, O 0 2.040108739720381e-07
into O 0 8.496947998537507e-07
COS O 0 0.0008889662567526102
- O 0 1.9293382138130255e-05
1 O 0 9.143877264250477e-07
cells O 0 1.3398200735537102e-06
confirmed O 0 7.240319632728642e-07
that O 0 8.302489362677079e-09
the O 0 1.0604193789731653e-07
mutant O 0 7.76403430791106e-06
minigene O 0 9.111221879720688e-05
was O 0 5.327434337232262e-06
responsible O 0 8.032129130697285e-07
for O 0 1.4970085615573225e-08
a O 0 1.7672232388576958e-07
mRNA O 0 3.811584576851601e-07
species O 0 1.36354159963048e-07
alternatively O 0 7.398331831609539e-07
spliced O 0 9.748816410137806e-06
at O 0 7.797812031640206e-06
an O 0 4.3449651343507867e-07
activated O 0 0.0003538612218108028
cryptic O 0 4.8815862101037055e-05
5 O 0 9.598991255188594e-07
splice O 0 3.8523900002473965e-05
site O 0 1.5034323041618336e-05
88 O 0 6.778999704692978e-06
bp O 0 1.738297396514099e-05
upstream O 0 7.176654435170349e-07
from O 0 5.856985652030744e-08
the O 0 8.220131064717862e-08
3 O 0 3.48884526601978e-07
end O 0 1.036295998346759e-06
of O 0 2.587951826171775e-07
exon O 0 0.0001464055967517197
6 O 0 6.712532922392711e-05
. O 0 6.459008091042051e-06

Our O 0 1.7461377410654677e-06
data O 0 8.828790214465698e-07
suggest O 0 6.070330869079044e-07
that O 0 1.9157990749363307e-08
the O 0 7.000166135640029e-08
C O 0 2.668691649887478e-06
to O 0 1.8563177661690133e-08
A O 0 7.180193506428623e-07
mutation O 0 1.8446970670993323e-06
at O 0 9.094791835195792e-07
the O 0 7.688985448339736e-08
penultimate O 0 7.0062292252259795e-06
nucleotide O 0 4.242594400238886e-07
of O 0 5.351125054176009e-08
exon O 0 1.7253441910725087e-05
6 O 0 3.4430079267622204e-06
of O 0 5.18785370218211e-08
the O 0 3.8633683629996085e-07
CYP27 O 0 0.00015482536400668323
gene O 0 4.136668849241687e-06
not O 0 2.9555985747720115e-07
only O 0 4.5871587417423143e-07
causes O 0 0.00015332202019635588
the O 0 1.3636728908750229e-05
deficiency B-Disease 1 0.9971011281013489
in I-Disease 0 4.679225185100222e-07
the I-Disease 0 6.157767984404927e-07
sterol I-Disease 0 0.0006248304271139205
27 I-Disease 0 8.870574674801901e-05
- I-Disease 0 9.631544526200742e-05
hydroxylase I-Disease 0 0.00022909832478035241
activity I-Disease 0 2.6006141524703708e-06
, O 0 3.2959411555566476e-07
but O 0 1.704919725398213e-07
also O 0 4.258951662450272e-07
partially O 0 1.4295656001195312e-05
leads O 0 1.1091674423369113e-06
to O 0 2.0196774030978304e-08
alternative O 0 4.700344220509578e-07
pre O 0 8.362618245882913e-06
- O 0 1.4157540135784075e-06
mRNA O 0 1.0366235869696538e-07
splicing O 0 1.7696210079520824e-06
of O 0 6.865582236059709e-08
the O 0 6.118197575233353e-07
gene O 0 3.478910730336793e-05
. O 0 9.216426406055689e-06

To O 0 1.4626685640450887e-07
our O 0 3.143311744224775e-07
knowledge O 0 6.932197038622689e-07
, O 0 4.606157517628162e-07
this O 0 4.003559794796274e-08
is O 0 9.018236823976622e-08
the O 0 5.7287778076897666e-08
first O 0 4.214981288441777e-07
report O 0 2.0997561023250455e-07
regarding O 0 6.364150806348334e-08
effects O 0 2.3000786768534454e-06
on O 0 4.4259448372940824e-07
pre O 0 3.8052717172831763e-06
- O 0 5.658601480718062e-07
mRNA O 0 3.602270837177457e-08
splicing O 0 5.389782131715037e-07
of O 0 3.711681273443901e-08
a O 0 5.745179691984958e-07
mutation O 0 4.337167865742231e-06
at O 0 2.7010144094674615e-06
the O 0 3.508370696181373e-07
- O 0 7.967868441483006e-06
2 O 0 6.497730282717384e-07
position O 0 6.390017119883851e-07
of O 0 1.369624680336301e-08
a O 0 9.777089644558146e-07
5 O 0 1.6391937833759584e-06
splice O 0 0.0001452266878914088
site O 0 8.471177716273814e-05
. O 0 1.0131381714018062e-05

ATM O 0 0.00444380147382617
germline O 0 0.008793656714260578
mutations O 0 0.001644318108446896
in O 0 2.248408054583706e-05
classical O 1 0.6161609888076782
ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.999983549118042
telangiectasia I-Disease 1 0.9999947547912598
patients O 0 0.09705615788698196
in O 0 1.84318128049199e-06
the O 0 1.345035570921027e-06
Dutch O 0 7.206868031062186e-05
population O 0 5.140633447808796e-07
. O 0 5.5953514674911276e-06

Germline O 0 0.0066240341402590275
mutations O 0 0.00033326572156511247
in O 0 4.944858460476098e-07
the O 0 1.37945008304996e-07
ATM O 0 1.9348162823007442e-05
gene O 0 3.344657670822926e-06
are O 0 9.680620394192374e-08
responsible O 0 4.2292699617973994e-06
for O 0 1.5327977962442674e-06
the O 0 0.0017072814516723156
autosomal B-Disease 1 0.9999994039535522
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999696016311646
telangiectasia I-Disease 1 0.9999793767929077
( O 0 0.0014316024025902152
A B-Disease 1 0.9998449087142944
- I-Disease 1 0.9988996982574463
T I-Disease 1 0.9997606873512268
) O 0 5.880890057596844e-06
. O 0 6.950964689167449e-06

In O 0 7.436984219566511e-07
our O 0 9.375690979140927e-07
study O 0 7.071370191624737e-07
, O 0 2.2702825219766964e-07
we O 0 7.231638932125861e-08
have O 0 2.936753062954267e-08
determined O 0 2.0409690648648393e-07
the O 0 7.553077807642694e-08
ATM O 0 1.7176316760014743e-05
mutation O 0 4.82216864838847e-06
spectrum O 0 5.607889761449769e-06
in O 0 3.0099883474576927e-07
19 O 0 1.8691705463425023e-06
classical O 0 2.9470573281287216e-05
A B-Disease 1 0.9995607733726501
- I-Disease 1 0.9994069337844849
T I-Disease 1 0.9999423027038574
patients O 0 6.837838009232655e-05
, O 0 1.4574081319551624e-07
including O 0 5.626637999966988e-08
some O 0 2.1627428736792353e-08
immigrant O 0 3.3118084274974535e-07
populations O 0 9.693183500303348e-08
, O 0 5.4791730264014404e-08
as O 0 4.4572555424338134e-08
well O 0 8.613373836396931e-08
as O 0 2.2340216787597456e-07
12 O 0 2.978620443627733e-07
of O 0 3.022385186568499e-08
Dutch O 0 8.90193859959254e-06
ethnic O 0 2.966739032217447e-07
origin O 0 1.7443037449993426e-06
. O 0 8.132872608257458e-06

Both O 0 5.234375066720531e-07
the O 0 3.538710586781235e-07
protein O 0 1.3050290590399527e-06
truncation O 0 3.7000852898927405e-05
test O 0 4.756467205879744e-06
( O 0 2.770468086055189e-07
PTT O 0 2.7207554012420587e-05
) O 0 6.81030911664493e-08
and O 0 6.346441949744985e-08
the O 0 1.4045220098068967e-07
restriction O 0 8.241322575486265e-07
endonuclease O 0 3.130007826257497e-05
fingerprinting O 0 1.5928355423966423e-05
( O 0 4.321064182022383e-07
REF O 0 0.00012383057037368417
) O 0 1.532395010883647e-08
method O 0 2.764217832407212e-08
were O 0 1.1698185531372474e-08
used O 0 3.9034841137208787e-08
and O 0 9.937407696725131e-08
compared O 0 3.238893668822129e-07
for O 0 4.987528168243216e-09
their O 0 2.7755607590052023e-08
detection O 0 7.2539178290753625e-06
efficiency O 0 4.947999514115509e-06
, O 0 4.2378468378956313e-07
identifying O 0 1.8609744074638002e-06
76 O 0 2.46249896918016e-06
% O 0 1.2661209858322309e-08
and O 0 8.7591175201851e-08
60 O 0 1.588597768886757e-07
% O 0 7.839975779688757e-09
of O 0 9.443333226499817e-09
the O 0 6.872480184938468e-07
mutations O 0 5.06967116962187e-05
, O 0 1.174638896372926e-06
respectively O 0 1.6186810171348043e-05
. O 0 5.126316409587162e-06

Most O 0 8.395830263907555e-06
patients O 0 1.3272360774863046e-05
were O 0 1.274843839382811e-07
found O 0 2.1467273825237498e-07
to O 0 4.509882245429253e-08
be O 0 3.941024715459207e-07
compound O 0 3.848038977594115e-05
heterozygote O 0 0.00030399911338463426
. O 0 1.2491600500652567e-05

Seventeen O 0 6.21350554865785e-05
mutations O 0 5.3338008001446724e-05
were O 0 2.4126825337589253e-07
distinct O 0 4.7067408104339847e-07
, O 0 2.8760078407685796e-07
of O 0 2.2414539557757962e-08
which O 0 8.398549766752694e-08
10 O 0 1.9690745034495194e-07
were O 0 8.69085354793242e-08
not O 0 1.8890752073730255e-07
reported O 0 8.601357876614202e-06
previously O 0 1.501187125541037e-05
. O 0 7.00335658621043e-06

Mutations O 0 0.0005795860197395086
are O 0 3.860451442960766e-07
small O 0 1.9741580672416603e-06
deletions O 0 4.849520337302238e-05
or O 0 7.462656867573969e-06
point O 0 2.612406387925148e-05
mutations O 0 9.188034891849384e-05
frequently O 0 1.5596104276482947e-05
affecting O 0 2.519964618841186e-05
splice O 0 0.0004463921650312841
sites O 0 7.726766489213333e-05
. O 0 2.289307303726673e-05

Moreover O 0 2.0769397451658733e-05
, O 0 1.939485855473322e-06
a O 0 3.5098203170491615e-06
16 O 0 1.6315038010361604e-05
. O 0 3.080814622080652e-06

7 O 0 0.00012105458881706
- O 0 6.801763811381534e-05
kb O 0 4.517640627454966e-05
genomic O 0 1.7727488739183173e-05
deletion O 0 1.1399698450986762e-05
of O 0 7.465779816584472e-08
the O 0 2.1319685572507296e-07
3 O 0 1.157208771473961e-06
end O 0 8.018751032068394e-07
of O 0 2.2425316714702603e-08
the O 0 1.1408777567112338e-07
gene O 0 1.8935317029900034e-06
, O 0 2.5115267021647014e-07
most O 0 9.12763979954434e-08
likely O 0 3.066540443796839e-07
a O 0 2.2223832729650894e-07
result O 0 2.837190322679817e-07
of O 0 1.802203186684892e-08
recombination O 0 3.3731816984072793e-07
between O 0 7.5454181569512e-08
two O 0 1.4253521385398926e-07
LINE O 0 1.882811739051249e-05
elements O 0 3.051614157811855e-06
, O 0 2.8426145490811905e-06
was O 0 2.7288133424008265e-05
identified O 0 1.3807869436277542e-05
. O 0 4.914408236800227e-06

The O 0 1.991885710594943e-06
most O 0 1.0201605391557678e-06
frequently O 0 1.0223568096989766e-05
found O 0 4.182178599876352e-06
mutation O 0 1.0078966624860186e-05
, O 0 2.9940247259219177e-07
identified O 0 3.511701436309522e-07
in O 0 8.541455542854237e-08
three O 0 1.4805932835315616e-07
unrelated O 0 1.5058113604027312e-05
Turkish O 0 7.570538582513109e-05
A B-Disease 1 0.9996309280395508
- I-Disease 1 0.9978285431861877
T I-Disease 1 0.9997147917747498
individuals O 0 2.503682594579004e-07
, O 0 6.99601457654353e-07
was O 0 5.809815320390044e-06
previously O 0 9.173294301945134e-07
described O 0 3.4544328286756354e-07
to O 0 7.797027912204157e-09
be O 0 3.351472699364422e-08
a O 0 1.7716021716296382e-07
Turkish O 0 1.357368273602333e-05
A B-Disease 1 0.9992400407791138
- I-Disease 1 0.9982390403747559
T I-Disease 1 0.9998002648353577
founder O 0 0.0007066779653541744
mutation O 0 0.0003791238705161959
. O 0 1.2936478015035391e-05

The O 0 9.017795719046262e-07
presence O 0 2.1255543742881855e-06
of O 0 1.594111296299161e-07
a O 0 4.923856522509595e-06
founder O 0 0.00011289066605968401
mutation O 0 2.882746593968477e-05
among O 0 3.726834449935268e-07
relatively O 0 9.880478728518938e-07
small O 0 2.913066339260695e-07
ethnic O 0 6.098530747067343e-08
population O 0 1.3683426836053059e-08
groups O 0 3.4190026809710616e-08
in O 0 5.702602834389836e-08
Western O 0 4.340649581990874e-07
Europe O 0 5.273791430226993e-06
could O 0 6.953815727683832e-07
indicate O 0 5.157988312021189e-07
a O 0 6.415473308152286e-07
high O 0 6.739419859513873e-06
carrier O 0 5.740766482631443e-06
frequency O 0 2.343659161851974e-06
in O 0 1.640456019913472e-07
such O 0 1.0610809653144315e-07
communities O 0 2.6825343866221374e-06
. O 0 7.398124125757022e-06

In O 0 3.058480433537625e-05
patients O 0 5.060198964201845e-05
of O 0 1.3660340414389793e-07
Dutch O 0 1.5585710571031086e-05
ethnic O 0 1.3521125197257788e-07
origin O 0 2.7665498691931134e-07
, O 0 6.969104902054823e-07
however O 0 3.0196201805665623e-07
, O 0 2.494911370831687e-07
no O 0 1.686989463678401e-07
significant O 0 4.7673211156507023e-07
founder O 0 2.8151347578386776e-05
effect O 0 3.224757620046148e-06
could O 0 7.713514378338004e-07
be O 0 5.282260531203065e-07
identified O 0 3.672801540233195e-06
. O 0 3.3043106668628752e-06

The O 0 5.20716275786981e-06
observed O 0 2.195533124904614e-05
genetic O 0 2.478385613358114e-05
heterogeneity O 0 1.1296950106043369e-05
including O 0 2.5942577508430986e-07
the O 0 3.624656983447494e-07
relative O 0 6.5927401919907425e-06
high O 0 4.348782749730162e-05
percentage O 0 1.8168650512961904e-06
of O 0 7.152596737114436e-08
splice O 0 0.0001405023504048586
- O 0 0.00017805265088099986
site O 0 2.3629672796232626e-05
mutations O 0 2.3150138076744042e-05
had O 0 1.244168288394576e-06
no O 0 1.8714092675509164e-07
reflection O 0 1.5312811001422233e-06
on O 0 2.786461436699028e-06
the O 0 3.0878450161253568e-06
phenotype O 0 0.0003538935852702707
. O 0 1.3128022146702278e-05

All O 0 7.053810350043932e-06
patients O 0 7.493292650906369e-05
manifested O 0 5.8838857512455434e-05
classical O 0 0.00015711803280282766
A B-Disease 1 0.9986577033996582
- I-Disease 1 0.7498964071273804
T I-Disease 1 0.998883068561554
and O 0 6.015341114107287e-07
increased O 0 4.4589310732590093e-07
cellular O 0 9.034411777975038e-05
radioresistant O 0 9.828853217186406e-05
DNA O 0 9.820461855269969e-06
synthesis O 0 2.7168482120032422e-05
. O 0 1.118714499170892e-05

Determination O 0 1.6560174117330462e-05
of O 0 2.2937844335046975e-07
the O 0 5.135297556080332e-07
genomic O 0 1.0351993296353612e-05
structure O 0 7.983361683727708e-06
of O 0 1.0135531880450799e-07
the O 0 5.435288699118246e-07
COL4A4 O 0 0.0002308753610122949
gene O 0 6.576802206836874e-06
and O 0 8.692799724485667e-07
of O 0 5.952908281869895e-07
novel O 0 0.0003012064553331584
mutations O 0 0.1739639937877655
causing O 1 0.9869931936264038
autosomal B-Disease 1 0.9998679161071777
recessive I-Disease 1 0.999984622001648
Alport I-Disease 1 0.9999973773956299
syndrome I-Disease 1 0.9999996423721313
. O 0 0.00048767158295959234

Autosomal B-Disease 1 0.999723494052887
recessive I-Disease 1 0.9999836683273315
Alport I-Disease 1 0.9999969005584717
syndrome I-Disease 1 0.9999996423721313
is O 0 0.00034351766225881875
a O 0 0.0003091348335146904
progressive O 1 0.9983465671539307
hematuric B-Disease 1 0.9990562796592712
glomerulonephritis I-Disease 1 0.9999934434890747
characterized O 0 0.23460014164447784
by O 0 1.6613495972706005e-05
glomerular B-Disease 1 0.9937065243721008
basement I-Disease 1 0.9948751330375671
membrane I-Disease 1 0.648962140083313
abnormalities I-Disease 1 0.9996901750564575
and O 0 4.430093213159125e-06
associated O 0 2.577193754405016e-06
with O 0 4.686500005846028e-07
mutations O 0 1.4296474546426907e-05
in O 0 1.6222567467139015e-07
either O 0 3.9169390220195055e-07
the O 0 4.2747521433739166e-07
COL4A3 O 0 0.0005145829054526985
or O 0 7.728175432930584e-07
the O 0 4.6509563844665536e-07
COL4A4 O 0 0.00012445183529052883
gene O 0 1.7845534330263035e-06
, O 0 1.1867007998489498e-07
which O 0 8.233778991950658e-09
encode O 0 6.933420593213668e-08
the O 0 4.295733333492535e-07
alpha3 O 0 0.0001707128540147096
and O 0 2.153951299987966e-06
alpha4 O 0 0.0010005806107074022
type O 0 0.0025594609323889017
IV O 1 0.9842661619186401
collagen O 0 0.06174428015947342
chains O 0 0.0025999199133366346
, O 0 6.0974421103310306e-06
respectively O 0 1.7132404536823742e-05
. O 0 7.392615771095734e-06

To O 0 3.368713237250631e-07
date O 0 2.747306780293002e-06
, O 0 2.877508507026505e-07
mutation O 0 1.1105180419690441e-06
screening O 0 2.5383707225046237e-07
in O 0 2.9617289953876025e-08
the O 0 2.8278270391979277e-08
two O 0 5.828690419207305e-08
genes O 0 1.520983914815588e-06
has O 0 1.7039459407897084e-06
been O 0 1.0101687166752527e-06
hampered O 0 5.076738671050407e-05
by O 0 1.0597662480904546e-07
the O 0 1.149569186509325e-07
lack O 0 1.5092856529008714e-06
of O 0 1.4775409340472834e-07
genomic O 0 1.3365731319936458e-05
structure O 0 3.0973187676863745e-05
information O 0 5.34096625415259e-06
. O 0 1.338652418780839e-05

We O 0 7.76259730628226e-06
report O 0 6.670495622529415e-07
here O 0 2.088181787485155e-07
the O 0 2.8653220240926203e-08
complete O 0 3.173649929522071e-07
characterization O 0 2.9040090794296702e-06
of O 0 5.115535017807815e-08
the O 0 3.155114711717033e-07
48 O 0 1.9182105006620986e-06
exons O 0 5.724496531911427e-06
of O 0 7.177496996746413e-08
the O 0 5.193764422983804e-07
COL4A4 O 0 0.0001999192900257185
gene O 0 3.011931767105125e-06
, O 0 1.522713972690326e-07
a O 0 1.1748343808903883e-07
comprehensive O 0 8.766083965383586e-07
gene O 0 1.435950707673328e-06
screen O 0 5.350525043468224e-06
, O 0 3.770290675220167e-07
and O 0 6.526266815853887e-08
the O 0 3.058881503648081e-08
subsequent O 0 5.724407969864842e-07
detection O 0 4.116047875868389e-06
of O 0 5.017108151150751e-08
10 O 0 5.062653940512973e-07
novel O 0 1.8382485222900868e-06
mutations O 0 1.3347491403692402e-05
in O 0 1.096393816624186e-06
eight O 0 2.082040191453416e-05
patients O 0 0.005065534729510546
diagnosed O 1 0.9998868703842163
with O 0 0.00028125266544520855
autosomal B-Disease 1 0.9999464750289917
recessive I-Disease 1 0.9999873638153076
Alport I-Disease 1 0.9999977350234985
syndrome I-Disease 1 0.9999995231628418
. O 0 0.0007066705147735775

Furthermore O 0 3.77319629478734e-05
, O 0 1.8533054344516131e-06
we O 0 3.881279440065555e-07
identified O 0 4.3447292341625143e-07
a O 0 2.52787884846839e-07
glycine O 0 2.509199930500472e-06
to O 0 6.401025842706076e-08
alanine O 0 9.878059245238546e-06
substitution O 0 3.6780448908757535e-07
in O 0 2.0126830690969655e-07
the O 0 3.661822916001256e-07
collagenous O 0 0.0008118319092318416
domain O 0 5.038185463490663e-06
that O 0 1.6501907396104798e-07
is O 0 3.855425916299282e-07
apparently O 0 3.8542716538358945e-06
silent O 0 8.161729056155309e-06
in O 0 6.18698763332759e-08
the O 0 6.683861641931799e-08
heterozygous O 0 2.773942071598867e-07
carriers O 0 1.150235220848117e-06
, O 0 2.0078518048194383e-07
in O 0 2.5964655492316524e-07
11 O 0 3.7331346902647056e-06
. O 0 1.5855054016356007e-06

5 O 0 4.21296226704726e-06
% O 0 2.4838191947651467e-08
of O 0 9.420864088838243e-09
all O 0 2.665384535305293e-08
control O 0 2.3621757918590447e-06
individuals O 0 7.262629253546038e-08
, O 0 3.043956269266346e-07
and O 0 2.4158873657142976e-07
in O 0 1.4245163981740916e-07
one O 0 2.1559785068347992e-07
control O 0 9.279265782424773e-07
individual O 0 5.0162949349896735e-08
homozygous O 0 9.357325438941189e-07
for O 0 4.30482103297436e-08
this O 0 4.149439547518341e-08
glycine O 0 1.1663378245430067e-05
substitution O 0 3.4718584629445104e-06
. O 0 8.208540748455562e-06

There O 0 1.837990794228972e-06
has O 0 7.690252914471785e-07
been O 0 2.145389004226672e-07
no O 0 7.243372124321468e-08
previous O 0 2.429000289794203e-07
finding O 0 1.441014063630064e-07
of O 0 1.0633638858337235e-08
a O 0 2.704043140511203e-07
glycine O 0 2.2592294044443406e-06
substitution O 0 1.195141692278412e-07
that O 0 1.312375452755532e-08
is O 0 5.65377966665892e-08
not O 0 2.042413171920998e-08
associated O 0 2.539329386763711e-07
with O 0 1.144980359413239e-07
any O 0 2.603281643587252e-07
obvious O 0 2.7404863431002013e-05
phenotype O 0 4.395245559862815e-05
in O 0 1.25301301068248e-06
homozygous O 0 1.1457529581093695e-05
individuals O 0 4.3982581132695486e-07
. O 0 5.510338269232307e-06

Founder O 0 0.0016355117550119758
BRCA1 O 0 0.0017602326115593314
and O 0 1.367445474897977e-05
BRCA2 O 0 0.0008935427176766098
mutations O 0 0.00015913874085526913
in O 0 3.970063062297413e-06
French O 0 0.002570843556895852
Canadian O 0 0.10369755327701569
breast B-Disease 1 0.9999172687530518
and I-Disease 1 0.9996209144592285
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
families O 0 2.4704238967387937e-05
. O 0 1.7479105736128986e-05

We O 0 1.364556624139368e-06
have O 0 1.0427711316651767e-07
identified O 0 2.969161982946389e-07
four O 0 5.232193700521748e-08
mutations O 0 1.933776957230293e-06
in O 0 9.431330738607357e-08
each O 0 3.8330103535599847e-08
of O 0 2.550929139033542e-07
the O 0 0.0001449723931727931
breast B-Disease 1 0.9998613595962524
cancer I-Disease 1 0.9997841715812683
- O 0 0.0007777228020131588
susceptibility O 0 6.418242264771834e-05
genes O 0 1.3805341041006614e-05
, O 0 2.1115286017447943e-06
BRCA1 O 0 8.823431562632322e-05
and O 0 3.180787189194234e-06
BRCA2 O 0 0.0001860626507550478
, O 0 1.50091034356592e-06
in O 0 1.1581715853026253e-06
French O 0 0.0018172173295170069
Canadian O 0 0.219817116856575
breast B-Disease 1 0.9999324083328247
cancer I-Disease 1 0.9999544620513916
and O 0 0.21126088500022888
breast B-Disease 1 0.999990701675415
/ I-Disease 1 0.9999562501907349
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999974966049194
families O 0 4.310837539378554e-06
from O 0 3.6819935758103384e-06
Quebec O 0 0.0028488188982009888
. O 0 1.794545096345246e-05

To O 0 1.3591122751677176e-06
identify O 0 1.367414188280236e-05
founder O 0 0.00015831585915293545
effects O 0 6.563246279256418e-05
, O 0 1.1564144415388e-06
we O 0 7.245693041113555e-07
examined O 0 8.829422768030781e-06
independently O 0 2.065674834739184e-06
ascertained O 0 3.5003951779799536e-05
French O 0 0.00020329181279521435
Canadian O 0 0.0010196150979027152
cancer B-Disease 1 0.981819748878479
families O 0 3.761498490462145e-08
for O 0 7.261518053525151e-09
the O 0 1.5751359327964565e-08
distribution O 0 8.248605354310712e-08
of O 0 1.0659326754591802e-08
these O 0 3.131277281909206e-08
eight O 0 2.6198865725746145e-06
mutations O 0 0.00013359569129534066
. O 0 6.495638444903307e-06

Mutations O 0 0.0001109404256567359
were O 0 5.825672246828617e-07
found O 0 8.570174827582377e-07
in O 0 2.6442040734764305e-07
41 O 0 1.6935175608523423e-06
of O 0 8.04247974883765e-08
97 O 0 8.52318225952331e-06
families O 0 9.582554412190802e-07
. O 0 5.9168423831579275e-06

Six O 0 2.554301090640365e-06
of O 0 8.527326400553648e-08
eight O 0 9.472007036492869e-07
mutations O 0 1.2155755030107684e-05
were O 0 1.4818137117345032e-07
observed O 0 4.713002908829367e-06
at O 0 9.835081982600968e-06
least O 0 1.042317194333009e-06
twice O 0 3.421542714932002e-05
. O 0 4.786637418874307e-06

The O 0 1.4795878087170422e-05
BRCA1 O 0 0.0015905185136944056
C4446T O 0 0.00042479162220843136
mutation O 0 4.9827114708023146e-05
was O 0 3.497930947560235e-06
the O 0 4.550137333581006e-08
most O 0 1.3851384039753611e-07
common O 0 3.1639176540920744e-06
mutation O 0 2.4027747713262215e-05
found O 0 2.0359314021334285e-06
, O 0 2.473744586950488e-07
followed O 0 4.952881909048301e-07
by O 0 1.4601515374579321e-07
the O 0 2.355373226237134e-06
BRCA2 O 0 0.0012408643960952759
8765delAG O 0 0.00182236242108047
mutation O 0 0.00048143896856345236
. O 0 1.4000854207552038e-05

Together O 0 2.85442342828901e-06
, O 0 4.1192700450665143e-07
these O 0 2.1292938967576447e-08
mutations O 0 2.496785100447596e-06
were O 0 6.873916191807439e-08
found O 0 2.0229357744483423e-07
in O 0 6.122738227531954e-08
28 O 0 7.002088864282996e-07
of O 0 2.380174635163712e-08
41 O 0 9.96557218968519e-07
families O 0 2.761851547461447e-08
identified O 0 3.4284462913092284e-07
to O 0 2.496719808675607e-08
have O 0 1.0775911363225532e-07
a O 0 3.8019311432435643e-06
mutation O 0 0.00012271413288544863
. O 0 7.612499757669866e-06

The O 0 3.462382210273063e-06
odds O 0 0.00012156390585005283
of O 0 1.7307280586464913e-07
detection O 0 1.1614872164500412e-05
of O 0 2.7684281533879584e-08
any O 0 4.809598408428428e-08
of O 0 2.6794937824092813e-08
the O 0 2.3191523723653518e-07
four O 0 1.6721154452170595e-06
BRCA1 O 0 0.00015446321049239486
mutations O 0 5.893078196095303e-05
was O 0 4.779791925102472e-05
18 O 0 8.41622386360541e-06
. O 0 3.6565538721333724e-06

7x O 0 0.0057373857125639915
greater O 0 3.1766553547640797e-06
if O 0 8.491373932884017e-07
one O 0 1.6028187133088068e-07
or O 0 2.6494444682612084e-07
more O 0 1.563346927468956e-07
cases O 0 1.882344986370299e-05
of O 0 0.0009194485610350966
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
were O 0 3.4931906611745944e-06
also O 0 3.566427437817765e-07
present O 0 1.322106584211724e-07
in O 0 4.328979343881656e-07
the O 0 6.476442422354012e-07
family O 0 1.593592060089577e-05
. O 0 1.2716234778054059e-05

The O 0 5.302552835928509e-06
odds O 0 9.44139901548624e-05
of O 0 7.136557655940123e-08
detection O 0 9.916767339746002e-06
of O 0 3.5739034842663386e-08
any O 0 5.3308326641854364e-08
of O 0 4.393378105760348e-08
the O 0 3.0123831606942986e-07
four O 0 2.5726360490807565e-06
BRCA2 O 0 0.00032965108403004706
mutations O 0 0.00016867817612364888
was O 0 9.481584856985137e-05
5 O 0 8.957686077337712e-06
. O 0 3.7307461298041744e-06

3x O 0 0.0009026138577610254
greater O 0 1.834024942581891e-06
if O 0 4.861570346292865e-07
there O 0 3.859081587620494e-08
were O 0 5.314335638217926e-08
at O 0 8.910722044674912e-07
least O 0 1.018166599919823e-07
five O 0 2.706646284877934e-07
cases O 0 1.0743891607489786e-06
of O 0 3.269760100010899e-06
breast B-Disease 1 0.9999077320098877
cancer I-Disease 1 0.9996572732925415
in O 0 1.5259222436725395e-06
the O 0 1.494009893576731e-06
family O 0 2.247108750452753e-05
. O 0 1.3917120668338612e-05

Interestingly O 0 5.590154978563078e-05
, O 0 4.4665705445368076e-07
the O 0 5.037426831222547e-08
presence O 0 8.102526294351264e-07
of O 0 5.236072411207715e-07
a O 0 0.0002559996210038662
breast B-Disease 1 0.9994255304336548
cancer I-Disease 1 0.9873453974723816
case O 0 4.763021934195422e-06
< O 0 9.618035619496368e-06
36 O 0 1.001396981337166e-06
years O 0 2.629142272780882e-07
of O 0 3.516576541073846e-08
age O 0 2.0152579054411035e-06
was O 0 1.893332978397666e-06
strongly O 0 2.9244847610243596e-07
predictive O 0 4.4521578956846497e-07
of O 0 1.449274300568959e-08
the O 0 5.228941546420174e-08
presence O 0 4.4077268057662877e-07
of O 0 1.5894896066015463e-08
any O 0 5.884800913236177e-08
of O 0 4.0651794819268616e-08
the O 0 4.456257158835797e-07
eight O 0 4.642740805138601e-06
mutations O 0 7.508714043069631e-05
screened O 0 5.632321335724555e-05
. O 0 9.255913028027862e-06

Carriers O 0 2.118581505783368e-05
of O 0 9.730472072533303e-08
the O 0 1.7346658864880737e-07
same O 0 5.319974434314645e-07
mutation O 0 6.240157290449133e-06
, O 0 8.538149387504745e-08
from O 0 1.4840956907846703e-08
different O 0 1.048126652136716e-08
families O 0 5.024731564162721e-08
, O 0 9.046387106081966e-08
shared O 0 9.059129268962351e-08
similar O 0 1.2383418379613431e-06
haplotypes O 0 2.613968899822794e-05
, O 0 7.283721856765624e-07
indicating O 0 1.3764096138402238e-06
that O 0 2.0359605557018767e-08
the O 0 9.011014867610356e-08
mutant O 0 2.0153174773440696e-06
alleles O 0 5.909444666940544e-07
were O 0 1.6254871582077612e-07
likely O 0 1.054849576576089e-07
to O 0 3.970326289959303e-09
be O 0 2.0991551608062764e-08
identical O 0 2.0396672084643797e-07
by O 0 3.535528847464775e-08
descent O 0 5.355929602046672e-07
for O 0 3.217564170654441e-08
a O 0 9.246051604350214e-07
mutation O 0 4.9942696023208555e-06
in O 0 2.403707242137898e-07
the O 0 4.1721060028976353e-07
founder O 0 4.7765155613888055e-05
population O 0 3.9814383967495814e-07
. O 0 3.8830180528748315e-06

The O 0 5.45837281151762e-07
identification O 0 1.0550764955041814e-06
of O 0 4.1649101945040456e-07
common O 0 5.8736208302434534e-05
BRCA1 O 0 0.0015745057025924325
and O 0 1.6514941307832487e-05
BRCA2 O 0 0.0007648241589777172
mutations O 0 4.758979775942862e-05
will O 0 1.5947894382861705e-07
facilitate O 0 8.327422165166354e-07
carrier O 0 6.865686009405181e-05
detection O 0 5.557010445045307e-05
in O 0 4.428369720699266e-06
French O 0 0.0015975654823705554
Canadian O 0 0.05215577408671379
breast B-Disease 1 0.9998440742492676
cancer I-Disease 1 0.9999510049819946
and O 0 0.40513747930526733
breast B-Disease 1 0.9999897480010986
/ I-Disease 1 0.9999644756317139
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
families O 0 2.038755155808758e-05
. O 0 2.110767127305735e-05

Are O 0 2.748698079813039e-06
Dp71 O 0 0.0008009959128685296
and O 0 1.3516652870748658e-05
Dp140 O 0 0.0017053791088983417
brain O 0 0.4575605094432831
dystrophin O 0 0.0008523326832801104
isoforms O 0 1.5156992049014661e-05
related O 0 3.269865192123689e-05
to O 0 7.620446467626607e-06
cognitive B-Disease 0 0.07085998356342316
impairment I-Disease 1 0.998322069644928
in O 0 0.007769001182168722
Duchenne B-Disease 1 0.9999878406524658
muscular I-Disease 1 0.9999760389328003
dystrophy I-Disease 1 0.9999531507492065
? O 0 0.16392281651496887

Molecular O 0 0.00031866083736531436
study O 0 5.722771675209515e-06
and O 0 7.282756087079179e-07
neuropsychological O 0 3.9096263208193704e-05
analysis O 0 2.996526689003076e-07
were O 0 6.368765781417096e-08
performed O 0 1.7262244682569872e-06
concurrently O 0 1.3167353927201475e-06
on O 0 5.315579073794652e-06
49 O 0 7.300497964024544e-05
patients O 0 0.00012131690891692415
with O 0 0.0005343326483853161
Duchenne B-Disease 1 0.9999864101409912
muscular I-Disease 1 0.999982476234436
dystrophy I-Disease 1 0.9999470710754395
( O 0 0.0001478816120652482
DMD B-Disease 1 0.9995369911193848
) O 0 7.904978929218487e-07
in O 0 1.334012011966479e-07
order O 0 6.751307779495619e-08
to O 0 1.2967148244058535e-08
find O 0 1.1315071901663032e-07
a O 0 2.6380257622804493e-07
molecular O 0 9.439872883376665e-06
explanation O 0 1.062531623574614e-06
for O 0 7.855846462234695e-08
the O 0 2.2108652046881616e-06
cognitive B-Disease 0 0.0014081877889111638
impairment I-Disease 0 0.008546107448637486
observed O 0 5.133773083798587e-05
in O 0 6.024600224918686e-06
most O 0 7.350443775067106e-05
DMD B-Disease 1 0.9998637437820435
patients O 0 0.014812689274549484
. O 0 4.3220334191573784e-05

Complete O 0 3.105445784967742e-06
analysis O 0 3.634133918239968e-07
of O 0 3.474665888347772e-08
the O 0 1.8231294518500363e-07
dystrophin O 0 5.476854494190775e-05
gene O 0 8.121393875626381e-06
was O 0 4.678779532696353e-06
performed O 0 6.744839993189089e-07
to O 0 1.389623260905637e-08
define O 0 4.569331792936282e-07
the O 0 2.411329660390038e-07
localization O 0 6.977484190429095e-06
of O 0 1.0451326204474753e-07
deletions O 0 2.0000015865662135e-05
and O 0 1.0084967243528808e-06
duplications O 0 3.6054010706720874e-05
in O 0 1.0394959417681093e-06
relation O 0 1.4472103657681146e-06
to O 0 1.0235386582735373e-07
the O 0 6.469645086326636e-07
different O 0 1.1929674656130373e-05
DMD B-Disease 1 0.9997338652610779
promoters O 0 0.0027116963174194098
. O 0 4.26452279498335e-05

Qualitative O 0 8.271501428680494e-06
analysis O 0 1.9850417629641015e-06
of O 0 8.517898208992847e-08
the O 0 3.175460392412788e-07
Dp71 O 0 0.00010245556040899828
transcript O 0 1.6327083358191885e-05
and O 0 5.160615614840935e-07
testing O 0 5.851893547514919e-07
for O 0 7.012725511401641e-09
the O 0 2.1461497468067137e-08
specific O 0 1.3801878750996366e-08
first O 0 3.3256011988669343e-07
exon O 0 7.5379753070592415e-06
of O 0 5.998006713525683e-08
Dp140 O 0 1.1661041753541213e-05
were O 0 3.377643338353664e-07
also O 0 4.3893285806007043e-07
carried O 0 1.0188012993239681e-06
out O 0 7.420144925163186e-07
. O 0 2.551245643189759e-06

Neuropsychological O 0 0.0017085919389501214
analysis O 0 9.008417691802606e-06
assessed O 0 3.02097323583439e-05
verbal O 0 3.494795237202197e-05
and O 0 3.5223608847445576e-06
visuospatial O 0 0.001774728181771934
intelligence O 0 0.00016910296108108014
, O 0 5.386984867072897e-06
verbal O 0 6.066962669137865e-05
memory O 0 0.0014755296288058162
, O 0 4.2345927795395255e-06
and O 0 1.1902727692358894e-06
reading O 0 1.591884756635409e-05
skills O 0 8.815398905426264e-05
. O 0 1.92624211194925e-05

Comparison O 0 5.0997418838960584e-06
of O 0 4.432644402641017e-07
molecular O 0 0.0001546657003927976
and O 0 6.101886356191244e-06
psychometric O 0 0.001066508935764432
findings O 0 2.305315683770459e-05
demonstrated O 0 7.255253422044916e-06
that O 0 9.777541265520995e-08
deletions O 0 7.1963295340538025e-06
and O 0 3.8994068063402665e-07
duplications O 0 1.3390507774602156e-05
that O 0 8.111651084163896e-08
were O 0 1.1712377556705178e-07
localized O 0 2.5525852834107354e-05
in O 0 4.1783647475313046e-07
the O 0 2.283561002514034e-07
distal O 0 0.000143880708492361
part O 0 1.0747723990789382e-06
of O 0 6.521513284951652e-08
the O 0 2.1856823195776087e-07
gene O 0 2.8175118131912313e-06
seemed O 0 2.698859134397935e-06
to O 0 1.6878189512681274e-08
be O 0 6.313855038797556e-08
preferentially O 0 8.534947255611769e-07
associated O 0 1.919502437885967e-06
with O 0 3.4195616080978652e-06
cognitive B-Disease 0 0.016188975423574448
impairment I-Disease 1 0.9764702916145325
. O 0 4.3549171095946804e-05

Two O 0 1.569762162034749e-06
altered O 0 3.675400876090862e-05
Dp71 O 0 0.00012824410805478692
transcripts O 0 5.75252761336742e-06
and O 0 1.7299326771080814e-07
two O 0 8.781515958844466e-08
deleted O 0 2.244437609988381e-06
Dp140 O 0 5.297270945447963e-06
DNA O 0 3.1213286888487346e-07
sequences O 0 5.595932250912483e-08
were O 0 5.736672292755429e-08
found O 0 2.1963910512567963e-07
in O 0 1.6604359132088575e-07
four O 0 1.58060345256672e-06
patients O 0 0.00011175022518727928
with O 0 0.00020785235392395407
severe O 1 0.9999524354934692
cerebral B-Disease 1 0.9999831914901733
dysfunction I-Disease 1 0.9997041821479797
. O 0 0.00022907012316863984

These O 0 9.721676406115876e-07
findings O 0 3.6320036542747403e-06
suggest O 0 2.578491660187865e-07
that O 0 6.12006223477124e-09
some O 0 1.388689829795453e-09
sequences O 0 6.479259440084206e-08
located O 0 9.129125828621909e-07
in O 0 1.2157141782154213e-07
the O 0 1.2757962508658238e-07
distal O 0 9.309318556915969e-05
part O 0 8.63566185671516e-07
of O 0 3.7317136047931854e-08
the O 0 1.668611275817966e-07
gene O 0 2.0623401724151336e-06
and O 0 6.965669285818876e-07
, O 0 2.4944833398876654e-07
in O 0 9.029871961274694e-08
particular O 0 2.0389185806379828e-07
, O 0 1.954455655095444e-07
some O 0 9.299627379277808e-08
DMD B-Disease 1 0.8440203070640564
isoforms O 0 1.613349581930379e-06
expressed O 0 1.0154470828638296e-06
in O 0 1.0031671990873292e-06
the O 0 4.720105152955512e-06
brain O 1 0.9975289702415466
may O 0 6.543269591929857e-06
be O 0 9.173768944492622e-08
related O 0 3.681343514472246e-07
to O 0 1.6431428662144754e-07
the O 0 4.1428511394769885e-06
cognitive B-Disease 0 0.011114006862044334
impairment I-Disease 1 0.8668655157089233
associated O 0 0.00010159039811696857
with O 0 8.27379190013744e-05
DMD B-Disease 1 0.9999344348907471
. O 0 1.7029407899826765e-05
. O 0 1.2940167835040484e-05

I1307K O 0 0.002677805256098509
APC O 0 0.0005283313221298158
and O 0 5.1742445066338405e-06
hMLH1 O 0 0.0002341860526939854
mutations O 0 6.626778485951945e-05
in O 0 7.389855909423204e-07
a O 0 1.7726849819155177e-06
non O 0 2.0203102394589223e-05
- O 0 4.415052535478026e-05
Jewish O 0 3.186008825650788e-06
family O 0 6.980085800023517e-06
with O 0 1.3829349882144015e-05
hereditary B-Disease 1 0.999860405921936
non I-Disease 1 0.9998830556869507
- I-Disease 1 0.9999939203262329
polyposis I-Disease 1 0.999994158744812
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.0002771137224044651

We O 0 3.7097427139087813e-06
describe O 0 4.5291676542547066e-06
a O 0 3.4669055821723305e-06
French O 0 0.00046414800453931093
Canadian O 0 0.0016403524205088615
hereditary B-Disease 1 0.9998470544815063
non I-Disease 1 0.9998955726623535
- I-Disease 1 0.9999948740005493
polyposis I-Disease 1 0.999993085861206
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
( O 0 0.00011841420200653374
HNPCC B-Disease 1 0.9435210824012756
) O 0 1.7494946860097116e-06
kindred O 0 0.0001288228522753343
which O 0 5.147118713466625e-07
carries O 0 1.1353729405527702e-06
a O 0 2.294673549840809e-06
novel O 0 1.1468985576357227e-05
truncating O 0 0.0005569887580350041
mutation O 0 0.0001793808041838929
in O 0 7.141798505472252e-06
hMLH1 O 0 0.0013148661237210035
. O 0 2.2266898668021895e-05

Interestingly O 0 8.376758341910318e-05
, O 0 1.401758936481201e-06
the O 0 6.670749712611723e-07
I1307K O 0 8.600696310168132e-05
APC O 0 7.244863081723452e-05
polymorphism O 0 1.1528903087310027e-05
, O 0 3.8215648601180874e-07
associated O 0 3.523076088640664e-07
with O 0 3.8754418341113706e-08
an O 0 4.745095054659032e-07
increased O 0 1.3661328011949081e-05
risk O 0 0.003307525534182787
of O 0 0.0303003191947937
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
, O 0 1.3538867278839462e-05
is O 0 2.741258526839374e-07
also O 0 1.1703792068828989e-07
present O 0 9.07471147115757e-08
in O 0 1.4704896500461473e-07
this O 0 9.770195674718707e-08
family O 0 7.504907898692181e-06
. O 0 7.429551715176785e-06

The O 0 4.9945219871005975e-06
I1307K O 0 0.0001313452812610194
polymorphism O 0 1.7222044334630482e-05
has O 0 6.910078127475572e-07
previously O 0 3.246776714149746e-07
only O 0 1.8621904018800706e-08
been O 0 1.7061557855413412e-07
identified O 0 1.845813102363536e-07
in O 0 2.5068118247872917e-08
individuals O 0 1.2822726880301616e-08
of O 0 2.0721786597732716e-07
self O 0 0.00033232406713068485
- O 0 0.03485488519072533
reported O 0 0.00010443994688102975
Ashkenazi O 0 0.00016034049622248858
Jewish O 0 1.2394345503707882e-05
origins O 0 9.080593736143783e-05
. O 0 3.0148201403790154e-05

In O 0 8.643662567919819e-07
addition O 0 6.899976483509818e-07
, O 0 4.2137151012866525e-07
in O 0 9.938071343640331e-08
this O 0 3.788831293149997e-08
family O 0 1.4652894151367946e-06
, O 0 2.3124694337184337e-07
there O 0 4.190336255760485e-08
appears O 0 3.2933675697677245e-07
to O 0 1.131549876021154e-08
be O 0 3.214987742694575e-08
no O 0 5.851458695360634e-08
relationship O 0 3.5158194577888935e-07
between O 0 1.9510643767262081e-07
the O 0 4.852343522543379e-07
I1307K O 0 3.2580806873738766e-05
polymorphism O 0 3.941659088013694e-06
and O 0 2.481040439761273e-07
the O 0 1.7011858233217936e-07
presence O 0 1.6278326029350865e-06
or O 0 3.9837318581703585e-06
absence O 0 3.9922957512317225e-05
of O 0 6.295158982538851e-06
cancer B-Disease 1 0.999345600605011
. O 0 2.0205538930895273e-06
. O 0 6.820111138949869e-06

Identification O 0 2.467915464876569e-06
of O 0 1.8109024324530765e-07
a O 0 1.6147873793670442e-06
novel O 0 5.565325409406796e-06
mutation O 0 7.073756933095865e-06
of O 0 5.7080217885641105e-08
the O 0 3.0168970965860353e-07
CPO O 0 2.4752936951699667e-05
gene O 0 2.7993264666292816e-06
in O 0 3.508778831928794e-07
a O 0 3.0180992780515226e-06
Japanese O 0 8.124877058435231e-05
hereditary B-Disease 1 0.997444748878479
coproporphyria I-Disease 0 0.4064030647277832
family O 0 0.000296116282697767
. O 0 3.507821020320989e-05

Hereditary B-Disease 1 0.9947921633720398
coproporphyria I-Disease 1 0.8999881744384766
( O 0 2.988456435559783e-05
HCP B-Disease 0 0.033158425241708755
) O 0 1.2393909400998382e-06
is O 0 1.2641502280530403e-06
an O 0 3.938735517294845e-06
autosomal B-Disease 1 0.9984645843505859
dominant I-Disease 1 0.9996567964553833
disease I-Disease 1 0.999963641166687
characterized O 0 0.0025806992780417204
by O 0 4.921133950119838e-06
a O 0 0.0004896169994026423
deficiency B-Disease 1 0.9984582662582397
of I-Disease 0 6.36718084479071e-07
coproporphyrinogen I-Disease 0 0.002025164430961013
oxidase I-Disease 0 6.62561651552096e-05
( O 0 1.2134291864640545e-06
CPO O 0 5.327451799530536e-05
) O 0 3.017694325535558e-07
caused O 0 4.570483270072145e-06
by O 0 3.057014907881239e-08
a O 0 5.420463367045159e-07
mutation O 0 4.268399607099127e-06
in O 0 1.5529259655977512e-07
the O 0 3.8055407003412256e-07
CPO O 0 6.82292302371934e-05
gene O 0 2.860062704712618e-05
. O 0 6.9117595558054745e-06

Only O 0 7.849987468944164e-07
11 O 0 1.8692721823754255e-06
mutations O 0 3.6507592540147016e-06
of O 0 1.3410091703747185e-08
the O 0 9.831004632587792e-08
gene O 0 1.2618869504876784e-06
have O 0 2.871061326459312e-07
been O 0 2.1769565137219615e-06
reported O 0 8.761288881942164e-06
in O 0 3.810054295172449e-06
HCP B-Disease 1 0.915887713432312
patients O 0 0.0011428706347942352
. O 0 1.383669859933434e-05

We O 0 8.61939861351857e-06
report O 0 8.75300202096696e-07
another O 0 1.9464069112018478e-07
mutation O 0 2.934896656370256e-06
in O 0 1.6041674655298266e-07
a O 0 9.73286432781606e-07
Japanese O 0 1.7233214748557657e-05
family O 0 1.2721778148261365e-05
. O 0 7.382864623650676e-06

Polymerase O 0 0.00029607341275550425
chain O 0 0.00029690840165130794
reaction O 0 3.1156570912571624e-05
- O 0 1.5209770026558544e-05
single O 0 1.253782784260693e-06
strand O 0 8.491297194268554e-06
conformational O 0 6.23981213720981e-06
polymorphism O 0 1.5562795852019917e-06
and O 0 2.9612317931082544e-08
direct O 0 4.794065233681977e-08
sequence O 0 3.666984582650912e-07
analyses O 0 1.0121899549631053e-06
demonstrated O 0 7.71458189774421e-07
a O 0 6.435388968384359e-07
C O 0 4.602772605721839e-06
to O 0 4.028361999530716e-08
T O 0 1.598226481291931e-05
substitution O 0 3.6157903338107644e-08
in O 0 4.435984379824731e-08
exon O 0 3.084301397393574e-06
1 O 0 2.469445234964951e-07
of O 0 2.0195193073391238e-08
the O 0 1.6060441510035162e-07
CPO O 0 1.2303031326155178e-05
gene O 0 7.246640052471776e-07
at O 0 1.5310738490370568e-06
nucleotide O 0 2.0493239389907103e-06
position O 0 4.245882792019984e-06
85 O 0 2.826441232173238e-06
, O 0 2.1498314595191914e-07
which O 0 1.3170691204322793e-07
lies O 0 1.2110408533771988e-06
in O 0 1.247624226152766e-07
the O 0 2.989567917666136e-07
putative O 0 1.5979583622538485e-05
presequence O 0 3.0240918931667693e-05
for O 0 3.9857610545368516e-08
targeting O 0 5.953476147624315e-07
to O 0 2.6393618668407726e-07
mitochondria O 0 0.00014056051441002637
. O 0 2.7033956939703785e-05

This O 0 3.054878334296518e-06
mutation O 0 2.9702612664550543e-05
changes O 0 1.725082256598398e-06
the O 0 3.0829437491775025e-07
codon O 0 1.1463979490144993e-06
for O 0 3.556380079317023e-08
glutamine O 0 1.0950791420327732e-06
to O 0 4.8300254462674275e-08
a O 0 9.56403937379946e-07
termination O 0 1.1684731362038292e-05
codon O 0 6.06785761192441e-06
at O 0 4.589448508340865e-06
amino O 0 2.004917860176647e-06
acid O 0 1.6626541764708236e-05
position O 0 1.4296582776296418e-05
29 O 0 5.489612522069365e-05
. O 0 2.2237325083551696e-06

MaeI O 0 0.0008884425624273717
restriction O 0 1.6511950207132031e-06
analysis O 0 3.417999323573895e-07
showed O 0 4.775821480507147e-07
two O 0 1.675780225696144e-08
other O 0 2.5514173884744196e-08
carriers O 0 1.9376814179850044e-06
in O 0 3.151088492359122e-07
the O 0 5.597564722847892e-07
family O 0 1.578116098244209e-05
. O 0 1.4528867723129224e-05

The O 0 2.2786192857893184e-05
C O 0 0.0035550063475966454
- O 0 0.008447240106761456
T O 0 0.006948682479560375
mutation O 0 3.7670273741241544e-05
is O 0 2.6790345941662963e-07
located O 0 3.52553627180896e-07
within O 0 1.6119825829719048e-07
a O 0 1.437716946384171e-06
recently O 0 1.0090306204801891e-05
proposed O 0 1.6017185089367558e-06
putative O 0 3.4610452530614566e-06
alternative O 0 4.5675020032831526e-07
translation O 0 7.049593477859162e-07
initiation O 0 3.004951622642693e-06
codon O 0 1.3070095519651659e-05
( O 0 9.165738674710155e-07
TIC O 0 0.00033862993586808443
- O 0 1.2643451555049978e-05
1 O 0 6.749311864950869e-07
) O 0 2.3079698152628225e-08
, O 0 4.594675928615288e-08
supporting O 0 2.2660644560801302e-07
that O 0 1.7796303097838972e-07
TIC O 0 0.0003740610263776034
- O 0 1.4840562471363228e-05
1 O 0 8.940421025727119e-07
is O 0 1.7037234556482872e-07
the O 0 2.2585500403238257e-07
real O 0 4.463672212295933e-06
TIC O 0 0.00046025149640627205
rather O 0 8.314415822496812e-07
than O 0 1.016003125187126e-06
TIC O 0 0.0008908414165489376
- O 0 4.011399869341403e-05
2 O 0 3.251928546887939e-06
. O 0 4.0458959915667947e-07
. O 0 1.9861267901433166e-06

Human B-Disease 0 6.209340790519491e-05
complement I-Disease 0 0.000204417432541959
factor I-Disease 0 0.01685924455523491
H I-Disease 1 0.9999954700469971
deficiency I-Disease 1 0.9999263286590576
associated O 0 0.005594496615231037
with O 1 0.5725287199020386
hemolytic B-Disease 1 0.9999996423721313
uremic I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999995231628418
. O 0 0.0007250775233842432

This O 0 2.4259466613330005e-07
study O 0 3.7996403534634737e-07
reports O 0 3.242639365907962e-07
on O 0 8.489560627822357e-07
six O 0 1.5289507473426056e-06
cases O 0 4.042901764478302e-06
of O 0 3.7407862691907212e-06
deficiency B-Disease 1 0.9997045397758484
in I-Disease 0 2.9807597456965595e-07
the I-Disease 0 1.4920691171482758e-07
human I-Disease 0 5.570203711613431e-07
complement I-Disease 0 1.0391024716227548e-06
regulatory I-Disease 0 1.910133687488269e-05
protein I-Disease 0 9.677565685706213e-06
Factor I-Disease 0 2.6389760023448616e-05
H I-Disease 1 0.9979575872421265
( O 0 1.4388679119292647e-06
FH O 0 5.446188151836395e-05
) O 0 4.494956939993244e-08
in O 0 2.4532717191050324e-08
the O 0 2.7051695994373404e-08
context O 0 6.848775910839322e-07
of O 0 1.2793736914318288e-06
an O 0 0.0008002921240404248
acute B-Disease 1 0.9999818801879883
renal I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 0.0009626646642573178

Five O 0 1.1694413615259691e-06
of O 0 6.927881912588418e-08
the O 0 1.6942043146173091e-07
cases O 0 4.377702964575292e-07
were O 0 1.332628585259954e-07
observed O 0 1.9032793261430925e-06
in O 0 3.0316698484966764e-07
children O 0 4.4319807557258173e-07
presenting O 0 3.584402656997554e-05
with O 0 0.00860620941966772
idiopathic O 1 0.999992847442627
hemolytic B-Disease 1 0.9999998807907104
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 0.0010482171783223748
HUS B-Disease 1 0.9996393918991089
) O 0 1.8969163647852838e-05
. O 0 1.9005343347089365e-05

Two O 0 5.181307756174647e-07
of O 0 5.90458881788436e-08
the O 0 3.1463346772397927e-07
children O 0 1.314357973569713e-06
exhibited O 0 0.00019717204850167036
a O 0 0.00014882483810652047
homozygous O 0 0.009695429354906082
deficiency O 1 0.9982397556304932
characterized O 0 8.067699673119932e-05
by O 0 1.5517667861786322e-07
the O 0 1.4984432539222325e-07
absence O 0 3.185279865647317e-06
of O 0 3.596894870838696e-08
the O 0 3.274145683462848e-07
150 O 0 1.334369926553336e-06
- O 0 1.7959044271265157e-05
kD O 0 4.1363669879501686e-05
form O 0 8.68795098085684e-07
of O 0 3.0570097919735417e-07
Factor O 0 7.981009730428923e-06
H O 1 0.9990828037261963
and O 0 7.44843987376953e-07
the O 0 1.6633458699288894e-07
presence O 0 4.2817370626835327e-07
, O 0 1.0722481391667316e-07
upon O 0 1.1415546907755925e-07
immunoblotting O 0 3.8321792089845985e-05
, O 0 2.5767340616766887e-07
of O 0 2.3711892893629738e-08
the O 0 4.41192412381497e-07
42 O 0 8.959941624198109e-06
- O 0 2.2437985535361804e-05
kD O 0 0.00010278289119014516
Factor O 0 9.25646054383833e-06
H O 0 0.026265744119882584
- O 0 6.510087587230373e-06
like O 0 4.5017051775175787e-07
protein O 0 6.232611440282199e-07
1 O 0 6.610895297853858e-07
( O 0 1.6832450455694925e-07
FHL O 0 0.00011324938532197848
- O 0 6.012363883201033e-06
1 O 0 4.697906206274638e-07
) O 0 1.7860514844869613e-08
and O 0 2.5647961976460465e-08
other O 0 9.853869897824552e-08
FH O 0 0.00015664428065065295
- O 0 1.2788633284799289e-05
related O 0 1.5972292430888047e-06
protein O 0 1.589027988302405e-06
( O 0 3.74231319710816e-07
FHR O 0 0.00014331219426821917
) O 0 4.1139389850286534e-07
bands O 0 4.4587643060367554e-05
. O 0 6.327649771264987e-06

Southern O 0 0.00015209145203698426
blot O 0 0.0011843768879771233
and O 0 9.13810595193354e-07
PCR O 0 3.9320552787103225e-06
analysis O 0 1.6656126433645113e-07
of O 0 1.9819434982082385e-08
DNA O 0 1.6192285556826391e-06
of O 0 7.900654708237198e-08
one O 0 2.112112724717008e-06
patient O 0 0.00015597595483995974
with O 0 1.8894686945714056e-05
homozygous O 0 0.009169942699372768
deficiency O 1 0.999415397644043
ruled O 0 3.407238546060398e-05
out O 0 9.255123956108946e-08
the O 0 3.971078044173737e-08
presence O 0 1.5322802937589586e-07
of O 0 1.5010428455752844e-08
a O 0 2.783338572953653e-07
large O 0 7.580497936032771e-07
deletion O 0 8.227499165514018e-06
of O 0 5.435465766367997e-08
the O 0 1.0630504903019755e-06
FH O 0 0.0002052635099971667
gene O 0 5.871122993994504e-06
as O 0 1.4232388139134855e-06
the O 0 1.1474041912151733e-06
underlying O 0 0.00035506757558323443
defect O 0 0.09797249734401703
for O 0 3.3675419217615854e-06
the O 0 0.0004766346828546375
deficiency O 1 0.9997554421424866
. O 0 3.4970089473063126e-05

The O 0 4.3036268948526413e-07
other O 0 1.112334189201647e-07
four O 0 2.2401766841539938e-07
children O 0 2.1387600668276718e-07
presented O 0 2.5157291929645e-06
with O 0 5.092228548164712e-06
heterozygous O 0 0.0002604795736260712
deficiency O 1 0.9974756836891174
and O 0 6.680216415588802e-07
exhibited O 0 2.216566826973576e-05
a O 0 1.0493126865185332e-06
normal O 0 1.0870104233617894e-05
immunoblotting O 0 8.879985398380086e-05
pattern O 0 9.360098374600057e-06
of O 0 2.4850985269608827e-08
proteins O 0 2.8968156584596727e-07
of O 0 1.7150631492768298e-07
the O 0 5.498411610460607e-06
FH O 0 0.0035658618435263634
family O 0 4.2372048483230174e-05
. O 0 1.2894785868411418e-05

Factor B-Disease 0 0.10560881346464157
H I-Disease 1 0.9999943971633911
deficiency I-Disease 1 0.9999188184738159
is O 0 3.7203114970907336e-06
the O 0 1.2558699609144242e-06
only O 0 8.167715350282378e-06
complement B-Disease 1 0.9993632435798645
deficiency I-Disease 1 0.999996542930603
associated O 0 0.00022678849927615374
with O 0 8.043011621339247e-05
HUS B-Disease 1 0.999704897403717
. O 0 0.0001217603130498901

These O 0 1.6491932797180198e-07
observations O 0 4.925082066620234e-06
suggest O 0 1.5303176041925326e-06
a O 0 4.172666479007603e-07
role O 0 1.5013843039923813e-06
for O 0 5.99938005052536e-07
FH O 0 0.00021624157670885324
and O 0 2.3354084532911656e-06
/ O 0 3.2091582397697493e-05
or O 0 5.331943157216301e-06
FH O 0 0.00019436542061157525
receptors O 0 1.5762378097861074e-05
in O 0 8.127801720547723e-07
the O 0 1.2986474757781252e-06
pathogenesis O 0 0.03331441804766655
of O 0 3.735482459887862e-05
idiopathic O 1 0.9998095631599426
HUS B-Disease 1 0.9999110698699951
. O 0 6.322340777842328e-05
. O 0 3.424157330300659e-05

Further O 0 3.523277598560526e-07
evidence O 0 1.6272926472993277e-07
for O 0 2.3774477497795488e-08
a O 0 1.4609527170250658e-06
major O 0 5.7632085372461006e-05
ancient O 0 0.00025433237897232175
mutation O 0 0.18744774162769318
underlying O 1 0.9844260215759277
myotonic B-Disease 1 0.9999876022338867
dystrophy I-Disease 1 0.9999943971633911
from O 0 2.565360591688659e-05
linkage O 0 0.00027025153394788504
disequilibrium O 0 0.0011642305180430412
studies O 0 6.648554517596494e-06
in O 0 5.32061335434264e-07
the O 0 3.063705094064062e-07
Japanese O 0 7.783361070323735e-06
population O 0 4.6532102260243846e-07
. O 0 5.500026873050956e-06

The O 0 0.008465716615319252
myotonic B-Disease 1 0.9999655485153198
dystrophy I-Disease 1 0.9999953508377075
( O 0 0.0006947575602680445
DM B-Disease 1 0.9999068975448608
) O 0 8.284724572149571e-06
mutation O 0 8.792061998974532e-05
is O 0 2.355413698751363e-06
an O 0 1.6460662664030679e-06
unstable O 0 0.080460324883461
( O 0 2.354825255679316e-06
CTG O 0 0.0001762769097695127
) O 0 3.839937221528089e-07
n O 0 1.1389603059797082e-05
repeat O 0 7.89094792708056e-06
, O 0 2.3012144367839937e-07
present O 0 6.311061184760547e-08
at O 0 7.080587351993017e-07
a O 0 7.400563362125467e-08
copy O 0 3.4193161013718054e-07
number O 0 3.0213477941742894e-08
of O 0 4.7854229023869266e-08
5 O 0 1.772279347278527e-06
- O 0 1.1342031029926147e-05
37 O 0 1.8701280168897938e-06
repeats O 0 2.7188157218915876e-06
on O 0 3.323118846765283e-07
normal O 0 1.3584242424258264e-06
chromosomes O 0 1.492050500928599e-06
but O 0 1.0496494695644287e-07
amplified O 0 1.7089598713937448e-06
to O 0 3.3735542359636383e-08
50 O 0 3.6827552207796543e-07
- O 0 2.1183884655329166e-06
3000 O 0 1.190120656247018e-06
copies O 0 8.854372595124005e-07
on O 0 3.505295899230987e-05
DM B-Disease 1 0.9973535537719727
chromosomes O 0 0.00023842528753448278
. O 0 2.084523657686077e-05

Previous O 0 2.716428389248904e-05
findings O 0 8.702265404281206e-06
in O 0 9.969775192075758e-07
Caucasian O 0 3.606188329285942e-05
populations O 0 2.368618652326404e-06
of O 0 5.209698770158866e-07
a O 0 0.00016985717229545116
DM B-Disease 1 0.9999548196792603
founder O 0 0.0005130594945512712
chromosome O 0 0.0001370994868921116
raise O 0 1.7636568827583687e-06
a O 0 4.6529794417438097e-07
question O 0 3.2609051459076e-07
about O 0 3.087403399604227e-08
the O 0 4.404335385288505e-08
molecular O 0 5.525303549802629e-06
events O 0 1.7509374572455272e-07
involved O 0 3.0186640742613235e-07
in O 0 2.382575985393487e-07
the O 0 4.865058258474164e-07
expansion O 0 3.980260225944221e-05
mutation O 0 0.0003051629464607686
. O 0 1.2279165275685955e-05

To O 0 2.573615063283796e-07
investigate O 0 2.8040742563462118e-06
whether O 0 2.6074235393025447e-07
a O 0 1.6198835055547534e-06
founder O 0 2.4953378670034e-05
chromosome O 0 3.07793561660219e-05
for O 0 3.447840413173253e-07
the O 0 9.677269190433435e-06
DM B-Disease 1 0.9998413324356079
mutation O 0 6.366646994138137e-05
exists O 0 1.1122891692139092e-06
in O 0 1.3681945176813315e-07
the O 0 8.219268465836649e-08
Japanese O 0 1.348412070001359e-06
population O 0 3.622520594603884e-08
, O 0 3.4637156431926996e-07
we O 0 3.0728023148185457e-07
genotyped O 0 3.079042653553188e-05
families O 0 8.585212896150551e-08
using O 0 9.48150557178451e-07
polymorphic O 0 8.361325308214873e-05
markers O 0 7.436862506438047e-05
near O 0 3.5824930819217116e-05
the O 0 1.3425059250948834e-06
( O 0 7.868230227359163e-07
CTG O 0 8.818400965537876e-05
) O 0 3.757777449209243e-07
n O 0 1.7716454749461263e-05
repeat O 0 2.7258978661848232e-05
region O 0 6.316447979770601e-06
and O 0 8.904393666853139e-07
constructed O 0 6.832520011812449e-05
haplotypes O 0 0.00043115366133861244
. O 0 1.774629890860524e-05

Six O 0 6.655708943981153e-07
different O 0 5.806453629020325e-08
haplotypes O 0 1.574615089339204e-05
were O 0 1.0459417580932495e-06
found O 0 2.917920255640638e-06
and O 0 6.06081948717474e-06
DM B-Disease 1 0.999293327331543
alleles O 0 1.2745433195959777e-05
were O 0 2.0731740733026527e-06
always O 0 5.528445399249904e-06
haplotype O 0 0.00018758534861262888
A O 0 2.522755676181987e-05
. O 0 9.788017450773623e-06

To O 0 2.1615146295062004e-07
find O 0 3.0228181913116714e-07
an O 0 4.184114388294802e-08
origin O 0 4.6715022961052455e-08
of O 0 5.198789665428194e-08
the O 0 4.1649622062323033e-07
( O 0 7.540295428043464e-07
CTG O 0 0.000139257128466852
) O 0 4.2989464077436423e-07
n O 0 1.444303688913351e-05
repeat O 0 1.804691601137165e-05
mutation O 0 8.55294092616532e-06
and O 0 1.0561743124526402e-07
to O 0 1.5610369885621367e-08
investigate O 0 6.250754722714191e-07
the O 0 5.8614446629690065e-08
mechanism O 0 1.1848026133520762e-06
of O 0 4.188530056126183e-08
the O 0 1.8161047421472176e-07
expansion O 0 5.556601990974741e-06
mutation O 0 1.592644002812449e-05
in O 0 1.3727846237543417e-07
the O 0 7.663056322826378e-08
Japanese O 0 8.305896699312143e-07
population O 0 1.1730135973664346e-08
we O 0 5.223817822752608e-08
have O 0 5.1903676023812295e-08
studied O 0 3.889340860041557e-06
90 O 0 2.842969706762233e-06
Japanese O 0 4.755939880851656e-05
DM B-Disease 1 0.9991679191589355
families O 0 4.53575353276392e-07
comprising O 0 1.0001762120737112e-06
190 O 0 3.3544740745128365e-06
affected O 0 2.157849394279765e-06
and O 0 4.77494666029088e-07
130 O 0 2.580934506113408e-06
unaffected O 0 6.427055632229894e-05
members O 0 1.4855819472359144e-06
. O 0 8.694625648786314e-06

The O 0 3.3723431442922447e-06
results O 0 6.539638889080379e-06
suggest O 0 7.443647405125375e-07
that O 0 2.0032800307490106e-08
a O 0 2.482948389115336e-07
few O 0 3.908867540758365e-07
common O 0 1.3196417967265006e-06
ancestral O 0 7.313538390008034e-06
mutations O 0 5.003800833947025e-05
in O 0 3.823795964308374e-07
both O 0 2.1636304836647469e-07
Caucasian O 0 6.388254405464977e-05
and O 0 2.1650910184689565e-06
Japanese O 0 9.166873496724293e-06
populations O 0 4.321991582401097e-07
have O 0 3.411830107324931e-08
originated O 0 2.159898997433629e-07
by O 0 1.3240820884163895e-08
expansion O 0 1.8913085853000666e-07
of O 0 2.1596594734774044e-08
an O 0 7.05255303046215e-08
ancestral O 0 6.485382073151413e-06
n O 0 3.930373350158334e-05
= O 0 9.544636668579187e-06
5 O 0 5.398007374424196e-07
repeat O 0 1.1394461125746602e-06
to O 0 9.768761088935207e-08
n O 0 1.007703485811362e-05
= O 0 8.544226147932932e-06
19 O 0 3.5066550481133163e-06
- O 0 6.50750553177204e-06
37 O 0 1.2779726148437476e-06
copies O 0 1.04935975286935e-06
. O 0 4.39406312580104e-06

These O 0 8.503143078542053e-08
data O 0 4.962479920322949e-07
support O 0 1.9893388980563032e-07
multistep O 0 3.80757192033343e-05
models O 0 9.705468983156607e-06
of O 0 6.716782650073583e-07
triplet O 0 0.0016473578289151192
repeat O 0 6.211621803231537e-05
expansion O 0 7.06950186213362e-06
that O 0 5.457093621430431e-08
have O 0 2.950801381018664e-08
been O 0 8.664371620170641e-08
proposed O 0 1.0241069503535982e-07
for O 0 6.988293677068214e-08
both O 0 1.159984094556421e-05
DM B-Disease 1 0.9999773502349854
and O 0 0.0001730975927785039
Friedreichs B-Disease 0 0.48075157403945923
ataxia I-Disease 1 0.9980159997940063
. O 0 2.875350219255779e-05
. O 0 1.6852101907716133e-05

The O 0 7.849298526707571e-07
molecular O 0 5.380309448810294e-05
basis O 0 9.63654565566685e-06
of O 0 0.00018112114048562944
C6 B-Disease 1 0.9999988079071045
deficiency I-Disease 1 0.9999988079071045
in O 0 3.6361552702146582e-06
the O 0 4.3698025820049224e-07
western O 0 1.0468515029060654e-05
Cape O 0 6.573538848897442e-05
, O 0 1.2047064501530258e-06
South O 0 2.4810835839161882e-06
Africa O 0 3.590542064557667e-06
. O 0 5.808829428133322e-06

Deficiency B-Disease 1 0.9984488487243652
of I-Disease 0 3.351553630182025e-07
the I-Disease 0 9.3087191999075e-07
sixth I-Disease 0 5.637194408336654e-05
component I-Disease 0 1.0934024430753198e-05
of I-Disease 0 1.35184052396653e-07
human I-Disease 0 2.6571162834443385e-06
complement I-Disease 0 6.089887392590754e-06
( O 0 1.905131512103253e-06
C6 O 0 0.0032774065621197224
) O 0 2.564701446772233e-07
has O 0 4.047142567742412e-07
been O 0 4.183819442005188e-07
reported O 0 3.150923078010237e-07
in O 0 1.3978801227665372e-08
a O 0 5.38415250161961e-08
number O 0 1.2515849689975767e-08
of O 0 6.307015354423129e-09
families O 0 1.684075989771827e-08
from O 0 7.327077611307686e-08
the O 0 2.3330481724315177e-07
western O 0 7.284199000423541e-06
Cape O 0 5.530397538677789e-05
, O 0 1.4107509969107923e-06
South O 0 4.260042260284536e-06
Africa O 0 5.1283996072015725e-06
. O 0 3.951339294872014e-06

Meningococcal B-Disease 1 0.9963710308074951
disease I-Disease 1 0.9998496770858765
is O 0 6.256624328671023e-05
endemic O 0 0.00027967849746346474
in O 0 6.358121140692674e-07
the O 0 9.707019898996805e-07
Cape O 0 1.1883663319167681e-05
and O 0 9.562327818457561e-08
almost O 0 2.2802009880251717e-07
all O 0 2.802851994943012e-08
pedigrees O 0 1.2943303772772197e-05
of O 0 3.0353896818269277e-06
total O 0 0.000458679161965847
C6 B-Disease 1 0.9999964237213135
deficiency I-Disease 1 0.9999990463256836
( O 0 8.881757821654901e-06
C6Q0 O 0 0.0005672778934240341
) O 0 7.519542322143025e-08
have O 0 7.045198913147033e-08
been O 0 3.269761350566114e-07
ascertained O 0 6.307995590759674e-06
because O 0 1.4566259096682188e-06
of O 0 6.514130745927105e-06
recurrent O 1 0.999685525894165
disease O 1 0.9999305009841919
. O 0 7.119421206880361e-05

We O 0 1.850167450356821e-06
have O 0 8.382370708659437e-08
sequenced O 0 1.7000617162921117e-06
the O 0 9.004916279309327e-08
expressed O 0 2.242252179485149e-07
exons O 0 6.194065008457983e-06
of O 0 1.620203420316102e-07
the O 0 1.0792916782520479e-06
C6 O 0 0.0032158575486391783
gene O 0 5.331683496478945e-06
from O 0 3.849782217457687e-07
selected O 0 3.1140709211285866e-07
cases O 0 3.019430039330473e-07
and O 0 1.1276291189687981e-07
have O 0 9.077498930309957e-08
found O 0 7.103008101694286e-07
three O 0 8.841007002047263e-07
molecular O 0 0.0027593367267400026
defects O 1 0.9995154142379761
leading O 0 0.0002386149571975693
to O 0 1.2039610055580852e-06
total O 0 2.087149550789036e-05
deficiency O 1 0.9994439482688904
879delG O 0 0.0012808229075744748
, O 0 1.7355954469167045e-06
which O 0 1.7309790223407617e-07
is O 0 1.5007744025297143e-07
the O 0 4.834873266190698e-07
common O 0 2.7804764613392763e-05
defect O 0 0.012307862751185894
in O 0 1.2622034546438954e-06
the O 0 2.3200116174848517e-06
Cape O 0 6.060809755581431e-05
and O 0 1.2204449149066932e-06
hitherto O 0 3.141233173664659e-05
unreported O 0 1.0180661774938926e-05
, O 0 5.975820158710121e-07
and O 0 6.590719863197592e-07
1195delC O 0 8.944285218603909e-05
and O 0 1.7334102722088574e-06
1936delG O 0 0.00012237722694408149
, O 0 4.1988087673416885e-07
which O 0 5.080491050080127e-08
have O 0 6.842769550985395e-08
been O 0 2.3803070803296578e-07
previously O 0 8.741490091779269e-07
reported O 0 2.2267797703534598e-06
in O 0 1.8457883754763316e-07
African O 0 1.2627874639292713e-06
- O 0 6.835621752543375e-05
Americans O 0 1.0527859330977662e-06
. O 0 4.559125954983756e-06

We O 0 3.570865828805836e-06
also O 0 3.1748487572258455e-07
show O 0 5.167140670891968e-07
that O 0 2.824334011108931e-08
the O 0 2.479720535575325e-07
879delG O 0 0.00018429153715260327
and O 0 1.0876657142944168e-05
1195delC O 0 0.03635001555085182
defects O 1 0.9987008571624756
are O 0 1.942735110560534e-07
associated O 0 1.457253915759793e-06
with O 0 9.574918067301041e-07
characteristic O 0 0.011838859878480434
C6 O 1 0.9982511401176453
/ O 0 0.015277991071343422
C7 O 1 0.9281212687492371
region O 0 0.00010510864376556128
DNA O 0 4.400663965498097e-05
marker O 0 4.9741516704671085e-05
haplotypes O 0 2.9919068765593693e-05
, O 0 5.120074320075219e-07
although O 0 1.546137156083205e-07
small O 0 5.294849074743979e-07
variations O 0 9.872202099359129e-06
were O 0 1.060226736626646e-06
observed O 0 1.7179625501739793e-05
. O 0 6.018066414981149e-06

The O 0 2.8362099328660406e-05
1936delG O 0 0.00819011777639389
defect O 0 0.011910855770111084
was O 0 2.320995190530084e-05
observed O 0 3.029680783583899e-06
only O 0 8.545872276499722e-08
once O 0 3.125050852759159e-06
in O 0 2.231172828714989e-07
the O 0 3.3475890859335777e-07
Cape O 0 2.0042783944518305e-05
, O 0 2.6929052410196164e-07
but O 0 3.959626937444227e-08
its O 0 5.603974884138552e-08
associated O 0 2.804582209137152e-06
haplotype O 0 7.360769086517394e-05
could O 0 1.647151293582283e-06
be O 0 3.6294269989411987e-07
deduced O 0 7.060950792947551e-06
. O 0 5.4270403779810295e-06

The O 0 1.822711965360213e-06
data O 0 1.370857944493764e-06
from O 0 2.4371587414862006e-07
the O 0 1.249677126224924e-07
haplotypes O 0 1.0539307368162554e-05
indicate O 0 5.008350854041055e-07
that O 0 6.8068786163166806e-09
these O 0 9.162206993096333e-09
three O 0 3.8513391587002843e-07
molecular O 0 0.002082195831462741
defects O 1 0.997327446937561
account O 0 4.7303564087997074e-07
for O 0 1.316058302336387e-07
the O 0 3.8079620026110206e-06
defects O 1 0.999057948589325
in O 0 3.228482512440678e-07
all O 0 2.945762744843705e-08
the O 0 4.3423679585430364e-07
38 O 0 9.211418728227727e-06
unrelated O 0 1.6823489204398356e-05
C6Q0 O 0 0.00034509587567299604
individuals O 0 6.735718471873042e-08
we O 0 2.294635521593591e-07
have O 0 1.0141680917286067e-07
studied O 0 2.849065595000866e-06
from O 0 3.181817191943992e-07
the O 0 2.441644710415858e-06
Cape O 0 0.00018680303764995188
. O 0 9.611507266527042e-06

We O 0 6.525384833366843e-06
have O 0 5.221382366471516e-07
also O 0 7.480773547285935e-07
observed O 0 4.457639988686424e-06
the O 0 1.5544313782811514e-06
879delG O 0 0.0004986097337678075
defect O 0 0.0008673988631926477
in O 0 2.4664120701345382e-06
two O 0 1.3414663044386543e-05
Dutch O 1 0.9771552085876465
C6 B-Disease 1 0.9999868869781494
- I-Disease 1 0.9997240900993347
deficient I-Disease 1 0.9996039271354675
kindreds O 0 0.007695428095757961
, O 0 4.789395461557433e-06
but O 0 6.459960104621132e-07
the O 0 1.1770048331527505e-06
879delG O 0 0.0014086978044360876
defect O 0 0.0037105707451701164
in O 0 1.2355095577731845e-06
the O 0 1.517377882009896e-06
Cape O 0 3.973797720391303e-05
probably O 0 2.9675984478672035e-06
did O 0 1.4637150513863162e-07
not O 0 1.4058668895700066e-08
come O 0 5.2687262552808534e-08
from O 0 2.610498306410136e-08
The O 0 1.4252745472731476e-07
Netherlands O 0 1.2139815225964412e-05
. O 0 7.883635930738819e-07
. O 0 2.644161440912285e-06

Complement B-Disease 1 0.7926077246665955
C7 I-Disease 1 0.9999961853027344
deficiency I-Disease 1 0.9999991655349731
: O 0 7.691853170399554e-06
seven O 0 6.649605666098068e-07
further O 0 6.260742111408035e-07
molecular O 0 0.005917923524975777
defects O 1 0.9995437264442444
and O 0 6.358515634019568e-07
their O 0 1.948189805034417e-07
associated O 0 2.8455076972022653e-05
marker O 0 0.00027707990375347435
haplotypes O 0 0.000632458075415343
. O 0 1.6452157069579698e-05

Seven O 0 1.2056017340000835e-06
further O 0 1.968725342749167e-07
molecular O 0 3.891978849424049e-05
bases O 0 6.187299732118845e-05
of O 0 0.0002639118174556643
C7 B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999997615814209
are O 0 8.746928870095871e-06
described O 0 0.00016344973118975759
. O 0 1.1855128832394257e-05

All O 0 1.2554347961213352e-07
these O 0 7.255817280338306e-08
new O 0 5.348418198991567e-06
molecular O 0 0.0016945936949923635
defects O 1 0.9746214747428894
involve O 0 3.7748093291156692e-06
single O 0 5.251427410257747e-06
- O 0 2.6515210265642963e-05
nucleotide O 0 2.3890224838396534e-06
events O 0 6.032869350747205e-07
, O 0 2.8308389232734044e-07
deletions O 0 2.557450216045254e-06
and O 0 3.6508703260551556e-07
substitutions O 0 3.6722797176480526e-06
, O 0 1.6626988497137063e-07
some O 0 1.0509292103222379e-08
of O 0 1.7977228594645567e-08
which O 0 8.962011577295925e-08
alter O 0 1.467599122406682e-05
splice O 0 4.482857548282482e-05
sites O 0 6.819968348281691e-06
, O 0 7.412329523504013e-07
and O 0 4.963994797435589e-07
others O 0 1.12664179141575e-06
codons O 0 3.402361835469492e-05
. O 0 6.922756710991962e-06

They O 0 5.867400432180148e-07
are O 0 2.657227327063083e-08
distributed O 0 5.466844754664635e-08
along O 0 5.307179549163266e-07
the O 0 9.341401323581522e-07
C7 O 0 0.0017981559503823519
gene O 0 9.26273969525937e-06
, O 0 5.974355872240267e-07
but O 0 3.1825418744801937e-08
predominantly O 0 2.5569711681328045e-08
towards O 0 7.167236759642037e-08
the O 0 3.1054321425472153e-07
3 O 0 4.5177484935265966e-06
end O 0 1.525221250631148e-05
. O 0 4.688333774538478e-06

All O 0 1.805260438914047e-07
were O 0 3.1907842412692844e-07
found O 0 4.7088465748856834e-07
in O 0 9.494411301602668e-08
compound O 0 2.9766824809485115e-06
heterozygous O 0 2.099104449371225e-06
individuals O 0 3.0305164955279906e-07
. O 0 5.930327461101115e-06

The O 0 0.00014678091974928975
C6 O 1 0.9771142601966858
/ O 0 0.0043169790878891945
C7 O 1 0.6061488389968872
marker O 0 0.0003730251337401569
haplotypes O 0 0.00019292929209768772
associated O 0 8.833355423121247e-06
with O 0 2.138043328159256e-06
most O 0 6.528857920784503e-05
C7 B-Disease 1 0.9997065663337708
defects I-Disease 1 0.9998385906219482
are O 0 1.4937135119907907e-06
tabulated O 0 0.00016956296167336404
. O 0 1.86000738722214e-06
. O 0 5.662959210894769e-06

A O 0 2.0537634554784745e-05
genome O 0 1.95469765458256e-05
- O 0 1.093323044187855e-05
wide O 0 1.9773951862589456e-06
search O 0 8.594057021582557e-07
for O 0 3.1108683629099687e-07
chromosomal O 0 0.004470917861908674
loci O 0 0.00028650942840613425
linked O 0 0.0015427835751324892
to O 0 1.0131874660146423e-05
mental O 1 0.9941954016685486
health O 0 0.0008351689903065562
wellness O 0 0.00010942152584902942
in O 0 1.465725404159457e-06
relatives O 0 7.887103492976166e-06
at O 0 0.00015828687173780054
high O 0 0.001004265621304512
risk O 0 0.000693446141667664
for O 0 3.010366708622314e-05
bipolar B-Disease 1 0.9999822378158569
affective I-Disease 1 0.9999058246612549
disorder I-Disease 1 0.9999696016311646
among O 0 3.900492174579995e-06
the O 0 1.387522388540674e-06
Old O 0 5.743434667238034e-05
Order O 0 1.7274744550377363e-06
Amish O 0 7.314057438634336e-05
. O 0 9.920730917656329e-06

Bipolar B-Disease 1 0.9999710321426392
affective I-Disease 1 0.9998742341995239
disorder I-Disease 1 0.9999880790710449
( O 0 0.0015500386944040656
BPAD B-Disease 1 0.9999617338180542
; O 0 0.09931819885969162
manic B-Disease 1 0.9999814033508301
- I-Disease 1 0.9999721050262451
depressive I-Disease 1 0.9999881982803345
illness I-Disease 1 0.999832034111023
) O 0 1.8401428860670421e-06
is O 0 7.661798235858441e-07
characterized O 0 7.407238172163488e-06
by O 0 1.4045072305179929e-07
episodes O 0 5.220991624810267e-06
of O 0 2.0740583295264514e-06
mania B-Disease 0 0.11852347105741501
and O 0 1.4064311471884139e-05
/ O 0 0.00038393851718865335
or O 0 4.844279101234861e-05
hypomania B-Disease 1 0.7632377743721008
interspersed O 0 0.0003070022794418037
with O 0 4.929946044285316e-06
periods O 0 0.00021013258083257824
of O 0 1.5784185961820185e-05
depression B-Disease 1 0.988201916217804
. O 0 3.212119190720841e-05

Compelling O 0 1.20528575280332e-05
evidence O 0 1.5390962744277203e-06
supports O 0 1.4336642379930709e-06
a O 0 7.672656465729233e-07
significant O 0 7.462880944331118e-07
genetic O 0 7.429197466990445e-06
component O 0 1.1632474524958525e-05
in O 0 4.3546225469981437e-07
the O 0 6.999752031333628e-07
susceptibility O 0 3.895751797244884e-05
to O 0 8.221688858611742e-07
develop O 0 0.0013925597304478288
BPAD B-Disease 1 0.9998724460601807
. O 0 7.923907833173871e-05

To O 0 4.683126917370828e-07
date O 0 5.106423031975282e-06
, O 0 4.583752115649986e-07
however O 0 1.5910342199276784e-07
, O 0 9.556803348687026e-08
linkage O 0 3.0894002520653885e-06
studies O 0 1.9826946129342105e-07
have O 0 2.6856950441356275e-08
attempted O 0 4.955707026965683e-07
only O 0 2.667490051067034e-08
to O 0 6.052906087461452e-08
identify O 0 5.000403234589612e-06
chromosomal O 0 0.003157367929816246
loci O 0 5.1309834816493094e-05
that O 0 9.644254532759078e-07
cause O 0 3.392098005861044e-05
or O 0 1.268868004444812e-06
increase O 0 6.312036475719651e-07
the O 0 1.4262089962358004e-06
risk O 0 5.717493695556186e-05
of O 0 1.0203259535046527e-06
developing O 0 0.002252721693366766
BPAD B-Disease 1 0.9999309778213501
. O 0 6.560269684996456e-05

To O 0 3.2986295650516695e-07
determine O 0 7.100508696566976e-07
whether O 0 1.3051605662894872e-07
there O 0 7.763330245325051e-08
could O 0 2.7354454346095736e-07
be O 0 1.2174521657470905e-07
protective O 0 1.4916031432221644e-05
alleles O 0 1.2653141538976342e-06
that O 0 5.457519947071887e-08
prevent O 0 5.9121443882759195e-06
or O 0 2.0867573766736314e-06
reduce O 0 7.429381639667554e-06
the O 0 3.2164371077669784e-06
risk O 0 3.53180366801098e-05
of O 0 3.3743111771400436e-07
developing O 0 0.0002682607446331531
BPAD B-Disease 1 0.9998761415481567
, O 0 1.129778183894814e-06
similar O 0 1.3090010497762705e-07
to O 0 2.0774708175963497e-08
what O 0 1.1504861419098233e-07
is O 0 1.6277971326417173e-07
observed O 0 1.8081275356962578e-06
in O 0 6.870953370707866e-07
other O 0 9.866958862403408e-06
genetic B-Disease 1 0.9996283054351807
disorders I-Disease 1 0.9999991655349731
, O 0 2.6119654648937285e-05
we O 0 5.0839844334404916e-06
used O 0 6.004403257975355e-05
mental O 1 0.9639267325401306
health O 0 0.0012564773205667734
wellness O 0 0.00025854079285636544
( O 0 8.916740625863895e-07
absence O 0 7.658944923605304e-06
of O 0 6.220450359251117e-07
any O 0 5.581696314038709e-05
psychiatric B-Disease 1 0.999754011631012
disorder I-Disease 1 0.9999090433120728
) O 0 2.3087254419351666e-07
as O 0 2.730946562223835e-07
the O 0 2.281016548977277e-07
phenotype O 0 8.429815352428705e-06
in O 0 2.256016102819558e-07
our O 0 6.875312124066113e-07
genome O 0 1.2036053703923244e-05
- O 0 1.5751676983200014e-05
wide O 0 7.3756514211709145e-06
linkage O 0 5.107963806949556e-05
scan O 0 0.00021836320229340345
of O 0 1.0363270064317476e-07
several O 0 1.893407528541502e-07
large O 0 2.865633632609388e-06
multigeneration O 0 0.00031499125179834664
Old O 0 2.6290310415788554e-05
Order O 0 2.6456268642505165e-07
Amish O 0 4.835523668589303e-06
pedigrees O 0 1.9755423636524938e-05
exhibiting O 0 2.105658313666936e-05
an O 0 1.0944099813059438e-06
extremely O 0 0.00032169162295758724
high O 0 0.0015907410997897387
incidence O 0 0.06550832092761993
of O 0 1.2567693374876399e-05
BPAD B-Disease 1 0.9998300075531006
. O 0 8.730971603654325e-05

We O 0 3.61780917046417e-06
have O 0 3.0821854579698993e-07
found O 0 3.2963495755211625e-07
strong O 0 1.781214677976095e-07
evidence O 0 6.39798685142523e-08
for O 0 4.001131870268182e-08
a O 0 7.953526619530749e-07
locus O 0 1.733422323013656e-05
on O 0 7.686274329898879e-06
chromosome O 0 0.0004557813808787614
4p O 0 0.01629507914185524
at O 0 4.742099918075837e-05
D4S2949 O 0 5.2521732868626714e-05
( O 0 4.4311141778052843e-07
maximum O 0 1.985878725463408e-06
GENEHUNTER O 0 0.00044161584810353816
- O 0 2.70964465016732e-05
PLUS O 0 5.547970886254916e-06
nonparametric O 0 7.429806373693282e-06
linkage O 0 4.562422418530332e-06
score O 0 8.94670563411637e-07
= O 0 3.6382084545039106e-06
4 O 0 3.892555184847879e-07
. O 0 5.107852274477409e-08
05 O 0 9.693850188341457e-06
, O 0 4.5274038029674557e-07
P O 0 1.4308096069726162e-05
= O 0 1.5321779756050091e-06
5 O 0 1.4941151960101706e-07
. O 0 2.284303057820125e-08
22 O 0 2.006025852097082e-07
x O 0 1.9706292277987814e-06
10 O 0 1.5947195208809717e-07
( O 0 6.09820460795163e-08
- O 0 2.10512689591269e-06
4 O 0 5.631908948089404e-07
) O 0 2.0851842919000774e-08
; O 0 5.014305415329545e-08
SIBPAL O 0 2.057811798295006e-05
Pempirical O 0 9.267891073250212e-06
value O 0 1.6591110352237592e-07
< O 0 2.5167082640109584e-06
3 O 0 6.142735173852998e-07
x O 0 5.289895398163935e-06
10 O 0 2.439298043555027e-07
( O 0 6.064358615276433e-08
- O 0 2.596034846646944e-06
5 O 0 3.5126222996950673e-07
) O 0 1.67710734189086e-08
) O 0 9.719023807974736e-09
and O 0 3.9145263031059585e-08
suggestive O 0 2.566157263572677e-06
evidence O 0 7.469112972557923e-08
for O 0 1.6533878266500324e-08
a O 0 1.2311963928368641e-06
locus O 0 2.176711495849304e-05
on O 0 3.180567728122696e-05
chromosome O 0 0.0017324605723842978
4q O 0 0.08505439013242722
at O 0 4.2167273932136595e-05
D4S397 O 0 5.694835272151977e-05
( O 0 1.6394457702517684e-07
maximum O 0 5.382991616897925e-07
GENEHUNTER O 0 0.00030679069459438324
- O 0 2.496951856301166e-05
PLUS O 0 4.603352408594219e-06
nonparametric O 0 6.727425898134243e-06
linkage O 0 7.915270543890074e-06
score O 0 1.2014639878543676e-06
= O 0 2.816072083078325e-06
3 O 0 3.184722459081968e-07
. O 0 6.397766583177145e-08
29 O 0 1.76108358118654e-06
, O 0 1.9007057971975883e-07
P O 0 7.973037099873181e-06
= O 0 8.619016966804338e-07
2 O 0 1.5513717244175496e-07
. O 0 2.4239225737687775e-08
57 O 0 2.9542516699621046e-07
x O 0 2.3200116174848517e-06
10 O 0 2.7356696818969795e-07
( O 0 5.0894524150635334e-08
- O 0 2.3783379674569005e-06
3 O 0 3.7583865264423366e-07
) O 0 2.8045953115451994e-08
; O 0 5.2897814128982645e-08
SIBPAL O 0 2.0855975890299305e-05
Pempirical O 0 7.818593076081015e-06
value O 0 1.507798117472703e-07
< O 0 2.080557806038996e-06
1 O 0 4.974999683327042e-07
x O 0 4.211937721265713e-06
10 O 0 2.1069473632451263e-07
( O 0 6.564706467315773e-08
- O 0 1.5220098248391878e-06
3 O 0 2.346581595702446e-07
) O 0 1.1801274624190228e-08
) O 0 7.837105187036286e-09
that O 0 6.732582491508765e-09
are O 0 3.9139365526352776e-08
linked O 0 4.058760896441527e-05
to O 0 5.139210315974196e-06
mental O 1 0.944936215877533
health O 0 0.0024350143503397703
wellness O 0 0.0020653698593378067
. O 0 2.4055858375504613e-05

These O 0 4.1708844378263166e-07
findings O 0 2.160918029403547e-06
are O 0 3.559848238410268e-08
consistent O 0 7.329649065468402e-07
with O 0 1.0589721455289691e-07
the O 0 3.7805523334100144e-07
hypothesis O 0 8.893878202798078e-07
that O 0 7.773610199990344e-09
certain O 0 4.477954007597873e-08
alleles O 0 1.2516934475570451e-06
could O 0 1.4184541896611336e-06
prevent O 0 2.8523388664325466e-06
or O 0 1.2130080904171336e-06
modify O 0 1.2981885447516106e-05
the O 0 2.103188307955861e-06
clinical O 0 0.00010773452231660485
manifestations O 0 0.00025653737247921526
of O 0 3.4984382182301488e-06
BPAD B-Disease 1 0.999964714050293
and O 0 1.0207035302300937e-05
perhaps O 0 1.1535832527442835e-05
other O 0 2.3650432012800593e-06
related O 0 0.015230589546263218
affective B-Disease 1 0.999925971031189
disorders I-Disease 1 0.9999887943267822
. O 0 0.0001973845937754959

Segregation O 0 0.0085320845246315
distortion O 1 0.8356301784515381
in O 0 0.007666487246751785
myotonic B-Disease 1 0.9999865293502808
dystrophy I-Disease 1 0.9999969005584717
. O 0 0.0005349809071049094

Myotonic B-Disease 1 0.9999761581420898
dystrophy I-Disease 1 0.9999967813491821
( O 0 0.0009970521787181497
DM B-Disease 1 0.9999176263809204
) O 0 2.8290301088418346e-06
is O 0 1.3315845990291564e-06
an O 0 2.494693035259843e-06
autosomal B-Disease 1 0.9977686405181885
dominant I-Disease 1 0.9995875954627991
disease I-Disease 1 0.9999524354934692
which O 0 2.9572806852229405e-06
, O 0 3.282878537902434e-07
in O 0 1.0514027337649168e-07
the O 0 1.3954084465694905e-07
typical O 0 8.496659575030208e-06
pedigree O 0 4.857828753301874e-05
, O 0 2.1239058867195126e-07
shows O 0 2.2836023561012553e-07
a O 0 2.72298308345853e-07
three O 0 2.311468421112295e-07
generation O 0 2.4082964955596253e-05
anticipation O 0 7.666589226573706e-05
cascade O 0 0.005552254151552916
. O 0 2.5504416043986566e-05

This O 0 2.488942072886857e-06
results O 0 4.806302604265511e-05
in O 0 8.112506475299597e-05
infertility B-Disease 1 0.9992184638977051
and O 1 0.9946519136428833
congenital B-Disease 1 1.0
myotonic I-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999997615814209
( O 0 1.5209014236461371e-05
CDM B-Disease 0 0.00012844604498241097
) O 0 6.797332474661744e-08
with O 0 7.474642416127608e-08
the O 0 4.4305900814833876e-07
disappearance O 0 2.9791119231958874e-05
of O 0 3.7945160329400096e-06
DM B-Disease 1 0.9999585151672363
in O 0 6.492659849755e-06
that O 0 1.3628438182422542e-06
pedigree O 0 0.0004916216130368412
. O 0 2.0301058611948974e-05

The O 0 8.77022330314503e-07
concept O 0 1.428964537808497e-06
of O 0 6.678012596239569e-07
segregation O 0 8.921371045289561e-05
distortion O 0 0.000828830583486706
, O 0 8.439270118287823e-07
where O 0 2.325273555925378e-07
there O 0 3.5407250464913886e-08
is O 0 5.291799709539191e-08
preferential O 0 5.73285433347337e-07
transmission O 0 2.441901779093314e-05
of O 0 2.733337645111078e-08
the O 0 6.587094247834102e-08
larger O 0 6.491802650998579e-07
allele O 0 9.746706382429693e-06
at O 0 2.6918807634501718e-05
the O 0 8.506493941240478e-06
DM B-Disease 1 0.9989629983901978
locus O 0 7.580790406791493e-05
, O 0 1.9278331819805317e-06
has O 0 4.043126580199896e-07
been O 0 2.703741301957052e-07
put O 0 4.0154597513719636e-07
forward O 0 2.895995123708417e-07
to O 0 4.814242515749356e-08
explain O 0 1.3553418511946802e-06
partially O 0 2.7240501367487013e-05
the O 0 9.733996648719767e-07
maintenance O 0 0.000381936552003026
of O 0 4.37968401456601e-06
DM B-Disease 1 0.9999315738677979
in O 0 2.311958724021679e-06
the O 0 7.365652550106461e-07
population O 0 3.0242139814617985e-07
. O 0 2.9246564281493193e-06

In O 0 3.453474846537574e-06
a O 0 5.856102688994724e-06
survey O 0 6.578433385584503e-06
of O 0 1.1292535191387287e-06
DM B-Disease 1 0.9996334314346313
in O 0 2.5251347324228846e-06
Northern O 0 7.4130612119915895e-06
Ireland O 0 9.549871720082592e-06
, O 0 1.6207239923460293e-06
59 O 0 5.666351626132382e-06
pedigrees O 0 1.1471917787275743e-05
were O 0 1.118383920584165e-06
ascertained O 0 9.22692270250991e-05
. O 0 9.12094401428476e-06

Sibships O 0 0.0011070489417761564
where O 0 1.3904392517360975e-06
the O 0 1.3342817339889734e-07
status O 0 4.6830686528664955e-07
of O 0 1.5866726599256253e-08
all O 0 1.9243687532366494e-08
the O 0 5.0412040764058474e-08
members O 0 3.0745926693498404e-08
had O 0 4.387156593566033e-07
been O 0 1.945638672395944e-07
identified O 0 1.6642154321289127e-07
were O 0 5.637336997210696e-08
examined O 0 1.933540943355183e-06
to O 0 1.3031837831078974e-08
determine O 0 8.886622993031779e-08
the O 0 1.7693919573957828e-07
transmission O 0 7.011553680058569e-05
of O 0 5.776049079031509e-07
the O 0 1.3538841812987812e-05
DM B-Disease 1 0.9996705055236816
expansion O 0 3.371374259586446e-05
from O 0 1.0585616792013752e-06
affected O 0 2.5792392079893034e-06
parents O 0 2.812653008277266e-07
to O 0 2.884568850447522e-08
their O 0 2.655295077147457e-07
offspring O 0 2.6358318791608326e-05
. O 0 7.3682977017597295e-06

Where O 0 3.428047875786433e-06
the O 0 1.2610893236342235e-06
transmitting O 0 0.0004945822292938828
parent O 0 9.536024299450219e-05
was O 0 2.1206958990660496e-05
male O 0 5.037339633418014e-06
, O 0 2.749049599515274e-06
58 O 0 2.0542473066598177e-05
. O 0 4.6133459363773e-06

3 O 0 5.512466941581806e-06
% O 0 5.2145299633821196e-08
of O 0 3.3984445479973147e-08
the O 0 3.4028786899398256e-07
offspring O 0 3.923005806427682e-06
were O 0 1.0942356993837166e-06
affected O 0 1.9074586816714145e-06
, O 0 2.0404222311753983e-07
and O 0 8.538881957065314e-08
in O 0 7.819444647338969e-08
the O 0 1.8659630995898624e-07
case O 0 6.344420171444654e-07
of O 0 2.017424982625471e-08
a O 0 5.344128339856979e-07
female O 0 3.640180011643679e-06
transmitting O 0 0.0005007781437598169
parent O 0 0.00013394073175732046
, O 0 4.690788955485914e-06
68 O 0 4.7019508201628923e-05
. O 0 5.592865363723831e-06

7 O 0 1.7009217117447406e-05
% O 0 1.3481121641234495e-07
were O 0 4.2573554992486606e-07
affected O 0 8.450862878817134e-06
. O 0 6.496882633655332e-06

Studies O 0 4.525644271780038e-06
on O 0 3.541502792359097e-06
meiotic O 0 0.00012268664431758225
drive O 0 2.6114297725143842e-05
in O 0 7.42972861189628e-06
DM B-Disease 1 0.999561607837677
have O 0 2.9457129357979284e-07
shown O 0 1.6799317847926432e-07
increased O 0 1.4464512787526473e-07
transmission O 0 1.3720697097596712e-05
of O 0 3.50000171067677e-08
the O 0 4.798575403697214e-08
larger O 0 6.484995651589998e-07
allele O 0 5.630219675367698e-06
at O 0 1.5907102351775393e-05
the O 0 6.0481165746750776e-06
DM B-Disease 1 0.9981118440628052
locus O 0 8.718325989320874e-05
in O 0 7.036334409349365e-06
non O 0 0.0005490242619998753
- O 1 0.7017099261283875
DM O 1 0.9987326264381409
heterozygotes O 0 0.00039593057590536773
for O 0 4.440913471626118e-06
CTGn O 0 0.002826480893418193
. O 0 2.2991944206296466e-05

This O 0 4.847653372053173e-07
study O 0 2.317312919331016e-07
provides O 0 6.76250735409667e-08
further O 0 3.7436834077198e-08
evidence O 0 2.1023490148763813e-07
that O 0 7.058649487134971e-08
the O 0 3.969983481511008e-06
DM B-Disease 1 0.9997268319129944
expansion O 0 4.604630885296501e-05
tends O 0 9.366349331685342e-06
to O 0 1.3594502945579734e-07
be O 0 5.432822263173875e-07
transmitted O 0 3.7326477468013763e-05
preferentially O 0 1.7840542568592355e-05
. O 0 4.229648766340688e-06

Diagnosis O 1 0.9896640181541443
of O 0 0.0003570741100702435
hemochromatosis B-Disease 1 0.9999934434890747
. O 0 0.0004535759217105806

If O 0 0.0011161131551489234
untreated O 1 0.9958094358444214
, O 0 0.0009507376234978437
hemochromatosis B-Disease 1 0.9999903440475464
can O 0 0.002951544476673007
cause O 1 0.957524836063385
serious O 1 0.997941792011261
illness O 1 0.9994877576828003
and O 0 3.96309496863978e-06
early B-Disease 0 4.582036490319297e-05
death I-Disease 0 5.987627446302213e-05
, O 0 7.028112918305851e-07
but O 0 4.756921043735929e-07
the O 0 2.594074658190948e-06
disease O 1 0.9896677732467651
is O 0 6.581009870387788e-07
still O 0 1.0058112138722208e-06
substantially O 0 1.7492679035058245e-05
under O 0 8.267829252872616e-05
- O 1 0.9956608414649963
diagnosed O 1 0.999315619468689
. O 0 1.0426152584841475e-05

The O 0 3.2368418487749295e-06
cornerstone O 0 0.0001096164996852167
of O 0 2.0939211253789836e-07
screening O 0 3.869898591801757e-06
and O 0 5.559345481742639e-07
case O 0 1.6019323538785102e-06
detection O 0 7.4582171691872645e-06
is O 0 1.0519082138671365e-07
the O 0 4.232474992704738e-08
measurement O 0 5.35299568582559e-06
of O 0 3.605577774123958e-07
serum O 0 4.2361301893834025e-05
transferrin O 0 6.295694765867665e-05
saturation O 0 1.1565872227947693e-05
and O 0 4.966025812791486e-07
the O 0 8.011366503524187e-07
serum O 0 0.00013134151231497526
ferritin O 0 0.00037047272780910134
level O 0 5.849696754012257e-05
. O 0 1.2353126294328831e-05

Once O 0 0.00010564634430920705
the O 0 8.770752174314111e-06
diagnosis O 0 0.10218697041273117
is O 0 2.8906993065902498e-06
suspected O 0 3.575182563508861e-05
, O 0 1.4764436855330132e-06
physicians O 0 3.6120104596193414e-06
must O 0 1.5164158639890957e-07
use O 0 7.354821605076722e-07
serum O 0 0.00013090604625176638
ferritin O 0 0.00046688455040566623
levels O 0 4.758407885674387e-05
and O 0 6.6435472945158836e-06
hepatic O 1 0.9977263808250427
iron O 1 0.9891345500946045
stores O 0 0.00011324409570079297
on O 0 0.0004029232950415462
liver O 1 0.9994826316833496
biopsy O 1 0.5777440667152405
specimens O 0 1.4751495655218605e-05
to O 0 3.5406245046942786e-07
assess O 0 4.7353845729958266e-05
patients O 0 1.0325303264835384e-05
for O 0 3.75321391743455e-08
the O 0 2.4646715246490203e-07
presence O 0 5.5521945796499494e-06
of O 0 3.1993818083719816e-06
iron B-Disease 1 0.9988683462142944
overload I-Disease 1 0.9904663562774658
. O 0 3.259068762417883e-05

Liver O 1 0.9993783235549927
biopsy O 1 0.991366446018219
is O 0 1.4060512967262184e-06
also O 0 4.1926863758590116e-08
used O 0 3.7877040170997134e-08
to O 0 1.0966311414506436e-08
establish O 0 3.432001847158972e-07
the O 0 2.800653930989938e-07
presence O 0 1.7041343198798131e-06
or O 0 2.000120275624795e-06
absence O 0 1.2409815099090338e-05
of O 0 3.4724182569334516e-06
cirrhosis B-Disease 1 0.9999428987503052
, O 0 9.090394996746909e-06
which O 0 9.061978971658391e-07
can O 0 2.0529837456706446e-06
affect O 0 4.034961239085533e-05
prognosis O 0 0.03735250607132912
and O 0 1.3015702279517427e-05
management O 0 0.0003492855466902256
. O 0 1.9958939446951263e-05

A O 0 1.4964331057853997e-05
DNA O 0 1.5302974134101532e-05
- O 0 1.4387099326995667e-05
based O 0 2.959262417334685e-07
test O 0 2.719158089803386e-07
for O 0 1.2788142100816913e-08
the O 0 1.2269667593045597e-07
HFE O 0 7.436486339429393e-05
gene O 0 1.5229840073516243e-06
is O 0 6.98139146493304e-08
commercially O 0 2.969091212889907e-07
available O 0 6.856187440007488e-08
, O 0 8.212232671667152e-08
but O 0 1.9239063675513535e-08
its O 0 8.921246852366949e-09
place O 0 1.0681799977874107e-07
in O 0 1.820188231249631e-07
the O 0 1.107408706957358e-06
diagnosis O 0 0.08716083317995071
of O 0 1.0148323781322688e-05
hemochromatosis B-Disease 1 0.9999969005584717
is O 0 5.08280900248792e-05
still O 0 9.316684554505628e-06
being O 0 5.385074018704472e-06
evaluated O 0 3.44527761626523e-05
. O 0 5.925431651121471e-06

Currently O 0 6.656116511294385e-06
, O 0 2.0617450502413703e-07
the O 0 2.017755917904651e-08
most O 0 1.6528328927734037e-08
useful O 0 7.603973273262454e-08
role O 0 2.2942658972624486e-07
for O 0 2.0358555730126682e-08
this O 0 1.963622686673716e-08
test O 0 2.9742292895207356e-07
is O 0 3.9218129188611783e-08
in O 0 3.161517625471788e-08
the O 0 1.1794325160963126e-07
detection O 0 2.8298933102632873e-05
of O 0 3.0281148610811215e-06
hemochromatosis B-Disease 1 0.9999781847000122
in O 0 3.914096396329114e-06
the O 0 5.609941808870644e-07
family O 0 1.1806168913608417e-06
members O 0 7.234149990154037e-08
of O 0 9.434749870251835e-08
patients O 0 3.3737426292645978e-06
with O 0 1.4129778946880833e-07
a O 0 4.063601409143303e-06
proven O 0 6.605378439417109e-05
case O 0 5.338654318620684e-06
of O 0 2.878546183637809e-07
the O 0 6.713256880175322e-05
disease O 1 0.9994274377822876
. O 0 1.8798207747749984e-05

It O 0 1.8233083665109007e-06
is O 0 9.037519816956774e-07
crucial O 0 2.1887597540626302e-05
to O 0 2.6516929210629314e-05
diagnose O 1 0.9998347759246826
hemochromatosis B-Disease 1 0.9999978542327881
before O 1 0.9844010472297668
hepatic B-Disease 1 0.9999439716339111
cirrhosis I-Disease 1 0.999990701675415
develops O 1 0.9095430970191956
because O 0 0.00032254779944196343
phlebotomy O 1 0.8884963989257812
therapy O 0 0.06486023217439651
can O 0 0.00016773860261309892
avert O 1 0.994110643863678
serious O 1 0.9998506307601929
chronic O 1 0.999998927116394
disease O 1 0.9999834299087524
and O 0 4.111999260203447e-06
can O 0 8.205028052543639e-07
even O 0 9.903288855639403e-07
lead O 0 1.8019682102021761e-06
to O 0 8.67677485416607e-08
normal O 0 8.05751551524736e-06
life O 0 5.424763912742492e-06
expectancy O 0 1.9631190298241563e-05
. O 0 7.873071581343538e-07
. O 0 2.7649064122670097e-06

Prevalence O 0 0.0009264726541005075
of O 0 3.7340495850912703e-07
the O 0 2.527001697671949e-06
I1307K O 0 0.00019284433801658452
APC B-Disease 0 0.00012704521941486746
gene O 0 1.3350648259802256e-05
variant O 0 9.980270988307893e-05
in O 0 6.703548933728598e-07
Israeli O 0 5.466257334774127e-06
Jews O 0 6.664893135166494e-07
of O 0 6.241319283617486e-08
differing O 0 8.2011479207722e-07
ethnic O 0 6.710309321533714e-07
origin O 0 1.7329756474282476e-06
and O 0 4.724937753053382e-05
risk O 1 0.5390527844429016
for O 1 0.9649381637573242
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 0.00018756600911729038

BACKGROUND O 0 0.0001833031274145469
& O 0 0.00012333622726146132
AIMS O 0 1.555323979118839e-05
Israeli O 0 5.393564606492873e-06
Jews O 0 6.129066036919539e-07
of O 0 1.194517267322226e-07
European O 0 1.037519996316405e-05
birth O 0 2.6732472178991884e-05
, O 0 2.3621489617653424e-06
i O 0 1.3219243555795401e-05
. O 0 1.5009518961051072e-07
e O 0 3.7091062949912157e-06
. O 0 1.9134148487864877e-07
, O 0 3.342892966884392e-07
Ashkenazim O 0 6.247455166885629e-05
, O 0 1.1602188578763162e-06
have O 0 3.3463697945990134e-07
the O 0 2.5756169634405524e-05
highest O 1 0.9993613362312317
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
incidence O 1 0.5599345564842224
of O 0 1.1401228761087623e-07
any O 0 1.3846471347278566e-07
Israeli O 0 8.298696229758207e-06
ethnic O 0 2.3021061679173727e-06
group O 0 2.1537647626246326e-05
. O 0 6.639088951487793e-06

The O 0 1.4247992112359498e-05
I1307K O 0 0.0002712414716370404
APC B-Disease 0 0.00013008787936996669
gene O 0 8.851502570905723e-06
variant O 0 0.00014340050984174013
was O 0 1.8456685211276636e-05
found O 0 1.8794287370837992e-06
in O 0 6.069953997211996e-07
6 O 0 2.384169965807814e-05
. O 0 4.848309799854178e-06

1 O 0 2.64789855464187e-06
% O 0 2.13449062869131e-08
of O 0 1.574189845143792e-08
American O 0 1.287259863147483e-07
Jews O 0 2.9050846706013544e-07
, O 0 4.2976469671884843e-07
28 O 0 1.0480125638423488e-06
% O 0 1.5851240320330362e-08
of O 0 1.54814230768352e-07
their O 0 0.00013356664567254484
familial O 1 0.9999938011169434
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
cases O 0 8.537059329682961e-05
, O 0 9.946251111614401e-07
but O 0 1.7073359970254387e-07
not O 0 7.205176189017948e-08
in O 0 2.7036873007091344e-07
non O 0 1.4889171325194184e-05
- O 0 0.00010565168486209586
Jews O 0 8.673780030221678e-06
. O 0 7.72361545386957e-06

We O 0 1.7735013898345642e-05
assessed O 0 1.767870162439067e-05
the O 0 1.2340858575043967e-06
I1307K O 0 0.0001767582871252671
prevalence O 0 2.915191544161644e-05
in O 0 1.8141919611025514e-07
Israeli O 0 1.488186740061792e-06
Jews O 0 4.04910366569311e-07
of O 0 4.4283087419216827e-08
differing O 0 4.5934277181913785e-07
ethnic O 0 4.6535430442418146e-07
origin O 0 1.02273816082743e-06
and O 0 5.755123856943101e-05
risk O 0 0.4409797191619873
for O 1 0.9906987547874451
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.0002821467933245003

METHODS O 0 2.297331411682535e-05
DNA O 0 8.73227691045031e-06
samples O 0 1.0412343272037106e-06
from O 0 2.084181005557184e-07
500 O 0 8.624246561339532e-07
unrelated O 0 2.0912239051540382e-06
Jews O 0 2.7277474146103486e-07
of O 0 5.907202549337853e-08
European O 0 5.82550592298503e-06
or O 0 7.140109119063709e-06
non O 0 3.3211501431651413e-05
- O 0 2.8318421755102463e-05
European O 0 1.8035361790680327e-06
origin O 0 1.8542218072070682e-07
, O 0 1.8410469238006044e-07
with O 0 4.285749000132455e-08
or O 0 6.129872076598986e-07
without O 0 1.829565263733457e-07
a O 0 4.5454098085428996e-07
personal O 0 6.555173513334012e-06
and O 0 3.33527714246884e-06
/ O 0 3.3710497518768534e-05
or O 0 4.1261209844378754e-06
family O 0 4.7811627155169845e-06
history O 0 4.267381882527843e-06
of O 0 1.0061546618089778e-06
neoplasia B-Disease 1 0.78859943151474
, O 0 1.740856873766461e-06
were O 0 2.1246290771159693e-07
examined O 0 8.826130397210363e-06
for O 0 2.371180052307409e-08
the O 0 7.553135361604291e-08
I1307K O 0 1.0385673704149667e-05
variant O 0 7.1454978751717135e-06
by O 0 3.973676498958412e-08
the O 0 7.729730810979163e-08
allele O 0 1.4284125882113585e-06
- O 0 5.288437478156993e-06
specific O 0 1.9853776223044406e-07
oligonucleotide O 0 6.470274092862383e-05
( O 0 4.023819201393053e-06
ASO O 0 0.07238105684518814
) O 0 6.160287853163027e-07
method O 0 7.40860878067906e-06
. O 0 6.903018402226735e-06

RESULTS O 0 3.934862979804166e-05
In O 0 5.550328978642938e-07
persons O 0 5.911626317356422e-07
at O 0 3.064246629946865e-05
average O 0 0.00020559180120471865
risk O 0 0.008029947057366371
for O 0 0.1611541509628296
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
, O 0 7.0362807491619606e-06
I1307K O 0 3.708439544425346e-05
was O 0 9.137635061051697e-06
found O 0 7.061948394948558e-07
in O 0 4.321183837419085e-07
5 O 0 4.905937203147914e-06
. O 0 4.249448011250934e-06

0 O 0 3.1006577501102583e-06
% O 0 1.7903522220308332e-08
of O 0 1.1227483831532936e-08
120 O 0 1.3413294652764307e-07
European O 0 8.64231026298512e-07
and O 0 2.2799340513302013e-06
1 O 0 1.9857854567817412e-05
. O 0 6.335517355182674e-06

6 O 0 8.25563711259747e-06
% O 0 3.705626383521121e-08
of O 0 4.205003634183413e-08
188 O 0 1.937167780852178e-06
non O 0 5.107879587740172e-06
- O 0 1.1860296581289731e-05
European O 0 2.5039219053724082e-06
Jews O 0 1.3823871540807886e-06
( O 0 9.288792739425844e-07
P O 0 7.09048326825723e-05
= O 0 6.787797701690579e-06
0 O 0 7.16489239493967e-07
. O 0 1.7988210743169475e-07
08 O 0 6.736810973961838e-06
) O 0 1.7811738928230625e-07
. O 0 1.7857348666439066e-06

It O 0 3.053069576708367e-06
occurred O 0 2.37717067648191e-05
in O 0 8.972236287263513e-07
15 O 0 6.787409347452922e-06
. O 0 2.611669287944096e-06

4 O 0 6.278216005739523e-06
% O 0 6.173902988848567e-08
of O 0 1.1263296784136401e-07
52 O 0 7.013235517661087e-06
Ashkenazi O 0 6.880610453663394e-05
Israelis O 0 1.267735569854267e-05
with O 0 1.8407590687274933e-05
familial O 1 0.9978649020195007
cancer B-Disease 1 0.9993104934692383
( O 0 3.310669626443996e-06
P O 0 0.000127218576380983
= O 0 9.737926120578777e-06
0 O 0 9.600208841220592e-07
. O 0 1.2382551517475804e-07
02 O 0 6.7838177528756205e-06
) O 0 1.999150001097405e-08
and O 0 6.734691027077133e-08
was O 0 8.126700663524389e-07
not O 0 3.952315452693256e-08
detected O 0 4.0638260543346405e-06
in O 0 7.97908583649587e-08
51 O 0 1.318552449447452e-06
non O 0 3.512452167342417e-06
- O 0 7.2473490035918076e-06
European O 0 1.2459148592824931e-06
Jews O 0 2.053743628493976e-06
at O 0 0.00014223804464563727
increased O 0 9.211590077029541e-05
cancer B-Disease 1 0.9991104006767273
risk O 0 0.0004464144876692444
. O 0 5.188306658965303e-06

Colorectal B-Disease 1 0.9984319806098938
neoplasia I-Disease 1 0.9900862574577332
occurred O 0 0.0012269814033061266
personally O 0 0.00010759427823359147
or O 0 1.838786715779861e-06
in O 0 2.393817908341589e-07
the O 0 1.0301880593033275e-07
families O 0 3.551499361265087e-08
of O 0 5.995479313014584e-08
13 O 0 1.570402901052148e-06
of O 0 8.67033946860829e-08
20 O 0 1.916981545946328e-06
Ashkenazi O 0 5.1971685024909675e-05
I1307K O 0 4.160296521149576e-05
carriers O 0 8.360091669601388e-06
, O 0 6.868424407002749e-07
8 O 0 4.827105613003368e-07
of O 0 2.816114808013026e-08
whom O 0 1.5333869214373408e-06
also O 0 6.037042226125777e-07
had O 0 1.1651076192720211e-06
a O 0 7.987983963175793e-07
personal O 0 5.848479304404464e-06
or O 0 3.7266995605023112e-06
family O 0 7.709912097197957e-06
history O 0 9.052797395270318e-06
of O 0 4.108647772227414e-06
noncolonic O 1 0.5547226667404175
neoplasia B-Disease 1 0.9955065250396729
. O 0 0.00012437529221642762

CONCLUSIONS O 0 6.092274998081848e-05
The O 0 4.580257609632099e-06
I1307K O 0 0.0002555995888542384
APC O 0 0.00021475314861163497
variant O 0 0.00023043925466481596
may O 0 2.5563481358403806e-06
represent O 0 1.1686191925264211e-07
a O 0 3.225883574486943e-06
susceptibility O 0 6.455009133787826e-05
gene O 0 5.323576260707341e-05
for O 0 3.529298919602297e-05
colorectal B-Disease 1 0.9999982118606567
, I-Disease 0 8.679389793542214e-06
or I-Disease 0 2.647918563525309e-06
other I-Disease 0 8.908588711165066e-07
, I-Disease 0 2.811274134728592e-05
cancers I-Disease 1 0.9976703524589539
in O 0 2.1814662432007026e-06
Ashkenazi O 0 0.00013972267333883792
Jews O 0 2.6824370706890477e-06
, O 0 1.2249200835867669e-06
and O 0 1.33982507577457e-06
partially O 0 0.00016131445590872318
explains O 0 1.2238656381668989e-05
the O 0 2.187971176681458e-06
higher O 0 0.00010658690734999254
incidence O 1 0.9131290316581726
of O 0 0.07665311545133591
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
in O 0 7.70072620071005e-06
European O 0 2.600043808342889e-05
Israelis O 0 0.00010214350186288357
. O 0 2.2791538867750205e-05

Systematic O 0 2.1196041416260414e-05
analysis O 0 4.94524010719033e-06
of O 0 1.3433088952297112e-06
coproporphyrinogen O 0 0.007775910198688507
oxidase O 0 0.001590569969266653
gene O 0 0.0021585924550890923
defects O 1 0.9990291595458984
in O 0 1.172363045043312e-05
hereditary B-Disease 1 0.9967508316040039
coproporphyria I-Disease 1 0.7409205436706543
and O 0 4.7183410060824826e-05
mutation O 0 0.000435100169852376
update O 0 0.0004156030772719532
. O 0 1.9847708244924434e-05

Hereditary B-Disease 1 0.9960811734199524
coproporphyria I-Disease 1 0.9683957099914551
( O 0 4.689220440923236e-05
HC B-Disease 1 0.9994988441467285
) O 0 3.3372084544680547e-06
is O 0 3.6108326639805455e-06
an O 0 2.1243555238470435e-05
acute O 1 0.9993334412574768
hepatic B-Disease 1 0.9999707937240601
porphyria I-Disease 1 0.9998502731323242
with O 0 0.0006871192599646747
autosomal O 1 0.9996778964996338
dominant O 1 0.9965957999229431
inheritance O 1 0.5987377166748047
caused O 0 0.007905223406851292
by O 0 2.0954121282557026e-06
deficient B-Disease 0 0.0011785175884142518
activity I-Disease 0 1.6675245433361852e-06
of I-Disease 0 1.9893008129656664e-07
coproporphyrinogen I-Disease 0 0.0012805728474631906
III I-Disease 0 0.18442918360233307
oxidase I-Disease 0 0.00012042964226566255
( O 0 2.0219108591845725e-06
CPO O 0 7.159889355534688e-05
) O 0 9.082951351047086e-07
. O 0 2.9111745334375883e-06

Clinical O 0 0.0011598902055993676
manifestations O 0 0.0013079578056931496
of O 0 4.326463567849714e-06
the O 0 0.00037199255893938243
disease O 1 0.9998132586479187
are O 0 1.131418230215786e-06
characterized O 0 0.0002095255913445726
by O 0 3.82878397431341e-06
acute O 1 0.9980871677398682
attacks O 0 0.0014739596517756581
of O 0 0.0001232828653883189
neurological B-Disease 1 0.9999949932098389
dysfunction I-Disease 1 0.9996788501739502
often O 0 9.473133104620501e-05
precipitated O 0 0.0007384457858279347
by O 0 4.003640299288236e-07
drugs O 0 7.974588697834406e-06
, O 0 7.32516980406217e-07
fasting O 0 1.0100692634296138e-05
, O 0 4.3895183807762805e-06
cyclical O 0 0.00836971402168274
hormonal O 0 0.013378340750932693
changes O 0 9.448314813198522e-05
, O 0 2.7179210519534536e-05
or O 0 0.00391647731885314
infectious B-Disease 1 0.9999291896820068
diseases I-Disease 1 0.999948263168335
. O 0 7.032397843431681e-05

Skin O 1 0.9983855485916138
photosensitivity O 1 0.9979314804077148
may O 0 0.00023523987329099327
also O 0 1.9088597582594957e-06
be O 0 2.422171689886454e-07
present O 0 1.4359932265506359e-06
. O 0 7.302164249267662e-06

The O 0 1.9811666334135225e-06
seven O 0 1.1192832971573807e-06
exons O 0 1.7799386114347726e-05
, O 0 7.076631618474494e-07
the O 0 5.41240524398745e-07
exon O 0 3.778792597586289e-05
/ O 0 1.4268715858634096e-05
intron O 0 4.7758639993844554e-05
boundaries O 0 5.313114570526523e-07
and O 0 2.941224579444679e-07
part O 0 3.655395914847759e-07
of O 0 8.77287789080583e-08
3 O 0 1.3636681615025736e-06
noncoding O 0 2.8201244276715443e-05
sequence O 0 4.973281875209068e-07
of O 0 4.530678054948112e-08
the O 0 1.7606861035801558e-07
CPO O 0 1.1364530109858606e-05
gene O 0 6.280422439886024e-07
were O 0 9.010791757191328e-08
systematically O 0 1.295638980991498e-06
analyzed O 0 1.2124078239139635e-06
by O 0 4.41446168508719e-08
an O 0 3.050506620638771e-07
exon O 0 3.919025766663253e-05
- O 0 5.251692346064374e-05
by O 0 2.0968116132280556e-06
- O 0 0.00035795310395769775
exon O 0 0.0004865783266723156
denaturing O 0 0.00624049874022603
gradient O 0 0.001270027132704854
gel O 0 0.002367394044995308
electrophoresis O 0 0.0002130177163053304
( O 0 1.0178398497373564e-06
DGGE O 0 8.545204036636278e-05
) O 0 5.869465979913002e-08
strategy O 0 2.754770775936777e-07
followed O 0 4.6150351096230224e-08
by O 0 1.7188013234914479e-09
direct O 0 8.525111283574915e-09
sequencing O 0 7.366916747741925e-07
in O 0 7.011136062828882e-07
seven O 0 2.6374170829512877e-06
unrelated O 0 0.00011728873505489901
heterozygous O 0 0.0001633546780794859
HC B-Disease 1 0.9978429079055786
patients O 0 0.0006113155395723879
from O 0 2.8064687285223044e-06
France O 0 0.0003063023614231497
, O 0 2.700725872273324e-06
Holland O 0 0.00030106864869594574
, O 0 5.932589829171775e-06
and O 0 8.159720891853794e-06
Czech O 0 0.3643587827682495
Republic O 0 0.0003927963552996516
. O 0 2.5371913579874672e-05

Seven O 0 5.0068019845639355e-06
novel O 0 3.9835913412389345e-06
mutations O 0 8.719628567632753e-06
and O 0 1.0364971103626885e-07
two O 0 6.587169565364093e-08
new O 0 7.313826699828496e-07
polymorphisms O 0 2.453582601447124e-05
were O 0 2.0068191588507034e-06
detected O 0 0.0002925938169937581
. O 0 4.429729870025767e-06

Among O 0 1.4468790823229938e-06
these O 0 9.38381674586708e-08
mutations O 0 1.046057150233537e-05
two O 0 2.975236270685855e-07
are O 0 2.626465800403821e-07
missense O 0 8.44255046104081e-05
( O 0 9.107655500883993e-07
G197W O 0 2.979947385028936e-05
, O 0 5.703602710127598e-07
W427R O 0 1.0614493476168718e-05
) O 0 6.247560691008403e-08
, O 0 6.217484838089149e-08
two O 0 4.946773302094698e-08
are O 0 1.0061567934371851e-07
nonsense O 0 1.9994999092887156e-05
( O 0 6.147124622657429e-07
Q306X O 0 2.0429120922926813e-05
, O 0 6.079548029447324e-07
Q385X O 0 8.899291970010381e-06
) O 0 5.961998539305569e-08
, O 0 4.257412200558974e-08
two O 0 2.2942323596453207e-08
are O 0 2.7220581344522543e-08
small O 0 5.244328349363059e-07
deletions O 0 1.8075470507028513e-05
( O 0 5.259188355921651e-07
662de14bp O 0 2.8399746952345595e-05
; O 0 6.79616505294689e-07
1168del3bp O 0 4.373712363303639e-05
removing O 0 3.356147772137774e-06
a O 0 1.0859304211408016e-06
glycine O 0 1.2460642210498918e-05
at O 0 5.603238605544902e-06
position O 0 1.6584117474849336e-06
390 O 0 7.057087714201771e-07
) O 0 4.742019044101653e-08
, O 0 5.2497874492019037e-08
and O 0 2.846974211934139e-08
one O 0 5.0028035047944286e-08
is O 0 5.012689285877059e-08
a O 0 2.961710094950831e-07
splicing O 0 1.6430580217274837e-05
mutation O 0 3.632212246884592e-05
( O 0 6.97968744134414e-07
IVS1 O 0 0.00024030606437008828
- O 0 6.503133045043796e-05
15c O 0 0.0001098505817935802
- O 0 3.165579619235359e-05
- O 0 1.9744065866689198e-05
> O 0 6.006403509672964e-06
g O 0 5.371312909119297e-06
) O 0 1.8344145757964725e-08
which O 0 2.6176030232250014e-08
creates O 0 2.950686734948249e-07
a O 0 1.6874625430318702e-07
new O 0 3.2751790968177374e-07
acceptor O 0 2.8356182610878022e-06
splice O 0 0.0003217422345187515
site O 0 0.0001303230383200571
. O 0 1.2371057891868986e-05

The O 0 7.917029506643303e-06
pathological O 0 0.00088706542737782
significance O 0 8.923630957724527e-06
of O 0 2.758635559985123e-07
the O 0 2.351795501454035e-06
point O 0 3.2538577215746045e-05
mutations O 0 6.152268906589597e-05
G197W O 0 9.017447155201808e-05
, O 0 1.3037465578236151e-06
W427R O 0 2.0287219740566798e-05
, O 0 5.945884140601265e-07
and O 0 2.14703874235056e-07
the O 0 3.162784878441016e-07
in O 0 1.4546380953106564e-06
- O 0 7.457357423845679e-05
frame O 0 8.417195931542665e-05
deletion O 0 6.624511297559366e-05
390delGly O 0 6.119111640146002e-05
were O 0 2.590139445146633e-07
assessed O 0 1.008016852210858e-06
by O 0 6.032584654036555e-09
their O 0 6.006270147906889e-09
respective O 0 2.0871664219157537e-07
expression O 0 4.389885361888446e-07
in O 0 1.7034894028711278e-07
a O 0 2.8742474000864604e-07
prokaryotic O 0 4.006488325103419e-06
system O 0 3.4330241760471836e-06
using O 0 1.0075699492517742e-06
site O 0 3.032718632312026e-05
- O 0 2.0362638679216616e-05
directed O 0 9.650998435972724e-07
mutagenesis O 0 0.0001883502845885232
. O 0 8.865349627740216e-06

These O 0 2.3997592961677583e-06
mutations O 0 9.429377678316087e-05
resulted O 0 8.192258064809721e-06
in O 0 4.93488073516346e-07
the O 0 3.731788922323176e-07
absence O 0 5.539634003071114e-06
or O 0 8.065428005465947e-07
a O 0 1.0829456869032583e-06
dramatic O 0 2.4502129235770553e-05
decrease O 0 1.5220623936329503e-05
of O 0 5.117511250318785e-07
CPO O 0 0.00021383514103945345
activity O 0 1.7986725652008317e-05
. O 0 6.761649729014607e-06

The O 0 8.016426136236987e-07
two O 0 5.206559876569372e-07
polymorphisms O 0 1.793961928342469e-05
were O 0 3.3168845448017237e-07
localized O 0 3.1907267839415e-05
in O 0 1.5891735074546887e-06
noncoding O 0 0.00010091684816870838
part O 0 5.560119689107523e-07
of O 0 1.8953652869413418e-08
the O 0 8.369589465928584e-08
gene O 0 7.538425847997132e-07
1 O 0 5.723348976971465e-07
) O 0 2.790077502368149e-08
a O 0 6.483153356384719e-07
C O 0 2.0404317183420062e-05
/ O 0 7.826806722732726e-06
G O 0 2.3849339413573034e-05
polymorphism O 0 2.767103751466493e-06
in O 0 2.776249914404616e-07
the O 0 8.681167287249991e-07
promotor O 0 0.0015724539989605546
region O 0 2.355650212848559e-05
, O 0 1.7337987401333521e-06
142 O 0 2.835077339113923e-06
bp O 0 3.0759285436943173e-05
upstream O 0 7.642481705261162e-07
from O 0 5.3123798693377466e-08
the O 0 2.02782963754089e-08
transcriptional O 0 6.526783522531332e-07
initiation O 0 2.219122507085558e-06
site O 0 8.654494195070583e-06
( O 0 3.465879956365825e-07
- O 0 7.342939170484897e-06
142C O 0 2.609791590657551e-05
/ O 0 9.167432835965883e-06
G O 0 1.3317571756488178e-05
) O 0 3.5575400403331514e-08
, O 0 7.116020128705713e-08
and O 0 9.362042163729711e-08
2 O 0 4.30287997232881e-07
) O 0 3.459812702999443e-08
a O 0 5.227805104368599e-07
6 O 0 3.6941632970410865e-06
bp O 0 4.257034379406832e-05
deletion O 0 4.099332727491856e-06
polymorphism O 0 1.5862723330428707e-06
in O 0 1.0965646879412816e-07
the O 0 9.799478561944852e-08
3 O 0 9.326589065494773e-07
noncoding O 0 3.683685645228252e-05
part O 0 3.3181723324560153e-07
of O 0 5.583511253348661e-08
the O 0 6.633579801018641e-07
CPO O 0 4.1488186980132014e-05
gene O 0 7.670011655136477e-06
, O 0 1.1259854773015832e-06
574 O 0 1.301783777307719e-05
bp O 0 4.755889676744118e-05
downstream O 0 4.4360963329381775e-06
of O 0 4.5564856776536544e-08
the O 0 2.5481159582341206e-07
last O 0 1.936694843607256e-06
base O 0 8.788533705228474e-07
of O 0 1.6808604286211448e-08
the O 0 2.782367403142416e-07
normal O 0 1.1817821359727532e-05
termination O 0 5.070295082987286e-05
codon O 0 1.747597343637608e-05
( O 0 4.431249465142173e-07
+ O 0 1.7684113117866218e-05
574 O 0 6.285071140155196e-05
delATTCTT O 0 0.00013374979607760906
) O 0 1.1673955668811686e-06
. O 0 3.316832135169534e-06

Five O 0 1.6752146621001884e-05
intragenic O 0 0.0009440688299946487
dimorphisms O 0 0.000649410649202764
are O 0 3.4867329645749123e-07
now O 0 1.8604597471494344e-06
well O 0 6.467566322498897e-07
characterized O 0 1.5268235074472614e-05
and O 0 3.0233286452130415e-07
the O 0 3.3582753644623153e-07
high O 0 1.7302447304246016e-05
degree O 0 3.5587461297836853e-06
of O 0 4.182630846116808e-07
allelic O 0 0.0003656955959741026
heterogeneity O 0 0.0003419324057176709
in O 0 2.947136090369895e-05
HC B-Disease 1 0.9992896318435669
is O 0 2.2554020233656047e-06
demonstrated O 0 1.2125339026169968e-06
with O 0 7.289984438330066e-08
seven O 0 1.1150191170372636e-07
new O 0 6.259141827058556e-08
different O 0 1.4508784396127794e-08
mutations O 0 1.379241211907356e-06
making O 0 1.2099886248506664e-07
a O 0 1.8746102625755157e-07
total O 0 6.130743201993027e-08
of O 0 1.6827411286612914e-07
nineteen O 0 4.9852733354782686e-05
CPO O 0 0.0008099658298306167
gene B-Disease 0 0.0009150085388682783
defects I-Disease 1 0.9981333613395691
reported O 0 3.871423177770339e-05
so O 0 8.77230604601209e-07
far O 0 2.1182754608162213e-06
. O 0 5.574651709139289e-07
. O 0 3.264021415816387e-06

Coincidence O 0 1.6238931493717246e-05
of O 0 1.7191374013236782e-07
two O 0 2.629026880640595e-07
novel O 0 3.2797190669953125e-06
arylsulfatase O 0 8.124242594931275e-05
A O 0 3.053582076972816e-06
alleles O 0 2.8216902592248516e-06
and O 0 1.969126515177777e-06
mutation O 0 3.3659747714409605e-05
459 O 0 2.6171666831942275e-05
+ O 0 2.1106643544044346e-05
1G O 0 0.00025054579600691795
> O 0 9.12721770873759e-06
A O 0 8.253419423454034e-07
within O 0 2.1208313683018787e-07
a O 0 1.3226884902906022e-06
family O 0 9.852694347500801e-06
with O 0 2.8299391487962566e-05
metachromatic B-Disease 1 0.9998304843902588
leukodystrophy I-Disease 1 0.9998438358306885
: O 0 2.0574682366714114e-06
molecular O 0 1.1388592611183412e-05
basis O 0 4.2052363369293744e-07
of O 0 3.034090809705958e-07
phenotypic O 0 0.00037530099507421255
heterogeneity O 0 0.002139013260602951
. O 0 6.549255340360105e-05

In O 0 1.1263925898674643e-06
a O 0 1.142852511293313e-06
family O 0 1.2358419780866825e-06
with O 0 3.644629202881333e-07
three O 0 3.873558398481691e-07
siblings O 0 6.655494416918373e-06
, O 0 2.6070455305671203e-07
one O 0 1.8909082655227394e-07
developed O 0 9.159393812296912e-06
classical O 0 0.00031094381120055914
late O 0 0.21738623082637787
infantile O 1 0.9991782307624817
metachromatic B-Disease 1 0.999839186668396
leukodystrophy I-Disease 1 0.9999635219573975
( O 0 0.00025162112433463335
MLD B-Disease 1 0.9985051155090332
) O 0 3.09576466861472e-06
, O 0 2.446296548441751e-06
fatal O 0 0.026465345174074173
at O 0 2.129629319824744e-05
age O 0 3.0752726161153987e-06
5 O 0 7.933481356303673e-07
years O 0 3.107351744802145e-07
, O 0 1.2459287290766952e-07
with O 0 5.675030934071401e-07
deficient O 0 0.002447342500090599
arylsulfatase O 0 0.0002991819055750966
A O 0 1.237099786521867e-05
( O 0 9.327274028692045e-07
ARSA O 0 0.0006095674470998347
) O 0 1.4056931263439765e-07
activity O 0 2.702086590034014e-07
and O 0 3.416943172851461e-07
increased O 0 1.9361482372914907e-06
galactosylsulfatide O 0 0.001265924540348351
( O 0 1.1138537956867367e-05
GS O 1 0.9979448914527893
) O 0 2.1530661342694657e-06
excretion O 0 7.533688039984554e-05
. O 0 1.0273452971887309e-05

The O 0 3.615873538365122e-07
two O 0 1.6448518636025256e-07
other O 0 1.4529061331813864e-07
siblings O 0 1.90608661796432e-05
, O 0 1.793190904209041e-06
apparently O 0 1.0329024917155039e-05
healthy O 0 3.7257188978401246e-06
at O 0 6.207902515598107e-06
12 O 0 5.442291239887709e-07
( O 0 3.352073818518875e-08
1 O 0 2.001357586323138e-07
/ O 0 8.457204785372596e-07
2 O 0 2.1792280335830583e-07
) O 0 1.537791405326061e-08
and O 0 3.642960777483495e-08
15 O 0 2.615150833662483e-07
years O 0 1.812939842693595e-07
, O 0 6.830720877815111e-08
respectively O 0 2.496213369340694e-07
, O 0 9.252512001012292e-08
and O 0 3.8886664555093375e-08
their O 0 5.0238686100101404e-08
father O 0 1.8954804545501247e-05
, O 0 1.210853724842309e-06
apparently O 0 6.609851425309898e-06
healthy O 0 4.051566975249443e-06
as O 0 3.835651227745984e-07
well O 0 8.007104952412192e-07
, O 0 7.046085670481261e-07
presented O 0 9.063483048521448e-06
ARSA O 0 0.0065861232578754425
and O 0 1.3996221241541207e-05
GS O 1 0.993176281452179
values O 0 4.184166471077333e-07
within O 0 3.187320203323907e-07
the O 0 6.841607387286786e-07
range O 0 2.2955136955715716e-05
of O 0 1.0989094334945548e-05
MLD B-Disease 1 0.9997292160987854
patients O 0 0.003855297574773431
. O 0 1.940725815074984e-05

Mutation O 0 8.958573744166642e-05
screening O 0 4.223969426675467e-06
and O 0 1.0292806962297618e-07
sequence O 0 7.249868190228881e-07
analysis O 0 8.233073458541185e-07
disclosed O 0 2.1507928977371193e-05
the O 0 1.4256524139000248e-07
involvement O 0 1.2701090099653811e-06
of O 0 6.942538277598942e-08
three O 0 1.944915197782393e-07
different O 0 6.333647206702153e-07
ARSA O 0 0.013622346334159374
mutations O 0 8.94570184755139e-05
being O 0 7.996162594281486e-07
the O 0 6.371621452672116e-08
molecular O 0 4.184719728073105e-06
basis O 0 3.3109176911239047e-07
of O 0 3.248387372423167e-07
intrafamilial O 0 0.0009808905888348818
phenotypic O 0 0.0005803311942145228
heterogeneity O 0 0.001313121523708105
. O 0 5.174188845558092e-05

The O 0 4.0593255107523873e-05
late O 0 0.005802099592983723
infantile O 1 0.9943828582763672
patient O 0 0.26542213559150696
inherited O 1 0.8066888451576233
from O 0 4.206674930173904e-06
his O 0 1.1133864973089658e-05
mother O 0 2.0632491214200854e-05
the O 0 3.209881072052667e-07
frequent O 0 1.0257455869577825e-05
0 O 0 4.872840690950397e-06
- O 0 3.097339504165575e-05
type O 0 4.637783786165528e-05
mutation O 0 3.5244553146185353e-05
459 O 0 1.0775253031169996e-05
+ O 0 9.410292477696203e-06
1G O 0 8.864738629199564e-05
> O 0 4.442883437150158e-06
A O 0 1.549617991258856e-06
, O 0 1.871455737045835e-07
and O 0 8.449096355889196e-08
from O 0 8.088815661722037e-08
his O 0 7.421483019243169e-07
father O 0 6.8478625507850666e-06
a O 0 1.0340520475438097e-06
novel O 0 8.134423978845007e-07
, O 0 1.514805632041316e-07
single O 0 6.430407211155398e-07
basepair O 0 4.9129139370052144e-05
microdeletion O 0 2.5070590709219687e-05
of O 0 3.922530922295664e-08
guanine O 0 3.1064885206433246e-06
at O 0 1.680279183347011e-06
nucleotide O 0 9.412906933903287e-07
7 O 0 1.0376062391515006e-06
in O 0 2.309983244686009e-07
exon O 0 2.1004600057494827e-05
1 O 0 3.5096393276035087e-06
( O 0 6.731159487571858e-07
7delG O 0 0.00013243983266875148
) O 0 1.4722563719260506e-06
. O 0 4.7373046072607394e-06

The O 0 3.890449988830369e-06
two O 0 4.532827460934641e-06
clinically O 0 0.0020884908735752106
unaffected O 0 0.00025875138817355037
siblings O 0 3.978636232204735e-05
carried O 0 3.8926027627894655e-06
the O 0 1.193286834677565e-06
maternal O 0 0.0001590199681231752
mutation O 0 9.703200339572504e-05
459 O 0 3.30901712004561e-05
+ O 0 2.0183151718811132e-05
1G O 0 0.00020030450832564384
> O 0 1.001317741611274e-05
A O 0 2.115110191880376e-06
and O 0 2.982283717756218e-07
, O 0 9.46986986605225e-08
on O 0 1.3289530897964141e-07
their O 0 2.547012201148391e-08
paternal O 0 3.5892994674213696e-06
allele O 0 4.763571723742643e-06
, O 0 3.5725412317333394e-07
a O 0 4.629935119737638e-07
novel O 0 9.79047058535798e-07
cytosine O 0 4.1052089727600105e-06
to O 0 5.631877542100483e-08
thymidine O 0 1.5148133570619393e-05
transition O 0 8.335452548635658e-06
at O 0 4.661916591430781e-06
nucleotide O 0 7.280239969986724e-06
2435 O 0 0.00046969502000138164
in O 0 1.2428779427864356e-06
exon O 0 3.752506017917767e-05
8 O 0 2.8640436084970133e-06
, O 0 1.3040967417055072e-07
resulting O 0 2.7855796247422404e-07
in O 0 5.66784841282697e-08
substitution O 0 1.42486825893684e-07
of O 0 1.8647818933459348e-07
alanine O 0 0.000187045443453826
464 O 0 4.08776177209802e-05
by O 0 2.427254912618082e-06
valine O 0 0.0012826662277802825
( O 0 2.004445377679076e-06
A464V O 0 0.0001229410117957741
) O 0 1.7490809796072426e-06
. O 0 4.091287792107323e-06

The O 0 5.690417310688645e-06
fathers O 0 2.0150264390395023e-05
genotype O 0 4.64115510112606e-05
thus O 0 1.465281911805505e-05
was O 0 5.27854535903316e-05
7delG O 0 0.00046659979852847755
/ O 0 0.00016933580627664924
A464V O 0 0.00043223905959166586
. O 0 1.3545235560741276e-05

Mutation O 0 0.00023643476015422493
A464V O 0 0.00010871203267015517
was O 0 7.527113666583318e-06
not O 0 1.0052475118982329e-07
found O 0 2.5259870994887024e-07
in O 0 4.413616068177362e-07
18 O 0 1.29251966427546e-05
unrelated O 0 0.0004348988295532763
MLD B-Disease 1 0.9996329545974731
patients O 0 0.0001514291507191956
and O 0 7.871472575970984e-07
50 O 0 1.9149917989125242e-06
controls O 0 8.104008884401992e-05
. O 0 1.5174246073001996e-05

A464V O 0 0.0011571215000003576
, O 0 5.210376912145875e-06
although O 0 1.6037896557463682e-06
clearly O 0 5.915437668591039e-06
modifying O 0 0.00016888770915102214
ARSA O 0 0.04796991124749184
and O 0 9.610415872884914e-05
GS O 1 0.9994086027145386
levels O 0 0.00011266762885497883
, O 0 2.9986076697241515e-06
apparently O 0 1.5255499420163687e-05
bears O 0 1.3968099665362388e-05
little O 0 1.3217262448961264e-06
significance O 0 1.4725191022080253e-06
for O 0 3.3873402571771294e-07
clinical O 0 5.792509546154179e-05
manifestation O 0 0.0004918374470435083
of O 0 1.7745707737049088e-05
MLD B-Disease 1 0.9998769760131836
, O 0 2.8720805858029053e-05
mimicking O 0 0.000440501666162163
the O 0 8.482782504870556e-06
frequent O 0 0.0004963107639923692
ARSA O 0 0.06619655340909958
pseudodeficiency O 0 0.005883148871362209
allele O 0 0.0006069373339414597
. O 0 5.250586764304899e-05

Our O 0 1.2235167559992988e-05
results O 0 6.11501673120074e-06
demonstrate O 0 1.1695974535541609e-06
that O 0 7.101240839801903e-08
in O 0 2.096974611731639e-07
certain O 0 1.048020635607827e-06
genetic O 0 0.0005093837389722466
conditions O 0 0.019831189885735512
MLD B-Disease 1 0.9997805953025818
- O 0 0.0072219520807266235
like O 0 7.950360304675996e-05
ARSA O 0 0.025207731872797012
and O 0 3.1177671189652756e-05
GS O 1 0.9906632900238037
values O 0 4.137033613460517e-07
need O 0 2.6613568593347736e-07
not O 0 2.8712085153870248e-08
be O 0 4.3143643324583536e-08
paralleled O 0 3.263800181230181e-06
by O 0 1.1335921499266988e-06
clinical O 0 0.001012361259199679
disease O 1 0.9980820417404175
, O 0 4.7661163193879474e-07
a O 0 4.4932255605090177e-07
finding O 0 1.0734459010564024e-06
with O 0 2.5978849862440256e-06
serious O 0 0.005421949550509453
diagnostic O 0 0.0027366764843463898
and O 0 2.389655855949968e-05
prognostic O 0 0.0343519002199173
implications O 0 0.0017604889580979943
. O 0 4.188472667010501e-05

Moreover O 0 0.0001096245541702956
, O 0 1.958201437446405e-06
further O 0 2.1001558252464747e-06
ARSA O 0 0.0050917817279696465
alleles O 0 2.2870835891808383e-05
functionally O 0 4.7884052037261426e-05
similar O 0 8.693909876456019e-07
to O 0 2.3208163213439548e-07
A464V O 0 3.347184610902332e-05
might O 0 6.031827979313675e-07
exist O 0 2.121721536241239e-07
which O 0 4.6298293199242835e-08
, O 0 2.1871768396408697e-08
together O 0 2.2292176993232715e-08
with O 0 1.399689466552445e-07
0 O 0 4.259445177012822e-06
- O 0 6.791477790102363e-05
type O 0 9.859889541985467e-05
mutations O 0 0.00023369934933725744
, O 0 4.474821253097616e-06
may O 0 1.909676575451158e-05
cause O 0 0.00017771546845324337
pathological O 0 0.02875140868127346
ARSA O 1 0.9361217021942139
and O 0 0.00018147414084523916
GS O 1 0.9995539784431458
levels O 0 0.00014192858361639082
, O 0 1.2527644912552205e-06
but O 0 1.7634083349093999e-07
not O 0 2.3399913118282711e-07
clinical O 0 3.477053178357892e-05
outbreak O 0 0.0006012324593029916
of O 0 2.7539095981410355e-07
the O 0 2.2491049094242044e-05
disease O 1 0.9993695616722107
. O 0 2.2818701381766004e-06
. O 0 4.42706914327573e-06

Human O 0 0.05711093172430992
MLH1 O 1 0.9962069988250732
deficiency O 1 0.9996920824050903
predisposes O 0 0.05818555876612663
to O 0 0.00011406080739106983
hematological B-Disease 1 0.9990845918655396
malignancy I-Disease 1 0.9997462630271912
and O 0 0.00046144152292981744
neurofibromatosis B-Disease 1 0.99973064661026
type I-Disease 1 0.6747429370880127
1 I-Disease 0 0.00028244793065823615
. O 0 1.598725066287443e-05

Heterozygous O 0 0.00011304277722956613
germ O 0 0.0037646018899977207
- O 0 0.0002505063312128186
line O 0 4.39665382145904e-05
mutations O 0 4.5436067011905834e-05
in O 0 3.329161586407281e-07
the O 0 7.461265454367094e-07
DNA O 0 5.917812086408958e-05
mismatch O 0 0.02128382958471775
repair O 0 0.3391767740249634
genes O 0 0.00012934993719682097
lead O 0 0.00019270040502306074
to O 0 4.031826028949581e-05
hereditary B-Disease 1 0.9999487400054932
nonpolyposis I-Disease 1 0.9999918937683105
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.00034489628160372376

The O 0 0.0002773962914943695
disease O 1 0.9982750415802002
susceptibility O 0 0.00040350714698433876
of O 0 4.3722621967390296e-07
individuals O 0 4.829891508961737e-07
who O 0 1.4698500308440998e-05
constitutionally O 0 5.7780329370871186e-05
lack O 0 3.1789888907951536e-06
both O 0 1.186815552500775e-06
wild O 0 3.6386121792020276e-05
- O 0 0.00017923788982443511
type O 0 5.3714604291599244e-05
alleles O 0 9.244356988347135e-06
is O 0 2.585691845524707e-06
unknown O 0 4.4511089072329924e-05
. O 0 8.426664862781763e-06

We O 0 3.0913454338588053e-06
have O 0 2.173151472106838e-07
identified O 0 8.172775096682017e-07
three O 0 8.406322393739174e-08
offspring O 0 1.6208971373998793e-06
in O 0 1.9216602140659234e-06
a O 0 0.0002537571417633444
hereditary B-Disease 1 0.9999306201934814
nonpolyposis I-Disease 1 0.9999903440475464
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
family O 0 0.0038129070308059454
who O 0 0.00014556566020473838
developed O 0 0.0012514300178736448
hematological B-Disease 1 0.9986072182655334
malignancy I-Disease 1 0.9982093572616577
at O 0 5.047124795964919e-05
a O 0 7.416119274239463e-07
very O 0 3.8091863530098635e-07
early O 0 2.440264324832242e-06
age O 0 1.4381009805219946e-06
, O 0 8.233609349872495e-08
and O 0 4.944217479874169e-08
at O 0 1.2549934353955905e-06
least O 0 2.0477960660514327e-08
two O 0 8.449737798343904e-09
of O 0 8.2107876053783e-09
them O 0 1.8383410349542828e-08
displayed O 0 1.1493862984934822e-05
signs O 0 4.9307680455967784e-05
of O 0 1.2804955531464657e-06
neurofibromatosis B-Disease 1 0.9984346032142639
type I-Disease 0 0.017167897894978523
1 I-Disease 0 7.619193638674915e-05
( O 0 4.22107768827118e-06
NF1 B-Disease 0 0.0008961435523815453
) O 0 1.9996091396023985e-06
. O 0 3.908151029463625e-06

DNA O 0 7.975561857165303e-06
sequence O 0 9.413050747753005e-07
analysis O 0 4.096962413768779e-07
and O 0 1.9400356165988342e-07
allele O 0 3.6632970932259923e-06
- O 0 6.068638867873233e-06
specific O 0 1.4648126978045184e-07
amplification O 0 5.729018539568642e-06
in O 0 2.4535157194804924e-07
two O 0 2.6808081088347535e-07
siblings O 0 1.8531272871769033e-05
revealed O 0 2.249420140287839e-05
a O 0 7.549118890892714e-06
homozygous O 0 7.100389484548941e-05
MLH1 O 0 0.008196933194994926
mutation O 0 0.00020960309484507889
( O 0 2.3791797048033914e-06
C676T O 0 0.00015960376185830683
- O 0 0.0004115454794373363
- O 0 0.00017621238657739013
> O 0 3.931648097932339e-05
Arg226Stop O 0 0.00020933987980242819
) O 0 9.902042847897974e-07
. O 0 2.3542145299870754e-06

Thus O 0 1.110760604206007e-05
, O 0 1.0596514812277746e-06
a O 0 2.6621867164067226e-06
homozygous O 0 3.114828359684907e-05
germ O 0 0.010142228566110134
- O 0 0.0012045198818668723
line O 0 0.0006514476845040917
MLH1 O 0 0.07142464816570282
mutation O 0 0.0013785758055746555
and O 0 3.5455690522212535e-05
consequent O 0 0.247591033577919
mismatch O 1 0.9997591376304626
repair O 1 0.999963641166687
deficiency O 1 0.9999707937240601
results O 0 5.823908941238187e-05
in O 0 2.5346455458929995e-06
a O 0 2.131453948095441e-05
mutator O 0 0.09531158208847046
phenotype O 0 0.0017066345317289233
characterized O 0 0.0006847921176813543
by O 0 2.3654880351386964e-05
leukemia B-Disease 1 0.9999438524246216
and O 0 0.0003505829372443259
/ O 1 0.8221675753593445
or O 1 0.9922921657562256
lymphoma B-Disease 1 1.0
associated O 0 0.00045293389121070504
with O 0 1.1073760106228292e-05
neurofibromatosis B-Disease 1 0.9994418025016785
type I-Disease 0 0.05056459829211235
1 I-Disease 0 3.6035758967045695e-05
. O 0 1.425208211003337e-06
. O 0 4.031993285025237e-06

Missense O 0 0.003096303902566433
mutations O 0 0.00030480208806693554
in O 0 5.900586188545276e-07
the O 0 9.949545898280121e-08
most O 0 1.0821120355331004e-07
ancient O 0 1.457673761251499e-06
residues O 0 5.3187332014204e-06
of O 0 9.178512527796556e-08
the O 0 1.1258898666710593e-06
PAX6 O 0 0.0022887687664479017
paired O 0 6.389381451299414e-05
domain O 0 1.2223224075569306e-05
underlie O 0 0.00021844732691533864
a O 0 8.485647413181141e-06
spectrum O 0 0.00019642747065518051
of O 0 1.77323763637105e-05
human O 1 0.9560527801513672
congenital B-Disease 1 0.9999998807907104
eye I-Disease 1 0.999977707862854
malformations I-Disease 1 0.9999755620956421
. O 0 0.0005958362016826868

Mutations O 0 0.0005261364276520908
of O 0 4.02280392108878e-07
the O 0 2.1410221506812377e-06
human O 0 9.133943967754021e-05
PAX6 O 0 0.1469171643257141
gene O 0 0.005901345517486334
underlie O 1 0.9824367761611938
aniridia B-Disease 1 0.999984622001648
( O 0 0.024809855967760086
congenital B-Disease 1 0.9999990463256836
absence I-Disease 0 0.000499779125675559
of I-Disease 0 4.955003305440187e-07
the I-Disease 0 3.7790127862535883e-06
iris I-Disease 0 0.04627466946840286
) O 0 5.049451488048362e-07
, O 0 4.1801183670031605e-07
a O 0 2.6116890694538597e-06
rare O 0 0.0006815658998675644
dominant O 1 0.9942423701286316
malformation B-Disease 1 0.999981164932251
of I-Disease 0 3.3488195185782388e-06
the I-Disease 0 3.598383773351088e-05
eye I-Disease 1 0.9955620765686035
. O 0 5.714305734727532e-05

The O 0 3.060798235310358e-06
spectrum O 0 7.521268707932904e-05
of O 0 3.5280761494504986e-06
PAX6 O 0 0.05081050470471382
mutations O 0 0.005417156033217907
in O 0 7.082057709340006e-05
aniridia B-Disease 1 0.9998378753662109
patients O 0 0.00035554516944102943
is O 0 5.096923132441589e-07
highly O 0 1.5171910945355194e-06
biased O 0 1.806755335564958e-06
, O 0 1.073136104423611e-07
with O 0 5.4503633606373114e-08
92 O 0 1.4892259514454054e-06
% O 0 6.556507337052153e-09
of O 0 9.092154584777745e-09
all O 0 8.117702066101629e-08
reported O 0 1.338500533165643e-05
mutations O 0 3.104200368397869e-05
leading O 0 1.4424796972889453e-05
to O 0 1.6578663064592547e-07
premature O 0 2.74794456345262e-05
truncation O 0 7.26076996215852e-06
of O 0 4.2019571822038415e-08
the O 0 2.0354175944703456e-07
protein O 0 1.92565221368568e-06
( O 0 2.893400221637421e-07
nonsense O 0 1.0240976735076401e-05
, O 0 1.6684424508639495e-07
splicing O 0 3.1957652026903816e-06
, O 0 7.23010714409611e-07
insertions O 0 5.6270901040988974e-06
and O 0 2.1898196678193926e-07
deletions O 0 1.207286118187767e-06
) O 0 3.878621868125265e-08
and O 0 5.295404292837702e-08
just O 0 2.0227216168677842e-07
2 O 0 1.5612253889685235e-07
% O 0 3.719482499775495e-09
leading O 0 2.007888042498962e-07
to O 0 4.569006950561061e-09
substitution O 0 1.8457262385140893e-08
of O 0 9.97133220437263e-09
one O 0 5.595633112420728e-08
amino O 0 2.4655579977661546e-07
acid O 0 2.035655597865116e-06
by O 0 4.407596421174276e-08
another O 0 6.926262585693621e-07
( O 0 4.2783577214322577e-07
missense O 0 7.75590306147933e-05
) O 0 1.5158100268308772e-06
. O 0 4.20870946982177e-06

The O 0 3.968669716414297e-06
extraordinary O 0 7.857905075070448e-06
conservation O 0 2.569360276538646e-06
of O 0 4.1853358112575734e-08
the O 0 2.7372067279429757e-07
PAX6 O 0 0.00021010493219364434
protein O 0 3.3053318020392908e-06
at O 0 2.697662694117753e-06
the O 0 1.6627208765385149e-07
amino O 0 9.957003612726112e-07
acid O 0 1.0109201866725925e-05
level O 0 4.605415597325191e-06
amongst O 0 1.9868864455929724e-06
vertebrates O 0 0.00016097823390737176
predicts O 0 9.50184985413216e-05
that O 0 6.908115324222308e-07
pathological O 0 0.0008220646413974464
missense O 0 0.000656035088468343
mutations O 0 0.000248374737566337
should O 0 2.0743193545058602e-06
in O 0 2.444759275022079e-07
fact O 0 2.8475261615312775e-07
be O 0 1.13939023549392e-07
common O 0 7.317775612136757e-07
even O 0 9.094982829083165e-07
though O 0 1.8113465216629265e-07
they O 0 2.258215481276693e-08
are O 0 1.4421654981333631e-08
hardly O 0 3.1037316148285754e-06
ever O 0 5.639408755087061e-06
seen O 0 2.5170222215820104e-05
in O 0 1.8199005353380926e-05
aniridia B-Disease 1 0.9990856647491455
patients O 0 0.0012014866806566715
. O 0 1.2221091310493648e-05

This O 0 7.476508585568808e-07
indicates O 0 1.4978431863710284e-06
that O 0 2.679171728914298e-08
there O 0 5.687699200507268e-08
is O 0 2.312716418373384e-07
a O 0 1.5570885807392187e-06
heavy O 0 0.0005219090380705893
ascertainment O 0 0.0012284716358408332
bias O 0 2.3791366402292624e-05
in O 0 4.946858211951621e-07
the O 0 2.234192209016328e-07
selection O 0 5.348737772692402e-07
of O 0 2.538646697303193e-07
patients O 0 1.1854031981783919e-05
for O 0 3.62683522325824e-07
PAX6 O 0 0.0009503363980911672
mutation O 0 1.4694422134198248e-05
analysis O 0 3.855367083360761e-07
and O 0 3.666725945095095e-07
that O 0 1.1335398397704921e-07
the O 0 1.4890001693856902e-06
missing O 0 0.00011437971261329949
PAX6 O 0 0.014431416988372803
missense O 0 0.005124540999531746
mutations O 0 0.0025393858086317778
frequently O 0 0.00021155268768779933
may O 0 4.114030161872506e-05
underlie O 0 0.0008552109939046204
phenotypes O 0 0.0003068342921324074
distinct O 0 1.4488877241092268e-05
from O 0 2.05136548174778e-05
textbook O 0 0.10871358215808868
aniridia B-Disease 1 0.9998258948326111
. O 0 0.00014540458505507559

Here O 0 6.140401637821924e-06
we O 0 5.702628982362512e-07
present O 0 3.0535656492247654e-07
four O 0 5.478430011862656e-07
novel O 0 1.1058341442549136e-05
PAX6 O 0 0.0017238343134522438
missense O 0 0.00034158866037614644
mutations O 0 0.00012852299551013857
, O 0 4.3198281218792545e-07
two O 0 1.1654449139086864e-07
in O 0 4.844164323003497e-07
association O 0 2.6307825464755297e-06
with O 0 2.231099188065855e-06
atypical O 0 0.010520902462303638
phenotypes O 0 0.007112708408385515
ectopia B-Disease 0 0.021143661811947823
pupillae I-Disease 0 0.008402431383728981
( O 0 1.6361483403670718e-06
displaced B-Disease 0 4.012882072856883e-06
pupils I-Disease 0 3.831121830444317e-06
) O 0 1.9856988728861324e-06
and O 0 0.00016825986676849425
congenital B-Disease 1 0.9999977350234985
nystagmus I-Disease 1 0.9866282939910889
( O 0 3.106378926531761e-06
searching B-Disease 0 1.7430367734050378e-05
gaze I-Disease 0 0.00010411757830297574
) O 0 1.2074330868472316e-07
, O 0 8.638068749178274e-08
and O 0 3.624400690682705e-08
two O 0 8.036100496155996e-08
in O 0 1.9031944020753144e-07
association O 0 6.82855784361891e-07
with O 0 1.561402456218275e-07
more O 0 5.155833946446364e-07
recognizable O 0 0.014522497542202473
aniridia B-Disease 1 0.9993255138397217
phenotypes O 0 0.01071669440716505
. O 0 4.676510798162781e-05

Strikingly O 0 0.00015087884094100446
, O 0 1.0718869134507258e-06
all O 0 3.5862903757788445e-08
four O 0 2.818143798322126e-07
mutations O 0 5.661269824486226e-06
are O 0 3.667697257014879e-08
located O 0 5.656988264490792e-07
within O 0 3.7439551192619547e-07
the O 0 7.212022978819732e-07
PAX6 O 0 0.0006170221022330225
paired O 0 1.4391023796633817e-05
domain O 0 1.800889322112198e-06
and O 0 3.716474168413697e-07
affect O 0 6.832491976638266e-07
amino O 0 4.0355570263272966e-07
acids O 0 6.475169698205718e-07
which O 0 1.459093024180902e-08
are O 0 1.7920391837122907e-09
highly O 0 1.25665906125505e-07
conserved O 0 3.015240395143337e-07
in O 0 4.4061756909741234e-08
all O 0 1.033886398715822e-08
known O 0 8.453624218418554e-07
paired O 0 4.812443421542412e-06
domain O 0 2.8273495900066337e-06
proteins O 0 7.390303835563827e-06
. O 0 9.495943231740966e-06

Our O 0 1.09080683614593e-05
results O 0 5.806286935694516e-06
support O 0 2.2593923176827957e-07
the O 0 2.546609607634309e-07
hypothesis O 0 4.1275163198406517e-07
that O 0 7.43701056293844e-09
the O 0 3.161210315738572e-08
under O 0 3.3857671155601565e-07
- O 0 1.2855120985477697e-06
representation O 0 7.623432907166716e-08
of O 0 5.566741378970619e-07
missense O 0 0.0011866155546158552
mutations O 0 0.00140483770519495
is O 0 1.380542107654037e-05
caused O 0 0.00015054098912514746
by O 0 1.655499431763019e-06
ascertainment O 0 0.001640776637941599
bias O 0 4.422114579938352e-05
and O 0 1.8365907408224302e-06
suggest O 0 1.0284325071552303e-06
that O 0 4.2681691070356464e-08
a O 0 1.0524616982365842e-06
substantial O 0 3.7071717997605447e-06
burden O 0 0.00011030172026949003
of O 0 5.43661326446454e-06
PAX6 B-Disease 1 0.9787138104438782
- I-Disease 1 0.9654061198234558
related I-Disease 0 0.006632436532527208
disease I-Disease 1 0.9996978044509888
remains O 0 1.7583832232048735e-05
to O 0 8.739174717220521e-08
be O 0 3.631012646110321e-07
uncovered O 0 2.2388308934750967e-05
. O 0 8.558315585105447e-07
. O 0 3.333687345730141e-06

The O 0 5.283114205667516e-06
chromosomal O 0 0.000641741615254432
order O 0 1.0006694992625853e-06
of O 0 1.971248480003851e-07
genes O 0 7.419440862577176e-06
controlling O 0 0.00016999521176330745
the O 0 4.249459834682057e-06
major O 0 0.0006172939320094883
histocompatibility O 1 0.9906151294708252
complex O 0 0.0013829679228365421
, O 0 7.889789230830502e-06
properdin O 0 0.00020538274839054793
factor O 0 1.157571477961028e-05
B O 0 0.00010536494664847851
, O 0 2.4974685857159784e-06
and O 0 3.4084867365891114e-05
deficiency B-Disease 1 0.9935683608055115
of I-Disease 0 6.529478469019523e-08
the I-Disease 0 1.8268330848059122e-07
second I-Disease 0 1.6129249615914887e-06
component I-Disease 0 3.5550383472582325e-06
of I-Disease 0 1.3563447964770603e-07
complement I-Disease 0 1.3310196663951501e-05
. O 0 2.5084604203584604e-05

The O 0 8.815530350148038e-07
relationship O 0 3.0506248549500015e-06
of O 0 5.64108013634268e-08
the O 0 1.2513180536188884e-07
genes O 0 1.3663224081028602e-06
coding O 0 1.609485480003059e-05
for O 0 2.068756685957851e-07
HLA O 0 1.2420329767337535e-05
to O 0 2.174182966996341e-08
those O 0 3.3519203412879506e-08
coding O 0 7.3701880864973646e-06
for O 0 1.839153469518351e-07
properdin O 0 0.00011781534703914076
Factor O 0 7.77197510615224e-06
B O 0 4.861591150984168e-05
allotypes O 0 0.00016844285710249096
and O 0 5.5977266129048076e-06
for O 0 7.341006494243629e-06
deficiency B-Disease 1 0.9976109266281128
of I-Disease 0 5.468398356356374e-08
the I-Disease 0 2.5572938966433867e-07
second I-Disease 0 1.020294803311117e-06
component I-Disease 0 3.464119345153449e-06
of I-Disease 0 8.342988166987197e-08
complement I-Disease 0 2.992368536069989e-06
( O 0 9.154172744274547e-07
C2 O 0 0.00014269285020418465
) O 0 1.1914794839640308e-07
was O 0 1.0596181709843222e-06
studied O 0 1.6546739516343223e-06
in O 0 8.660125416781739e-08
families O 0 2.6158312849133836e-08
of O 0 1.5037457501421159e-07
patients O 0 0.00010363696492277086
with O 0 9.278459037886932e-05
connective O 1 0.9999310970306396
tissue O 1 0.9999756813049316
disorders O 1 0.999994158744812
. O 0 0.000252253346843645

Patients O 0 7.405068026855588e-05
were O 0 1.464302812337337e-07
selected O 0 1.1523725618189928e-07
because O 0 1.230687587394641e-07
they O 0 2.4709054358140747e-08
were O 0 6.657397477738414e-08
heterozygous O 0 4.520630341176002e-07
or O 0 2.571841150711407e-06
homozygous O 0 8.59130232129246e-05
for O 0 0.00021750169980805367
C2 B-Disease 1 0.9999845027923584
deficiency I-Disease 1 0.9999984502792358
. O 0 9.028486965689808e-05

12 O 0 6.814962034695782e-06
families O 0 5.6634608114336515e-08
with O 0 1.8410013069569686e-07
15 O 0 2.2693850496580126e-06
matings O 0 0.00010688398469937965
informative O 0 0.00010015832958742976
for O 0 0.0005626257043331861
C2 B-Disease 1 0.9999781847000122
deficiency I-Disease 1 0.9999977350234985
were O 0 9.633678928366862e-06
found O 0 1.8223787265014835e-05
. O 0 7.473311143257888e-06

Of O 0 1.2878706456831424e-06
57 O 0 6.8923741309845354e-06
informative O 0 5.624975528917275e-06
meioses O 0 0.00013167144788894802
, O 0 1.8304064042240498e-07
two O 0 1.9255473659995914e-08
crossovers O 0 1.0982009825966088e-06
were O 0 1.8262461765061744e-07
noted O 0 9.784777148524881e-07
between O 0 1.878681473499455e-06
the O 0 0.00041857556789182127
C2 B-Disease 1 0.9998801946640015
deficiency I-Disease 1 0.9999555349349976
gene O 0 1.694350430625491e-05
and O 0 9.14867484880233e-07
the O 0 1.0328269581805216e-06
HLA O 0 7.570748130092397e-05
- O 0 3.0751689337193966e-05
B O 0 6.116405074862996e-06
gene O 0 4.5650762103832676e-07
, O 0 3.429178008218514e-08
with O 0 7.2975070430914e-09
a O 0 1.057952587757427e-07
recombinant O 0 2.272559243010619e-07
fraction O 0 3.3205748195541673e-07
of O 0 1.6997992702272313e-07
0 O 0 7.248772817547433e-06
. O 0 4.451582299225265e-06

035 O 0 0.1593044400215149
. O 0 0.00013867011875845492

A O 0 1.6201698599616066e-05
lod O 0 0.00034265013528056443
score O 0 9.050249900610652e-07
of O 0 9.339105844219375e-08
13 O 0 1.178996740236471e-06
was O 0 9.94168999568501e-07
calculated O 0 1.438402392750504e-07
for O 0 7.939492974173845e-08
linkage O 0 0.00020554865477606654
between O 0 0.004134105984121561
C2 B-Disease 1 0.9999688863754272
deficiency I-Disease 1 0.9999938011169434
and O 0 2.4592400222900324e-05
HLA O 0 0.000244348804699257
- O 0 5.917732778470963e-05
B O 0 1.266784511244623e-05
at O 0 1.3957201190351043e-06
a O 0 1.3422302913568274e-07
maximum O 0 7.665526879918616e-08
likelihood O 0 1.4038282358797005e-07
value O 0 1.8029458814794452e-08
of O 0 5.26983923165858e-09
the O 0 3.5337624382236754e-08
recombinant O 0 4.542731915080367e-07
fraction O 0 6.455027232732391e-07
of O 0 2.1756834200914454e-07
0 O 0 8.027604053495452e-06
. O 0 5.346898433344904e-06

04 O 0 0.014619274996221066
. O 0 4.659892510971986e-05

18 O 0 7.028889740468003e-06
families O 0 7.596087669980989e-08
with O 0 1.9482901336687064e-07
21 O 0 1.3941171346232295e-06
informative O 0 6.413026767404517e-07
matings O 0 1.0006323464040179e-05
for O 0 7.013036196212852e-08
both O 0 2.9849925908820296e-07
properdin O 0 9.060968295671046e-05
Factor O 0 4.238725978211733e-06
B O 0 2.2334614186547697e-05
allotype O 0 7.921610813355073e-05
and O 0 4.006491963082226e-06
HLA O 0 0.00014771193673368543
- O 0 7.331165397772565e-05
B O 0 2.2685113435727544e-05
were O 0 5.805943601444596e-07
found O 0 2.645235781528754e-06
. O 0 2.517289203751716e-06

Of O 0 1.9620504190243082e-06
72 O 0 2.0447034330572933e-05
informative O 0 1.2464302017178852e-05
meioses O 0 0.0004315617261454463
, O 0 6.933241252227162e-07
three O 0 1.1700733182351541e-07
recombinants O 0 2.81412030744832e-05
were O 0 2.094014917020104e-07
found O 0 2.3986467567738146e-07
, O 0 2.7586979811644596e-08
giving O 0 2.3366144574765713e-08
a O 0 7.626356079981633e-08
recombinant O 0 4.003296680821222e-07
fraction O 0 4.970972895534942e-07
of O 0 1.6311707895511063e-07
0 O 0 8.236927897087298e-06
. O 0 3.8077512272138847e-06

042 O 0 0.020599855110049248
. O 0 0.00014143940643407404

A O 0 2.5852335966192186e-05
lod O 0 0.0002460162795614451
score O 0 1.2314511650401982e-06
of O 0 8.276246887817251e-08
16 O 0 9.837500556386658e-07
between O 0 8.299276714751613e-07
HLA O 0 9.241205407306552e-05
- O 0 3.6135694244876504e-05
B O 0 8.196103408408817e-06
and O 0 2.6325341195843066e-07
Factor O 0 1.312674271503056e-06
B O 0 1.0055665370600764e-05
allotypes O 0 2.2622525648330338e-05
was O 0 1.5297456457119551e-06
calculated O 0 1.32193264335001e-07
at O 0 3.9807474649933283e-07
a O 0 1.1106530450888386e-07
maximum O 0 1.2047738096043759e-07
likelihood O 0 2.0570628578298056e-07
value O 0 1.5998644187220634e-08
of O 0 9.437967740666409e-09
the O 0 2.1520481396919422e-08
recombinant O 0 2.55703525908757e-07
fraction O 0 4.1296820540992485e-07
of O 0 1.550887986923044e-07
0 O 0 8.371555850317236e-06
. O 0 5.272142061585328e-06

04 O 0 0.016686806455254555
. O 0 6.749730528099462e-05

A O 0 3.55828433384886e-06
crossover O 0 3.053069576708367e-06
was O 0 3.4814806895155925e-06
shown O 0 7.521407496824395e-08
to O 0 8.001348028585653e-09
have O 0 1.970853169552811e-08
occurred O 0 1.8644102794951323e-07
between O 0 2.692604006426791e-08
genes O 0 2.1937157157481124e-07
for O 0 2.4464123171696883e-08
Factor O 0 4.7102255962272466e-07
B O 0 6.318086434475845e-06
and O 0 1.8065934455080424e-06
HLA O 0 0.00022237288067117333
- O 0 0.0003370886843185872
D O 0 0.000656544289086014
, O 0 2.2772367458401277e-07
in O 0 1.2817500305573049e-07
which O 0 8.064704957178037e-07
HLA O 0 0.0001392934937030077
- O 0 0.0002716030285228044
D O 0 0.0005032302578911185
segregared O 0 3.275967173976824e-05
with O 0 1.0815534778885194e-06
HLA O 0 0.00011146596079925075
- O 0 2.8623548132600263e-05
A O 0 5.684245024895063e-06
and O 0 2.9649108910234645e-06
B O 0 0.00012598384637385607
. O 0 6.9203470047796145e-06

These O 0 3.452710473084153e-07
studies O 0 7.18035778390913e-07
suggest O 0 3.231396306091483e-07
that O 0 1.1204037697609692e-08
the O 0 2.96107920405575e-08
genes O 0 4.338667451975198e-07
for O 0 3.993721406914119e-07
Factor O 0 2.1728665160480887e-05
B O 0 0.006144669838249683
and O 0 0.030335819348692894
C2 B-Disease 1 0.9999896287918091
deficiency I-Disease 1 0.999997615814209
are O 0 1.390428394643095e-07
located O 0 6.444515179282462e-07
outside O 0 2.918227437476162e-07
those O 0 4.442538426019382e-08
for O 0 9.242440057732892e-08
HLA O 0 2.901114203268662e-05
, O 0 2.243054240125275e-07
that O 0 8.173256738075452e-09
the O 0 4.425783828310159e-08
order O 0 9.081308860459103e-08
of O 0 7.161305859426648e-08
genese O 0 0.00011626385094132274
is O 0 1.6230827668550774e-06
HLA O 0 2.7281943403068e-05
- O 0 7.998672117537353e-06
A O 0 2.28116959988256e-06
, O 0 6.11265704719699e-07
- O 0 1.0311614460079e-05
B O 0 1.2926047020300757e-05
, O 0 1.169267420664255e-06
- O 0 4.8568836064077914e-05
D O 0 0.00019983616948593408
, O 0 5.118429271533387e-07
Factor O 0 1.5255163816618733e-06
B O 0 7.671532512176782e-05
allotype O 0 0.006841195281594992
, O 0 0.0033600288443267345
C2 B-Disease 1 0.9999651908874512
deficiency I-Disease 1 0.9999915361404419
, O 0 6.617960366384068e-07
that O 0 1.4288452199195945e-08
the O 0 8.965242415115426e-08
genes O 0 8.244534910772927e-06
coding O 0 0.0006920765154063702
for O 0 0.0002705763909034431
C2 B-Disease 1 0.9999583959579468
deficiency I-Disease 1 0.9999915361404419
and O 0 4.858353804593207e-06
Factor O 0 4.190210802335059e-06
B O 0 1.5021710169094149e-05
allotypes O 0 1.2221709766890854e-05
are O 0 8.298293607822416e-09
approximately O 0 2.5451084795236056e-08
3 O 0 9.164655239146668e-07
- O 0 9.341773875348736e-06
- O 0 7.183726665971335e-06
5 O 0 3.5335338566255814e-07
centimorgans O 0 8.57547638588585e-06
from O 0 5.586525730905123e-08
the O 0 1.3839368762091908e-07
HLA O 0 1.7855487385531887e-05
- O 0 6.581325578736141e-06
A O 0 1.8970654309669044e-06
and O 0 1.0414180451334687e-06
HLA O 0 6.95298658683896e-05
- O 0 3.7577556213364005e-05
B O 0 9.461450645176228e-06
loci O 0 2.7173173293704167e-06
, O 0 2.2028899593351525e-07
and O 0 9.069675854789239e-08
that O 0 1.269322336128198e-08
the O 0 1.1744893413379032e-07
apparent O 0 1.1962576536461711e-05
lack O 0 2.1696816929761553e-06
of O 0 1.4385287272489222e-07
recombinants O 0 3.9937505789566785e-05
between O 0 3.1802034072825336e-07
the O 0 8.058492539930739e-07
Factor O 0 7.470667696907185e-06
B O 0 0.00010326447227271274
gene O 0 0.00011300182086415589
and O 0 0.0018730066949501634
C2 B-Disease 1 0.9999501705169678
deficiency I-Disease 1 0.9999881982803345
gene O 0 9.405680430063512e-06
suggests O 0 5.979684942758468e-07
that O 0 3.1620044360636257e-09
these O 0 2.7472861763300216e-09
two O 0 4.1525119343077677e-08
genes O 0 8.599910756856843e-07
lie O 0 4.712440841103671e-06
in O 0 6.470749980280743e-08
close O 0 6.427409289244679e-07
proximity O 0 9.306082802140736e-07
to O 0 1.3384287456119637e-07
one O 0 3.2438799735245993e-07
another O 0 1.4048717957848567e-06
. O 0 3.0527901344612474e-06

Distribution O 0 4.9576728997635655e-06
of O 0 9.953282642527483e-07
emerin O 0 0.0009290351299569011
and O 0 5.7802490118774585e-06
lamins O 0 0.003458930179476738
in O 0 3.2773243674455443e-06
the O 0 5.556633823289303e-06
heart O 0 0.2910625636577606
and O 0 5.594828508037608e-06
implications O 0 9.534278069622815e-05
for O 0 1.3139458133082371e-05
Emery B-Disease 1 0.989687979221344
- I-Disease 1 0.9993525147438049
Dreifuss I-Disease 1 0.9996750354766846
muscular I-Disease 1 0.9998770952224731
dystrophy I-Disease 1 0.9997313618659973
. O 0 0.0002762087096925825

Emerin O 0 0.0013115154579281807
is O 0 8.774615025686217e-07
a O 0 6.817872986175644e-07
nuclear O 0 1.0912460311374161e-05
membrane O 0 2.57136298387195e-06
protein O 0 5.059367254034441e-07
which O 0 1.1461722948524766e-07
is O 0 1.4725834773798852e-07
missing O 0 2.335533281438984e-06
or O 0 1.3076127061140141e-06
defective O 0 0.0022437316365540028
in O 0 3.031365486094728e-05
Emery B-Disease 1 0.9946596026420593
- I-Disease 1 0.9996581077575684
Dreifuss I-Disease 1 0.9997668862342834
muscular I-Disease 1 0.9999362230300903
dystrophy I-Disease 1 0.9998490810394287
( O 0 0.00012270818115212023
EDMD B-Disease 1 0.999609649181366
) O 0 6.781921911169775e-06
. O 0 7.984191142895725e-06

It O 0 1.2215767810630496e-06
is O 0 2.20468891143355e-07
one O 0 5.156994475896681e-08
member O 0 1.3208816085352737e-07
of O 0 1.6767650379279075e-08
a O 0 1.113496864491026e-06
family O 0 3.826652118732454e-06
of O 0 8.94383049399039e-07
lamina O 1 0.5565711259841919
- O 0 0.00015657229232601821
associated O 0 1.7231717492904863e-06
proteins O 0 4.2989259441128524e-07
which O 0 1.7096073179345694e-07
includes O 0 7.853956276449026e-07
LAP1 O 0 0.0005912460619583726
, O 0 2.0294394289521733e-06
LAP2 O 0 0.000433561421232298
and O 0 4.646094112104038e-06
lamin O 0 0.0014235229464247823
B O 0 0.00046515808207914233
receptor O 0 0.00015077859279699624
( O 0 8.507670827384572e-06
LBR O 0 0.023016467690467834
) O 0 2.9062089197395835e-06
. O 0 5.192355729377596e-06

A O 0 3.849867425742559e-05
panel O 0 2.9945931601105258e-05
of O 0 2.3610196819845441e-07
16 O 0 4.107919266971294e-06
monoclonal O 0 5.8810751397686545e-06
antibodies O 0 4.043001808895497e-06
( O 0 2.1534961547331477e-07
mAbs O 0 1.3487139767676126e-05
) O 0 1.0685508300412039e-07
has O 0 1.6570665195558831e-07
been O 0 1.018104427430444e-07
mapped O 0 4.334019081397855e-07
to O 0 7.277824121132426e-09
six O 0 4.592275004711155e-08
specific O 0 7.283684322345607e-09
sites O 0 1.399851043970557e-07
throughout O 0 2.0461726535359048e-07
the O 0 1.5022435206901719e-07
emerin O 0 2.2198795704753138e-05
molecule O 0 3.0906910524208797e-06
using O 0 1.4409826007977244e-06
phage O 0 3.41940249199979e-05
- O 0 7.237292720674304e-06
displayed O 0 1.8710038602876011e-06
peptide O 0 6.203364932844124e-07
libraries O 0 6.20414652985346e-08
and O 0 1.1296483393152812e-07
has O 0 1.1027247381889538e-07
been O 0 4.095344152688085e-08
used O 0 3.375897250634807e-08
to O 0 3.435665618667372e-08
localize O 0 3.7943420466035604e-05
emerin O 0 0.0002053433854598552
in O 0 9.035184120875783e-07
human O 0 6.228610345715424e-06
and O 0 1.027541293296963e-05
rabbit O 0 0.016493333503603935
heart O 1 0.9904165267944336
. O 0 5.755178426625207e-05

Several O 0 2.7155324460181873e-06
mAbs O 0 0.0001702695299172774
against O 0 1.454730977457075e-06
different O 0 3.6805221270697075e-07
emerin O 0 0.0008882626425474882
epitopes O 0 0.00021466676844283938
did O 0 4.291607638151618e-06
not O 0 1.4502067813282338e-07
recognize O 0 2.75527509074891e-06
intercalated O 0 5.135408355272375e-05
discs O 0 7.799864397384226e-05
in O 0 1.447489125894208e-06
the O 0 3.5401149034441914e-06
heart O 1 0.567068874835968
, O 0 1.0205428679910256e-06
though O 0 2.7567185156840424e-07
they O 0 1.3168366308491386e-07
recognized O 0 2.675475343494327e-06
cardiomyocyte O 0 0.00012937768769916147
nuclei O 0 1.928574602061417e-05
strongly O 0 3.85747034670203e-06
, O 0 2.185086174222306e-07
both O 0 1.507878693018938e-07
at O 0 1.585678728588391e-05
the O 0 8.089523930721043e-07
rim O 0 0.00011370245192665607
and O 0 1.2988060689167469e-06
in O 0 9.334241894976003e-07
intranuclear O 0 0.00015102651377674192
spots O 0 2.179931652790401e-05
or O 0 2.5114454729191493e-06
channels O 0 2.413575566606596e-05
. O 0 2.0147706891293637e-05

A O 0 7.984945841599256e-05
polyclonal O 0 0.0007736956467851996
rabbit O 0 0.00137995439581573
antiserum O 0 0.0007715222309343517
against O 0 1.3113120076013729e-05
emerin O 0 0.00044832139974460006
did O 0 2.2937306312087458e-06
recognize O 0 1.8237691392641864e-06
both O 0 4.635625998616888e-07
nuclear O 0 8.943040302256122e-05
membrane O 0 1.6666401279508136e-05
and O 0 1.0438342314955662e-06
intercalated O 0 4.166768485447392e-05
discs O 0 7.590511813759804e-05
but O 0 5.653250809700694e-07
, O 0 8.763261405420053e-08
after O 0 2.7193863161301124e-07
affinity O 0 4.522277663454588e-07
purification O 0 9.330431566922925e-06
against O 0 3.9219852965288737e-07
a O 0 7.260897518790443e-07
pure O 0 3.147858251395519e-06
- O 0 4.1331295506097376e-05
emerin O 0 5.152538506081328e-05
band O 0 1.1614893992373254e-05
on O 0 6.058728558855364e-07
a O 0 7.350186592702812e-07
western O 0 5.1734796215896495e-06
blot O 0 0.0011882325634360313
, O 0 1.576737304276321e-06
it O 0 2.2054796033899038e-07
stained O 0 0.0006174003938212991
only O 0 2.5299891603935976e-07
the O 0 7.504225436605338e-07
nuclear O 0 0.00023057441285345703
membrane O 0 0.00019732136570382863
. O 0 1.787199653335847e-05

These O 0 3.2098262181534665e-07
results O 0 1.5783093658683356e-06
would O 0 1.0240405856620782e-07
not O 0 3.466331932600042e-08
be O 0 9.50267278199135e-08
expected O 0 4.1700374708852905e-07
if O 0 3.890195046096778e-07
immunostaining O 0 5.274283466860652e-05
at O 0 7.29126713849837e-06
intercalated O 0 2.0194895114400424e-05
discs O 0 1.8388853277429007e-05
were O 0 1.820867083779376e-07
due O 0 3.038842919522722e-07
to O 0 9.654726795815805e-09
a O 0 8.865241341027286e-08
product O 0 2.3168003338014387e-07
of O 0 2.0246064380557982e-08
the O 0 2.2378920050414308e-07
emerin O 0 6.839729758212343e-05
gene O 0 3.2916732379817404e-06
and O 0 7.3956442747658e-07
, O 0 3.27149251688752e-07
therefore O 0 1.815666621496348e-07
, O 0 9.091360197999165e-08
cast O 0 2.4548216970288195e-07
some O 0 2.0871022243795778e-08
doubt O 0 4.3159366214240436e-07
upon O 0 1.655655808008305e-07
the O 0 5.640896461045486e-07
hypothesis O 0 1.3013642274017911e-05
that O 0 3.029562321898993e-06
cardiac B-Disease 1 0.998964786529541
defects I-Disease 1 0.9996178150177002
in O 0 3.7225450796540827e-05
EDMD B-Disease 1 0.9999520778656006
are O 0 1.8657920008990914e-06
caused O 0 6.793583452235907e-05
by O 0 2.94398887490388e-07
absence O 0 9.08768197405152e-06
of O 0 3.313277261440817e-07
emerin O 0 0.0012478192802518606
from O 0 3.821990958385868e-06
intercalated O 0 0.001141488435678184
discs O 0 0.0033315822947770357
. O 0 2.8647387807723135e-05

Although O 0 2.521214264561422e-05
emerin O 0 0.0006522530457004905
was O 0 8.922090273699723e-06
abundant O 0 9.995136451834696e-07
in O 0 2.5546611936988484e-07
the O 0 2.724313219459873e-07
membranes O 0 4.08201631216798e-05
of O 0 3.5639251905195124e-07
cardiomyocyte O 0 0.00028637831564992666
nuclei O 0 5.807138222735375e-05
, O 0 1.0095975540025393e-06
it O 0 2.608351223898353e-07
was O 0 4.901929059997201e-06
absent O 0 3.482852207525866e-06
from O 0 9.039953141609658e-08
many O 0 3.5758198180246836e-08
non O 0 1.781663922884036e-05
- O 0 0.0003286572464276105
myocyte O 0 0.0009616415482014418
cells O 0 1.2415213859640062e-05
in O 0 1.1994593478448223e-06
the O 0 5.685914857167518e-06
heart O 1 0.5141448378562927
. O 0 1.6536499970243312e-05

This O 0 1.075742872558294e-07
distribution O 0 3.537789439178596e-07
of O 0 1.7458000911574345e-07
emerin O 0 0.00029531194013543427
was O 0 6.4721721173555125e-06
similar O 0 1.9313667110054666e-07
to O 0 2.9526027844894998e-08
that O 0 1.9264986050870903e-08
of O 0 5.330273467052393e-08
lamin O 0 8.954483200795949e-05
A O 0 3.219515292585129e-06
, O 0 2.4296073775076366e-07
a O 0 2.6761387061924324e-07
candidate O 0 5.254015036371129e-07
gene O 0 5.040935207034636e-07
for O 0 5.342477393810441e-08
an O 0 4.642846533897682e-07
autosomal O 0 0.00979111809283495
form O 0 0.00010676633974071592
of O 0 4.4935706682736054e-05
EDMD B-Disease 1 0.9999547004699707
. O 0 0.0001350746606476605

In O 0 8.265144970209803e-06
contrast O 0 3.8139460230013356e-05
, O 0 2.1330321033019572e-05
lamin O 0 0.018282273784279823
B1 O 0 0.28409597277641296
was O 0 8.633467223262414e-05
absent O 0 4.089680078322999e-05
from O 0 1.6606385315753869e-06
cardiomyocyte O 0 0.00021070677030365914
nuclei O 0 4.4211446947883815e-05
, O 0 2.2292849735094933e-06
showing O 0 8.092323696473613e-06
that O 0 8.010221108634141e-07
lamin O 0 0.0017705811187624931
B1 O 0 0.0021761376410722733
is O 0 2.45888685412865e-07
not O 0 1.1856098325324638e-08
essential O 0 8.394977868420028e-08
for O 0 3.332083053919632e-08
localization O 0 4.974941020918777e-06
of O 0 1.3092807193970657e-07
emerin O 0 0.0001707554911263287
to O 0 6.222657589205483e-07
the O 0 7.237168574647512e-06
nuclear O 0 0.018029116094112396
lamina O 0 0.35135525465011597
. O 0 4.3831860239151865e-05

Lamin O 0 0.12335322052240372
B1 O 0 0.15176145732402802
is O 0 5.292115474730963e-06
also O 0 1.918243469845038e-06
almost O 0 1.8681849951462937e-06
completely O 0 4.623070344678126e-05
absent O 0 0.00013704353477805853
from O 0 5.7684533203428145e-06
skeletal O 1 0.9158155918121338
muscle O 0 0.2294314056634903
nuclei O 0 0.0024720067158341408
. O 0 3.142884452245198e-05

In O 0 5.678269008058123e-05
EDMD B-Disease 1 0.998795747756958
, O 0 2.3660943497816334e-06
the O 0 1.3347144545150513e-07
additional O 0 1.9652830474115035e-07
absence O 0 8.491944754496217e-06
of O 0 1.2589540574481362e-06
lamin O 0 0.07719247043132782
B1 O 0 0.47762224078178406
from O 0 2.5648712835391052e-05
heart O 1 0.9754183888435364
and O 0 2.743331242527347e-05
skeletal O 1 0.995558500289917
muscle O 0 0.32249021530151367
nuclei O 0 0.00032399321207776666
which O 0 2.8736960757669294e-06
already O 0 6.373246833391022e-06
lack O 0 7.101008122845087e-06
emerin O 0 0.0007208373281173408
may O 0 1.9387757674849126e-06
offer O 0 1.0280642470661405e-07
an O 0 2.951082755942025e-08
alternative O 0 4.6323779656631814e-07
explanation O 0 3.874585559060506e-07
of O 0 6.182457923387119e-08
why O 0 7.766572025502683e-07
these O 0 8.702664189286224e-08
tissues O 0 8.810231520328671e-05
are O 0 2.426011747047596e-07
particularly O 0 2.803282768581994e-06
affected O 0 4.032024207845097e-06
. O 0 6.538832053593069e-07
. O 0 4.906803042104002e-06

Genetic O 0 0.00015334348427131772
mapping O 0 5.427823998616077e-05
of O 0 1.1490686802062555e-06
the O 0 1.789107955119107e-05
copper B-Disease 1 0.9012967944145203
toxicosis I-Disease 1 0.8167585134506226
locus O 0 0.00020998915715608746
in O 0 4.754780093207955e-06
Bedlington O 0 0.0007237193640321493
terriers O 0 0.00033875551889650524
to O 0 6.275818122958299e-07
dog O 0 0.00017078465316444635
chromosome O 0 8.119232370518148e-05
10 O 0 1.5997155742297764e-06
, O 0 1.6935857161115564e-07
in O 0 7.036711480168378e-08
a O 0 1.0583123639662517e-06
region O 0 7.359456049016444e-06
syntenic O 0 0.00011144353629788384
to O 0 3.488875108814682e-07
human O 0 1.4059176464797929e-05
chromosome O 0 0.00020826379477512091
region O 0 7.551094313384965e-05
2p13 O 0 0.0004459343326743692
- O 0 0.0004281165893189609
p16 O 0 0.0003449514915701002
. O 0 1.727280323393643e-05

Abnormal O 1 0.981709897518158
hepatic B-Disease 1 0.9995594620704651
copper I-Disease 1 0.9985262155532837
accumulation I-Disease 0 0.008397797122597694
is O 0 3.321548547319253e-06
recognized O 0 4.674574029195355e-06
as O 0 9.027088708535302e-06
an O 0 0.00025063511566258967
inherited B-Disease 1 0.9999977350234985
disorder I-Disease 1 0.9999994039535522
in O 0 7.898536568973213e-05
man O 0 0.0012262441450729966
, O 0 4.5523347580456175e-06
mouse O 0 0.0002197334833908826
, O 0 6.093582214816706e-06
rat O 0 0.0009878836572170258
and O 0 5.712749043595977e-06
dog O 0 0.0016031715786084533
. O 0 2.224100535386242e-05

The O 0 1.2407449503371026e-05
major O 0 0.0004494173626881093
cause O 0 0.0008800903451628983
of O 0 1.0919091437244788e-05
hepatic B-Disease 1 0.9996967315673828
copper I-Disease 1 0.9981581568717957
accumulation I-Disease 0 0.006802593823522329
in O 0 1.0391963769507129e-05
man O 0 0.00013945378304924816
is O 0 1.239367293237592e-06
a O 0 6.980026682867901e-06
dysfunctional O 0 0.006143377162516117
ATP7B O 0 0.007141281384974718
gene O 0 0.0005171270458959043
, O 0 6.658336496911943e-05
causing O 0 0.10667863488197327
Wilson B-Disease 1 0.5666744709014893
disease I-Disease 1 0.999154806137085
( O 0 1.2135727956774645e-05
WD B-Disease 0 0.016793785616755486
) O 0 4.81332472190843e-06
. O 0 7.399231890303781e-06

Mutations O 0 0.00047546278801746666
in O 0 1.1864669886563206e-06
the O 0 1.0948871249638614e-06
ATP7B O 0 0.0002432008332107216
genes O 0 2.325345349163399e-06
have O 0 1.4861046793157584e-07
also O 0 1.9395196204641252e-07
been O 0 1.4425759786718118e-07
demonstrated O 0 7.746984351797437e-07
in O 0 7.071848244777357e-07
mouse O 0 0.00014200089208316058
and O 0 1.5304243788705207e-05
rat O 0 0.01230065431445837
. O 0 1.4019049558555707e-05

The O 0 1.0154074516321998e-05
ATP7B O 0 0.0005653979605995119
gene O 0 1.864634032244794e-05
has O 0 1.7100848026530002e-06
been O 0 3.234115695249784e-07
excluded O 0 4.625980807304586e-07
in O 0 4.598147640422212e-08
the O 0 7.431568604943095e-08
much O 0 1.2410197314238758e-06
rarer O 0 0.00111256237141788
human O 0 0.0003248945577070117
copper B-Disease 1 0.9982892870903015
overload I-Disease 1 0.9982300400733948
disease O 1 0.9989379048347473
non B-Disease 0 0.0005935757653787732
- I-Disease 0 0.003777140751481056
Indian I-Disease 0 4.379196252557449e-05
childhood I-Disease 0 0.038804586976766586
cirrhosis I-Disease 1 0.9997885823249817
, O 0 1.0260547242069151e-05
indicating O 0 4.41126903751865e-05
genetic O 0 0.00019247509771957994
heterogeneity O 0 0.000670477922540158
. O 0 3.6797457141801715e-05

By O 0 2.53595135291107e-06
investigating O 0 2.4677654437255114e-05
the O 0 2.5005188035720494e-06
common O 0 0.00031728544854559004
autosomal O 1 0.9991451501846313
recessive O 1 0.9994378685951233
copper B-Disease 1 0.9996082186698914
toxicosis I-Disease 1 0.996570348739624
( O 0 1.3182280781620648e-05
CT B-Disease 0 0.004684009589254856
) O 0 3.9060728340700734e-07
in O 0 8.700106377546035e-07
Bedlington O 0 0.00021559142624028027
terriers O 0 0.00025118462508544326
, O 0 7.878321639509522e-07
we O 0 1.260408595271656e-07
have O 0 2.2877870264892408e-08
identified O 0 1.273644443244848e-07
a O 0 1.785823968702971e-07
new O 0 1.1370308357072645e-06
locus O 0 3.3228574466193095e-05
involved O 0 2.1917006961302832e-05
in O 0 0.00018380244728177786
progressive O 1 0.9996309280395508
liver B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999992847442627
. O 0 0.0004697820986621082

We O 0 9.341541954199784e-06
examined O 0 3.1370487704407424e-05
whether O 0 6.306536874944868e-07
the O 0 1.665974764364364e-06
WD B-Disease 0 0.0016505890525877476
gene O 0 5.151319783180952e-05
ATP7B O 0 0.001284437719732523
was O 0 1.4996775462350342e-05
also O 0 6.046607268217485e-07
causative O 0 1.2631086974579375e-05
for O 0 2.4802622533570684e-07
CT B-Disease 0 0.001097660860978067
by O 0 3.756078967853682e-07
investigating O 0 5.003976184525527e-06
the O 0 1.584586470926297e-06
chromosomal O 0 0.006379724480211735
co O 0 0.0004574528429657221
- O 0 5.20038629474584e-05
localization O 0 2.261348708998412e-05
of O 0 3.7661723695237015e-07
ATP7B O 0 0.0005164785543456674
and O 0 9.477889193476585e-07
C04107 O 0 1.3688362741959281e-05
, O 0 8.464146361575331e-08
using O 0 1.6080703346688097e-07
fluorescence O 0 6.654796379734762e-06
in O 0 1.2728421552310465e-06
situ O 0 8.545008313376456e-05
hybridization O 0 4.603694378602086e-06
( O 0 7.544078357568651e-07
FISH O 0 7.393772648356389e-06
) O 0 9.04390844880254e-07
. O 0 3.5496689179126406e-06

C04107 O 0 0.0008075367077253759
is O 0 1.376286149934458e-06
an O 0 1.9804136286438734e-07
anonymous O 0 4.421389803610509e-06
microsatellite O 0 0.00016843016783241183
marker O 0 3.213016680092551e-05
closely O 0 3.7390350371424574e-06
linked O 0 4.606326183420606e-05
to O 0 1.7813347312767291e-06
CT B-Disease 0 0.38782086968421936
. O 0 1.522483398730401e-05

However O 0 2.8632721296162345e-05
, O 0 1.064307798515074e-05
BAC O 0 0.0004243203438818455
clones O 0 2.1366558939917013e-05
containing O 0 4.165667178313015e-06
ATP7B O 0 0.0009375163936056197
and O 0 1.8428297607897548e-06
C04107 O 0 3.748543167603202e-05
mapped O 0 8.711250302440021e-06
to O 0 1.1708055325243549e-07
the O 0 1.3444918067762046e-06
canine O 0 0.0017791982972994447
chromosome O 0 0.0011423684190958738
regions O 0 5.0561859097797424e-05
CFA22q11 O 0 0.0008212911197915673
and O 0 6.818583187850891e-06
CFA10q26 O 0 0.00046341633424162865
, O 0 2.3254451662069187e-06
respectively O 0 4.3281888792989776e-06
, O 0 7.166641466938017e-07
demonstrating O 0 4.5160986701375805e-06
that O 0 3.676445885503199e-07
WD B-Disease 0 0.0006209769635461271
cannot O 0 2.2854637791169807e-06
be O 0 1.2296223417251895e-07
homologous O 0 3.2956529594230233e-06
to O 0 1.3699300325242803e-06
CT B-Disease 0 0.029301302507519722
. O 0 1.4673262739961501e-05

The O 0 6.480633601313457e-06
copper O 0 0.0014166178880259395
transport O 0 3.2124778954312205e-05
genes O 0 3.9613270928384736e-05
CTR1 O 0 0.0012913210084661841
and O 0 2.5816364086495014e-06
CTR2 O 0 0.000438519986346364
were O 0 4.017780952381145e-07
also O 0 5.365964739212359e-07
excluded O 0 1.1092658951383783e-06
as O 0 2.391095961229439e-07
candidate O 0 6.591034207303892e-07
genes O 0 4.087732179414161e-07
for O 0 2.826924685450649e-07
CT B-Disease 0 0.004058672580868006
since O 0 3.85461316909641e-06
they O 0 4.5650455859913563e-08
both O 0 7.605336804772378e-08
mapped O 0 3.1200092962535564e-06
to O 0 2.6484264026294113e-07
canine O 0 0.0012378012761473656
chromosome O 0 0.001166941481642425
region O 0 0.00018677239131648093
CFA11q22 O 0 0.0039255041629076
. O 0 2.7902673537028022e-05

2 O 0 0.00014302850468084216
- O 0 0.00043171088327653706
22 O 0 3.572101559257135e-05
. O 0 3.233676352465409e-06

5 O 0 0.0001379318709950894
. O 0 2.347888221265748e-05

A O 0 5.3881408348388504e-06
transcribed O 0 9.026717634696979e-06
sequence O 0 2.957176320705912e-06
identified O 0 2.558089363446925e-06
from O 0 9.618337060146587e-08
the O 0 2.1036446185007662e-07
C04107 O 0 4.5447162847267464e-05
- O 0 2.6552608687779866e-05
containing O 0 2.4540661343053216e-06
BAC O 0 0.000164628800121136
was O 0 2.290921202074969e-06
found O 0 5.4805319393835816e-08
to O 0 4.351170090899359e-09
be O 0 7.670466928288988e-09
homologous O 0 8.190801281671156e-08
to O 0 8.685530517027473e-09
a O 0 1.6132867131091189e-07
gene O 0 8.806119353721442e-07
expressed O 0 2.5743932496880007e-07
from O 0 2.055888188579047e-07
human O 0 1.9195263121218886e-06
chromosome O 0 0.00010461996134836227
2p13 O 0 0.00014495385403279215
- O 0 6.858167762402445e-05
p16 O 0 3.143067078781314e-05
, O 0 5.082449092697061e-07
a O 0 6.331630402200972e-07
region O 0 2.6692594019550597e-06
devoid O 0 3.5756129364017397e-06
of O 0 3.1096426766907825e-08
any O 0 1.0066769817740351e-07
positional O 0 5.254187635728158e-05
candidate O 0 2.585618494777009e-05
genes O 0 4.059294587932527e-05
. O 0 1.9694365619216114e-05

Molecular O 0 7.787734648445621e-05
analysis O 0 9.424746281183616e-07
of O 0 1.3373953322570742e-07
the O 0 6.242016183932719e-07
APC B-Disease 0 4.866476228926331e-05
gene O 0 2.9063780857541133e-06
in O 0 6.974124744374421e-07
205 O 0 2.3132467958930647e-06
families O 0 1.2114458058931632e-07
: O 0 1.863455594275365e-07
extended O 0 1.3404027185970335e-06
genotype O 0 5.685578071279451e-05
- O 0 0.00018767319852486253
phenotype O 0 7.925819227239117e-05
correlations O 0 2.8239299354027025e-05
in O 0 2.0539316665235674e-06
FAP B-Disease 0 4.666278255172074e-05
and O 0 1.7531111495827645e-07
evidence O 0 8.596338574307083e-08
for O 0 1.854286502123159e-08
the O 0 8.048618127531881e-08
role O 0 2.2049591734685237e-06
of O 0 7.152555099310121e-07
APC B-Disease 0 0.00016329146455973387
amino O 0 2.3195039830170572e-05
acid O 0 0.00029533306951634586
changes O 0 0.00033460475970059633
in O 0 0.14037050306797028
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
predisposition O 1 0.991664707660675
. O 0 0.00011940258264075965

BACKGROUND O 0 0.00031175033655017614
/ O 0 0.00011297143646515906
AIMS O 0 1.6751668226788752e-05
The O 0 9.973464329959825e-07
development O 0 1.9837074432871304e-05
of O 0 0.027562497183680534
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
and O 0 3.973589628003538e-06
a O 0 1.5420818044731277e-06
variable O 0 1.910776882141363e-05
range O 0 6.0019033298885915e-06
of O 0 9.830607723415596e-07
extracolonic O 0 0.018861496821045876
manifestations O 0 0.12091346830129623
in O 0 0.0013766176998615265
familial B-Disease 1 0.9999935626983643
adenomatous I-Disease 1 0.9999607801437378
polyposis I-Disease 1 0.9999909400939941
( O 0 0.0001521906815469265
FAP B-Disease 0 0.0005512171192094684
) O 0 3.2184854603656277e-07
is O 0 1.5029199573746155e-07
the O 0 1.107507401343355e-07
result O 0 7.908839734227513e-07
of O 0 8.975113985343341e-08
the O 0 1.054814902090584e-06
dominant O 0 0.003462196094915271
inheritance O 0 0.01737143099308014
of O 0 0.0020524149294942617
adenomatous B-Disease 1 0.9999936819076538
polyposis I-Disease 1 0.9999219179153442
coli I-Disease 1 0.9998061060905457
( O 0 2.0463281543925405e-05
APC B-Disease 0 0.00028186768759042025
) O 0 2.212404979218263e-06
gene O 0 7.501378422603011e-05
mutations O 0 0.0005319219781085849
. O 0 2.732633765845094e-05

In O 0 1.4528385463563609e-06
this O 0 7.001688118180027e-08
study O 0 1.4027550321316085e-07
, O 0 2.1403449679269215e-08
direct O 0 4.614823723159134e-08
mutation O 0 2.4554144602007e-06
analysis O 0 1.931527009446654e-07
of O 0 3.2631628954504777e-08
the O 0 3.4949124483318883e-07
APC B-Disease 0 1.5215572602755856e-05
gene O 0 2.64283039541624e-06
was O 0 2.5167539661197225e-06
performed O 0 1.2753148439514916e-06
to O 0 5.971318728370534e-08
determine O 0 1.1244252391406917e-06
genotype O 0 3.131070843664929e-05
- O 0 5.978276385576464e-05
phenotype O 0 1.4527287930832244e-05
correlations O 0 3.6564422316587297e-06
for O 0 2.3963190187714645e-07
nine O 0 3.2350828860217007e-06
extracolonic O 0 0.00025398682919330895
manifestations O 0 9.674659668235108e-05
and O 0 5.706089041268569e-07
to O 0 9.846692705650639e-08
investigate O 0 3.5122175177093595e-06
the O 0 1.6527578736713622e-06
incidence O 0 0.00039450867916457355
of O 0 4.341535770890914e-07
APC B-Disease 0 0.0003578002215363085
mutations O 0 0.0003812693466898054
in O 0 3.638969428720884e-05
non O 1 0.97676020860672
- O 1 0.9999438524246216
FAP O 1 0.9993916749954224
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
. O 0 0.00018174549040850252

METHODS O 0 2.6245523258694448e-05
The O 0 2.545233428463689e-06
APC B-Disease 0 5.976281681796536e-05
gene O 0 6.676651992165716e-06
was O 0 5.49847982256324e-06
analysed O 0 2.5039219053724082e-06
in O 0 6.106423029450525e-07
190 O 0 2.281432898598723e-06
unrelated O 0 2.299356674484443e-05
FAP B-Disease 0 0.00011365616228431463
and O 0 3.340590183142922e-06
15 O 0 5.573722592089325e-05
non O 1 0.7892535924911499
- O 1 0.9999326467514038
FAP O 1 0.9994480013847351
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
patients O 0 0.0009966837242245674
using O 0 2.3552076527266763e-05
denaturing O 0 0.0058548604138195515
gradient O 0 0.0006307293078862131
gel O 0 0.000841007917188108
electrophoresis O 0 7.297747652046382e-05
, O 0 1.3397095699474448e-07
the O 0 4.829196598166163e-08
protein O 0 5.285666588861204e-07
truncation O 0 1.7112339264713228e-05
test O 0 1.5015274357210728e-06
, O 0 5.097963295952468e-08
and O 0 1.8031762749615154e-08
direct O 0 1.625571002250581e-07
sequencing O 0 9.568980203766841e-06
. O 0 1.1120187082269695e-05

RESULTS O 0 8.78844948601909e-05
Chain O 0 5.0642203859752044e-05
terminating O 0 1.0299291716364678e-05
signals O 0 9.196899554808624e-06
were O 0 9.192334715635297e-08
only O 0 3.730902520260315e-08
identified O 0 9.006648724607658e-07
in O 0 3.873192611081322e-07
patients O 0 3.394426585145993e-06
belonging O 0 6.754308969902922e-07
to O 0 1.2516164815679076e-07
the O 0 3.0650892313133227e-06
FAP B-Disease 0 0.00033700227504596114
group O 0 4.037888629682129e-06
( O 0 7.696232842135942e-07
105 O 0 1.0115722034242935e-05
patients O 0 2.6615685783326626e-05
) O 0 5.966071512375493e-07
. O 0 2.7074154331785394e-06

Amino O 0 2.440567550365813e-05
acid O 0 2.6467208954272792e-05
changes O 0 6.243384973458888e-07
were O 0 7.374185884145845e-08
identified O 0 1.7749320591065043e-07
in O 0 5.143605008584018e-08
four O 0 4.6701973133167485e-07
patients O 0 4.859905857301783e-06
, O 0 1.1353487394671902e-07
three O 0 6.825159459822316e-08
of O 0 3.7800685248612353e-08
whom O 0 1.6088249594758963e-06
belonged O 0 3.7185025121289073e-06
to O 0 8.826132358308314e-08
the O 0 1.3243242165117408e-06
non O 0 0.00015404255827888846
- O 0 0.008337410166859627
FAP O 0 0.0017086116131395102
group O 0 0.000154289067722857
of O 0 0.003918846137821674
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 1 0.7889748811721802
. O 0 3.647363337222487e-05

Genotype O 0 0.002393713453784585
- O 0 0.000933574337977916
phenotype O 0 0.0001472402800573036
correlations O 0 3.098503657383844e-05
identified O 0 5.109019639348844e-06
significant O 0 5.463899128699268e-07
differences O 0 5.000259989174083e-06
in O 0 7.708925409133371e-07
the O 0 3.266616772634734e-07
nature O 0 3.383541297807824e-06
of O 0 1.601184038690917e-07
certain O 0 2.0687718915723963e-06
extracolonic O 0 0.004070884082466364
manifestations O 0 0.0021284595131874084
in O 0 1.1365103091520723e-05
FAP B-Disease 0 0.002348434180021286
patients O 0 1.8973867554450408e-05
belonging O 0 1.8569252233646694e-06
to O 0 1.0172794873142266e-07
three O 0 1.6263521729342756e-06
mutation O 0 0.00017326931993011385
subgroups O 0 6.0441758250817657e-05
. O 0 1.621525370865129e-05

CONCLUSIONS O 0 6.154746370157227e-05
Extended O 0 1.4575663954019547e-05
genotype O 0 0.0002965609892271459
- O 0 0.000217944267205894
phenotype O 0 3.908142389263958e-05
correlations O 0 7.108611043804558e-06
made O 0 7.227542937471299e-07
in O 0 2.0539165745958599e-07
this O 0 3.475567211808084e-08
study O 0 2.250484953947307e-07
may O 0 3.1181662052404135e-07
have O 0 2.260318510138859e-08
the O 0 4.75041055381098e-08
potential O 0 2.0417711255049653e-07
to O 0 1.4265713943473202e-08
determine O 0 2.0387416554967785e-07
the O 0 7.866926665656138e-08
most O 0 9.535372669233766e-08
appropriate O 0 2.0312155868396076e-07
surveillance O 0 2.081948878185358e-05
and O 0 2.5676995392132085e-06
prophylactic O 0 0.0003756656078621745
treatment O 0 0.00022885641374159604
regimens O 0 3.957905573770404e-05
for O 0 6.706899569053348e-08
those O 0 1.6334310259935592e-07
patients O 0 3.0398680337384576e-06
with O 0 2.558808773756027e-07
mutations O 0 6.0914677305845544e-05
associated O 0 6.8649014792754315e-06
with O 0 3.153447323711589e-06
life O 0 0.00019288774637971073
threatening O 1 0.5952168107032776
conditions O 0 0.005241026170551777
. O 0 3.312230546725914e-05

This O 0 5.401164457907726e-07
study O 0 3.5592952940532996e-07
also O 0 8.537579532230666e-08
provided O 0 4.352973803634086e-08
evidence O 0 5.434667471604371e-08
for O 0 3.075056298484924e-08
the O 0 3.9447775179723976e-07
pathological O 0 0.0006814391817897558
nature O 0 3.7796469314343994e-06
of O 0 8.083063107733324e-08
amino O 0 1.5751140836073318e-06
acid O 0 1.3145811863068957e-05
changes O 0 2.51910728366056e-06
in O 0 3.5738463566303835e-07
APC O 0 2.6749632525024936e-05
associated O 0 1.697412812973198e-06
with O 0 2.3727959330699377e-07
both O 0 1.721566945889208e-06
FAP B-Disease 0 0.0008082157000899315
and O 0 5.767447146354243e-05
non O 1 0.9920424818992615
- O 1 0.9999566078186035
FAP O 1 0.9994207620620728
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
patients O 0 0.008772854693233967
. O 0 2.323472472198773e-06
. O 0 7.795678357069846e-06

Inherited B-Disease 1 0.9998440742492676
colorectal I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999101161956787
and O 1 0.9859381318092346
cancer B-Disease 1 0.9999109506607056
risk O 0 0.0007130259764380753
of O 0 3.1564931646244077e-07
the O 0 5.772260919911787e-06
APC O 0 0.0007733193342573941
I1307K O 0 0.00048595701809972525
polymorphism O 0 0.00022345833713188767
. O 0 1.4712974007125013e-05

Germ O 0 0.016350295394659042
- O 0 0.00040689934394322336
line O 0 7.077736518112943e-05
and O 0 1.4102048453423777e-06
somatic O 0 4.482028089114465e-05
truncating O 0 0.00037113309372216463
mutations O 0 7.2629249189049e-05
of O 0 1.7098894034006662e-07
the O 0 3.2754229550846503e-07
APC B-Disease 0 3.314401692477986e-05
gene O 0 1.747495502968377e-06
are O 0 8.81322890222691e-08
thought O 0 2.1472569642355666e-06
to O 0 2.2266099222179037e-06
initiate O 0 0.0519479475915432
colorectal B-Disease 1 0.9999996423721313
tumor I-Disease 1 0.9997379183769226
formation O 0 0.4583289623260498
in O 0 0.0028504824731498957
familial B-Disease 1 0.9999949932098389
adenomatous I-Disease 1 0.9999932050704956
polyposis I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999994039535522
and O 0 0.004123831633478403
sporadic O 1 0.998292863368988
colorectal O 1 0.9999995231628418
carcinogenesis O 1 0.9986806511878967
, O 0 5.26805488334503e-05
respectively O 0 5.471592157846317e-05
. O 0 1.124318987422157e-05

Recently O 0 0.0003615267632994801
, O 0 1.9130877717543626e-06
an O 0 1.2966006579517853e-06
isoleucine O 0 0.0014341037021949887
- O 0 0.00030606737709604204
- O 0 8.424968837061897e-05
> O 0 1.5492603779421188e-05
lysine O 0 1.511276605015155e-05
polymorphism O 0 5.365573542803759e-06
at O 0 5.0449448281142395e-06
codon O 0 1.1958583854720928e-05
1307 O 0 0.0001912001898745075
( O 0 2.4456150526930287e-07
I1307K O 0 6.112078153819311e-06
) O 0 3.4532860127001186e-08
of O 0 1.4936373915475087e-08
the O 0 2.3075631361280102e-07
APC B-Disease 0 1.3307378139870707e-05
gene O 0 1.9812875962088583e-06
has O 0 6.875397389194404e-07
been O 0 2.1275000960940815e-07
identified O 0 1.807874099313267e-07
in O 0 4.880253356986941e-08
6 O 0 6.961711846997787e-07
% O 0 2.0885158491523725e-08
- O 0 3.083510364376707e-06
7 O 0 8.818001902000105e-07
% O 0 1.235503965801854e-08
of O 0 1.6584159823196387e-08
the O 0 5.987662916595582e-07
Ashkenazi O 0 0.00015751959290355444
Jewish O 0 1.3058084732620046e-05
population O 0 5.773405291620293e-07
. O 0 5.994729235681007e-06

To O 0 1.2277679388716933e-06
assess O 0 2.832052814483177e-05
the O 0 1.83731776814966e-06
risk O 0 1.5131125110201538e-05
of O 0 3.8281299907794164e-08
this O 0 1.0572647113349376e-07
common O 0 1.5036788681754842e-05
APC B-Disease 0 0.0005583192105405033
allelic O 0 0.001018588780425489
variant O 0 0.04389457032084465
in O 0 0.0012744615087285638
colorectal O 1 0.9999985694885254
carcinogenesis O 1 0.9937350153923035
, O 0 4.239328518451657e-06
we O 0 4.663845913910336e-07
have O 0 8.070784929259389e-08
analyzed O 0 1.1438251021900214e-06
a O 0 4.762940477576194e-07
large O 0 1.807639478101919e-06
cohort O 0 1.5426790923811495e-05
of O 0 2.6961660637425666e-07
unselected O 0 0.0018429619958624244
Ashkenazi O 0 0.0012535958085209131
Jewish O 0 5.3015992307337e-05
subjects O 0 0.00016164501721505076
with O 0 0.00025650730822235346
adenomatous B-Disease 1 0.997921884059906
polyps I-Disease 1 0.9960905909538269
and O 0 4.986737985746004e-05
. O 0 4.7788711526663974e-05
or O 1 0.9988238215446472
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
, I-Disease 0 1.9005476588063175e-06
for O 0 6.465186430659742e-08
the O 0 7.550729037575366e-07
APC O 0 0.00021887138427700847
I1307K O 0 0.00026419476489536464
polymorphism O 0 8.332471770700067e-05
. O 0 1.2994220924156252e-05

The O 0 1.2094021258235443e-05
APC O 0 0.00021655250748153776
I1307K O 0 6.0902766563231125e-05
allele O 0 1.1693270607793238e-05
was O 0 3.8051593946875073e-06
identified O 0 7.241189337037213e-07
in O 0 8.963225184288603e-08
48 O 0 3.266526391598745e-07
( O 0 1.7176352784531446e-08
10 O 0 4.485082527594386e-08
. O 0 1.2341896393763818e-08
1 O 0 5.4404342364478e-08
% O 0 4.4462402648548505e-09
) O 0 1.8387057210134117e-08
of O 0 9.400530132097629e-08
476 O 0 0.00015735221677459776
patients O 0 0.0002177276328438893
. O 0 1.0311135156371165e-05

Compared O 0 4.6862728595442604e-06
with O 0 7.163382775843274e-08
the O 0 6.106806438310741e-08
frequency O 0 8.717447599337902e-07
in O 0 4.969564315615571e-08
two O 0 1.6045891726435002e-08
separate O 0 1.1706626423801936e-07
population O 0 4.229900341101711e-08
control O 0 2.817756239892333e-06
groups O 0 1.77752198737835e-07
, O 0 3.2812664585435414e-07
the O 0 5.998476240165473e-07
APC O 0 8.109552436508238e-05
I1307K O 0 6.801044219173491e-05
allele O 0 1.084122050087899e-05
is O 0 5.112560188536008e-07
associated O 0 7.726148965048196e-07
with O 0 1.0049350862573192e-07
an O 0 2.7417709702604043e-07
estimated O 0 7.853865895413037e-07
relative O 0 5.0689804993453436e-06
risk O 0 1.6606638382654637e-05
of O 0 3.388684319816093e-07
1 O 0 1.885478377516847e-05
. O 0 6.3122924984782e-06

5 O 0 7.524540706072003e-05
- O 0 0.00021070436923764646
1 O 0 2.217949804617092e-05
. O 0 4.466904556466034e-06

7 O 0 0.00034608429996296763
for O 0 6.568882963620126e-05
colorectal B-Disease 1 0.9999970197677612
neoplasia I-Disease 1 0.9902909398078918
( O 0 2.9056102448521415e-06
both O 0 3.721596158356988e-06
P O 0 0.0010004081996157765
= O 0 4.381009057397023e-05
. O 0 1.2174909898021724e-06
01 O 0 0.00015645797247998416
) O 0 6.804764893786341e-07
. O 0 2.8713457140838727e-06

Furthermore O 0 1.5182539755187463e-05
, O 0 8.041518526624714e-07
compared O 0 1.4968251207392314e-06
with O 0 5.277566970107728e-07
noncarriers O 0 0.0006709682638756931
, O 0 2.2794299638917437e-06
APC O 0 5.253215567790903e-05
I1307K O 0 2.7680549465003423e-05
carriers O 0 4.070528575539356e-06
had O 0 9.848296258496703e-07
increased O 0 4.826148369829752e-07
numbers O 0 6.628040978284844e-07
of O 0 2.084601646856754e-06
adenomas B-Disease 1 0.9938365817070007
and O 1 0.8576338291168213
colorectal B-Disease 1 0.9999998807907104
cancers I-Disease 1 0.9999125003814697
per O 0 2.4180148102459498e-05
patient O 0 0.00027231709100306034
( O 0 1.9197459550923668e-06
P O 0 0.00020302762277424335
= O 0 7.734265636827331e-06
. O 0 2.9748957786068786e-07
03 O 0 1.189234808407491e-05
) O 0 3.468156961616842e-08
, O 0 2.5709086415304228e-08
as O 0 3.7664374730184136e-08
well O 0 4.728282121391203e-08
as O 0 1.422045983190401e-07
a O 0 6.436640660467674e-07
younger O 0 6.49394723950536e-06
age O 0 1.3345606930670328e-05
at O 0 9.032223169924691e-05
diagnosis O 0 0.3029129207134247
. O 0 1.2357721061562188e-05

We O 0 4.615630132320803e-06
conclude O 0 6.176044280437054e-06
that O 0 7.962423609342295e-08
the O 0 6.406448846973944e-07
APC O 0 0.0001085487674572505
I1307K O 0 0.0001650799240451306
variant O 0 0.0004384150670375675
leads O 0 4.004451329819858e-05
to O 0 1.6003137943698675e-06
increased O 0 9.375617082696408e-05
adenoma B-Disease 1 0.9999723434448242
formation O 0 0.0008392106974497437
and O 0 7.912566957202216e-07
directly O 0 3.040773322027235e-07
contributes O 0 4.0674680690244713e-07
to O 0 2.764987527825724e-08
3 O 0 2.462554959947738e-07
% O 0 1.7732341817122688e-08
- O 0 1.3445392141875345e-06
4 O 0 2.7251343226453173e-07
% O 0 7.358334386253773e-09
of O 0 2.74901736929678e-08
all O 0 1.831328063417459e-06
Ashkenazi O 1 0.8929001688957214
Jewish O 1 0.9991232752799988
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 0.0001762221218086779

The O 0 2.217669134552125e-06
estimated O 0 1.410771119481069e-06
relative O 0 5.891218734177528e-06
risk O 0 1.764987791830208e-05
for O 0 1.9005445039965707e-07
carriers O 0 8.639452971692663e-06
may O 0 1.2040873116347939e-06
justify O 0 3.5928843544752453e-07
specific O 0 6.810556385516975e-08
clinical O 0 3.11454527945898e-06
screening O 0 4.045548678277555e-07
for O 0 1.436269059240658e-08
the O 0 2.7178456818433006e-08
360 O 0 4.747154491724359e-07
, O 0 1.1624823059719347e-07
000 O 0 1.1124318177735404e-07
Americans O 0 3.096155154480584e-08
expected O 0 1.6085948573163478e-07
to O 0 4.869736969226324e-08
harbor O 0 4.998257281840779e-06
this O 0 1.2791362635766745e-08
allele O 0 5.379588969844917e-07
, O 0 9.5787747511622e-08
and O 0 8.595518607990016e-08
genetic O 0 3.972346803493565e-06
testing O 0 1.9108833839709405e-06
in O 0 7.728360884584617e-08
the O 0 4.387583274478857e-08
setting O 0 1.5898585843387991e-06
of O 0 1.2690371420376323e-07
long O 0 2.484675860614516e-05
- O 0 9.914024849422276e-05
term O 0 1.28128522192128e-05
- O 0 1.683937807683833e-05
outcome O 0 2.1903513243159978e-06
studies O 0 7.923424618638819e-07
may O 0 1.3887072327634087e-06
impact O 0 9.405152013641782e-06
significantly O 0 0.00018311043095309287
on O 1 0.997469425201416
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
prevention O 0 0.01139393262565136
in O 0 5.283953328216739e-07
this O 0 9.511213505675187e-08
population O 0 1.3504913454198686e-07
. O 0 2.0966756437701406e-06

Localization O 0 0.00015347485896199942
of O 0 7.850563292777224e-07
human O 0 1.650725789659191e-05
BRCA1 O 0 0.00020712414698209614
and O 0 9.68859581007564e-07
its O 0 7.92876164723566e-07
loss O 0 7.72767307353206e-05
in O 0 1.4195353514878661e-06
high O 0 0.0002248635864816606
- O 0 0.00024131858663167804
grade O 0 0.0002797638881020248
, O 0 1.3656860573973972e-05
non B-Disease 0 0.005143157672137022
- I-Disease 1 0.9985942244529724
inherited I-Disease 1 0.9997174143791199
breast I-Disease 1 0.999954342842102
carcinomas I-Disease 1 0.9999946355819702
. O 0 0.00022534260642714798

Although O 0 2.5974165964726126e-06
the O 0 4.4817264210905705e-07
link O 0 1.2210968634462915e-05
between O 0 3.2315119824488647e-06
the O 0 1.8813219867297448e-05
BRCA1 O 0 0.10661680996417999
tumour B-Disease 1 0.9999337196350098
- O 0 0.0017400856595486403
suppressor O 0 0.0003432090161368251
gene O 0 7.804595225024968e-05
and O 0 5.161055742064491e-05
hereditary B-Disease 1 0.9998247027397156
breast I-Disease 1 0.999988317489624
and I-Disease 1 0.9997809529304504
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
is O 0 1.9844133021251764e-06
established O 0 4.0784996713227883e-07
, O 0 1.2806135885057301e-07
the O 0 3.2155639928532764e-08
role O 0 7.332669724746665e-07
, O 0 2.922499504620646e-07
if O 0 5.772960420813433e-08
any O 0 2.989390779362111e-08
, O 0 1.3161850631604466e-07
of O 0 6.100135863107425e-08
BRCA1 O 0 9.234315803041682e-05
in O 0 4.855944553128211e-06
non B-Disease 0 0.0012554049026221037
- I-Disease 1 0.9890658855438232
familial I-Disease 1 0.9984850287437439
cancers I-Disease 1 0.9999309778213501
is O 0 1.3179828783904668e-05
unclear O 0 1.4559353985532653e-05
. O 0 4.842695034312783e-06

BRCA1 O 0 0.0069521223194897175
mutations O 0 0.00026731734396889806
are O 0 3.589257744351926e-07
rare O 0 2.3467040591640398e-05
in O 0 5.405232968769269e-06
sporadic B-Disease 0 0.009867977350950241
cancers I-Disease 1 0.9998395442962646
, O 0 1.0914010090345982e-05
but O 0 4.767830432683695e-06
loss O 0 5.941969357081689e-05
of O 0 2.642651111273153e-07
BRCA1 O 0 0.0003158561303280294
resulting O 0 1.0757530617411248e-05
from O 0 4.5620211608365935e-07
reduced O 0 1.5157723964875913e-06
expression O 0 1.0191365618084092e-06
or O 0 1.0747385204012971e-06
incorrect O 0 7.439030923706014e-06
subcellular O 0 4.8732050345279276e-05
localization O 0 5.1616167183965445e-05
is O 0 5.153272581992496e-07
postulated O 0 1.7762624793249415e-06
to O 0 1.7129178075947493e-08
be O 0 2.6618739212835862e-08
important O 0 1.700257996617438e-07
in O 0 1.3525218491849955e-06
non B-Disease 0 0.0005135047249495983
- I-Disease 1 0.9720208644866943
familial I-Disease 1 0.9988873600959778
breast I-Disease 1 0.9999639987945557
and I-Disease 1 0.9994739890098572
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999995231628418
. O 0 0.00042594363912940025

Epigenetic O 0 0.008498874492943287
loss O 0 0.013427824713289738
, O 0 3.519852498357068e-06
however O 0 6.268246011131851e-07
, O 0 2.8739651725118165e-07
has O 0 2.0122435273606243e-07
not O 0 2.7376575673088155e-08
received O 0 1.965481715160422e-07
general O 0 3.5065573911197134e-07
acceptance O 0 3.0952687666285783e-06
due O 0 1.0260762792313471e-05
to O 0 2.4318396185663005e-07
controversy O 0 3.955286501877708e-06
regarding O 0 3.8015070913388627e-07
the O 0 1.3810533516789292e-07
subcellular O 0 1.1690014616760891e-05
localization O 0 1.2916829291498289e-05
of O 0 3.1191001426122966e-07
BRCA1 O 0 9.029648936120793e-05
proteins O 0 1.6474938320243382e-06
, O 0 5.043224291512161e-07
reports O 0 1.7960407205919182e-07
of O 0 2.754260464143954e-08
which O 0 1.107458800220229e-07
have O 0 6.063999791194874e-08
ranged O 0 6.38414167042356e-06
from O 0 3.925509872715338e-08
exclusively O 0 3.9645019001000037e-07
nuclear O 0 5.02029070048593e-05
, O 0 1.315200108820136e-07
to O 0 2.7012871939291472e-08
conditionally O 0 2.4408005629084073e-05
nuclear O 0 4.227162935421802e-05
, O 0 1.7378847871896141e-07
to O 0 2.2013981748614242e-08
the O 0 9.622757488614297e-07
ER O 0 0.0005956352106295526
/ O 0 4.2206778744002804e-05
golgi O 0 0.0013069153064861894
, O 0 4.1004332729244197e-07
to O 0 4.3238628677499946e-08
cytoplasmic O 0 3.623416660047951e-06
invaginations O 0 3.772254058276303e-05
into O 0 3.4257922720826173e-07
the O 0 6.690941063425271e-07
nucleus O 0 3.151735654682852e-05
. O 0 8.654708835820202e-06

In O 0 1.7611289422347909e-06
an O 0 1.1040842906595572e-07
attempt O 0 6.394649858521007e-07
to O 0 9.771015641035774e-08
resolve O 0 6.95026210451033e-06
this O 0 9.80894085955697e-08
issue O 0 9.253179769075359e-07
, O 0 2.481116325725452e-07
we O 0 2.493153772320511e-07
have O 0 2.9592735018013627e-07
comprehensively O 0 9.204952948493883e-05
characterized O 0 8.712796989129856e-05
19 O 0 3.7352117942646146e-05
anti O 0 0.0006376036908477545
- O 0 0.0011406118283048272
BRCA1 O 0 0.0006587862735614181
antibodies O 0 3.7354933738242835e-05
. O 0 4.1239336496801116e-06

These O 0 4.3617006895146915e-07
reagents O 0 3.3840464311651886e-05
detect O 0 0.00010283259325660765
a O 0 2.098304094033665e-06
220 O 0 1.5050842421260313e-06
- O 0 1.0952193406410515e-05
kD O 0 2.9125685614417307e-05
protein O 0 7.818152880645357e-07
localized O 0 8.172788511728868e-06
in O 0 1.546870151969415e-07
discrete O 0 2.1641949388140347e-06
nuclear O 0 0.0001451018324587494
foci O 0 3.3306754630757496e-05
in O 0 2.168133477198353e-07
all O 0 1.139546768058608e-07
epithelial O 0 0.00026346780941821635
cell O 0 0.000508556084241718
lines O 0 9.025628969538957e-05
, O 0 5.315247904036369e-07
including O 0 1.2373426727663173e-07
those O 0 1.5154097354752594e-07
derived O 0 2.92868116957834e-06
from O 0 2.830449193425011e-05
breast B-Disease 1 0.9971938133239746
malignancies I-Disease 1 0.9747995138168335
. O 0 5.276682713883929e-05

Immunohistochemical O 0 0.006490492261946201
staining O 0 0.0017094876384362578
of O 0 6.001044312142767e-06
human O 0 0.0005067752790637314
breast O 1 0.9968472123146057
specimens O 0 0.00014415646728593856
also O 0 8.064395842666272e-06
revealed O 0 0.00015804452414158732
BRCA1 O 0 0.002185510704293847
nuclear O 0 0.0047796317376196384
foci O 0 0.001862786477431655
in O 0 9.325987775810063e-05
benign O 1 0.9989319443702698
breast O 1 0.9995051622390747
, O 0 0.00024951068917289376
invasive B-Disease 1 0.9981393814086914
lobular I-Disease 1 0.9998782873153687
cancers I-Disease 1 0.9999362230300903
and O 0 0.000222258415305987
low B-Disease 1 0.5990153551101685
- I-Disease 1 0.9909605383872986
grade I-Disease 1 0.8824999928474426
ductal I-Disease 1 0.9995594620704651
carcinomas I-Disease 1 0.9999884366989136
. O 0 0.00031692266929894686

Conversely O 0 0.0004127614956814796
, O 0 7.43179089113255e-06
BRCA1 O 0 0.0001259562122868374
expression O 0 4.310944405006012e-06
was O 0 1.631740087759681e-05
reduced O 0 2.8193906018714188e-06
or O 0 1.5991512327673263e-06
undetectable O 0 0.00012213090667501092
in O 0 1.6407847169830347e-07
the O 0 1.024036606622758e-07
majority O 0 8.44345819928094e-08
of O 0 1.7644345007283846e-07
high O 0 0.0011504522990435362
- O 0 0.00546943349763751
grade O 0 0.0063561671413481236
, O 0 0.00016167000285349786
ductal B-Disease 1 0.9992857575416565
carcinomas I-Disease 1 0.9999948740005493
, O 0 2.102055077557452e-05
suggesting O 0 7.805058885423932e-06
that O 0 1.9723034938579076e-07
absence O 0 4.687381533585722e-06
of O 0 2.900879394474032e-07
BRCA1 O 0 0.0002336249453946948
may O 0 2.0421832687134156e-06
contribute O 0 1.3635519735544221e-07
to O 0 1.9232714976169518e-08
the O 0 1.886655525140668e-07
pathogenesis O 0 0.00017219448636751622
of O 0 3.5255492747410244e-08
a O 0 7.422664793921285e-07
significant O 0 1.3786534509563353e-06
percentage O 0 3.8902348933334e-06
of O 0 1.1894160252268193e-06
sporadic B-Disease 0 0.4871631860733032
breast I-Disease 1 0.9998369216918945
cancers I-Disease 1 0.9997910857200623
. O 0 7.079196620907169e-06
. O 0 8.368969247385394e-06

